<SEC-DOCUMENT>0001213900-21-055241.txt : 20211029
<SEC-HEADER>0001213900-21-055241.hdr.sgml : 20211029
<ACCEPTANCE-DATETIME>20211029061850
ACCESSION NUMBER:		0001213900-21-055241
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20211029
DATE AS OF CHANGE:		20211029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		211360533

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2021_immuronlimited.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:39 UTC 2021 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:imc="http://immuron.com/20210630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
<title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric> <b>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">June 30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition period
from </b><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span><b>to </b><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric> <b>SHELL COMPANY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date of event requiring
this shell company report <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission file number
<ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">000-38104</ix:nonNumeric></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>IMMURON LIMITED</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant
as specified in its charter<br/>
and translation of Registrant&#8217;s name into English)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><b>Australia</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Jurisdiction of incorporation
or organization)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">Level 3, 62 Lygon Street</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Carlton South</ix:nonNumeric>, Victoria, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">3053</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Australia</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive
offices)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Dr. Jerry Kanellos</ix:nonNumeric>, Chief
Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">Level 3, 62 Lygon Street</ix:nonNumeric>,
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Carlton South</ix:nonNumeric>, Victoria, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">3053</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Australia</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">+61 (0)3 9824 5254 <b>(phone);
</b>+<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">61</ix:nonNumeric> (0)<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">3 9822 7735</ix:nonNumeric> <b>(fax)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, telephone, e-mail
and/or facsimile number and address of company contact person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered or
to be registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b></span></td> <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares,  <br/>
each representing 40 Ordinary Shares</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><b>IMRN</b></ix:nonNumeric></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants (expiring June 2022)</b></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>IMRNW</b></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The NASDAQ Stock Market LLC</b></span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered or to be registered pursuant
to Section 12(g) of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of
each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Ordinary Shares, as of June 30, 2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">227,246,596</ix:nonFraction></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 (d) of the Securities Exchange
Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 9pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;2232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top"> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
<tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224; The term &#8220;new or revised financial
accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. GAAP &#9744;</span></td> <td style="width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board &#9746;</span></td> <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Item 17 &#9744; Item 18 &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this is an annual report, indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">INTRODUCTION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial and clinical-stage
biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of
specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. Our polyclonal antibodies offer
delivery within the gastrointestinal (&#8220;GI&#8221;) tract and essentially do not cross into the bloodstream, potentially leading to
much improved safety and tolerability, without sacrificing efficacy. We believe that our lead drug candidates, currently in clinical development,
have the potential to transform the existing treatment paradigms for moderate to severe campylobacteriosis, Enterotoxigenic <i>Escherichia
coli</i> (ETEC) infections, travelers&#8217; diarrhea and for <i>Clostridiodes difficile (C.difficle) </i>infections. We currently market
our flagship commercial products Travelan&#174; and Protectyn&#174; in Australia, where both products are listed medicines on the Australian
Register for Therapeutic Goods. Travelan&#174; (AUST L 106709) is an over-the-counter product indicated to reduce the risk of travelers&#8217;
diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial and is sold in pharmacies throughout Australia. Protectyn&#174;
is currently sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive
function and liver. We also market Travelan&#174; (NPN 80046016) in Canada where it is licensed as a natural health product indicated to
reduce the risk of travelers&#8217; diarrhea, and presently market Travelan&#174; in the U.S. as a dietary supplement for digestive tract
protection.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also have several early-stage
assets under development. Our technology platform can be used to block viruses or bacteria and neutralize the toxins they produce at mucosal
surfaces such as the Gastrointestinal tract. We have completed the manufacture of three new <i>Shigella</i>-specific therapeutic products
using proprietary vaccines developed by the Walter Reed Army Institute of Research (WRAIR). This collaboration aims to develop an oral
therapeutic for shigellosis, a severe form of dysentery that affects about 165 million people a year, mostly children, and causes up to
a million deaths. Symptoms of shigellosis, also known as bacillary dysentery, include severe and bloody diarrhea, fever, and stomach cramps.
We also are pursuing a research program focused on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes
COVID-19. Our Hyper-immune Bovine Colostrum used to manufacture our commercial products Travelan&#174; and Protectyn&#174; has demonstrated
antiviral activity against SARS-CoV-2 in laboratory studies. Our research is focused on identifying the inhibitory substance/s unique
to the colostrum samples.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our American Depositary
Shares (each, an &#8220;ADS&#8221; and, collectively the &#8220;ADSs&#8221;) and warrants (each, a &#8220;Warrant&#8221; and collectively,
the &#8220;Warrants&#8221;) are listed on The NASDAQ Capital Market under the symbols &#8220;IMRN&#8221; and &#8220;IMRNW&#8221;, respectively.
Each ADS represents 40 of our ordinary shares, no par value. Each Warrant has a per ADS exercise price of US$10.00 and expires five years
from the date of issuance. Our ordinary shares are also listed on the Australian Securities Exchange under the symbol &#8220;IMC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our consolidated financial
statements appearing in this annual report are prepared in Australian dollars and in accordance with the International Financial Reporting
Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our consolidated financial statements appearing
in this annual report comply with the IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In this annual report, all
references to &#8220;U.S. dollars&#8221; or &#8220;US$&#8221; are to the currency of the United States, and all references to &#8220;Australian
dollars&#8221;, &#8220;A$&#8221; or &#8220;$&#8221; are to the currency of Australia. Unless otherwise indicated or the context implies
otherwise, items included in the financial statements of each of the group&#8217;s entities are measured using the currency of the primary
economic environment in which the entity operates (&#8216;the functional currency&#8217;). The consolidated financial statements are
presented in Australian dollar (&#8220;A$&#8221; or &#8220;$&#8221;), which is Immuron Limited&#8217;s functional and presentation currency.
Unless otherwise indicated or the context implies otherwise all references to &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;
refers to Immuron Limited, an Australian corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Statements made in this
annual report concerning the contents of any contract, agreement or other document are summaries of such contracts, agreements or documents
and are not complete descriptions of all of their terms. If we filed any of these documents as an exhibit to this annual report or to
any registration statement or annual report that we previously filed, you may read the document itself for a complete description of
its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except for the historical
information contained in this annual report, the statements contained in this annual report are &#8220;forward-looking statements&#8221;
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, with respect to our business,
financial condition and results of operations. Such forward-looking statements reflect our current view with respect to future events
and financial results. We urge you to consider that statements which use the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; or the negative of these terms or other comparable terminology. are
intended to identify forward-looking statements. We remind readers that forward-looking statements are merely predictions and therefore
inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance,
levels of activity, or our achievements, or industry results, to be materially different from any future results, performance, levels
of activity, or our achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities
laws of the United States, we undertake no obligation to publicly release any update or revision to any forward-looking statements to
reflect new information, future events or circumstances, or otherwise after the date hereof. We have attempted to identify significant
uncertainties and other factors affecting forward-looking statements in the Risk Factors section that appears in Item 3.D. &#8220;<i>Key
Information-Risk Factors.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="white-space: nowrap; vertical-align: top; width: 10%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: top; width: 82%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    I</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1</b></span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY
    OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER
    STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected
    Consolidated Financial Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization
    and Indebtedness</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons
    for the Offer and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION
    ON THE COMPANY</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History
    and Development of the Company</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    Overview</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational
    Structure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
    Plant and Equipment</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4A.&#160;&#160;&#160;&#160;&#160;&#160;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED
    STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Results</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
    and Capital Resources</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development, Patents and Licenses</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend
    Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS,
    SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Senior Management</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    Practices</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Ownership</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR
    SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
    Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Party Transactions</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests
    of Experts and Counsel</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: top; width: 82%"><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
    INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements and Other Financial Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    Changes</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER
    AND LISTING</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer
    and Listing Details</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of
    Distribution</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
    Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    of the Issue</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL
    INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Capital</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum
    and Articles of Association</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    Contracts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    Controls</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    and Paying Agents</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="vertical-align: top"><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement
    by Experts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="vertical-align: top"><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents
    on Display</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_053">Subsidiary
    Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: top; width: 82%"><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="vertical-align: bottom; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center">81</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    and Rights</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
    Depositary Shares</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_060"><b>PART
    II</b></a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>84</b></span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS,
    DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL
    MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS
    AND PROCEDURES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
    Report on Internal Control over Financial Reporting</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attestation
    Report of the Registered Public Accounting Firm</span></a></td>
    <td style="vertical-align: bottom; text-align: center">85</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in Internal Control over Financial Reporting</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESERVED</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16A.&#160;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT
    COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16B.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF
    ETHICS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16C.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL
    ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16D.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS
    FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16E.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES
    OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16F.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE
    IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16G.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE
    GOVERNANCE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16H.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY
    DISCLOSURE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">ITEM
    16I.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#finna_001">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></td>
    <td style="vertical-align: bottom; text-align: center">86</td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_077"><b>PART
    III</b></a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>87</b></span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    17.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_078">FINANCIAL
    STATEMENTS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    18.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_079">FINANCIAL
    STATEMENTS</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    19.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#a_080"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_082">SIGNATURE</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM&#160;1. IDENTITY OF DIRECTORS, SENIOR
MANAGEMENT AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM&#160;2. OFFER STATISTICS AND EXPECTED
TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM&#160;3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="font-variant: small-caps">Selected
Consolidated Financial Data</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The tables below set forth
selected consolidated financial data as of and for the five years ended June 30, 2021, which is derived from our audited consolidated
financial statements. The audited consolidated financial statements as of June 30, 2021 and 2020 appear in this annual report. The consolidated
income statement data for the years ended June 30, 2021, 2020 and 2019 and the consolidated balance sheet data as of June 30, 2021 and
2020 are derived from our audited consolidated financial statements included in &#8220;ITEM 18: Financial Statements&#8221;. The consolidated
financial data as of June 30, 2019, 2018 and 2017 and for the years ended June 30, 2018 and 2017 have been derived from our audited consolidated
financial statements, which are not included in this annual report. The selected consolidated financial data set forth below should be
read in conjunction with and is qualified entirely by reference to Item 5. &#8220;Operating and Financial Review and Prospects&#8221;
and our consolidated financial statements and notes thereto included elsewhere in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Statement of Comprehensive Income:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>For the year ended June 30,</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> &#160;A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2018</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2017</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Consolidated Statement of Profit or Loss and Other Comprehensive Income Data:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue from contracts with
    customers</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,518,566</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,842,909</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,396,197</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of Goods Sold</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(418,693</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(337,546</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">94,705</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,829,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,720,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,424,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,058,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other Income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">617,110</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,849,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,605,987</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other gains/(losses) &#8211; net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,342,293</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(375,479</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3,978,679</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,703,990</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,694,306</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,410,254</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,682,766</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,116,013</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,343,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59,975</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(522,665</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,367,054</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,178,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,044,528</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,257,224</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,630,674</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Selling and marketing expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(287,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(864,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(686,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,271,526</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,379,908</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,905,575</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,656,460</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,045,621</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,818,472</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9,204</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,386</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(13,761</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,631</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,199</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(89,654</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Finance costs - net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,557</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,631</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,961</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,268</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before income tax</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,384,465</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,927,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,656,421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,068,582</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,899,740</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income Tax Expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,384,465</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,927,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,656,421</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,068,582</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,899,740</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Items that may be reclassified to profit or
    loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exchange differences on translation of
    foreign operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(79,599</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,017</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total Comprehensive Loss for the Period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,399,418</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,824,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,594,575</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,148,181</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,859,723</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss per share, basic and diluted (in cents per share)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3.79</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.66</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.30</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.48</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Weighted-average number of shares outstanding, basic and diluted</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">221,062,229</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,393,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,740,535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,660,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,866,110</td><td style="text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> &#160;A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> &#160;A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2018</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2017</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Consolidated Statement of Financial Position Data:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash and cash equivalents</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">25,047,281</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,250,468</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,119,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,727,430</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,994,924</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,752,778</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,409,041</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,682,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,050,437</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,267,654</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">27,053,106</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,561,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,242,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,286,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,121,853</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">516,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,195,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">803,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,158,049</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">558,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,210,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">803,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,895,057</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,643,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,351,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,439,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,574,926</td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Capitalization
and Indebtedness</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="font-variant: small-caps">Reasons
for the Offer and Use of Proceeds</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="font-variant: small-caps">Risk
Factors</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Investing in our ADSs
involves a high degree of risk and uncertainty. You should carefully consider the risks and uncertainties described below before investing
in our ADSs. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect
our business. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could
be harmed. In that case, the price of our ADSs could decline, and you could lose all or part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary&#160;of&#160;Risk&#160;Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The following summarizes
some, but not all, of the risks provided below. Please carefully consider all of the information discussed in this Item 3.D. &#8220;Risk
Factors&#8221; in this annual report for a more thorough description of these and other risks:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Risks Related to Our Financial
Condition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>As a company predominantly
focused on the research and development activities of our existing patent portfolio we have incurred operating losses; we expect to continue
to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Risks Related to Our Business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Clinical trials are expensive
and time consuming, and their outcome is uncertain.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We may not be successful
in obtaining or maintaining other rights necessary for the development of our pipeline through acquisitions and in-licenses.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We grant licenses to our
collaborators to use our hyper-immune colostrum technology exclusively for the development of product candidates for certain conditions.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We may not be able to
complete the development of IMM-124E, IMM-529 or develop other pharmaceutical products.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>Our research and development
efforts will be seriously jeopardized if we are unable to retain key personnel and cultivate key academic and scientific collaborations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>Acceptance of our products
in the marketplace is uncertain, and failure to achieve market acceptance will negatively impact our business and operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We face competition from
entities that have developed or may develop product candidates for our target disease indications, including companies developing novel
treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies or product
candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to develop
and successfully commercialize product candidates may be compromised.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>Our product candidates
and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay
or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences
following any potential marketing approval.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We currently depend upon
a sole manufacturer of our lead compound and on a sole manufacturer to produce finished drug products and could incur significant costs
and delays if we are unable to promptly find a replacement for either of them.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>Our future prospects may
also be dependent on our or our collaborators&#8217; ability to successfully develop a pipeline of additional product candidates, and
we and our collaborators may not be successful in efforts to use our platform technologies to identify or discover additional product
candidates.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>We may not be able to
obtain orphan drug exclusivity for some of our product candidates.</i></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Risks Related to Government Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>If we do not obtain the
necessary governmental approvals, we will be unable to commercialize our pharmaceutical products.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Our product candidates
are based on our hyper-immune colostrum technology. Currently, no prescription product candidates utilizing our technology have been approved
for commercial sale and our approach to the development of our technology may not result in safe, effective or marketable products.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>We are early in our product
development efforts and have only two product candidates in early-stage clinical trials. All of our other current product candidates are
still in preclinical development. We have no late-stage clinical trials (post-proof of concept) and may not be able to obtain regulatory
approvals for the commercialization of some or all of our product candidates.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Risks Related to Our Intellectual
Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Our success depends upon
our ability to protect our intellectual property and our proprietary technology, to operate without infringing the proprietary rights
of third parties and to obtain marketing exclusivity for our products and technologies.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>We may face difficulties
in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual property rights
in those jurisdictions.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Confidentiality agreements
with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Risks Related to Our Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The dual listing of our
ordinary shares and the ADSs may adversely affect the liquidity and value of the ADS.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>As a foreign private issuer,
we are permitted, and we expect to follow certain home country corporate governance practices in lieu of certain NASDAQ requirements applicable
to domestic issuers. This may afford less protection to holders of our ADSs.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>As a foreign private issuer,
we are permitted to file less information with the SEC than a company incorporated in the U.S. Accordingly, there may be less publicly
available information concerning us than there is for companies incorporated in the U.S.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>We are an emerging growth
company as defined in the JOBS Act and the reduced disclosure requirements applicable to emerging growth companies may make the ADS less
attractive to investors and, as a result, adversely affect the price of the ADS and result in a less active trading market for the ADS.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>If we fail to comply with
the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional
material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs
could decline significantly and raising capital could be more difficult.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>ADS holders may be subject
to additional risks related to holding ADS rather than ordinary shares.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Our Constitution and Australian
laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>You will have limited
ability to bring an action against us or against our directors and officers, or to enforce a judgment against us or them, because we are
incorporated in Australia and certain of our directors and officers reside outside the U.S.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Australian companies may
not be able to initiate shareholder derivative actions, thereby depriving shareholders of the ability to protect their interests.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Anti-takeover provisions
in our Constitution and our right to issue preference shares could make a third-party acquisition of us difficult.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Condition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COVID-19</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Judgement has been exercised in considering the impacts that the Coronavirus
(COVID-19) pandemic has had, or may have, on the group based on known information. This consideration extends to the nature of the products
and services offered, customers, supply chain, staffing and geographic regions in which the group operates. Sales of Travelan have significantly
dropped from March 2020 and as at reporting date it is unknown the prolonged effect that COVID-19 will continue to have on sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>As a company predominantly focused on the research
and development activities of our existing patent portfolio we have incurred operating losses; we expect to continue to incur operating
losses for the foreseeable future and may never achieve or maintain profitability.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred losses
in every period since we began operations in 1994 and we have reported net losses of A$8,384,465, A$2,927,206, A$4,656,421, A$3,068,582
and A$6,899,740 during the fiscal years ended June 30, 2021, 2020, 2019, 2018 and 2017, respectively. As of June 30, 2021, our accumulated
deficit was A$65,932,888. We are budgeting to continue to incur additional operating losses for the next several years as we expand our
research and development activities for the treatment of infectious diseases, commence new trials for our product candidate IMM-529 for
C. <i>difficile</i>, and potential other assets/indications. We may never be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our actual cash requirements
may vary materially from those now planned and will depend upon numerous factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the continued progress
    of our research and development programs;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, scope, results
    and costs of pre-clinical studies and clinical trials;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcome
    of regulatory submissions and approvals;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determinations as to the
    commercial potential of our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">spending on our marketed
    assets;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    expand our contract manufacturing services;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    and maintain collaborative arrangements; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the status and timing of
    competitive developments.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021, we
had A$25,047,281 in cash and cash equivalents. Developing prescription products is expensive and we will need to secure additional financing
in order to continue to meet our longer-term business objectives, including advancement of our research and development programs. We
may also require additional funds to pursue regulatory clearances, defend our intellectual property rights, establish commercial scale
manufacturing facilities, develop marketing and sales capabilities and fund operating expenses. We intend to seek such additional funding
through public or private financings and/or through licensing of our assets or strategic alliances or other arrangements with corporate
partners. The global economic climate could adversely impact our ability to obtain such funding, license our assets or enter into alliances
or other arrangements with corporate partners. Any shortfall in funding could result in our having to curtail or cease our operations,
including our research and development activities, which would be expected to adversely affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have never generated any revenue from prescription
product sales and this area of our business may never be profitable.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to generate
significant revenue from prescription products and achieve profitability depends on our ability to, alone or with strategic collaboration
partners, successfully complete the development of and obtain the regulatory approvals for our prescription product candidates, to manufacture
sufficient supply of our product candidates, to establish a sales and marketing organization or suitable third-party alternative for
the marketing of any approved products and to successfully commercialize any approved products on commercially reasonable terms. All
of these activities will require us to raise sufficient funds to finance business activities. Currently, we do not expect any milestone
payments from our collaborative partners to be significant in the foreseeable future. However, we are actively pursuing potential partner
collaboration. In addition, we do not anticipate generating revenue from commercializing product candidates for the foreseeable future,
if ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to generate
future revenues from commercializing our intellectual property (&#8220;IP&#8221;) assets depends heavily on our success in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing proof of concept
    in preclinical studies and clinical trials for our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully completing
    clinical trials of our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory and
    marketing approvals for product candidates for which we complete clinical trials;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining, protecting
    and expanding our intellectual property portfolio, and avoiding infringing on intellectual property of third parties;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining
    successful licenses, collaborations and alliances with third parties;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing a sustainable,
    scalable, reproducible and transferable manufacturing process for our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining
    supply and manufacturing relationships with third parties that can provide products and services adequate, in amount and quality,
    to support clinical development and commercialization of our product candidates, if approved;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing
    any product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched
    independently, by establishing a sales, marketing and distribution infrastructure;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance
    of any product candidates that receive regulatory approval as viable treatment options;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining favorable coverage
    and reimbursement rates for our products from third-party payors;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing any competing
    technological and market developments;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and validating
    new product candidates; and</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms
    in any collaboration, licensing or other arrangements into which we may enter.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The process of developing
product candidates for the prevention and treatment of gut mediated pathogens contains several inherent risks and uncertainties, including
clinical and regulatory risks.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if one or more of our
product candidates is approved for commercial sale, we may incur significant costs associated with commercializing any approved product
candidate. As one example, our expenses could increase beyond expectations if we are required by the Food and Drug Administration, or
FDA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently
anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need
to obtain additional funding to continue operations, which could have an adverse effect on our business, financial condition, results
of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are a commercial and development stage company
and our success is uncertain.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial and clinical-stage
biopharmaceutical company and our pharmaceutical products are designed to treat a range of infectious diseases. Other than our Travelan
and Protectyn products, we have not sufficiently advanced the development of any of our products, including our current lead product candidate,
IMM-124E, to market or generate revenues from their commercial application. Our current or any future product candidates, if successfully
developed, may not generate sufficient or sustainable revenues to enable us to be profitable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We receive Australian government research
and development income tax concession refunds. If our research and development expenditures are not deemed eligible for the refund, we
may encounter difficulties in the funding of future research and development projects, which could harm our operating results.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have historically received,
and expect to continue to receive, refunds from the Australian Federal Government&#8217;s Research and Development Tax Incentive program,
under which the government provides a cash refund for the 43.5% of eligible research and development expenditures by small to medium
size Australian entities during the year ended June 30, 2021, which are defined as Australian entities with less than A$20 million in
revenue, having a tax loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Research and Development
Tax Incentive refunds are made by the Australian federal government for eligible research and development purposes based on the filing
of an annual application and subsequent income tax returns for the fiscal year. We recognized Research and Development Tax Concession
Incentive refunds in the fiscal years ended June 30, 2020, June 30, 2019, June 30, 2018 and June 30, 2017 of A$308,225, A$531,005, A$1,849,123
and A$1,575,315, respectively, and we have recognized A$306,154 for the fiscal year ended June 30, 2021, that includes an estimate of
the receipt for the claim yet to be filed.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These refunds are available
to fund our ongoing activities including our research and development activities in Australia, as well as activities in the U.S. to the
extent such overseas-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities
and are approved by the Australian government. To the extent our research and development expenditures are deemed to be &#8220;ineligible,&#8221;
then our refunds would decrease. In addition, the Australian government may in the future modify the requirements of or reduce the amounts
or percentage claimable in turn reducing the refunds available under the Research and Development Tax Incentive program, or discontinue
the incentive program entirely. Any such change in the Research and Development Tax Incentive program would have a negative effect on
our future cash flows and our potential associated future expenditures.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A variety of general risk factors associated
with commercializing our products and product candidates internationally could materially adversely affect our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We, or our licensing
partners, may seek regulatory approval for our products or product candidates in multi- jurisdictions, accordingly, we expect that we
will be subject to additional risks for our products and product candidates related to operating in foreign countries if we obtain the
necessary approvals, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>differing regulatory requirements in foreign countries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>economic weakness, including inflation, or political instability in particular foreign economies and markets;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>compliance with tax, employment, immigration and labour laws for employees living or traveling abroad;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>foreign taxes, including withholding of payroll taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 0">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues,
and other obligations incident to doing business in another country;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>difficulties staffing and managing foreign operations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>workforce uncertainty in countries where labour unrest is more common than in the U.S.;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 0">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries
that do not respect and protect intellectual property rights to the same extent as in the EU or the U.S.;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 0">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>business interruptions resulting from geo-political actions, including war and terrorism.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These and
other risks associated with our or our licensing partners&#8217; international operations may materially adversely affect our ability
to attain or maintain profitable operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are faced with uncertainties related to
our research.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research programs are
based on scientific hypotheses and experimental approaches that may not lead to desired results. In addition, the timeframe for obtaining
proof of principle and other results may be considerably longer than originally anticipated, or may not be possible given time, resource,
financial, strategic and collaborator scientific constraints. Success in one stage of testing is not necessarily an indication that the
particular program will succeed in later stages of testing and development. It is not possible to predict whether any of the drugs designed
for these programs will prove to be safe, effective, and suitable for human use. Each drug will require additional research and development,
scale-up, formulation and extensive clinical testing in humans. Unsatisfactory results obtained from a particular study relating to a
program may cause us to abandon our commitment to that program or to the lead compound or product candidate being tested. The discovery
of toxicities, lack of sufficient efficacy, unacceptable pharmacology, inability to increase scale of manufacture, market attractiveness,
regulatory hurdles, competition, as well as other factors, may make our targets, lead therapies or product candidates unattractive for
further development or unsuitable for human use, and we may abandon our commitment to that program, target, lead therapy or product candidate.
Any delay in obtaining or failure to obtain required approvals could materially and adversely affect our ability to generate revenue
from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the
price of the ADS. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which
we may market the product. These limitations may limit the size of the market for the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical trials are expensive and time consuming,
and their outcome is uncertain.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to obtain approvals
to market a new drug product, we or our potential partners must demonstrate proof of safety and efficacy in humans. To meet these requirements,
we or our potential partners will have to conduct extensive preclinical testing and &#8220;adequate and well- controlled&#8221; clinical
trials. Conducting clinical trials is a lengthy, time-consuming and expensive process. The length of time may vary substantially according
to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per trial. Even if
we obtain positive results from preclinical or initial clinical trials, we may not achieve the same success in future trials. Clinical
trials may not demonstrate statistically sufficient safety and effectiveness to obtain the requisite regulatory approvals for product
candidates employing our technology. The failure of clinical trials to demonstrate safety and efficacy for a particular desired indication
could harm development of that product candidate for other indications as well as other product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to commence new
clinical trials from time to time in the course of our business as our product development work continues. Any change in, or termination
of, our clinical trials could materially harm our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We rely on third parties to conduct our preclinical
studies and clinical trials. If these third parties do not meet our deadlines or otherwise conduct the studies as required, we may be
delayed in progressing, or ultimately may not be able to progress, product candidates to clinical trials, our clinical development programs
could be delayed or unsuccessful, and we may not be able to commercialize or obtain regulatory approval for our product candidates when
expected, or at all.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have the ability
to conduct all aspects of our preclinical testing or clinical trials ourselves. We are dependent on third parties to conduct the clinical
trials for IMM-124E and IMM-529, and preclinical studies for our other product candidates, and therefore the timing of the initiation
and completion of these trials and studies is reliant on third parties and may occur at times substantially different from our estimates
or expectations.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we cannot contract with
acceptable third parties on commercially reasonable terms, or if these third parties do not carry out their contractual duties, satisfy
legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical
development programs could be delayed or discontinued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may experience delays in one or any of
our clinical trial programs that could have an adverse effect on our business and operations, and future commercialization opportunities
of our clinical pipeline.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent we do our
best to plan and mitigate against known risk aspects of our clinical trial programs, we do not know with any certainty whether the planned
clinical trials will begin on time, whether we will complete any of our clinical trials on schedule, or at all, or within the forecasted
budget. Our ability to commence and complete clinical trials may be delayed by many factors, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government or regulatory
    delays, including delays in obtaining approvals from applicable hospital ethics committees and internal review boards;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower than expected patient
    enrollment;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to manufacture
    sufficient quantities of our new proprietary compound or our other product candidates or matching controls;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues;
    or</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of efficacy or unacceptable
    toxicity during the clinical trials or non-clinical studies.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patient enrollment is a
function of, among other things, the nature of the clinical trial protocol, the existence of competing protocols, the size and longevity
of the target patient population, and the availability of patients who comply with the eligibility criteria for the clinical trial. Delays
in planned patient enrollment may result in increased costs, delays or termination of the clinical trials. Moreover, we rely on third
parties such as clinical research organizations to assist us in clinical trial management functions including clinical trial database
management, statistical analyses, site management and monitoring. Any failure by these third parties to perform under their agreements
with us may cause the trials to be delayed or result in a failure to complete the trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we experience delays
in testing, in gaining the receipt of necessary approvals, or if we need to perform more, larger or more complex clinical trials than
planned, our product development costs may increase. Significant delays could adversely affect the commercial prospects of our product
candidates and our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be successful in obtaining or maintaining
other rights necessary for the development of our pipeline through acquisitions and in-licenses.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our product candidates may
require specific formulations to work effectively, and efficiently, and rights to such formulations may be held by others. We may be
unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third
parties that we identify on terms that we find acceptable, or at all. The licensing and acquisition of third-party intellectual property
rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party
intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due
to their size, cash resources and greater clinical development and commercialization capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, we sometimes
collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements
with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s
rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may
be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so,
the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, companies that
perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party
intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully
obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could
suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We rely on research institutions to conduct
our clinical trials and we may not be able to secure and maintain research institutions to conduct our future trials.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our reliance upon research
institutions, including public and private hospitals and clinics, provides us with less control over the timing and cost of clinical
trials, clinical study management personnel and the ability to recruit subjects. If we are unable to reach agreements with suitable research
institutions on acceptable terms, or if any resulting agreement is terminated, we may be unable to secure, maintain, or quickly replace
the research institution with another qualified institution on acceptable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We grant licenses to our collaborators to
use our hyper-immune colostrum technology exclusively for the development of product candidates for certain conditions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may out-license to our
collaborators the right to use our hyper-immune colostrum technology for the development of product candidates for certain conditions,
so long as our collaborators comply with certain requirements. That means that once our technology is licensed to a collaborator for
a specified condition, we are generally prohibited from developing product candidates for that condition and from licensing to any third
party for that condition. The limitations imposed by these exclusive licenses could prevent us from expanding our business and increasing
our development of product candidates with new collaborators, both of which could adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be able to complete the development
of IMM-124E, IMM-529 or develop other pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may not be able to progress
with the development of our current, or any future, pharmaceutical product candidates to a stage that will attract a suitable collaborative
partner for the development of any current or future pharmaceutical product candidates. The projects initially specified in connection
with any such collaboration and any associated funding may change or be discontinued as a result of changing interests of either the
collaborator or us, and any such change may change the budget for the projects under the collaboration. Additionally, our research may
not lead to the discovery of additional product candidates, and any of our current and future product candidates may not be successfully
developed, prove to be safe and efficacious in clinical trials, meet applicable regulatory standards and receive regulatory approval,
be capable of being produced in commercial quantities at reasonable costs, or be successfully or profitably marketed, either by us or
a collaborative partner. The products we develop may not be able to penetrate the potential market for a particular therapy, or indication,
or gain market acceptance among health care providers, patients and third-party payers. We cannot predict if or when the development
of IMM-124E, IMM-529 or any future pharmaceutical product will be completed or commercialized, whether funded by us, as part of a collaboration
or through a grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may need to prioritize the development
of our most promising candidates at the expense of the development of other products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may need to prioritize
the allocation of development resources and/or funds towards what we believe to be our most promising product or products. The nature
of the drug development process is such that there is a constant availability of new information and data that could positively or adversely
affect any of our products in development. We cannot predict how such new information and data may impact in the future the prioritization
of the development of our current or future product candidates or that any of our products, regardless of its development stage or the
investment of time and funds in its development, will continue to be funded or developed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our research and development efforts will
be seriously jeopardized if we are unable to retain key personnel and cultivate key academic and scientific collaborations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our future success depends
to a large extent on the continued services of our senior management and key scientific personnel, including Dr. Jerry Kanellos who is
currently our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Competition among biotechnology
and pharmaceutical companies for qualified employees is intense, including competition from larger companies with greater resources,
and we may not be able to continue to attract and retain qualified management, technical and scientific personnel critical to our success.
Our success is highly dependent on our ability to develop and maintain important relationships with leading academic institutions and
scientists who conduct research at our request or assist us in formulating our research and development strategies. These academic and
scientific collaborators are not our employees and may have commitments to, or consulting or advisory contracts with, other entities
that may limit their availability to us. In addition, these collaborators may have arrangements with other companies to assist such companies
in developing technologies that may prove competitive to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we are unable to successfully keep pace
with technological change or with the advances of our competitors, our technology and products may become obsolete or non-competitive.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The biotechnology and pharmaceutical
industries are subject to rapid and significant technological change. Our competitors are numerous and include major pharmaceutical companies,
biotechnology firms, universities and other research institutions. These competitors may develop technologies and products that are more
effective than any that we are developing, or which would render our technology and products obsolete or non-competitive. Many of these
competitors have greater financial and technical resources and manufacturing and marketing capabilities than we do. In addition, many
of our competitors have much more experience than we do in pre-clinical testing and human clinical trials of new or improved drugs, as
well as in obtaining regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We know that competitors
are developing or manufacturing various technologies or products for the treatment of diseases that we have targeted for product development.
Some of these competitive products use therapeutic approaches that compete directly with our product candidates. Our ability to further
develop our products may be adversely affected if any of our competitors were to succeed in obtaining regulatory approval for their competitive
products sooner than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Acceptance of our products in the marketplace
is uncertain, and failure to achieve market acceptance will negatively impact our business and operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current or future products
may not achieve market acceptance even if they are approved by regulatory authorities. The degree of market acceptance of such products
will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt and timing
    of regulatory approvals for the uses that we are studying;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment and demonstration
    to the medical community of the safety, clinical efficacy or cost-effectiveness of our product candidates and their potential advantages
    over existing therapeutics and technologies; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement
    policies of governments and third-party payors.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Physicians, patients, third-party payors or
others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale
or licensing of our product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain approval
for a product candidate, we may not generate or sustain revenue from sales of the product if the product cannot be sold at a competitive
cost or if it fails to achieve market acceptance by physicians, patients, third-party payors or others in the medical community. These
market participants may be hesitant to adopt a novel treatment based on hyper-immune colostrum technology, and we may not be able to
convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates
developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and efficacy
    of our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to offer our
    products for sale at competitive prices;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative convenience
    and ease of administration of our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity
    of any adverse side effects associated with our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any approvals
    and the countries in which approvals are obtained;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings
    contained in any labeling approved by the FDA or comparable foreign regulatory authorities;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions upon the approval
    imposed by FDA or comparable foreign regulatory authorities, including, but not limited to, a Risk Evaluation and Mitigation Strategy
    (&#8220;REMS&#8221;);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients
    to try new treatments and of physicians to prescribe these treatments;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of government
    and other third-party payor coverage and adequate reimbursement; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of alternative
    effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and
    costs of those treatments.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additional risks apply in relation to any disease indications we pursue
which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as
the U.S. or European Union. If pricing is not approved or accepted in the market at an appropriate level for any approved product for
which we pursue and receive an orphan drug designation, such product may not generate enough revenue to offset costs of development, manufacturing,
marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, for a period
of time. Orphan exclusivity could temporarily delay or block approval of one of our products if a competitor obtains orphan drug designation
for its product first. However, even if we obtain orphan exclusivity for one of our products upon approval, our exclusivity may not block
the subsequent approval of a competitive product that is shown to be clinically superior to our product.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Market size is also a variable
in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different
from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes
in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We face competition from entities that have
developed or may develop product candidates for our target disease indications, including companies developing novel treatments and technology
platforms based on modalities and technology similar to ours. If these companies develop technologies or product candidates more rapidly
than we do or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize
product candidates may be compromised.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The development and commercialization
of pharmaceutical products is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized
biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have
developed, are developing or could develop product candidates and processes competitive with our product candidates. Competitive therapeutic
treatments include those that have already been approved and accepted by the medical community, patients and third-party payors, and
any new treatments that enter the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that a significant
number of products are currently under development, and may become commercially available in the future, for the treatment of conditions
for which we are developing, and may in the future try to develop, product candidates. We are aware of multiple companies that are working
in the field of infectious diseases, travelers&#8217; diarrhea and C. <i>difficile </i>therapeutics, including Cosmo Technologies, PanTheryx,
Proctor and Gamble, and Scandinavian BioPharma which are all developing therapeutics for travelers&#8217; diarrhea and, Acetelion, Assembly
Biotechnology, Creston Pharma, Da Volterra, Seres, Synthetic Biotechnology and Rebiotix Inc. for C. <i>difficile</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have limited large scale manufacturing
experience with our product candidates. Delays in manufacturing sufficient quantities of such materials to the required standards for
pre-clinical and clinical trials may negatively impact our business and operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While we have extensive
experience in producing therapeutic colostrum, we may not be able to manufacture sufficient quantities of our product candidates in a
cost-effective or timely manner. Manufacturing includes the production, formulation and stability testing of an active pharmaceutical
ingredient and its formulation into pharmaceutical products, such as capsules or tablets. Any delays in production would delay our pre-clinical
and human clinical trials, which could adversely affect our business, financial condition and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be required to enter
into contracting arrangements with third parties to manufacture our product candidates for large-scale, pre-clinical and/or clinical
trials. We may not be able to make the transition from laboratory-scale to development-scale or from development-scale to commercial
production. We may need to develop additional manufacturing resources, enter into collaborative arrangements with other parties who have
established manufacturing capabilities, or have third parties manufacture our products on a contract basis. We may not have access on
acceptable terms to the necessary and substantial financing that would be required to scale-up production and develop effective commercial
manufacturing processes and technologies. We may not be able to enter into collaborative or contracting arrangements on acceptable terms
with parties that will meet our requirements for quality, quantity and timeliness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are not able to obtain
an acceptable purity for any product candidate or an acceptable product specification, pre-clinical and clinical trials would be delayed,
which could adversely affect the priority of the development of our product candidates, our business, financial condition and results
of operations. This may adversely impact the cost of goods or feasibility of market scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our product candidates and the process for
administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory
approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing
approval.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Treatment with our product
candidates may produce undesirable side effects or adverse reactions or events. If any such adverse events occur, our clinical trials
could be suspended or discontinued, and the FDA or comparable foreign regulatory authorities could order us to cease further development
or deny approval of our product candidates for any or all targeted indications. The product-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the trial. If we elect or are required to delay, suspend or discontinue any
clinical trial of any of our product candidates, the commercial prospects of such product candidates will be harmed and our ability to
generate product revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business,
financial condition and prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We currently depend upon a sole manufacturer
of our lead compound and on a sole manufacturer to produce finished drug products and could incur significant costs and delays if we
are unable to promptly find a replacement for either of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At this time, we are relying
on a single manufacturer to develop Good Manufacturing Practice (&#8220;GMP&#8221;), processes for our lead compound. Our lead compound,
IMM-124E, is manufactured by Synlait Milk Limited based in New Zealand. This manufacturer enables efficient large-scale manufacture of
colostrum to provide drug substance for our current and prospective clinical trials. We also rely on contract manufacturers such as Mayne
Pharma International and Australian Blister Sealing to produce all of our marketed products and PCI Clinical Services to package our
investigational drug products. We are actively seeking additional and back-up manufacturers but may be unsuccessful in our efforts or
may incur material additional costs and substantial delays.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The failure to establish sales, marketing
and distribution capability would materially impair our ability to successfully market and sell our pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have limited
experience in the marketing, sales or distribution of pharmaceutical products. If we develop any commercially marketable pharmaceutical
products and decide to perform our own sales and marketing activities, we will require additional resources and, will need to hire sales
and marketing personnel which will require additional capital. Qualified personnel may not be available in adequate numbers or at a reasonable
cost. Furthermore, our sales staff may not achieve success in their marketing efforts. Alternatively, we may be required to enter into
marketing arrangements with other parties who have established appropriate marketing, sales and distribution capabilities. We may not
be able to enter into marketing arrangements with any marketing partner, or if such arrangements are established, our marketing partners
may not be able to commercialize our products successfully. Other companies offering similar or substitute products may have well-established
and well-funded marketing and sales operations in place that will allow them to market their products more effectively. Failure to establish
sufficient marketing capabilities would materially impair our ability to successfully market and sell our pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If healthcare insurers and other organizations
do not pay for our products, or impose limits on reimbursement, our future business may suffer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The drugs we hope to develop
may be rejected by the marketplace due to many factors, including cost. The continuing efforts of governments, insurance companies, health
maintenance organizations and other payors of healthcare costs to contain or reduce healthcare costs may affect our future revenues and
profitability and those of our potential customers, suppliers and collaborative partners, as well as the availability of capital. In
Australia and certain foreign markets, the pricing or profitability of prescription pharmaceuticals is already subject to government
control. We expect initiatives for similar government control at both the state and federal level to continue in the U.S. and elsewhere.
The adoption of any such legislative or regulatory proposals could adversely affect our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to commercially
exploit our products successfully will depend in part on the extent to which reimbursement for the cost of our products and related treatment
will be available from government health administration authorities, private health coverage insurers and other organizations. Third-party
payors, such as government and private health insurers, are increasingly challenging the price of medical products and services. Uncertainty
exists as to the reimbursement status of newly approved health care products and in foreign markets, including the U.S. If third-party
coverage is not available to patients for any of the products we develop, alone or with collaborators, the market acceptance of these
products may be reduced, which may adversely affect our future revenues and profitability. In addition, cost containment legislation
and reductions in government insurance programs may result in lower prices for our products and could materially adversely affect our
ability to operate profitably.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be exposed to product liability claims,
which could harm our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The testing, marketing,
and sale of human health care products also entail the inherent risk of product liability. We may incur substantial liabilities or be
required to limit development or commercialization of our products if we cannot successfully defend ourselves against product liability
claims. We have historically obtained no fault compensation insurance for our clinical trials and will continue to obtain similar coverage
for all future clinical trials. Such coverage may not be available in the future on acceptable terms, or at all. This may result in our
inability to pursue further clinical trials or to obtain adequate protection in the event of a successful claim. We may not be able to
obtain product liability insurance in the event of the commercialization of a product or such insurance may not be available on commercially
reasonable terms. Even if we have adequate insurance coverage, product liability claims, or recalls could result in negative publicity
or force us to devote significant time, attention and financial resources to those matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Breaches of network or information technology
security, natural disasters or terrorist attacks could have an adverse effect on our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cyber-attacks or other breaches
of network or information technology (&#8220;IT&#8221;) security, natural disasters, terrorist acts or acts of war may cause equipment
failures or disrupt our research and development operations. In particular, both unsuccessful and successful cyber-attacks on companies
have increased in frequency, scope and potential harm in recent years. Such an event may result in our inability, or the inability of
our partners, to operate the research and development facilities, which even if the event is for a limited period of time, may result
in significant expenses and/or significant damage to our experiments and trials. In addition, a failure to protect employee confidential
data against breaches of network or IT security could result in damage to our reputation. Any of these occurrences could adversely affect
our results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We expect to expand our drug development,
regulatory and business development capabilities, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to experience
significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of drug
development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement and
improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated
growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability
to manage growth could delay the execution of our business plans or disrupt our operations and have a materially adverse effect on our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Positive results from preclinical studies
of our product candidates are not necessarily predictive of future results of planned clinical trials of our product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Positive results in preclinical
proof-of-concept and animal studies of our product candidates may not result in positive results in clinical trials in humans. Many companies
in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results
in preclinical development or early stage clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks
have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations
made in clinical trials, including adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations
and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical
trials nonetheless failed to obtain FDA or other regulatory authority approval. If we fail to produce positive results in our clinical
trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates,
and, correspondingly, our business and financial prospects, would be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our future prospects may also be dependent
on our or our collaborators&#8217; ability to successfully develop a pipeline of additional product candidates, and we and our collaborators
may not be successful in efforts to use our platform technologies to identify or discover additional product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The success of our business
depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. We only have three
product candidates currently in clinical development and several in early stage research and preclinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our other product candidates
derived from our platform technology may not successfully complete IND-enabling studies, and our research programs may fail to identify
other potential product candidates for clinical development for a number of reasons. Our and our collaborators&#8217; research methodology
may be unsuccessful in identifying potential product candidates, our potential product candidates may not demonstrate the necessary preclinical
outcomes to progress to clinical studies, or our product candidates may be shown to have harmful side effects or may have other characteristics
that may make the products unmarketable or unlikely to receive marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these events occur,
we may be forced to discontinue our development efforts for a program or programs. Research programs to identify new product candidates
require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product
candidates that ultimately prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be able to obtain orphan drug exclusivity
for some of our product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Of our current product candidates,
the only one designed for treatment of an indication that would likely qualify for rare disease status is IMM-529 for the treatment of
recurrent C. <i>difficile</i>. Regulatory authorities in some jurisdictions, including the U.S. and the European Union, may designate
drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient
population of fewer than 200,000 individuals annually in the U.S. The FDA may also designate a product as an orphan drug if it is intended
to treat a disease or condition of more than 200,000 individuals in the U.S. and there is no reasonable expectation that the cost of
developing and making a drug or biological product available in the U.S. for this type of disease or condition will be recovered from
sales of the product candidate. Under the European Union orphan drug legislation, a rare disease or condition means a disease or condition
which affects not more than five in ten thousand persons in the European Union at the time of the orphan drug designation application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, if a product
with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation,
the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for
the same drug for that time period. During the marketing exclusivity period, in the European Union, the European Medicines Agency, or
the EMA, is precluded from approving a similar drug with an identical therapeutic indication. The applicable period is seven years in
the U.S. and ten years in the European Union. The European Union exclusivity period can be reduced to six years if a drug no longer meets
the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.
Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain orphan
drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can
be approved for the same condition, and the same drug could be approved for a different condition. Even after an orphan drug is approved,
the FDA can subsequently approve the same drug, made by a competitor, for the same condition if the FDA concludes that the competitive
product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the
European Union, the EMA can approve a competitive product if the orphan drug no longer meets the criteria for orphan designation (including
sufficient profitability), if the competitive product is safer, more effective or otherwise clinically superior, or if the orphan drug
cannot be supplied in sufficient quantities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have not entered into agreements with any
third-party manufacturers to support commercialization of our pharmaceutical product candidates. Additionally, no manufacturers have
experience producing our product candidates at commercial levels, and any manufacturer that we work with may not achieve the necessary
regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to support commercialization.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not yet secured
manufacturing capabilities for commercial quantities of our product candidates or established facilities in the desired locations to
support commercialization of our product candidates. We intend to rely on third-party manufacturers for commercialization, and currently
we have only entered into agreements with such manufacturers to support our clinical trials for IMM-124E. We may be unable to negotiate
agreements with third-party manufacturers to support our commercialization activities on commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may encounter technical
or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds.
Currently, we do not have the capacity to manufacture our product candidates on a commercial scale. In addition, our product candidates
are novel, and no manufacturer currently has experience producing our product candidates on a large scale. If we are unable to engage
manufacturing partners to produce our product candidates on a larger scale on reasonable terms, our commercialization efforts will be
harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we timely develop
a manufacturing process and successfully transfer it to the third-party manufacturers of our product candidates, if such third-party
manufacturers are unable to produce the necessary quantities of our product candidates, or do so in compliance with Current Good Manufacturing
Practice (&#8220;cGMP&#8221;) or with pertinent foreign regulatory requirements, and within our planned time frame and cost parameters,
the development and sales of our product candidates, if approved, may be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we do not obtain the necessary governmental
approvals, we will be unable to commercialize our pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ongoing research and
development activities are, and the production and marketing of our pharmaceutical product candidates derived from such activities will
be, subject to regulation by numerous international regulatory authorities. Prior to marketing, any therapeutic product developed must
undergo rigorous pre-clinical testing and clinical trials and, to the extent that any of our pharmaceutical products under development
are marketed abroad, by the relevant international regulatory authorities. For example, in Australia, principally the Therapeutics Goods
Administration (&#8220;TGA&#8221;), the FDA in the U.S.; the Medicines and Healthcare products Regulatory Agency, (&#8220;MHRA&#8221;)
in the United Kingdom; the Medical Products Agency (&#8220;MPA&#8221;) in Sweden; and the EMA in Europe. These regulatory processes can
take many years and require the expenditure of substantial resources. Governmental authorities may not grant regulatory approval due
to matters arising from pre-clinical animal toxicology, safety pharmacology, drug formulation and purity, clinical side effects or patient
risk profiles, or medical contraindications. Failure or delay in obtaining regulatory approvals would adversely affect the development
and commercialization of our pharmaceutical product candidates. We may not be able to obtain the clearances and approvals necessary for
clinical testing or for manufacturing and marketing our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We will not be able to commercialize any current
or future product candidates if we fail to adequately demonstrate their safety, efficacy and superiority over existing therapies.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before obtaining regulatory
approvals for the commercial sale of any of our pharmaceutical products, we must demonstrate through pre-clinical testing and clinical
studies that our product candidates are safe and effective for use in humans for each target indication. Results from early clinical
trials may not be predictive of results obtained in large-scale, later-stage clinical testing. Even though a potential drug product shows
promising results in clinical trials, regulatory authorities may not grant the necessary approvals without sufficient safety and efficacy
data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may not be able to undertake
further clinical trials of our current and future product candidates as therapies for infectious diseases, C. <i>difficile </i>or other
indications or to demonstrate the safety and efficacy or superiority of any of these product candidates over existing therapies or other
therapies under development, or enter into any collaborative arrangement to commercialize our current or future product candidates on
terms acceptable to us, or at all. Clinical trial results that show insufficient safety and efficacy could adversely affect our business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Even if we obtain regulatory approval for
a product candidate, our products may remain subject to regulatory scrutiny.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain regulatory
approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of
our product candidates or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example,
the holder of an approved biologics license application (&#8220;BLA&#8221;) is obligated to monitor and report to the FDA adverse events
and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Advertising and promotional
materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable foreign, federal and
state laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue a warning letter
    asserting that we are in violation of the law;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek an injunction or impose
    civil or criminal penalties or monetary fines;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory
    approval;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any ongoing clinical
    trials;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to permit government
    reimbursement of our product by government-sponsored third-party payors;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve a pending
    BLA or supplements to a BLA submitted by us for other indications or new product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize our product; or</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to allow us to enter
    into or continue supply contracts, including government contracts.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Healthcare reform measures and other statutory
or regulatory changes could adversely affect our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In both the United States
and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in
ways that could impact our business. For example, the Patient Protection and Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), enacted in March 2010, substantially changed the way healthcare is
financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. With regard to pharmaceutical
products, among other things, the ACA is expected to expand and increase industry rebates for drugs covered under Medicaid programs and
make changes to the coverage requirements under the Medicare D program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
our reporting and payment obligations under the Medicaid program or other governmental pricing programs, we could be subject to additional
reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition,
results of operations and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we obtain FDA approval
for any of our product candidates and begin commercializing those products in the United States, our operations may be directly or indirectly
through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback
Statute, the federal False Claims Act, and physician sunshine laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The pharmaceutical and biotechnology
industries are subject to extensive regulation, and from time to time legislative bodies and governmental agencies consider changes to
such regulations that could have significant impact on industry participants. For example, in light of certain highly-publicized safety
issues regarding certain drugs that had received marketing approval, the U.S. Congress has considered various proposals regarding drug
safety, including some which would require additional safety studies and monitoring and could make drug development costlier. Additional
legislation or regulation, if any, relating to the implementation of cost containment measures or other aspects of drug development may
prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse
effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval
and may affect our overall financial condition and ability to develop product candidates. In addition, it is possible that there will
be further legislation or regulation that could harm our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our product candidates are based on our hyper-immune
colostrum technology. Currently, no prescription product candidates utilizing our technology have been approved for commercial sale and
our approach to the development of our technology may not result in safe, effective or marketable products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have concentrated our
product research and development efforts on our hyper-immune colostrum technology, and our future success depends on successful clinical
development of this technology. We plan to develop a pipeline of product candidates using our technology and deliver therapeutics for
a number of infectious and life-threatening conditions, including moderate to severe campylobacteriosis, C. <i>difficile </i>Infections
(&#8220;CDI&#8221;), Shigellosis (bacillary dysentery) and Traveler&#8217;s Diarrhea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The scientific research
that forms the basis of our efforts to develop product candidates is based on the pre-clinical and clinical data in conditions such as
CDI, Shigellosis (bacillary dysentery) and Traveler&#8217;s Diarrhea, and the identification, optimization and delivery of hyper-immune
colostrum- based product candidates is relatively new. The scientific evidence to support the feasibility of successfully developing
therapeutic treatments based on our technology is preliminary and limited. There can be no assurance that any development and technical
problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can
be solved. We may be unable to reach an agreement on favorable terms, or at all, with providers of vectors needed to optimize delivery
of our product candidates to target disease cells and we may also experience unanticipated problems or delays in expanding our manufacturing
capacity or transferring our manufacturing process to commercial partners, any of which may prevent us from completing our clinical trials
or commercializing our products on a timely or profitable basis, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Only a few product candidates
based on our technology have been tested in either animals or humans. We may discover that the applications of our pharmaceutical drug
candidates do not possess properties required for a therapeutic benefit. In addition, application of hyper-immune- based products in
humans may result in safety problems. We currently have only limited long-term data, and no conclusive evidence, to suggest that we can
effectively produce efficacious therapeutic treatments using our hyper-immune colostrum technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are early in our product development efforts
and have only two product candidates in early-stage clinical trials. All of our other current product candidates are still in preclinical
development. We have no late-stage clinical trials (post-proof of concept) and may not be able to obtain regulatory approvals for the
commercialization of some or all of our product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The research, testing, manufacturing,
labeling, approval, selling, marketing and distribution of biologics is subject to extensive regulation by the FDA and other regulatory
authorities, and these regulations differ from country to country. We do not have any prescription products on the market and are early
in our development efforts. We have two product candidates in clinical trials and all of our other product candidates are in preclinical
development. All of our current and future product candidates are subject to the risks of failure typical for development of biologics.
The development and approval process is expensive and can take many years to complete, and its outcome is inherently uncertain. In addition,
the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not submitted an
application, or received marketing approval, for any of our product candidates and will not submit any applications for marketing approval
for several years. We have limited experience in conducting and managing clinical trials necessary to obtain regulatory approvals for
prescription product candidates. To receive approval, we must, among other things, demonstrate with evidence from clinical trials that
the product candidate is both safe and effective for each indication for which approval is sought, and failure can occur in any stage
of development. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary
substantially, based on the type, complexity and novelty of the pharmaceutical product. We cannot predict if or when we might receive
regulatory approvals for any of our product candidates currently under development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and foreign regulatory
authorities also have substantial discretion in the pharmaceutical and biological product approval process. The numbers, types and sizes
of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the
disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate.
Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate&#8217;s clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from
preclinical studies or clinical trials, any of which may cause delays or limitations in the approval or the decision not to approve an
application. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign
    regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate
    to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its
    proposed indication;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical
    trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory authorities
    for approval;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patients recruited
    for a particular clinical program may not be sufficiently broad or representative to assure safety in the full population for which
    we seek approval;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical
    trials may not confirm the positive results from earlier preclinical studies or clinical trials;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate
    that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign
    regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from
    clinical trials of our product candidates may not be sufficient to the satisfaction of FDA or comparable foreign regulatory authorities
    to support the submission of a biologics license application, or BLA, or other comparable submission in foreign jurisdictions or
    to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign
    regulatory authorities may only agree to approve a product candidate under conditions that are so restrictive that the product is
    not commercially viable;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory agencies might
    not approve or might require changes to our manufacturing processes or facilities; or</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory agencies may
    change their approval policies or adopt new regulations in a manner rendering our clinical data insufficient for approval.</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any delay in obtaining or
failure to obtain required approvals could materially and adversely affect our ability to generate revenue from the particular product
candidate, which likely would result in significant harm to our financial position and adversely impact the price of the ADSs. Furthermore,
any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product.
These limitations may limit the size of the market for the product.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not permitted to
market our product candidates in the U.S. or in other countries until we receive approval of a BLA from the FDA or marketing approval
from applicable regulatory authorities outside the U.S. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process.
If we fail to obtain FDA approval to market our product candidates, we will be unable to sell our product candidates in the U.S., which
will significantly impair our ability to generate any revenues. In addition, failure to comply with FDA and non-U.S. regulatory requirements
may, either before or after product approval, if any, subject us to administrative or judicially imposed sanctions, including:</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on our ability
    to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the products,
    manufacturers or manufacturing process;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil and criminal penalties;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of regulatory approvals;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizures, detentions
    or import bans;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary or mandatory
    product recalls and publicity requirements;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial suspension
    of production;</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of restrictions
    on operations, including costly new manufacturing requirements; and</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    BLAs or supplements to approved BLAs.</span></td></tr>
</table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>



</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we do receive regulatory
approval to market a product candidate, any such approval may be subject to limitations on the indicated uses for which we may market
the product. It is possible that none of our existing product candidates or any product candidates we may seek to develop in the future
will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any delay in obtaining,
or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates, generating revenues
and achieving and sustaining profitability.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If our ability to use cumulative carry forward
net operating losses is or becomes subject to certain limitations, our results of operations and financial condition may be adversely
affected.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an Australian company
subject to taxation in Australia and other jurisdictions. As of June 30, 2021, our cumulative operating losses have a total potential
tax benefit of A$11,486,431 at local tax rates (excluding other temporary differences). These losses may be available for use once we
are in a tax profitable position. These losses were incurred in different jurisdictions and can only be offset against profits earned
in the relevant jurisdictions. Tax losses are able to be carried forward at their nominal amount indefinitely in Australia and for losses
generated prior to January 1, 2018 for up to 20 years in the U.S. as long as certain conditions are met. In order to use these tax losses,
it is necessary to satisfy certain tests and, as a result, we cannot assure you that the tax losses will be available to offset profits
if and when we earn them. Utilization of our net operating loss and research and development credit carryforwards in the U.S. may be
subject to substantial annual limitation due to ownership change limitations that could occur in the future provided by Section 382 of
the Internal Revenue Code of 1986, as amended. Our carry forward net operating losses in the U.S. first start to expire in 2035.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We could be adversely affected by violations
of the U.S. Foreign Corrupt Practices Act.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business operations
may be subject to anti-corruption laws and regulations, including restrictions imposed by the U.S. Foreign Corrupt Practices Act the
FCPA. The FCPA and similar anti-corruption laws in other jurisdictions generally prohibit companies and their intermediaries from making
improper payments to government officials for the purpose of obtaining or retaining business. We cannot provide assurance that our internal
controls and procedures will always protect us from criminal acts committed by our employees or third parties with whom we work. If we
are found to be liable for violations of the FCPA or similar anti-corruption laws in international jurisdictions, either due to our own
acts or out of inadvertence, or due to the acts or inadvertence of others, we could suffer from criminal or civil penalties which could
have a material and adverse effect on our results of operations, financial condition and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our success depends upon our ability to protect
our intellectual property and our proprietary technology, to operate without infringing the proprietary rights of third parties and to
obtain marketing exclusivity for our products and technologies.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any future success will
depend in large part on whether we can:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain patents
    to protect our own products and technologies;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain orphan designation
    for our products and technologies;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain licenses to the
    patented technologies of third parties;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate without infringing
    on the proprietary rights of third parties; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect our trade secrets,
    know-how and other confidential information.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patent matters in biotechnology
are highly uncertain and involve complex legal and factual questions. Accordingly, the availability and breadth of claims allowed in
biotechnology and pharmaceutical patents cannot be predicted. Any of the pending or future patent applications filed by us or on our
behalf may not be approved, we may not develop additional proprietary products or processes that are patentable, or we may not be able
to license any other patentable products or processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our products may be eligible
for orphan designation for particular therapeutic indications that are of relatively low prevalence and for which there is no effective
treatment. Orphan drug designation affords market exclusivity post marketing authorization for a product for a specified therapeutic
utility. The period of orphan protection is dependent on jurisdiction, for example, seven years in the U.S. and ten years in Europe.
The opportunity to gain orphan drug designation depends on a variety of requirements specific to each marketing jurisdiction and can
include; a showing of improved benefit relative to marketed products, that the mechanism of action of the product would provide plausible
benefit and the nature of the unmet medical need within a therapeutic indication. It is uncertain if our products will be able to obtain
orphan drug designation for the appropriate indications and in the jurisdictions sought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success will
also depend, in part, on our ability to avoid infringement of patents issued to others. If a court determines that we were infringing
any third-party patents, we could be required to pay damages, alter our products or processes, obtain licenses or cease certain activities.
Licenses required under patents held by third parties may not be made available on terms acceptable to us, or at all. To the extent that
we are unable to obtain such licenses, we could be foreclosed from the development, export, manufacture or commercialization of the product
requiring such license or encounter delays in product introductions while we attempt to design around such patents, and any of these
circumstances could adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may have to resort to
litigation to enforce any patents issued or licensed to us or to determine the scope and validity of third-party proprietary rights.
We may have to defend the validity of our patents in order to protect or enforce our rights against a third party. Third parties may,
in the future, assert against us infringement claims or claims that we have infringed a patent, copyright, trademark or other proprietary
right belonging to them. Any infringement claim, even if not meritorious, could result in the expenditure of significant financial and
managerial resources and could negatively affect our profitability. While defending our patents, the scope of the claim may be reduced
in breadth and inventorship of the claimed subject matter, and proprietary interests in the claimed subject matter may be altered or
reduced. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their substantially greater financial resources. Any such litigation or proceedings, regardless of outcome, could be expensive and
time consuming, and adverse determinations in any such litigation or proceedings could prevent us from developing, manufacturing or commercializing
our products and could adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The patents for our product
candidates have varying expiration dates and, if these patents expire, we may be subject to increased competition and we may not be able
to recover our development costs or market any of our approved products profitably. In some of the larger potential market territories,
such as the U.S. and Europe, patent term extension or restoration may be available to compensate for time taken during aspects of the
product&#8217;s development and regulatory review or by procedural delays before the relevant patent office. However, such an extension
may not be granted, or if granted, the applicable time period or the scope of patent protection afforded during any extension period
may not be sufficient. In addition, even though some regulatory authorities may provide some other exclusivity for a product under their
own laws and regulations, we may not be able to qualify the product or obtain the exclusive time period. If we are unable to obtain patent
term extension/restoration or some other exclusivity, we could be subject to increased competition and our opportunity to establish or
maintain product revenue could be substantially reduced or eliminated. Furthermore, we may not have sufficient time to recover our development
costs prior to the expiration of our U.S. and non-U.S. patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may face difficulties in certain jurisdictions
in protecting our intellectual property rights, which may diminish the value of our intellectual property rights in those jurisdictions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The laws of some jurisdictions
do not protect intellectual property rights to the same extent as the laws in the U.S. and the European Union, and many companies have
encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our collaboration partners
encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important
for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others
in those jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many countries have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the
enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited
remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition
and results of operations may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual property rights do not address
all potential threats to our competitive advantage.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may be able to make
    products that are similar to ours but that are not covered by the claims of the patents that we own;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may independently
    develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property
    rights;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or any of our collaboration
    partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications
    that we own, license or will own or license;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or any of our collaboration
    partners might not have been the first to file patent applications covering certain of the patents or patent applications that we
    or they own or have obtained a license, or will own or will have obtained a license;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is possible that our
    pending patent applications will not lead to issued patents;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued patents that we
    own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our competitors might conduct
    research and development activities in countries where we do not have patent rights, or in countries where research and development
    safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our
    major commercial markets;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patents of third parties
    or pending or future applications of third parties, if issued, may have an adverse effect on our business; and/or</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compulsory licensing provisions
    of certain governments to patented technologies that are deemed necessary for the government to access.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in patent laws or patent jurisprudence
could diminish the value of patents in general, thereby impairing our ability to protect our products or product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As is the case with other
pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents
involves both technological complexity and legal complexity and is costly, time-consuming and inherently uncertain. In addition, the
America Invents Act was recently enacted in the U.S., resulting in significant changes to the U.S. patent system. The U.S. Supreme Court
has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending
on decisions by the U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office, or USPTO, the laws and regulations governing
patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent
years. In addition, the European patent system is relatively stringent with regard to the type of amendments that are allowed during
prosecution. These changes could limit our ability to obtain new patents in the future that may be important for our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Confidentiality agreements with employees
and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We consider proprietary
trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or
confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However,
trade secrets and/or confidential know-how can be difficult to maintain as confidential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To protect this type of
information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and
advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisers
may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide
an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third-party obtained
illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability
of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Failure to obtain or maintain
trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors
may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the
same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential
know-how.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The market price and trading volume of our
ADS may be volatile and may be affected by economic conditions beyond our control.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market price of our
ADS may be highly volatile and subject to wide fluctuations. In addition, the trading volume of the ADS may fluctuate and cause significant
price variations to occur. If the market price of the ADS declines significantly, you may be unable to resell your ADS at or above the
purchase price, if at all. We cannot assure you that the market price of the ADS will not fluctuate or significantly decline in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some specific factors that
could negatively affect the price of the ADS or result in fluctuations in their price and trading volume include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or expected fluctuations
    in our operating results;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in market valuations
    of similar companies;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our key personnel;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates
    or recommendations by securities analysts;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading prices of our ordinary
    shares on the Australian Securities Exchange (&#8220;ASX&#8221;);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in trading volume
    of ADS on The NASDAQ Capital Market, or NASDAQ, and of our ordinary shares on the ASX;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of the ADS or ordinary
    shares by us, our executive officers or our shareholders in the future; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions in the financial
    markets or changes in general economic conditions.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The dual listing of our ordinary shares and
the ADSs may adversely affect the liquidity and value of the ADS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares are
listed on the ASX. We cannot predict the effect of this dual listing on the value of our ordinary shares and ADS. However, the dual listing
of our ordinary shares and ADS may dilute the liquidity of these securities in one or both markets and may impair the development of
an active trading market for the ADS in the U.S. The trading price of the ADSs could also be adversely affected by trading in our ordinary
shares on the ASX.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>As a foreign private issuer, we are permitted,
and we expect to follow certain home country corporate governance practices in lieu of certain NASDAQ requirements applicable to domestic
issuers. This may afford less protection to holders of our ADSs.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer
whose shares are listed on NASDAQ, we are permitted to follow certain home country corporate governance practices instead of certain
requirements of the NASDAQ Stock Market Rules. Among other things, as a foreign private issuer we have elected to follow home country
practice with regard to, the composition of the board of directors and the audit committee, the financial expert, director nomination
procedure, compensation of officers and quorum at shareholders&#8217; meetings. In addition, we may follow our home country law, instead
of the NASDAQ Stock Market Rules, which require that we obtain shareholder approval for certain dilutive events, such as for the establishment
or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the company, certain
transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the
stock or assets of another company. Accordingly, our shareholders may not be afforded the same protection as provided under NASDAQ&#8217;s
corporate governance rules. See Item 16G - Corporate Governance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>As a foreign private issuer, we are permitted
to file less information with the SEC than a company incorporated in the U.S. Accordingly, there may be less publicly available information
concerning us than there is for companies incorporated in the U.S.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are exempt from certain rules under the Exchange Act that impose disclosure requirements as well as procedural requirements for proxy
solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the
reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act. Moreover, we are not required to
file periodic reports and financial statements with the SEC as frequently or as promptly as a company that files as a U.S. company whose
securities are registered under the Exchange Act, nor are we required to comply with the SEC&#8217;s Regulation FD, which restricts the
selective disclosure of material non-public information. Accordingly, there may be less information publicly available concerning us
than there is for a company that files as a domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are an emerging growth company as defined
in the JOBS Act and the reduced disclosure requirements applicable to emerging growth companies may make the ADS less attractive to investors
and, as a result, adversely affect the price of the ADS and result in a less active trading market for the ADS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an emerging growth
company as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies. For example, we have elected to rely on an exemption from the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act relating to internal control over financial reporting, and we will
not provide such an attestation from our auditors for so long as we qualify as an emerging growth company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may avail ourselves of
these disclosure exemptions until we are no longer an emerging growth company. We cannot predict whether investors will find the ADS
less attractive because of our reliance on some or all of these exemptions. If investors find the ADS less attractive, it may cause the
trading price of the ADS to decline and there may be a less active trading market for the ADS.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will cease to be an emerging
growth company upon the earliest of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the end of the fiscal year
    in which the fifth anniversary of completion of our initial public offering (&#8220;IPO&#8221;) occurs;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the end of the first fiscal
    year in which the market value of our ordinary shares held by non-affiliates exceeds US$700 million as of the end of the second quarter
    of such fiscal year;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the end of the first fiscal
    year in which we have total annual gross revenues of at least US$1.07 billion; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which we have
    issued more than US$1 billion in non-convertible debt securities in any rolling three-year period.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with the rules&#160;under
the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses
and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly
and raising capital could be more difficult.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
the rules&#160;under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures in the future, or, if we discover material
weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and
raising capital could be more difficult. Section&#160;404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness
of our internal control over financial reporting. As of June 30, 2021, our management determined that we had no material weaknesses in
our internal control over financial reporting. If material weaknesses or significant deficiencies are discovered or if we otherwise fail
to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that
we have effective internal controls over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act. Moreover,
effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial
fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors
could lose confidence in our reported financial information, and the trading price of our ordinary shares and ADSs could drop significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>ADS holders may be subject to additional risks
related to holding ADS rather than ordinary shares.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ADS holders do not hold
ordinary shares directly and, as such, are subject to, among others, the following additional risks:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an
    ADS holder, we will not treat you as one of our shareholders and you will not be able to exercise shareholder rights, except through
    the ADR depositary as permitted by the amended and revised deposit agreement among the Company, The Bank of New York Mellon, as depositary,
    and owners and holders of our ADSs (the &#8220;Deposit Agreement&#8221;);</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distributions on the ordinary
    shares represented by your ADS will be paid to the ADR depositary, and before the ADR depositary makes a distribution to you on behalf
    of your ADSs, any withholding taxes that must be paid will be deducted. Additionally, if the exchange rate fluctuates during a time
    when the ADR depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We and the ADR depositary
    may amend or terminate the Deposit Agreement without the ADS holders&#8217; consent in a manner that could prejudice ADS holders.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>You must act through the ADR depositary to
exercise your voting rights and, as a result, you may be unable to exercise your voting rights on a timely basis.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a holder of ADS (and
not the ordinary shares underlying your ADSs), we will not treat you as one of our shareholders, and you will not be able to exercise
shareholder rights. The ADR depositary will be the holder of the ordinary shares underlying your ADS, and ADS holders will be able to
exercise voting rights with respect to the ordinary shares represented by the ADS only in accordance with the Deposit Agreement relating
to the ADS. There are practical limitations on the ability of ADS holders to exercise their voting rights due to the additional procedural
steps involved in communicating with these holders. For example, holders of our ordinary shares will receive notice of shareholders&#8217;
meetings by mail and will be able to exercise their voting rights by either attending the shareholders meeting in person or voting by
proxy. ADS holders, by comparison, will not receive notice directly from us. Instead, in accordance with the Deposit Agreement, we will
provide notice to the ADR depositary of any such shareholders meeting and details concerning the matters to be voted upon at least 30
days in advance of the meeting date. If we so instruct, the ADR depositary will mail to holders of ADS the notice of the meeting and
a statement as to the manner in which voting instructions may be given by holders as soon as practicable after receiving notice from
us of any such meeting. To exercise their voting rights, ADS holders must then instruct the ADR depositary as to voting the ordinary
shares represented by their ADSs. Due to these procedural steps involving the ADR depositary, the process for exercising voting rights
may take longer for ADS holders than for holders of ordinary shares. The ordinary shares represented by ADS for which the ADR depositary
fails to receive timely voting instructions will not be voted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we are classified as a &#8220;passive foreign
investment company,&#8221; then our U.S. shareholders could suffer adverse tax consequences as a result.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, if, for any taxable
year, at least 75% of our gross income is passive income (including our pro rata share of the gross income of our 25% or more owned corporate
subsidiaries) or at least 50% of the average quarterly value of our total gross assets (including our pro rata share of the gross assets
of our 25% or more owned corporate subsidiaries) is attributable to assets that produce passive income or are held for the production
of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income
tax purposes. For purposes of these tests, passive income includes dividends, interest, and gains from the sale or exchange of investment
property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active
conduct of a trade or business. If we are characterized as a PFIC, a U.S. holder of our ordinary shares or ADSs may suffer adverse tax
consequences, including having gains recognized on the sale of our ordinary shares or ADSs treated as ordinary income, rather than capital
gain, the loss of the preferential rate applicable to dividends received on our ordinary shares or ADSs by individuals who are U.S. holders,
and having interest charges added to their tax on distributions from us and on gains from the sale of our ordinary shares or ADS. See
&#8220;Taxation&#8212;United States Federal Income Tax Considerations&#8212;<i>Passive Foreign Investment Company</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our status as a PFIC may
also depend, in part, on how quickly we utilize any cash proceeds from any offering. Since PFIC status depends on the composition of
our income and the composition and value of our assets, which may be determined in large part by reference to the market value of our
ordinary shares or ADS, which may be volatile, there can be no assurance that we will not be a PFIC for any taxable year. While we expect
that we were not a PFIC for our taxable year ended June 30, 2021, no assurance of our PFIC status can be provided for such taxable year
or future taxable years. Prospective U.S. investors should discuss the issue of our possible status as a PFIC with their tax advisors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Currency fluctuations may adversely affect
the price of our ordinary shares and ADS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares are
quoted in Australian dollars on the ASX and the ADS are quoted in U.S. dollars on NASDAQ. Movements in the Australian dollar/U.S. dollar
exchange rate may adversely affect the U.S. dollar price of the ADS. In the past year the Australian dollar has generally weakened against
the U.S. dollar. However, this trend may not continue and may be reversed. If the Australian dollar weakens against the U.S. dollar,
the U.S. dollar price of the ADS could decline, even if the price of our ordinary shares in Australian dollars increases or remains unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have never declared or paid dividends on
our ordinary shares and we do not anticipate paying dividends in the foreseeable future.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid cash dividends on our ordinary shares. For the foreseeable future, we currently intend to retain all available funds and any future
earnings to support our operations and to finance the growth and development of our business. Any future determination to declare cash
dividends will be made at the discretion of our board of directors, subject to compliance with applicable laws and covenants under current
or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend on our financial condition, operating
results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. We do not
anticipate paying any cash dividends on our ordinary shares in the foreseeable future. As a result, a return on your investment will
only occur if our ADS price appreciates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>You may not receive distributions on our ordinary
shares represented by the ADS or any value for such distribution if it is illegal or impractical to make them available to holders of
ADS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While we do not anticipate
paying any dividends on our ordinary shares in the foreseeable future, if such a dividend is declared, the depositary for the ADS has
agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited
securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares
your ADS represent. However, in accordance with the limitations set forth in the Deposit Agreement, it may be unlawful or impractical
to make a distribution available to holders of ADS. We have no obligation to take any other action to permit the distribution of the
ADS, ordinary shares, rights or anything else to holders of the ADS. This means that you may not receive the distributions we make on
our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may have
a material adverse effect on the value of your ADS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Australian takeover laws may discourage takeover
offers being made for us or may discourage the acquisition of a significant position in our ordinary shares or ADS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Australia
and are subject to the takeover laws of Australia. Among other things, we are subject to the Australian Corporations Act 2001, or the
Corporations Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in
our issued voting shares if the acquisition of that interest will lead to a person&#8217;s voting power in us increasing to more than
20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being
made for us or may discourage the acquisition of a significant position in our ordinary shares. This may have the ancillary effect of
entrenching our board of directors and may deprive or limit our shareholders&#8217; or ADS holders&#8217; opportunity to sell their ordinary
shares or ADSs and may further restrict the ability of our shareholders and ADS holders to obtain a premium from such transactions. See
Item 10. &#8211; Additional Information &#8220;Change of Control&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Constitution and Australian laws and regulations
applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As an Australian company,
we are subject to different corporate requirements than a corporation organized under the laws of the states of the U.S. Our Constitution,
as well as the Australian Corporations Act, set forth various rights and obligations that are unique to us as an Australian company.
These requirements may operate differently than those of many U.S. companies. See Item 10 - Additional Information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>You will have limited ability to bring an
action against us or against our directors and officers, or to enforce a judgment against us or them, because we are incorporated in
Australia and certain of our directors and officers reside outside the U.S.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Australia,
certain of our directors and officers reside outside the U.S. and substantially all of the assets owned by such persons are located outside
of the U.S.. As a result, it may be impracticable or at least more expensive for you to bring an action against us or against these individuals
in Australia in the event that you believe that your rights have been infringed under the applicable securities laws or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>You may be subject to limitations on transfer
of the ADSs.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ADSs are only transferable
on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient
in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of
ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deem it advisable to
do so because of any requirement of law or of any government or governmental body, or under any provision of the Deposit Agreement, or
for any other reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Australian companies may not be able to initiate
shareholder derivative actions, thereby depriving shareholders of the ability to protect their interests.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australian companies may
not have standing to initiate a shareholder derivative action in a federal court of the U.S. The circumstances in which any such action
may be brought, and the procedures and defenses that may be available in respect to any such action, may result in the rights of shareholders
of an Australian company being more limited than those of shareholders of a company organized in the U.S. Accordingly, shareholders may
have fewer alternatives available to them if they believe that corporate wrongdoing has occurred. Australian courts are also unlikely
to recognize or enforce against us judgments of courts in the U.S. based on certain liability provisions of U.S. securities law and to
impose liabilities against us, in original actions brought in Australia, based on certain liability provisions of U.S. securities laws
that are penal in nature. Although the courts of Australia may recognize and enforce the non-penal judgment of a foreign court of competent
jurisdiction without retrial on the merits upon being satisfied about all the relevant circumstances upon which such judgment was obtained,
there is no statutory recognition in Australia of judgments obtained in the U.S..</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-takeover provisions in our Constitution
and our right to issue preference shares could make a third-party acquisition of us difficult.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some provisions of our Constitution
may discourage, delay or prevent a change in control of our company or management that shareholders may consider favorable, including
provisions that only require one-third of our board of directors to be elected annually and authorize our board of directors to issue
an unlimited number of shares of capital stock and preference shares in one or more series and to designate the price, rights, preferences,
privileges and restrictions of such preference shares by amending the Constitution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>A. History
and Development of the Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated under the laws of the Commonwealth of Australia in
1994 and have been listed on the ASX since April 30, 1999. Our ADSs and Warrants have traded on The NASDAQ Capital Market since June 13,
2017. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone
number is +61 (0)3 9824 5254. Our agent for service in the U.S. is Puglisi &amp; Associates, 850 Library Avenue, Suite 204, Newark, DE
19711.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Business
Overview</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial and clinical-stage
biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of
specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. Our oral polyclonal antibodies
offer delivery within the gastrointestinal (&#8220;GI&#8221;) tract and essentially do not cross into the bloodstream, potentially leading
to much improved safety and tolerability, without sacrificing efficacy. We currently market our flagship commercial products Travelan&#174;
and Protectyn&#174; in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods. Travelan&#174;
(AUST L 106709) is an over-the-counter orally administered passive immunotherapeutic product and is indicated to reduce the risk of travelers&#8217;
diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial and is sold in pharmacies throughout Australia. Protectyn&#174;
(AUST L 231001) is currently sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a
healthy digestive function and liver. We also market Travelan&#174; (NPN 80046016) in Canada where it is licensed as a natural health product
indicated to reduce the risk of travelers&#8217; diarrhea, and presently market Travelan&#174; in the U.S. as a dietary supplement for
digestive tract protection.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have three
lead drug candidates in clinical development, which we believe have the potential to transform the existing treatment paradigms for moderate
to severe campylobacteriosis, <i>Clostridiodies difficle (C.difficle) Infections, </i>Enterotoxigenic <i>Escherichia coli</i> (ETEC)
infections and travelers&#8217; diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they
produce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also have several early-stage
<span style="font-family: Times New Roman, Times, Serif">assets under development. Our technology platform can be used to block viruses
or bacteria and neutralize the toxins they produce at mucosal surfaces such as the Gastrointestinal tract. We have completed the manufacture
of three new <i>Shigella</i>-specific therapeutic products using proprietary vaccines developed by the Walter Reed Army Institute of Research
(WRAIR). This collaboration aims to develop an oral therapeutic for shigellosis, a severe form of dysentery that affects about 165 million
people a year, mostly children, and causes up to a million deaths. Symptoms of shigellosis, also known as bacillary dysentery, include
severe and bloody diarrhea, fever, and stomach cramps. We are also pursuing a research program focused on the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. Our Hyper-immune Bovine Colostrum used to manufacture our commercial
products Travelan&#174; and Protectyn&#174; has demonstrated antiviral activity against SARS-CoV-2 in laboratory studies. Our research is
focused on identifying the inhibitory substance/s unique to the colostrum samples.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Travelan sales for fiscal
year 2021, 2020 and 2019 were gross A$166 thousand (net: A$146 thousand), A$2.7 million (net: A$2.5 million) and A$2.5 million (net:
A$2.3 million), respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUR STRATEGY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our goal is to become one
of the leading biopharmaceutical companies developing and commercializing therapeutics to address increased unmet medical needs in the
anti-infective area. The critical components of our strategy include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing
    our lead oral polyclonal antibody drug candidates presently in clinical development for the treatment of moderate to severe campylobacteriosis,
    travelers&#8217; diarrhea and to treat recurrent <i>C. difficile </i>infections (CDI);</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
    our technology platform and our collaborations to expand our differentiated polyclonal-based product pipeline across multiple indications
    including various novel anti-infective programs with the U.S. Department of Defense (DoD);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing
    to invest in and growing Travelan and Protectyn sales worldwide, including in the U.S., Australia, Canada, and in new markets;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing
    to invest in mechanism of action studies that expand our understanding of our novel mechanism of action across our targeted diseases
    and conditions, and potentially identify new opportunities for investment; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protect
    and leverage our intellectual property portfolio and patents. We believe that our intellectual property protection strategy, grounded
    in securing composition of matter patents on the biologics we develop, as well as broader patents to protect our technology platform,
    has best positioned us to gain broad and strong protection for our assets. </span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>OUR PLATFORM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our platform technology
is based on oral polyclonal immunoglobulins. Prior to calving, cows are immunized with proprietary vaccines to ensure maximum immunogenicity
and after calving, the first milk, called bovine colostrum is harvested and processed to produce a hyper-immune bovine colostrum powder.
This proprietary process of vaccinating cows with specific vaccines generated against antigens for therapeutic targets ensures that the
colostrum contains a high concentration of polyclonal antibodies and high concentrations of immunoglobulin G1 against the specified antigens.
The technology can be applied to a variety of diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The underlying nature of
our platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to
block viruses or bacteria at mucosal surfaces (such as the GI tract) and neutralize the toxins they produce. Additionally, the dairy
origins of our antibodies enable us to commercialize our platform through most regulatory pathways, including prescription (Rx), medical
foods, over-the-counter medicines, and dietary supplements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The active pharmaceutical
ingredient (API) for a particular application is prepared using the first milking colostrum of dairy cows that have been immunized with
patented vaccines for the specific therapeutic use to produce very high levels of antibodies against selected surface antigens. Pregnant
dairy cows at commercial dairy farms are immunized through a proprietary process. Such inoculation of dairy cows with specific vaccines
activates a generalized immune response in the host animal to produce antibodies which recognize and bind to bacterial cell-surface epitopes
that the vaccines were designed against. These polyclonal antibodies in the harvested bovine colostrum are present in high concentration
within the raw material which is further processed to produce the final drug product which contains at least 35% immunoglobulins (Ig),
composed mainly of IgG (mostly IgG1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Risk management covering
the source of colostrum must focus on assurance of absence of Bovine Spongiform Encephalopathy (&#8220;BSE&#8221;), commonly known as
Mad Cow Disease attributable to the liquid raw product. BSE is a transmissible and fatal neurodegenerative disease that affects cattle.
BSE has never been detected in cattle in Australia or New Zealand. The World Organization for Animal Health recognizes both countries
as having a negligible BSE risk status. Australia and New Zealand are two of only 16 countries in the world to-date assessed by the European
Union as meeting all criteria for the lowest geographical BSE risk level.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUR PIPELINE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We presently have three drug
candidates in clinical development that have the potential to transform the existing treatment paradigms for moderate to severe campylobacteriosis,
recurrent <i>C. difficile</i> infections, Enterotoxigenic <i>Escherichia coli</i> (ETEC) infections and travelers&#8217; diarrhea, a digestive
tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. As we have already reported to our shareholders,
the sales of Travelan remain severely impaired due to COVID-19 restrictions and the associated reduction in long-haul travel impact every
Travelan&#174; market. The COVID-19 pandemic resulted in international travel restrictions and brought to an abrupt halt the travel plans
of millions throughout the world. Many countries went into total lockdown with people unable to leave their homes except for very limited
purposes. The sales of Travelan are likely to remain suppressed until the impact of COVID-19 on travel restrictions and lockdowns by government
bodies are reduced. The company is pleased to report albeit a small uplift of sales in the United States as domestic and international
travel resumes on the back of over 380 million total vaccine doses administered in the country to date. The pandemic has also caused significant
disruptions to global clinical development with many planned studies being delayed, paused or closed.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Immuron&#8217;s IMM-124E used to manufacture
Travelan&#174; and Protectyn&#174; demonstrates antiviral activity against the COVID-19 virus in laboratory studies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company announced to the market in July 2020
that the hype-Immune bovine colostrum used to manufacture the company&#8217;s flag ship commercially available and over-the-counter gastrointestinal
and digestive health immune supplements Travelan&#174; and Protectyn&#174; demonstrated neutralizing activity against the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. The in-vitro assessment of the neutralization of SARS-CoV-2 was performed
on four production lots of product used to manufacture Travelan&#174; and Protectyn&#174; using the SARS-CoV-2 hCoV-19/Australia/VIC01/2020
virus obtained from Melbourne&#8217;s Peter Doherty Institute for Infection and Immunity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2021, the company reported that Monash
University Research Scientists at the Biomedicine Discovery Institute had completed the developed of two new immunologically based assays
utilizing two recombinant reagents, the SARS-CoV-2 Spike protein and a receptor binding domain protein obtained from Melbourne&#8217;s
Peter Doherty Institute for Infection and Immunity. The studies completed by Monash suggested that the SARS-CoV-2 inhibitory activity
in the hyper-Immune colostrum used to manufacture Travelan&#174; and Protectyn&#174; does not target the spike protein or the receptor binding
domain that the virus uses to dock to the cells it infects. The research team has also completed the purification of the major immune
components (IgA and IgG) from the hype-Immune bovine colostrum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">CSIRO Biomedical Manufacturing
has also completed additional characterization work performed on the hype-Immune bovine colostrum which demonstrated neutralizing activity
against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The work focused on peptide sequencing by liquid chromatography
tandem-mass spectrometry (LC-MS/MS) and identified several Ig-like proteins as major components that appear to be enriched in bovine colostrum
samples compared to Control Milk Powder. The LC-MSMS analysis is very sensitive and detected a total of 375 proteins across all samples
tested. Work continues with the data analysis to identify other key proteins unique to the colostrum samples that are not present in the
milk powder controls. Once completed the neutralizing activity of the various immune components will be tested against the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We know that SARS-CoV-2 causes
an influenza-like disease that is primarily thought to infect the lungs with transmission through the respiratory route ranging from mild
respiratory symptoms to severe lung injury, multiorgan failure, and death. Understandably, respiratory symptoms have dominated the clinical
focus, however gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain are also observed in a subset of patients often
presenting with no respiratory symptoms. In the United States the Centers for Disease Control and Prevention updated the symptoms of coronavirus
to include diarrhea. Clinical research suggests that the Gastrointestinal tract may present another viral target organ. The virus RNA
has been detected in anal swabs of some patients even after nasopharyngeal testing has turned negative, and cells in the inner-gut lining
express high amounts of the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses to gain entry to cells implying the potential
for gastrointestinal infection and a fecal&#8211;oral transmission route. However, fecal&#8211;oral transmission has not been demonstrated
to be a significant factor in the pandemic and the current research is still inconclusive. The company has filed a provisional patent
application in respect of the findings.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July 2020 we announced
the findings of 360 biolabs, a Melbourne-based Contract Research Organization using the SARS-CoV-2 hCoV-19/Australia/VIC01/2020 virus
obtained from Melbourne&#8217;s Peter Doherty Institute for Infection and Immunity. The in-vitro assessment of the neutralization of
SARS-CoV-2 was performed on four production lots of product used to manufacture Travelan&#174; and Protectyn&#174;. The In-vitro susceptibility
of the virus to IMM-124E was determined using a quantitative assay which measures virus replication in the presence of increasing concentrations
of the product compared to replication in the absence of the product. The effective concentration of IMM-124E was reported as the concentration
of the product at which virus replication is inhibited by 50 percent (EC<sub>50</sub>) or 90 percent (EC<sub>90</sub>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.7pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.7pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All four production lots
produced mean EC<sub>50 </sub>values of 40.5 to 91.9 ug/mL and inhibited viral replication at concentrations which there was no observed
cell toxicity. The concentration of IMM-124E at which virus replication was inhibited by 90 percent (EC<sub>90</sub>) produced mean EC<sub>90
</sub>values ranging from 48.7 to 155.4 ug/mL for all four lots tested again at concentrations at which there was no observed cell toxicity.
A commercially available high protein milk powder product was used as a placebo in the studies and produced EC<sub>50 </sub>values greater
than the observed cellular cytotoxicity concentration of &gt;4800 ug/mL. The control milk powder inhibited viral replication at doses&gt;
25,000 ug/mL and more importantly did not inhibit viral replication at doses at which it was cytotoxic to cells. Another major finding
made during the study was that cell viability in the presence of IMM-124E was greatly enhanced when compared to placebo. IMM-124E improved
cell viability by 180 to 260% relative to controls. These results indicate that IMM-124E at concentrations which inhibited SARS-CoV-2
replication also improved cell viability.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>US Department of Defense New Drug Candidate
to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The COVID-19 pandemic has disrupted clinical trials
globally and following over a 12-month hiatus the NMRC has reported that most of the inpatient clinical trial sites in the USA are slowly
coming off COVID-19 based restrictions and the Company looks forward to the recommencement of the planned NMRC clinical development programs.
In July 2020, Immuron announced that the NMRC received written guidance from the U.S. Food and Drug administration (FDA) in relation to
the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis
and Enterotoxigenic Escherichia coli (ETEC) infections. The Type B meeting with the FDA discussed the Chemistry, Manufacturing and Controls
including the proposed release testing specifications of the product as well as the planned clinical studies evaluating the safety and
efficacy of the product. The NMRC has addressed the FDA questions posed in the briefing documentation and is in the process of finalizing
the IND application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company initiated the second vaccination campaign
in March 2021 and utilized the bispecific vaccine developed by the NMRC which is made up of the capsule of <i>C. jejuni </i>chemically
conjugated to the CFA/I pilin of ETEC. The second vaccination campaign was successfully completed in May 2021 and each animal in the second
herd received three doses of the vaccine. The hyper-immune colostrum was harvested in July 2021 and samples were shipped to the NMRC for
immunological evaluation. The NMRC confirmed that the conjugated vaccine produced a robust immunological response and reported that the
new Hyper-immune therapeutic contains high levels of antibodies which specifically target <i>Campylobacter jejuni </i>capsule and Enterotoxigenic
<i>Escherichia coli </i>(ETEC) colonization factor antigen 1 (CFA/1). These are key antigenic targets predicted to be protective against
diarrhea induced by both pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacturing campaign
for the drug substance was completed in August 2021 and the company plans to complete the manufacture of active drug product in October
2021. Once completed the investigational medical products will be transferred to the Johns Hopkins Bloomberg School of Public Health (JHBSPH)
in the USA the clinical trial site which will be conducting the two planned Controlled Human Infection Model clinical studies. Work on
the Investigational New Drug (IND) application and the clinical protocols for evaluating the safety and efficacy of the product in moderate
to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections continues. The NMRC now plans to file the IND application
with the U.S. Food and Drug administration (FDA) in Q1 2022. The ability of the new hyperimmune product to protect volunteers from moderate
to severe campylobacteriosis and ETEC disease will be assessed during two inpatient clinical trials the first of which is scheduled to
commence in the first half of 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For all the disruption caused
by the COVID-19 pandemic, our partnerships with components of the US Department of Defense remain strong, close, and strategically vital.
We will continue the clinical development of a new oral therapeutic to treat moderate to severe campylobacteriosis and Enterotoxigenic
<i>Escherichia coli</i> (ETEC) infections in conjunction with the US Naval Medical Research Centre.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>IMM-124E Travelers&#8217; Diarrhea Efficacy Field Trial</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Several meetings have been held this year with
our US Department of Defense (US DoD) associates to review the proposed company sponsored phase III clinical trial protocol, address key
questions identified by the FDA clinical reviewers and to identify potential endemic countries and clinical sites of interest to the US
DoD. During these meetings the company was invited to present its strategic plan for the Biologics License Application (BLA), to the Military
Infectious Diseases Research Program (MIDRP). MIDRP manages research and development programs for the US DoD and its mission is to protect
the U.S. military against naturally occurring infectious diseases via the development of U.S. Food and Drug Administration (FDA) approved
vaccines, drugs, and diagnostic assays. The meeting also focused on funding opportunities available to support the BLA and the associated
approval process, as well as to provide some additional insights on the processes the company would need to navigate to advance Travelan
with FDA licensure and DoD acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The proposed development program is based on the
past commercial and clinical trial experience with Travelan&#174;. Two company sponsored clinical studies have demonstrated that Travelan&#174;
conferred 84% to over 90% protective efficacy against moderate to severe diarrhea upon challenge with ETEC in comparison to a placebo.
These clinical studies were performed using two different doses of Travelan&#174; (200 mg and 400 mg), administered 3 times a day. Ongoing
discussions with Army and Navy leadership have highlighted that such a regimen is cumbersome for military personnel deployed in austere
environments and military field studies have shown that compliance is low with products dosed more than once per day. The rationale behind
the company&#8217;s proposal is to leverage the current BLA program to obtain US Government funding to test the efficacy of one large
daily dose regimen of Travelan&#174; in a controlled human infection model (CHIM) clinical study using the ETEC strain H10407. This dose
regime is potentially more amenable for use in military populations. Results of the proposed clinical study will inform dosing in the
planned pivotal Phase 3 studies for BLA licensure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company&#8217;s presentation was held on the
25 May 2021 and was well attended by the US Government sponsors. The Government reviewers were very much engaged and interested in the
technology and the proposal. Advanced Technology International (ATI), the MTEC Consortium Management Firm formally notified the Company
on the 25 June 2021 that our proposal was considered eligible for award and requested Immuron to submit a full proposal for consideration
which was prepared and submitted to the MTEC Contracts team on the 13 July 2021. The company received formal notification confirming that
the US Government sponsors had completed the evaluation of our proposal and intends to select it for award subject to funding availability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Uniformed Services University Phase II P4TD
Field Trial targeting travelers&#8217; diarrhea</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company received a purchase order and in May
2021 supplied Travelan&#174; drug substance (IMM-124E) to support the Uniformed Services University (USU) planned clinical trial program
to evaluate the efficacy of Travelan&#174; and two other non-antibiotic OTC products in Travelers&#8217; Diarrhea. USU&#8217;s Infectious
Diseases Clinical Research Program (IDCRP), the UK Ministry of Defense and the New York City Travel Clinic are jointly planning to conduct
a randomized clinical trial to evaluate the efficacy of three nutraceutical products for TD and inform strategies for Defense Force Health
Protection. The P4TD study is a randomized, double-blind, placebo controlled multicenter clinical trial designed to evaluate the effectiveness
of 3 commercially available nutraceuticals: A prebiotic (Bimuno&#174;), a probiotic (Florastor&#174;) and IMM-124E (Travelan&#174;) passive
immunoprophylaxis verses a placebo, for prophylaxis during deployment or travel to a high-TD risk region</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IMM-124E is manufactured
from colostrum harvested from dairy cows that have been immunized against the 13 most common pathogenic strains of enterotoxigenic <i>E.coli
</i>(ETEC). IMM-124E is designed to block and reduce bacterial growth without negatively impacting essential microbiota, and is a first-in-class,
oral polyclonal antibody therapeutic which targets gram negative ETEC and other cross-reactive pathogenic bacteria in the gut, leading
to the blockage of their pathologic activities.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earlier Clinical Studies on IMM-124E</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IMM-124E was evaluated as
a potential drug to treat non-alcoholic steatohepatitis (NASH) under FDA IND #014933. The primary endpoint was the mean change from baseline
in the hepatic fat fraction (HFF, %), as measured by MRI at week 24 for two doses of IMM-124E compared with placebo. Both doses of IMM-124E
did not lead to significant reduction in fat at the end of 24 weeks of therapy. Topline results from this earlier IMM-124E phase II NASH
clinical study were reported in March 2018. The 24-week treatment study which was conducted in Australia, Israel, and the U.S. involved
133 biopsy-proven NASH patients. The study results demonstrated that IMM-124E, a first-in-class, oral antibody therapy targeting the
endotoxin lipopolysaccharide (LPS) and other bacterial components in the gastrointestinal tract, resulted in a statistically significant
reduction of serum LPS in patients with biopsy proven NASH. IMM-1214E was developed to target ETEC pathogens, preventing LPS from translocating
into the portal circulation. The study results demonstrated a statistically significant reduction of serum LPS levels in the drug treatment
arms when compared to placebo, providing proof-of-concept for a novel mechanism of action. Serum ALT was also significantly reduced when
compared to placebo as well as AST and cytokeratin-18 (CK-18) demonstrating metabolic endotoxemia can be decreased with IMM-124E which
can lower serum LPS levels and reduce LPS -associated liver inflammation. The data showed a small statistically significant reduction
in serum lipopolysaccharide (LPS), and reductions in two biomarkers associated with liver function, but the drug did not display signs
of clinical benefit in reducing fat content of the liver in patients with NASH. Consequently, we decided not to continue clinical development
of IMM-124E specifically to treat NASH. Data from this trial, however, showed that IMM-124E was not systemically absorbed, and the trial
provided further support for IMM-124E&#8217;s safety profile, and for its potential use in other therapeutics areas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Two additional clinical
studies, sponsored and funded by the National Institute of Health, have been performed with IMM-124E: 1) a Phase II clinical study in
patients with severe alcoholic hepatitis (SAH) conducted under FDA IND #015675, and 2) a Phase II clinical study in pediatric patients
with non-alcoholic fatty liver disease (NAFLD) conducted under FDA IND #017066.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Top-line results from the
SAH trial with Dr. Arun Sanyal of Virginia Commonwealth University as the lead Principal Investigator were released on August 8, 2019.
The primary objective of this study was to evaluate the safety and efficacy of IMM-124E at two oral dosage levels as compared with a
placebo in patients with severe alcoholic hepatitis and with all patients being treated with steroids. A total of 57 patients with SAH
with a model for end stage liver disease (MELD) score ranging from 21-28 were enrolled into the clinical study and were treated with
either IMM-124E or placebo for 28 days (placebo N=20, IMM-124E 2400 mg/day N=18, IMM-124E 4800 mg/day N= 19). No suspected unexpected
serious adverse reactions were reported and no differences in serious adverse events (SAE) were observed across the three arms of the
study and no SAE was considered related to the study drug by investigators. Both doses of IMM-124E in the study (2400mg and 4800mg) were
well tolerated. There were 9 deaths reported over a six-month period for the entire cohort and there were no significant differences
across study groups. The data showed that IMM-124E is safe to use in patients with SAH but does not reduce circulating lipopolysaccharide
levels, mortality or have an impact on MELD score in the study population, and we will not continue clinical development of IMM-124E
specifically to treat SAH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The COVID-19 pandemic has
also impacted the IMM-124E pediatric clinical study in Nonalcoholic Fatty Liver Disease. The study&#8217;s Principle Investigator Dr
Miriam Vos from the Emory University School of Medicine closed the study earlier this year with only 22 subjects out of a target 40 completed
the study protocol. The study findings were reported as negative as there was no substantial changes in ALT (Primary study end point)
in the active arm of the study when compared to placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>IMM-529 to Treat Recurrent C. difficile Infections (CDI)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company has completed the assessment of the
acceptability of the orphan drug designation (ODD) application for IMM-529. Based on the literature related to <i>Clostridiodes difficile</i>,
treatment of recurring infection, and the information available on the center for disease control (CDC) and prevention site, our regulatory
consultants have concluded that it would be challenging to secure an ODD designation for IMM-529 based on the available data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company has established a Medical Advisory Committee to review the clinical development plans and establish a clinical protocol for IMM-529
in recurrent <i>Clostridiodes difficle</i> Infections (CDI). Members include Professor Teena Chopra, Professor of Medicine Wayne State
University School of Medicine, Detroit Michigan. Professor Chopra is an Infectious Disease Epidemiologist with a specific interest in
CDI. Professor Paul Feuerstadt assistant Clinical Professor of Medicine, Yale University School of Medicine and Professor Sahil Khanna,
Professor of Medicine at the Mayo Clinic. The committee members have an in depth understanding on CDI and currently treat a large number
of patients with recurring CDI. The Medical Advisory Committee has completed their review of the clinical trial protocol following several
meetings held this year and we are currently in the process of finalizing the clinical protocol, identifying suitable clinical trial sites
and updating the Project plan which will be presented to the Board of Directors for approva</span>l.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Background on <i>C. difficile</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>C</i>. <i>difficile </i>is
a gram-positive, toxin-producing, spore-forming bacterium that generally causes severe and persistent diarrhea in infected individuals,
but can also lead to more severe outcomes, including in the most serious cases, death. <i>C. difficile </i>infection (CDI) is most often
associated with the prior use of antibiotics. The U.S. Centers for Disease Control has identified CDI as one of the top three most urgent
antibiotic-resistant bacterial threats in the U.S. and is now the most common cause of hospital acquired infection in the U.S. CDI is
responsible for approximately 29,000 deaths in the U.S. annually. The prevalence of CDI is estimated at more than 450,000 infections
annually, with nearly 100,000 cases of first recurrences. Research suggests that the risk of recurrence is approximately 25% after the
primary occurrence of CDI, 40% after a first recurrence and greater than 60% for those experiencing two or more recurrences. CDI leads
to an increased length of hospitalization and as of 2015, an estimated US$1.1 billion in health care costs annually in the U.S. The rise
of community-acquired CDI is now a growing problem and led to the recognition that CDI is not simply limited to just hospitals. This
increase in CDI incidence, which is now a growing problem worldwide due to the widespread and increased use of antibiotics, is the driver
behind a growing market for <i>C</i>. <i>difficile </i>therapeutics. The CDI market across the seven major markets of the US, France,
Germany, Italy, Spain, the UK and Japan, is set to grow from $630 million in 2016 to almost $1.7 billion by 2026, representing a compound
annual growth rate of 10.2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>C</i>. <i>difficile </i>can
cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In the most serious cases, <i>C</i>. <i>difficile
</i>infections can lead to fulminant colitis, megacolon and even death from colon perforation and peritonitis. <i>C difficile </i>is
acquired from contact with humans or objects harboring these bacteria. It can be commonly acquired during hospitalization. Up to 30%
of those who have spent a prolonged period in the hospital leave carrying these bacteria in the bowel flora, especially if antibiotics
have been administered. This is because CDI is most often associated with the prior use of broad-spectrum antibiotics, which decrease
the natural resistance of the body to <i>C</i>. <i>difficile</i>. Chronic CDI is estimated to occur in perhaps 15-30% of those infected.
In some cases, reinfections can occur with the same or with a different strain. Risk factors for relapse include the number of previous
episodes, the need to use antibiotics recurrently, and older age groups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Human infection occurs through
ingestion of the highly infectious spores, which survive acid and bile on their passage into the bowel. Normally, this infectious process
may be eradicated or substantially reduced by the normal bowel flora since the microbes that collectively make up the flora provide colonization
resistance against pathogenic species through competition for essential nutrients and attachment sites to the gut wall. However, if the
bowel flora is suppressed because of concomitant use of antibiotics, or if the bowel flora has a deficiency, <i>C</i>. <i>difficile </i>can
colonize the flora and remain with the patient. In some individuals, it seems that antibiotics are not required for colonization to take
place, which may be related to inadequate defense of the naturally occurring flora within the bowel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When <i>C</i>. <i>difficile
</i>takes hold, the toxins produced by the bacterium, especially Toxin B, act by inactivation of Rho GTPases leading to cell death, and
stimulation of an inflammatory cascade that exacerbates tissue damage, diarrhea, and pseudomembranous colitis. When faced with a CDI
infection, the standard of care is typically either a course of vancomycin or metronidazole, both of which are broad spectrum antibiotics.
While these agents are very effective at treating the primary infections, they also severely impact the rest of the gut flora, creating
an ideal environment for the <i>C</i>. <i>difficile </i>spores to once again take hold. This creates a vicious cycle, as more courses
of antibiotic treatments worsen recurrence. Vancomycin and metronidazole treatments are plagued by increasing rate of CDI recurrences,
underscoring the need for new treatments. There is also growing concern of resistance to vancomycin treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>C</i>. <i>difficile </i>is
a very hardy organism, most likely because it sheds spores that are unable to be eradicated by any known antibiotics. Since <i>C. difficile
</i>spores are able to survive for long periods of time outside of the body, and because healthcare settings are often sites of significant
antibiotic use, CDI transmission rates in hospitals, long-term acute care facilities and nursing homes have been increasing. CDI is also
a cause of morbidity and mortality among hospitalized cancer patients and bone marrow transplant patients, as their immune systems are
suppressed by cytotoxic drugs and sometimes by antibiotics that are administered to prevent opportunistic infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">IMM-529 &#8211; Novel Triple Action offers a Revolutionary Treatment
for Recurrent CDI</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our second lead compound,
IMM-529, targets the <i>C</i>. <i>difficile </i>bacterium and contains polyclonal antibodies cross-reactive to Toxin B, spores and vegetative
cells of the bacterium. IMM-529 is an oral biologic which does not destroy the microbiome like antibiotic treatments, allowing the microbiome
to return to a healthy state, while treating the virulent CDI. The antibodies in IMM-529 have been demonstrated to be cross-reactive
with a variety of human and animal <i>C</i>. <i>difficile </i>isolates and to their associated Toxin B, vegetative cells and spore components.
The antibodies in IMM-529 have also been shown to neutralize Toxin B from a historical <i>C</i>. <i>difficile </i>strain (630), and from
a hypervirulent strain which caused recent worldwide outbreaks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IMM-529 was developed and
tested extensively in pre-clinical models in collaboration with Dr. Dena Lyras and her team at Monash University, Australia. Dr. Lyras
is one of the world&#8217;s foremost experts in <i>C</i>. <i>difficile</i>. IMM-529 targets the virulent Toxin B, the spores and the
vegetative cells. It is a three-pronged approach that is unique and which has yielded promising results in pre-clinical studies, including
(1) prevention of primary disease, (2) treatment of primary disease and (3) suppression of disease recurrence. To our knowledge, IMM-529
is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_001.jpg" style="height: 225.75pt; width: 367.5pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Preclinical studies with
IMM-529 yielded promising results in a number of pre-clinical animal models (shown below). All results were highly statistically significant:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevention
    of <i>C</i>. <i>difficile </i>infection: approximately 70% (17/24) survival vs. 0% survival in the control groups:</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
    group #1 (0/14) treated with water; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
    group #2 (0/15) treated with non-hyperimmune colostrum.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_002.jpg" style="height: 95.25pt; width: 244.5pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment:
    approximately 80% survival (11/14) vs. &lt;7% survival in the control groups:</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
    group #1 (0/14): Treated with water alone following vancomycin treatment; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
    group #2 (1/15): Treated with non-hyperimmune colostrum following vancomycin treatment.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_003.jpg" style="height: 96pt; width: 248.25pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relapse:
    approximately 90% survival in IMM-529 + vancomycin group (n=7/9); vs. 11% survival in the control group which received vancomycin
    alone (n=1/9).</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_004.jpg" style="height: 95.25pt; width: 236.25pt"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The results of these studies
were published in Scientific Reports (Hutton et al. Bovine antibodies targeting primary and recurrent <i>Clostridium difficile </i>disease
are potent antibiotic alternatives), SCI Rep. 2017 Jun 16:7(1):3665.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Phase I/IIa clinical trial of IMM-529 in <i>C. difficile </i>patients</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A first-in-man Phase I/II clinical
trial was initiated at two clinical sites in Israel at the end of 2017 in CDI patients. This trial was intended to evaluate the safety,
tolerability and effectiveness of IMM-529 together with standard of care (SOC) antibiotic treatment in patients with CDI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 19, 2019, we provided
an update regarding the status of the IMM-529 clinical trial in patients with CDI, along with a refocusing of our efforts to develop
IMM-529. The Phase I/II clinical trial of IMM-529 in patients with <i>C. difficile</i> initiated at the end of 2017 at two clinics in
Israel provided us with disappointing numbers of enrolled patients. Only 9 out of 60 patients have been randomized into the study and
the company has decided to close these sites. We decided to further develop IMM-529 to treat CDI patients through a formal filing of
an IND with FDA, and to develop a new clinical plan for the drug candidate with input from FDA. The focus for IMM-529 will be to explore
how the drug can be developed to determine its impact on reducing recurrent CDI disease, a major unmet medical need in treatment of patients
suffering with <i>C. difficile </i>infections. We are planning to file a Type B meeting request with FDA to develop IMM-529 to treat
patients with CDI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>IMM-529 &#8211; Competitive Advantage</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that IMM-529
has novel competitive advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Triple
    Mechanism of Action &#8211;</i></b> IMM-529 not only targets Toxin B, but also contains antibodies to spores and vegetative cells.
    This is unique among all clinical drug candidates currently in development.</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effective
    Against Virulent Strains &#8211; </i></b>As discussed above, IMM-529 has been shown to be effective against a number of virulent
    strains of CDI, providing a strong proof-of-concept model that IMM-529 can be a frontline agent.</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effective
    in All Phases of the Disease </i></b>&#8211; IMM-529 has been shown to be an effective agent in animal models designed to mimic all
    phases of the disease including prevention of infection, treatment of primary disease and recurrence. This is novel compared to all
    of our competitors and indicates a much larger potential use for IMM-529 than current development programs which primarily target
    recurrence.</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Oral
    Therapy &#8211; </i></b>IMM-529 is an oral therapy lessening costs/burden issues covering patients, hospitals and the healthcare
    system overall.</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Not
    an Antibiotic &#8211; </i></b>IMM-529 is not an antibiotic, and only targets components of <i>C. difficile - </i>its Toxin B, spores
    and vegetative cells. Consequently, IMM-529 is not expected to negatively impact the bacterial flora, allowing the flora to return
    to normal, while fighting the primary infection / recurrence.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other Development Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also have a research
collaboration with the U.S. Department of Defense (DoD) involving programs with the Walter Reed Army Institute of Research, for the development
of three Shigella-specific therapeutic products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Collaborations with U.S.
Army and U.S. Navy</b>. We believe that our collaborations with the DoD are a powerful validation of the potential of our platform to
develop novel anti-infectives. These collaborations also open the door to explore and develop potentially low risk / low cost therapeutics
with some of the most advanced research facilities in the world. The DoD earlier commissioned several studies to characterize the polyclonal
antibodies contained in Travelan. The aim was to conduct trials to determine the product&#8217;s effectiveness in neutralizing pathogenic
GI bacterial infections as a preventative treatment for U.S. military personnel and civilians stationed or traveling in locations where
such infections can be debilitating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Armed Forces Research
Institute of Medical Sciences</b>. In June 2016, we signed an agreement with the Walter Reed Army Institute of Research (&#8220;WRAIR&#8221;)
to develop a therapeutic for a form of dysentery that kills up to one million people a year. WRAIR is the largest and most diverse biomedical
research organization in the DoD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The project&#8217;s aim
is to develop an oral therapeutic for shigellosis, a severe form of dysentery that affects about 165 million people a year, mostly children,
and causes up to a million deaths. Symptoms of shigellosis, also known as bacillary dysentery, include severe and bloody diarrhea, fever,
and stomach cramps. We plan to develop the product for both civilian and military use in areas where endemic diseases such as shigellosis
can compromise the health and readiness of the local community, travelers, contractors and defense personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January 2018, we reported
that the DoD-commissioned study showed Travelan was immunologically reactive to a number of dangerous and potentially fatal infectious
bacteria. The Department of Enteric Diseases unit of the Armed Forces Research Institute of Medical Sciences (&#8220;AFRIMS&#8221;) performed
the study. It took place at a WRAIR laboratory in Bangkok, Thailand. The study, one of three involving Travelan, looked at 60 clinical
isolates of each of Campylobacter, ETEC, and Shigella obtained from infected U.S. defense personnel in southeast Asia between 1993 and
2016. The study indicated that, compared to the control, Travelan antibodies were reactive to all 180 clinical isolates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2018, we reported
the findings of a study conducted by AFRIMS. The study evaluated the therapeutic potential of Travelan in a non-human primate (&#8220;NHP&#8221;)
preclinical Shigella challenge model that closely mimics the disease seen in humans. The study was performed in collaboration with the
Department of Enteric Diseases and the Department of Veterinary Medicine, AFRIMS, and the Department of Enteric Infections, Bacterial
Diseases Branch, WRAIR. The placebo-controlled study was carried out in 12 NHPs segregated into 2 groups: a Travelan treatment cohort
of 8 and a placebo cohort of 4, which were treated with either Travelan or placebo respectively twice daily for a total of 12 doses over
a 6-day period. The animals received treatment for 3 days prior to oral challenge with approximately 3 x 10<sup>9</sup> viable <i>Shigella
flexneri</i> strain 2a organisms. All (4 of 4 - 100%) placebo-treated animals displayed acute dysentery symptoms within 24 to 36 hours
of the <i>Shigella flexneri</i> 2a challenge. Seven of the eight individuals in the Travelan treatment cohort (87.5%) remained symptom-free
to 4 days post the <i>Shigella flexneri</i> 2a challenge. Only one of the Travelan-treated cohort displayed dysentery symptoms during
the same time frame as the placebo arm. Once the treatment period was concluded a second individual in the Travelan treatment group developed
symptoms. Six of the eight Travelan treated cohort animals remained symptom-free to the conclusion of the study which was 11 days post
the <i>Shigella flexneri</i> 2a challenge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In June 2019, we updated
the market on the latest developments arising from our cooperative research and development efforts with the DoD. AFRIMS completed the
histopathological analysis, which provides a comprehensive view of the clinical disease and its effect on tissues of gut, revealed that
all animals in the placebo-treated group displayed severe inflammation in different parts of the gastrointestinal tract. These animals
also had very high levels of inflammatory cytokines (IL-1b, IL-6 and IL-8) in fecal samples collected throughout the study. The inflammation
seen in the gastrointestinal tract and the increase in inflammatory cytokines in the feces were closely associated with the observed
clinical outcomes of dysentery. Only 3 of the 8 Travelan-treated animals had signs of inflammation in the gastrointestinal tract, and
only 2 of those had high levels of inflammatory cytokines in fecal samples. All other animals in the Travelan-treated group were clinically
healthy and did not excrete any inflammatory cytokines. Overall the results suggest that Travelan&#174; is functionally cross-reactive
and may have prophylactic activity against Shigellosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In June 2019, we also reported
the completion of the manufacture of three new <i>Shigella</i>-specific therapeutic products using proprietary vaccines developed by WRAIR.
The immune reactivity of the three hyper-immune Shigella specific products were evaluated by the WRAIR using Enzyme-Linked ImmunoSorbent
Assay and Western Blot analysis. The antibodies in the products were shown to react with the specific antigens present in the vaccines.
The antibodies within the three products were also reactive to 4 different clinical isolates of Shigella (<i>S. flexneri </i>2a, <i>S.
flexneri </i>3a, <i>S. flexneri </i>6, and <i>S. sonnei</i>). The three Immuron <i>Shigella</i>-specific therapeutic products will now
go on to evaluation in WRAIR&#8217;s preclinical models of shigellosis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2019, we announced
the results of the study, sponsored by the DoD and funded through the Defense Health Agency, which was performed at the overseas laboratory
of the WRAIR located in Bangkok, Thailand. The goal was to investigate the breadth of Travelan&#174;&#8217;s immunological reactivity against
pathogenic <i>Vibrio cholera</i> bacterial isolates. Clinical isolates were collected from infected personnel located in Bangladesh, Cambodia,
and Thailand, enabling researchers to gauge Travelan&#174;&#8217;s potential against bacterial strains typically seen in the field. When
compared to a placebo control, researchers found that the polyclonal antibodies comprising Immuron&#8217;s Travelan&#174; product were
reactive to all 71 clinical isolates from these infected individuals. The ability of Travelan&#174; to bind these bacteria highlights the
broad-spectrum recognition by Travelan&#174; of surface antigens on potentially debilitating and even life-threatening bacteria.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>U.S. Naval Medical Research
Center (&#8220;NMRC&#8221;).</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2019, we announced
that the U.S. Department of Defense had approved USD$3.7 million in funding in connection with a new research agreement with the Naval
Medical Research Center (NMRC), Silver Spring, MD, USA to develop and clinically evaluate a new oral therapeutic targeting Campylobacter
and ETEC. The focus of this new agreement will be to develop a combined Campylobacter and enterotoxigenic <i>E. coli</i> (ETEC)-specific
anti-microbial preventative for clinical evaluation. Under this agreement, Immuron and NMRC will be collaborating on the manufacture
and evaluation of the new product designed to protect against travelers&#8217; diarrhea caused by Campylobacter and ETEC pathogens. The
protective efficacy of the product will be tested utilizing two controlled human infection-model clinical trials, with one trial focusing
on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis, and the second trial focusing
on ETEC infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Campylobacter&#8217;s main
reservoir is poultry; however, humans can contract the disease from contaminated food. At least a dozen species of <i>Campylobacter </i>have
been implicated in human disease, with <i>C. jejuni</i> and <i>C. coli </i>being the most common. <i>C. jejuni</i> is now recognized
as one of the main causes of bacterial foodborne disease in many developed countries as well as developing countries where poultry is
common.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ETEC is one of the leading
bacterial causes of diarrhea in the developing world, as well as the most common cause of travelers&#8217; diarrhea. Conservative estimates
suggest that each year, about 157,000 deaths occur, mostly in children, from ETEC, but no vaccines exist, highlighting the need for new
treatment modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, we believe
that the breadth and depth of our technology, and the support we are receiving from the NIH, the DoD and other leading institutions and
Key Opinion Leaders, demonstrates the importance of our technology platform, and makes us truly a unique and attractive player in the
therapeutic areas we are targeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUR ADVISORY BOARD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our company&#8217;s programs
are supported by an advisory board consisting of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Professor Teena Chopra, Professor of Medicine Wayne State University School of Medicine, Detroit Michigan.
Professor Chopra is an Infectious Disease Epidemiologist with a specific interest in CDI.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                   </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Professor Paul Feuerstadt is an attending Gastroenterologist at the Gastroenterology Center of Connecticut/PACT-Gastroenterology
Center Hamden, CT and is also an Assistant Clinical Professor of Medicine at and the Yale University School of Medicine, New Haven, CT
and the Frank H. Netter School of Medicine of Quinnipiac University, Hamden, CT.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Professor Sahil Khanna, Professor of Medicine at the Mayo Clinic. Professor Khanna clinical practice focusses
on the care and treatment of patients with CDI and he was instrumental in the establishment and implementation of the Fecal Microbiota
Transplantation program at Mayo Clinic, Rochester, MN.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Dr. Glenn Tillotson is a healthcare scientist with sound global infectious disease (ID) background and
experience in anti-infective drug development and global medical educational and medical affairs. He has developed a significant network
of sites/experts in the ID field and has authored many publications in the various aspects of ID.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                           </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Dr. Dena Lyras (PhD) &#8211; Monash University. Dr. Lyras, an associate professor at Monash University,
is one of the world&#8217;s leading experts in C. <i>difficile</i>. Dr. Lyras has spent her research career developing world-leading knowledge
of C. <i>difficile</i>. She was the lead author of a seminal study published in Nature in 2009, which shed new light on the essential
role specific toxins play in causing disease, a discovery that disproved prevailing opinion.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Arun
    Sanyal (MD<b>) &#8211; </b>University of Virginia. Professor of Medicine and Former Chairman of the Division of Gastroenterology,
    Hepatology and Nutrition, VCU Medical Center. Dr. Sanyal is an internationally renowned expert in liver diseases. He is a former
    President of the American Association for the Study of Liver Diseases and is the current Chair of the Liver Study Section at the
    NIH.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Stephen
    Harrison (MD) &#8211; Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Physician,
    San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas. Chief of Residents, Internal Medicine, Brooke U.S. Army
    Medical Center. Dr. Harrison is an internationally renowned expert in NASH and his group has published seminal work on many aspects
    in the field. Dr. Harrison is the Principal Investigator of Galectin&#8217;s GR-MD-02&#8217;s Phase 2 trial and hold&#8217;s key
    roles in other leading clinical NASH studies.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Miriam
    Vos (MD) &#8211; Emory University. Dr. Vos is an associate professor of pediatrics at the Emory University School of Medicine, and
    an attending Hepatologist at Children&#8217;s Healthcare of Atlanta. She specializes in the treatment of GI disease in children as
    well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity Solution for Kids.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in">&#160;</td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Manal
    Abdelmalek (MD) &#8211; Duke University Medical Center. Dr. Abdelmalek is Associate Professor of Medicine at Duke Medical University
    Medical Center, Division of Gastroenterology &amp; Hepatology, Section of Hepatobiliary Diseases &amp; Liver Transplantation. Dr.
    Abdelmalek is a leading investigator in the field of NASH.</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Gerhard
    Rogler (MD, PhD) &#8211; Zurich University. Dr. Rogler was the principal investigator of our Colitis preclinical program. He ceased
    to be a member of our advisory board when the scientific results were published on January 25, 2019. Dr. Rogler is the Chairman of
    the Scientific Advisory Board of the University of Zurich and Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist
    at the Division of Gastroenterology &amp; Hepatology, Department of Medicine, Z&#252;rich University Hospital, Switzerland.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUR MARKETED ASSETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Travelan &#8211; Our
Flagship Commercial Asset. </b>Travelan is our over-the-counter gastrointestinal and digestive health supplement. In Australia, Travelan&#174;
is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709), and is indicated to reduce the risk of Travelers&#8217;
Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&#174; is a licensed natural health
product (NPN 80046016) and is indicated to reduce the risk of Travelers&#8217; Diarrhea. In the U.S., Travelan&#174; is sold as a dietary
supplement for digestive tract protection in accordance with section 403 (r)(6) of the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic caused massive international travel restrictions in mid to late March 2020, affecting every Travelan<sup>&#174;</sup>
market, which had a flow-on effect to Q4 FY20 Travelan&#174; sales due to the product&#8217;s positioning as a Travelers&#8217; Diarrhea
therapeutic. Gross worldwide sales of Travelan&#174; increased by 5% in the 2020 fiscal year to A$2.7M. This decline in global sales followed
on from a strong period of ~60% growth in the first 3 quarters of 2020. In the 2021 fiscal year, gross worldwide sales of Travelan&#174;
significantly decreased to A$165,686. </span>&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
re-focused our marketing to promote Travelan<sup>&#174; </sup>and its sister product, Protectyn<sup>&#174;</sup>, for their gut and digestive
health benefits. When travel stops and lockdown requirements see people isolated at home, dietary habits change, with an increasing prevalence
of home food preparation and deliveries of take-away meals. With these adjustments comes the increased risk of variable personal and commercial
food hygiene standards.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OVERVIEW OF TECHNOLOGY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial and
clinical-stage Australian biopharmaceutical company with a proprietary technology platform focused on developing a novel class of biological
polyclonal antibodies that can address significant unmet medical needs. Our primary focus is on developing first-in-class oral polyclonal
antibodies drugs to treat a range of infectious diseases. Compared to other therapeutics, our oral polyclonal antibodies offer targeted
delivery within the gastrointestinal tract and do not cross into the bloodstream, potentially leading to much improved safety and tolerability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The underlying nature of our platform technology enables the development
of medicines across a large range of infectious diseases. The platform can be used to directly block viruses or bacteria and neutralize
the toxins they produce at mucosal surfaces (such as the GI tract). Additionally, the dairy origins of our antibodies enable us to commercialize
our platform through most regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing Process</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">Our active pharmaceutical
ingredients are manufactured under cGMP conditions and many of the components are the same as those of normal cow&#8217;s milk. However,
the main differentiation between milk and our active ingredient constituents is the presence of antibodies in bovine colostrum of the
order of 35-45% by weight of dry colostrum powder. The main classes of immunoglobulins found in the active ingredient are IgG with smaller
amounts of IgM and IgA. Immunoglobulins account for up to 70&#8211;80% of the total protein content in colostrum, whereas in milk they
account for only 1&#8211;2% of total protein. The major class of immunoglobulin G found in bovine colostrum is IgG1 making up between
65% and 90% of total immunoglobulins, in contrast to milk which comprises predominantly IgA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Vaccination</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The active drug substance
is prepared using the first milking colostrum of dairy cows that have been immunized with patented vaccines to produce very high levels
of specific antibodies against selected surface antigens. Pregnant dairy cows at commercial dairy farms are immunized through a proprietary
process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Colostrum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The colostrum is harvested
from immunized Holstein Friesian and Jersey cows registered for milk production for human consumption and at the time of harvesting are
free from antibiotics. They are not given steroids at any stage of the process. Colostrum is harvested at the first milking which will
be within twelve hours of calving, leaving plenty for the calf to feed on.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once harvested, preparation
of the active ingredient complies with processes that are regulated by Dairy Safe standards in addition to the TGA, which is a Federal
requirement and known globally for its stringent criteria. The raw colostrum material is first pasteurized then cooled and centrifuged
using a milk separator to remove somatic cells, cell debris, some bacteria and fat. It is then subjected to membrane ultra-filtration,
removing much of the water, salts and lactose. The colostrum wet concentrate is then spray dried to produce a powder, which is milled
to 200 microns. The processes are typical for the dairy industry and for production of dairy foods. After spray drying, the active ingredient
is ready for further processing into the oral dosage form.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Tableting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The product excipients are
all standard, FDA acceptable oral compounds that are granulated, milled and finally compressed into caplets and blister packaged (pharmaceutical
grade packaging materials).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Batch Consistency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The IgG component of our
active ingredient ranges between 36% and 45%. The parameters are stable within batches and across batches. Our product is stable according
to ICH guidelines and the IgG component of our active ingredient is stable over time and is manufactured under cGMP conditions with all
associated QA and QC processes ensuring the stability of these parameters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Trademarks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have rights to trademarks
and trade names (both registered and unregistered) used in this Annual Report on Form 20-F (this &#8220;Annual Report&#8221;) which are
important to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These trademarks are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
    (registration in U.S.);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan
(registration in U.S., Australia, Canada and China); and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protectyn (registration in Australia and Canada);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Solely for convenience,
trademarks and trade names referred to in this Annual Report appear without the &#8220;<sup>&#174;</sup>&#8221; or &#8220;&#8482;&#8221;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible under
applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or
display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship
of us by, any other companies. Each trademark, trade name or service mark of any other company appearing in this Annual Report is the
property of its respective holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PATENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have a policy to identify,
capture and protect all relevant intellectual property associated within our core business strategies. We own a number of patent families
that have been filed to protect both the vaccine that is used to generate our colostrum enriched with antibodies of choice, as well as
methods of treating certain conditions with the resulting hyper-immune colostrum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our patent rights are supplemented
by a comprehensive body of confidential and proprietary expertise that has been developed over many years and relates to the methods of
production of the hyper-immune colostrum. These trade secrets include information relating to the production system and an effective immunization
process that is approved by an independent animal ethics committee.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended June 30, 2021, we continued
to expand our patent portfolio in various global jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of our principal patent families is set out in the table
below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiry</b></span></td></tr>

<tr style="vertical-align: bottom">
    <td colspan="7" style="font-weight: bold; text-align: left">Composition and Method for the Treatment and Prevention of Enteric Bacterial Infections</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">2004216920</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: center">Australia</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center">Granted</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2,517,911</td>
    <td>&#160;</td>
    <td style="text-align: center">Canada&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EP 16020270.1&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Europe&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Accepted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">230664 B&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">India</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">542088</td>
    <td>&#160;</td>
    <td style="text-align: center">New Zealand</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">9,402,902</td>
    <td>&#160;</td>
    <td style="text-align: center">USA</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">March 4, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">8,637,025</td>
    <td>&#160;</td>
    <td style="text-align: center">USA</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">February 25, 2028</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#8239;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#8239;&#160; &#8239;&#160; &#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8239;&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8239;&#160;&#8239;&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="7" style="font-weight: bold; text-align: left">Methods and Compositions for the Treatment and/or Prophylaxis of Clostridium Difficile Associated Disease</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2014253685</td>
    <td>&#160;</td>
    <td style="text-align: center">Australia&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2,909,636</td>
    <td>&#160;</td>
    <td style="text-align: center">Canada&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Pending</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2986316</td>
    <td>&#160;</td>
    <td style="text-align: center">Europe&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Pending</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">14/785,527</td>
    <td>&#160;</td>
    <td style="text-align: center">USA&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">20210506081.2</td>
    <td>&#160;</td>
    <td style="text-align: center">China&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Pending</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">713233</td>
    <td>&#160;</td>
    <td style="text-align: center">New Zealand&#8239;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Granted</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">April 17, 2034</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="6" style="font-weight: bold; text-align: left">Methods and Compositions</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">PCT/AU2021/050772</td>
    <td>&#160;</td>
    <td style="text-align: center">International</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">Pending</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">July 17, 2041</td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>REGULATORY CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our clinical assets are
considered as biologics by the FDA, conferring 12 years of market exclusivity from date of approval in the U.S. for approved drugs derived
from our technology program. New products in Europe have 10 years of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ongoing research and
development activities, and the production and marketing of our pharmaceutical product candidates derived from those activities will be
subject to regulation by human research ethics committees and institutional research boards, as well as numerous governmental authorities
in Australia, principally the TGA, the FDA in the U.S., the MHRA in the United Kingdom and the EMA in Europe. Prior to marketing, any
therapeutic product developed must undergo rigorous pre-clinical testing and clinical trials, as well as an extensive regulatory approval
process mandated by the TGA and, to the extent that any of our pharmaceutical products under development are marketed abroad, by foreign
regulatory agencies, including the FDA, EMA and MHRA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials can take
many years to complete and require the expenditure of substantial resources. The length of time varies substantially according to the
type, complexity, novelty and intended use of the product candidate. We cannot make any assurances that once clinical trials are completed
by us or our collaborative partners, we will be able to submit as scheduled a marketing approval request to the applicable governmental
regulatory authority, or that such request and application will be reviewed and cleared by such governmental authority in a timely manner,
or at all. Although we intend to make use of fast-track and abbreviated regulatory approval programs when possible and commercially appropriate,
we cannot be certain that we will be able to obtain the clearances and approvals necessary for clinical testing or for manufacturing and
marketing our pharmaceutical products candidates. Delays in obtaining regulatory approvals could adversely affect the development and
commercialization of our pharmaceutical product candidates and could adversely impact our business, financial condition and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the course of clinical
trials and non-clinical studies, including toxicology studies, product candidates may exhibit unforeseen and unacceptable drug-related
toxicities or side effects. If any unacceptable toxicities or side effects were to occur, we may, or regulatory authorities may require
us to, interrupt, limit, delay or abort the development of our potential products. In addition, unacceptable toxicities could ultimately
prevent the clearance of our product candidates by human research ethics committees, institutional research boards, the TGA, EMA, FDA
or other regulatory authority for any or all targeted indications. Even after being cleared by a regulatory authority, any of our products
may later be shown to be unsafe or not to have its purported effect, thereby preventing widespread use or requiring withdrawal from the
market. We cannot make any assurances that IMM-124E, IMM-529 or any other development or product candidate will be safe or effective
when administered to patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. ORGANIZATIONAL STRUCTURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have three wholly-owned
subsidiaries, Immuron Inc., Anadis EPS Pty Ltd (formed for the sole purpose to act as trustee for the Immuron Limited Executive Officer
Share Plan Trust) and Immuron Canada Ltd. All costs associated with the operations of these companies are borne by Immuron Limited. Anadis
ESP Pty Ltd does not form a part of the consolidated accounts as they are not material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. PROPERTY, PLANT AND EQUIPMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate headquarters
are located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia. Our principal office is located at Suite 10, 25-37
Chapman Street, Blackburn North, Victoria 3130 and consists of approximately 1,500 square feet of office and warehouse space under a lease
agreement which is expiring in December 2021, with an ongoing further three-year option for extension. We have no dedicated research and
development facility as our research and development activities are provided by third party suppliers who are responsible for their own
premises. We believe that our existing facilities are adequate for our current needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>The following discussion and
analysis includes certain forward-looking statements with respect to the business, financial condition and results of operations of our
company. The words &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;intend&#8221;, &#8220;expect&#8221; and similar expressions
are intended to identify forward-looking statements within the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by such
forward-looking statements, including those risk factors contained in Item 3.D. of this Annual Report. You should read the following
discussion and analysis in conjunction with our consolidated financial statements and the notes thereto included in this Annual Report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="font-variant: small-caps">Operating
Results</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated under
the laws of Australia in 1994 and have been listed on the ASX since April 30, 1999. Our ADSs and Warrants have traded on The NASDAQ Capital
Market since June 13, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our consolidated financial
statements appearing in this annual report comply with IFRS as issued by IASB. In this annual report, all references to &#8220;U.S. dollars&#8221;
or &#8220;US$&#8221; are to the currency of the U.S., and all references to &#8220;Australian dollars&#8221;, &#8220;A$&#8221; or &#8220;$&#8221;
are to the currency of Australia. Unless otherwise indicated or the context implies otherwise, items included in the financial statements
of each of the group&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#8216;the functional currency&#8217;). The consolidated financial statements are presented in Australian dollar (&#8220;A$&#8221; or
&#8220;$&#8221;), which is Immuron Limited&#8217;s functional and presentation currency. All of our revenues are generated in Australian
dollars, United States dollars and Canadian dollars, and the majority of our expenses are incurred in Australian dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a summary
of the material accounting policies adopted by us in the preparation of the financial report. The accounting policies have been consistently
applied, unless otherwise stated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Basis of Consolidation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements incorporate the financial statements of our company and the entities controlled by us (our subsidiaries) referred to as &#8220;the
group&#8221; or &#8220;the Group&#8221; in the financial statements. Control is achieved where the consolidated entity is exposed to,
or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
to direct the activities of the entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A list of controlled entities
is contained in note 10 to the financial statements. All controlled entities have a June 30 financial year-end. All intra-group transactions,
balances, income and expenses are eliminated in full on consolidation. Accounting policies of subsidiaries have been changed where necessary
to ensure consistency with those policies applied by the parent entity. Subsidiaries are accounted for at cost in the parent entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Revenue Recognition</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>(i) Sale of hyperimmune products</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue arises mainly from
the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with
a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance
obligations and recognising revenue when performance obligations are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue from the sale of
hyperimmune products is recognized when or as the group transfers control of the assets to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is no variable consideration
or significant cost to obtain the contract. There is no warranties and no refunds. Returns are provided where this is outlined in a customer
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>(ii) Financing components</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The group does not expect
to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer
exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Fair value of R&amp;D tax incentive</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The group&#8217;s research
and development (R&amp;D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has
assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized
when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured.
For the year ended June 30, 2021, the group has included an item in other income of A$306,154 (2020: A$308,225) to recognize income over
the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate. Furthermore, the group
subsequently received additional $50,055 in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Intangible Assets &#8211;
Research&#160;&amp;&#160;Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Expenditure on research
activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the statement
of profit or loss and other comprehensive income as an expense when it is incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Expenditure on development
activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially
improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or
service is technically and commercially feasible, will generate probable economic benefits and adequate resources are available to complete
development and cost can be measured reliably. Other development expenditure is recognized in the statement of profit or loss and other
comprehensive income as an expense as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Interest Bearing Loans
and Borrowings</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, loans and borrowings
are initially recognized at cost, being the fair value of the consideration received net of issue costs associated with the borrowing.
After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest
method. Amortized cost is calculated by taking into account any issue costs and any discount or premium on settlement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Inventories</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Raw materials, work in progress
and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct material, freight and import duty.
Management classifies a portion of inventory as a current asset based on an assessment of expected use in the next 12 months. The remainder
is classified as a non-current asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Costs are assigned to individual
items of finished goods inventory on basis of weighted average costs. Net realizable value is the estimated selling price in the ordinary
course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Share-based payments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Share-based compensation
benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option Plan (&#8220;ESOP&#8221;).
Options are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements.
Any options granted are made in accordance with the terms of our ESOP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fair value of options
granted under employment and consultancy agreements are recognized as an employee benefit expense with a corresponding increase in equity.
The fair value is measured at grant date and recognized over the period during which the employees become unconditionally entitled to
the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fair value at grant
date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the
vesting and performance criteria, the impact of dilution, the non-tradable nature of the option, the share price at grant date and expected
price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fair value of the options
granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting
conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the
entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognized
each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognized in the
statement of profit or loss and other comprehensive in come with a corresponding adjustment to equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the exercise of options,
the balance of the share-based payments reserve relating to those options is transferred to contributed equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates and Judgments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management evaluates estimates
and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates
assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>R&amp;D tax incentive</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Group&#8217;s research
and development activities are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management
has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended June 30,
2021 the Group has recorded other income of $306,154 (2020: $308,225) to recognize this amount which relates to this financial year. Furthermore,
the Group subsequently received additional $50,055 in current financial year as part of the R&amp;D claim for financial year ended June
30, 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Impairment of inventories</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The provision for impairment
of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account
the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected
shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Inventory split</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the current financial
period, management performed an assessment on its raw materials and its utilization within 12 months from reporting date. Management determined
that no raw materials relating to Colostrum will be consumed within 12 months from reporting date; the remaining balance of $1,266,587
(2020: $1,722,349) will be consumed after 12 months from reporting dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended June
30, 2020, management has performed an assessment on its raw materials and their utilization within 12 months from reporting date and have
determined none of raw materials relating to Colostrum is expected to be consumed within 12 months (2019: $225,765) and the remaining
balance of $1,722,349 (2019: $1,862,063) is expected to be consumed after 12 months from reporting date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Provision for employee benefits</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.1pt">Provision for employee benefits
represents amounts accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued
for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed
the required period of service. Refer to note 1(r) for policies on provisions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Share-based payments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value attributed to
share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option
pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing
of the conversion of the options to shares and the value of volatility of the price of the underlying shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Fair value measurement hierarchy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the financial
statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements.
Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses.
Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations
of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will
seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections
where applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Estimates and judgements
are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may
have a financial impact on the entity and that are believed to be reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
relates to our consolidated results of operations, financial condition and capital resources. You should read this discussion in conjunction
with our consolidated financial statements and the notes thereto contained elsewhere in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><b><i>Comparison of the
fiscal years ended June 30, 2021 and 2020</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">&#160;<b><i>Revenue and
Other income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the fiscal year ended</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">June
    30,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>Increase/
    </b>&#160;</span></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>(Decrease)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration:underline">Revenue:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Revenue from contracts with
    customers</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>145,776</b></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,518,566</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,372,790</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b>&#160;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Other Income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b>&#160;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Australian Federal R&amp;D tax concession
    refund</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b>356,209</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">308,225</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">COVID-19 government assistance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b>161,600</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">154,904</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,696</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">R&amp;D grants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b>74,821</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">74,821</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>24,480</b></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,545</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,935</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Other Income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>617,110</b></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">473,674</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>143,436</b></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenues received from the
sale of goods decreased by A$2,372,790, or 94%, from fiscal 2020 to fiscal 2021, primarily due to the sales decline in the Australian,
U.S. and North American markets for Travelan products due to the prolonged Covid-19 pandemic. We anticipate that revenues from sales
of our Travelan product will not be able to increase in the near future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the fiscal 2021, the
group has included an item in other income of $306,154 (2020: $308,225) to recognize income over the year necessary to match the R&amp;D
tax incentive on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received
additional $50,055 in fiscal 2021 as part of the R&amp;D claim for fiscal 2020. As a result, our R&amp;D tax concession income recognized
for fiscal 2021 has slightly decreased as compared to for fiscal 2020. The overall decrease is attributed to a decrease in R&amp;D tax
concession expenditure relating to eligible research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The group&#8217;s other
grant income consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group
is reasonably assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June
2021, the group has recognized $161,600 (2020: $154,904) in the COVID-19 government assistance packages and a $74,821 (2020: Nil) R&amp;D
grant from the Henry M Jackson Foundation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other (residual) income,
which is income from inventory disposal and freight income, increased by A$13,935 in fiscal 2021, primarily due to the disposal of inventory
of A$23,249.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Goods Sold and Gross Profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the fiscal year ended</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">June
    30,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase/</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(Decrease)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Revenue from contracts with customers</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">2,518,566</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">(2,372,790</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cost of Goods Sold</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">637,765</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross Profit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">94,705</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,829,730</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,735,025</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our key manufacturing partners
provide us with a quality product at a known price which from a strategic point of view provides us with certainty around the manufacturing
margins. The Company&#8217;s cost of goods sold margin increased to 35% in fiscal 2021 from 27% in fiscal 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; font: bold 10pt Times New Roman, Times, Serif">For the fiscal year ended</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>June
    30,</b></span></td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>Increase/
    </b>&#160;</span></td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2021
    </b>&#160; &#160;</span></td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>(Decrease)</b></span></td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>A$
    </b>&#160; &#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>A$
    </b>&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Expenses:</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>3,978,679</b></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">3,703,990</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">274,689</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><b>2,116,013</b></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(533,912</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,649,925</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b>1,367,054</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,178,685</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">188,369</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>287,684</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">871,551</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(583,867</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><b>7,749,430</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5,220,314</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,529,116</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General and administrative
expenses. </i>General and administrative expenses increased by A$274,689 from fiscal 2020 to fiscal 2021. The increase is mainly attributed
to additional consulting services provided to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Share-based payment expenses.
</i>Share-based payment expenses increased by A$2,649,925 from fiscal 2020 to fiscal 2021. The increase is mainly attributed to the share-based
payments made to employees, consultants and directors of the Company amounting to A$2,116,013 in fiscal 2021 compared to A$73,088 in fiscal
2020. In addition, options granted to Dr Gary Jacob on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject
to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders
with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Research and development
expenses. </i>Research and development expenses increased by A$188,369 from fiscal 2020 to fiscal 2021. The slight increase in the research
and development expenditure reflects the Company&#8217;s continued strategic focus and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Selling and marketing
expenses</i>. Selling and marketing expenses decreased by A$583,867 from fiscal 2020 to fiscal 2021 as the sales decline due to the prolonged
Covid-19 pandemic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Loss for the period</i>.
As a result of the foregoing, our loss for the period after income tax benefit increased by A$5,457,259, or 186%, from A$2,927,206 in
fiscal 2020 to A$8,384,465 in fiscal 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Given our, and our subsidiaries&#8217;,
history of recent losses, we have not recognized a deferred tax asset with regard to unused tax losses and other temporary differences,
as it has not been determined whether we, or our subsidiaries, will generate sufficient future taxable income against which we can utilize
these unused tax losses and any uncalculated potential deferred tax assets, together with any other temporary differences. Should the
need arise, we can, and will, revisit this position.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the fiscal years ended June
30, 2020 and 2019</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the fiscal year ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Increase/</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Decrease)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenue:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Revenue from contracts with customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">131,140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Other Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Australian Federal R&amp;D tax concession refund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(222,780</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Other Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">473,674</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">532,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(58,376</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenues received from the
sale of goods increased by A$131,140, or 5%, from fiscal 2019 to fiscal 2020. The COVID-19 pandemic caused massive international travel
restrictions in mid to late March 2020, affecting every Travelan<sup>&#174;</sup> market which had a flow-on effect to Q4 FY20 Travelan&#174;
sales due to the product&#8217;s positioning as a Travelers&#8217; Diarrhea therapeutic. This decline in global sales followed on from
a strong period of ~60% growth in the first 3 quarters of 2020. In April we re-focussed our marketing to promote Travelan<sup>&#174;</sup>
and its sister product, Protectyn<sup>&#174;</sup>, for their gut and digestive health benefits.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our R&amp;D tax concession
income recognized during fiscal 2020 decreased by A$222,780 compared to fiscal 2019. The overall decrease is attributed to a decrease
in R&amp;D tax concession expenditure relating to eligible research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The group&#8217;s other
grant income consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group
is reasonably assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June
2020, the group has recognized A$154,904 in assistance packages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other (residual) income,
which is interest income, increased by A$9,500 in fiscal 2020, primarily due to an increase in cash and cash equivalents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Goods Sold and Gross Profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the fiscal year ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Increase/</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Decrease)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revenue from contracts with customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">131,140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of Goods Sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,465</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,829,730</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,720,055</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">109,675</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our key manufacturing partners
provide us with a quality product at a known price, which, from a strategic point of view, provides us with certainty around the manufacturing
margins. The Company&#8217;s cost of goods sold margin was broadly maintained year on year with a slight decrease to 27% in fiscal 2020
from 28% in fiscal 2019. As we expand our sales efforts in North America, we have been able to maintain economies of scale thereby broadly
maintaining our cost of goods sold margins.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the fiscal year ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Increase/</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Decrease)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,170,078</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,037,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,867,728</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,178,685</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,044,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,157</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">871,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">864,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,907</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,220,314</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,946,978</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,726,664</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General and administrative
expenses. </i>General and administrative expenses decreased by A$1,867,728 from fiscal 2019 to fiscal 2020. The decrease is mainly attributed
to the share-based payments made to employees, consultants and directors of the Company amounting to A$1,343,500 in fiscal 2019 compared
to A$(533,912) in fiscal 2020 and the resignation of Dr Gary S. Jacob and Mr Richard Jay Berman during fiscal 2020. In December 2019,
a revaluation of share-based payments made to Dr Gary S. Jacob results in a decrease of A$607,000 in the share-based payment expense
recognized in fiscal 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The value and revaluation of
the options granted to Dr Gary S. Jacob and Mr Richard Jay Berman did not result in an actual allocation of shares. The exercise price
of the options is A$0.50 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Research and development
expenses. </i>Research and development expenses increased by A$134,157 from fiscal 2019 to fiscal 2020. The increase in the research
and development expenditure reflects the Company&#8217;s new strategic focus and development pipeline during fiscal 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Selling and marketing
expenses</i>. Selling and marketing expenses increased by A$6,907 from fiscal 2019 to fiscal 2020 as we increased our promotional efforts
for Travelan, our existing flagship consumer product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Loss for the period</i>.
As a result of the foregoing, our loss for the period after income tax benefit decreased by A$1,729,215, or 37%, from A$4,656,421 in
fiscal 2019 to A$2,927,206 in fiscal 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Given our and our subsidiaries&#8217;
history of recent losses, we have not recognized a deferred tax asset with regard to unused tax losses and other temporary differences,
as it has not been determined whether we, or our subsidiaries, will generate sufficient future taxable income against which we can utilize
these unused tax losses and any uncalculated potential deferred tax assets, together with any other temporary differences. Should the
need arise, we can, and will, revisit this position.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inflation and Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management believes inflation
has not had a material impact on our company&#8217;s operations or financial condition and that our operations are not currently subject
to seasonal influences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Conditions in Australia</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are incorporated under the
laws of, and our principal offices and research and development facilities are located in, the Commonwealth of Australia. Therefore,
we are directly affected by political and economic conditions in Australia. See Item 3.D. &#8220;Key Information &#8211; Risk Factors&#8221;
for a description of factors that could materially affect our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Liquidity
and Capital Resources</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred cumulative
losses and negative cash flows from operations since our inception in 1994 and as of June 30, 2021 we had accumulated losses of A$65,932,888.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July 2019, the Company
completed an underwritten public offering of 339,130 ADSs at a public offering price of US$4.00 per ADS for gross proceeds US$1,356,520
(prior to deducting underwriting discounts, commissions and other estimated offering expenses). In May 2019, the Company completed an
underwritten public offering of 500,000 ADSs at a public offering price of US$4.00 per ADS for gross proceeds US$2,000,000 (prior to
deducting underwriting discounts, commissions and other estimated offering expenses). In June 2017, we sold 610,000 ADSs and Warrants
to purchase 701,500 ADSs (not including the 35,075 Representative&#8217;s Warrants) in an initial public offering in the U.S. The aggregate
net offering proceeds to us, after deducting underwriting discounts and commissions, was US$5,673,000. Additionally, in mid-March 2018,
we completed a A$5,161,585 private placement with a large US institutional investment fund. The funds will support current and future
clinical programs, support continued Travelan marketing, and our working capital. We anticipate that we will continue to incur losses
for the foreseeable future. We expect that as we continue research efforts and the development of our product candidates, hire additional
staff, including clinical, scientific, operational, financial and management personnel we will need additional capital to fund our operations
which we may raise through a combination of equity offerings, debt financings, other third-party funding and other collaborations, strategic
alliances and licensing arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The commitment to these
projects will require additional external funding, at least until we are able to generate sufficient cash flow from sale of one or more
of our products to support our continued operations. If adequate funding is not available, we may be required to delay, scale back or
eliminate certain aspects of our operations or attempt to obtain funds through unfavorable arrangements with partners or others that
may force us to relinquish rights to certain of our technologies, products or potential markets or that could impose onerous financial
or other terms. Management is continuing its efforts to obtain additional funds so that we can meet our obligations and sustain operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sale of additional equity
or convertible debt could result in additional dilution to our shareholders. The incurrence of indebtedness would result in debt service
obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that
financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are unable to secure adequate additional
funding we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or
suspend or curtail planned programs. Any of these actions could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not currently have
any credit facilities in place.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021, we
had cash of A$25,047,281 as compared to cash of A$3,250,468 as of June 30, 2020. The company is in a position to meet future commitments
in the current business cycle and pay its debts as and when they fall due. Furthermore, the company is able to progress its research
and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly,
the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts
and classification of liabilities that might be necessary should the group not continue as a going concern. The company is a going concern
and is of the opinion that no asset is likely to be realized for an amount lower than the amount at which it is recorded in our Consolidated
Statement of Financial Position as of June 30, 2021.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that our current
cash, cash equivalents will be sufficient to fund our capital requirements for at least 12 months from the issuance date of the financial
statements. Our future funding requirements will depend on many factors, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and costs of
    our planned clinical trials for our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and costs of
    our planned preclinical studies for our product candidates;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics
    of product candidates that we pursue;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome, timing and
    costs of seeking regulatory approvals;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue received from commercial
    sales of any of our product candidates that may receive regulatory approval;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of
    any future collaborations, licensing, consulting or other arrangements that we may establish;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount and timing of
    any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and
    enforcement of any patents or other intellectual property rights;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing,
    filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual
    property related claims; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we
    need to in-license or acquire other products and technologies.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with our initial
public offering in June 2017, we sold Warrants to purchase 701,500 ADSs at an initial exercise price of US$10.00 per ADS. The Warrants
will expire five years from the date of issuance. Any proceeds from the exercise of the Warrants will be added to our working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the closing of our
initial public offering, we issued Warrants to purchase 30,500 ADSs to the representatives (the &#8220;Representative&#8217;s Warrants&#8221;).
The Representative&#8217;s Warrants are exercisable at a per ADS exercise price equal to US$12.50. The Representative&#8217;s Warrants
are exercisable at any time and from time to time, in whole or in part, during the four-year period commencing one year from the effective
date of the offering. Any proceeds from the exercise of the Representative&#8217;s Warrants will be added to our working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with our public
offering in May and July 2019, we issued Warrants to purchase 20,000 and 13,565 ADSs to the representatives (the &#8220;Representative&#8217;s
Warrants&#8221;), respectively. The Representative&#8217;s Warrants are exercisable at a per ADS exercise price equal to US$5.00. The
Representative&#8217;s Warrants are exercisable at any time and from time to time, in whole or in part, during the four-year period commencing
one year from the effective date of the offering. Any proceeds from the exercise of the Representative&#8217;s Warrants will be added
to our working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the primary sources
and uses of cash for each of the periods set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><b>For the year ended June 30,</b></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,078,747</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,147,328</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,798,579</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash (used in)/from investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,574</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(864</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,008</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash from financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,480,182</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,156,952</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,069,183</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Operating activities.
</i>During the twelve months ended June 30, 2020 and 2021, net cash used in operating activities increased by A$931,419 from A$3,147,328
to A$4,078,747, respectively. Net cash used in operating activities increased by A$1,348,749 from A$1,798,579 in fiscal year 2019 to
A$3,147,328 in fiscal year 2020. The use of net cash in all periods resulted from our ordinary business operations. Net cash used in
operating activities increased by approximately 30% in fiscal year 2021 due to more prompt payments to suppliers during the year which
resulted in increase in operational cash payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Investing activities.
</i>Net cash used in investing activities during the twelve months ended June 30, 2021, 2020 and 2019 were relatively minimal and solely
related to interest received and pertained to purchases of office and computer equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Financing activities.
</i>During the twelve months ended June 30, 2021, net cash provided by financing activities was A$26,480,182, which comprised of proceeds
from issue of securities through a public offering of ADSs (less costs associated with the issue)<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the twelve months
ended June 30, 2020, net cash provided by financing activities was A$1,156,952, which comprised of proceeds from issue of securities
through a public offering of ADSs (less costs associated with the issue).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the twelve months
ended June 30, 2019, net cash provided by financing activities was A$2,069,183, which comprised of proceeds from issue of securities
through a public offering of ADSs (less costs associated with the issue)<i>.</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Contractual Obligations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The group had no contractual obligations other
than those disclosed in Note 14. Leases. The group had no contingent liabilities at 30 June 2021 (2020: nil).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off balance sheet arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not a party to any material off-balance
sheet arrangements. In addition, we have no unconsolidated special purpose financing or partnership entities that are likely to create
material contingent obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Quantitative and qualitative disclosures about market risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risk related to changes in interest rates and exchange rates. As of June 30, 2021, we had cash and cash equivalents
of A$25,047,281, primarily held in bank accounts.</span>&#160;<span style="font-size: 10pt">&#160;&#160;</span> &#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary exposure to market risk is interest rate sensitivity, which is affected primarily by changes in the general level of Australian
interest rates. We are exposed to interest rate risks relating to our cash and borrowings. Interest rate risk is the risk that a financial
instrument&#8217;s value will fluctuate as a result of changes in market interest rates.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to fluctuations
in foreign currencies that arise from foreign currencies held in bank accounts and the translation of results from our operations outside
Australia. Our foreign exchange exposure is primarily to the U.S. dollar and Canadian dollar. Foreign currency risks arising from commitments
in foreign currencies are managed by holding cash in that currency. Foreign currency translation risk is not hedged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="font-variant: small-caps">Research
and Development, Patents and Licenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In recent years, we have
continued our practice of building valuable research collaborations with institutes based in Australia, the United States, Europe and
other countries to enable us to investigate a variety of therapeutic indications including Campylobacter, ETEC, Shigella and Clostridiodies
Infections. These collaborative arrangements ensure that we work with well-respected key opinion leaders and laboratories with specific
expertise in screening and animal modelling of relevance to the particular indication, without incurring ongoing administrative and personnel
costs. We maintain in-house patent counsel and research and development project expertise to coordinate these research collaborations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When a lead compound is
identified as suitable for clinical development, we establish a project team to coordinate all non-clinical and clinical development
and manufacturing activities. Typically, we would project manage all the project activities, tasks and milestones and engage clinical
research organizations and contract manufacturing organizations to assist. We manage our manufacturing campaigns through contract manufacturing
organizations for quality assurance and cGMP compliance. All clinical, non-clinical, clinical development and manufacturing of our compounds
is performed in compliance with the appropriate governing authorities, regulators and standards (for example, the International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
expenses amounted to A$1,044,528, A$1,178,685 and A$1,367,054 during the years ended June 30, 2019, 2020 and 2021, respectively. Costs
associated with patent applications and defense of patent applications are classified as research and development expenses and amounted
to approximately A$142,000, A$79,000 and A$61,000, during the years ended June 30, 2019, 2020 and 2021, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
expenses consist primarily of expenses for contracted research and development activities conducted by third parties on our behalf, including
personnel, testing facilities and other payments in accordance with our research and clinical agreements. Research and development expenses
also include costs associated with the acquisition and development of patents. Due to the numerous variables and the uncertain nature
of the development of a clinical compound, including obtaining regulatory approvals, we are not able to reasonably estimate the nature,
timing and costs of the future expenditures necessary to complete our research and development projects, the anticipated completion dates
of each project and when material net cash flows from our research and development programs will commence.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="font-variant: small-caps">Trend
Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial and clinical
development stage company, and while we believe that our technology will offer novel therapeutic strategies into an expanding market,
we cannot predict with any degree of accuracy the outcome of our research or commercialization efforts. Accordingly, any trends within
the markets in which we operate are expected to have more direct impact on our business in the event that we are successful in commercializing
our new product candidates, including our current lead product candidates.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Over the past few years,
there has been increasing pressure to reduce drug prices in the developed markets as a consequence of political initiatives and regulations
aiming to curb continuous increases in healthcare spending. Any revenue we earn in the future may be negatively affected by such political
initiatives and regulations. The increased burden of healthcare costs in the aging population have led to an increased focus on reducing
costs and, therefore, have further increased the pressure to lower drug prices. We expect this trend to continue in the years ahead.
However, we believe spending in the healthcare industry, as compared to many other industries, is less linked to economic trends. We
expect sales growth to continue at higher levels in emerging markets and also for niche, orphan indications. We also expect that demographic
developments, increased treatment penetration, especially in newly established drug markets, and better diagnostic tools to enable the
tailoring of drugs to specific needs, will result in continuing growth in overall global drug sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. DIRECTORS, SENIOR
MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="font-variant: small-caps">Directors
and Senior Management</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of September 27, 2021, our directors and executive
officers are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 26%; border-bottom: black 1.5pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; border-bottom: black 1.5pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 67%; border-bottom: black 1.5pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Roger Aston</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Chairman</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Daniel Pollock</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Stephen Anastasiou</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Ravi Savarirayan</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jerry Kanellos, Ph.D.</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Phillip Hains</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Secretary</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationships among our directors
and senior executives.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Dr. Roger Aston</i></b>&#160;has
been a member of our board of directors and the board&#8217;s Independent Non-Executive Chairman since March 2012. He also has special
responsibilities as a member of the audit and risk committee and chair of the remuneration committee. Dr. Aston holds a BSc (Hons) and
PhD. He has more than 20 years&#8217; experience in the pharmaceutical and biotechnology industries. Dr Aston was previously the chief
executive officer and a director of Mayne Pharma Group Limited (ASX: MYX). Prior to his position at Mayne Pharma, some of his previous
positions have included chief executive officer of Peptech Limited (ASX: PTD), director of Cambridge Antibody Technology Limited (LSE:
CAT and NASDAQ: CATG) and chairman of Bio Focus Plc (formerly: Cambridge Drug Discovery Limited). Dr Aston was also founder and chief
executive officer of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a director of pSivida
Ltd. During the past 20 years of his career, Dr Aston has been closely involved in the development of many successful pharmaceutical
and biotechnology companies. He has extensive experience including negotiating global license agreements, overseeing product registration
activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials,
overseeing manufacturing of human and veterinary products, private and public fund-raising activities and the introduction of corporate
governance procedures. Dr. Aston&#8217;s other current directorships are with Oncosil Limited (ASX: OSL) since March 2013, Pharmaust
Limited (ASX: PAA) since August 2013, and Resapp Health Limited (ASX: RAP) since July 2015. He held the position of director and chairman
of Regeneus Limited (ASX:RGS) until April 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><b><i>Daniel Pollock&#160;</i></b>has
been a member of our board of directors and our Independent Non-Executive Director since October 2012. He also has special responsibilities
as chair of the audit and risk committee and a member of the remuneration committee. Mr. Pollock holds a Bachelor of Laws and Diploma
in Professional Legal Practice and is a lawyer admitted in both Scotland and Australia and holding practicing certificates in both jurisdictions.
He is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specializes in commercial law.
Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria.
Mr. Pollock has had historical involvement as a seed investor and board member of a number of small unlisted companies. The most recent
of these was an e-pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health
services company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Stephen Anastasiou&#160;</i></b>has
been a member of our board of directors and our Independent Non-Executive Director since May 2013. Mr. Anastasiou holds a Bachelor of
Science (Hons), Graduate Diploma in Marketing and Master of Business Administration. He has over 20 years of experience in general management,
marketing and strategic planning within the healthcare industry. His breadth of experience incorporates medical diagnostics, pharmaceuticals,
hospital, dental and over-the-counter products, with companies including the international pharmaceutical company Bristol-Myers Squibb
(NYSE: BMY). While working with KPMG Peat Marwick as a management consultant, Mr. Anastasiou previously led project teams in a diverse
range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder
of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr. Anastasiou&#8217;s
companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Professor Ravi Savarirayan&#160;</i></b>has
been a member of our board of directors and our Independent Non-Executive Director since April 2017. Prof. Savarirayan holds a Doctor
of Medicine from the University of Melbourne, a Bachelor of Medicine and Bachelor of Surgery from the University of Adelaide, is a Fellow
of the Royal Australasian College of Physicians (FRACP) and is a member of the American Academy of Physician Assistants (ARC-PA, Hons).
He has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and
research group leader of skeletal biology and disease at the Murdoch Children&#8217;s Research Institute since September 2000. Prof.
Savarirayan has served as a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has acted as the chair
of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was
president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international
working committees on constitutional diseases of bone. Prof. Savarirayan&#8217;s primary research focus is on inherited disorders of
the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with
peers from over 30 countries. He has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics
since July 2007, American Journal of Medical Genetics since December 2011 and the Journal of Medical Genetics since June 2005.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Dr. Jerry Kanellos,
Ph.D.</i></b> has been our Chief Executive Officer since March 2020 and our Chief Operating Officer since July 2015, and also served
as our CEO from August 2017 until November 2018 and our Chief Scientific Officer from July 2015 to November 2018. In addition, since
April 2018, Dr. Kanellos has served as a director of Immuron Canada Limited. Dr. Kanellos has over 25 years of experience in the pharmaceutical
and biotechnology industry, and has held leadership roles in executive management, business development, project management, intellectual
property portfolio management research and development. From 2008 until 2012, Dr. Kanellos was the Chief Operating Officer of TransBio
Limited where he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along
with development, management and maintenance responsibility for the intellectual property portfolio, research and development and technology
transfer. Prior to this, Dr. Kanellos worked for five years as a consultant to the biotechnology industry and provided development and
commercialization strategies for various bodies including academic institutes, private and publicly listed companies and government departments
both national and international. He has also been involved in the establishment and management of several startup biotechnology companies.
During his ten year tenure in research and development at CSL Limited, a global specialty biotherapeutics company that develops and delivers
innovative biotherapies, Dr. Kanellos gained considerable experience in the international drug development process, formulation development
through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls programs for the
approval, manufacture and launch of several products. Dr. Kanellos holds a PhD degree in Medicine from the University of Melbourne.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Company secretary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Mr. Phillip Hains
</i></b>was appointed as the secretary of the Company in April 2013. Mr. Hains is a Chartered Accountant operating a specialist public
practice, &#8216;The CFO Solution&#8217;. The CFO Solution focuses on providing back office support, financial reporting and compliance
systems for listed public companies. A specialist in the public company environment, Mr. Hains has served the needs of a number of company
boards and their related committees. He has over 30 years of experience in providing businesses with accounting, administration, compliance
and general management services. He holds a Master of Business Administration from RMIT University and a Public Practice Certificate
from the Chartered Accountants Australia and New Zealand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Compensation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our remuneration policy
is designed to ensure that directors and senior management are appropriately remunerated having regard to their relevant experience,
their performance, the performance of our company, industry norms and standards and the general pay environment as appropriate. Our remuneration
policy has been established to enable us to attract, motivate and retain suitably qualified directors and senior management who will
create value for shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our remuneration policy
is not directly based on our earnings. Our earnings have remained negative since inception due to the nature of our company. Shareholder
wealth reflects this speculative and volatile market sector. No dividends have ever been declared by us. We continue to focus on the
research and development of our intellectual property portfolio with the objective of achieving key development and commercial milestones
in order to add further shareholder value.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Executive Director Remuneration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Similarly, our remuneration
policy is designed to ensure that non-executive directors are appropriately remunerated with respect to their relevant experience, individual
performance, the performance of our company, industry norms/standards and the general pay environment as appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Constitution and the
ASX Listing Rules specify that the aggregate remuneration of non-executive directors shall be determined from time to time by a meeting
of shareholders. An amount (not exceeding the amount approved at the shareholders&#8217; meeting) is determined by the Board and then
divided between the non-executive directors. The latest determination was at the shareholders&#8217; meeting held on November 19, 2018
when shareholders approved the aggregate maximum cash sum to be paid or provided as remuneration to the directors as a whole (other than
the managing director and executive directors) for their services as A$500,000 per annum. This compensation is cash based and includes
stock-based compensation.&#160; As per the ASX announcement on 27 April 2020, the Board of Directors have resolved, for the foreseeable
future, to relinquish cash payments of fees from 1 April 2020 and in lieu of the same receive common stock in the company.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the year ended June 30,
2021, our Non-Executive directors received an aggregate of A$2,532,170, including superannuation and additional consulting fees, and
our executive directors received A$1,673,681. The manner in which the aggregate remuneration is apportioned among non-executive directors
is reviewed periodically. The Board is responsible for reviewing its own performance. Both Board and Board committee performance is monitored
on an informal basis throughout the year with a formal review conducted during the financial year. No retirement benefits are payable
other than statutory superannuation, if applicable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Director and Executive Officer Remuneration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our remuneration policy
is also designed to ensure that executive directors are appropriately remunerated with respect to their relevant experience, individual
performance, the performance of our company, industry norms/standards and the general pay environment as appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our non-executive directors
are responsible for evaluating the performance of the Chief Executive Officer (&#8220;CEO&#8221;) who in turn evaluates the performance
of the other senior executives. The evaluation process is intended to assess our business performance, whether long-term strategic objectives
are being achieved, and the achievement of individual performance objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The performance of our CEO
and senior executives are monitored on an informal basis throughout the year and a formal evaluation is performed annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Fixed Remuneration. </i>Executives&#8217;
fixed remuneration comprises salary and superannuation and is reviewed annually by the CEO, and in turn, the Remuneration Committee.
This review takes into account the executives&#8217; experience, performance in achieving agreed objectives and market factors as appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Variable Remuneration
- Short Term Incentive Scheme. </i>Executives may be entitled to receive a combination of short term incentives (&#8220;STI&#8221;) and
long term incentives (&#8220;LTI&#8221;) as part of their total remuneration if they achieve certain performance indicators as set by
the Board. These STI /LTI may be paid either by cash, or a combination of cash and the issue of equity in our company, at the determination
of the Board and Remuneration Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Remuneration Committee
approves the issuance of bonuses following the recommendations of the CEO in the annual review of the performance of the executives,
and our company as a whole, against agreed key performance indicators (&#8220;KPIs&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Variable Remuneration
- Long Term Incentive Scheme</i>. Executives may also be provided with longer-term incentives through our Employee Share and Option Plan
(&#8220;ESOP&#8221;) that was approved by shareholders at our annual general meeting held on November 13, 2014. The goal of the ESOP
is to allow the executives to participate in, and benefit from, the growth of our company as a result of their efforts and to assist
in motivating and retaining those key employees over the long term. Continued service is the condition attached to the vesting of the
options. The Board at its discretion determines the total number of options granted to each executive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Remuneration paid in Fiscal 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.1pt">The following table sets
forth all compensation we paid for the year ended June 30, 2021 with respect to each of our executive officers and directors during the
2021 fiscal year:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.1pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">Short-term benefits</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Post-<br/> employment<br/> benefits</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Long-<br/> term<br/> benefits</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Share-<br/> based<br/> payments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Cash<br/> salary and fees</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Cash <br/>bonus</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Annual leave</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Super-<br/> annuation</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Long<br/> service<br/> leave</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Other*</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares<sup>1</sup></span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options<sup>2</sup></span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Total</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Non-executive directors</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 19%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Roger Aston<sup>3</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">35,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3,325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">178,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">37,837</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">394,020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">648,682</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Daniel Pollock<sup>4</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">638,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Stephen Anastasiou<sup>5</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">622,520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Ravi Savarirayan<sup>6</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">622,522</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Executive directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter Anastasiou<sup>7</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">857,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,301,158</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other KMP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Dr Jerry Kanellos</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">310,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,609</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,694</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,220</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">372,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total KMP compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">450,002</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">32,609</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,869</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,220</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,571,138</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,912</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,970,100</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,205,850</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.1pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Notes</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>1.</sup></td><td style="text-align: justify">Due to the
                                            ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their
                                            director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that value.
                                            At 30 June 2020, no shares have been issued to directors however the expense of the shares
                                            owed to them is $73,088. As at 30 June 2021, the expenses of have been reclassified from
                                            reserves to share capital and 2,737,500 shares with a total value of $219,000 have been issued
                                            to directors given the shareholders' approval at the AGM held on 29 October 2020.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>2.</sup></td><td style="text-align: justify">Given the shareholders'
                                            approval at the AGM held on 29 October 2020, a total of 9,000,000 ESOP Options were issued
                                            to directors on 13 November 2020 and valued at $1,970,100 in total using the Black-Scholes
                                            option pricing model.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Notes to Other*</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>3.</sup></td><td style="text-align: justify">Dr Roger Aston
                                            received $178,500 of consulting services in relation to research and development portfolio
                                            and clinical review.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>4.</sup></td><td style="text-align: justify">Mr Daniel Pollock
                                            received $178,500 of consulting services in relation to contracts and legal activities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>5.</sup></td><td style="text-align: justify">Mr Stephen
                                            Anastasiou received $178,500 of consulting services in relation to strategic marketing consultancy
                                            and monitoring, strategic market analysis, planning and trend monitoring.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>6.</sup></td><td style="text-align: justify">Prof. Ravi
                                            Savarirayan received $178,500 of consulting services in relation to scientific strategy and
                                            evaluation of current and future medical/scientific projects, patent lodging, and day to
                                            day operational management inputs/activities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>7.</sup></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter Anastasiou resigned on 24 September 2021. During FY 2021, he received $857,138 of consulting fees for the development of the IMM-124E cover antibody research and patents, fees and bonuses for initiation, management of capital raise.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements with Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have contracts with all of our senior management
and employees, and letters of appointment for each of our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Jerry Kanellos</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 23, 2015, we entered
into an Executive Service Agreement with Dr. Jerry Kanellos (the &#8220;Kanellos Agreement&#8221;), pursuant to which Dr. Kanellos is
serving as our Chief Operating &amp; Scientific Officer. Pursuant to the Kanellos Agreement, we will pay Dr. Kanellos A$160,000 per annum.
Following Dr. Kanellos&#8217; appointment as Interim-Chief Executive Officer on August 3, 2017, we increased his base salary to A$210,000
per annum plus 9.5% Australia superannuation guarantee equating to a total remuneration package of A$229,950 per annum. On November 19,
2018, Dr. Jerry Kanellos resigned as Interim CEO and moved to the role of Chief Operating Officer on the same date with no change in
remuneration. On March 25, 2020, Dr. Jerry Kanellos was appointed as CEO. Following Dr. Kanellos&#8217; appointment as CEO, we increased
his base salary to A$260,000 per annum plus 9.5% Australia superannuation guarantee equating to a total remuneration package of A$284,700
per annum.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board will consider
a short and long term share and/or share option incentive package for Dr. Kanellos after twelve months of continuous employment, subject
to any applicable shareholder approval. We or Dr. Kanellos may terminate the Kanellos Agreement without cause on thirty days&#8217; written
notice. Subject to applicable laws and rules, we may elect to pay Dr. Kanellos thirty days&#8217; base salary instead of providing notice.
We may also terminate the Kanellos Agreement for Cause (as defined in the Kanellos Agreement).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Employee Share Option
Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the term of the ESOP
the Board may offer options to key management staff and consultants and in special circumstances may provide financial assistance to
an entitled option holder to assist in the exercise of the ESOP options. The aggregate number of shares that may be issued upon the exercise
of the ESOP options, together with all other share purchase plans for eligible persons, may not at any time exceed 5% of the total number
of our outstanding ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The assessed fair value of
options granted to personnel at their grant date is allocated equally over the period from grant date to vesting date, and the amount
for the current financial year is included in the remuneration table as set out above. Fair values at grant date are determined using
the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the
share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest
rate for the term of the option. The expected price volatility is based on the historic volatility (based on the remaining life of the
options), adjusted for any expected changes to future volatility due to publicly available information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021 the
number of options over ordinary shares in our company held by each director and other key management personnel of our company, including
their personally related parties, are set out below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021 our executive
officers and directors as a group, then consisting of seven persons, held options under our ESOP to purchase an aggregate of 10,422,680
ordinary shares. Of such options, options to purchase 8,100,000 ordinary shares at an exercise price of A$0.12 expire on April 14, 2024,
options to purchase 1,322,680 ordinary shares at an exercise price of US$10 per 40 options expire on June 13, 2022, and options to purchase
1,000,000 ordinary shares at an exercise price of A$0.50 expire on July 1, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><div><a id="a_027"></a></div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="font-variant: small-caps">Board
Practices&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021, our
board of directors consisted of seven members. Directors are elected at each annual general meeting of our shareholders and serve until
their successors are elected or appointed unless their office is earlier vacated. We believe that each of our directors has relevant
industry experience. The membership of our board of directors is directed by the following requirements:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Constitution specifies
    that there must be a minimum of three directors and a maximum of ten directors, and our board of directors may determine the number
    of directors within those limits;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as set forth in our Board
    Charter, the membership of the board of directors should consist of a majority of independent directors who satisfy the criteria
    recommended by the ASX Corporate Governance Principles and Recommendations of the Australian Securities and Investments Commission
    (&#8220;ASIC&#8221;);</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Chairman of our Board
    should be an independent director who satisfies the criteria for independence recommended by the ASX Corporate Governance Principles
    and Recommendations; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors
    should, collectively, have the appropriate level of personal qualities, skills, experience, and time commitment to properly fulfill
    its responsibilities or have ready access to such skills where they are not available.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
delegated responsibility for the conduct of our businesses to the Chief Executive Officer, but remains responsible for overseeing the
performance of management. Our board of directors has established delegated limits of authority, which define the matters that are delegated
to management and those that require board of directors&#8217; approval. Under the Corporations Act, at least two of our directors must
be resident Australians. None of our directors have any service contracts with us that provide for benefits upon termination of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not entered into
any service contracts with our directors providing for benefits upon termination of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Committees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To assist our board of directors
with the effective discharge of its duties, it has established a Remuneration and Nomination Committee and an Audit and Risk Committee,
which committees operate under a specific charter approved by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Remuneration and Nomination
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The members of our Remuneration
and Nomination Committee are Roger Aston and Daniel Pollock, each of whom our board of directors has determined meets the criteria for
independence under NASDAQ Listing Rule 5605(a)(2). Dr. Aston acts as chairman of the committee. The committee&#8217;s role involves:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, evaluating
    and recommending qualified nominees to serve on our board of directors;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating, adopting and
    administering our compensation plans and similar programs advisable for us, as well as modifying or terminating existing plans and
    programs;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing policies with
    respect to equity compensation arrangements; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing, reviewing and
    reporting on various remuneration matters to our board of directors.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Audit and Risk Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The members of our Audit
and Risk Committee are Daniel Pollock and Roger Aston, each of whom our board of directors has determined meets the criteria for independence
of audit committee members set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and the applicable rules of the NASDAQ Capital Market. Each member of our audit committee meets the financial literacy requirements of
the listing standards of the NASDAQ Capital Market. Daniel Pollock acts as the chairman of the audit committee. The principal duties
and responsibilities of our audit committee include, among other things:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and reporting
    on various auditing and accounting matters to our board of directors, including the selection of our independent accountants, the
    scope of our annual audits, fees to be paid to the independent accountants, the performance of our independent accountants and our
    accounting practices;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and reporting
    on various risk management matters to our board of directors;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering and approving
    or disapproving all related-party transactions;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our annual and
    semi-annual financial statements and reports and discussing the statements and reports with our independent registered public accounting
    firm and management;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and pre-approving
    the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating the performance
    of our independent registered public accounting firm and deciding whether to retain their services; and</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures
    for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="font-variant: small-caps">Employees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2021, we had
four full-time employees. Of these full-time employees, two are employed in manufacturing and quality control positions, one is employed
in U.S. sales, one is our COO and CEO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our employees are located in Australia and the
U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. <span style="font-variant: small-caps">Share
Ownership</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Beneficial Ownership of Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth certain information as of September 27, 2021 regarding the beneficial ownership of our ordinary shares by each of our directors
and executive officers and by all of our directors and executive officers as a group.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated,
to our knowledge each shareholder possesses sole voting and investment power over the ordinary shares listed subject to community property
laws, where applicable. None of our shareholders have different voting rights from other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
Ordinary Shares<br/>
Beneficially<br/>
Owned&#160;<sup>(1)</sup></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of<br/>
Ownership&#160;<sup>(2)</sup></b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Roger Aston<sup>(3)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,320,376</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Daniel Pollock<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,568,030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Stephen Anastasiou<sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,990,668</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.47</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof. Ravi Savarirayan<sup>(6)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,777,840</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jerry Kanellos (PhD)<sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Phillip Hains</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">816,804</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers and directors as a group (6 persons)<sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,473,718</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.01</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
                                            ownership is determined in accordance with the rules of the SEC and generally includes voting
                                            or investment power with respect to securities. Ordinary shares relating to options currently
                                            exercisable or exercisable within 60 days of the date of this table are deemed outstanding
                                            for computing the percentage of the person holding such securities but are not deemed outstanding
                                            for computing the percentage of any other person. Except as indicated by footnote, and subject
                                            to community property laws where applicable, the persons named in the table above have sole
                                            voting and investment power with respect to all shares shown as beneficially owned by them.
                                            Except as set forth herein, the address for each of the persons listed in the table above
                                            is Immuron Limited, Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            percentages shown are based on 227,246,596 ordinary shares outstanding as of September 27,
                                            2021, but do not include (i) 16,568,318 ordinary shares issuable upon the exercise of currently
                                            exercisable options that are traded on the ASX and (ii) 27,541,160 ordinary shares issuable
                                            upon exercise of outstanding warrants. Certain warrants have an exercise price of US$10.00
                                            per ADS while other warrants have an exercise price of US$5.00, US$12.50 and US$23.4375 per
                                            ADS.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            warrants to purchase 1,800,000 ordinary shares.</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes warrants to purchase 1,800,000 ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes warrants to purchase 3,108,280 ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes warrants to purchase 900,000 ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the fiscal 2021 year-end, options to purchase 1,000,000 ordinary shares expired on July 1, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 7,608,280 ordinary shares.</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>ITEM 7.
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>A. <span style="font-variant: small-caps">Major
Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth as of September 27, 2021 certain information regarding the beneficial ownership by all shareholders known to us to own beneficially
5% or more of our ordinary shares:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares <br/>
Beneficially Owned <sup>(1)</sup></b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent <sup>(2)</sup></b></span></td>
    <td>&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BNYMC Group</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 9%; text-align: right">97,848,520</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 9%; text-align: right">43.06</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grandlodge Capital Pty Ltd<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">12,261,419</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">5.40</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
                                            ownership is determined in accordance with the rules of the SEC and generally includes voting
                                            or investment power with respect to securities. Ordinary shares relating to options currently
                                            exercisable or exercisable within 60 days of the date of this table are deemed outstanding
                                            for computing the percentage of the person holding such securities but are not deemed outstanding
                                            for computing the percentage of any other person. Except as indicated by footnote, and subject
                                            to community property laws where applicable, the persons named in the table above have sole
                                            voting and investment power with respect to all shares shown as beneficially owned by them.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The
                                            percentages shown are based on 227,246,596 ordinary shares outstanding as of September 27,
                                            2021, but do not include (i) 16,568,318 ordinary shares issuable upon the exercise of currently
                                            exercisable options that are traded on the ASX and (ii) 27,541,160 ordinary shares issuable
                                            upon exercise of outstanding warrants. Certain warrants have an exercise price of US$10.00
                                            per ADS while other warrants have an exercise price of US$5.00, US$12.50 and US$23.4375 per
                                            ADS.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes warrants to purchase 14,400 ordinary shares. Mr. Peter Anastasiou
(resigned on 24 September 2021) is the majority owner of Grandlodge.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant Changes in the Ownership of Major Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Previous substantial shareholders
Citicorp Nominees Pty Limited and Authentics Australia Pty Ltd ceased to be major shareholders following the issuance of securities pursuant
to our public offering in July 2020 as their existing shareholdings were diluted below 5% ownership.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Major Shareholders Voting Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of our shareholders,
including the shareholders listed below, have the same voting rights attached to their ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Record Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of September 27, 2021,
there were 2,895 Immuron shareholders holding 227,246,596 fully paid ordinary shares. These numbers are not representative of the number
of beneficial holders of our shares nor are they representative of where such beneficial holders reside, since many of these ordinary
shares were held of record by brokers or other nominees. The majority of trading by our U.S. investors is done by means of ADS that are
held of record by HSBC Nominees Ltd., which held 98,045,283 (43.14%) of our ordinary shares as of such date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Related
Party Transactions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Grandlodge Capital Pty Ltd
is an entity part-owned and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on
24 September 2021) and Mr. David Plush is also owners of Grandlodge, and its associated entities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Commenced on June 1, 2013,
Grandlodge provides warehousing, distribution and invoicing services for our products for A$70,000 per year. During the 2020 financial
year, the fees of A$70,000 equivalent were repaid by issuance of 437,500 ordinary shares based on a price of A$0.16 per share representing
the share price of our ordinary shares at the commencement date of an oral agreement between us and Grandlodge. During the 2019 financial
year, the fees of A$70,000 equivalent were repaid by issuance of 437,500 ordinary shares based on a price of A$0.16 per share representing
the share price of our ordinary shares at the commencement date of an oral agreement between us and Grandlodge. During the 2018 financial
year, the fees of A$140,000 equivalent were repaid by issuance of 875,000 ordinary shares based on a set price of A$0.16 per share representing
the share price of our ordinary shares at the commencement date of an oral agreement between us and Grandlodge. The 875,000 shares issued
to Grandlodge were in relation to the 2017 and 2018 financial years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Fair value of equity
instruments:</i> Shares issued to Grandlodge Pty Ltd for services. Commencing 1 June 2013, Immuron Limited contracted Grandlodge on normal
commercial terms and conditions to provide warehousing, distribution, and invoicing services for Immuron&#8217;s products for A$70,000
per annum. The terms of the agreement was to have fees payable in new fully paid ordinary shares in Immuron Limited as a set price of
A$0.16 per share. The fair value of the equity instrument has been identified as not having been previously assessed and accounted for
in accordance with IFRS 2 Share Based Payments. Management has undertaken an assessment of the impact of this and concluded this to be
an immaterial error. This has been corrected in the prior year by restating the prior period financial statements presented and the related
notes included herein to present the fair value of equity instruments issued. The immaterial error to record the fair value of the equity
instruments issued for the years 30 June 2014 to 30 June 2017 resulted in an increase of A$297,204 in share capital and a corresponding
increase in accumulated losses. The impact of the 2014-2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years
presented. General and administrative expenses have been revised to increase by A$57,653 and A$23,678 for the fair value of the equity
instruments issued in 2018 and 2019 respectively, with a corresponding increase in share capital for the same amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A new agreement to provide
warehousing, distribution, and invoicing services for Immuron&#8217;s products commenced on July 1, 2020. Grandlodge was contracted on
commercial terms to provide warehousing, distribution and invoicing services for Immuron's products for $70,000 per annum. The terms of
the agreement were to have fees payable in cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Grandlodge is reimbursed
in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both
Grandlodge and we agree to an alternative method of payment. The oral agreement may be terminated by either party upon providing the
other party with 30 days written notice of the termination of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective January 2016, we
executed a Lease Agreement with Wattle Laboratories Pty Ltd, (&#8220;Wattle&#8221;), an entity part-owned and operated by our non-executive
director, Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities for our operations at a rental rate of A$38,940
per year, payable in monthly installments. The rental agreement is subject to annual rental increases, and effective January 2017, the
annual rent was increased to A$39,525. The lease is for a three-year term with an additional three-year option period. The lease may be
terminated by either party upon six months&#8217; written notice. During the fiscal years ended June 30, 2018, 2019 and 2020, we paid
Wattle A$30,019, A$53,958 and A$41,369 (excluding Goods and Services Tax), respectively. The lease was renewed, commencing January 1,
2019 for three years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="font-variant: small-caps">Interests
of Experts and Counsel</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="font-variant: small-caps">Consolidated Statements and Other Financial Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See our consolidated financial statements, including
the notes thereto, included in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not involved in any
legal proceedings nor are we subject to any threatened litigation that is material to our business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend Distribution Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never paid cash
dividends to our shareholders. We intend to retain future earnings for use in our business and do not anticipate paying cash dividends
on our ordinary shares in the foreseeable future. Any future dividend policy will be determined by the Board of Directors and will be
based upon various factors, including our results of operations, financial condition, current and anticipated cash needs, future prospects,
contractual restrictions and other factors as the Board of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Significant
Changes</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been no significant
changes in the operation or financial condition of our company since June 30, 2021.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>ITEM 9.
THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b>A. <span style="font-variant: small-caps">Offer
and Listing Details</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b>Australian Securities Exchange</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ordinary shares have traded on the ASX since
April 30, 1999 under the symbol IMC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NASDAQ Capital Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ADSs and Warrants have
been listed on The NASDAQ Capital Market under the symbol &#8220;IMRN&#8221; and &#8220;IMRNW&#8221;, respectively, since June 13, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>B. <span style="font-variant: small-caps">Plan
of Distribution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>C. <span style="font-variant: small-caps">Markets</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The principal listing of
our ordinary shares is on the ASX, and since June 9, 2017, our ADSs and warrants have traded on The NASDAQ Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>D. <span style="font-variant: small-caps">Selling
Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>E. <span style="font-variant: small-caps">Dilution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>F. <span style="font-variant: small-caps">Expenses
of the Issue</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>ITEM 10.
ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>A. <span style="font-variant: small-caps">Share
Capital</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="font-variant: small-caps">Memorandum
and Articles of Association</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Constitution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Constitution is similar
in nature to the bylaws of a U.S. corporation. It does not provide for or prescribe any specific objectives or purposes of our company.
Our Constitution is subject to the terms of the ASX Listing Rules and the Corporations Act. It may be amended or repealed and replaced
by special resolution of shareholders, which is a resolution passed by at least 75% of the votes cast by shareholders entitled to vote
on the resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Australian law, a
company has the legal capacity and powers of an individual both within and outside Australia. The material provisions of our Constitution
are summarized below. This summary is not intended to be complete or to constitute a definitive statement of the rights and liabilities
of our shareholders. Our Constitution is filed as an exhibit to this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interested Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director may not vote
in respect of any contract or arrangement in which the director has, directly or indirectly, any material interest according to our Constitution.
Such director must not be counted in a quorum, must not vote on the matter and must not be present at the meeting while the matter is
being considered. However, that director may execute or otherwise act in respect of that contract or arrangement notwithstanding any
material personal interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless a relevant exception
applies, the Corporations Act requires our directors to provide disclosure of certain interests or conflicts of interests and prohibits
directors from voting on matters in which they have a material personal interest and from being present at the meeting while the matter
is being considered. In addition, the Corporations Act and the ASX Listing Rules require shareholder approval of any provision of related
party benefits to our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Borrowing Powers Exercisable by Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our Constitution,
the management and control of our business affairs are vested in our board of directors. Our board of directors has the power to raise
or borrow money, and charge any of our property or business or any uncalled capital, and may issue debentures or give any other security
for any of our debts, liabilities or obligations or of any other person, in each case, in the manner and on terms it deems fit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Retirement of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our Constitution
and the ASX Listing Rules, there must be an election of directors at each annual general meeting. The directors, other than the managing
director, who are to stand for election at each annual general meeting are: (i) any director required to retire after a period of three
years in office, (ii) any director appointed by the other directors in the year preceding the annual general meeting, (iii) any new directors,
or (iv) if no person is standing for election for the aforementioned reasons then the director longest in office since last being elected.
A director, other than the director who is the Chief Executive Officer, must retire from office at the conclusion of the third annual
general meeting after which the director was elected. Retired directors are eligible for a re-election to the board of directors unless
disqualified from acting as a director under the Corporations Act or our Constitution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Rights and Restrictions on Classes of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights attaching to
our ordinary shares are detailed in our Constitution. Our Constitution provides that our directors may issue shares with preferred, deferred
or other special rights, whether in relation to dividends, voting, return of share capital or otherwise as our board of directors may
determine. Subject to any approval which is required from our shareholders under the Corporations Act and the ASX Listing Rules (see
&#8220;&#8212;Exemptions from Certain NASDAQ Corporate Governance Rules&#8221; and &#8220;&#8212;Change of Control&#8221;), any rights
and restrictions attached to a class of shares, we may issue further shares on such terms and conditions as our board of directors resolve.
Currently, our outstanding share capital consists of only one class of ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dividend Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
from time to time determine to pay dividends to shareholders. All dividends unclaimed for one year after having been declared may be
invested or otherwise made use of by our board of directors for our benefit until claimed or otherwise disposed of in accordance with
our Constitution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our Constitution,
and subject to any voting exclusions imposed under the ASX Listing Rules (which typically exclude parties from voting on resolutions
in which they have an interest), the rights and restrictions attaching to a class of shares, each shareholder has one vote on a show
of hands at a meeting of the shareholders unless a poll is demanded under the Constitution or the Corporations Act. On a poll vote, each
shareholder shall have one vote for each fully paid share and a fractional vote for each share held by that shareholder that is not fully
paid, such fraction being equivalent to the proportion of the amount that has been paid to such date on that share. Shareholders may
vote in person or by proxy, attorney or representative. Under Australian law, shareholders of a public company are not permitted to approve
corporate matters by written consent. Our Constitution does not provide for cumulative voting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Note that ADS holders may
not directly vote at a meeting of the shareholders but may instruct the depositary to vote the number of deposited ordinary shares their
ADSs represent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Right to Share in Our Profits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our Constitution,
our shareholders are entitled to participate in our profits only by payment of dividends. Our board of directors may from time to time
determine to pay dividends to the shareholders; however, no dividend is payable except in accordance with the thresholds set out in the
Corporations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Rights to Share in the Surplus in the Event of Liquidation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Constitution provides
for the right of shareholders to participate in a surplus in the event of our liquidation, subject to the rights attaching to a class
of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Redemption Provision for Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no redemption
provisions in our Constitution in relation to ordinary shares. Under our Constitution, any preference shares may be issued on the terms
that they are, or may at our option be, liable to be redeemed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Variation or Cancellation of Share Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the terms of
issue of shares of that class, the rights attached to shares in a class of shares may only be varied or cancelled by a special resolution
of our company together with either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a special resolution
                                            passed at a separate general meeting of members holding shares in the class; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the written consent
                                            of members with at least 75% of the shares in the class.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Directors May Make Calls</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Constitution provides
that subject to the terms on which the shares have been issued directors may make calls on a shareholder for amounts unpaid on shares
held by that shareholder, other than monies payable at fixed times under the conditions of allotment. Shares represented by the ADSs
are fully paid and are not subject to calls by directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General Meetings of Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General meetings of shareholders
may be called by our board of directors. Except as permitted under the Corporations Act, shareholders may not convene a meeting. The
Corporations Act requires the directors to call and arrange to hold a general meeting on the request of shareholders with at least 5%
of the votes that may be cast at a general meeting or at least 100 shareholders who are entitled to vote at the general meeting. Notice
of the proposed meeting of our shareholders is required at least 28 clear days prior to such meeting under the Corporations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Foreign Ownership Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no limitations
on the rights to own securities imposed by our Constitution. However, acquisitions and proposed acquisitions of securities in Australian
companies may be subject to review and approval by the Australian Federal Treasurer under the Foreign Acquisitions and Takeovers Act
1975, or the FATA, which generally applies to acquisitions or proposed acquisitions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">by a foreign person
                                            (as defined in the FATA) or associated foreign persons that would result in such persons
                                            having an interest in 20% or more of the issued shares of, or control of 20% or more of the
                                            voting power in, an Australian company; and</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">by non-associated
                                            foreign persons that would result in such foreign person having an interest in 40% or more
                                            of the issued shares of, or control of 40% or more of the voting power in, an Australian
                                            company, where the Australian company is valued above the monetary threshold prescribed by
                                            FATA.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, no such review
or approval under the FATA is required if the foreign acquirer is a U.S. entity and the value of the target is less than A$1.094 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Australian Federal Treasurer
may prevent a proposed acquisition in the above categories or impose conditions on such acquisition if the Treasurer is satisfied that
the acquisition would be contrary to the national interest. If a foreign person acquires shares or an interest in shares in an Australian
company in contravention of the FATA, the Australian Federal Treasurer may order the divestiture of such person&#8217;s shares or interest
in shares in that Australian company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ownership Threshold</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no provisions
in our Constitution that require a shareholder to disclose ownership above a certain threshold. The Corporations Act, however, requires
a shareholder to notify us and the ASX once it, together with its associates, acquires a 5% interest in our ordinary shares, at which
point the shareholder will be considered to be a &#8220;substantial&#8221; shareholder. Further, once a shareholder owns a 5% interest
in us, such shareholder must notify us and the ASX of any increase or decrease of 1% or more in its holding of our ordinary shares, and
must also notify us and the ASX on its ceasing to be a &#8220;substantial&#8221; shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issues of Shares and Change in Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to our Constitution,
the Corporations Act, the ASX Listing Rules and any other applicable law, we may at any time issue shares and grant options or warrants
on any terms, with preferred, deferred or other special rights and restrictions and for the consideration and other terms that the directors
determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the requirements
of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including relevant shareholder approvals,
we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our share capital (provided that
the reduction is fair and reasonable to our shareholders as a whole and does not materially prejudice our ability to pay creditors) or
buy back our ordinary shares whether under an equal access buy-back or on a selective basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Change of Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Takeovers of listed Australian
public companies, such as ours are regulated by the Corporations Act, which prohibits the acquisition of a &#8220;relevant interest&#8221;
in issued voting shares in a listed company if the acquisition will lead to that person&#8217;s or someone else&#8217;s voting power
in our company increasing from 20% or below to more than 20% or increasing from a starting point that is above 20% and below 90%, subject
to a range of exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a person will
have a relevant interest in securities if the person:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">is the holder
                                            of the securities;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">has power to exercise,
                                            or control the exercise of, a right to vote attached to the securities; or</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">has the power
                                            to dispose of, or control the exercise of a power to dispose of, the securities, including
                                            any indirect or direct power or control.</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If, at a particular time, a person has a relevant
interest in issued securities and the person:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">has entered or
                                            enters into an agreement with another person with respect to the securities;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">has given or gives
                                            another person an enforceable right, or has been or is given an enforceable right by another
                                            person, in relation to the securities (whether the right is enforceable presently or in the
                                            future and whether or not on the fulfillment of a condition);</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">has granted or
                                            grants an option to, or has been or is granted an option by, another person with respect
                                            to the securities; or</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the other person
                                            would have a relevant interest in the securities if the agreement were performed, the right
                                            enforced or the option exercised; the other person is presumed to already have a relevant
                                            interest in the securities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are a number of exceptions
to the above prohibition on acquiring a relevant interest in issued voting shares above 20%. In general terms, some of the more significant
exceptions include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            results from the acceptance of an offer under a formal takeover bid;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            is conducted on market by or on behalf of the bidder under a takeover bid, the acquisition
                                            occurs during the bid period, the bid is for all the voting shares in a bid class and the
                                            bid is unconditional or only conditioned on prescribed matters set out in the Corporations
                                            Act;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when shareholders
                                            of our company approve the takeover by resolution passed at general meeting;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an acquisition
                                            by a person if, throughout the six months before the acquisition, that person or any other
                                            person has had voting power in our company of at least 19% and, as a result of the acquisition,
                                            none of the relevant persons would have voting power in our company more than three percentage
                                            points higher than they had six months before the acquisition;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            results from the issue of securities under a rights issue;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            results from the issue of securities under dividend reinvestment schemes;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            results from the issue of securities under underwriting arrangements;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">when the acquisition
                                            results from the issue of securities through operation of law;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an acquisition
                                            that arises through the acquisition of a relevant interest in another listed company which
                                            is listed on a prescribed financial market or a financial market approved by ASIC;</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an acquisition
                                            arising from an auction of forfeited shares conducted on-market; or</td>
</tr></table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an acquisition
                                            arising through a compromise, arrangement, liquidation or buy-back.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Breaches of the takeovers
provisions of the Corporations Act are criminal offenses. ASIC and the Australian Takeover Panel have a wide range of powers relating
to breaches of takeover provisions, including the ability to make orders canceling contracts, freezing transfers of, and rights attached
to, securities, and forcing a party to dispose of securities. There are certain defenses to breaches of the takeover provisions provided
in the Corporations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Access to and Inspection of Documents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inspection of our records
is governed by the Corporations Act. Any member of the public has the right to inspect or obtain copies of our registers on the payment
of a prescribed fee. Shareholders are not required to pay a fee for inspection of our registers or minute books of the meetings of shareholders.
Other corporate records, including minutes of directors&#8217; meetings, financial records and other documents, are not open for inspection
by shareholders. Where a shareholder is acting in good faith and an inspection is deemed to be made for a proper purpose, a shareholder
may apply to the court to make an order for inspection of our books.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>C. <span style="font-variant: small-caps">Material
Contracts</span></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We entered into a Development
and Supply Agreement with Synlait Milk Ltd. on June 21, 2016. Pursuant to the agreement, Synlait Milk, a large dairy farm company located
in New Zealand, agreed to vaccinate their cow herds with IMM- 124E vaccine and to collect the hyperimmune colostrum from the first milking
of the cows at calving. This colostrum, which contains the vaccine antibodies, is then spray or freeze dried and tested for the vaccine
properties. If levels of the vaccine are sufficient and meet our product specifications, the dried hyperimmune colostrum is then shipped
to our warehouse in Melbourne, Australia.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 16, 2016, we
entered into a Convertible Security and Share Purchase Agreement with SBI Investments which provided us with a line of funding from which
we could draw down funding to continue our ongoing operations. The convertible note comprised of three tranches, of which we drew down
the first two tranches, totaling A$1.2 million in the aggregate. The note was repayable in 18 equal monthly installments payable on the
15th day of each month either by the issuance of equity at a discount to the market rate at the time of issue, or by a cash payment plus
a 2.5% premium. The final payment with respect to this convertible note was repaid on September 10, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><b>D. <span style="font-variant: small-caps">Exchange
Controls</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australia has largely abolished
exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In addition, there are currently
no specific rules or limitations regarding the export from Australia of profits, dividends, capital, or similar funds belonging to foreign
investors, except that certain payments to non-residents must be reported to the Australian Cash Transaction Reports Agency, which monitors
such transactions, and amounts on account of potential Australian tax liabilities may be required to be withheld unless a relevant taxation
treaty can be shown to apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Foreign Acquisitions and Takeovers Act 1975</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Australian law, in
certain circumstances foreign persons are prohibited from acquiring more than a limited percentage of the shares in an Australian company
without notification to or approval from the Australian Treasurer. These limitations are set forth in the Australian Foreign Acquisitions
and Takeovers Act, or the Takeovers Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Takeovers Act,
as currently in effect, any foreign person, together with associates, is prohibited from acquiring 15% or more of the shares in any company
having total assets exceeding A$252 million or more. In addition, a foreign person may not acquire shares in a company having total assets
of A$252 million or more if, as a result of that acquisition, the total holdings of all foreign persons and their associates will exceed
40% in aggregate without the approval of the Australian Treasurer. However, for &#8220;U.S. Investors&#8221; and investors from certain
other countries, a threshold of A$1.094 million applies (except in certain circumstances) to each of the previous acquisitions. A &#8220;U.S.
Investor&#8221; is defined by the Takeovers Act as a U.S. national or a U.S. enterprise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the necessary approvals
are not obtained, the Treasurer may make an order requiring the acquirer to dispose of the shares it has acquired within a specified
period of time. Under the current Australian foreign investment policy, however, it is unlikely that the Treasurer would make such an
order where the level of foreign ownership exceeds 40% in the ordinary course of trading, unless the Treasurer finds that the acquisition
is contrary to the national interest. The same rule applies if the total holdings of all foreign persons and their associates already
exceeds 40% and a foreign person (or its associate) acquires any further shares, including in the course of trading in the secondary
market of the ADSs. At present, we do not have total assets of A$252 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the level of foreign
ownership exceeds 40% at any time, we would be considered a foreign person under the Takeovers Act. In such event, we would be required
to obtain the approval of the Treasurer for our company, together with our associates, to acquire (i) more than 15% of an Australian
company or business with assets totaling over A$252 million; or (ii) any direct or indirect ownership interest in Australian residential
real estate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The percentage of foreign
ownership in our company would also be included in determining the foreign ownership of any Australian company or business in which it
may choose to invest. Since we have no current plans for any such acquisitions and do not own any property, any such approvals required
to be obtained by us as a foreign person under the Takeovers Act will not affect our current or future ownership or lease of property
in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Constitution does not
contain any additional limitations on a non-resident&#8217;s right to hold or vote our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australian law requires
the transfer of shares in our company to be made in writing. No stamp duty will be payable in Australia on the transfer of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>E. <span style="font-variant: small-caps">Taxation</span></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a discussion
of Australian and U.S. tax considerations material to our shareholders. To the extent that the discussion is based on tax legislation
which has not been subject to judicial or administrative interpretation, the views expressed in the discussion might not be accepted
by the tax authorities in question or by court. The discussion is not intended, and should not be construed, as legal or professional
tax advice and does not exhaust all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><b>Holders of our ADSs should
consult their own tax advisors as to the United States, Australian or other tax consequences of the purchase, ownership and disposition
of ADSs, including, in particular, the effect of any foreign, state or local taxes.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AUSTRALIAN TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In this section, we discuss
the material Australian tax considerations that apply to non-Australian tax residents with respect to the acquisition, ownership and disposal
of the absolute beneficial ownership of ADSs, which are evidenced by ADRs. This discussion is based upon existing Australian tax law as
of the date of this annual report, which is subject to change, possibly retrospectively. This discussion does not address all aspects
of Australian income tax law which may be important to particular investors in light of their individual investment circumstances, such
as ADSs or shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt
organizations). In addition, this summary does not discuss any foreign or state tax considerations, other than stamp duty.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prospective investors are
urged to consult their tax advisors regarding the Australian and foreign income and other tax considerations of the purchase, ownership
and disposition of the ADSs or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nature of ADSs for Australian Taxation Purposes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Holders of our ADSs are
treated as the owners of the underlying ordinary shares for Australian income tax and capital gains tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Therefore, dividends paid
on the underlying ordinary shares will be treated for Australian tax purposes as if they were paid directly to the owners of ADSs, and
the disposal of ADSs will be treated for Australian tax purposes as the disposal of the underlying ordinary shares. In the following
analysis we discuss the application of the Australian income tax and capital gains tax rules to non-Australian resident holders of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Taxation of Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australia operates a dividend
imputation system, under which dividends may be declared to be &#8216;franked&#8217; to the extent of tax paid on company profits. Fully
franked dividends are not subject to dividend withholding tax. Dividends that are not franked or are partly franked and are paid to non-Australian
resident shareholders are subject to dividend withholding tax, but only to the extent the dividends are not franked.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unfranked dividends paid
to a non-resident shareholder are subject to withholding tax at 30%, unless the shareholder is a resident of a country with which Australia
has a double taxation agreement. In accordance with the provisions of the Double Taxation Convention between Australia and the U.S.,
the maximum rate of Australian tax on unfranked dividends to which a resident of the U.S. is beneficially entitled is 15%, where the
U.S. resident holds less than 10% of the voting rights in our company, or 5% where the U.S. resident holds 10% or more of the voting
rights in our company. The Double Taxation Convention between Australia and the U.S. does not apply to limit the tax rate on dividends
where the ADSs are effectively connected to a permanent establishment or a fixed base carried on by the owner of the ADSs in Australia
through which the shareholder carries on business or provides independent personal services, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Tax on Sales or other Dispositions of Shares - Capital Gains Tax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australian capital gains
derived by non-Australian residents in respect of the disposal of capital assets that are not taxable Australian property will be disregarded.
Non-Australian resident shareholders will not be subject to Australian capital gains tax on the capital gain made on a disposal of our
shares, unless they, together with associates, hold 10% or more of our issued capital, tested either at the time of disposal or over
any continuous 12 month period in the 24 months prior to disposal, and the value of our shares at the time of disposal are wholly or
principally attributable to Australian real property assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Australian capital gains
tax applies to net capital gains at a taxpayer&#8217;s marginal tax rate. Previously, certain shareholders, such as individuals were
entitled to a discount of 50% for capital gains on shares held for greater than 12 months. However, as part of the 2012-2013 Federal
Budget measures, the Australian Government announced changes to the application of the CGT discount for foreign resident individuals
on taxable Australian assets, including shares. These changes became effective on 29 June 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The effect of the change
is to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Retain access
                                            to the full CGT discount for discount capital gains of foreign resident individuals in respect
                                            of the increase in the value of a CGT asset that occurred before 9 May 2013; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Remove the CGT
                                            discount for discount capital gains for foreign resident individuals that arise after 8 May
                                            2013.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign residents will still
have access to a discount on discount capital gains accrued prior to 8 May 2013 provided they choose to obtain a market valuation for
their assets as at that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net capital gains are calculated
after reduction for capital losses, which may only be offset against capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Tax on Sales or other Dispositions of Shares - Shareholders Holding
Shares on Revenue Account</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some non-Australian resident
shareholders may hold shares on revenue rather than on capital account, for example, share traders. These shareholders may have the gains
made on the sale or other disposal of the shares included in their assessable income under the ordinary income provisions of the income
tax law, if the gains are sourced in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-Australian resident
shareholders assessable under these ordinary income provisions in respect of gains made on shares held on revenue account would be assessed
for such gains at the Australian tax rates for non-Australian residents, which start at a marginal rate of 32.5% for non-Australian resident
individuals. Some relief from the Australian income tax may be available to such non-Australian resident shareholders under the Double
Taxation Convention between the U.S. and Australia, for example, because the shareholder does not have a permanent establishment in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent an amount
would be included in a non-Australian resident shareholder&#8217;s assessable income under both the capital gains tax provisions and
the ordinary income provisions, the capital gain amount would generally be reduced, so that the shareholder would not be subject to double
tax on any part of the income gain or capital gain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dual Residency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a shareholder were a
resident of both Australia and the U.S. under those countries&#8217; domestic taxation laws, that shareholder may be subject to tax as
an Australian resident. If, however, the shareholder is determined to be a U.S. resident for the purposes of the Double Taxation Convention
between the U.S. and Australia, the Australian tax applicable would be limited by the Double Taxation Convention. Shareholders should
obtain specialist taxation advice in these circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stamp
Duty</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
transfer of shares of a company listed on the ASX is not subject to Australian stamp duty except in some circumstances where one person,
or associated persons, acquires 90% or more of the shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
Death Duty</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia
does not have estate or death duties. No capital gains tax liability is realized upon the inheritance of a deceased person&#8217;s shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disposal of inherited shares by beneficiaries, may, however, give rise to a capital gains tax liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
and Services Tax</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issue or transfer of shares will not incur Australian goods and services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain material U.S. federal income tax consequences that generally apply to U.S. Holders (as defined below)
who hold ADSs as capital assets. This summary is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;),
Treasury regulations promulgated thereunder, judicial and administrative interpretations thereof, and the bilateral taxation convention
between Australia and the U.S. (the &#8220;Tax Treaty&#8221;), all as in effect on the date hereof and all of which are subject to change
either prospectively or retroactively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not discuss all the tax consequences that may be relevant to an investment in ADSs by a U.S. Holder in light of such holder&#8217;s
particular circumstances or to U.S. Holders subject to special rules, including broker-dealers, banks or other financial institutions,
traders in securities who elect to use a mark-to-market method of accounting for securities holdings, insurance companies, investors
liable for alternative minimum tax, tax-exempt organizations, regulated investment companies or real estate investment trusts, non-resident
aliens of the U.S. or taxpayers whose functional currency is not the U.S. dollar, partnerships or other pass-through entities for U.S.
federal income tax purposes or persons holding ADSs through any such entities, persons who acquired their ADSs through the exercise or
cancellation of any employee stock options or otherwise as compensation for their services, investors that actually or constructively
own 10% or more of our shares by vote or value, and investors holding ADSs as part of a straddle or appreciated financial position or
as part of a hedging or conversion transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership or an entity treated as a partnership for U.S. federal income tax purposes owns ADSs, the U.S. federal income tax treatment
of a partner in such a partnership will generally depend upon the status of the partner and the activities of the partnership. A partnership
that owns ADSs and each partner in such partnership should consult its own tax advisors about the U.S. federal income tax consequences
of holding and disposing of ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not address the effect of any U.S. federal taxation other than U.S. federal income taxation. In addition, this summary does
not include any discussion of U.S. federal estate and gift tax, state, local or foreign taxation. You are urged to consult your tax advisors
regarding the particular U.S. federal income tax consequences to you relating to the purchase, ownership and disposition of ADSs, the
consequences to you under any foreign taxing jurisdiction, as well as the U.S. federal, state and local tax considerations of an investment
in ADSs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this summary, the term &#8220;U.S. Holder&#8221; means an (i) individual who is a citizen or, for U.S. federal income tax
purposes, a resident of the U.S., (ii) a corporation or other entity taxable as a corporation created or organized in or under the laws
of the U.S. or any political subdivision thereof, (iii) an estate whose income is subject to U.S. federal income tax regardless of its
source, or (iv) a trust if (a) a court within the U.S. is able to exercise primary supervision over administration of the trust, and
one or more U.S. persons have the authority to control all substantial decisions of the trust or (b) it has a valid election in effect
under applicable U.S. Treasury regulations to be treated as a U.S. person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation
of Dividends on ADSs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
U.S. federal income tax purposes, U.S. Holders of ADSs will be treated as owning the underlying ordinary shares represented by the ADSs
held by them. Subject to the passive foreign investment company, or PFIC rules discussed below, the gross amount of any distributions
received with respect to the underlying ordinary shares represented by the ADSs, including the amount of any taxes withheld therefrom,
will constitute dividends for U.S. federal income tax purposes, to the extent of our current and accumulated earnings and profits, as
determined under U.S. federal income tax principles. You will be required to include this amount of dividends in gross income as ordinary
income. Distributions in excess of our earnings and profits will be treated as a non-taxable return of capital to the extent of your
tax basis in the ADSs, and any amount in excess of your tax basis will be treated as gain from the sale of ADSs. See &#8220;<i>Disposition
of ADSs</i>&#8221; below for the discussion on the taxation of capital gains. Dividends will not qualify for the dividends-received deduction
generally available to corporations under Section 243 of the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
that we pay in Australian dollars, including the amount of any Australian taxes withheld therefrom, will be included in your income in
a U.S. dollar amount calculated by reference to the exchange rate in effect on the day such dividends are received. A U.S. Holder who
receives payment in Australian dollars and converts Australian dollars into U.S. dollars at an exchange rate other than the rate in effect
on such day will likely have a foreign currency exchange gain or loss, which would be treated as U.S.-source ordinary income or loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to complex limitations, any Australian withholding tax imposed on our dividends will be a foreign income tax eligible for credit against
a U.S. Holder&#8217;s U.S. federal income tax liability (or, alternatively, for deduction against income in determining such tax liability).
The limitations set forth in the Code include computational rules under which foreign tax credits allowable with respect to specific
classes of income cannot exceed the U.S. federal income taxes otherwise payable with respect to each such class of income. Dividends
generally will be treated as foreign-source passive category income or general category income for U.S. foreign tax credit purposes,
depending upon the holder&#8217;s circumstances. The rules relating to the determination of the foreign tax credit are complex. You should
consult with your own tax advisors to determine whether and to what extent you would be entitled to this credit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, &#8220;qualified dividend income&#8221; received by a non-corporate U.S. Holder will be subject to tax at a reduced
maximum tax rate of 20 percent. Distributions taxable as dividends generally qualify for the 20 percent rate provided that either: (i)
the issuer is entitled to benefits under the Tax Treaty or (ii) the ADSs are readily tradable on an established securities market in
the U.S. and certain other requirements are met. We believe that we are entitled to benefits under the Tax Treaty and that the ADSs currently
are readily tradable on an established securities market in the U.S. However, no assurance can be given that the ADSs will remain readily
tradable. Furthermore, the reduced rate does not apply to dividends received from PFICs. The amount of foreign tax credit is limited
in the case of foreign qualified dividend income. U.S. Holders of ADSs should consult their own tax advisors regarding the effect of
these rules in their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disposition
of ADSs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you sell or otherwise
dispose of ADSs, you will recognize gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the
amounts realized on the sale or other disposition and your adjusted tax basis in the ADSs. Subject to the PFIC rules discussed below,
such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if you have held the ADSs for more
than one year at the time of the sale or other disposition. In general, any gain that you recognize on the sale or other disposition
of ADSs will be U.S.-source for purposes of the foreign tax credit limitation; losses will generally be allocated against U.S.-source
income. Deduction of capital losses is subject to certain limitations under the Code. U.S. Holders are urged to consult their tax advisors
regarding the tax consequences that may occur when a foreign withholding tax is imposed on a disposition of our ADSs, including the availability
of the foreign tax credit under such U.S. Holder&#8217;s particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Passive
Foreign Investment Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Code provides special, generally adverse, rules regarding certain distributions received by U.S. Holders with respect to, and sales,
exchanges and other dispositions, including pledges, of, shares of stock of a PFIC. A foreign corporation will be a PFIC for any taxable
year if at least 75% of its gross income for the taxable year is passive income or at least 50% of its gross assets during the taxable
year, based on a quarterly average and generally by value, produce or are held for the production of passive income. Passive income for
this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions
and gains from the disposition of assets that produce or are held for the production of passive income. In determining whether a foreign
corporation is a PFIC, a pro-rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least
a 25% interest (by value) is taken into account.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on our business results
for the last fiscal year and the composition of our assets, we believe that we were not a PFIC for U.S. federal income tax purposes for
the taxable year ended June 30, 2021. However, the determination of PFIC status is a factual determination that must be made annually
at the close of each taxable year and therefore, there can be no certainty as to our PFIC status for a taxable year until the close of
that taxable year. Our PFIC status could change depending upon, among other things, a decrease in the trading price of our ordinary shares
or ADSs and how quickly we make use of the cash proceeds from any offering, as well as changes in the composition and relative values
of our assets and the composition of our income. Moreover, the rules governing whether certain assets are active or passive are complex
and in some cases their application can be uncertain. If we were a PFIC in any year during a U.S. Holder&#8217;s holding period for the
ordinary shares or ADSs, we generally would continue to be treated as a PFIC for each subsequent year during which the U.S. Holder owned
the ordinary shares or ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds ordinary shares or ADSs, any &#8220;excess distribution&#8221; that
the holder receives and any gain recognized from a sale or other disposition (including a pledge) of such ordinary shares or ADSs will
be subject to special tax rules, unless the U.S. Holder makes a mark-to-market election (provided the ADSs are &#8220;marketable&#8221;)
or qualified electing fund election, as discussed below. Any distribution in a taxable year that is greater than 125% of the average
annual distribution received by a U.S. Holder during the shorter of the three preceding taxable years or such holder&#8217;s holding
period for the ordinary shares or ADSs will be treated as an excess distribution. Under these special tax rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            excess distribution or gain will be allocated ratably over the U.S. Holder&#8217;s holding
                                            period for the ordinary shares or ADSs;</span></td></tr>
</table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amount allocated to the current taxable year, and any taxable year prior to the first taxable
                                            year in which we were a PFIC in the U.S. Holder&#8217;s holding period, will be treated as
                                            ordinary income arising in the current taxable year; and</span></td></tr>
</table><div>
</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amount allocated to each other year will be subject to income tax at the highest rate in
                                            effect for that year and applicable to the U.S. Holder and the interest charge generally
                                            applicable to underpayments of tax will be imposed on the resulting tax attributable to each
                                            such year.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC, the tax liability for amounts allocated to years prior to the year of disposition or excess distribution cannot be offset
by any net operating loss, and gains (but not losses) recognized on the transfer of the ordinary shares or ADSs cannot be treated as
capital gains, even if the ordinary shares or ADSs are held as capital assets. In addition, non-corporate U.S. Holders will not be eligible
for reduced rates of taxation on any dividends that we pay if we are a PFIC for either the taxable year in which the dividend is paid
or the preceding year. Furthermore, unless otherwise provided by the U.S. Treasury Department, each U.S. Holder of a PFIC is required
to file an annual report containing such information as the U.S. Treasury Department may require.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which any of our non-U.S. subsidiaries is also a PFIC, a U.S. Holder of ordinary shares or
ADSs during such year would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes
of the application of these rules to such subsidiary. You should consult your tax advisors regarding the tax consequences if the PFIC
rules apply to any of our subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, in lieu of being subject to the adverse tax rules discussed above, you may make an election to include gain on
the stock of a PFIC as ordinary income under a mark-to-market method, provided that such stock is regularly traded on a qualified exchange,
or &#8220;marketable&#8221;. Under current law, the mark-to-market election may be available to U.S. Holders of ADSs if the ADSs are
listed on NASDAQ, which constitutes a qualified exchange. As stated above, the ADSs will be listed on NASDAQ. However, there can be no
assurance that the ADSs will be &#8220;regularly traded&#8221; for purposes of the mark-to-market election. It should also be noted that
it is intended that only the ADSs and not the ordinary shares will be listed on NASDAQ. While we would expect the Australian Stock Exchange,
on which the ordinary shares are listed, to be considered a qualified exchange, no assurance can be given as to whether the Australian
Stock Exchange is a qualified exchange, or that the ordinary shares would be traded in sufficient frequency to be considered regularly
traded for these purposes. Additionally, because a mark-to-market election cannot be made for equity interests in any lower-tier PFIC
that we may own, a U.S. Holder that makes a mark-to-market election with respect to its ADSs may continue to be subject to the PFIC rules
with respect to any indirect investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes.
If you make an effective mark-to-market election, you will include as ordinary income in each year that we are a PFIC, the excess of
the fair market value of your ordinary shares or ADSs at the end of your taxable year over your adjusted tax basis in such ordinary shares
or ADSs. You will be entitled to deduct as an ordinary loss in each such year the excess of your adjusted tax basis in the ordinary shares
or ADSs over their fair market value at the end of the year, but only to the extent of the net amount previously included in income as
a result of the mark-to-market election. If you make an effective mark-to-market election, any gain you recognize upon the sale or other
disposition of your ordinary shares or ADSs in a year that we are a PFIC will be treated as ordinary income and any loss will be treated
as ordinary loss, but only to the extent of the net amount previously included in income as a result of the mark-to-market election.
Any gain or loss you recognize upon the sale or other disposition of your ordinary shares or ADSs in a year when we are not a PFIC will
be a capital gain or loss. See <i>Disposition of ADSs above </i>for the treatment of capital gains and losses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
adjusted tax basis in the ordinary shares or ADSs will be increased by the amount of any income inclusion and decreased by the amount
of any losses under the mark-to-market rules. If you make a mark-to-market election, it will be effective for the taxable year for which
the election is made and all subsequent taxable years unless the ordinary shares or ADSs are no longer regularly traded on a qualified
exchange or the IRS consents to the revocation of the election. You are urged to consult your tax advisors about the availability of
the mark-to-market election, and whether making the election would be advisable in your particular circumstances. In the case of a valid
mark-to-market election, any distributions we make would generally be subject to the rules discussed above under &#8220;<i>Taxation of
Dividends</i>,&#8221; except the reduced rates of taxation on any dividends received from us would not apply if we are a PFIC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternatively,
you can sometimes avoid the PFIC rules described above by electing to treat us as a &#8220;qualified electing fund&#8221; under Section
1295 of the Code. However, this option will not be available to you because we do not intend to comply with the requirements necessary
to permit you to make this election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders are urged to contact their own tax advisors regarding the determination of whether we are a PFIC and the tax consequences of
such status.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Tax on Investment Income</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders that are individuals, estates, or trusts and whose income exceeds certain thresholds will be subject to a 3.8% Medicare contribution
tax on net investment income, which will include dividends on and capital gains from the sale or other taxable disposition of ADSs, subject
to certain limitations and exceptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Backup
Withholding and Information Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
in respect of ADSs may be subject to information reporting to the IRS and to U.S. backup withholding tax at a rate equal to the fourth
lowest income tax rate applicable to individuals (which, under current law, is 24%). Backup withholding will not apply, however, if you
(i) are a corporation or come within certain exempt categories and demonstrate the fact when so required or (ii) furnish a correct taxpayer
identification number and make any other required certification.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Amounts withheld under the backup withholding rules may be credited against a U.S. Holder&#8217;s
U.S. tax liability. A U.S. Holder may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing
the appropriate claim for refund with the IRS, which is generally an annual income tax return.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. Holders who are individuals
generally will be required to report our name, address, and such information relating to an interest in the ADSs as is necessary to identify
the class or issue of which the ADSs are a part. These requirements are subject to exceptions, including an exception for ADSs held in
accounts maintained by certain financial institutions and an exception applicable if the aggregate value of all &#8220;specified foreign
financial assets&#8221; (as defined in the Code) does not exceed $50,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their tax advisors regarding the application of these information reporting rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_050"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
<span style="font-variant: small-caps">Dividends And Paying Agents</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_051"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
<span style="font-variant: small-caps">Statement By Experts</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_052"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
<span style="font-variant: small-caps">Documents on display</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting requirements of the Exchange Act, as applicable to &#8220;foreign private issuers&#8221; as defined in Rule
3b-4 thereunder. As a foreign private issuer, we are exempt from certain provisions of the Exchange Act. Accordingly, our proxy solicitations
are not subject to the disclosure and procedural requirements of Regulation 14A under the Exchange Act, transactions in our equity securities
by our officers and directors are exempt from reporting and the &#8220;short-swing&#8221; profit recovery provisions contained in Section
16 of the Exchange Act. In addition, we are not required to file periodic reports and financial statements as frequently or as promptly
as U.S. companies whose securities are registered under the Exchange Act. However, we file with the Securities and Exchange Commission
an annual report on Form 20-F containing financial statements that have been examined and reported on, with an opinion expressed by,
an independent registered public accounting firm, and we submit reports to the Securities and Exchange Commission on Form 6-K containing
(among other things) press releases and unaudited financial information for the first six months of each fiscal year. We post our annual
report on Form 20-F on our website (www.immuron.com.au/corporate-directory-and-governance) promptly following the filing of our annual
report with the Securities and Exchange Commission. The information on our website is not incorporated by reference into this Annual
Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report and the exhibits thereto and any other document we file pursuant to the Exchange Act may be inspected without charge and
copied at prescribed rates at the Securities and Exchange Commission public reference room at 100 F Street, N.E., Room 1580, Washington,
D.C. 20549. You may obtain information on the operation of the Securities and Exchange Commission&#8217;s public reference room in Washington,
D.C. by calling the Securities and Exchange Commission at 1-800-SEC-0330. The Exchange Act file number for our Securities and Exchange
Commission filings is 001-38104.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities and Exchange Commission maintains a website at www.sec.gov that contains reports, proxy and information statements, and other
information regarding registrants that make electronic filings with the Securities and Exchange Commission using its EDGAR (Electronic
Data Gathering, Analysis, and Retrieval) system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
documents concerning our company referred to in this Annual Report may also be inspected at our offices located at Level 3, 62 Lygon
Street, Carlton Victoria, Australia, 3053.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_053"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
<span style="font-variant: small-caps">Subsidiary Information</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_054"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We invest our excess cash
in interest-bearing accounts and term deposits with banks in Australia. Our management believes that the financial institutions that
hold our investments are financially sound and accordingly, minimal credit risk exists with respect to these investments. Certain of
our cash equivalents are subject to interest rate risk. Due to the short duration and conservative nature of these instruments, we do
not believe that we have a material exposure to interest rate risk. Our major market risk is changes in foreign exchange rates as we
had approximately A$25,047,281 on deposit on June 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conduct our activities
almost exclusively in Australia. We are required to make certain payments in U.S. dollars and other currencies, however such payments
are not significant to our operations and we believe an adverse movement in end-of-period exchange rates would not have a material impact
on our operating results. In the twelve months ended June 30, 2021, the Australian dollar depreciated against the U.S. dollar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently utilize derivative financial instruments or other financial instruments subject to market risk.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_055"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_056"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Debt Securities</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_057"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Warrants and Rights</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of the Warrants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms of the Warrants is not complete and is subject to, and qualified in its entirety by the provisions
of the ADS Warrant Agent Agreement and Form of Global Warrant to Purchase ADSs, which are incorporated by reference as exhibits to this
annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Global
Certificates, Book-entry Interests</b>. The Warrants are represented by one or more global certificates in registered form. The global
certificate are deposited with the Warrant Agent as custodian for DTC and registered in the name of Cede &amp; Co., as nominee of DTC.
Ownership of interests in the global warrant certificate will be limited to persons that have accounts with DTC or persons that have
accounts with DTC participants. Book-entry interests in the Warrants will be shown on, and transfers of such interests will be effected
only through records maintained by DTC and its participants. So long as the Warrants are held in global form, DTC will be considered
the sole holder of the Warrants. Beneficial owners must rely on the procedures of the participants through which they own book-entry
interests to exercise their Warrants or transfer their Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisability</b>.
The Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance. The
Warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of ADSs purchased upon such exercise. We will pay the ADS issuance fee of US$0.05 per ADS and any other
applicable charges and taxes in connection with any such exercise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum
Percentage</b>. A holder of a Warrant will not have the right to exercise such Warrant, to the extent that after giving effect to such
exercise, such person (together with such person&#8217;s affiliates and certain other persons), would beneficially own in excess of 4.99%
(the &#8220;Maximum Percentage&#8221;) of the ordinary shares outstanding immediately after giving effect to such exercise. Subject to
certain exceptions, &#8220;beneficial ownership&#8221; for purposes of determining the Maximum Percentage is calculated in accordance
with Section 13(d) of the Exchange Act and the regulations of the SEC thereunder. Upon request by a Warrant holder, we will provide current
information regarding the number of our outstanding ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
Price</b>. The initial exercise price per ADS purchasable upon exercise of the Warrants is US$10.00.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restrictive
Legend Events</b>. We will notify the Warrant Agent and each holder if we are unable to deliver ADSs via DTC transfer or otherwise (without
restrictive legend), because (a) the SEC has issued a stop order with respect to the registration statement relating to the ADSs, (b)
the SEC otherwise has suspended or withdrawn the effectiveness of such registration statement, either temporarily or permanently, (c)
we have suspended or withdrawn the effectiveness of the registration statement, either temporarily or permanently, or (d) otherwise (each
a &#8220;Restrictive Legend Event&#8221;). If a Restrictive Legend Event occurs after a Warrant holder has exercised a Warrant in accordance
with its terms but prior to the delivery of the ADSs, or if we do not cause the depositary to timely deliver ADSs to a Warrant holder
upon exercise of the Warrants, we will be obligated to pay a cash buy-in amount to the holder of the Warrants who did not receive ADSs
upon such holder&#8217;s exercise of Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Dilution
Provisions</b>. The exercise price per Warrant and the numbers of Warrants will be subject to adjustment from time to time in accordance
with the ASX Listing Rules upon the occurrence of certain stock dividends and distributions, stock splits, stock subdivisions and combinations,
reclassifications, rights issues, or similar events affecting our ADSs or ordinary shares, or upon the occurrence of a change in ADS
ratio.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Agent and Exchange Listing</b>. The Warrants are issued in registered form under an ADS Warrant Agent Agreement between The Bank of New
York Mellon, as warrant agent and us and listed on the NASDAQ Capital Market under the symbol &#8220;IMRNW&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights
as a Shareholder</b>. Except as otherwise provided in the ADS Warrant Agent Agreement or by virtue of such holder&#8217;s ownership of
ADSs or ordinary shares, holders of Warrants do not have rights or privileges of a holder of ADSs or ordinary shares, including any voting
rights, until the holder exercises the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_058"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Other Securities</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Not
applicable.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_059"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
American Depository Shares</b></span></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
and Charges Payable by ADS Holders</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below summarizes
the fees and charges that a holder of our ADSs may have to pay, directly or indirectly, to our depositary, The Bank of New York Mellon,
pursuant to the Amended and Revised Deposit Agreement, between Immuron Limited and The Bank of New York Mellon, as depositary, and Owners
and Holders of the American Depositary Shares, which was filed as Exhibit 4.1 to Amendment No.4 of our Registration Statement on Form
F-1/A filed with the SEC on May 18, 2017, and the types of services and the amount of the fees or charges paid for such services. The
disclosure under this heading &#8220;Fees and Charges Payable by ADS Holders&#8221; is subject to and qualified in its entirety by reference
to the full text of the Deposit Agreement. The holder of an ADS may have to pay fees and charges in connection with ownership of the
ADS:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>



</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Persons
    depositing or withdrawing shares or ADS holders must pay:</i></b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For</i>:</b></span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$5.00 (or less) per 100
    ADSs (or portion of 100 ADSs)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ADSs, including
    issuances resulting from a distribution of shares or rights or other property</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of ADSs for
    the purpose of withdrawal, including if the Deposit Agreement terminates</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$0.05 (or less) per ADS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to
    ADS holders</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent to the
    fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of securities
    distributed to holders of deposited securities which are distributed by the depositary to ADS holders</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$0.05 (or less) per ADS
    per calendar year</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depositary services</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration or transfer
    fees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer and registration
    of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the depositary</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile
    transmissions (when expressly provided in the Deposit Agreement) converting foreign currency to U.S. dollars</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental
    charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty
    or withholding taxes</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
<tr style="font-size: 7pt; vertical-align: top">
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by
    the depositary or its agents for servicing the deposited securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>



</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the
purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting
those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect
its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry
system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable
to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its
fees for those services are paid.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the depositary may make payments to us to reimburse and/or share revenue from the fees collected from ADS holders, or waive
fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the
ADS program. In performing its duties under the Deposit Agreement, the depositary may use brokers, dealers or other service providers
that are affiliates of the depositary and that may earn or share fees or commissions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
and Payments Made by Us to the Depositary</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended June
30, 2021, we paid The Bank of New York Mellon a total of US$5,180 for services pursuant to the 2020 Annual General Meeting (AGM).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><div><a id="a_060"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
II</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_061"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_062"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_063"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
15. CONTROLS AND PROCEDURES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_064"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Disclosure Controls and Procedures</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain disclosure controls
and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is
accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate,
to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving the desired control objectives. Our management, after evaluating the effectiveness of our disclosure
controls and procedures as of the evaluation date, concluded that as of the evaluation date, our disclosure controls and procedures were
effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management assessed
the effectiveness of our internal control over financial reporting as of June 30, 2021, utilizing the criteria described in Internal
Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Management&#8217;s
Report on Internal Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Completed Actions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to the many completed
actions taken by the Company, management has concluded that the material weakness identified as of June 30, 2020 has been eliminated as
of June 30, 2021. We, along with our Audit Committee, will continue to monitor and evaluate the effectiveness of these remedial actions
and make further changes as deemed appropriate. Management, with the oversight of our Audit Committee, has devoted considerable effort
to remediate as of June 30, 2021 the material weakness identified as of June 30, 2020, which is evidenced through the completed actions
during fiscal 2021 detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Completed Actions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate
    the staffing level and qualifications of finance department personnel, make changes and continue to invest in training where deemed
    appropriate;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
    of accounting position papers for complex accounting issues to ensure compliance with all applicable accounting standards;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Undertake a review
                                            of contracts in place to ensure compliance with the applicable accounting standards and to
                                            ensure complex accounting issues have been identified; and&#160;&#160;</p></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilize
    external resources, to ensure compliance with the applicable accounting standards and to ensure complex accounting issues have been
    identified.</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control over Financial Reporting.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management of the Company
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control is designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with IFRS, as issued by IASB. Management regularly monitors its internal control over financial reporting, and actions
are taken to correct deficiencies as they are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Attestation Report
of the Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report does
not include an attestation report of our company&#8217;s Registered Public Accounting firm due to a transition period established by
the rules of the SEC for &#8220;emerging growth companies&#8221; and our non-accelerated filing status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Changes in Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See &#8220;Completed Actions&#8221;
above for changes in internal controls over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of October 29, 2021,
there have been no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange
Act) that occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially
affect, the Company&#8217;s internal control over financial reporting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>






</div><div><a id="a_068"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16. RESERVED</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_069"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16A.</b></span><b> AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a financial expert sitting as a member of the audit committee. We believe that the cost related to retaining a
financial expert on the audit committee at this time is prohibitive as we are a small company that needs to apply our limited cash resources
to the development of our product portfolio, which we believe is in the best interest of our shareholders. Our audit committee members
include a highly experienced commercial lawyer, and a former biotechnology and pharmaceutical company CEO who continues to serve as a
director of many other biotechnology and pharmaceutical companies. The committee currently believes that these skills sets, together
with the support of Company Secretary and CFO who also sit as advisors to this committee and hold Accounting, Chartered Accountant, and
MBA degrees, provide sufficient expertise for this committee to be able to serve and function effectively for the purpose for which it
is intended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_070"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16B. CODE OF ETHICS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all senior financial officers of our company, including our chief executive officer, chief
financial officer, chief accounting officer or controller, or persons performing similar functions. The code of ethics is publicly available
under &#8220;Investor Centre&#8221; on our website at <i>www.Immuron.com</i>. Written copies are available upon request. If we make any
substantive amendment to the code of ethics or grant any waivers, including any implicit waiver, from a provision of the codes of ethics,
we will disclose the nature of such amendment or waiver on our website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_071"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
</b></span><b>16C. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></b></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
Paid to Independent Public Accountants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit and review of financial statements <sup>(1)</sup></span></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">179,742</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160,918</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">179,742</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Approval
Policies and Procedures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee has adopted policies and procedures for the pre-approval of audit and non-audit services rendered by our independent
registered public accounting firm. Pre-approval of an audit or non-audit service may be given as a general pre-approval, as part of the
audit committee&#8217;s approval of the scope of the engagement of our independent registered public accounting firm, or on an individual
basis. Any proposed services exceeding general pre-approved levels also requires specific pre-approval by our audit committee. The policy
prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in Section
201 of the Sarbanes-Oxley Act or the rules of the Securities and Exchange Commission, and also requires the audit committee to consider
whether proposed services are compatible with the independence of the registered public accounting firm. All of the fees described above
were pre- approved by our Audit Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>






</div><div><a id="a_072"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_073"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchase of Equity Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither we, nor any affiliated
purchaser of our company, has purchased any of our securities during the year ended June 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT</b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Not applicable.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_075"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16G. CORPORATE GOVERNANCE</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NASDAQ rules allow for a foreign private issuer,
such as our company, to follow our home country practices in lieu of certain of the NASDAQ&#8217;s corporate governance standards. We
rely on exemptions from certain corporate governance standards that are contrary to the laws, rules, regulations or generally accepted
business practices in Australia. These exemptions being sought are described below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on an exemption from the independence requirements for a majority of our board of directors as prescribed by NASDAQ Listing Rules. The ASX Listing Rules do not require us to have a majority of independent directors although ASX Corporate Governance Principles and Recommendations do recommend a majority of independent directors. During fiscal 2021, we did not, have a majority of directors who were &#8220;independent&#8221; as defined in the ASX Corporate Governance Principles and Recommendations, which definition differs from NASDAQ&#8217;s definition.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on an exemption from the requirement that our independent directors meet regularly in executive sessions under NASDAQ Listing Rules. The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on an exemption from the quorum requirements applicable to meetings of shareholders under NASDAQ Listing Rules. In compliance with Australian law, our Constitution provides that three shareholders present, in person or by proxy, attorney or a representative, shall constitute a quorum for a general meeting. NASDAQ Listing Rules require that an issuer provide for a quorum as specified in its by-laws for any meeting of the holders of ordinary shares, which quorum may not be less than 33% (1/3) of the outstanding shares of an issuer&#8217;s voting ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on an exemption from the requirement prescribed by NASDAQ Listing Rules that issuers obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions, private placements of securities, or the establishment or amendment of certain stock option, purchase or other compensation plans. Applicable Australian law and the ASX Listing Rules differ from NASDAQ requirements, with the ASX Listing Rules providing generally for prior shareholder approval in numerous circumstances, including (i) issuance of equity securities exceeding 15% of our issued share capital in any 12-month period (but, in determining the 15% limit, securities issued under an exception to the rule or with shareholder approval are not counted), (ii) issuance of equity securities to related parties (as defined in the ASX Listing Rules) and (iii) issuances of securities to directors or their associates under an employee incentive plan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_076"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16H. MINE SAFETY DISCLOSURE</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><div><a id="finna_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_077"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
III</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_078"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
17. FINANCIAL STATEMENTS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our company has elected to furnish
financial statements and related information specified in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_079"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
18. FINANCIAL STATEMENTS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: justify"><a href="#fca_001">Index to Consolidated Financial Statements</a></td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#fin_001">Report of Independent Registered Public Accounting Firm</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_002">Consolidated Statement of Profit or Loss and Other Comprehensive Income</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#fin_003">Consolidated Statement of Financial Position</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_004">Consolidated Statement of Change in Equity</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#fin_005">Consolidated Statement of Cash Flows</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#fin_006">Notes to Consolidated Financial Statements</a></td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
</table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>






</div><div><a id="a_080"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
19. EXHIBITS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>



</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Exhibit Number</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exhibit Description</td><td style="font-weight: bold">&#160;</td>
    <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Incorporated by Reference</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Filing Date/ Period End</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Form</td><td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exhibit</td><td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">1.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577416008996/s104967_ex3-1.htm">Constitution
    of Registrant.</a></td><td>&#160;</td>
    <td style="text-align: center">F-1</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">3.1</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">12/21/2016</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 9%; text-align: center; vertical-align: top">2.1</td><td style="width: 1%">&#160;</td>
    <td style="width: 54%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417002101/s106053_ex4-1.htm">Form
    of Amended and Revised Deposit Agreement between Immuron Limited and The Bank of New York Mellon, as depositary, and Owners and Holders
    of the American Depositary Shares</a></td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center; vertical-align: top">F-1/A</td><td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 11%; text-align: center; vertical-align: top">4.1</td><td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 11%; text-align: center; vertical-align: top">5/8/2017</td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2(d)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390020033685/f20f2020ex2d_immuron.htm">Description of Securities</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">20-F</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">2(d)</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">10/28/2020</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top">4.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417000429/s105189_ex10-1.htm">Development
    and Supply Agreement by and between Immuron Limited and Synlait Milk Ltd. dated June 28, 2013</a></td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">F-1/A</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">10.1</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">2/9/2017</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">4.2</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417000429/s105189_ex10-2.htm">Variation
    of Development and Supply Agreement by and between Immuron Limited and Synlait Milk Ltd. dated June 21, 2016 (1)</a></td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">F-1/A</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">10.2</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">2/9/2017</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top">4.3</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417000429/s105189_ex10-3.htm">Marketing
    and Master Distribution Agreement by and between Immuron Limited and UniFirst-First Aid Corporation d/b/a MEDIQUE Products dated
    as of June 28, 2016 (1)</a></td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">F-1/A</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">10.3</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">2/9/2017</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">4.4</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417001568/s105818_ex10-8.htm">Convertible
    Security and Share Purchase Agreement by and between Immuron Limited and SBI Investments dated February 16, 2016</a></td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">F-1/A</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">10.8</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">4/10/2017</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top">4.5</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577417000429/s105189_ex10-10.htm">Executive
    Service Agreement by and between Immuron Limited and Dr. Jerry Kanellos dated July 23, 2015</a></td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">F-1/A</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">10.10</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top">2/9/2017</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390019021197/f20f2019ex4-4_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
    Lease Agreement with Wattle Laboratories Pty Ltd.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/2019</span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390019021197/f20f2019ex4-7_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement by and between Immuron Limited and Dr. Gary S. Jacob dated February 11, 2019</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/2019</span></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify; width: 54%"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000161577419008398/s118534_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement by and between Immuron Limited and ThinkEquity, a Division of Fordham Financial Management, Inc. dated
    May 23, 2019</span></a></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/24/2019</span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390019013161/f6k071819ex1-1_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement by and between Immuron Limited and ThinkEquity, a Division of Fordham Financial Management, Inc. dated
    July 16, 2019</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/19/2019</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390020018328/ea124432ex10-1_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement dated as of July 21, 2020 between Immuron Limited and the investors listed therein</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/23/2020</span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390020018328/ea124432ex10-2_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
    Letter by and between Immuron Limited and H.C. Wainwright &amp; Co., LLC dated July 20, 2020</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/23/2020</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390020018328/ea124432ex10-3_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Engagement Letter by and between Immuron Limited and H.C. Wainwright &amp; Co., LLC dated July 22, 2020</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/23/2020</span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390020018328/ea124432ex10-4_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Compensation Warrant to be issued by Immuron Limited on July 23, 2020</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/23/2020</span></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1660046/000121390019021197/f20f2019ex8-1_immuron.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries of the Registrant.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/28/2019</span></td></tr>

<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top; width: 9%">12.1*</td><td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 54%"><a href="f20f2021ex12-1_immuron.htm">Certification of Chief Executive Officer pursuant
    to Rule 13a-14(a) under the Securities Exchange Act, as amended.</a></td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">12.2*</td><td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex12-2_immuron.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
    under the Securities Exchange Act, as amended.</a></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top">13.1*</td><td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex13-1_immuron.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C.
    Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top">13.2*</td><td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex13-2_immuron.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C.
    Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; vertical-align: top">23.1*</td><td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex23-1_immuron.htm">Consent of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Thornton Audit Pty Ltd</span></a></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    INS*</span></td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Instance Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center">101.SCH*</td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">101.CAL*</td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Calculation Linkbase Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center">101.DEF*</td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Definition Linkbase Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">101.LAB*</td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Label Linkbase Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center">101.PRE*</td><td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Presentation Linkbase Document</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">104</td><td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL and contained
in Exhibit 101).</p></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                            herewith.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
                                            treatment has been sought for certain portions of this document</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>






</div><div><a id="fca_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 92%">Consolidated Financial Statements</td>
    <td style="text-align: center; width: 8%; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_001">Report of Independent Registered Public Accounting Firm</a></td>
    <td style="text-align: center; vertical-align: bottom">F-2</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_002">Consolidated Statement of Profit or Loss and Other Comprehensive
    Income for the Years Ended June 30, 2021, 2020 and 2019</a></td>
    <td style="text-align: center; vertical-align: bottom">F-3</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_003">Consolidated Statement of Financial Position as of June
    30, 2021 and 2020</a></td>
    <td style="text-align: center; vertical-align: bottom">F-4</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_004">Consolidated Statement of Changes in Equity for the Years
    Ended June 30, 2021, 2020 and 2019</a></td>
    <td style="text-align: center; vertical-align: bottom">F-5</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_005">Consolidated Statement of Cash Flows for the Years Ended
    June 30, 2021, 2020 and 2019</a></td>
    <td style="text-align: center; vertical-align: bottom">F-6</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><a href="#fin_006">Notes to Consolidated Financial Statements</a></td>
    <td style="text-align: center; vertical-align: bottom">F-7</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>



</div><!-- Field: Page; Sequence: 94; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Board of Directors and Shareholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Immuron Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Opinion on the financial statements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
statements of financial position of Immuron Limited and subsidiaries (the &#8220;Company&#8221;) as of June 30, 2021 and 2020, the related
consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for each of the three years
in the period ended June 30 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2021
and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity
with International Financial Reporting Standards, as issued by International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Basis for opinion </b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 8pt">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 8pt">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ GRANT THORNTON AUDIT PTY LTD&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company&#8217;s auditor since 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Melbourne, Australia</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">October 29, 2021</p><div>

</div><p style="margin: 0pt 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>






</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="fin_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Profit or Loss and Other Comprehensive Income</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended 30 June</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Revenue from contracts with customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Cost of Goods Sold</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">51,071</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">688,836</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">667,371</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Gross Profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">94,705</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,829,730</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,720,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Other Income</td><td>&#160;</td>
    <td style="text-align: center">2</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">617,110</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">473,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">532,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: center">2</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">1,342,293</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">11,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">38,413</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">3</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,978,679</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,703,990</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,694,306</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: center">19</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:SharebasedPaymentsExpenses" scale="0" unitRef="aud">2,116,013</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:SharebasedPaymentsExpenses" scale="0" sign="-" unitRef="aud">533,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:SharebasedPaymentsExpenses" scale="0" unitRef="aud">1,343,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,367,054</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,178,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,044,528</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center">3</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">287,684</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">871,551</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">864,644</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">8,379,908</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">2,905,575</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">4,656,460</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Finance income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IncomeFinance" scale="0" sign="-" unitRef="aud">9,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:IncomeFinance" scale="0" sign="-" unitRef="aud">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Finance expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:CostOfFinance" scale="0" sign="-" unitRef="aud">13,761</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:CostOfFinance" scale="0" sign="-" unitRef="aud">21,631</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Finance costs - net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:FinanceCostsNet" scale="0" unitRef="aud">4,557</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:FinanceCostsNet" scale="0" unitRef="aud">21,631</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:FinanceCostsNet" scale="0" sign="-" unitRef="aud">39</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss Before Income Tax</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Income Tax Expense</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 9pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: justify; text-indent: -9pt; padding-left: 9pt">Items that may be reclassified to profit
    or loss:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Exchange differences on translation of foreign operations</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Total Comprehensive Loss for the Period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">8,399,418</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">2,824,268</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">4,594,575</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Basic/Diluted Loss per Share (in cents per share)</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">3.79</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">1.66</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">3.22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes form part of these financial statements.</span></p><div>




</div><p style="margin: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="margin: 0"><b>Consolidated Statement of Financial Position</b></p><div>

</div><p style="margin: 0"><b>As of 30 June</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="text-decoration:underline">ASSETS</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; text-align: justify"><span style="text-decoration:underline">Current Assets</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">7</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">25,047,281</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">3,250,468</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: center">8</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud">334,707</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud">327,689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: center">9</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">292,532</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">797,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Other current assets</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud">78,258</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud">33,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="aud">25,752,778</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="aud">4,409,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Non-Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="aud">33,741</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="aud">70,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: center">9</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InventoriesTotal" scale="0" unitRef="aud">1,266,587</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InventoriesTotal" scale="0" unitRef="aud">1,722,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Total Non-Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="aud">1,300,328</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="aud">1,793,122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">TOTAL ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">27,053,106</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">6,202,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: justify">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center">11</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud">758,494</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud">384,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Provision for sales returns</td><td>&#160;</td>
    <td style="text-align: center">12</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" scale="0" unitRef="aud">213,024</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Employee benefit obligations</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeBenefitObligation" scale="0" unitRef="aud">129,837</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeBenefitObligation" scale="0" unitRef="aud">89,838</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Other current liabilities</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="aud">42,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="aud">1,121,853</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="aud">516,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Non-Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Employee benefit obligations</td><td>&#160;</td>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeBenefitObligationNonCurrent" scale="0" unitRef="aud">36,196</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeBenefitObligationNonCurrent" scale="0" unitRef="aud">22,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Other non-current liabilities</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="0" unitRef="aud">18,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Total Non-Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="aud">36,196</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="aud">41,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">1,158,049</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">558,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">NET ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="0" unitRef="aud">25,895,057</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="0" unitRef="aud">5,643,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-decoration: underline; text-align: justify">EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Issued capital</td><td>&#160;</td>
    <td style="text-align: center">15</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud">88,361,303</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud">62,426,991</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Reserves</td><td>&#160;</td>
    <td style="text-align: center">16</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">3,466,642</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">1,133,345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud">65,932,888</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud">57,916,423</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">TOTAL EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud">25,895,057</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud">5,643,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying notes form part of these
financial statements.</span></p><div>

</div><p style="margin: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>



</div><div><a id="fin_004"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Changes in Equity</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended 30 June</b></span></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Issued<br/> Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Reserves</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated Losses</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify">Balance as at 30 June 2018</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">58,237,314</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">3,096,308</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" sign="-" unitRef="aud">52,894,272</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">8,439,350</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Loss after income tax expense for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other comprehensive income for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Total comprehensive loss for the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">4,594,575</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-decoration: underline; text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Shares issued, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">2,052,461</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">2,052,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Options/warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" unitRef="aud">1,453,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" unitRef="aud">1,453,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Options/warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsExercised" scale="0" unitRef="aud">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsExercised" scale="0" sign="-" unitRef="aud">100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Options/warrants lapsed/expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionswarrantsForfeited" scale="0" sign="-" unitRef="aud">311,635</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionswarrantsForfeited" scale="0" unitRef="aud">311,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Balance as at 30 June 2019</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">60,289,875</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">4,300,319</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" sign="-" unitRef="aud">57,239,058</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">7,351,136</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Change in accounting policy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="imc:ChangeInAccountingPolicy" scale="0" sign="-" unitRef="aud">1,479</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ChangeInAccountingPolicy" scale="0" sign="-" unitRef="aud">1,479</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Revised total equity at 1 July 2019</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="imc:RestatedTotalEquityAt1July2019" scale="0" unitRef="aud">60,289,875</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="imc:RestatedTotalEquityAt1July2019" scale="0" unitRef="aud">4,300,319</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="imc:RestatedTotalEquityAt1July2019" scale="0" sign="-" unitRef="aud">57,239,058</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:RestatedTotalEquityAt1July2019" scale="0" unitRef="aud">7,351,136</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss after income tax expense for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Other comprehensive income for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total comprehensive loss for the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">2,824,268</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Shares issued, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">1,652,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">1,652,436</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Options/warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" unitRef="aud">484,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" sign="-" unitRef="aud">484,680</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Options/warrants lapsed/expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionswarrantsForfeited" scale="0" sign="-" unitRef="aud">2,251,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionswarrantsForfeited" scale="0" unitRef="aud">2,251,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Re-valuation of options issued in prior period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationOfOptionIssuedInPriorPeriod" scale="0" sign="-" unitRef="aud">607,000</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationOfOptionIssuedInPriorPeriod" scale="0" sign="-" unitRef="aud">607,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeShareSchemesValueOfEmployee" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:EmployeeShareSchemesValueOfEmployee" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Balance as at 30 June 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">62,426,991</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">1,133,345</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" sign="-" unitRef="aud">57,916,423</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">5,643,913</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss after income tax expense for the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Other comprehensive income for the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherComprehensiveIncomeLossForPeriod" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total comprehensive loss for the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud">8,399,418</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Shares issued, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">24,386,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud">24,386,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Options/warrants issued/expensed</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" unitRef="aud">3,003,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsIssuedExpensed" scale="0" unitRef="aud">3,003,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Options/warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsExercised" scale="0" unitRef="aud">1,329,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsExercised" scale="0" sign="-" unitRef="aud">213,722</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsExercised" scale="0" unitRef="aud">1,115,585</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Options/warrants forfeited</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsForteitedLapsed" scale="0" unitRef="aud">368,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsOrWarrantsForteitedLapsed" scale="0" sign="-" unitRef="aud">368,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 7.1pt">Shares issued to directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="imc:StockIssuedDuringPeriodValueIssuedToDirectors" scale="0" unitRef="aud">145,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:StockIssuedDuringPeriodValueIssuedToDirectors" scale="0" unitRef="aud">145,912</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Transfer to share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferToShareCapital" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferToShareCapital" scale="0" sign="-" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Balance as at 30 June 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">88,361,303</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">3,466,642</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" sign="-" unitRef="aud">65,932,888</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:EquityBalance" scale="0" unitRef="aud">25,895,057</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes form part of these financial statements. </span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>





</div><div><a id="fin_005"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Cash Flows</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended 30 June</b></span></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020 <br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$
                                            </b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Cash flows Related to Operating
    Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Receipts from customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" unitRef="aud">192,185</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" unitRef="aud">2,914,614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" scale="0" unitRef="aud">2,619,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Payments to suppliers and employees</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:PaymentsToSuppliersForGoodsAndService" scale="0" sign="-" unitRef="aud">4,865,633</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:PaymentsToSuppliersForGoodsAndService" scale="0" sign="-" unitRef="aud">6,748,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:PaymentsToSuppliersForGoodsAndService" scale="0" sign="-" unitRef="aud">5,608,262</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other - R&amp;D tax concession refund</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="0" unitRef="aud">358,280</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="0" unitRef="aud">531,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" scale="0" unitRef="aud">1,190,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Government grants and other grants received</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" unitRef="aud">236,421</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" unitRef="aud">154,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Net Cash Flows Used In Operating Activities</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">4,078,747</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">3,147,328</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">1,798,579</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Cash Flows Related to Investing
    Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Payment for purchases of plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="aud">6,630</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="aud">864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="aud">2,047</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest received</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="0" unitRef="aud">9,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="0" unitRef="aud">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Net Cash Flows (Used In)/From Investing Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" unitRef="aud">2,574</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="aud">864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="aud">2,008</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: justify">Cash Flows Related to Financing
    Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Proceeds from issues of securities</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="aud">29,281,421</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="aud">1,957,164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="aud">2,894,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Capital raising costs</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:CapitalCost" scale="0" unitRef="aud">2,746,871</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:CapitalCost" scale="0" unitRef="aud">374,728</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:CapitalCost" scale="0" unitRef="aud">825,055</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Proceeds from borrowings</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="aud">212,794</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Repayment of borrowings</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="aud">212,794</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="aud">366,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Principal elements of lease payments</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="aud">40,607</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="aud">41,390</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest and other costs of finance paid</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="0" unitRef="aud">13,761</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="0" unitRef="aud">17,439</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Net Cash Flows From Financing Activities</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud">26,480,182</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud">1,156,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud">2,069,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" unitRef="aud">22,404,009</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" sign="-" unitRef="aud">1,991,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" unitRef="aud">268,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Cash and cash equivalents at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">3,250,468</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">5,119,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">4,727,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Effects of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" sign="-" unitRef="aud">607,196</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="aud">121,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="aud">123,861</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Cash and Cash Equivalents at the End of the Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">7</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">25,047,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">3,250,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud">5,119,887</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes
form part of these financial statements.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes to the Consolidated
Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporate Information</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial report of Immuron Limited
(&#8220;the Company&#8221;) for the year ended June 30, 2021, 2020 and 2019 was authorized for issue in accordance with a resolution of
the Directors on October 29, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited is a listed public company limited
by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and The
NASDAQ Capital Market (&#8220;NASDAQ&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s principal activity is oral
immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment
and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting
travelers&#8217; diarrhea and Protectyn an OTC immune supplement for GI tract and liver health.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForBasisOfPresentation"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of preparation</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_2" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These general purpose financial statements
have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards
Board and the <i>Corporations Act 2001</i>. Immuron Limited is a for-profit entity for the purpose of preparing the financial statements.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_3" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Compliance with
                                            IFRS</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_8"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_4" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The consolidated financial statements
of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_9"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_5" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Historical cost
                                            convention</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_11" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_10"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_6" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The financial statements have been prepared on a historical
cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_12" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_11"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_7" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0"></td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Significant
    estimates and judgements</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_13" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_12"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_8" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Going concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_14" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_13"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_9" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group is in a position to meet future commitments in the current
business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs
for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not
include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of
liabilities that might be necessary should the group not continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_15" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_14"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_10" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>COVID-19</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_16" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_15"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_11" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Judgement has been exercised in considering
the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration
extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group
operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that
COVID-19 will continue to have on sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_17" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_16"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_12" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note provides a list of the significant
accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed
in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial
statements are for the group consisting of Immuron Limited and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_18" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_17"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_13" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(iv) New standards and interpretations not
yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_19" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_18"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_14" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no standards that are not yet effective
and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future
transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_20" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_19"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_15" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(v)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revision of immaterial error</i></span></td></tr>
  </table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_21" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_20"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_16" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_15"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">During the year ended June 2020 the following immaterial
error corrections were identified.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_22" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_21"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_17" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_16"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Representative warrants</i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_23" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_22"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_18" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Immuron Limited raised capital in June
2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for
at the time of these capital raisings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_24" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_23"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_19" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Management has undertaken an assessment of the impact of this and concluded
this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and
the related notes included herein to include the representative warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_25" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_24"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_20" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Reserves as of 30 June 2017 has been
revised to increase by A$<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="imc:RepresentativesWarrants" scale="0" unitRef="usd">489,586</ix:nonFraction> for the June 2017 representative warrants (<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareCapital" scale="0" unitRef="usd">1,220,000</ix:nonFraction> options) with a corresponding decrease in share
capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_26" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_25"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_21" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_20"><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Reserves as of 30 June 2019 has been revised to increase by A$<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:RepresentativesWarrants" scale="0" unitRef="usd">110,400</ix:nonFraction>
for the May 2019 representative warrants (<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareCapital" scale="0" unitRef="usd">800,000</ix:nonFraction> options) with a corresponding decrease in share capital of the same amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_27" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_26"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_22" id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Summary of significant accounting policies</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_28" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_27"><ix:continuation id="_DescriptionOfAccountingPolicyForBasisOfPresentation-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material accounting
policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless
otherwise stated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_29" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(b)</b></td><td style="text-align: justify"><b>Principles of consolidation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_30" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_29"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_2" id="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>(i) Subsidiaries</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_31" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_30"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_3" id="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Subsidiaries are all entities (including
structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from
the date that control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_32" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_31"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_4" id="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The acquisition method of accounting
is used to account for business combinations by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_33" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_32"><ix:continuation id="_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Intercompany transactions, balances
and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to
ensure consistency with the policies adopted by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_34" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(c)</b></td><td style="text-align: justify"><b>Segment reporting</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_35" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_34"><ix:continuation id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive
management team consisting of the CEO and COO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>




</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_36" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_35"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(d)</b></td><td style="text-align: justify"><b>Foreign currency translation</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_37" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_36"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Functional and
                                            presentation currency</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_38" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_37"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Items included in the financial statements
of each of the group&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#8216;the functional currency&#8217;). The consolidated financial statements are presented in Australian dollar (&#8220;A$&#8221; or
&#8220;$&#8221;), which is Immuron Limited&#8217;s functional and presentation currency.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_39" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_38"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Transactions
                                            and balances</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_40" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_39"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign currency transactions are translated
into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at
year end exchange rates are generally recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_41" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_40"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign exchange gains and losses that
relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs.
All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income
on a net basis within other gains/(losses).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_42" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_41"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Non-monetary items that are measured
at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation
differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation
differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit
or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair
value through other comprehensive income are recognized in other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_43" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_42"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Group companies</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_44" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_43"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_8"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The results and financial position
of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from
the presentation currency are translated into the presentation currency as follows:</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_45" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_44"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">assets and liabilities for each
                                            consolidated balance sheet presented are translated at the closing rate at the date of that
                                            consolidated balance sheet;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td></td><td>&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">income and expenses for each consolidated statement of
                         profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at
                         average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates
                         prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions);
                         and</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="text-align: justify; padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td></td><td>&#9679;</td><td style="padding-right: 1.3pt">all resulting exchange differences are recognized in other comprehensive income.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_46" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_45"><ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_10"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">On consolidation, exchange differences
arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated
as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming
part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or
loss on sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_47" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(e)</b></td><td style="text-align: justify"><b>Revenue recognition</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_48" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_47"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale
                                            of hyperimmune products</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_49" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_48"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying
the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction
price to the performance obligations and recognising revenue when performance obligations are satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_50" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_49"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_4" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_51" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_50"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_5" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_4"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided
where this is outlined in a customer agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_52" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_51"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_6" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
                                            components</i></span></td>
</tr></table><p style="margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_53" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_52"><ix:continuation id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_6"><p style="margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The group does
not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment
by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.</span></p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_54" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(f)</b></td><td style="text-align: justify"><b>Government grants</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_55" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_54"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_2" id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Grants from the government are recognized
at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached
conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_56" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_55"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_3" id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Fair value of other grants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_57" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_56"><ix:continuation id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group&#8217;s other grant income
consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable
assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the
group has recognized A$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:AssistancePackages" scale="0" unitRef="aud">154,904</ix:nonFraction> in assistance packages.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>




</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_58" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(g)</b></td><td style="text-align: justify"><b>Income tax</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_59" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_58"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The income tax expense or credit for
the period is the tax payable on the current period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction
adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_60" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_59"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The current income tax charge is calculated
on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and
its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns
with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate
on the basis of amounts expected to be paid to the tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_61" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_60"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred income tax is provided in full,
using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts
in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition
of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_62" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_61"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred tax assets are recognized only
if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_63" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_62"><ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Current and deferred tax is recognized
in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this
case, the tax is also recognized in other comprehensive income or directly in equity, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_64" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_63"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; "> <td style="width: 0; font-size: 10pt"></td> <td style="width: 0.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(h)</b></span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AASB Interpretation 23 Uncertainty over Income Tax Treatments</b></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_65" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_64"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock-c0_cont_2" id="_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Interpretation 23 requires the assessment of whether the effect of
uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses,
unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax
treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity
determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes
in facts and circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_66" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_65"><ix:continuation id="_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The group has adopted Interpretation 23 from 1 July 2019, based on
an assessment of whether it is &#8216;probable&#8217; that a taxation authority will accept an uncertain tax treatment. This assessment
takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group&#8217;s
books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment
used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority
will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending
on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation
23 in this reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:continuation></ix:continuation><div>

</div><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_67" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(i)</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_68" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_67"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1">The accounting policies for the group's leases are explained in note
14(iii)</ix:continuation>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_69" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(j)</b></td><td style="text-align: justify"><b>Impairment of assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_70" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_69"><ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">An impairment loss is recognized for
the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s
fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels
for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups
of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal
of the impairment at the end of each reporting period.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_71" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(k)</b></td><td style="text-align: justify"><b>Cash and cash equivalents</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_72" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_71"><ix:continuation id="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For the purpose of presentation in
the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings
in current liabilities in the consolidated balance sheet.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_73" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_72"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(l)</b></td><td style="text-align: justify"><b>Trade receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_74" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_73"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are recognized initially
at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for
a description of the group&#8217;s impairment policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_75" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_74"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification
                                            as trade receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_76" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_75"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are amounts due from
customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days
and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional
unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with
the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method. Details about the group&#8217;s impairment policies and the calculation of the loss allowance are provided below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_77" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_76"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Accrued receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_78" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_77"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">These amounts primarily comprise receivables
from the Australian Taxation Office in relation to the R&amp;D tax incentive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_79" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_78"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Fair value
                                            of trade and other receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_80" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_79"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Due to the short-term nature of the
current receivables, their carrying amount is considered to be the same as their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_81" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_80"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Impairment
                                            and risk exposure</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_82" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_81"><ix:continuation id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Information about the impairment of
trade receivables and the group&#8217;s exposure to credit risk and foreign currency risk can be found in note 21.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_83" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_82"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(m)</b></td><td style="text-align: justify"><b>Inventories</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_84" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_83"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_2" id="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Raw materials and stores, work in progress and finished
goods</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_85" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_84"><ix:continuation id="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Raw materials and stores, work in progress
and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate
proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are
assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting
rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs
of completion and the estimated costs necessary to make the sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_86" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_85"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(n)</b></td><td style="text-align: justify"><b>Investments and other financial assets</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_87" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_86"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_88" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_87"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The group classifies its financial assets in the following
measurement categories:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_89" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_88"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            subsequently at fair value (either through other comprehensive income or through profit or
                                            loss); and</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_90" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_89"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            at amortised cost.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_91" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_90"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
classification depends on the group&#8217;s business model for managing the financial assets and the contractual terms of the cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_92" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_91"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_7" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For assets measured at fair value, gains and
losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held
for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for
the equity investment at fair value through other comprehensive income (FVOCI).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_93" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_92"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_8" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Recognition
                                            and derecognition</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_94" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_93"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_9" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Regular way purchases and sales of
financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has
transferred substantially all the risks and rewards of ownership.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_95" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_94"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_10" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Measurement</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_96" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_95"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_11" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">At initial recognition, the group measures
a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction
costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL
are expensed in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_97" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_96"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_12" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="text-align: justify"><i>Impairment</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_98" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_97"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_13" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The group assesses on a forward looking
basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends
on whether there has been a significant increase in credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_99" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_98"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_14" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For
                                            trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires
                                            expected lifetime losses to be recognized from initial recognition of the receivables, see
                                            note 21(b) for further details.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_100" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_99"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_15" id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><i>(v)</i></td><td style="text-align: justify"><i>Income recognition
                                            Interest income</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_101" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_100"><ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Interest income is recognized using
the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being
the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount
as interest income. Interest income on impaired loans is recognized using the original effective interest rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_102" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_101"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(o)</b></td><td style="text-align: justify"><b>Property, plant and equipment</b></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_103" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_102"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Property, plant and equipment is stated
at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_104" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_103"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Subsequent costs are included in the
asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits
associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component
accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during
the reporting period in which they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_105" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_104"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Depreciation is calculated using the
straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or,
in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_106" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_105"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">Plant and equipment	<ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">2</ix:nonNumeric> - <ix:nonNumeric contextRef="c31" format="ixt-sec:duryear" name="imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">5</ix:nonNumeric> years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td></td><td>&#9679;</td><td style="padding-right: 1.3pt">Furniture, fittings and equipment	<ix:nonNumeric contextRef="c32" format="ixt-sec:duryear" name="imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c33" format="ixt-sec:duryear" name="imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">15</ix:nonNumeric> years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td></td><td>&#9679;</td><td style="padding-right: 1.3pt">Right-of-use assets	<ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">3</ix:nonNumeric> years</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_107" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_106"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The assets&#8217; residual values and
useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_108" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_107"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">An asset&#8217;s carrying amount is
written down immediately to its recoverable amount if the asset&#8217;s carrying amount is greater than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_109" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_108"><ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Gains and losses on disposals are determined
by comparing proceeds with carrying amount. These are included in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_110" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_109"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(p)</b></td><td style="text-align: justify"><b>Intangible assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_111" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_110"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Research and development</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_112" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_111"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on research activities,
undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated
statement of profit or loss and other comprehensive income as an expense when it is incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_113" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_112"><ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on development activities,
being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved
products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is
technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development
and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other
comprehensive income as an expense as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_114" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_113"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(q)</b></td><td style="text-align: justify"><b>Trade and other payables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_115" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_114"><ix:continuation id="_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These amounts represent liabilities
for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually
paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12
months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using
the effective interest method.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_116" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_115"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(r)</b></td><td style="text-align: justify"><b>Employee benefits</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_117" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_116"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Short-term obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_118" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_117"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Liabilities for wages and salaries,
including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after
the end of the period in which the employees render the related service are recognized in respect of employees&#8217; services up to
the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as current employee benefit obligations in the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_119" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_118"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Other long-term
                                            employee benefit obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_120" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_119"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">In some countries, the group also has
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the
period in which the employees render the related service. These obligations are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit
method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_121" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_120"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Consideration is given to expected
future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using
market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as
possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions
are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_122" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_121"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The obligations are presented as current
liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after
the reporting period, regardless of when the actual settlement is expected to occur.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_123" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_122"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Share-based
                                            payments</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_124" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_123"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Share-based compensation benefits are
provided to employees via the &#8216;executive share and option plan&#8217; (ESOP). Information relating to these schemes is set out
in note 19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_125" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_124"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Employee options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_126" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_125"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The fair value of options granted under
the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined
by reference to the fair value of the options granted:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_127" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_126"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_11"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">including
                                            any market performance conditions (e.g. the company&#8217;s share price);</p></td></tr>
<tr style="vertical-align: top">
<td></td><td>-</td><td style="text-align: justify; padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">excluding
                                            the impact of any service and non-market performance vesting conditions (e.g. profitability,
                                            sales growth targets and remaining an employee of the company over a specified time period);
                                            and</p></td></tr>
<tr style="vertical-align: top">
<td></td><td>-</td><td style="text-align: justify; padding-right: 1.3pt">including the impact of any non-vesting conditions (e.g. the
                   requirement for employees to save or holdings shares for a specific period of time).</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_128" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_127"><ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The total expense is recognized over
the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period,
the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.
It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_129" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_128"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEquityPolicyTextBlock-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForEquityPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(s)</b></td><td style="text-align: justify"><b>Contributed equity</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_130" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_129"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEquityPolicyTextBlock-c0_cont_2" id="_DescriptionOfAccountingPolicyForEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Ordinary shares are classified as equity.</p></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_131" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_130"><ix:continuation id="_DescriptionOfAccountingPolicyForEquityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Incremental costs directly attributable
to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_132" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_131"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(t)</b></td><td style="text-align: justify"><b>Loss per share</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_133" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_132"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Basic loss per
                                            share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_134" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_133"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Basic loss per share is calculated by dividing:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_135" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_134"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">the loss attributable to owners
                                            of the company, excluding any costs of servicing equity other than ordinary shares</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td></td><td>&#9679;</td><td style="padding-right: 1.3pt">by the weighted average number of ordinary shares outstanding during the financial
                         year, adjusted for bonus elements in ordinary shares issued during the year.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>




</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_136" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_135"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Diluted loss
                                            per share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_137" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_136"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Diluted loss per share adjusts the figures used in the determination
of basic loss per share to take into account:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_138" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_137"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">the after
                                            income tax effect of interest and other financing costs associated with dilutive potential
                                            ordinary shares, and</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_139" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_138"><ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the weighted average
                                            number of additional ordinary shares that would have been outstanding assuming the conversion
                                            of all dilutive potential ordinary shares.</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_140" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_139"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(u)</b></td><td style="text-align: justify"><b>Rounding of amounts</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_141" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_140"><ix:continuation id="_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The company is of a kind referred to
in ASIC Legislative Instrument 2016/191, relating to the &#8216;rounding off&#8217; of amounts in the financial statements. Amounts in
the financial statements have been rounded off in accordance with the instrument to the nearest dollar.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_142" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_141"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_1" escape="true" name="imc:DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(v)</b></td><td style="text-align: justify"><b>Goods and services tax (GST)</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_143" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_142"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Revenues, expenses and assets are recognized
net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized
as part of the cost of acquisition of the asset or as part of the expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_144" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_143"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Receivables and payables are stated
inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the consolidated balance sheet.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_145" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_144"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Cash flows are presented on a gross
basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the
taxation authority, are presented as operating cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Options: NewSection; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_146" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_145"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Critical Accounting Estimates and Judgments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_147" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_146"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management evaluates estimates and judgments
incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable
expectation of future events and are based on current trends and economic data, obtained both internally and externally.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_148" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_147"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Share-based payments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_149" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_148"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value attributed to share options and remunerations
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value of volatility of the price of the underlying shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_150" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_149"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value of options granted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_151" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_150"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_9"><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_152" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_151"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of inventories</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_153" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_152"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for impairment of inventories assessment
requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience,
the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed
on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability
study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_154" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_153"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was a $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="0" unitRef="aud">328,833</ix:nonFraction> (2020: <span style="-sec-ix-hidden: hidden-fact-58">Nil</span>) finished goods
impairment and a $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">430,932</ix:nonFraction> (2020: <span style="-sec-ix-hidden: hidden-fact-59">Nil</span>) raw materials impairment of inventories recognised during year ended 30 June 2021 for inventory
obsolescence in the consolidated statement of profit or loss and other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_155" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_154"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Inventory split</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_156" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_155"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended 30 June 2021, management
performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials
relating to Colostrum will be consumed within 12 months from reporting date (2020: <span style="-sec-ix-hidden: hidden-fact-60">Nil</span>); the remaining balance of A$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:NonCurrentRawMaterials" scale="0" unitRef="aud">1,266,587</ix:nonFraction> (2020:
A$<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:NonCurrentRawMaterials" scale="0" unitRef="aud">1,722,349</ix:nonFraction>) was estimated to be consumed beyond 12 months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 108; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_157" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_156"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provision for employee benefits</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_158" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_157"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provision for employee benefits represents amounts
accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual
leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the
required period of service. Refer to note 1(q) for policies on provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_159" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_158"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>R&amp;D tax incentive</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_160" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_159"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s research and development activities
are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities
and expenditure to determine which are likely to be eligible under the incentive scheme.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_161" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_160"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2021 the Group has
recorded other income of A$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:RAndDTaxConcessionRefund" scale="0" unitRef="aud">306,154</ix:nonFraction> (2020: A$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:RAndDTaxConcessionRefund" scale="0" unitRef="aud">308,225</ix:nonFraction>) to recognise income over the year necessary to match the R&amp;D tax incentive on
a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:AdditionalRAndDTaxReceived" scale="0" unitRef="aud">50,055</ix:nonFraction>
in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_162" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_161"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value measurement hierarchy</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_163" id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_162"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements requires
management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually
evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases
its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the
related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-c0_cont_163"><ix:continuation id="_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the convertible notes classified
as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs
that required significant adjustments based on unobservable inputs.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 109; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRevenueExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. Revenue and other income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_2" id="_DisclosureOfRevenueExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue from Operating Activities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Revenue from contracts with customers</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Revenue from Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australian Federal R&amp;D Tax Concession Refund</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:AustralianFederalRdTaxConcessionRefund" scale="0" unitRef="aud">356,209</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:AustralianFederalRdTaxConcessionRefund" scale="0" unitRef="aud">308,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:AustralianFederalRdTaxConcessionRefund" scale="0" unitRef="aud">531,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">COVID-19 government assistance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherGovernmentAssistanceIncome" scale="0" unitRef="aud">161,600</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherGovernmentAssistanceIncome" scale="0" unitRef="aud">154,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ResearchAndDevelopmentGrants" scale="0" unitRef="aud">74,821</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomes" scale="0" unitRef="aud">24,480</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomes" scale="0" unitRef="aud">10,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomes" scale="0" unitRef="aud">1,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomeFromNonOperatingActivities" scale="0" unitRef="aud">617,110</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomeFromNonOperatingActivities" scale="0" unitRef="aud">473,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomeFromNonOperatingActivities" scale="0" unitRef="aud">532,050</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Gains/(Losses) &#8211; Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net foreign exchange gains/(losses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NetForeignExchangeGainLoss" scale="0" sign="-" unitRef="aud">582,528</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:NetForeignExchangeGainLoss" scale="0" unitRef="aud">11,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NetForeignExchangeGainLoss" scale="0" unitRef="aud">51,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impairment losses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLoss" scale="0" unitRef="aud">759,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLoss" scale="0" unitRef="aud">13,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Gains/(Losses) &#8211; Net</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">1,342,293</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">11,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">38,413</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_3" id="_DisclosureOfRevenueExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_4" id="_DisclosureOfRevenueExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale
                                            of hyperimmune products</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_5" id="_DisclosureOfRevenueExplanatory-c0_cont_4"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue arises mainly from the sale of products in the hyperimmune
category. To determine whether to recognise revenue, the group follows the process of identifying the contract with a customer, identifying
the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising
revenue when performance obligations are satisfied.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_6" id="_DisclosureOfRevenueExplanatory-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue from the sale of hyperimmune products is recognised when or
as the group transfers control of the assets to the customer.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_7" id="_DisclosureOfRevenueExplanatory-c0_cont_6"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no variable consideration or significant cost to obtain the
contract. There is no warranties and no refunds. Returns are provided where this is outlined in a customer agreement.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_8" id="_DisclosureOfRevenueExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
                                            value of R&amp;D tax incentive</i></span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_9" id="_DisclosureOfRevenueExplanatory-c0_cont_8"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The group's research and development (R&amp;D) activities are eligible
under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine
which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of
the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2021, the group has
included an item in other income of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomeOfResearchAndDevelopment" scale="0" unitRef="aud">306,154</ix:nonFraction> (2020: $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherIncomeOfResearchAndDevelopment" scale="0" unitRef="aud">308,225</ix:nonFraction>) to recognise income over the year necessary to match the R&amp;D tax incentive
on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:AdditionalOtherIncome" scale="0" unitRef="aud">50,055</ix:nonFraction>
in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_10" id="_DisclosureOfRevenueExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
                                            value of COVID-19 government assistance and R&amp;D grants</i></span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_11" id="_DisclosureOfRevenueExplanatory-c0_cont_10"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The group's other grant income is recognised when compliance with
the conditions attached to the grant have been determined and the group has ascertained the grant will be received.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfRevenueExplanatory-c0_cont_11"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the year ended 30 June 2021, the group has recognised $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:GovernmentAssistancePackages" scale="0" unitRef="aud">161,600</ix:nonFraction>
(2020: $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:GovernmentAssistancePackages" scale="0" unitRef="aud">154,904</ix:nonFraction>) in the COVID-19 government assistance packages and a $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ResearchAndDevelopmentsGrants" scale="0" unitRef="aud">74,821</ix:nonFraction> (2020: <span style="-sec-ix-hidden: hidden-fact-65">Nil</span>) R&amp;D grant from the Henry M Jackson Foundation.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 110; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfExpensesByNatureExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfExpensesByNatureExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2020<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">General and administrative expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounting and audit</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:AccountingAndAudit" scale="0" unitRef="aud">547,055</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:AccountingAndAudit" scale="0" unitRef="aud">389,798</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:AccountingAndAudit" scale="0" unitRef="aud">496,983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bad debts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:BadDebts" scale="0" unitRef="aud">5,472</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:BadDebts" scale="0" unitRef="aud">26,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:BadDebts" scale="0" unitRef="aud">50,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ConsultingExpenses" scale="0" unitRef="aud">126,215</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ConsultingExpenses" scale="0" unitRef="aud">181,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ConsultingExpenses" scale="0" unitRef="aud">243,508</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">43,662</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">44,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">5,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud">1,775,809</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud">1,531,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud">1,599,023</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" sign="-" unitRef="aud">30,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" sign="-" unitRef="aud">3,991</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" unitRef="aud">34,046</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud">341,202</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud">469,844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud">307,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investor relations</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:InvestorRelationsExpenses" scale="0" unitRef="aud">38,568</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:InvestorRelationsExpenses" scale="0" unitRef="aud">197,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:InvestorRelationsExpenses" scale="0" unitRef="aud">128,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Legal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:LegalExpenses" scale="0" unitRef="aud">205,722</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LegalExpenses" scale="0" unitRef="aud">184,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:LegalExpenses" scale="0" unitRef="aud">171,145</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Listing and share registry</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ListingAndShareRegistry" scale="0" unitRef="aud">292,113</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ListingAndShareRegistry" scale="0" unitRef="aud">212,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ListingAndShareRegistry" scale="0" unitRef="aud">186,013</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Occupancy</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:UtilitiesExpense" scale="0" unitRef="aud">51,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:UtilitiesExpense" scale="0" unitRef="aud">105,606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Superannuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:SuperannuationExpenses" scale="0" unitRef="aud">41,964</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:SuperannuationExpenses" scale="0" unitRef="aud">48,877</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:SuperannuationExpenses" scale="0" unitRef="aud">55,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel and entertainment</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="0" unitRef="aud">1,398</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="0" unitRef="aud">91,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="0" unitRef="aud">159,911</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="0" unitRef="aud">589,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="0" unitRef="aud">278,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="0" unitRef="aud">151,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,978,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,703,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="aud">3,694,306</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ResearchAndDevelopmentConsultingExpenses" scale="0" unitRef="aud">1,006,086</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ResearchAndDevelopmentConsultingExpenses" scale="0" unitRef="aud">262,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ResearchAndDevelopmentConsultingExpenses" scale="0" unitRef="aud">430,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Project research and development</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyDevelopmentAndProjectManagementExpense" scale="0" unitRef="aud">360,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyDevelopmentAndProjectManagementExpense" scale="0" unitRef="aud">915,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyDevelopmentAndProjectManagementExpense" scale="0" unitRef="aud">613,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,367,054</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,178,685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,044,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Selling</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingExpense" scale="0" unitRef="aud">25,858</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingExpense" scale="0" unitRef="aud">340,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingExpense" scale="0" unitRef="aud">277,478</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Marketing</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:MarketingExpenses" scale="0" unitRef="aud">90,652</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:MarketingExpenses" scale="0" unitRef="aud">295,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:MarketingExpenses" scale="0" unitRef="aud">377,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Distribution costs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DistributionCosts" scale="0" unitRef="aud">171,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DistributionCosts" scale="0" unitRef="aud">236,244</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DistributionCosts" scale="0" unitRef="aud">209,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">287,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">871,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="aud">864,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. Income Tax Benefit</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_2" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">30
    June <br/>2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Unused tax losses for which no deferred tax asset has been recognised</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" unitRef="aud">44,178,579</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" unitRef="aud">40,018,956</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Potential tax benefit @ 26% (2020: 27.5%)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="0" unitRef="aud">11,486,431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="0" unitRef="aud">11,005,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_3" id="_DisclosureOfIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Numerical reconciliation of income tax expense
to prima facie tax payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfIncomeTaxExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfIncomeTaxBenefitExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-style: normal; font-weight: normal">30
    June<br/> 2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss from continuing operations before income tax expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tax at the Australian tax rate of 26% (2020: 27.5%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" sign="-" unitRef="aud">2,179,961</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" sign="-" unitRef="aud">804,982</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax effect of amounts which are not deductible (taxable) in calculating taxable income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectofResearchAndDevelopmentTaxIncentive" scale="0" sign="-" unitRef="aud">92,614</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectofResearchAndDevelopmentTaxIncentive" scale="0" sign="-" unitRef="aud">84,762</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting expenditure subject to R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" scale="0" unitRef="aud">212,907</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" scale="0" unitRef="aud">194,855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfShareBasedPayments" scale="0" unitRef="aud">550,163</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfShareBasedPayments" scale="0" sign="-" unitRef="aud">146,826</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impact of other amounts not deductible (taxable)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" scale="0" unitRef="aud">428,003</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" scale="0" sign="-" unitRef="aud">18,678</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfTaxPayable" scale="0" sign="-" unitRef="aud">1,081,502</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TaxEffectOfTaxPayable" scale="0" sign="-" unitRef="aud">860,393</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax losses and other timing differences for which no deferred tax asset is recognised</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" scale="0" unitRef="aud">1,081,502</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" scale="0" unitRef="aud">860,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 111; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. Key Management Personnel Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_2" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note details the nature and amount of remuneration
for each Director of Immuron Limited, and for the Key Management Personnel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_3" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Directors of Immuron Limited during the year
ended June 30, 2021 were:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_4" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following persons held office as Directors
of Immuron Limited during the financial year:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_5" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Dr Roger Aston, Independent Non-Executive
Chairman</p></ix:continuation><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_6" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Peter Anastasiou, Executive Vice
Chairman (resigned on 24 September 2021)</p></ix:continuation><div>
</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_7" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Daniel Pollock, Independent Non-Executive
Director</p></ix:continuation><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_8" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Stephen Anastasiou, Independent
Non-Executive Director</p></ix:continuation><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_9" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Prof. Ravi Savarirayan, Independent
Non-Executive Director</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_10" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following persons held office as Key Management
Personnel of Immuron Limited during the financial year ended June 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_11" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Dr Jerry Kanellos, Chief Operating
Officer and Chief Executive Officer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_12" id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate compensation made to Directors
and Other Key Management Personnel of the Company is set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Key Management Personnel Compensation</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Short-term employee benefits</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud">450,002</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud">867,054</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud">952,406</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Other short-term benefits, including consulting services by KMP and their related entities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" scale="0" unitRef="aud">1,603,747</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Post-employment benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud">27,869</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud">29,213</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud">32,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Long-term benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="0" unitRef="aud">8,220</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="0" unitRef="aud">3,610</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="0" unitRef="aud">3,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Share-based payment expenses to KMP and their related entities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud">2,116,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud">1,296,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Key Management Personnel Compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud">4,205,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud">972,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud">2,284,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6. Loss per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEarningsPerShareExplanatory-c0_cont_2" id="_DisclosureOfEarningsPerShareExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfDetailsOfEarningsPerShareExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic/Diluted loss per share (in cents)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">3.79</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">1.66</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:BasicAndDilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares">3.22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">a) Net loss used in the calculation of basic and diluted loss
    per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" scale="0" unitRef="aud">8,384,465</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" scale="0" unitRef="aud">2,927,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" scale="0" unitRef="aud">4,656,421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">b) Weighted average number of ordinary shares outstanding
    during the period used in the calculation of basic and diluted loss per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:WeightedAverageNumberOfShares" scale="0" unitRef="shares">221,062,229</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:WeightedAverageNumberOfShares" scale="0" unitRef="shares">176,393,354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:WeightedAverageNumberOfShares" scale="0" unitRef="shares">144,740,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_DisclosureOfEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently in a loss making position
and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company&#8217;s options and warrants
and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCashExplanatory-c0_cont_1" escape="true" name="imc:DisclosureOfCashExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. Cash</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCashExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DetailedInformationAboutCashExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Cash at Bank and in hand:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Cash at bank and in hand</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:CashAtBankAndInHand" scale="0" unitRef="aud">25,047,281</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:CashAtBankAndInHand" scale="0" unitRef="aud">3,250,468</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Cash</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud">25,047,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud">3,250,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 112; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8. Trade and Other Receivables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_2" id="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DetailedInformationAboutTradeAndOtherReceivablesExplanatory-c0_cont_1" escape="true" name="imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Trade receivables*</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:TradeReceivables" scale="0" unitRef="aud">28,553</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:TradeReceivables" scale="0" unitRef="aud">49,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:LossOnAllowanceTradeReceivables" scale="0" sign="-" unitRef="aud">30,055</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued income**</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:AccruedIncomeOtherThanContractAssets" scale="0" unitRef="aud">306,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:AccruedIncomeOtherThanContractAssets" scale="0" unitRef="aud">308,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Trade and Other Receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherReceivables" scale="0" unitRef="aud">334,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherReceivables" scale="0" unitRef="aud">327,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_3" id="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_2"><ix:continuation continuedAt="_DetailedInformationAboutTradeAndOtherReceivablesExplanatory-c0_cont_2" id="_DetailedInformationAboutTradeAndOtherReceivablesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trade receivables are non-interest bearing.</span></ix:footnote></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfTradeAndOtherReceivablesExplanatory-c0_cont_3"><ix:continuation id="_DetailedInformationAboutTradeAndOtherReceivablesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;D tax concession for the year.</span></ix:footnote></td></tr>
</table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInventoriesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9. Inventories</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_DisclosureOfInventoriesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DetailedInformationAboutInventoriesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30 June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">30 June <br/>2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Raw materials and stores (Colostrum)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentInventories" scale="0" unitRef="aud">1,266,587</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">1,266,587</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentInventories" scale="0" unitRef="aud">1,722,349</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">1,722,349</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Work in progress</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">117,576</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">117,576</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Finished goods (Travelan and Protectyn)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">292,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">292,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">680,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">680,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">292,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentInventories" scale="0" unitRef="aud">1,266,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">1,559,119</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="aud">797,690</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentInventories" scale="0" unitRef="aud">1,722,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:InventoriesNet" scale="0" unitRef="aud">2,520,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ControlledEntitiesTextBlock-c0_cont_1" escape="true" name="imc:ControlledEntitiesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10. Controlled Entities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ControlledEntitiesTextBlock-c0_cont_2" id="_ControlledEntitiesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries at 30 June 2021
are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the
Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or
registration is also their principal place of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_ControlledEntitiesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="imc:ScheduleOfSubsidiariesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Percentage
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Ownership</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Country of Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Parent Entity:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Immuron Limited</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c41" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Subsidiaries of Immuron Limited:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Immuron Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c43" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Anadis EPS Pty Ltd</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c45" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">IMC Canada Ltd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c47" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11. Trade and Other Payables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Trade payables</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="aud">106,893</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="aud">157,644</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="0" unitRef="aud">625,980</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="0" unitRef="aud">210,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="aud">25,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="aud">16,019</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud">758,494</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud">384,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfProvisionForSalesReturnsExplantory-c0_cont_1" escape="true" name="imc:DisclosureOfProvisionForSalesReturnsExplantory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12. Provision for Sales Returns</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfProvisionForSalesReturnsExplantory-c0_cont_2" id="_DisclosureOfProvisionForSalesReturnsExplantory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfSalesReturnProvisionExplantory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"><b>Sales return provision due to the ongoing COVID-19 pandemic</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carrying amount at the start of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Sales return provision recognised</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud">213,024</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts transferred from non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Carrying amount at the end of the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud">213,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfProvisionForSalesReturnsExplantory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The sales return provision has been assessed by management based on
external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled
in the next year.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 114; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ContingentLiabilitiesTextBlock-c0_cont_1" escape="true" name="imc:ContingentLiabilitiesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 13. Contingent liabilities and Commitments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_ContingentLiabilitiesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group had <ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" scale="0" unitRef="usd">no</ix:nonFraction> contingent liabilities or commitments
at June 30, 2021 (2020: <span style="-sec-ix-hidden: hidden-fact-84">Nil</span>).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 14. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_2" id="_DisclosureOfLeasesExplanatory-c0_cont_1"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts
    recognized in the balance sheet</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_3" id="_DisclosureOfLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The balance sheet shows the following amounts relating to leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_4" id="_DisclosureOfLeasesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAmountsRecognizedinBalanceSheet-c0_cont_1" escape="true" name="imc:ScheduleOfAmountsRecognizedinBalanceSheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">30
                                            June</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
                                            A$</span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right-of-use assets<sup>1</sup></b></span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud">19,471</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud">58,095</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud">19,471</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud">58,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease liabilities<sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud">42,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud">18,929</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="aud">61,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_5" id="_DisclosureOfLeasesExplanatory-c0_cont_4"><ix:continuation continuedAt="_ScheduleOfAmountsRecognizedinBalanceSheet-c0_cont_2" id="_ScheduleOfAmountsRecognizedinBalanceSheet-c0_cont_1"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">1.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Included in the line item &#8216;property, plant and equipment&#8217; in the consolidated balance sheet.</ix:footnote></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_6" id="_DisclosureOfLeasesExplanatory-c0_cont_5"><ix:continuation id="_ScheduleOfAmountsRecognizedinBalanceSheet-c0_cont_2"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">2.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Included in the line items &#8216;other current liabilities&#8217; and &#8216;other non-current liabilities&#8217; in the consolidated balance sheet.</ix:footnote></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_7" id="_DisclosureOfLeasesExplanatory-c0_cont_6"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts
    recognized in the statement of profit or loss</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_8" id="_DisclosureOfLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of profit or loss shows the following amounts relating
to leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_9" id="_DisclosureOfLeasesExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="imc:ScheduleOfProfitOrLossAmountsRelatedToLeases"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
    A$</span></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold">Depreciation charge of right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud">38,624</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud">38,729</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud">38,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud">38,729</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense (included in finance cost)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="aud">1,152</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="aud">4,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to variable lease payments not included in lease liabilities (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash paid for principal payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="aud">40,607</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="aud">41,390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_10" id="_DisclosureOfLeasesExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total finance cash outflow for leases in 2021 was A$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="aud">1,152</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_11" id="_DisclosureOfLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total finance cash outflow for leases in 2020 was A$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="aud">4,192</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_12" id="_DisclosureOfLeasesExplanatory-c0_cont_11"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    group&#8217;s leasing activities and how these are accounted for</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_13" id="_DisclosureOfLeasesExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="ifrs-full:InformationAboutNatureOfLesseesLeasingActivities">In January 2019, the group entered into a three-year
commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option
for a further 3 years by written request to the landlord before 31 December 2021.</ix:nonNumeric> There is no variability and no covenants included in
the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 115; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_14" id="_DisclosureOfLeasesExplanatory-c0_cont_13"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases are recognized as a right-of-use asset
and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated
between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant
periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter
of the asset&#8217;s useful life and the lease term on a straight-line basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_15" id="_DisclosureOfLeasesExplanatory-c0_cont_14"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities arising from a lease are
initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_16" id="_DisclosureOfLeasesExplanatory-c0_cont_15"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fixed
    payments (including in-substance fixed payments), less any lease incentives receivable</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variable
    lease payment that are based on an index or a rate</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
    expected to be payable by the lessee under residual value guarantees</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.</span></td></tr>
</table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_17" id="_DisclosureOfLeasesExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The lease payments are discounted using the interest
rate implicit in the lease, if that rate can be determined, or the group&#8217;s incremental borrowing rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_18" id="_DisclosureOfLeasesExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right-of-use assets are measured at cost comprising the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_19" id="_DisclosureOfLeasesExplanatory-c0_cont_18"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of the initial measurement of lease liability</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    lease payments made at or before the commencement date, less any lease incentives received</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    initial direct costs, and</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restoration
    costs.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfLeasesExplanatory-c0_cont_19"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments associated with short-term leases and
leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with
a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 116; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15. Share capital</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_2" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Ordinary shares</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; padding-bottom: 1.5pt">Fully paid</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">227,246,596</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">178,279,566</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">163,215,706</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">88,361,303</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">62,426,991</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">60,289,875</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">227,246,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">178,279,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares">163,215,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">88,361,303</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">62,426,991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:AmountOfOrdinaryShares" scale="0" unitRef="aud">60,289,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_3" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Movements in ordinary
    shares:</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_4" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOrdinarySharesExplanatory-c0_cont_1" escape="true" name="imc:DisclosureOfOrdinarySharesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Details</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2018</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinaryShare" scale="0" unitRef="shares">142,778,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfEquityToOrdinaryvalue" scale="0" unitRef="usd">58,237,314</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at $0.16 in lieu
    of payment for services (2018-11-22)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" scale="0" unitRef="shares">437,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" scale="0" unitRef="usd">93,678</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at US$0.10 pursuant
    to ADS public offering (2019-05-30)<sup>2</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="imc:ProceedsFromIssuedSharesAtADSPublicOffering" scale="0" unitRef="shares">20,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="imc:ProceedsFromIssuedAtADSPublicOffering" scale="0" unitRef="usd">2,894,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Reclassify exercised options from reserves to share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:StockIssuedDuringValueReclassifyToStockOptionsExercised" scale="0" unitRef="usd">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs arising
    on representative warrants issued<sup>3</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:TransactionCostsArisingOnRepresentativeWarrantsIssued" scale="0" sign="-" unitRef="usd">110,400</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:BusinessAcquisitionCostOfTransactionCost" scale="0" sign="-" unitRef="usd">825,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinaryShare" scale="0" unitRef="shares">163,215,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfEquityToOrdinaryvalue" scale="0" unitRef="usd">60,289,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:IssuePursuantToAdsPublicOfferingShares" scale="0" unitRef="shares">13,565,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:IssuePursuantToAdsPublicOffering" scale="0" unitRef="usd">1,926,186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at A$0.16 in lieu
    of payment for services (2019-11-12)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="imc:IssueInLieuOfPaymentForServicesShares" scale="0" unitRef="shares">437,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="imc:IssueInLieuOfPaymentForServices" scale="0" unitRef="usd">100,978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of NASDAQ Warrants (2020-06-23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrantsShares" scale="0" unitRef="shares">86,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrants" scale="0" unitRef="usd">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of representative warrants (2020-06-15, 2020-06-22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrantShares" scale="0" unitRef="shares">974,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrant" scale="0" unitRef="usd">540,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Transaction costs arising on representative warrants issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:TransactionCostsArisingOnRepresentativeWarrantsIssued" scale="0" sign="-" unitRef="usd">55,454</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:BusinessAcquisitionCostOfTransactionCost" scale="0" sign="-" unitRef="usd">374,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify">Balance at 30 June 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinaryShare" scale="0" unitRef="shares">178,279,566</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfEquityToOrdinaryvalue" scale="0" unitRef="usd">62,426,991</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%">Exercise of representative warrants (2020-07-02)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrants1" scale="0" unitRef="shares">5,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS047PursuantToADSPublicOffering" scale="0" unitRef="shares">42,666,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS047PursuantToADSPublicOffering1" scale="0" unitRef="usd">28,165,836</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAt050OnExerciseOfESOPUnlistedOption" scale="0" unitRef="shares">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAt050OnExerciseOfESOPUnlistedOptions" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS025OnExerciseOfNASDAQWarrants" scale="0" unitRef="shares">3,008,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS025OnExerciseOfNASDAQWarrants1" scale="0" unitRef="usd">1,051,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS025OnExerciseOfNASDAQWarrant" scale="0" unitRef="shares">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtUS025OnExerciseOfNASDAQWarrant1" scale="0" unitRef="usd">13,959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferFromReservesOnExerciseOfESOPUnlistedOption" scale="0" unitRef="usd">15,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferFromReservesOnExerciseOfNASDAQWarrants" scale="0" unitRef="usd">1,012</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtA008InLieuOfCashForServicesRendered20201113" scale="0" unitRef="shares">2,737,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueAtA008InLieuOfCashForServicesRendered" scale="0" unitRef="usd">219,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" scale="0" unitRef="shares">409,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" scale="0" unitRef="usd">197,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:BusinessAcquisitionCostOfTransactionCost" scale="0" sign="-" unitRef="usd">3,779,831</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance at 30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinaryShare" scale="0" unitRef="shares">227,246,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfEquityToOrdinaryvalue" scale="0" unitRef="usd">88,361,303</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_5" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Notes</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_6" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_5"><ix:continuation continuedAt="_DisclosureOfOrdinarySharesExplanatory-c0_cont_2" id="_DisclosureOfOrdinarySharesExplanatory-c0_cont_1"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#8217;s products for A$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:PaymentForServices" scale="0" unitRef="aud">70,000</ix:nonFraction> per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="audPershares">0.16</ix:nonFraction> per share, representing Immuron Limited&#8217;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.</span></ix:footnote></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_7" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_6"><ix:continuation id="_DisclosureOfOrdinarySharesExplanatory-c0_cont_2"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><ix:nonNumeric contextRef="c53" name="imc:IssuanceOfOrdinarySharesDescription"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</span></ix:footnote></ix:nonNumeric></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_8" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Ordinary
    shares</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_9" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares entitle the holder to participate
in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_10" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a show of hands every holder of ordinary shares
present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_11" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares have no par value and the Company
does not have a limited amount of authorized capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 117; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_12" id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td><span style="text-decoration:underline">Options</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information relating to options, including details
of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set
out in notes 15 and 18.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16. Other reserves</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows a breakdown of the
consolidated statement of financial position line item &#8216;other reserves&#8217; and the movements in these reserves during the year.
A description of the nature and purpose of each reserve is provided below the table.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_3" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationOtherReserve-c0_cont_1" escape="true" name="imc:DisclosureOfDetailedInformationOtherReserve"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify">At 1 July 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%"></td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">3,139,625</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" sign="-" unitRef="aud">43,317</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">3,096,308</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="imc:CurrencyTranslationDifferences" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:CurrencyTranslationDifferences" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="0" unitRef="aud">61,846</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsIssuedexpensed" scale="0" unitRef="aud">1,453,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsIssuedexpensed" scale="0" unitRef="aud">1,453,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsExercised" scale="0" sign="-" unitRef="aud">100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsExercised" scale="0" sign="-" unitRef="aud">100</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Options and warrants lapsed/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsLapsed" scale="0" sign="-" unitRef="aud">311,635</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsLapsed" scale="0" sign="-" unitRef="aud">311,635</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">4,281,790</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">18,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">4,300,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_4" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_3"><ix:continuation continuedAt="_DisclosureOfDetailedInformationOtherReserve-c0_cont_2" id="_DisclosureOfDetailedInformationOtherReserve-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At
    1 July 2019</b></span></td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">4,281,790</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">18,529</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,300,319</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="imc:CurrencyTranslationDifferences" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="0" unitRef="aud">102,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,938</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="imc:SharebasedPaymentExpenses" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,088</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsIssuedexpensed" scale="0" sign="-" unitRef="aud">484,680</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(484,680</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants lapsed/expired</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsLapsed" scale="0" sign="-" unitRef="aud">2,251,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,251,320</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Re-valuation of options issued in prior period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">16(iii)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationOfOptionsIssuedInPriorPeriod" scale="0" sign="-" unitRef="aud">607,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">1,011,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">121,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,133,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_5" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_4"><ix:continuation id="_DisclosureOfDetailedInformationOtherReserve-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-based payments<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign currency translation<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total other reserves<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">At 1 July 2020</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">1,011,878</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">121,467</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">1,133,345</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="imc:CurrencyTranslationDifferences" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:CurrencyTranslationDifferences" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="0" sign="-" unitRef="aud">14,953</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transfer to share capital</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferToShareCapitalinDollars" scale="0" sign="-" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TransferToShareCapitalinDollars" scale="0" sign="-" unitRef="aud">73,088</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsIssuedexpensed" scale="0" unitRef="aud">3,003,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsIssuedexpensed" scale="0" unitRef="aud">3,003,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsExercised" scale="0" sign="-" unitRef="aud">213,722</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsExercised" scale="0" sign="-" unitRef="aud">213,722</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Options and warrants forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsForfeited" scale="0" sign="-" unitRef="aud">368,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsAndWarrantsForfeited" scale="0" sign="-" unitRef="aud">368,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">At 30 June 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">3,360,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">106,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="aud">3,466,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_6" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Nature
    and purpose of other reserves</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_7" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_8" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The share-based payment reserve records items
recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_9" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency translation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_10" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exchange differences arising on translation of
foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve
within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 118; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_11" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Movements
    in options and warrants:</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_12" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfDetailedInformationMovementsInOptionsAndWarrants"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Details</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
&#160;A$</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2018</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 11%; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares">72,569,180</ix:nonFraction></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="aud">3,139,625</ix:nonFraction></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-07-13)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" scale="0" unitRef="shares">1,300,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" scale="0" unitRef="aud">204,100</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-11-26)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" scale="0" unitRef="shares">2,000,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" scale="0" unitRef="aud">164,400</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of ESOP unlisted options at $0.50 (2018-10-01)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" scale="0" sign="-" unitRef="shares">1,050,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" scale="0" sign="-" unitRef="aud">98,385</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2019-02-11)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" scale="0" unitRef="shares">5,000,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" scale="0" unitRef="aud">975,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.57 (2019-02-24)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueLapseOfUnlistedOptionOne" scale="0" sign="-" unitRef="shares">1,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfValueIssueLapseOfUnlistedOptionOne" scale="0" sign="-" unitRef="aud">185,601</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $1.892 (2019-02-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueLapseOfUnlistedOptionTwo" scale="0" sign="-" unitRef="shares">15,380</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfValueIssueLapseOfUnlistedOptionTwo" scale="0" sign="-" unitRef="aud">1,173</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.30 (2019-05-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueLapseOfUnlistedOptionThree" scale="0" sign="-" unitRef="shares">140,056</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfValueIssueLapseOfUnlistedOptionThree" scale="0" sign="-" unitRef="aud">13,390</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify exercised options from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" scale="0" sign="-" unitRef="aud">100</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify lapsed options from reserves to accumulated losses</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" scale="0" sign="-" unitRef="aud">13,086</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-05-23)<sup>1</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsSharesOne" scale="0" unitRef="shares">800,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsOne" scale="0" unitRef="aud">110,400</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2019</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares">79,463,744</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="aud">4,281,790</ix:nonFraction></b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-valuation of options issued in prior period (2019-11-06)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iii)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationOfOptionsIssuedInPriorPeriod" scale="0" sign="-" unitRef="aud">607,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-07-16)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsTwoShares" scale="0" unitRef="shares">542,600</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsTwo" scale="0" unitRef="aud">55,454</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2019-11-27)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsAtZeroPointFiveShares" scale="0" sign="-" unitRef="shares">7,625,532</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsAtZeroPointFive" scale="0" sign="-" unitRef="aud">2,086,920</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.55 (2019-11-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" scale="0" sign="-" unitRef="shares">25,289,894</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2020-06-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" scale="0" sign="-" unitRef="shares">2,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsAtZeroPointFiveOne" scale="0" sign="-" unitRef="aud">164,400</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" scale="0" sign="-" unitRef="shares">218,800</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" scale="0" sign="-" unitRef="aud">72</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-06-15, 2020-06-22)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrantsShares" scale="0" sign="-" unitRef="shares">2,065,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrants" scale="0" sign="-" unitRef="aud">540,062</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2020</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares">42,807,118</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="aud">938,790</ix:nonFraction></b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-07-2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfRepresentativeWarrantsSharesOne" scale="0" sign="-" unitRef="shares">9,640</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of ESOP unlisted options at $0.50 (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfESOPUnlistedOptions" scale="0" sign="-" unitRef="shares">100,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfESOPUnlistedOptionsValue" scale="0" sign="-" unitRef="aud">15,700</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" scale="0" sign="-" unitRef="shares">3,048,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" scale="0" sign="-" unitRef="aud">1,012</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options (2020-09-25)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsOne" scale="0" sign="-" unitRef="shares">5,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:LapseOfUnexercisedOptionsValue" scale="0" sign="-" unitRef="aud">368,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants at US$23.44 per 40 options (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsThreeShares" scale="0" unitRef="shares">2,560,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:IssueOfRepresentativeWarrantsThree" scale="0" unitRef="aud">1,032,960</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.12 (2020-10-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" scale="0" unitRef="shares">9,000,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" scale="0" unitRef="aud">1,970,100</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:CashlessExerciseOfESOPUnlistedOptions" scale="0" sign="-" unitRef="shares">900,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:CashlessExerciseOfESOPUnlistedOptionsValue" scale="0" sign="-" unitRef="aud">197,010</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify share-based payments expenses from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iv)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" scale="0" sign="-" unitRef="aud">73,088</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares">45,309,478</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="aud">3,360,128</ix:nonFraction></b></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_13" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 13 July 2018, the Company issued Dr. <ix:nonNumeric contextRef="c54" name="imc:OtherReserveMaturityDateDescription">Jerry Kanellos, Chief Operating Officer of Immuron Limited, <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesUnlistedOption" scale="0" unitRef="shares">1,000,000</ix:nonFraction> unlisted options exercisable at $<ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="imc:UnlistedOptionExercisable" scale="0" unitRef="usdPershares">0.50</ix:nonFraction> on or before 1 July 2021.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_14" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c55" name="imc:OtherReserveMaturityDateDescription">On 26 November 2018, the Company issued Mr. Richard
J. Berman, a Non-Executive Director of Immuron Limited, <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesUnlistedOption" scale="0" unitRef="shares">2,000,000</ix:nonFraction> unlisted options exercisable at $<ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="imc:UnlistedOptionExercisable" scale="0" unitRef="usdPershares">0.50</ix:nonFraction> on or before June 30, 2021.</ix:nonNumeric> During
the 2019 annual general meeting, the shareholders approved the issuance of the options to Richard Berman.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_15" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 11 February 2019, the Company issued Dr. Gary
S. Jacob <ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfSharesUnlistedOption" scale="0" unitRef="shares">5,000,000</ix:nonFraction> unlisted options exercisable at $<ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="imc:UnlistedOptionExercisable" scale="0" unitRef="usdPershares">0.50</ix:nonFraction>. These options were subsequently forfeited on September 25, 2020, being 6 months
after his resignation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_16" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the shareholders' approval at the AGM held
on 29 October 2020, a total of <ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="imc:ESOPOptionsIssued" scale="0" unitRef="usd">9,000,000</ix:nonFraction> ESOP Options were issued to directors on 13 November 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 119; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_17" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revaluation
                                            of options issued in prior period</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_18" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_17"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options granted to Dr Gary Jacob on 11 February 2019 and valued at
$<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsGranted" scale="0" unitRef="usd">975,000</ix:nonFraction> in the 30 June 2019 financials were subject to shareholder approval. <ix:nonNumeric contextRef="c58" name="imc:RevaluedAtGrantDate">In line with IFRS 2, these were re-measured at grant date
6 November 2019 after being approved by shareholders with a value of $<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationOfShareholdersApprovedValue" scale="0" unitRef="usd">368,000</ix:nonFraction>, being a revaluation of $<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationFinancialsAmount" scale="0" unitRef="usd">607,000</ix:nonFraction> in the 30 June 2020 financials.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_19" id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
                                            payment expenses</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfReservesAndOtherEquityInterestExplanatory-c0_cont_19"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the ongoing crisis of COVID-19, the groups
directors decided to forgo cash payments of their director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that
value. In prior year, no shares were issued to directors, however the expense of the shares owed to them was A$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpenseOfSharesOwed" scale="0" unitRef="aud">73,088</ix:nonFraction>. As at 30 June
2021, shares have been issued to directors given the shareholders' approval at the AGM held on 29 October 2020.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Segment Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_2" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of segments and principal activities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_3" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group has identified its operating segments
based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the
allocation of resources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_4" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management considers the business from both a
product and a geographic perspective and has identified <ix:nonFraction contextRef="c2" decimals="0" format="ixt-sec:numwordsen" name="imc:NumberOfSegment" scale="0" unitRef="pure">two</ix:nonFraction> reportable segments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_5" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (R&amp;D): income and
expenses directly attributable to the group&#8217;s R&amp;D projects performed in Australia, Israel and United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_6" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hyperimmune products: income and expenses directly
attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_7" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial breakdown</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_8" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2021 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_9" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosuresOfProductsAndServicesExplanatory-c0_cont_1" escape="true" name="imc:DisclosuresOfProductsAndServicesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">51,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">51,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">94,705</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">94,705</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">431,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">24,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">161,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">617,110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">759,765</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">582,528</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">1,342,293</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">3,978,679</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">3,978,679</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" sign="-" unitRef="aud">2,116,013</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" sign="-" unitRef="aud">2,116,013</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,367,054</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,367,054</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">287,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">287,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">936,024</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">928,264</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">6,515,620</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">8,379,908</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="aud">9,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="aud">9,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="aud">13,761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="aud">13,761</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">936,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">928,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">6,520,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">306,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">1,587,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">25,159,280</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">27,053,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">306,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">1,587,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">25,159,280</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">27,053,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">243,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">284,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">629,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">1,158,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">243,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">284,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">629,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">1,158,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_10" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2020 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_11" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_10"><ix:continuation continuedAt="_DisclosuresOfProductsAndServicesExplanatory-c0_cont_2" id="_DisclosuresOfProductsAndServicesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">688,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">688,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,829,730</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,829,730</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">308,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">10,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">154,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">473,674</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">11,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">11,335</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">3,170,078</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">3,170,078</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,178,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,178,685</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">871,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">871,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">870,460</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" unitRef="aud">968,724</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">3,003,839</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">2,905,575</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="aud">21,631</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="aud">21,631</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">870,460</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" unitRef="aud">968,724</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">3,025,470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">308,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">2,539,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">3,354,435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">6,202,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">308,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">2,539,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">3,354,435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">6,202,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">101,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">30,377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">426,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">558,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">101,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">30,377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">426,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">558,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_12" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2019 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_13" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_12"><ix:continuation id="_DisclosuresOfProductsAndServicesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:HyperimmuneProductsRevenue" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">667,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="aud">667,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,720,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" unitRef="aud">1,720,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">531,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">1,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud">532,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud">13,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">51,807</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud">38,413</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">5,037,806</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:GeneralAndAdministrativeExpenses" scale="0" unitRef="aud">5,037,806</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,044,528</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud">1,044,528</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">864,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:SellingAndMarketingExpenses" scale="0" sign="-" unitRef="aud">864,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">513,523</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" unitRef="aud">843,062</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">4,985,999</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="aud">4,656,460</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="aud">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="aud">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">513,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" unitRef="aud">843,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">4,985,960</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">531,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">2,705,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">5,324,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentAssets" scale="0" unitRef="aud">8,561,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">531,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">2,705,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">5,324,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud">8,561,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">221,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">191,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">797,155</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentLiabilities" scale="0" sign="-" unitRef="aud">1,210,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">221,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">191,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">797,155</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud">1,210,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_14" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Information on geographical regions:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_15" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group derives revenue from the transfer of
hyperimmune products at a point in time in the following major product lines and geographical regions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_16" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeographicalAreasExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyperimmune
    products revenue<sup>1</sup></span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="ifrs-full:Revenue" scale="0" sign="-" unitRef="aud">10,308</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="ifrs-full:Revenue" scale="0" unitRef="aud">4,264</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="ifrs-full:Revenue" scale="0" unitRef="aud">101,639</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" id="ix_22_fact" name="ifrs-full:Revenue" scale="0" unitRef="aud">50,181</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="ifrs-full:Revenue" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" sign="-" unitRef="aud">10,308</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">4,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">101,639</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">50,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">145,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_17" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>1.</sup></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Returns are provided where outlined in a customer&#8217;s agreement.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_18" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_17"><ix:continuation continuedAt="_DisclosureOfGeographicalAreasExplanatory-c0_cont_2" id="_DisclosureOfGeographicalAreasExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Hyperimmune products revenue</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="aud">1,240,393</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="aud">926,325</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="aud">301,915</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="aud">49,933</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">1,240,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">926,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">301,915</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">49,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">2,518,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_19" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_18"><ix:continuation id="_DisclosureOfGeographicalAreasExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Segment revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">1,162,628</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">1,016,468</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">149,283</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">58,683</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">364</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:SegmentRevenue" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">1,162,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">1,016,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">149,283</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">58,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFromExternalCustomers" scale="0" unitRef="aud">2,387,426</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_20" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Information on major customers:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_21" id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended June 30, 2021, 2020 and
2019, the Company had the following major customers in the hyperimmune product segment with revenues amounting to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:PercentageOfEntityRevenue" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:PercentageOfEntityRevenue" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:PercentageOfEntityRevenue" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent or more
of total group revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_21"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Customer A</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">41,040</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">27,563</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer C</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">25,319</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer D</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">23,214</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">462,490</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">611,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer E</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">22,886</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer F</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">442,916</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">228,661</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer G</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">438,065</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">659,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer H</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">327,559</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">266,111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Customer I</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">227,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">249,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">140,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">1,898,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:RevenueFormContractWithCustomer" scale="0" unitRef="aud">2,015,851</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_1" escape="true" name="imc:DisclosureOfCashFlowInformationExplanatoryTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 18. Cash Flow Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_2" id="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation of cash
    flow from operations with loss after income tax</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_3" id="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: justify">Net Loss for the Year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">8,384,465</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">2,927,206</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud">4,656,421</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Adjustments for</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Depreciation expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">43,662</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">44,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="0" unitRef="aud">5,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Distribution costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:AdjustmentsForDistributionCosts" scale="0" unitRef="aud">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:AdjustmentsForDistributionCosts" scale="0" unitRef="aud">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" sign="-" unitRef="aud">30,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" sign="-" unitRef="aud">3,991</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ExpectedCreditLosses" scale="0" unitRef="aud">34,046</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Finance costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="0" unitRef="aud">13,761</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="0" unitRef="aud">21,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Finance income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="0" unitRef="aud">9,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="0" unitRef="aud">39</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Leave provision expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:LeaveProvisionExpense" scale="0" unitRef="aud">53,610</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:LeaveProvisionExpense" scale="0" unitRef="aud">19,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:LeaveProvisionExpense" scale="0" unitRef="aud">4,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Share-based payments (income)/expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareBasedPaymentsExpense" scale="0" unitRef="aud">2,116,013</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareBasedPaymentsExpense" scale="0" sign="-" unitRef="aud">533,912</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareBasedPaymentsExpense" scale="0" unitRef="aud">1,343,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Unrealized net foreign currency gains</p></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" unitRef="aud">592,243</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" sign="-" unitRef="aud">18,883</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" sign="-" unitRef="aud">62,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add decrease in trade and other receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="0" unitRef="aud">23,037</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="0" unitRef="aud">641,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="0" unitRef="aud">680,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in inventories</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="0" unitRef="aud">960,920</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="0" sign="-" unitRef="aud">113,635</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="0" unitRef="aud">263,365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in other operating assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="0" sign="-" unitRef="aud">45,065</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="0" unitRef="aud">16,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="0" unitRef="aud">92,510</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Add (decrease) / increase in trade and other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" unitRef="aud">586,796</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" sign="-" unitRef="aud">362,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" unitRef="aud">426,271</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">4,078,747</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">3,147,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud">1,798,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_4" id="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-cash financing and
    investing activities</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfCashFlowInformationExplanatoryTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See note 19 for details regarding issues of options
to employees and for details surrounding the issue of shares to suppliers.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c3" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 19. Share-based Payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive share and
    option plan</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The establishment of the &#8216;executive share
and option plan&#8217; (ESOP) was approved by shareholders at the 2017 annual general meeting. The plan is designed to provide long-term
incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board&#8217;s
discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_4" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued to Dr Gary Jacob expire within
6 months upon his resignation without good reason or termination. All other options issued expire upon departure from the company if
they are determined to be a &#8216;bad leaver&#8217;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_5" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set out below are summaries of all listed and
unlisted options, including those issued under ESOP:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_6" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_5"><ix:nonNumeric contextRef="c134" escape="true" name="imc:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; text-indent: -9pt; padding-left: 9pt">As at 1 July</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.40</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">42,807,118</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.46</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">79,463,744</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">72,569,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.28</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares">11,560,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares">542,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares">9,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.23</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" scale="0" sign="-" unitRef="shares">4,057,640</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" scale="0" sign="-" unitRef="shares">424,840</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/lapsed during the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" scale="0" sign="-" unitRef="shares">5,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" scale="0" sign="-" unitRef="shares">36,774,386</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" scale="0" sign="-" unitRef="shares">2,205,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">As at 30 June</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">45,309,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">42,807,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfOutstandingShareOption" scale="0" unitRef="shares">79,463,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at 30 June</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.31</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares">45,309,478</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares">42,807,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" scale="0" unitRef="audPershares">0.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares">79,463,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_7" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share options outstanding at the end of the year
have the following expiry date and exercise prices:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_8" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_7"><ix:nonNumeric contextRef="c3" escape="true" name="imc:ScheduleOfDeemedValuationOfOptionsExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry<br/> date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/> price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Grant date</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(A$ unless stated otherwise)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">30 June<br/>
 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">30 June<br/>
 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">2012-06-29</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c135" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2021-11-30</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c135" name="imc:ExercisePrice">1.944</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">14,493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">14,493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2012-06-29</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c137" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2022-01-17</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c137" name="imc:ExercisePrice">1.876</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">29,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">29,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-13 (warrants)</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c139" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2022-06-13</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c139" name="imc:ExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.25</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">24,493,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">27,541,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c141" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2023-03-15</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c141" name="imc:ExercisePrice">0.468</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">7,897,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">7,897,647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-09 (warrants)</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c143" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2022-06-08</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c143" name="imc:ExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.3125</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">198,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">198,240</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c145" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2023-03-15</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c145" name="imc:ExercisePrice">0.585</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">526,510</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">526,510</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2019-05-23 (warrants)</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c147" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-05-23</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c147" name="imc:ExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">173,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">181,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-07-16 (warrants)</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c149" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-07-16</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c149" name="imc:ExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">116,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">117,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2018-07-13</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c151" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2021-07-01</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c151" name="imc:ExercisePrice">0.500</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">1,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">1,300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-11-06</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c153" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-02-10</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c153" name="imc:ExercisePrice">0.500</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2020-10-29</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c155" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-04-14</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c155" name="imc:ExercisePrice">0.12</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">8,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">2020-07-24 (warrants)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c157" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2025-07-21</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c157" name="imc:ExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.5859</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">2,560,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">45,309,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:ShareOptionsOutstanding" scale="0" unitRef="shares">42,807,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average remaining contractual life of options outstanding at end of period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="imc:ShareOptionsPerShare" scale="0" unitRef="usdPershares">1.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="imc:ShareOptionsPerShare" scale="0" unitRef="usdPershares">2.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_9" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_8"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><i>(i)</i></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><i>Fair value of options granted</i></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_10" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 124; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_11" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2021 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_12" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_11"><ix:nonNumeric contextRef="c134" continuedAt="_ScheduleOfDeemedValuationOfOptionsExplanatory-c134_cont_1" escape="true" name="imc:ScheduleOfDeemedValuationOfOptionsExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiry date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend yield</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free interest rate</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
 at grant<br/>
 date per<br/>
 option
    <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%"><ix:nonNumeric contextRef="c159" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2020-07-24</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c159" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2025-07-21</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">2,560,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">127.93</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.43</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.4035</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><ix:nonNumeric contextRef="c160" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2020-10-29</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c160" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-04-14</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">9,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">142.70</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.2189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">11,560,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_13" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2020 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_14" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_13"><ix:continuation continuedAt="_ScheduleOfDeemedValuationOfOptionsExplanatory-c134_cont_2" id="_ScheduleOfDeemedValuationOfOptionsExplanatory-c134_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%"><ix:nonNumeric contextRef="c161" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2019-11-06</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><ix:nonNumeric contextRef="c161" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-02-10</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">5,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.88</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.0736</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">5,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_15" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2019 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_16" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_15"><ix:continuation id="_ScheduleOfDeemedValuationOfOptionsExplanatory-c134_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%"><ix:nonNumeric contextRef="c162" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2018-07-13</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><ix:nonNumeric contextRef="c162" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2021-07-01</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">1,300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.32</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">92.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">2.09</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.1570</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td><ix:nonNumeric contextRef="c163" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2018-11-26</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c163" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2020-06-30</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">92.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">2.02</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.0822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><ix:nonNumeric contextRef="c164" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">2019-02-11</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c164" name="imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">2024-02-11</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="imc:ExercisePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="imc:WeightedAverageSharePriceShareOptionsGranted1" scale="0" unitRef="audPershares">0.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">100.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">1.69</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="imc:ValuePerShareOptionsGranted" scale="0" unitRef="audPershares">0.1950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:NumberOfInstrumentOtherEquityInstrumentGranted" scale="0" unitRef="shares">8,300,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_17" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected life of the options is based on
historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption
that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_18" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses arising from
    share-based payment transactions</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_19" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total expenses arising from share-based payment
transactions recognized during the period were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_20" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_19"><ix:nonNumeric contextRef="c3" escape="true" name="imc:ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020<sup>1</sup><br/>
    A$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options issued under ESOP</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsIssuedUnderESOP" scale="0" unitRef="aud">1,970,100</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="imc:OptionsIssuedUnderESOP" scale="0" sign="-" unitRef="aud">607,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OptionsIssuedUnderESOP" scale="0" unitRef="aud">1,343,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payments to directors<sup>2</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="imc:SharebasedPaymentsToDirectors" scale="0" unitRef="aud">145,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="imc:SharebasedPaymentsToDirectors" scale="0" unitRef="aud">73,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:TotalExpenses" scale="0" unitRef="aud">2,116,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="imc:TotalExpenses" scale="0" sign="-" unitRef="aud">533,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:TotalExpenses" scale="0" unitRef="aud">1,343,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_21" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>1.</sup></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" name="imc:OptionGrantedDescription">Options granted to a former managing director on 11 February 2019 and
valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at
grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:RevaluationFinancialsAmount" scale="0" unitRef="usd">607,000</ix:nonFraction> in the 30 June
2020 financials.</ix:nonNumeric></p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c3_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>2.</sup></td><td style="text-align: justify">Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:SharesIssuedToDirectorsForTheDirectorFees" scale="0" unitRef="usd">145,913</ix:nonFraction> incurred during the financial year ended 30 June 2021 and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:SharesIssuedToDirectorsForTheDirectorFees" scale="0" unitRef="usd">73,088</ix:nonFraction> incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 125; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 20. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_2" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_3" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests in subsidiaries are set out in note
10.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_4" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions with other
    related parties</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_5" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following transactions occurred with related
parties:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_6" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory-c0_cont_1" escape="true" name="imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; font: italic 10pt Times New Roman, Times, Serif; text-align: left">Amounts settled in cash or shares for goods
    and services</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchases of various
    goods and services from entities controlled by key management personnel (i)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="0" unitRef="aud">110,607</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="0" unitRef="aud">142,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_30_fact" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="0" unitRef="aud">147,636</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_7" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_6"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><i>(i)</i></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><i>Purchases from entities controlled by key
    management personnel</i></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_8" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group acquired the following goods and services
from entities that are controlled by members of the group&#8217;s key management personnel:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_9" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rental of an office suite
    (Wattle Laboratories Pty Ltd); and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_10" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January 2016, we executed a Lease Agreement
with Wattle Laboratories Pty Ltd, (&#8220;Wattle&#8221;), an entity part-owned and operated by our non-executive directors, Mr. Peter
Anastasiou (a director resigned on 24 September 2021) and Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities
for our operations at a rental rate of A$<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="aud">38,940</ix:nonFraction> per year, payable in monthly installments. The rental agreement is subject to annual rental
increases, and effective January 2017, the annual rent was increased to A$<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="aud">39,525</ix:nonFraction>. The lease is for a three-year term with an additional
three-year option period. The lease may be terminated by either party upon six months&#8217; written notice. During the fiscal years ended
June 30, 2019, 2020 and 2021, we paid Wattle A$<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="aud">53,958</ix:nonFraction>, A$<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="aud">41,369</ix:nonFraction> and A$<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="aud">40,607</ix:nonFraction> (excluding Goods and Services Tax), respectively. The lease
was renewed, commencing <ix:nonNumeric contextRef="c169" format="ixt:date-monthname-day-year-en" name="imc:LeaseRenewed">January 1, 2019</ix:nonNumeric> for three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_11" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warehousing, distribution
    and invoicing services (Grandlodge Capital Pty Ltd).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_12" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge Capital Pty Ltd is an entity part-owned
and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on 24 September 2021) and
Mr. David Plush are also owners of Grandlodge, and its associated entities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_13" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commenced on June 1, 2013, Grandlodge provides
warehousing, distribution and invoicing services for our products for A$<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="imc:WarehousingDistributionAndInvoicingServices" scale="0" unitRef="aud">70,000</ix:nonFraction> per year. The terms of the agreement were to have fees
payable in new fully paid ordinary shares in Immuron Limited as a set price of A$<ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="imc:SharesIssuedPricePerShare1" scale="0" unitRef="audPershares">0.16</ix:nonFraction> per share. The fair value of the equity instrument
has been assessed and accounted for in accordance with IFRS 2 Share Based Payments in the 2020 financial statements. During the 2020 financial
year, the fees of A$<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="imc:WarehousingDistributionAndServicesFees" scale="0" unitRef="aud">100,978</ix:nonFraction> equivalent were repaid by issuance of <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinarySharesIssued" scale="0" unitRef="shares">437,500</ix:nonFraction> ordinary shares based on their fair value. During the 2019 financial
year, the fees of A$<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="imc:WarehousingDistributionAndServicesFees" scale="0" unitRef="aud">93,678</ix:nonFraction> equivalent were repaid by issuance of <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="imc:OrdinarySharesIssued" scale="0" unitRef="shares">437,500</ix:nonFraction> ordinary shares based on based on their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_14" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge is reimbursed in cash for all reasonable
costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to
an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written
notice of the termination of the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_15" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A new
agreement commenced on July 1, 2020. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing
services for Immuron's products for $<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="imc:WarehousingDistributionAndInvoicingServices" scale="0" unitRef="usd">70,000</ix:nonFraction> per annum. The terms of the agreement were to have fees payable in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_16" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate amounts of each of the above types
of other transactions with key management personnel of Immuron Limited:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_17" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_16"><ix:continuation id="_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Amounts settled in cash or shares during the period</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Rental of an office suite from Wattle Laboratories
    Pty Ltd</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">40,607</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">41,369</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">53,958</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Services rendered by Grandlodge Capital
    Pty Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">70,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">100,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">93,678</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">110,607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">142,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions" scale="0" unitRef="aud">147,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_18" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding balances
    arising from sales/purchases of goods and services</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_19" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following balances are outstanding at the
end of the reporting period in relation to transactions with related parties:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfRelatedPartyExplanatory-c0_cont_19"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Current payables (purchases of goods and services)</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Entities controlled by key management personnel</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" scale="0" unitRef="aud">70,000</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 21. Financial Risk Management Objectives
and Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_2" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note explains the Group&#8217;s exposure
to financial risks and how these risks could affect the Group&#8217;s future financial performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_3" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s risk management is predominantly
controlled by the Board. The Board monitors the Group&#8217;s financial risk management policies and exposures and approves substantial
financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_4" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Risk Management Policy</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 36.85pt 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_5" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is responsible for overseeing the establishment
and implementation of the risk management system, and reviews and assesses the effectiveness of the Company&#8217;s implementation of
that system on a regular basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_6" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board and Senior Management identify the
general areas of risk and their impact on the activities of the Company, with Management performing a regular review of:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.1pt 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_7" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the major risks that occur
    within the business; the degree of risk involved;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_8" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the current approach to
    managing the risk; and</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if appropriate, determine:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_9" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any inadequacies of the
    current approach; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_10" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possible new approaches
    that more efficiently and effectively address the risk.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_11" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management report risks identified to the Board
through the monthly Operations Report.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_12" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company seeks to ensure that its exposure
to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; "><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_13" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Market risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_14" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Foreign exchange risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_15" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group undertakes certain transactions denominated
in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_16" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign exchange rate risk arises from financial
assets and financial liabilities denominated in a currency that is not the group's functional currency. Exposure to foreign currency
risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange
rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency
of the group including United States dollar (USD), Canadian dollar (CAD) and Israeli Shekel (ILS). This risk is measured using sensitivity
analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_17" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exposure</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_18" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s exposure to foreign currency
risk at the end of the reporting period, expressed in Australian dollars, was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_19" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">USD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">ILS<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="usd">2,742,688</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="cad">108,688</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="usd">2,954,589</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="cad">107,605</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="0" unitRef="usd">23,801</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="0" unitRef="usd">45,591</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Trade payables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="usd">18,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="cad">43,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="usd">29,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="cad">1,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="ils">41,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="0" unitRef="usd">2,785,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="0" unitRef="cad">152,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="0" unitRef="usd">3,030,126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="0" unitRef="cad">109,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="0" unitRef="ils">41,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_20" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_21" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As shown in the table above, the Group is primarily
exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD
denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial
statements into AUD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 127; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_22" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has conducted a sensitivity analysis
of its exposure to foreign currency risk. The Group is currently materially exposed to the United States dollar (USD). The sensitivity
analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement
in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to
is listed below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_23" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">USD: <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="imc:PercentageOfForeignExchangeRates" scale="-2" unitRef="pure">4.9</ix:nonFraction>% (2020: <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="imc:PercentageOfForeignExchangeRates" scale="-2" unitRef="pure">3.3</ix:nonFraction>%)</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_24" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_23"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfExchangerateTableExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on loss for<br/>
 the period</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on other components<br/>
 of equity</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">USD/AUD exchange rate &#8211; change by 4.9% (2020:
    3.3%)</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:ImpactOnLossForPeriods" scale="0" unitRef="aud">136,467</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:ImpactOnLossForPeriods" scale="0" unitRef="aud">99,994</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="imc:ImpactOnOtherComponentOfEquity" scale="0" unitRef="aud">5,219</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="imc:ImpactOnOtherComponentOfEquity" scale="0" unitRef="aud">4,035</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_25" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_24"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holding
    all other variables constant</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_26" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss is more sensitive to movements in the AUD/USD
exchange rates in 2021 than 2020 because of the increased amount of USD denominated cash and cash equivalents and the increased variability
of the AUD/USD exchange rate. Equity is more sensitive to movements in the AUD/USD exchange rates in 2021 than 2020 because of the increased
size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group's exposure to other foreign
exchange movements is not material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_27" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Credit risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_28" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exposure to credit risk relating to financial
assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the
group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_29" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_28"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk management</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_30" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is managed through the maintenance
of procedures (such as the utilisation of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures
against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible
that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for
impairment. Credit terms are normally 30 days from the invoice date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_31" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk is also minimised through investing surplus
funds in financial institutions that maintain a high credit rating.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_32" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_31"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Security</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_33" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For some trade receivables the group may obtain
security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default
under the terms of the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_34" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_33"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment of financial
    assets</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_35" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group has one type of financial asset subject
to the expected credit loss model:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_36" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_35"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
                                            receivables for sales of inventory</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_37" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While cash and cash equivalents are also subject
to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_38" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Trade receivables</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_39" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group applies the IFRS 9 simplified approach
to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_40" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To measure the expected credit losses, trade
receivables assets have been grouped based on shared credit risk characteristics and the days past due.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_41" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected loss rates are based on the payment
profiles of sales over a period of 60 months before June 30, 2021 and the corresponding historical credit losses experienced within this
period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting
the ability of the customers to settle the receivables.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></ix:continuation><div>

</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_42" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On that basis, the loss allowance as at June
30, 2021 was determined as follows for trade receivables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_43" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_42"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherReceivablesTableExplanatory-c0_cont_1" escape="true" name="imc:DisclosureOfTradeAndOtherReceivablesTableExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Days past due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Current</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">1-30</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">31-60</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">61-90</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">91-120</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">121+</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c186" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c187" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c188" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">13.07</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">21.88</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c190" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">34.09</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c191" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">53.58</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">23,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">4,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">28,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_44" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_43"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On that basis, the loss allowance as at June
30, 2020 was determined as follows for trade receivables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_45" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_44"><ix:continuation id="_DisclosureOfTradeAndOtherReceivablesTableExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Days past due</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">30 June 2020</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1-30<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-60<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">61-90<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">91-120<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">121+<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c193" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">0.60</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c194" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">8.06</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c195" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">23.35</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c197" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">38.30</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c198" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedCreditLossRate" scale="-2" unitRef="pure">100.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">2,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">1,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">14,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">7,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">23,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="imc:GrossCarryingAmount" scale="0" unitRef="aud">49,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">17</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">85</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">3,380</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">2,852</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">23,721</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="imc:LossAllowance" scale="0" unitRef="aud">30,055</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_46" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade receivables are written off when there
is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the
failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater
than 121 days past due.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_47" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_46"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment losses on trade receivables are presented
as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same
line item.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_48" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_47"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Previous accounting policy for impairment
of trade receivables</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_49" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_48"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the prior year, the impairment of trade receivables
was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing
the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that
an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognized in
a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following indicators were
present:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_50" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_49"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant financial difficulties
    of the debtor;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_51" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_50"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">probability that the debtor
    will enter bankruptcy or financial reorganization; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_52" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_51"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">default or late payments
    (more than 121 days overdue).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_53" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_52"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receivables for which an impairment provision
was recognized were written off against the provision when there was no expectation of recovering additional cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_54" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_53"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity risk</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_55" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_54"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk arises from the possibility that
the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The
group manages this risk through the following mechanisms:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_56" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_55"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing forward looking
    cash flow analyses in relation to its operating, investing and financing activities;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_57" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_56"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining funding from
    a variety of sources;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_58" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_57"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a reputable
    credit profile;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_59" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_58"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing credit risk related
    to financial assets;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_60" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_59"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investing cash and cash
    equivalents and deposits at call with major financial institutions; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_61" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_60"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">comparing the maturity
    profile of financial liabilities with the realisation profile of financial assets.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 129; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_62" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_61"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Maturities of financial liabilities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_63" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_62"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below analyze the group&#8217;s financial
liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual
discounted cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_63"><ix:nonNumeric contextRef="c0" escape="true" name="imc:DisclosureOfTradeAndOtherPayablesTableExplanatory"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Contractual maturities of financial liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Less than 6 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6 - 12 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 1 and 2 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 2 and 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Over 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total contractual cash flows</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount (assets)/ liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">At 30 June 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">132,514</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">132,514</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">132,514</ix:nonFraction></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">20,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">153,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">153,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">153,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">At 30 June 2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">173,663</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">173,663</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="imc:TradeAndOtherPayable" scale="0" unitRef="aud">173,663</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">20,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">21,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">21,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">63,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="aud">63,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">194,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">21,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">21,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">237,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" unitRef="aud">237,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 22. Events occurring after the Reporting
Date</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_2" id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, Immuron identified a transformational
COVID-19 asset, for which it entered a binding contract to acquire. The company&#8217;s securities were placed in suspension by the Australian
Securities Exchange (ASX) until the company met the requirements set out by the Exchange. Unfortunately, after filing an ASX In-Principal
Advice Application and subsequent lengthy discussions and exchanges with the ASX, Immuron was unable to satisfy the ASX that the combined
group, following the proposed acquisition, would meet the requirements of the Listing Rules. Ultimately the ASX has an absolute discretion
whether to approve such a major acquisition. Immuron is now unable to satisfy the pre-conditions for this proposed acquisition due to
the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_3" id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 23 September 2021, as a result of the company
not proceeding with the major transaction the ASX has lifted the suspension and the company's securities have now re-commenced trading
on the ASX and NASDAQ official list.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_4" id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 24 September 2021, Mr Peter Anastasiou resigned
as a director of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No other matter or circumstance has occurred
subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those
operations or the state of affairs of the group or economic entity in subsequent financial years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompanyDetailsExplanatory-c0_cont_1" escape="true" name="imc:DisclosureOfCompanyDetailsExplanatory"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 23. Company Details</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompanyDetailsExplanatory-c0_cont_2" id="_DisclosureOfCompanyDetailsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The registered office of the Company is:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompanyDetailsExplanatory-c0_cont_3" id="_DisclosureOfCompanyDetailsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3, 62 Lygon Street, Carlton,
Victoria, Australia 3053.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompanyDetailsExplanatory-c0_cont_4" id="_DisclosureOfCompanyDetailsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The principal place of business of the Company
is:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompanyDetailsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Unit 10, 25-37 Chapman Street, Blackburn,
Victoria, Australia 3130.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 130; Value: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_082"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron Limited</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerry
    Kanellos</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry Kanellos</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 29, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">89</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>






</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="imc:IncomeFinance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="imc:CostOfFinance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="ifrs-full:OtherNoncurrentLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-7" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-8" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-9" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-10" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-11" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-12" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-13" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-14" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-16" name="imc:OptionsOrWarrantsExercised" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-17" name="imc:OptionsOrWarrantsExercised" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-18" name="imc:OptionswarrantsForfeited" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-19" name="imc:OptionswarrantsForfeited" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-20" name="imc:ChangeInAccountingPolicy" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-21" name="imc:ChangeInAccountingPolicy" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-24" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-25" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-26" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-27" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-28" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-29" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-30" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-31" name="imc:OptionswarrantsForfeited" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-32" name="imc:OptionswarrantsForfeited" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-33" name="imc:RevaluationOfOptionIssuedInPriorPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-34" name="imc:RevaluationOfOptionIssuedInPriorPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-35" name="imc:EmployeeShareSchemesValueOfEmployee" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-36" name="imc:EmployeeShareSchemesValueOfEmployee" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-37" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-38" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-39" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-40" name="imc:OtherComprehensiveIncomeLossForPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-41" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-42" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-43" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-44" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-45" name="imc:OptionsOrWarrantsIssuedExpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-46" name="imc:OptionsOrWarrantsExercised" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-47" name="imc:OptionsOrWarrantsForteitedLapsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="imc:OptionsOrWarrantsForteitedLapsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="imc:StockIssuedDuringPeriodValueIssuedToDirectors" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-50" name="imc:StockIssuedDuringPeriodValueIssuedToDirectors" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-51" name="imc:TransferToShareCapital" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="imc:TransferToShareCapital" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-53" name="ifrs-full:RevenueFromGovernmentGrants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-54" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-55" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-56" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-57" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-58" name="ifrs-full:FinishedGoods" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-59" name="us-gaap:InventoryRawMaterials" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="ifrs-full:RawMaterials" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-61" name="imc:OtherGovernmentAssistanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-62" name="imc:ResearchAndDevelopmentGrants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-63" name="imc:ResearchAndDevelopmentGrants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-64" name="ifrs-full:ImpairmentLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-65" name="imc:ResearchAndDevelopmentsGrants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="ifrs-full:UtilitiesExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-68" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-69" name="imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-70" name="imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-71" name="imc:LossOnAllowanceTradeReceivables" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-72" name="ifrs-full:Inventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-73" name="ifrs-full:Inventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-74" name="ifrs-full:Inventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-75" name="ifrs-full:NoncurrentInventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-76" name="imc:InventoriesNet" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-77" name="ifrs-full:NoncurrentInventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-78" name="ifrs-full:NoncurrentInventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-79" name="ifrs-full:NoncurrentInventories" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-80" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-81" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="ifrs-full:Provisions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="ifrs-full:AdjustmentsForProvisions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-84" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-85" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-87" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-89" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-90" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-91" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-92" name="imc:StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-93" name="imc:TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-94" name="imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-95" name="imc:TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-96" name="imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-97" name="imc:ExerciseOfRepresentativeWarrant1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-98" name="imc:TransferFromReservesOnExerciseOfESOPUnlistedOptions" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-99" name="imc:TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-100" name="imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-101" name="imc:CurrencyTranslationDifferences" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-102" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-103" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-104" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-105" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-106" name="imc:OptionsAndWarrantsIssuedexpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-107" name="imc:OptionsAndWarrantsExercised" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-108" name="imc:OptionsAndWarrantsLapsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-109" name="imc:CurrencyTranslationDifferences" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-110" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-111" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-112" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-113" name="imc:SharebasedPaymentExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-114" name="imc:OptionsAndWarrantsIssuedexpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-115" name="imc:OptionsAndWarrantsLapsed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-116" name="imc:RevaluationOfOptionsIssuedInPriorPeriod" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-117" name="imc:CurrencyTranslationDifferences" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-118" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-119" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-120" name="imc:TransactionsWithOwnersInTheirCapacityAsOwners" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-121" name="imc:TransferToShareCapitalinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-122" name="imc:OptionsAndWarrantsIssuedexpensed" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-123" name="imc:OptionsAndWarrantsExercised" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-124" name="imc:OptionsAndWarrantsForfeited" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-125" name="imc:NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-126" name="imc:NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-127" name="imc:RevaluationOfOptionsIssuedInPriorPeriodShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-128" name="imc:LapseOfUnexercisedOptionsAtZeroPointFiveFive" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-129" name="ifrs-full:IssueOfConvertibleInstruments" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-130" name="imc:ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-131" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-132" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-133" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-134" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-135" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-136" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-137" name="ifrs-full:OtherGainsLosses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-138" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-139" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-140" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-141" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-142" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-143" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-144" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-145" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-146" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-147" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-148" name="ifrs-full:FinanceCosts" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-149" name="ifrs-full:FinanceCosts" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-150" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-151" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-152" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-153" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-154" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-155" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-156" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-157" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-158" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-159" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-160" name="ifrs-full:OtherGainsLosses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-161" name="ifrs-full:OtherGainsLosses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-162" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-163" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-164" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-165" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-166" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-167" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-168" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-169" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-170" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-171" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-172" name="ifrs-full:FinanceCosts" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-173" name="ifrs-full:FinanceCosts" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-174" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-175" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-176" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-177" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-178" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-179" name="imc:HyperimmuneProductsRevenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-180" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-181" name="ifrs-full:CostOfSales" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-182" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-183" name="ifrs-full:GrossProfit" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-184" name="ifrs-full:OtherIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-185" name="ifrs-full:OtherGainsLosses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-186" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-187" name="imc:GeneralAndAdministrativeExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-188" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-189" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-190" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-191" name="imc:SellingAndMarketingExpenses" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-192" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-193" name="ifrs-full:FinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-194" name="ifrs-full:Revenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-195" name="imc:RevenueFromExternalCustomers" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-196" name="ifrs-full:Revenue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-197" name="imc:RevenueFromExternalCustomers" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_6_footnote" xml:lang="en-US">Returns are provided where outlined in a customer&#8217;s agreement.
</ix:footnote><!--Text not found in footnote sections assigned to Schedule of information on geographical regions-->
<ix:nonFraction contextRef="c108" id="hidden-fact-198" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-199" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-200" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-201" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-202" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c115" id="hidden-fact-203" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-204" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-205" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c122" id="hidden-fact-206" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c125" id="hidden-fact-207" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c128" id="hidden-fact-208" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-209" name="imc:RevenueFormContractWithCustomer" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-210" name="imc:AdjustmentsForDistributionCosts" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-211" name="ifrs-full:AdjustmentsForFinanceIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-212" name="imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-213" name="imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c153" id="hidden-fact-214" name="imc:ShareOptionsOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c156" id="hidden-fact-215" name="imc:ShareOptionsOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-216" name="imc:ShareOptionsOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-217" name="imc:SharebasedPaymentsToDirectors" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_7_footnote" xml:lang="en-US">Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.
</ix:footnote><!--Text not found in footnote sections assigned to Schedule of total expenses arising from share-based payment transactions-->
<ix:footnote id="ix_8_footnote" xml:lang="en-US">Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.
</ix:footnote><!--Text not found in footnote sections assigned to Schedule of total expenses arising from share-based payment transactions-->
<ix:footnote id="ix_9_footnote" xml:lang="en-US">Purchases from entities controlled by key management personnel</ix:footnote><!--Text not found in footnote sections assigned to Schedule of information about other related party transactions-->
<ix:nonFraction contextRef="c3" id="hidden-fact-218" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-219" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c182" id="hidden-fact-220" name="ifrs-full:TradeReceivables" unitRef="cad" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c184" id="hidden-fact-221" name="ifrs-full:TradeReceivables" unitRef="cad" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-222" name="ifrs-full:TradeReceivables" unitRef="ils" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c192" id="hidden-fact-223" name="ifrs-full:ExpectedCreditLossRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c188" id="hidden-fact-224" name="imc:GrossCarryingAmount" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c189" id="hidden-fact-225" name="imc:GrossCarryingAmount" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-226" name="imc:GrossCarryingAmount" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-227" name="imc:GrossCarryingAmount" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c186" id="hidden-fact-228" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c187" id="hidden-fact-229" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c188" id="hidden-fact-230" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c189" id="hidden-fact-231" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-232" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-233" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c192" id="hidden-fact-234" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c199" id="hidden-fact-235" name="ifrs-full:ExpectedCreditLossRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c195" id="hidden-fact-236" name="imc:GrossCarryingAmount" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c195" id="hidden-fact-237" name="imc:LossAllowance" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-238" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-239" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-240" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-241" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-242" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-243" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-244" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-245" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-246" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-247" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-248" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-249" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-250" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-251" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c210" id="hidden-fact-252" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-253" name="imc:TradeAndOtherPayable" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c210" id="hidden-fact-254" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-255" name="ifrs-full:GrossLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c210" id="hidden-fact-256" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-257" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001660046</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="imc-20210630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_2_fact ix_3_fact" toRefs="ix_1_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_4_fact ix_5_fact ix_6_fact ix_7_fact" toRefs="ix_2_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_8_fact ix_9_fact hidden-fact-85 ix_10_fact ix_11_fact ix_12_fact" toRefs="ix_3_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_13_fact ix_14_fact" toRefs="ix_4_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_15_fact ix_16_fact ix_17_fact ix_18_fact" toRefs="ix_5_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_19_fact ix_20_fact ix_21_fact ix_22_fact hidden-fact-194 ix_23_fact" toRefs="ix_6_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_24_fact ix_25_fact hidden-fact-217" toRefs="ix_7_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_26_fact ix_25_fact ix_27_fact" toRefs="ix_8_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_28_fact ix_29_fact ix_30_fact" toRefs="ix_9_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imc:PlantAndEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imc:PlantAndEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:RawMaterialsAndStoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:RawMaterialsAndStoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:WorkInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:WorkInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:FinishedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:FinishedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:AnadisEPSPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:AnadisEPSPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:IMCCanadaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:IMCCanadaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrJerryKanellosMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2018-07-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:MrRichardJBermanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-11-01</xbrli:startDate>
    <xbrli:endDate>2018-11-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrGarySJacobMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrGarySJacobMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGy24MXszw21WJLGZQg5L4nf] CSR-->
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imc:EmployeeStockOption1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateNineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateNineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateElevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateElevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwelveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwelveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceSixteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TypesOfArrangementsAxis">imc:ShortTermFundingAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-01-01</xbrli:startDate>
    <xbrli:endDate>2016-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="imc:TypesOfArrangementsAxis">imc:ShortTermFundingAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-01</xbrli:startDate>
    <xbrli:endDate>2019-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:ContractualCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:CarryingAssetsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:ContractualCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001660046</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:CarryingAssetsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="aud">
  <xbrli:measure>iso4217:AUD</xbrli:measure>
</xbrli:unit><xbrli:unit id="audPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>f20f2021ex12-1_immuron.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jerry Kanellos, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20-F of Immuron Limited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other
certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a- 15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the period covered by the
annual report that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: October 29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jerry Kanellos</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jerry Kanellos</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
originally executed copy of this Certification will be maintained at the Registrant&rsquo;s offices and will be made available
for inspection upon request.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>f20f2021ex12-2_immuron.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Philip Hains, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20-F of Immuron Limited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a- 15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: October 29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Phillip Hains</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phillip Hains</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
originally executed copy of this Certification will be maintained at the Registrant&rsquo;s offices and will be made available
for inspection upon request.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>f20f2021ex13-1_immuron.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of
Immuron Limited (the &ldquo;Company&rdquo;) on Form 20-F for the period ended June 30, 2021, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Jerry Kanellos, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report
fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jerry Kanellos</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jerry Kanellos</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
originally executed copy of this Certification will be maintained at the Company&rsquo;s offices and will be made available for
inspection upon request.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>5
<FILENAME>f20f2021ex13-2_immuron.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of
Immuron Limited (the &ldquo;Company&rdquo;) on Form 20-F for the period ended June 30, 2021, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Philip Hains, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The information contained in the Report
fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Phillip Hains</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phillip Hains</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
originally executed copy of this Certification will be maintained at the Company&rsquo;s offices and will be made available for
inspection upon request.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>f20f2021ex23-1_immuron.htm
<DESCRIPTION>CONSENT OF GRANT THORNTON AUDIT PTY LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 181.05pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Consent of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have issued our report dated October 29, 2021 with respect to the
consolidated financial statements of Immuron Limited (and subsidiaries) included in the Annual Report on Form 20-F for the year ended
June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference of the said report in
the Registration Statement of Immuron Limited on Form F-3 (File No. 333-230762) and Post Effective Amendment on Form F-3 to F-1 (File
No. 333-215204).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ GRANT THORNTON AUDIT PTY LTD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Melbourne, Australia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 29, 2021</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M >H# 2(  A$! Q$!_\0
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M?^"^>"&_X*3;4/4_\+U^*C]R?N_9,'TQZXX'6E_X<Y?\%Z!G?_P4F\X?W?\
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MU,?))7;EC\2HIMV3NZ44M=%KJV?R%?\ #F__ (+)XQ_PW/8XQC_DM?Q5]/\
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M-Q>8X:E]6AA(5L-]6KTL'.&,6+K49QE7:J2I0PTG5J1ISE3BXPJ-?#(T#5$
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M.)EG-.IB<LJQ]K65.4G03E**Q+E&,'S1A9W\:M_VF;:W W:A\5)B>0)/$6G
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M&=8LK$Z18;#<WFGZPUN3<PQI7N5S^U5^T/;QB_@\"^#K_P *&ZT[3;#QM:>
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MC26:W',<$SJ@>6W@;?\ 9U>1]I+."-Q%.!(& S <=&/;;CG.?X1]><YW-EH
M!)[L2QY)Y/7&>@] , =@*N-"49*5HZ)K1][>7E_P_2'9RNH1CYIMO_+7K]XB
M(J#:HP,DGJ22>I)/4]OH!3P"QP$;(ZGL?PST]R,?C25\O_M 7_[2D.L^#[#X
M$7<&EZ5-93W7BG59O"NE>*)&NI/$6B:9#8V\6IZC8I;^5HE[K&K(R*^;FPA#
MY1F0E52C%>;MOILWJ^B*BDVW9-Q5X\ST4G[M[=;)MKSU/4?C=K'C3P_\'/B?
MK_P\BFN?'VB^$-9N_",=O:_:[A]>%LHTV".U"SM<.9$V8,15E 7;P37PY>?M
M'?M9^%/'7B?0_%_PJT2=&E\&S>%["PM_%WBC2M?>?PQX;;5/"&@^)-*T>#^S
M]=>_U'5?$.K:EK$;6%I%I4UE9K+)B-N7N?B5_P %&M4U=[/4/",GAC2]$G\'
MWU]+X;\'Z9JFK^(='L=5TT:C/ID][?+I-MJ_B6274;?6]#64Q:9IH62TGC*!
MSSVE?%7_ (*+ZAXGO=9/@;Q3:W>GV>LZ?X/\+:AX&T>Q\'^+[BZN_#FI6ECX
MXU&+6(CX8M]+MI-=TZW\4Z<MP=UO;6VPM*9*YK6;=E=JV]OZO?[]MRH4U%<D
MJKE3YO:<S4754]W%2_Y][1M?X5L?1O[,OQ\^._QB^)>JZ;\1/!NG^#O!]AX*
MURXLX+;P?XGTD:AXJT[Q3IUK&;/Q)K+K:WUG#H5XT5Q:-:VDL]S"UU%&&RH^
M\)=L9"LAW-P!SCISS_0]>F:_(CQ)XC_X*!>)FOM3T&P\<V$,'AUX-,UD>$]&
MT'6K'5#/8ZCK$S>"6U.ZT^ZN]-NVU+P]H5Y>7,D/B#1[>WU":UCG8,NE9_%_
M_@HRX\_5/AZZ6B^-?#EK)I.G^!K*?6!HMP=02Y@M=3FU(Z:=-GL(=)O]4O6@
MFFL]2N+BW@N!YBK%<)..[33U>J3V\]^_0<H\SE4M3@V_>46VI-))/;1M6OYG
M=?\ !8Q_+_X)D_M>NHP3\,F'/)P=8TS.![] >V0:_@);QVWPV^(?[+_Q!2?6
M[1O!7PL^$_B1+SPTVGIX@M3I>I:M=>9HYU>WNM*>^D\OR8HM1@EMY_-:%U <
MNG]^/_!8]@__  3$_:_D9=I;X7AFA9@9()6U;2FDB=5W*K1L2OR.R-@E3@5_
MGWZX/#TOC3]E]/%FMR^&/"K?#;X.'Q-XCM+"/4[S0]#CUO47U'4[?3Y%==0:
MSMEDG:P*.D^Q7>*7R@A_JOZ/]6^3YY2A&5ZV-K\T%I[>*R^A>BVKN%U=*4$W
M[VJVO_-OC G+/,M:E#]W0P56,YI..'<,=*]3EVJ:VDHS?+IOJ?H5;?\ !1SX
M<>&_BQHGQGTCX+?$K2_'7@O0/$7@+P/H]_XULAX>F\ >,_%^B^.=1\6ZP-0M
M+C7K3QM-<6%VFDV&E7C>&XK75[5+;RH[55KPWP_^W/;:CX(L_A]\0;[XVP6(
M\*>&-*O_ (D?#KXIOI_Q'_M_PU\2_$7Q"M[:+6=;-Y"GA?Q+'XCCT?7-*:6*
M9+W3+?4(O.%K%$?9OV[_ !]^SY^T/\9?@Q\4/!_Q4\*>*_%X\4>"OA3XX^"_
MA*UU/4/!7A[P#8^(532_&%E\1-5T717\2WGC""94\1:'<)!;> [ZYET/34^P
MP0I!Z)\5/B1^R'\-+WX^V?B?2OV5/&/Q!T7QMXL\-? +3O@S\.O$$6B>%/A*
MGC71]$U;1?&T.K0VFF:M\2+;3(M:G\'7T[ZE/9:C%?W=W?M9R66W[[#2RNM2
MPT/]5\RJXO'1K4IT)8FO*KEKPF-J4*-'#5<7"<*M*M*K+%591LY0JR45)I6^
M4JT\\E5Q52/$> =#!2I5E55+#4(8Q8O#TI557H0JP:=.$(4::A!^]!R=G)M^
M1?%#_@H=X1^*/CRU^+)\)_&;PSXF\*ZS=G1/AC8_%?2A\&_&NGR^+K?QBNI?
M&738M+CN_$/BBZ^RG2?&'V"PDB\20KI]SJ$UE%:@R8?QH_X* 6OQ)^('P5\:
MZ'X1UK5$^$GQ9U7XT7&A^/QX35+[4O$%Q97%SX2TRZT"VS;>'M-A@NA9ZGJ(
M:22^%EJCV<8C /N7Q*^)7_!-CQ%KOAGPA?>&? 6F?#OQ5J_B?3%\<_""RU&\
M\;?#'X8:7I]CXA\"76M:>-)TBT_X2_4M9TU_"NMPWTVNZ_\ 9]:U">;4+FW2
M%EL^ ?C)_P $[]:\)>#M4\7?#;X1Z!97NI_VAXZ\&W=CKI\<Z)\1F^(1OXCI
M4%AI$^I7G@&T^',>GV;(/$BZ1+IZSVRZ:NKL)&UPN*R["TL/BJ?"'$*G@Z5?
M#*;JU;1^NP>&]E&K2I49*I&:;O&G5A"%G*:ZY8NEC,0Z]#^V\IA2=>%2NU3M
M>I3I*K3KTOWEXX>DO<J4WRNM--N+O<\F\1_M\62? KQ9\'_A2_[2$\^L>)M2
M\4ZE\4?B)\5X->\0^'8?$OCSP9XNO_"]O>>'+2*XL?#\3>&TT%6?4 =1EO4N
MY(TB,EO7J7@'_@H[X5O_ !]%9^*?#^L>#/"7B*_\16]_K-UXCNM7B\$6?BCX
M@7GC>?Q#I%KIMC/?V&OZ<NH):6FM:5I]R^EZHZ:BMO<112BO$O$'[2?PHU?]
MG;XT:;H>C?"#PM\3OB?X0G\'7WA[PC\.FT33FM?"GQXM=5\ MI2!KBRTK6(/
MAW=W37>IBZ6\NUL8FNWEU N1Z3\'_'/[$UKX \.6_P 4I/@7=_"\?!SPQ9ZW
MX2N?!_BFY_:BG_: MM9TT^-=8F\46-NUO+X6G@DO)K,V^J'3W\*;;&P@35$D
MDK:6&RNGE>*JUN'<]]K_ &KB<-.-#$S>*C[3#4ZTLSAB9X54FG5G"C"G14XS
M5*<9RA&5ER4L;CZV88/#4\_R^:C"E.$IT91P2Y8UHTZ,Z49N4XU*=.<:M6<G
M*FZL)03:/:)/VX_AK\'_  IX#^&WPXU7XN?&/P3X%\,Z!+K_ ,=?[1C\7^(I
M/&?A[QYXG\3P^"KKQMXZT'3;/4_"EYI_BO1X]0G6QMWTC5Q!Y45\F+=_%=-_
MX*0:M-\5KSQQKVF^/],T74?!OPR\/Z;X=\+^*=*DA\&W_P /_$=]K>MZYH&A
MZQ9KX:'_  D]E?W^D:BFG:=I][%9ZAJ4L5]%YUOM]2UO]JSX8?#[]G_Q1X+L
M?$?[*OC_ .)=_=^*Y-%\-?#/X6>(?^%7/H6L?%GX4:IX9NM=T;5M.T[2;_Q;
M9> ?#NJ7B73RF>R6RG%\]UJK*7Z/2/B1_P $S]/MXX+7PM\+[WP-_P )-K.H
M>*M/UVU\1IXWNO'EYXIT_4M!NO"^GV>ARZS)\.=.TMIH#86FOVNFW&B6^JV-
M_;7$TUO*GGX+#Y?AJ&+CB.%<YQ^*Q57%8"CBY3J5JTZ%-4I5:E+VE&A'#5%*
M<5SP2=XU7&ZUEVYA4QN*GA5@N*,LP]*A2I9A+#U:,(T<-B)U*L/W<U4DZU./
MLYW5=).,X.UUI\8^!_VK/A_X?USXM1R^'_BEX*\(^/OC/X;^-7AB7X5?$:VT
MCQKIC>$+S4/[/\ >,/$>JK=3Z_X!U3[;NU/RY-^GW8DN46Z:5-G2?%_]M+6O
MCC8_%'3[OPGKEEHGC[X1?#[P39>%-.\02ZEX3^'VH^#OB#JGB^[\2Z7HUJC6
M%C;ZW%K#:,+ZW@@NH97=KVYD@E2$_0?AOXQ_L2:W\/O#FL:_X'_9^'B&29[S
MQ7HFN6NK>$;M/BM;>/FFT^[M+7PUHFKW-G\+8_ D4</FV>NWFAOI?VF&^T.Z
MUI\#QKP_\8/@1X!^._[6<:7WA+Q+\'/B3X(MO">E-HG@J.VM-9M;KQAX!U#7
M]#\$6<-M9PZ;+%IB^)K73=<@BT^#4;G3[?5(;2SBN88'^QHX_!8S&8G,:7"&
M9K-LNHTJN$^LXS$7K_4(X+!-8*4J#I1Q,:/M)N$TU4E3DE)?$OE,3A,PH0P6
M _UBRSZAF&(K4,2\/1I*M2IYA.>+EB\1/V\I4Z+J)1A.C*,X\R]VSL>L']MK
MX.^)O@C<>#M?O_VC=%\9:9+\$K&77? 7CS2-#\8>,[7X9Q7TKP3W5I;#PII_
MAC2((;30KHM%I^O:M'/;WDD%Q/I^6O0_\%%+2P^(6G_%[4OAKX]TKQ=_8-SX
M;TKX::5XTM[#X%/X8NO&%YXHA^(MCX6FTV.^O/B1$28[GQ';"?3KOQ%#=ZW'
M>Q22FVB^:?VI_$OP7U;PSH%MX,U/X,:MXOB^(OBNX\-W7P+\-:MX9TC3/@ ^
MGI#X&\.?$8:U;VT>H?$RUU#;_IKQS:E;VR:F+^^N9+B#R_>? ?Q[_9DUW2?A
M-X#^.NC>!]6\&?#W]FWP3IEOK\7A#59O%T'QGT[X@^)M0DT'6M<LY!J5_P"#
M]+T?5;*X\0Z18QQVNH:%+<"">:]1_+PCD64TL%3S&ID.?8REC<SS#$8_!SQJ
MCB<%3C2=:#I4'0CST<57:5M6Z;DE%Z*6,<TQ[QRP4<[RZA]5HTZ.#Q\\-!T<
M3*-;V$*4Y3J*%.5.D[U*DFE.I.G*3N]-7PE_P4<O=,\"^$]"O+'QS'XTTG1(
M/"$^NZ+J/@W4(]3L#XUO/%+>-WOO$%CJ^I:SX^GCNXK.[T^\AEL[JY7[5%>0
MH75?GY/&6E?$+]JW4?&NB>&]5\&Z1XEU_P 3ZC'X:UO4Y]4U?3[H>$=66^2_
MN=0DWFXGOQ+>75BI$>FB9+>V'EHBCZ>3XB_LTV7@[Q%+X@U;]F6;XSVNB:3J
M>H^-OAGX$UN?PI?ZQHWC6'4?!OAGP#X.UC1K?3)M0U'PPJ6?Q!\4:=+HLVAS
MV^GF)]5SJK-\Z:UX]T[XF_MJ>./'NB7&DSZ-XJ\=>.-8T.71]+.D:?J&E/X?
MUA+24V$AB:+[1&"]P^?G6-'V\\^IPG3R[#X_-L9EO#N8Y?4J9-B%B,1F&(K5
M</!5:^%=3"8;"U80C*5:FE[&I42G0JQJ\JCS)OP^)JF;2PV41Q^>X'%QCF5"
MD\+@</1A6]E2HXN$W5K0E)P<&U.4Z5U*G4A9MW2\<\:L5\._!AP1N_X4YH'+
M$JO&M>)#D\''?L?H:Z+X0?&"_P#A&?B!>Z)#,VH>-? Z>#H[RTU8:7#:LOBO
MP_XCN_MEU _F36%Y8:%<Z+J$-G)&_P!GOY4DRC,IZ;P1?_#S3_&O[+=Y\6(8
MKGX>0?#;P[-X@-[!<7>EE?[4\61:=-KMA9/%?77AJTU?[+-KUK:21W4^G),(
MG&3GZYN_&GP%;PQX:BC\4_L=I^TY!HVI1ZEXWC^&GB>/X &WE\>7%U/IFHZ+
M-I@L7\:W?@LZ>-+O8])-G_94.JVHG?5Y[>Y3Z+.N(</A,%@\FKY%C\YPF98:
ME2G7PLI4:=*%3$S5/#5G2HU>:-*5%RQ,DU4O*/)&;:1\M@,E]OF>(S*EF&%R
MRM@JL90IXFM.=:<882E4IRY:DX0F\0ZB5)RO=Q:DTCL=<_X*$6VK:];7.K^
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MB[M[:UTN+0;G5K&*-;:+3YYV7Y;^'_Q9^!_@?1?VF(KN[\(^,KV;Q1XF\0_
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M^%-2CDG\'_$BQM4 ^RR:W;1>5XBT^#?#9:]:ZA$LA7@?4R[_ "V?RRQ0C<%
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M/^!0)_:0_;E(VC;\2_@X6+ $*G_"E/#!<X/!.T$#/ SGJ!7U@.OX-_(U\F_
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M[3_XW1_PK[P'_P!"CX<_\$]I_P#&ZZVBCV4/Y5]R_P @^K8;_H&PW_A-A_\
MY2<E_P *^\!_]"CX<_\ !/:?_&Z/^%?> _\ H4?#G_@GM/\ XW76T4>RA_*O
MN7^0?5L-_P! V&_\)L/_ /*3DO\ A7W@/_H4?#G_ ()[3_XW1_PK[P'_ -"C
MX<_\$]I_\;KK:*/90_E7W+_(/JV&_P"@;#?^$V'_ /E)R7_"O? ?_0I>'/\
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M@#V&:^OJ*'X=9'WQMMO]YJ:KYUF8_P#$S?B#>;C/*K37*O\ A/IZ1Z?A_P
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M?Z_X5ZA16G^HN LO]JQNFMUB)7T5O^?I;\>^,&DIQRN27? 4=5\J:_S/+_\
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M3FCO=_*$Y+Y26C79K1K45N\I1[QDH<T>Z=DU==;-KLVM1E%/V'^Z_P#WP?\
M&C8?[K_]\'_&I]K3_O?^"YB]MAO^?\O_ "A_\M&44_8?[K_]\'_&C8?[K_\
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M'FQJ?+&UE=)V2NEL?R_C_@I'^W9CGXOZ\#ST\&Z9QTQ_RX]OZT?\/(_VZ_\
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M0_\ CM+_ ,,L_!7_ *%^Y_\ !Q?C_P!G/\_YT?ZF\1?]%5CO_!6*_P#FD4O
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M[;/X=^)7AZ_\/6M])\0]-O9KQY--M(K^Z6)Y-'MO[ &G2R":=-4MW6L/0_\
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MAY\/)_ UMK6C^*/&.FWH2;P9?ZOK4>H6L^EB34]-O%6V.E7MQ]M2*I+WX?\
M[-FL>$M1^&'@;X?:GJESX4^)7QGU'3["+XE:%_PLGXZ:K\.]!\*1:#X6L_%-
MU:0KH&F:M)K6K:Y9VFE3-%/I^C3PZ:LVH%PO$#]D[]GWQ1=ZKI7@D_$[4Y?#
M'C;XE^&OB;JTNOZ=+<>"5\+:7XLN/"%AXA\)76G1:K=Z-XVG\,/>Z)XQTVXN
MM'O+G^T_#]W!9:A86Y;BOA]\ OV>K[X0_!GQK\0_$VL:+XH^)EO#J=M9:;XU
MTA=5UK4H_BA8^#1X2\+^ !I%SK45A-HUQJ6K1^//M\%OI]]:+;30.]Q#7E5,
MQGB:<:^,XNSG$/ 8VEAL-A\+@ZZQ4IU*=?%/$UL/2Q/O8.A023Q$H\JA9NFW
M[T>O!Y53IXCDPG#^0Q>/P$ZTL1BZ_)AHT*52EAEA*-6I#ECB,153DES<W-=1
M:6AZG\0?V6_A-X3TFQO_  G\-?B)X[UG6=$T6]\8>"[/XS^$H-5_9T-]X.&O
M->>+KXQR0>(1?:@\MQ9G6/LEA%9V+Z5>;M<F4+P'[2/[//P,^&7PATWQ;\/]
M=\6:KXB35/!-II_B:_NDE\+?%/3/%'AV+4];U31XI+B2.S?P_J;2VD#^'([N
MTL1!+;:Q(MU)&C?$OCSPA9>#/'OCSP? OGQ^$_&GBGPO]JD8&6^AT37=0T^.
M6[9')G^TQ6L4L^28I)27VAC7+Q6\$(B"1(5@$H@5AN\@3_Z[R"3N@\P8#")D
M  ^4+DFOT?).$^)*<\IQ]3BW&XK#PK_VDH.E4@\PP52+JT\+B92G**C3I5::
M<%!*I%<M12D^8^"SCB3(81S7 QX8PU#&5:,<N:A6IU:6#QE)TJ=?$8?EA&;=
M:;=I>T?(WS1Y3T[PN?\ A(_!?BKP-< 2/X8TN\\?>!C(K$Z6NG30'QCX=M9&
MRXTS4]/F35H;9 B175M-)#&@N)@_G<<A=$?:6W(K;A+( VX YP' &<YP  .P
M%>D_"6,'Q3JC'+'_ (0+XB,5)+*2OA:Y R&+$C: A!8@H ,<9KR^ E885' $
M48 P. $  K[_  5&E0S#,<OC6C3H4887&0DDK3JXY5*E5*T=.1I1Y=(KHD?'
M9A"GC<+@<743K23Q6#YE4E!QC@ZJI0@_9SIJ7)'W5*2E-I>]*3U/ZM_^#9_)
M_P""?_Q2)Y*?MN_M,JGLIU'P[D<>Y/7FOZ%*_GK_ .#9_P#Y1_\ Q1]_VWOV
MF<_^#+0/\/T]J_H4K_(C/9>TSG.'U_M3$/[U_P  _P!;\KM_9N$_PL4=?P;^
M1KY0^!*A_P!H_P#;G0LJ[OB3\'5RP)PK?!/PNK[2/NOM8[&ZJ>5(."/JY.@_
MW3_Z":^3?@9M_P"&D/VY-S,I/Q+^#FW9DNQ'P4\+DA%!Y; )'7!&>U>%BN?W
M>17E;1/K[\+_ /DO,=\W)49<BO.Z4%WG*<8Q_P#)I(R_V4+&'Q5K7Q]^.%Y"
ML]]X_P#B]XF\,^'M1G8S7,/@;X;SGPGHVEP,Q806":A9:K?I;QA5:YO'N'+R
M[''V(  6(!RVW=UP2!C(#' X&6(Y8G<Q9B2?C;]EF]'@;Q1\;?V>=440:KX'
M^)7B'X@>%XUVQQZI\./BEJEQXBTC4[*(\20:5J=QJFA7ZJ-L-Y:ACAI :^R
MH!<+N5205!9G*9&#'O8DLR,"&()^;(R36.6*FL.DF^9^WE5DG9\\:\]+[Z;)
M?RI)75K_ #/"JHU,IC/F<J\<17AB(RU:S#VU5YBWUYXU/94E)^_[-\J?+:_F
M'QL\(1^.?ACXN\+R^,M5\ 0WUBER?&>B&V-_X;DTJ:#4X[HPWP>PN[9S 5NK
M2[VQW-O(T R67'XSZI\*OB5HFJ_V9JW[<_A?3K.661I+SPU\!_#=CXP:&Y;#
M&W?7_%5O80W3QL&1XK22!W.Y5"L5K]5_VI_B%H?PW^&DFK>.O#EEXC^$^MWS
M^$_BLDSWZ7.F^&O$>G7NGZ1J$;6+>:B2^*CI6D7$L;1RV<6IPWL3K)&K#\?/
M"D'[!UO:SZ)XD_8;M+[Q]9_:XM:F\6^*M0GM1KVC6MYK'BK3+SQ=X_\ $-Q>
M>'HM%L[7[+HLFLRPQ^);Z.6WTU"Y4GY_/LHJYG7A5HT\-.2IM?[2IN$VG\+5
M.K1<GI]IM6OI?4]/&X/$8B49T_9S4'\%:=:,+);)49)M]+2NFK]4CZ?\ ?LY
M_LP6G@OQWHV@_M(_%S3/C1XKL]#UCQM\9?%>KVB?%.YTC0KV4:?IFA:-?V,O
M@Z+P6NH7;HFA>'[:XMX;NYB>ZF<['KY0\?Z!^P[\-;V71O%7[5/Q[U7QI*X\
M[7]>_:/L-%U1-17_ ):Q^#]!T2^TVTB+8W17-F5V YX) 7PUJW[">G>)-6UW
MPI^S1X\NO"?BRT/@G6YO'OQ5UFW\,^"? U[I^H^(=:'A#2-9U>XO/"FLW>O^
M'K&SB@MIXKB^M1'>Z7=16_EK-[S\%/VBOV8/ DB:)\.OV1O!W@7P'9:7=:EX
M@U2UL_#'B;QC<2Z5=:C#XKO+Z>>&YU:^L/#VF6/]OSZS<WEW]HMTNK>.W1T%
M<7^K>,J4*5%1R?#R49^U@L)5J[).+I\V*]R6CNXZO2^QS/*,;B4H.A@*4'&7
MP4<37YFK?\_*]-0MNG[S=][I&7^QYJ'P@\0^ ?VS/AU\'?B;\3?CA\1_$GPV
M37=7U/Q-K.A>)M,;3KO1-5T'PSHNBS^%[+3=)@\0I<O+_:\=_9PZI>,89[HF
M,!1^C/@S]G_QE!X4\.6UW^T7\;]/N;;PUH-K<:8MUX+@73[J'3[=+B 1OX9<
M)&C*T:*S.5 P&/)K@?@'^U'\)?'WQ8F^&7PZ^$.I>"1K.DWGB>3Q1;:)X?T/
M3-8,.D6'B"SN-0L]/AM-1GM]7T/5-/OM)U*6-E#R-:MSD5]S-]YN>3_0_GQG
MZ<<>_L8/)E"%)U?9SE1PSI-J6,H*_M)2]V$,1--/6\GKTM8^PRG.,?DN40P%
M"%&/L\6\55Q-#"X>K5C^[A1]F\+C/K+G"T>;VB<5=N-M&?/G_"AO%B89?VEO
MCCD'MJ/@8>O3'A7(STZ_3%-E^!?BJ0(L_P"TM\="K31D$7W@EFR%?Y&V^%6
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M>^,X[5_I-?\ !:SG_@E+^VN2,_\ %I9CZGC7-((Q_2O\UOXS*6M_@02)"O\
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M:Y[.#G%2=]GBL+@L#BG3GALSP]"2O&E2J<\I-I)2E&*OK=7;3M=W=KG6W?\
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M5I-.E1+2SU'7KF&6X?4[N;RY;)[=;>":8B;]02SN2[C#-\S>F]R7<+D!E +
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MJV?4H9));/5?L<<\"Q7"R!59KELG?FT].M]4;I2M*R;E%)I*V]UINOS/ /\
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M2OZ%J_R.SS_D<YQ?_H98A?@_^ ?ZY98K9?AEY-KT6C_&X)T'^Z?_ $$U\G?
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MB\#A\%2492Q-5XO%5Z$:7,L/#$UXU:"=DU%U*=Y.%E*.TM3^KO\ X-E6+?\
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M$5S\*-.\):%XFT769-/NFA\-_$?1O'NJZ2L)-NDESJ$6FPPM,Q8W5H3!%(K
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MAZEJ&G7^@:A=1PQ6^K6GG3Z?JB113X0EL])\+OV*OVB? +Z/\7DL?#F@^)?
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M:39RW.I^*[&VAC:\U?59+66&9]*$\R[+.*4"X$;K)ERH/SII?[0$$_C/X1>
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M%[PE>_"J+2[[7[31[2.2^\57<>L:Y;74FBR-:7?V**VAEED,>HQRS2- 2AC
M.5_"?]D#]MK]HGP5X7TOX'>$?A]\/_BEX9\.VU_K'AV?X@ZCK/AV+X:>&7NV
MU'69=6\8Z5K&G6MOX-LKYI)TGUMW$$MR;>R5YY_+;_1'Z%_%U?*LKSSB#.:6
M)KT*&:U<)-4&JV*I_6,-AG":I3E34EHTHJ2O?=6/X4^F?X5YCX@9!@^&^':F
M#I9A4C@,PA]<FZ5&I]7KU:56#J14W!^^I-N#22:L[G[_ /;V_P ?_P!5)7Y=
MW/\ P56\":#(;?Q#X.\*>-]1B+)>3?"C2/&H\*1RJ2K0:9KGCGQ[I-WJRHP8
MB^@TR*RN -UJS1[270?\%:OA?*KM%\#_ !5*B9=L::DABC+!!O8?$XA4#,H#
MG:I+  #(%?WP_&_((1_Y%N>+W4J:GA,/!MQ23]KS8I1HWBN=.4FN62=]3_,6
MK]#;Q$IRI*KFO#$/:-0<O[0FZ=/E5.#<YRI0Y5SN4;.*MROND?J%17Y@_P##
MV3X;H\BGX#>+<Q2QQ2*=)&Z*67"PQ2 _$W,<LQ $<4A#2' 0$\4V7_@K+\,(
MMS3? SQ;%ME\IVDTE$1)\9,+%OB<H67;N;RF.\*"V,"L?^([<-:WP^.<OLTH
M2P,ZTWVC26+YG\KG#3^B!XASNGF7#*DM(QCF2G*J]?X244YQ>G++[2:=D?J!
M17YB1_\ !5WX:RQ1W,7P'\921S3"""1-&=TFG9RBPQ.OQ+,<DID!411LS[@0
M%R"!-)_P5;^'D:S-+\"/&*QVCJEZ6T1D6T=^$2Z=OB6%MG=CA5FV,V1M!S6<
MO'KAU2I*6#S&,*M94&W+!^VC)TVW_L_UIUFU4_=)<JO)[] E]$+Q BXQ>9</
M1;JSI2C/&<LH<BUDU9W7-:-D^:[5ELG^FM%?F"O_  5H^%7F!%^"7B4.5W!#
M91(Q7^]G_A9Q.W) !"X+8&<];EK_ ,%6?AS?R^38_ ;QA>3 J#%8:8U]-EY$
MCC!BM/B1+(N^62*--RC=))%&N7D16[Z?C3DD:?M995FZHM)^TJ4Z%-V[N+K-
M[M:7ZG1'Z'7B3>,HXW())OW7#$8EN6^D5]6U=KO2_7M<_3'(]1_G_/\ (]Q1
MD'H0?QK\U+K_ (*I?#K3KI[/4?@+XST^\4*9++4M)ET^\C#.45GM;SXE0W*!
MI%:,%HP&=&0$LA A_P"'L/PMP6;X)^)0,@ _9$9<EBH&?^%E2 $E2N,C)!&,
MC-='_$9\B45*64YRE).46J5!Q<4KWYO;63MLFTF[:I.YI+Z'_B0M)8W(=[<K
MQ&)4K_X5AKNV[71'Z94>OK]/3_\ 7T/O7YO7W_!4KP!IK6ZZK^S[XZTDW47G
MVBZMHEUI;7,!<Q">V2^^(EH;B!I5,8GA22(R*T8<N"!#_P /5?A;SCX)>)B,
MLF1;PD;P S+_ ,E/SN4$$J?F7.3@53\9N'YQC*AE><5)\O/2YHX>G.%6+5G'
MV.+FI-:WC*6J;7)U0_HA^(-)VEF.01IOE=:,J^(Y:E-.[A*4L+S1O=-.FXSN
ME[W+=/\ ;[P!^TA?>!]$\$>$[CPKI^M^'O#&C_$C0]8TZXU/4;&?Q-HGQ*:U
M;5K6'4;$?:O#]Y:+;!+2\M92&#DNBLQ(]%3]M&2T@UW1+#X.Z&OACQ'X9T#X
M>:UHTWB_Q#<WQ^'/A?1[C3/#OABSUJ3==KJ5E>W U*^\0NQN[E@(9V>,#'X
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M[N+KQ)X]T[1M&TNVV2W>LZWJ<_B*'3M'TJU4(DNH7<T:^8RPJKS2+&WH[?\
M!23P5H$C6FO>%/"OC744/E7$WPJT;QC)X;CGC^6:V@U_Q=XTT)]7%JX9#=V6
MF"SD==L4K@J]==/#^%^'H1R_"\+YI4IPQ>69CR2=*,YX[+(5?JN*K)XMKVU!
MU94U91C.CRIQ>C.6IX8>/.*Q%7,:_%V658UL%F.7.4:_/&CALTY'BZ%*,<*_
M9TZG)&;A+FCSWDDKV/T6<*#MRP,;;8QQC844$R=&+D*C GG!/K3*_/B+_@IQ
M\+WP?^%*>(AD G,$))/ YS\2/IP>1@<XQFPO_!3/X9/E5^"WB,8QR+6$CGW'
MQ('(_K^7Z?#Q7P?+&$<IS5JG"--7CAKJ--*$8O\ ?ZN,8Q5^MMC\LJ_14X]E
M4G*KF.27G*<W/VM:/-SSG-SDH8=1YI2G)MI+T/O^BO@=?^"D_P - <_\*9\1
MG=R1]FBZ_P#AR#G.?\*N)_P4D^&3+D_!KQ$#G&/LL77C_JI'3WYK6/BI@V[/
M*<T7GR8;_P"7[>=SFG]%7C5-WS+);K?][7?X^R1]V45\-Q_\%%_AE(=__"F_
M$8SS_P >T0Z?+DC_ (61[# ]<GZWE_X*&?#*8!1\'/$F2 ,_9HL9XZ?\7('7
M P>.Y)K5>)^&>V49H_\ MS#6^_V[,9?1;XQBK_VID?\ X-K_ /RK^NQ]K48/
MI_G_ "#^5?&T7_!0'X:2\GX0>) 0!G-M#C@#@'_A8W3C&?;)QC-7HOV]?AK+
MB1?@_P"(P1\PR$Y/M_Q<0DYY'"MTY!K1>)>";2_L7.+NUOW>'M=V_P"GVUS!
M_1IXOC\6>\.VUT6)Q#?72WL-]+6[GUW17RC'^W7\.)0"?A'XB&3T^3.?Q\?'
MH1P!^ Y%75_;B^&[* /A#XC<]>0@XX&<_P#"?#GZ'O71'Q#HRLO[&S5IZ?#A
M_7_G]Y=#'_B6_BN,E?.<C:3OI4Q%[>GLM'ZGU#17S&/VU_ARQ'_%H?$0!)&=
MT><9SD?\5_TZ#O\ EQ5AOVOO VH(8+'P=;>%IV"-'J'C72_$^H^'Q,KCRHKZ
M7PCXNU/5--MW;"OJ"Z?>)"/]9"8\L*EX@8:%I2R3.I14E=4:.'K5+-M75-5T
MVE>\FGI%-DU/HZ\3/W/[<R&EK&7/6K8F%-)-.S<:$WS2TC%<MG)V;6Y]&ZJ/
M^*1^(_'/_"L/'H]_^0,3C^M?E!;_ /'O!_UQB_\ 0%KZ-^*OQT^+LFCWG@N_
M\*?#CP1HGC&P*2>+/ VI:QXA7Q=X7G<7$D'A[Q!JVH7%E:Z=>W$*QZH+.VBU
M0>4+6\A@9D5_FM))51%R@PJC"7 1!@ 856CW*HZ*K?,!@'D5MEF:4LPQ&,S6
MI2Q&#P>*C0HX-S>'JUJRPRFJLJM&&(YL/*,I*/)-MWN[GZGPMPGC^$LJ61XR
MI#%XRCB:V(K/!TZTZ,(UU#V7+4E"#GS1CS7Y5O:US^CO_@W8^$_PS\2?L=^.
MO'>N_#OPAXG\6Z=^V-^T?IVF>(=?TF#4KO3+:TU?P_/;QV_VM)X(W24YC9;+
M<'4$2KM!K^@_Q3HGA[Q78ZCX?\5Z1I'B?2-21&O=#\0V-I?Z7-Y2B18GMKF-
MXFDCD7%LT8A: @!&4@"OPR_X-P2&_8$^);G=&H_;7_:64@!L9.K:$2,*..N,
MG@9)K]Z+>&%S-(0&3D8.-S'KM![<XY_#-?X&>(<82XMS5SC%\N/Q$9-K2:=#
M#7<[+LNA_O'PM)O(LLGS2E..#5&,&_=_=RJ5(R6M^:3G:RT5MKG&^ _AU\+?
MAG;RI\/OA_X4\$-J:&&\;P]I-I97%ZC9EVW5[ AN)U$IVB*:?:#\JH2,5XC\
M"[R$?M!?MJ6L-U;3/+\0_A/&;:"^M6E!3X->&8Y!)%'*\@6-T:.0,HVR*8WV
MN-H^HW@>WC2XD62$QL&2*,J9 V?D*?PG/\7?!!SBOR[_ &,?V)-2^ /[<?\
MP47_ &@KA-9E\/\ [0/BKX<W7PVM]6U&\NX+#2Y-"_MSQD;*UFGDBA5O%$R6
MT),4<D=I8Q1Q9MB*^1I4J'U;'*511O#]S3IZI6KQJI1O9OE]Y*]]&[7:N>MB
M)R?LO:3C%N2NIJ;M9_W5\E?6Q^I:/$B[%:5?+< IN#0J<G[H'W3D?/Q@Y'U,
M32-]J:1D!C "\#J><'@ 9 QD\_D:DF*'RE)N(W^]A0 IY^9FR!P<'!/WN=O
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M<0L;.X64,-I;(-?;?P&_X*AZ)\*T-IJ/[,?P]T+[1BUU#7?A+9Z?X:U.XB)
M/^AWL,ZK W+/$-4P_P!PA<Y'ZB_$']AWX2^.(I?^); JN'9DUBPM-7C\P$[
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M;XA^)/$%K;ZW\1TO)M4TB[@T;2WT==;FTW2[8/\ V7-;P7>GV;"Y/<']@O\
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M.KOE=TC\?;:4/'EC]WK^!&?7!R1@8SDC K:21?+#(ZDQG)(884KD8)SZ@_\
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M &IH()7 ^8CE@#U( )K]_!%E&C8K'&0=CQM\S''5E(*G(R&7&&!V]6K\!_\
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M#>?:]&U)9X+<RI%=7C7*I_9JP6\1DF6X2Y,<H3Y#DJ#_ $"_'OXUQ? 3X1?
M;6?AFXE\!>&/AQIWA;4WT\1/%I5YJUEI^M'Q'?PQ%YW_ +9U$7$-W>RJSQS9
M5WCB!0].8<)\.9C1AEU/!X/!SC::K0C2C)Q5E93H\G5:W?-N[VT"M@G.FJ<*
M=*4WM5DE[2,5IRQDK2Y>MKV;=]V?K?XO_;M/@60?\)%X5T+2]-#('N9KK56M
M[7S#M8WUW:O/-;1[\+)>?99%B!)D&PMCLKC]LC3=<\"Q>(/"VC-IUW)JUEH;
M7>K7%K=:0+W4;?[3:?\ ".:I:2_9O$%O+#ON'N_+A2UACVW'[X[1_')\:?\
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M:*-AR>2>#@=O7&*_S=/CJ%-E\!8),[9OV:?ANA"LH?>[:_&A3<>2 Y9E52S
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MO2_&=YJOA<:#;6FCZOK(L8-+FMK.^N=#U#2-2TK6UU!83Y$>7XU_8;_X)]>
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M\;_B_P"*=)G^(6N:?\'KWQW+'>WNFZB3:6^CP7\,*0:C9:3(C:?)JTEK$O\
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M\YYG=I2V,L6+,>,G!&=>SE:*2)S+="5$C@@NA=W8N8X8U98K>&Y$WGP6X5W
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MOX"\"'R;B%DW!7^\HKQ&/X?M<R/_ ,3=4^42'.G%@2Q8$!1?HJ\J3E5'!VX
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ME'P:OP_;YMNKHI.,G^SC[^E^OZYJR_P\>18R=7B.%(^;2V?OZMJ7?_Z]=?\
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MC_BF,9Z9Y]#7(2?#H\?\3=.F/^0=(.!CTU/^>:=#\.Y=Z*-;4*6;*_V=(0>
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MMS9'.YOF.<GDUU\/@)HY0IU9'W(3EK"7WSG_ (F1)S@]^_M5W_A!'_Z"R?\
M@OD_^65?0X>:R^+I48^UYG><Y_%)K2[;NW^AX>(OCYJ=5^RY%RPA32E&,?+X
'4GWLOF?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !_ 48# 2(  A$! Q$!_\0
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M_P#\D_YR?;'S!^V)_P $<?VH_P!BGX!^*_VAO'G[0W@'QCX6\)7_ (;T[4]
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MBKPE\.K#XEZUH8NII$TZ]*Z)J5M9Z=J-I.]CJNJ+/:V;LT,FT&?H+2$@=?\
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M=GI@FDU:1Y=*NH7CD-L()[QC912&1=Q!'VL!@ >@ YZ\4-T/T/\ *O@+3?\
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MDC(VD@/G&>\TC>OJ3W]..]%?ZB4Z].%*C%MW5*FG9/M(_P XL3_%_P"W*?\
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MOUQ='UGP]_;W[2_[3^H)X>\3V3Z7XETC'QO\:V\]MJ^FL6:TN%9#,L;N3MD
M^[BOO*OC']BI$;X??$V4HIDD_:J_:A:23:H=FC^-'C)$+,H!)5$51G/"^HS7
MV=3 **** *UQ]W\8_P#T8M?G9^S"<_M>?\%#_;QY\'A_YC*TK]$[C[OXQ_\
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M&1)5>2%U=&F+GX\^"?\ P5P_81^.W[2WC/\ 9E^&/Q/U2^^+W@^6.RUBSO\
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MW1^/\S3J:GW1^/\ ,TZLELO1?D?1+9>B_)!1113 **** "BBB@ I"JDY*@D
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M^+UMTOIN?Z_']K6?_/[9#ODW-MCUY_?].>?;'K48U:U./^)AII^EU;Y[=,W
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>;\[G\YU(5IU)RIWA3<Y*$8W48P4FHJ*6B26B1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  4L# 2(  A$! Q$!_\0
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M+OOV%_Q"[A'_ *!,9_X<,0?P=K_P:>_M:9&[]J3]G_'?'A3QR3^ (Q^=$O\
MP:A?M:1(7B_:E^ 2R94(P\*>-QL)(&[*X88R>G/?(ZU_>%Y?O^G_ ->F.F%.
M#R<#ICZ]_3-6_&[Q%2?)F&&YK/EME^&A*]NDU*\7VDM5\R7X7\)6?-A,4EU<
ML?7G%;6;@U:2O;1[Z'^3=^WO^Q/XU_X)]?M"W7[-_P 0?&OAGQ]XCT_PCX9\
M92^(?"=GJNGZ0UEXD-V+*T-OJ[-=&YB%C*78\88#C<*\.\)@_P#"/V'!_P"7
MKL?^?VYK]D_^#EQ3_P /1O$@(P3\#OA#@9ZD1Z_G],GWZU^-_A%E'A[3^?\
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M"/V.UD"^1_PSC\)]X)&QU/A#2@V]6"@H$W&3+%"N<C%?Q1X]M/%3\N(<YO\
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MQ-O\[?C\SU;S9/1?^^U_^)H,KD8(7_OH'^@KR?\ X0OQU_T5'6O_  4Z%_\
M(_O_ )P*/^$+\='_ )JEK0ZY_P")3H7IT_X]_P"73M4K-JC:7]G8_7_I]@?\
MF-X*@D_^%#!+S6'QC?W/3[]#U7>WM_GGU_STZU5N)&#*69!$J,7!^]UPNT\C
M+-QC(]>AY\S?P7X[&-OQ4UGOG.C:&W\K=?KSGT'&:H:AX%\>3V<\8^*NN)*T
M4JQ21Z'HY\MI(GC$C!8-S>2S+*JJP)*Y;(SE5<RK>RJ2CEF92E"$JBIPQ6#H
MRJ^S7/[+VBC[JJ6Y7KLV*&!H5)0A/,\ H5)1A.53!XB<8QD[2ERQ]YRBO>C;
M6ZO9[/U^!BR_+P,G=EU?!P"<,,@@>F1SDX%([#?\V\@ CH<<],'!ZY.>>WMS
MY/\  [P/XU\!>!;;P]\0/'M]\1/$$-]J-Q+XEOK2.RFFMKJZ::TM1 @"!+6$
MA ^.267^$5[!L8X^?Y<'Y< KSC'.,^I/H2:[L!B98S"8;$UL/5P53$1Y_85I
M0J5,*H/6BJMN6KSI/WH7>JY;NQPXW#4</6K8:A4ABJ.'JQ5.M24J:K4^9-S]
MG-\\'?9RO97OW/S$_;0_8-^)G[5GC3X5>*O!W[9'QQ^ MA\.O'-MXNU'POX#
MOK>+1_$&FVRV\;:(T2"SDA2=HG>9[I]1B;S2IM^,G[&U[X:^*-2^%5W\/]&^
M*/B6/Q.C:?\ 9?B%K1M=0\1*UAJ$%_*]V-.BL(;D201"W5#%$%5_WID&Y6Y/
MXN_"'XF>-/$GA[5O _QX\5?#JPL?$EIJNNZ/IVCZ7JMEJNF6L1AFT>WEN(HY
M[+SGQ(\DCW*!QQ%C-=[XQ\ ^+M3^&VH^$?#GQ#U72/%,Z6WV3QQ?PP7%_ UO
M>P7CM<V]LMLDOG01&WDCCCV-&S(17ISXESO-,NP618[#4\/EN0+$X/+$X86-
M2&'Q=>6,J5)XFGA:.+Q4ZLYN5L76K5*46H*7*E;Q<-5F\?CTL'B%15>,G5K8
MVE7I34E92P]*#<J=FFI<VZM'>+/E_5_V9/VCYM<^''B+PY^V-XSL=1\*_P!G
M:)XXDU/0-*U#3/&OAV'Q._B#5(+O28X(M.L]<N(95T2WU)52:/2%$0=<"6F1
M_L[_ +7+ZAX!U8?M<7UC?:#K$$?CN$^%;+4--\:>&K7Q5JFM+I]O8W<:)I=]
M<:)?6>ES7%NS((;..(/(6XT;W]G7]IUO%GPO\6Z3^UCJEO<^%K.'2/'^F:CX
M3L;S1O'.@SZS)J]XITN(0V%AKTD+KI]MJ*P&>#3E2+!89,/_  H3]L$ZIX%U
MN/\ :QBL[C20UKXZT[_A";#4-*\5:9!XBU?5H&T^WG;.DWTNF7NFV5Y/$OSQ
MV*I$$#2$XJ*4%",EH_BD[<V]WKOJ>M-1;?N7:Z*>UUW?J:&D_L\_M%M\"_B]
M\(?%?[1^KWWC'XE/XVO?#?QKT6UELO&_@&Y\0:N+CP]!H=AY2Z?%9^&M*@CM
MX"$!ED!7)&:M?#;]GS]H[PCIT_A_QI^U#KGCK1F^"$?P]@O/^$>LM-UU/B9)
M<:J]W\6'OX@\T.J7/VVU/V3[0T4?V;9'M#+MDTGX%_M!R? [XA_"CQ5^T!?M
MXU\7KXEO=#^-V@)):>+/"NLZMK+7.FQ:9IDR_8'TK0-*BMOL]IMVR.+A'+K(
M ,:#X#_M=0:,FB0?M<A4B\$> M%M=4_X0;3'U:?Q=H+2MXN\43SW/GC;XOF>
MW:2UD+BV/FI L.01M)MM63DK)76MG;6Z6MMM14D[--*#3;UE=-=+2ZM]EL<_
M=?LZ_MEP:7+!X:_;+OH;B7X>>,/#5LVK>#-*U*VT_P ::K%H</A'Q5;2O#'<
M7$/AJ#3]1/V2=_+O+K5)W>;**PW]"_9S_:9T_P 8^&_$>I?MA>+;O2;#Q!:Z
M[XA\*CPWHD^D>*K7^Q]"LM8TB59K4RVEB=0L;^]T^VM)HQ$NH2S9D (;<\<?
M _\ :B\0>)GU[PQ^U;+X)TN3^S)#I6G^ ],NH9!82W!%B\%_+<1K:W2S,EY]
MF\JZE8J\3IY:"F:I\'/VM8;SXL:EHW[4]@#XKA@'PXTG4_A_I;Z3\/)8M2MI
M&F(A(NM0M7L$N[1FFED9?/C)Y44-65U:UO\ AUZW_K0J+NVGHD[7?^1R$_[-
MG[6&I^')=/UC]L_7DU*>V^(EG->Z)X5TK38IH/$NO:GJ/A"82(CW%M/X.T^6
MPTBTNK>4!HK6<2[GG#1_>^F?:;73=.M[F26[N[6SMK>XFEW_ &B^NK6V2"XN
M-C!6=IVCDN58A3*"[D# !^25^#_[4R>*-$U?_AIVU?P_#\1O#7BCQ%X>E^'^
MD+%>^ =+T@V/B'P-I]Z 7M+;6]09=3^U-NNK9GVQ2J%%>4^.?V?_ -L/Q1XV
M^(GA/1OCW#HWP6\7>"-;N=!O-TZ^*?#OCO4/$4%[9:2DMB8]3BT"#2XY+=]0
MLKZ&ZCAFE2(*54!!=7:733[C])/M!51F,\-Y>"3G?M+*#A6 # <EB"N1D9--
M^V#>%\LX/F8?=\N8M@;/R[@NYPH8K@D'MS7QO/\  _\ :%30_A-IVE_M$76A
MZQX3^'UIX4\97]OI,>IP>+=:M9XKEO$=O:ZFL\SW310I9W$U\[M+;,TC?Z0Q
M>O/G^ _[:=Y:>&K+6/VN+&X&E>#8;'6+G3? 5EI%QXB\=1>+Y=6A\0W#1?):
M:3%X>:'P[<Z2H47C)YTAS\QA*;:3>CWVT7]7&?H6MT6&XQ':0#D.I(R 0&4[
M6!ZYX(RK $T-< D*5 SG!W Y9?OH!URJD-D@ @U\'>'O@9^V9IGASPUINK_M
M?6>NZUIOQ*O/$_B/7+CX9Z/%-K?@.?1[FU@\$0VEN$2 :;K$D6H6]\$$DRP&
M.9F#UZG\#/A3\;? FN2ZG\6OC9>_%59_!&F^'WMI=)M=&M%U^RUV_P!0?7TM
M+1$C6ZN=)NK;3YRJA#]F7: Q8DIP_>S][2.L?-]//J3)7BUZ?G%_H?P4?\'-
M#$?\%2_$(''_ !8SX0#Z@IKY_I7XO>$R?[ L.3_R]]_^GVYK]G_^#F@_\;3/
M$/\ M? _X/)_XYKI_K[_ .'XT^#[=7\.:<Q9@3]KX&.U]=#T]J_O?PVJ*'!&
M01EI_P )F VUO[F)L_ST/Y!XSBWQ3G5NF.KM^DY*4?P6O8\$\"2,?VH/ QXR
MG[0O@H+QV_X618#G\ *_=/XV@+\9OBWDD!?B-XK^;CY FIN5<Y'W4+%W[[0<
M=A7X4> \_P##3O@<]_\ AH7P;]>/B/IQ&?7J?\]/W7^-9_XO5\70VW;_ ,+%
M\7YWDJN/[0?DLHW<'L.IPO>OKO"/3,\R;DH)99*\W>T;8JG>3MK9;Z=C\V\>
M_=RC)%:[>8325D[MX'#V33:O?:U];G[N_P#!-WXM1?LI?L=P_%OQ]\<_&.G_
M  [^)?Q!\0:%H'PY\'?"H?%2R\+:WITL::IJ-RL%K>WFF7&LQLEXUE<1PVL^
MQ)9%8MQ^.'[97C'P[X__ &C?B!XY\.?$+Q]\1-/\2S:5J"^+?BAH2^$_%%U=
MSVL4D^D?\(^UO;G3=&TXE;/2K>.W15M2 AVKBOV6_85^+5QX5_X)Z>!_#GPN
M_:E^!W[+GCV;XM>.M0\3ZQ\4- C\0IXQTTWBK;PA=2,,%EK*LB1X5II#:1JJ
M[<BOQM_;;UKQ'XH_:(\;ZMXK^+W@;X\^(Y-,\.PS_$OX>:;%HO@O5X[>S!@M
M]-T^'=]FELPHM[F=9#YDY$A9E&:\3P^=.OXJ\:YA4P4Y9DL3G%*%2$7A?K,:
M&(I?5W4HX/+(X1J7+'D;S2K/$-IU(*I+]WX7&M6N_#+@_"^TA7RQX;+\76H5
M-*>"J5[O%1C.MF$,=[6,(J=*D\):,H)4DJ<E*7[0_P#!)WQGJ_P2^''C?X._
M&_X3?'3X:0^)O$=Y\4/#/C[2/AQX@UO1?%6F^)?#%QH5MH_B)]%TN^G>&R@N
MO[7TVVE7[.V(ICAAS^<__!4CXB:;XY^.O@+1M&\-?$+1]"^%WPGT;X>Z/XL^
M)_ANY\,>+/B/;Z9=W4S>+&T^]BAN_P"RWDG:QTZ2>&-C';AMB<*/U2^%?[3'
MP<?]CG5OVE]2^(G[=T&A?#?6?!GP>U/0O"WC?3+O4M9\41:7:0SS:5IMOHLT
M>G^'[&-FCBN[XQ)]G\F$L\DH9?S5_P""MF@6>E?&[X/:WIOBSXH^,M$\<_ 3
MPWXRTO5/BUK2:SXMM+/5KZZFBTUHQ86#:9#;YQ+I[0R^7<^;(DSJZ@?-\ XB
M&,\;L?F&.R_%83,\35S?#UW4JXN%%8S"T8.NXX>O3;4YX-T(^RJUY*FG[2DE
MS*$/H^+J,\+X.8/+<+C:&,R_"X?"XNA6FL//%2P>-K<U*$JL*E2:Y,2Y6HI\
M\4KU5%:O\$?^"H2_\4#^P\2,%?@-\2L<D[O^+H:DNXYX)(Y8>IR>HK_30_X)
MSPQO^P3^QVK]&_9R^$ZE">)$/@_3 R-G<-C*V'7'S X[5_F7?\%/\GX??L/L
M6W_\6'^)H! *G ^)^I$#:3USC..I]J_TT?\ @G1((_V"?V.-Q*AOV<OA(-PQ
MG+^#M,(P.H("DLW"A<GCM^.^//\ O57_ +*'.?\ T\_Z]#^EO!96R+ ;_P#)
M/Y/KT_@]#GOV/]-US3/&G[4^GZRDUC9VWQFOCX:T:?P?X2\--H>@D7,>G00:
M]X<U*\U+QAI^HA#J-IJ?B*TM+^U-VUJT+LCUV=I^W3^SO>>/;OX8VWCAI_&N
MF_%J;X'ZAI2Z1J!6U^(L&EOK,VERW7D"-;1;%5*ZD$:V,A\LJS$,.5_9A^&O
MC+P?\6OVK_%_C'X<_#7P;9_$GXCZ9J?@_P 1>#?'%WXO\0^-O#NFP7D5CJ/C
M.UN8X;/PYJ.Z1I;'2[0$(]Q/&;B;R4<?3R_!#X/+KS^*5^&7@F/Q*WBB#QJ^
MO)X=TV/6'\716)TR/Q')J"0"Z?6([!FM5O6E:;RC@N3S7\_O3E7:G#;;X4?M
MI\I_L0^-/#7C[Q=^V-XE\)ZE_:FC7/[3NNZ>EXUK=V)-WI'A?PW8WT!M;^WM
M;I#%=1/$LAB,4Z@/"[*01^@-?$_[*?S?$W]LXG)*_M'7*KDG"J/!GA<A5'11
MGD@  M\QRW-?;%( HHHH K7' !_V7'X8'^)KX(\)?\I(_B__ -FI_"__ -6%
MXCK[UN2>!V*-VS@DC!_S[U\'>%5'_#Q_XO$84_\ #*GPT);/)V_$+Q!@$YQ@
M9Q_7FNO!27)F=[_\BZK"5DY<D95L/:K*R?+3;TYGHG:[5U?Q<U5ZV4VU:S:B
MVM%9+#XV>[:6T6O5H^\#&-Q8[L'H=W '< '' [<GG/2EV @C<Q!'0G@>XXZ]
M\G/09S30XS@A\D#/ *]!T]CWP/4X[U*/_K] ,?@ ,5YU1<LI0Y)2YVY7]M)6
MYE>-MU%2?NQ2:1[/(DE.5/EDDK6DFGYM1;U:WW]0 3 ^7]1_\31A?[B_D?\
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M@4444 %%%% #61&&&56!()#*",@Y!P1U!Y![&C8ASE5.[K\HYQTSQSCWIU%
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MLQI+MPPA$RPEW&2(]_TK_,R_X*D _P#"!?L1MV_X4/\ $Q_^ _\ "T-43/\
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MG>N.N!CZ[UH=&,K)RJ-76CFWN[?DW;S%#XX>4HO[F?+W_!4<X^'_ .Q#ZGX
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M6O>/_%5_XNT_PWJ 5Y%@UFRTR:!]0LG8S6;31I<!7R*_T[?^"<;LO[ W['
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MLBDKIXBW^!?YG^E,99,\*OXA\_\ H-)YLO\ =3\I/_B:_P UK_B*0_X*J_\
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?BAFN:X[&86+=*M7J55[6\9N525Y2:3^TDKK[DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !_ 3L# 2(  A$! Q$!_\0
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M;.K5C-:]K)V^;U/\ZO\ XA./^"F''_%^/V=S[-XG\>D'V(.B_P!.O;' 5?\
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M_P#LJK_B+'&2T^M8333_ )%]#T_F%_J+D/\ S[QR\EB%;Y:;=C_/*_XA3_\
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MEQ55A&.40P.)RBEE;Y7_ ,Q%/&PEF6(3CR*?*FXNSLFVSF=',\15IXC"4W/
MTY3CB9NA5G"3NE!>TA"5.'*U))SE'F?PN5M/J.Z\>>"].\0#POJ/BO0+#Q%%
M!IUVVBWVJV-C?M;ZM//9Z7)%!=SPM-]ONK>XM[5(?,DFEA>-%+#!H>'OB_\
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M5J5_G!6^^QY]^STV?VW/@HN/^;G/" SGT\>0^U?LQ\0!GX@>/@>,^._&&/\
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MO]6\2Z;=?:6>X<ZAJ-V]T6^UPS"VD2.OE;P-^SY^P3X:^*WA'4O#WQ4#^/\
M3OVL?BCX]T+1;WQ3Y9U;X]:MX;9O&GA-K6]T^$O-IFC :A-:V[Q2M&4CDO+P
M,4;X-^[B+O1.FTK6O>RT]._;\3[.>M-V_P"?D5VU3MK?MT[Z;GH7[ GA'P5X
M(^+7[>V@^ 97G\-_\-*Z3J<#OXGU'Q>3J>J?"SPK=:NW]N:IJ.JW<@^UR2+_
M &8UZZ:40;=(8 -E?IK7Y>_\$^=-^%^E?%3]O6R^#B>%H?!,7[3.ER10^#;R
M&ZT--<F^&/AA_$;B2":XMSJ,M^9&U%(Y R3_ 'EC(*U^H50DTK/>[_%W7X,M
M[OY?D@HHHIB"F?QCZG_T%:?3/XQ]3_Z"M+K?LG^G^0'YV_LA?\G/_P#!1/\
M[+G\/_\ U4FAU^AM?G9^R2[1_M._\%$=I"E_CI\/ &DVJJ@_"?0PV 7&X$#C
MG=GD(17Z#_:'(RI0L" 557.#@'#DD%5DSA&"L,]S7M<6+ES>%Y)<V5Y-R[^\
MWDN3-1B^767E>^C>RN<N M[&2NKSKXF:5U?EA6JJ3?9WVW&[BJA0-QY!5<XR
M1]#@ 8YZ@=J^=OA$K1_%7X_#S$V#QIH*X+@N4_X12S<948PV\E54G! )R#\M
M?3(B"@E20Q4C^$\D<<[>WXBOG77OV>=.U+Q7X@\7Z9\0OB1X4U/Q/=V=[JUO
MX;\00V&G375E9K902BW-A,RM]G55):8[FR> =M? YW2Q+K8#%83!T\;B,)BE
M4Y:E98?EI?5Y4VZ<G&2<U*7NQMTO?2Q[N5SP\*6,PV)QD\+2Q5&G#VE2A/&M
MU(5(S][V<H2BK+XE?R1]!,_R\'DD!=^ NX] Q ) ^G->%?%KXE?!"PTS7? ?
MQ;U'PW?Z9JVB(/$O@W6](N=?M-2\,ZS(=/:+6M'2RN[6[TN_D8VUQ;7B/;2J
MZK*A#8K'/[/VH,,'XW_&H#(/R^,(ESCH"5T\$CU&<'N"*IO^S<7FEN'^+OQ8
MGN+B-8;B:X\0Z=/+/!&28X)9)M)=G@C)8I$3M5FW@!PK#!9MGEU?(Y6ZVS"%
M_DO9(UAEV4W5\]I-=O[.QVOE=UM/NZ&#X(^)_P"RE\,]9U?P7\-;7PGX7U?6
M]<MH]7T;P/X%DT,ZUKMM;0:1#=WYTC1+*UU&XM;&TMK!;Z4O]FL;>TM]RQQK
MGZR=F!#(@!4=6;^\,\#OUP1Q\PP>17S6/V<90S.GQ=^*\<K%F\Z+Q!IL5PKN
MP>21+A-)6=7E8;I") '/48  G3]G_4EFY^-WQE1"I.!XMMP=V3W&GY(/N<Y[
M\@!2S?.Y.,'D5;DG*,)<F9TH3Y9:.TG2=M%K:S:=D]RY99D_*Y+.</>"<X^T
MRW&SCSQUC[JK+9ZI_H?0SW"JX0N@;Y=R_,K_ ##=N&5PRA>Z%L'@X[7XI \*
MML9<@D!B-V,G' X^88(QC.03S7R!:?LUZQI_Q:\(_$#_ (75\4]9LO#-M>12
M^%]:UF/4=*UA[M-B_:0D4(V1KD[7C)#\JQ&17V!;*K01MD_=Z ; -I(QM[8Q
MCWZ],8]'*<;F&.AB(XO+_P"S%A:WL<-3]LL4Y16OUB=>,8*4VKQ]G9O5N^C.
M+,<%@L'.@\)CEF4L3A_;5ZJHU\*HS<N5T(4:TYV@D^;VB=KI1MJSC_&7@S0_
M'&A7&@:]'/+IEQ+')-%#<7-G)(\+%HR)[*>VG54;G:'PQ'S<<'Q#X6_LF_!S
MX0:M=Z[X5TG5DU6[UFXUP7%YK^KW45O?W0 F,5LUT()(SSA;M+AEZJ_%?49@
M5@07<Y)/)7N<_P!WH.U*(4'')&,<D=/3IT^M/%Y#EN+QM/,*F#H5,PH)>QQU
M=2J3@W;G5.DI)0NXKF;NG96VU*&:YGA<'5RW#XRO1RW$.,JV"H2C3C*44[.I
M.S<[7=K..[O=6/D'XL?LC:)\6/BGI'Q5D^)GQ&\'ZGIL'@R!]*\(ZS+IFFZC
M_P (3K-_K6FF^$<RM<17,VHSP7\$J/%<6X1)%;:,>)Z?_P $VM&\.'QY#X+_
M &A?C?X4TGQGHNCV%KX=LM?:XT#PSJMC\0[KXAZMKNDV,MPLC7'B2]NGTW5H
M)+E0UBH2*=4_<C]+0BC''3IT_P \=J=7LKFY5&?O-)*4M$I.UKJ.\5TM<X%L
ME:T5I%;M+=\SZN]]3\Z_$'_!/BTUCQ;XZ\4Z;^T1\;O#,/CCPS\2M"G\+Z+K
MQA\+Z;J/Q'_LLW/B:WTQYV\[5]*;32+0O*D+Q7=Q&BVQ(>O9/ ?[(W@_P3X?
M_9KT@^-/B/J5[^S)IE[I_AB^A\6:II&G^+WU+2)=(O;CX@:!9W+:?XH4I,]W
M:0:@TPL[S]]'(QSGZPHIV]WEOIJ]%U?7O^-K]!GYI>*_^":O@WQ+>_'6_B^*
M?B_37^-_Q3T'XJW>GMI.D:IH/A[6-(TJ_P!$NH8-%U%Y;;57O[#496AN[QHE
MTO4+73M2L[3[79!Y/>?A=^R;H/PK^)_CCXB:5XSUW5XO&_A30O#%WIFMZ?I5
MSK5F-$T33-!^U1^-UB3Q'/;SVVEQ7$6E2RBSL+V:>XML%]H^M**+6BHWO965
MP/A#XA_L!?#;X@? C0_V?+KQ[\5X/!^AR^,)(]:U+QEJ/B+QM=_\)I%J2:@+
MOQ1JDK7\AL)-3FDT9L_\2U8K:& !(5KY93_@BY\%HO!/[-G@I?C7\>V@_9L\
M9:GXSTK5G\8W$FK>/KS5O&VC^/KK3_']RTN[6],_M[0].:.UE+)':P+;*%BW
MJ_[*T@&,^Y)_.HC%PDI)W]>GHM@/SN^-?_!/3P[\9?&?Q'\>3_%_X@Z'K_Q)
M^$\WP@U.2:WTCQ%;6OAJY\70>*ID@M-1CBM5%N(GTO2?LD5C>Z;;RF?^T+F9
M5KV;X$_LG>$O@'\1_C?\2/#GB;Q+JEY\;K[P=?:KH.IS@Z!X?/@WPS:^&[9=
M#LQ)(8Y-02U^VWD\C[C/*R*I'S'ZJV_[3?G22L5C9AU _F<54$TW?NGO<F;M
M";>RC)OY1;_0_P Y'_@ZYR/^"E'@0#O^S3X1.?3;XG\2G'XX_#-?A5\.(R?!
M>BD/@$:A_"/^@I?9[^N?Z<5^Z?\ P=<-_P ;)O 3,#S^S1X1X .?F\4^)%]^
MQ/XXY['\+?AO(!X+T48/34.Q_P"@K?>U?V%P [<+9')[2RZ%K=O;5-UW/PC-
M(N7$>=22TE4HV^5.S].AP/[.N3^W#\%,\_\ &3_@P?@?',;$<>I/Z<8YK]H/
M'S-_PL'X@\]/'?B_L._B#53_ #YY^GM7XO?L[$_\-Q?!;V_:A\%_E_PG48Q[
M?IV'85^S_CWGX@_$+/\ T/?B_'..?[?U3^E?KW@2HO,,\Y[M/#85-Q:3M[:4
MFTWHG:HDF]$TWL?SC](GW,NX>:UY:^.5MKM4:#\VK^E_4E^']CX3U?QWX.TG
MQ_-XF@\$ZIXAT_3O%$W@S3/[9\71Z1=R^1/_ ,(SI(#'4=:>22*.RM!',99)
M.(GQBOZ@;?XZ_ W3/AMX,^"WP"^-W[<MEI'PK^%EMX=\=Z-\,_@9IVO^+_!$
M=LMT#%\0]0U/PVM_X/\ &,-B?WVF6$H1[01S(OF2!S_-+\"?B<WP5^-'PO\
MBZNA6OB8_#CQGHWBW^P;N2.*'4UTN8R26_F2JT:2[&9X&()$RH1C&1^T,/\
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M?LZ_\GR?!+_LYOPC_P"I[%7[3>/ ?^%@>/N/^9^\8]?7_A(=6Q[]?UXK]?\
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MDPB%Y?1W$#P1@%&5AFO\X_\ X)6_\K)&B_\ 9S'[2G_J/^-*_P!&[]IH6_\
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MM\*?"MOI.J+JVGI' 3JUBD=XU@5\RQ$@CD))X_2VK-FK-]=OR04444 %%%%
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MJU=V2>C[6>C/YB^D=>6 R""Y?>Q.*BN9M)<RA#5J^GN)MI=_ER,X)C*A2Y)
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M?[/&L_"7QIINA?#'P[XNUF[^.^B7T]O!)XG\*W6CW,6FVUM VGW4U[);ZC)
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M7?"VH:/X8TJ:*1K'2['3)+>&-#<,P_FD'_!Y3J0&T?L%\'C'_"Y(!G@#)/\
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DV:O*^E]6V?B_$&(E+-L77PU64?;3;E*+DN9)VC?35I>ED?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>imc-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:37 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://immuron.com/20210630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:imc="http://immuron.com/20210630" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="imc-20210630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="imc-20210630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="imc-20210630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="imc-20210630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://immuron.com/role/ConsolidatedIncomeStatement" id="imc_r_ConsolidatedIncomeStatement">
        <link:definition>001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ConsolidatedBalanceSheet" id="imc_r_ConsolidatedBalanceSheet">
        <link:definition>002 - Statement - Consolidated Statement of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ShareholdersEquityType2or3" id="imc_r_ShareholdersEquityType2or3">
        <link:definition>003 - Statement - Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ConsolidatedCashFlow" id="imc_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SummaryofSignificantAccountingPolicies" id="imc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>005 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/Revenueandotherincome" id="imc_r_Revenueandotherincome">
        <link:definition>006 - Disclosure - Revenue and other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/Expenses" id="imc_r_Expenses">
        <link:definition>007 - Disclosure - Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/IncomeTaxBenefit" id="imc_r_IncomeTaxBenefit">
        <link:definition>008 - Disclosure - Income Tax Benefit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/KeyManagementPersonnelCompensation" id="imc_r_KeyManagementPersonnelCompensation">
        <link:definition>009 - Disclosure - Key Management Personnel Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/LossperShare" id="imc_r_LossperShare">
        <link:definition>010 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/Cash" id="imc_r_Cash">
        <link:definition>011 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/TradeandOtherReceivables" id="imc_r_TradeandOtherReceivables">
        <link:definition>012 - Disclosure - Trade and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/Inventories" id="imc_r_Inventories">
        <link:definition>013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ControlledEntities" id="imc_r_ControlledEntities">
        <link:definition>014 - Disclosure - Controlled Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/TradeandOtherPayables" id="imc_r_TradeandOtherPayables">
        <link:definition>015 - Disclosure - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ProvisionforSalesReturns" id="imc_r_ProvisionforSalesReturns">
        <link:definition>016 - Disclosure - Provision for Sales Returns</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ContingentliabilitiesandCommitments" id="imc_r_ContingentliabilitiesandCommitments">
        <link:definition>017 - Disclosure - Contingent liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/Leases" id="imc_r_Leases">
        <link:definition>018 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ShareCapital" id="imc_r_ShareCapital">
        <link:definition>019 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/OtherReserves" id="imc_r_OtherReserves">
        <link:definition>020 - Disclosure - Other Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SegmentReporting" id="imc_r_SegmentReporting">
        <link:definition>021 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/CashFlowInformation" id="imc_r_CashFlowInformation">
        <link:definition>022 - Disclosure - Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SharebasedPayments" id="imc_r_SharebasedPayments">
        <link:definition>023 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/RelatedPartyTransactions" id="imc_r_RelatedPartyTransactions">
        <link:definition>024 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies" id="imc_r_FinancialRiskManagementObjectivesandPolicies">
        <link:definition>025 - Disclosure - Financial Risk Management Objectives and Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/EventsoccurringaftertheReportingDate" id="imc_r_EventsoccurringaftertheReportingDate">
        <link:definition>026 - Disclosure - Events occurring after the Reporting Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/CompanyDetails" id="imc_r_CompanyDetails">
        <link:definition>027 - Disclosure - Company Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/AccountingPoliciesByPolicy" id="imc_r_AccountingPoliciesByPolicy">
        <link:definition>028 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/RevenueandotherincomeTables" id="imc_r_RevenueandotherincomeTables">
        <link:definition>029 - Disclosure - Revenue and other income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ExpensesTables" id="imc_r_ExpensesTables">
        <link:definition>030 - Disclosure - Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/IncomeTaxBenefitTables" id="imc_r_IncomeTaxBenefitTables">
        <link:definition>031 - Disclosure - Income Tax Benefit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/KeyManagementPersonnelCompensationTables" id="imc_r_KeyManagementPersonnelCompensationTables">
        <link:definition>032 - Disclosure - Key Management Personnel Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/LossperShareTables" id="imc_r_LossperShareTables">
        <link:definition>033 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/CashTables" id="imc_r_CashTables">
        <link:definition>034 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/TradeandOtherReceivablesTables" id="imc_r_TradeandOtherReceivablesTables">
        <link:definition>035 - Disclosure - Trade and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/InventoriesTables" id="imc_r_InventoriesTables">
        <link:definition>036 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ControlledEntitiesTables" id="imc_r_ControlledEntitiesTables">
        <link:definition>037 - Disclosure - Controlled Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/TradeandOtherPayablesTables" id="imc_r_TradeandOtherPayablesTables">
        <link:definition>038 - Disclosure - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ProvisionforSalesReturnsTables" id="imc_r_ProvisionforSalesReturnsTables">
        <link:definition>039 - Disclosure - Provision for Sales Returns (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/LeasesTables" id="imc_r_LeasesTables">
        <link:definition>040 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ShareCapitalTables" id="imc_r_ShareCapitalTables">
        <link:definition>041 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/OtherReservesTables" id="imc_r_OtherReservesTables">
        <link:definition>042 - Disclosure - Other Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SegmentReportingTables" id="imc_r_SegmentReportingTables">
        <link:definition>043 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/CashFlowInformationTables" id="imc_r_CashFlowInformationTables">
        <link:definition>044 - Disclosure - Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SharebasedPaymentsTables" id="imc_r_SharebasedPaymentsTables">
        <link:definition>045 - Disclosure - Share-based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/RelatedPartyTransactionsTables" id="imc_r_RelatedPartyTransactionsTables">
        <link:definition>046 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables" id="imc_r_FinancialRiskManagementObjectivesandPoliciesTables">
        <link:definition>047 - Disclosure - Financial Risk Management Objectives and Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails" id="imc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>048 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/RevenueandotherincomeDetails" id="imc_r_RevenueandotherincomeDetails">
        <link:definition>049 - Disclosure - Revenue and other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofrevenueandotherincomeTable" id="imc_r_ScheduleofrevenueandotherincomeTable">
        <link:definition>050 - Disclosure - Revenue and other income (Details) - Schedule of revenue and other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofexpensesTable" id="imc_r_ScheduleofexpensesTable">
        <link:definition>051 - Disclosure - Expenses (Details) - Schedule of expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable" id="imc_r_ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable">
        <link:definition>052 - Disclosure - Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofincometaxbenefitTable" id="imc_r_ScheduleofincometaxbenefitTable">
        <link:definition>053 - Disclosure - Income Tax Benefit (Details) - Schedule of income tax benefit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable" id="imc_r_ScheduleofkeymanagementpersonnelcompensationTable">
        <link:definition>054 - Disclosure - Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable" id="imc_r_ScheduleofbasicanddilutedlosspershareTable">
        <link:definition>055 - Disclosure - Loss per Share (Details) - Schedule of basic and diluted loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofbalancesundercashTable" id="imc_r_ScheduleofbalancesundercashTable">
        <link:definition>056 - Disclosure - Cash (Details) - Schedule of balances under cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable" id="imc_r_ScheduleoftradeandotherreceivablesTable">
        <link:definition>057 - Disclosure - Trade and Other Receivables (Details) - Schedule of trade and other receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofinventoriesTable" id="imc_r_ScheduleofinventoriesTable">
        <link:definition>058 - Disclosure - Inventories (Details) - Schedule of inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofsubsidiariesTable" id="imc_r_ScheduleofsubsidiariesTable">
        <link:definition>059 - Disclosure - Controlled Entities (Details) - Schedule of subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleoftradeandotherpayablesTable" id="imc_r_ScheduleoftradeandotherpayablesTable">
        <link:definition>060 - Disclosure - Trade and Other Payables (Details) - Schedule of trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable" id="imc_r_ScheduleofprovisionforsalesreturnsTable">
        <link:definition>061 - Disclosure - Provision for Sales Returns (Details) - Schedule of provision for sales returns</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails" id="imc_r_ContingentliabilitiesandCommitmentsDetails">
        <link:definition>062 - Disclosure - Contingent liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/LeasesDetails" id="imc_r_LeasesDetails">
        <link:definition>063 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable" id="imc_r_ScheduleofamountsrelatingtoleasesinbalancesheetTable">
        <link:definition>064 - Disclosure - Leases (Details) - Schedule of amounts relating to leases in balance sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable" id="imc_r_ScheduleofprofitorlossamountsrelatingtoleasesTable">
        <link:definition>065 - Disclosure - Leases (Details) - Schedule of profit or loss amounts relating to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ShareCapitalDetails" id="imc_r_ShareCapitalDetails">
        <link:definition>066 - Disclosure - Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofsharecapitalTable" id="imc_r_ScheduleofsharecapitalTable">
        <link:definition>067 - Disclosure - Share Capital (Details) - Schedule of share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofordinarysharesTable" id="imc_r_ScheduleofordinarysharesTable">
        <link:definition>068 - Disclosure - Share Capital (Details) - Schedule of ordinary shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/OtherReservesDetails" id="imc_r_OtherReservesDetails">
        <link:definition>069 - Disclosure - Other Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofotherreservesTable" id="imc_r_ScheduleofotherreservesTable">
        <link:definition>070 - Disclosure - Other Reserves (Details) - Schedule of other reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable" id="imc_r_ScheduleofmovementsinoptionsandwarrantsTable">
        <link:definition>071 - Disclosure - Other Reserves (Details) - Schedule of movements in options and warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SegmentReportingDetails" id="imc_r_SegmentReportingDetails">
        <link:definition>072 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable" id="imc_r_ScheduleofsegmentinformationforthereportablesegmentsTable">
        <link:definition>073 - Disclosure - Segment Reporting (Details) - Schedule of segment information for the reportable segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofinformationongeographicalregionsTable" id="imc_r_ScheduleofinformationongeographicalregionsTable">
        <link:definition>074 - Disclosure - Segment Reporting (Details) - Schedule of information on geographical regions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofmajorcustomersTable" id="imc_r_ScheduleofmajorcustomersTable">
        <link:definition>075 - Disclosure - Segment Reporting (Details) - Schedule of major customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable" id="imc_r_ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable">
        <link:definition>076 - Disclosure - Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/SharebasedPaymentsDetails" id="imc_r_SharebasedPaymentsDetails">
        <link:definition>077 - Disclosure - Share-based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable" id="imc_r_ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable">
        <link:definition>078 - Disclosure - Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable" id="imc_r_ScheduleofgrantedvaluationofoptionsTable">
        <link:definition>079 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0" id="imc_r_ScheduleofgrantedvaluationofoptionsTable0">
        <link:definition>080 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGwRV+rC4CeikHMX82WA5yds6Ra5exBqSKU=] CSR-->
      <link:roleType roleURI="http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable" id="imc_r_ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable">
        <link:definition>081 - Disclosure - Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/RelatedPartyTransactionsDetails" id="imc_r_RelatedPartyTransactionsDetails">
        <link:definition>082 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable" id="imc_r_ScheduleofinformationaboutotherrelatedpartytransactionsTable">
        <link:definition>083 - Disclosure - Related Party Transactions (Details) - Schedule of information about other related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable" id="imc_r_ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable">
        <link:definition>084 - Disclosure - Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails" id="imc_r_FinancialRiskManagementObjectivesandPoliciesDetails">
        <link:definition>085 - Disclosure - Financial Risk Management Objectives and Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofforeigncurrencyriskTable" id="imc_r_ScheduleofforeigncurrencyriskTable">
        <link:definition>086 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofexchangeratesTable" id="imc_r_ScheduleofexchangeratesTable">
        <link:definition>087 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleoftradereceivablesTable" id="imc_r_ScheduleoftradereceivablesTable">
        <link:definition>088 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable" id="imc_r_ScheduleofcontractualundiscountedcashflowsTable">
        <link:definition>089 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuron.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="ConsolidatedStatementOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ConsolidatedStatementOfChangesInEquityAbstract"/>
  <xs:element name="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
  <xs:element name="DisclosureOfRevenueTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfRevenueTextBlockAbstract"/>
  <xs:element name="ScheduleOfRevenueAndOtherIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfRevenueAndOtherIncomeAbstract"/>
  <xs:element name="DisclosureOfExpensesByNatureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
  <xs:element name="ScheduleOfExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfExpensesAbstract"/>
  <xs:element name="DisclosureOfIncomeTaxTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
  <xs:element name="ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfIncomeTaxBenefitAbstract"/>
  <xs:element name="DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
  <xs:element name="ScheduleOfKeyManagementPersonnelCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract"/>
  <xs:element name="DisclosureOfEarningsPerShareTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract"/>
  <xs:element name="DisclosureOfCashExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCashExplanatoryAbstract"/>
  <xs:element name="ScheduleOfBalancesUnderCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfBalancesUnderCashAbstract"/>
  <xs:element name="DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
  <xs:element name="ScheduleOfTradeAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfTradeAndOtherReceivablesAbstract"/>
  <xs:element name="DisclosureOfInventoriesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfInventoriesTextBlockAbstract"/>
  <xs:element name="ScheduleOfInventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfInventoriesAbstract"/>
  <xs:element name="ControlledEntitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ControlledEntitiesAbstract"/>
  <xs:element name="ScheduleOfSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfSubsidiariesAbstract"/>
  <xs:element name="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
  <xs:element name="ScheduleOfTradeAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfTradeAndOtherPayablesAbstract"/>
  <xs:element name="DisclosureOfProvisionForSalesReturnsExplantoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
  <xs:element name="ScheduleOfProvisionForSalesReturnsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfProvisionForSalesReturnsAbstract"/>
  <xs:element name="ContingentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ContingentLiabilitiesAbstract"/>
  <xs:element name="DisclosureOfLeasesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfLeasesTextBlockAbstract"/>
  <xs:element name="ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract"/>
  <xs:element name="ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract"/>
  <xs:element name="DisclosureOfClassesOfShareCapitalTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfOrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfOrdinarySharesAbstract"/>
  <xs:element name="DisclosureOfReservesWithinEquityTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
  <xs:element name="ScheduleOfOtherReservesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfOtherReservesAbstract"/>
  <xs:element name="ScheduleOfMovementsInOptionsAndWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract"/>
  <xs:element name="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
  <xs:element name="ScheduleOfSegmentInformationForTheReportableSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract"/>
  <xs:element name="ScheduleOfInformationOnGeographicalRegionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfInformationOnGeographicalRegionsAbstract"/>
  <xs:element name="ScheduleOfMajorCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfMajorCustomersAbstract"/>
  <xs:element name="DisclosureOfCashFlowInformationExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract"/>
  <xs:element name="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
  <xs:element name="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract"/>
  <xs:element name="ScheduleOfGrantedValuationOfOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfGrantedValuationOfOptionsAbstract"/>
  <xs:element name="ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract"/>
  <xs:element name="DisclosureOfRelatedPartyTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
  <xs:element name="ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract"/>
  <xs:element name="ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract"/>
  <xs:element name="DisclosureOfFinancialRiskManagementTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
  <xs:element name="ScheduleOfForeignCurrencyRiskAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfForeignCurrencyRiskAbstract"/>
  <xs:element name="ScheduleOfExchangeRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfExchangeRatesAbstract"/>
  <xs:element name="ScheduleOfTradeReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfTradeReceivablesAbstract"/>
  <xs:element name="ScheduleOfContractualUndiscountedCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfContractualUndiscountedCashFlowsAbstract"/>
  <xs:element name="DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract"/>
  <xs:element name="DisclosureOfCompanyDetailsExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCompanyDetailsExplanatoryAbstract"/>
  <xs:element name="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract"/>
  <xs:element name="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0"/>
  <xs:element name="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00"/>
  <xs:element name="RevenueFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RevenueFromOperatingActivitiesAbstract"/>
  <xs:element name="OtherGainsLossesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherGainsLossesNetAbstract"/>
  <xs:element name="GeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="SellingAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SellingAndMarketingExpensesAbstract"/>
  <xs:element name="TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract"/>
  <xs:element name="KeyManagementPersonnelCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_KeyManagementPersonnelCompensationAbstract"/>
  <xs:element name="ParentEntityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ParentEntityAbstract"/>
  <xs:element name="SubsidiariesOfImmuronLimitedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SubsidiariesOfImmuronLimitedAbstract"/>
  <xs:element name="DepreciationChargeOfRightOfUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DepreciationChargeOfRightOfUseAssetsAbstract"/>
  <xs:element name="OrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OrdinarySharesAbstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_AssetsAbstract0"/>
  <xs:element name="LiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LiabilitiesAbstract0"/>
  <xs:element name="AssetsAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_AssetsAbstract00"/>
  <xs:element name="LiabilitiesAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LiabilitiesAbstract00"/>
  <xs:element name="AdjustmentsForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_AdjustmentsForAbstract"/>
  <xs:element name="ChangeInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="At30June2020Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_At30June2020Abstract"/>
  <xs:element name="SharebasedPaymentsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SharebasedPaymentsExpenses"/>
  <xs:element name="IncomeFinance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_IncomeFinance"/>
  <xs:element name="CostOfFinance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_CostOfFinance"/>
  <xs:element name="FinanceCostsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_FinanceCostsNet"/>
  <xs:element name="BasicAndDilutedEarningsLossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_BasicAndDilutedEarningsLossPerShare"/>
  <xs:element name="EmployeeBenefitObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_EmployeeBenefitObligation"/>
  <xs:element name="EmployeeBenefitObligationNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_EmployeeBenefitObligationNonCurrent"/>
  <xs:element name="EquityBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_EquityBalance"/>
  <xs:element name="OtherComprehensiveIncomeLossForPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherComprehensiveIncomeLossForPeriod"/>
  <xs:element name="OptionsOrWarrantsIssuedExpensed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsOrWarrantsIssuedExpensed"/>
  <xs:element name="OptionsOrWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsOrWarrantsExercised"/>
  <xs:element name="OptionswarrantsForfeited" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionswarrantsForfeited"/>
  <xs:element name="RevaluationOfOptionIssuedInPriorPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluationOfOptionIssuedInPriorPeriod"/>
  <xs:element name="EmployeeShareSchemesValueOfEmployee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_EmployeeShareSchemesValueOfEmployee"/>
  <xs:element name="OptionsOrWarrantsForteitedLapsed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsOrWarrantsForteitedLapsed"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuedToDirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_StockIssuedDuringPeriodValueIssuedToDirectors"/>
  <xs:element name="TransferToShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferToShareCapital"/>
  <xs:element name="ChangeInAccountingPolicy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ChangeInAccountingPolicy"/>
  <xs:element name="RestatedTotalEquityAt1July2019" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_RestatedTotalEquityAt1July2019"/>
  <xs:element name="PaymentsToSuppliersForGoodsAndService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_PaymentsToSuppliersForGoodsAndService"/>
  <xs:element name="CapitalCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_CapitalCost"/>
  <xs:element name="DisclosureOfCashExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCashExplanatory"/>
  <xs:element name="ControlledEntitiesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ControlledEntitiesTextBlock"/>
  <xs:element name="DisclosureOfProvisionForSalesReturnsExplantory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfProvisionForSalesReturnsExplantory"/>
  <xs:element name="ContingentLiabilitiesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ContingentLiabilitiesTextBlock"/>
  <xs:element name="DisclosureOfCashFlowInformationExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfCompanyDetailsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfCompanyDetailsExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForBasisOfPresentation" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForBasisOfPresentation"/>
  <xs:element name="DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets"/>
  <xs:element name="DescriptionOfAccountingPolicyForEquityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory"/>
  <xs:element name="DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock"/>
  <xs:element name="DisclosureOfIncomeTaxBenefitExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfIncomeTaxBenefitExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationOfRelatedPartyExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
  <xs:element name="DisclosureOfDetailsOfEarningsPerShareExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
  <xs:element name="DetailedInformationAboutCashExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DetailedInformationAboutCashExplanatory"/>
  <xs:element name="DetailedInformationAboutTradeAndOtherReceivablesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory"/>
  <xs:element name="DetailedInformationAboutInventoriesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DetailedInformationAboutInventoriesExplanatory"/>
  <xs:element name="ScheduleOfSubsidiariesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfSubsidiariesExplanatory"/>
  <xs:element name="DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock"/>
  <xs:element name="DisclosureOfSalesReturnProvisionExplantory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfSalesReturnProvisionExplantory"/>
  <xs:element name="ScheduleOfAmountsRecognizedinBalanceSheet" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfAmountsRecognizedinBalanceSheet"/>
  <xs:element name="ScheduleOfProfitOrLossAmountsRelatedToLeases" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases"/>
  <xs:element name="DisclosureOfOrdinarySharesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfOrdinarySharesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationOtherReserve" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfDetailedInformationOtherReserve"/>
  <xs:element name="DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants"/>
  <xs:element name="DisclosuresOfProductsAndServicesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosuresOfProductsAndServicesExplanatory"/>
  <xs:element name="DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory"/>
  <xs:element name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory"/>
  <xs:element name="ScheduleOfDeemedValuationOfOptionsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfDeemedValuationOfOptionsExplanatory"/>
  <xs:element name="ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions"/>
  <xs:element name="SharebasedPaymentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SharebasedPaymentsTablesTable"/>
  <xs:element name="SharebasedPaymentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SharebasedPaymentsTablesLineItems"/>
  <xs:element name="DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory"/>
  <xs:element name="DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory"/>
  <xs:element name="DisclosureOfExchangerateTableExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfExchangerateTableExplanatory"/>
  <xs:element name="DisclosureOfTradeAndOtherReceivablesTableExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory"/>
  <xs:element name="DisclosureOfTradeAndOtherPayablesTableExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory"/>
  <xs:element name="AustralianFederalRdTaxConcessionRefund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_AustralianFederalRdTaxConcessionRefund"/>
  <xs:element name="OtherGovernmentAssistanceIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherGovernmentAssistanceIncome"/>
  <xs:element name="ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ResearchAndDevelopmentGrants"/>
  <xs:element name="OtherIncomes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherIncomes"/>
  <xs:element name="OtherIncomeFromNonOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherIncomeFromNonOperatingActivities"/>
  <xs:element name="NetForeignExchangeGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NetForeignExchangeGainLoss"/>
  <xs:element name="AccountingAndAudit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_AccountingAndAudit"/>
  <xs:element name="BadDebts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_BadDebts"/>
  <xs:element name="ConsultingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ConsultingExpenses"/>
  <xs:element name="ExpectedCreditLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExpectedCreditLosses"/>
  <xs:element name="InvestorRelationsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_InvestorRelationsExpenses"/>
  <xs:element name="LegalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LegalExpenses"/>
  <xs:element name="ListingAndShareRegistry" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ListingAndShareRegistry"/>
  <xs:element name="SuperannuationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SuperannuationExpenses"/>
  <xs:element name="ResearchAndDevelopmentConsultingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ResearchAndDevelopmentConsultingExpenses"/>
  <xs:element name="MarketingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_MarketingExpenses"/>
  <xs:element name="TaxEffectofResearchAndDevelopmentTaxIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectofResearchAndDevelopmentTaxIncentive"/>
  <xs:element name="TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive"/>
  <xs:element name="TaxEffectOfShareBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectOfShareBasedPayments"/>
  <xs:element name="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses"/>
  <xs:element name="TaxEffectOfTaxPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TaxEffectOfTaxPayable"/>
  <xs:element name="DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss"/>
  <xs:element name="KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities"/>
  <xs:element name="WeightedAverageNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageNumberOfShares"/>
  <xs:element name="CashAtBankAndInHand" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_CashAtBankAndInHand"/>
  <xs:element name="LossOnAllowanceTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LossOnAllowanceTradeReceivables"/>
  <xs:element name="InventoriesDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_InventoriesDomain"/>
  <xs:element name="InventoriesDetailsScheduleofinventoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_InventoriesDetailsScheduleofinventoriesTable"/>
  <xs:element name="InventoriesDetailsScheduleofinventoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_InventoriesDetailsScheduleofinventoriesLineItems"/>
  <xs:element name="InventoriesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_InventoriesNet"/>
  <xs:element name="ControlledEntitiesDetailsScheduleofsubsidiariesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable"/>
  <xs:element name="ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems"/>
  <xs:element name="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
  <xs:element name="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems"/>
  <xs:element name="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable"/>
  <xs:element name="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems"/>
  <xs:element name="AmountOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_AmountOfOrdinaryShares"/>
  <xs:element name="OrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_OrdinaryShare"/>
  <xs:element name="IssueOfEquityToOrdinaryvalue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfEquityToOrdinaryvalue"/>
  <xs:element name="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1"/>
  <xs:element name="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1"/>
  <xs:element name="ProceedsFromIssuedSharesAtADSPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ProceedsFromIssuedSharesAtADSPublicOffering"/>
  <xs:element name="ProceedsFromIssuedAtADSPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ProceedsFromIssuedAtADSPublicOffering"/>
  <xs:element name="StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised"/>
  <xs:element name="StockIssuedDuringValueReclassifyToStockOptionsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised"/>
  <xs:element name="TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares"/>
  <xs:element name="TransactionCostsArisingOnRepresentativeWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued"/>
  <xs:element name="BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares"/>
  <xs:element name="BusinessAcquisitionCostOfTransactionCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_BusinessAcquisitionCostOfTransactionCost"/>
  <xs:element name="IssuePursuantToAdsPublicOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssuePursuantToAdsPublicOfferingShares"/>
  <xs:element name="IssuePursuantToAdsPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssuePursuantToAdsPublicOffering"/>
  <xs:element name="IssueInLieuOfPaymentForServicesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueInLieuOfPaymentForServicesShares"/>
  <xs:element name="IssueInLieuOfPaymentForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueInLieuOfPaymentForServices"/>
  <xs:element name="ExerciseOfNasdaqWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrantsShares"/>
  <xs:element name="ExerciseOfNasdaqWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrants"/>
  <xs:element name="ExerciseOfRepresentativeWarrantShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrantShares"/>
  <xs:element name="ExerciseOfRepresentativeWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrant"/>
  <xs:element name="ExerciseOfRepresentativeWarrants1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrants1"/>
  <xs:element name="ExerciseOfRepresentativeWarrant1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrant1"/>
  <xs:element name="IssueAtUS047PursuantToADSPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS047PursuantToADSPublicOffering"/>
  <xs:element name="IssueAtUS047PursuantToADSPublicOffering1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS047PursuantToADSPublicOffering1"/>
  <xs:element name="IssueAt050OnExerciseOfESOPUnlistedOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAt050OnExerciseOfESOPUnlistedOption"/>
  <xs:element name="IssueAt050OnExerciseOfESOPUnlistedOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAt050OnExerciseOfESOPUnlistedOptions"/>
  <xs:element name="IssueAtUS025OnExerciseOfNASDAQWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS025OnExerciseOfNASDAQWarrants"/>
  <xs:element name="IssueAtUS025OnExerciseOfNASDAQWarrants1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1"/>
  <xs:element name="IssueAtUS025OnExerciseOfNASDAQWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS025OnExerciseOfNASDAQWarrant"/>
  <xs:element name="IssueAtUS025OnExerciseOfNASDAQWarrant1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1"/>
  <xs:element name="TransferFromReservesOnExerciseOfESOPUnlistedOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions"/>
  <xs:element name="TransferFromReservesOnExerciseOfESOPUnlistedOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption"/>
  <xs:element name="TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729"/>
  <xs:element name="TransferFromReservesOnExerciseOfNASDAQWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnExerciseOfNASDAQWarrants"/>
  <xs:element name="IssueAtA008InLieuOfCashForServicesRendered20201113" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtA008InLieuOfCashForServicesRendered20201113"/>
  <xs:element name="IssueAtA008InLieuOfCashForServicesRendered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueAtA008InLieuOfCashForServicesRendered"/>
  <xs:element name="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209"/>
  <xs:element name="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions"/>
  <xs:element name="OtherReservesDetailsScheduleofotherreservesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_OtherReservesDetailsScheduleofotherreservesTable"/>
  <xs:element name="OtherReservesDetailsScheduleofotherreservesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherReservesDetailsScheduleofotherreservesLineItems"/>
  <xs:element name="CurrencyTranslationDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_CurrencyTranslationDifferences"/>
  <xs:element name="TransactionsWithOwnersInTheirCapacityAsOwners" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransactionsWithOwnersInTheirCapacityAsOwners"/>
  <xs:element name="OptionsAndWarrantsIssuedexpensed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsAndWarrantsIssuedexpensed"/>
  <xs:element name="OptionsAndWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsAndWarrantsExercised"/>
  <xs:element name="OptionsAndWarrantsLapsed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsAndWarrantsLapsed"/>
  <xs:element name="SharebasedPaymentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SharebasedPaymentExpenses"/>
  <xs:element name="RevaluationOfOptionsIssuedInPriorPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
  <xs:element name="TransferToShareCapitalinDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TransferToShareCapitalinDollars"/>
  <xs:element name="OptionsAndWarrantsForfeited" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsAndWarrantsForfeited"/>
  <xs:element name="ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
  <xs:element name="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption"/>
  <xs:element name="ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption"/>
  <xs:element name="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne"/>
  <xs:element name="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne"/>
  <xs:element name="NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
  <xs:element name="ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
  <xs:element name="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
  <xs:element name="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
  <xs:element name="NumberOfSharesIssueLapseOfUnlistedOptionOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne"/>
  <xs:element name="NumberOfValueIssueLapseOfUnlistedOptionOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfValueIssueLapseOfUnlistedOptionOne"/>
  <xs:element name="NumberOfSharesIssueLapseOfUnlistedOptionTwo" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo"/>
  <xs:element name="NumberOfValueIssueLapseOfUnlistedOptionTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo"/>
  <xs:element name="NumberOfSharesIssueLapseOfUnlistedOptionThree" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree"/>
  <xs:element name="NumberOfValueIssueLapseOfUnlistedOptionThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfValueIssueLapseOfUnlistedOptionThree"/>
  <xs:element name="NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital"/>
  <xs:element name="NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital"/>
  <xs:element name="NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
  <xs:element name="NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
  <xs:element name="IssueOfRepresentativeWarrantsSharesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsSharesOne"/>
  <xs:element name="IssueOfRepresentativeWarrantsOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsOne"/>
  <xs:element name="RevaluationOfOptionsIssuedInPriorPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluationOfOptionsIssuedInPriorPeriodShares"/>
  <xs:element name="IssueOfRepresentativeWarrantsTwoShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsTwoShares"/>
  <xs:element name="IssueOfRepresentativeWarrantsTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsTwo"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFiveShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFive"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFiveFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne"/>
  <xs:element name="LapseOfUnexercisedOptionsAtZeroPointFiveOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne"/>
  <xs:element name="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares"/>
  <xs:element name="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions"/>
  <xs:element name="ExerciseOfRepresentativeWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrantsShares"/>
  <xs:element name="ExerciseOfRepresentativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrants"/>
  <xs:element name="ExerciseOfRepresentativeWarrantsSharesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfRepresentativeWarrantsSharesOne"/>
  <xs:element name="ExerciseOfESOPUnlistedOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfESOPUnlistedOptions"/>
  <xs:element name="ExerciseOfESOPUnlistedOptionsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfESOPUnlistedOptionsValue"/>
  <xs:element name="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne"/>
  <xs:element name="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne"/>
  <xs:element name="LapseOfUnexercisedOptionsOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsOne"/>
  <xs:element name="LapseOfUnexercisedOptionsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LapseOfUnexercisedOptionsValue"/>
  <xs:element name="IssueOfRepresentativeWarrantsThreeShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsThreeShares"/>
  <xs:element name="IssueOfRepresentativeWarrantsThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_IssueOfRepresentativeWarrantsThree"/>
  <xs:element name="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree"/>
  <xs:element name="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree"/>
  <xs:element name="CashlessExerciseOfESOPUnlistedOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CashlessExerciseOfESOPUnlistedOptions"/>
  <xs:element name="CashlessExerciseOfESOPUnlistedOptionsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_CashlessExerciseOfESOPUnlistedOptionsValue"/>
  <xs:element name="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital"/>
  <xs:element name="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue"/>
  <xs:element name="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable"/>
  <xs:element name="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems"/>
  <xs:element name="HyperimmuneProductsRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_HyperimmuneProductsRevenue"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_GeneralAndAdministrativeExpenses"/>
  <xs:element name="SellingAndMarketingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SellingAndMarketingExpenses"/>
  <xs:element name="SegmentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentAssets"/>
  <xs:element name="SegmentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentLiabilities"/>
  <xs:element name="MajorProductLinesDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_MajorProductLinesDomain"/>
  <xs:element name="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable"/>
  <xs:element name="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems"/>
  <xs:element name="RevenueFromExternalCustomers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevenueFromExternalCustomers"/>
  <xs:element name="SegmentRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentRevenue"/>
  <xs:element name="SegmentReportingDetailsScheduleofmajorcustomersTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SegmentReportingDetailsScheduleofmajorcustomersTable"/>
  <xs:element name="SegmentReportingDetailsScheduleofmajorcustomersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems"/>
  <xs:element name="RevenueFormContractWithCustomer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevenueFormContractWithCustomer"/>
  <xs:element name="AdjustmentsForDistributionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_AdjustmentsForDistributionCosts"/>
  <xs:element name="LeaveProvisionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LeaveProvisionExpense"/>
  <xs:element name="ShareBasedPaymentsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareBasedPaymentsExpense"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1"/>
  <xs:element name="NumberOfOutstandingShareOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfOutstandingShareOption"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1"/>
  <xs:element name="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1"/>
  <xs:element name="NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1"/>
  <xs:element name="NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1"/>
  <xs:element name="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
  <xs:element name="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
  <xs:element name="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
  <xs:element name="ExercisePrice" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExercisePrice"/>
  <xs:element name="ShareOptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareOptionsOutstanding"/>
  <xs:element name="ShareOptionsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareOptionsPerShare"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate"/>
  <xs:element name="ExercisePriceShareOptionsGranted1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExercisePriceShareOptionsGranted1"/>
  <xs:element name="NumberOfInstrumentOtherEquityInstrumentGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfInstrumentOtherEquityInstrumentGranted"/>
  <xs:element name="WeightedAverageSharePriceShareOptionsGranted1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WeightedAverageSharePriceShareOptionsGranted1"/>
  <xs:element name="ValuePerShareOptionsGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ValuePerShareOptionsGranted"/>
  <xs:element name="OptionsIssuedUnderESOP" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsIssuedUnderESOP"/>
  <xs:element name="SharebasedPaymentsToDirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SharebasedPaymentsToDirectors"/>
  <xs:element name="TotalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_TotalExpenses"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems"/>
  <xs:element name="OtherTransactionsWithKeyManagementRelatedPartyTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems"/>
  <xs:element name="ImpactOnLossForPeriods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ImpactOnLossForPeriods"/>
  <xs:element name="ImpactOnOtherComponentOfEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ImpactOnOtherComponentOfEquity"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems"/>
  <xs:element name="GrossCarryingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_GrossCarryingAmount"/>
  <xs:element name="LossAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_LossAllowance"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable"/>
  <xs:element name="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems"/>
  <xs:element name="TradeAndOtherPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_TradeAndOtherPayable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="RepresentativesWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_RepresentativesWarrants"/>
  <xs:element name="ShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ShareCapital"/>
  <xs:element name="AssistancePackages" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_AssistancePackages"/>
  <xs:element name="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod"/>
  <xs:element name="NonCurrentRawMaterials" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_NonCurrentRawMaterials"/>
  <xs:element name="RAndDTaxConcessionRefund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_RAndDTaxConcessionRefund"/>
  <xs:element name="AdditionalRAndDTaxReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_AdditionalRAndDTaxReceived"/>
  <xs:element name="OtherIncomeOfResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherIncomeOfResearchAndDevelopment"/>
  <xs:element name="AdditionalOtherIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_AdditionalOtherIncome"/>
  <xs:element name="GovernmentAssistancePackages" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_GovernmentAssistancePackages"/>
  <xs:element name="ResearchAndDevelopmentsGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_ResearchAndDevelopmentsGrants"/>
  <xs:element name="PaymentForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_PaymentForServices"/>
  <xs:element name="IssuanceOfOrdinarySharesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IssuanceOfOrdinarySharesDescription"/>
  <xs:element name="TitlesOfIndividualDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TitlesOfIndividualDomain"/>
  <xs:element name="OtherReservesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_OtherReservesDetailsTable"/>
  <xs:element name="OtherReservesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherReservesDetailsLineItems"/>
  <xs:element name="OtherReserveMaturityDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherReserveMaturityDateDescription"/>
  <xs:element name="NumberOfSharesUnlistedOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSharesUnlistedOption"/>
  <xs:element name="UnlistedOptionExercisable" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_UnlistedOptionExercisable"/>
  <xs:element name="ESOPOptionsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ESOPOptionsIssued"/>
  <xs:element name="OptionsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionsGranted"/>
  <xs:element name="RevaluedAtGrantDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluedAtGrantDate"/>
  <xs:element name="RevaluationOfShareholdersApprovedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluationOfShareholdersApprovedValue"/>
  <xs:element name="RevaluationFinancialsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="imc_RevaluationFinancialsAmount"/>
  <xs:element name="ExpenseOfSharesOwed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_ExpenseOfSharesOwed"/>
  <xs:element name="NumberOfSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_NumberOfSegment"/>
  <xs:element name="PercentageOfEntityRevenue" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_PercentageOfEntityRevenue"/>
  <xs:element name="OptionGrantedDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OptionGrantedDescription"/>
  <xs:element name="SharesIssuedToDirectorsForTheDirectorFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_SharesIssuedToDirectorsForTheDirectorFees"/>
  <xs:element name="TypesOfArrangementsDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TypesOfArrangementsDomain"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="imc_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="LeaseRenewed" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_LeaseRenewed"/>
  <xs:element name="WarehousingDistributionAndInvoicingServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_WarehousingDistributionAndInvoicingServices"/>
  <xs:element name="SharesIssuedPricePerShare1" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="imc_SharesIssuedPricePerShare1"/>
  <xs:element name="WarehousingDistributionAndServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="imc_WarehousingDistributionAndServicesFees"/>
  <xs:element name="OrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OrdinarySharesIssued"/>
  <xs:element name="PercentageOfForeignExchangeRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_PercentageOfForeignExchangeRates"/>
  <xs:element name="InventoriesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="imc_InventoriesAxis"/>
  <xs:element name="MajorProductLinesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="imc_MajorProductLinesAxis"/>
  <xs:element name="TitlesOfIndividualAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="imc_TitlesOfIndividualAxis"/>
  <xs:element name="TypesOfArrangementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="imc_TypesOfArrangementsAxis"/>
  <xs:element name="AccumulatedLossesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_AccumulatedLossesMember"/>
  <xs:element name="AnadisEPSPtyLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_AnadisEPSPtyLtdMember"/>
  <xs:element name="CarryingAssetsLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CarryingAssetsLiabilitiesMember"/>
  <xs:element name="ContractualCashFlowsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ContractualCashFlowsMember"/>
  <xs:element name="CustomerAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerAMember"/>
  <xs:element name="CustomerBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerBMember"/>
  <xs:element name="CustomerCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerCMember"/>
  <xs:element name="CustomerDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerDMember"/>
  <xs:element name="CustomerEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerEMember"/>
  <xs:element name="CustomerFMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerFMember"/>
  <xs:element name="CustomerGMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerGMember"/>
  <xs:element name="CustomerHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerHMember"/>
  <xs:element name="CustomerIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_CustomerIMember"/>
  <xs:element name="DrGarySJacobMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DrGarySJacobMember"/>
  <xs:element name="DrJerryKanellosMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DrJerryKanellosMember"/>
  <xs:element name="EmployeeStockOption1Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_EmployeeStockOption1Member"/>
  <xs:element name="ExercisePriceOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExercisePriceOneMember"/>
  <xs:element name="ExercisePriceSixteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExercisePriceSixteenMember"/>
  <xs:element name="ExercisePriceTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ExercisePriceTwoMember"/>
  <xs:element name="FinishedGoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_FinishedGoodsMember"/>
  <xs:element name="ForeignCurrencyTranslationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ForeignCurrencyTranslationMember"/>
  <xs:element name="GrandlodgeCapitalPtyLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrandlodgeCapitalPtyLtdMember"/>
  <xs:element name="GrantDateEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateEightMember"/>
  <xs:element name="GrantDateElevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateElevenMember"/>
  <xs:element name="GrantDateFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateFiveMember"/>
  <xs:element name="GrantDateFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateFourMember"/>
  <xs:element name="GrantDateNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateNineMember"/>
  <xs:element name="GrantDateOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateOneMember"/>
  <xs:element name="GrantDateSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateSevenMember"/>
  <xs:element name="GrantDateSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateSixMember"/>
  <xs:element name="GrantDateTenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateTenMember"/>
  <xs:element name="GrantDateThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateThreeMember"/>
  <xs:element name="GrantDateTwelveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateTwelveMember"/>
  <xs:element name="GrantDateTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_GrantDateTwoMember"/>
  <xs:element name="IMCCanadaLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_IMCCanadaLtdMember"/>
  <xs:element name="ImmuronIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ImmuronIncMember"/>
  <xs:element name="ImmuronLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ImmuronLimitedMember"/>
  <xs:element name="MrRichardJBermanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_MrRichardJBermanMember"/>
  <xs:element name="OtherCountriesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherCountriesMember"/>
  <xs:element name="OtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_OtherMember"/>
  <xs:element name="PlantAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_PlantAndEquipmentMember"/>
  <xs:element name="ProtectynMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ProtectynMember"/>
  <xs:element name="RawMaterialsAndStoresMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RawMaterialsAndStoresMember"/>
  <xs:element name="RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember"/>
  <xs:element name="ReservesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ReservesMember"/>
  <xs:element name="SegmentHyperImmuneProductsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentHyperImmuneProductsMember"/>
  <xs:element name="SegmentResearchAndDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_SegmentResearchAndDevelopmentMember"/>
  <xs:element name="ServicesRenderedByGrandlodgeCapitalPtyLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember"/>
  <xs:element name="ShortTermFundingAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_ShortTermFundingAgreementsMember"/>
  <xs:element name="TravelanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_TravelanMember"/>
  <xs:element name="WattleLaboratoriesPtyLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WattleLaboratoriesPtyLtdMember"/>
  <xs:element name="WorkInProgressMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_WorkInProgressMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="imc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>imc-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:37 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedIncomeStatement" roleURI="http://immuron.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedBalanceSheet" roleURI="http://immuron.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedCashFlow" roleURI="http://immuron.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofrevenueandotherincomeTable" roleURI="http://immuron.com/role/ScheduleofrevenueandotherincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofexpensesTable" roleURI="http://immuron.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofkeymanagementpersonnelcompensationTable" roleURI="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofbalancesundercashTable" roleURI="http://immuron.com/role/ScheduleofbalancesundercashTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherreceivablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherpayablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherpayablesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherGainsLosses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="imc_SharebasedPaymentsExpenses" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="imc_FinanceCostsNet" xlink:href="imc-20210630.xsd#imc_FinanceCostsNet"/>
    <loc xlink:type="locator" xlink:label="imc_IncomeFinance" xlink:href="imc-20210630.xsd#imc_IncomeFinance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_FinanceCostsNet" xlink:to="imc_IncomeFinance" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_CostOfFinance" xlink:href="imc-20210630.xsd#imc_CostOfFinance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_FinanceCostsNet" xlink:to="imc_CostOfFinance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="imc_FinanceCostsNet" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InventoriesTotal" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligation" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="imc_EmployeeBenefitObligation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligationNonCurrent" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligationNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="imc_EmployeeBenefitObligationNonCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_Assets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_Liabilities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_PaymentsToSuppliersForGoodsAndService" xlink:href="imc-20210630.xsd#imc_PaymentsToSuppliersForGoodsAndService"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="imc_PaymentsToSuppliersForGoodsAndService" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGweRCEGdbvJGmBCZTNYpT/D5JokzMbqRrw=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_CapitalCost" xlink:href="imc-20210630.xsd#imc_CapitalCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="imc_CapitalCost" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofrevenueandotherincomeTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomeFromNonOperatingActivities" xlink:href="imc-20210630.xsd#imc_OtherIncomeFromNonOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="imc_AustralianFederalRdTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_AustralianFederalRdTaxConcessionRefund"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_AustralianFederalRdTaxConcessionRefund" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_OtherGovernmentAssistanceIncome" xlink:href="imc-20210630.xsd#imc_OtherGovernmentAssistanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_OtherGovernmentAssistanceIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_ResearchAndDevelopmentGrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomes" xlink:href="imc-20210630.xsd#imc_OtherIncomes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_OtherIncomes" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <loc xlink:type="locator" xlink:label="imc_NetForeignExchangeGainLoss" xlink:href="imc-20210630.xsd#imc_NetForeignExchangeGainLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="imc_NetForeignExchangeGainLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_ImpairmentLoss" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="imc_AccountingAndAudit" xlink:href="imc-20210630.xsd#imc_AccountingAndAudit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_AccountingAndAudit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_BadDebts" xlink:href="imc-20210630.xsd#imc_BadDebts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_BadDebts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_ConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ConsultingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_ConsultingExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_OtherEmployeeExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_ExpectedCreditLosses" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_InsuranceExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_InvestorRelationsExpenses" xlink:href="imc-20210630.xsd#imc_InvestorRelationsExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_InvestorRelationsExpenses" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_LegalExpenses" xlink:href="imc-20210630.xsd#imc_LegalExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_LegalExpenses" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_ListingAndShareRegistry" xlink:href="imc-20210630.xsd#imc_ListingAndShareRegistry"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_ListingAndShareRegistry" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UtilitiesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UtilitiesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_UtilitiesExpense" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_SuperannuationExpenses" xlink:href="imc-20210630.xsd#imc_SuperannuationExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="imc_SuperannuationExpenses" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_TravelExpense" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_OtherExpenseByNature" order="14" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentConsultingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="imc_ResearchAndDevelopmentConsultingExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyDevelopmentAndProjectManagementExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_MarketingExpenses" xlink:href="imc-20210630.xsd#imc_MarketingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="imc_MarketingExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DistributionCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DistributionCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_DistributionCosts" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofbalancesundercashTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <loc xlink:type="locator" xlink:label="imc_CashAtBankAndInHand" xlink:href="imc-20210630.xsd#imc_CashAtBankAndInHand"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Cash" xlink:to="imc_CashAtBankAndInHand" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_TradeReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="imc_LossOnAllowanceTradeReceivables" xlink:href="imc-20210630.xsd#imc_LossOnAllowanceTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="imc_LossOnAllowanceTradeReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_AccruedIncomeOtherThanContractAssets" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_Accruals" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_OtherPayables" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>imc-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:37 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedIncomeStatement" roleURI="http://immuron.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedBalanceSheet" roleURI="http://immuron.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareholdersEquityType2or3" roleURI="http://immuron.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedCashFlow" roleURI="http://immuron.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immuron.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Revenueandotherincome" roleURI="http://immuron.com/role/Revenueandotherincome"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Expenses" roleURI="http://immuron.com/role/Expenses"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_IncomeTaxBenefit" roleURI="http://immuron.com/role/IncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_KeyManagementPersonnelCompensation" roleURI="http://immuron.com/role/KeyManagementPersonnelCompensation"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LossperShare" roleURI="http://immuron.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Cash" roleURI="http://immuron.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherReceivables" roleURI="http://immuron.com/role/TradeandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Inventories" roleURI="http://immuron.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ControlledEntities" roleURI="http://immuron.com/role/ControlledEntities"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherPayables" roleURI="http://immuron.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ProvisionforSalesReturns" roleURI="http://immuron.com/role/ProvisionforSalesReturns"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ContingentliabilitiesandCommitments" roleURI="http://immuron.com/role/ContingentliabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Leases" roleURI="http://immuron.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapital" roleURI="http://immuron.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReserves" roleURI="http://immuron.com/role/OtherReserves"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReporting" roleURI="http://immuron.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashFlowInformation" roleURI="http://immuron.com/role/CashFlowInformation"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPayments" roleURI="http://immuron.com/role/SharebasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactions" roleURI="http://immuron.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPolicies" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_EventsoccurringaftertheReportingDate" roleURI="http://immuron.com/role/EventsoccurringaftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CompanyDetails" roleURI="http://immuron.com/role/CompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_AccountingPoliciesByPolicy" roleURI="http://immuron.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RevenueandotherincomeTables" roleURI="http://immuron.com/role/RevenueandotherincomeTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ExpensesTables" roleURI="http://immuron.com/role/ExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_IncomeTaxBenefitTables" roleURI="http://immuron.com/role/IncomeTaxBenefitTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_KeyManagementPersonnelCompensationTables" roleURI="http://immuron.com/role/KeyManagementPersonnelCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LossperShareTables" roleURI="http://immuron.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashTables" roleURI="http://immuron.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherReceivablesTables" roleURI="http://immuron.com/role/TradeandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_InventoriesTables" roleURI="http://immuron.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ControlledEntitiesTables" roleURI="http://immuron.com/role/ControlledEntitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherPayablesTables" roleURI="http://immuron.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ProvisionforSalesReturnsTables" roleURI="http://immuron.com/role/ProvisionforSalesReturnsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LeasesTables" roleURI="http://immuron.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapitalTables" roleURI="http://immuron.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReservesTables" roleURI="http://immuron.com/role/OtherReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReportingTables" roleURI="http://immuron.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashFlowInformationTables" roleURI="http://immuron.com/role/CashFlowInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPaymentsTables" roleURI="http://immuron.com/role/SharebasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactionsTables" roleURI="http://immuron.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPoliciesTables" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofrevenueandotherincomeTable" roleURI="http://immuron.com/role/ScheduleofrevenueandotherincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofexpensesTable" roleURI="http://immuron.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable" roleURI="http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofincometaxbenefitTable" roleURI="http://immuron.com/role/ScheduleofincometaxbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofkeymanagementpersonnelcompensationTable" roleURI="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofbasicanddilutedlosspershareTable" roleURI="http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofbalancesundercashTable" roleURI="http://immuron.com/role/ScheduleofbalancesundercashTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherreceivablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinventoriesTable" roleURI="http://immuron.com/role/ScheduleofinventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsubsidiariesTable" roleURI="http://immuron.com/role/ScheduleofsubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherpayablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofprovisionforsalesreturnsTable" roleURI="http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofamountsrelatingtoleasesinbalancesheetTable" roleURI="http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofprofitorlossamountsrelatingtoleasesTable" roleURI="http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsharecapitalTable" roleURI="http://immuron.com/role/ScheduleofsharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofordinarysharesTable" roleURI="http://immuron.com/role/ScheduleofordinarysharesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofotherreservesTable" roleURI="http://immuron.com/role/ScheduleofotherreservesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmovementsinoptionsandwarrantsTable" roleURI="http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsegmentinformationforthereportablesegmentsTable" roleURI="http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinformationongeographicalregionsTable" roleURI="http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmajorcustomersTable" roleURI="http://immuron.com/role/ScheduleofmajorcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable" roleURI="http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable" roleURI="http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofgrantedvaluationofoptionsTable" roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofgrantedvaluationofoptionsTable0" roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable" roleURI="http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinformationaboutotherrelatedpartytransactionsTable" roleURI="http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable" roleURI="http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofforeigncurrencyriskTable" roleURI="http://immuron.com/role/ScheduleofforeigncurrencyriskTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofexchangeratesTable" roleURI="http://immuron.com/role/ScheduleofexchangeratesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradereceivablesTable" roleURI="http://immuron.com/role/ScheduleoftradereceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofcontractualundiscountedcashflowsTable" roleURI="http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RevenueandotherincomeDetails" roleURI="http://immuron.com/role/RevenueandotherincomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ContingentliabilitiesandCommitmentsDetails" roleURI="http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LeasesDetails" roleURI="http://immuron.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapitalDetails" roleURI="http://immuron.com/role/ShareCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReservesDetails" roleURI="http://immuron.com/role/OtherReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReportingDetails" roleURI="http://immuron.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPaymentsDetails" roleURI="http://immuron.com/role/SharebasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactionsDetails" roleURI="http://immuron.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPoliciesDetails" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#DocumentAndEntityInformation" roleURI="http://immuron.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherGainsLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="imc_SharebasedPaymentsExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IncomeFinance" xlink:href="imc-20210630.xsd#imc_IncomeFinance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="imc_IncomeFinance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CostOfFinance" xlink:href="imc-20210630.xsd#imc_CostOfFinance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="imc_CostOfFinance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_FinanceCostsNet" xlink:href="imc-20210630.xsd#imc_FinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_CostOfFinance" xlink:to="imc_FinanceCostsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_CostOfFinance" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_CostOfFinance" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_CostOfFinance" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ComprehensiveIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_BasicAndDilutedEarningsLossPerShare" xlink:href="imc-20210630.xsd#imc_BasicAndDilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="imc_BasicAndDilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InventoriesTotal" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligation" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="imc_EmployeeBenefitObligation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligationNonCurrent" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligationNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="imc_EmployeeBenefitObligationNonCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Liabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NetAssetsLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ReservesMember" xlink:href="imc-20210630.xsd#imc_ReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="imc_ReservesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AccumulatedLossesMember" xlink:href="imc-20210630.xsd#imc_AccumulatedLossesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="imc_AccumulatedLossesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_EquityBalance" xlink:href="imc-20210630.xsd#imc_EquityBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="imc_EquityBalance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherComprehensiveIncomeLossForPeriod" xlink:href="imc-20210630.xsd#imc_OtherComprehensiveIncomeLossForPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="imc_OtherComprehensiveIncomeLossForPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsIssuedExpensed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsIssuedExpensed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_OptionsOrWarrantsIssuedExpensed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_OptionsOrWarrantsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsForteitedLapsed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsForteitedLapsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_OptionsOrWarrantsForteitedLapsed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringPeriodValueIssuedToDirectors" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringPeriodValueIssuedToDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_StockIssuedDuringPeriodValueIssuedToDirectors" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferToShareCapital" xlink:href="imc-20210630.xsd#imc_TransferToShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_TransferToShareCapital" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionswarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionswarrantsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_OptionswarrantsForfeited" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionIssuedInPriorPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_RevaluationOfOptionIssuedInPriorPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeShareSchemesValueOfEmployee" xlink:href="imc-20210630.xsd#imc_EmployeeShareSchemesValueOfEmployee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_EmployeeShareSchemesValueOfEmployee" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ChangeInAccountingPolicy" xlink:href="imc-20210630.xsd#imc_ChangeInAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="imc_ChangeInAccountingPolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RestatedTotalEquityAt1July2019" xlink:href="imc-20210630.xsd#imc_RestatedTotalEquityAt1July2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="imc_RestatedTotalEquityAt1July2019" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_PaymentsToSuppliersForGoodsAndService" xlink:href="imc-20210630.xsd#imc_PaymentsToSuppliersForGoodsAndService"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="imc_PaymentsToSuppliersForGoodsAndService" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CapitalCost" xlink:href="imc-20210630.xsd#imc_CapitalCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="imc_CapitalCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/Revenueandotherincome">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/Expenses">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/IncomeTaxBenefit">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/KeyManagementPersonnelCompensation">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/Cash">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfCashExplanatoryAbstract" xlink:to="imc_DisclosureOfCashExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherReceivables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInventoriesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ControlledEntities">
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesAbstract" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ControlledEntitiesAbstract" xlink:to="imc_ControlledEntitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherPayables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ProvisionforSalesReturns">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:to="imc_DisclosureOfProvisionForSalesReturnsExplantory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ContingentliabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="imc_ContingentLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_ContingentLiabilitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ContingentLiabilitiesAbstract" xlink:to="imc_ContingentLiabilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/Leases">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReserves">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/CashFlowInformation">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:to="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPayments">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/EventsoccurringaftertheReportingDate">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/CompanyDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCompanyDetailsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:to="imc_DisclosureOfCompanyDetailsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForBasisOfPresentation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/RevenueandotherincomeTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ExpensesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/IncomeTaxBenefitTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfIncomeTaxBenefitExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxBenefitExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="imc_DisclosureOfIncomeTaxBenefitExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/KeyManagementPersonnelCompensationTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:to="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:to="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutCashExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutCashExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfCashExplanatoryAbstract" xlink:to="imc_DetailedInformationAboutCashExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:to="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInventoriesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutInventoriesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:to="imc_DetailedInformationAboutInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ControlledEntitiesTables">
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesAbstract" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfSubsidiariesExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfSubsidiariesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ControlledEntitiesAbstract" xlink:to="imc_ScheduleOfSubsidiariesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ProvisionforSalesReturnsTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfSalesReturnProvisionExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfSalesReturnProvisionExplantory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:to="imc_DisclosureOfSalesReturnProvisionExplantory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfAmountsRecognizedinBalanceSheet" xlink:href="imc-20210630.xsd#imc_ScheduleOfAmountsRecognizedinBalanceSheet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="imc_ScheduleOfAmountsRecognizedinBalanceSheet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases" xlink:href="imc-20210630.xsd#imc_ScheduleOfProfitOrLossAmountsRelatedToLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfOrdinarySharesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfOrdinarySharesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="imc_DisclosureOfOrdinarySharesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReservesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationOtherReserve" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOtherReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="imc_DisclosureOfDetailedInformationOtherReserve" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosuresOfProductsAndServicesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosuresOfProductsAndServicesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="imc_DisclosuresOfProductsAndServicesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/CashFlowInformationTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:to="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsTablesLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsTablesTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SharebasedPaymentsTablesLineItems" xlink:to="imc_SharebasedPaymentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SharebasedPaymentsTablesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeStockOption1Member" xlink:href="imc-20210630.xsd#imc_EmployeeStockOption1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="imc_EmployeeStockOption1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsTablesLineItems" xlink:to="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfDeemedValuationOfOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsTablesLineItems" xlink:to="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsTablesLineItems" xlink:to="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfExchangerateTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfExchangerateTableExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_DisclosureOfExchangerateTableExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTableExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofrevenueandotherincomeTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfRevenueAndOtherIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFromOperatingActivitiesAbstract" xlink:href="imc-20210630.xsd#imc_RevenueFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="imc_RevenueFromOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevenueFromOperatingActivitiesAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AustralianFederalRdTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_AustralianFederalRdTaxConcessionRefund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="imc_AustralianFederalRdTaxConcessionRefund" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherGovernmentAssistanceIncome" xlink:href="imc-20210630.xsd#imc_OtherGovernmentAssistanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="imc_OtherGovernmentAssistanceIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="imc_ResearchAndDevelopmentGrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomes" xlink:href="imc-20210630.xsd#imc_OtherIncomes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="imc_OtherIncomes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomeFromNonOperatingActivities" xlink:href="imc-20210630.xsd#imc_OtherIncomeFromNonOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="imc_OtherIncomeFromNonOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherGainsLossesNetAbstract" xlink:href="imc-20210630.xsd#imc_OtherGainsLossesNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="imc_OtherGainsLossesNetAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NetForeignExchangeGainLoss" xlink:href="imc-20210630.xsd#imc_NetForeignExchangeGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherGainsLossesNetAbstract" xlink:to="imc_NetForeignExchangeGainLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherGainsLossesNetAbstract" xlink:to="ifrs-full_ImpairmentLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_GeneralAndAdministrativeExpensesAbstract" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfExpensesAbstract" xlink:to="imc_GeneralAndAdministrativeExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AccountingAndAudit" xlink:href="imc-20210630.xsd#imc_AccountingAndAudit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_AccountingAndAudit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_BadDebts" xlink:href="imc-20210630.xsd#imc_BadDebts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_BadDebts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ConsultingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_ConsultingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_OtherEmployeeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_ExpectedCreditLosses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_InsuranceExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_InvestorRelationsExpenses" xlink:href="imc-20210630.xsd#imc_InvestorRelationsExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_InvestorRelationsExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LegalExpenses" xlink:href="imc-20210630.xsd#imc_LegalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_LegalExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ListingAndShareRegistry" xlink:href="imc-20210630.xsd#imc_ListingAndShareRegistry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_ListingAndShareRegistry" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UtilitiesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UtilitiesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_UtilitiesExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SuperannuationExpenses" xlink:href="imc-20210630.xsd#imc_SuperannuationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_SuperannuationExpenses" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_TravelExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfExpensesAbstract" xlink:to="imc_ResearchAndDevelopmentExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentConsultingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ResearchAndDevelopmentExpensesAbstract" xlink:to="imc_ResearchAndDevelopmentConsultingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyDevelopmentAndProjectManagementExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SellingAndMarketingExpensesAbstract" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfExpensesAbstract" xlink:to="imc_SellingAndMarketingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_SellingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_MarketingExpenses" xlink:href="imc-20210630.xsd#imc_MarketingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="imc_MarketingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DistributionCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DistributionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_DistributionCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofincometaxbenefitTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfIncomeTaxBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectofResearchAndDevelopmentTaxIncentive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfShareBasedPayments" xlink:href="imc-20210630.xsd#imc_TaxEffectOfShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_TaxEffectOfShareBasedPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" xlink:href="imc-20210630.xsd#imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfTaxPayable" xlink:href="imc-20210630.xsd#imc_TaxEffectOfTaxPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_TaxEffectOfTaxPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:href="imc-20210630.xsd#imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfKeyManagementPersonnelCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_KeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:to="imc_KeyManagementPersonnelCompensationAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBasicAndDilutedLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_BasicAndDilutedEarningsLossPerShare" xlink:href="imc-20210630.xsd#imc_BasicAndDilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="imc_BasicAndDilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageNumberOfShares" xlink:href="imc-20210630.xsd#imc_WeightedAverageNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="imc_WeightedAverageNumberOfShares" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofbalancesundercashTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfBalancesUnderCashAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBalancesUnderCashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfBalancesUnderCashAbstract" xlink:to="ifrs-full_CashAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CashAtBankAndInHand" xlink:href="imc-20210630.xsd#imc_CashAtBankAndInHand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="imc_CashAtBankAndInHand" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_Cash" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTradeAndOtherReceivablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LossOnAllowanceTradeReceivables" xlink:href="imc-20210630.xsd#imc_LossOnAllowanceTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="imc_LossOnAllowanceTradeReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_AccruedIncomeOtherThanContractAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivables" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinventoriesTable">
    <loc xlink:type="locator" xlink:label="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDetailsScheduleofinventoriesTable" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="imc_InventoriesDetailsScheduleofinventoriesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesAxis" xlink:href="imc-20210630.xsd#imc_InventoriesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_InventoriesDetailsScheduleofinventoriesTable" xlink:to="imc_InventoriesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDomain" xlink:href="imc-20210630.xsd#imc_InventoriesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="imc_InventoriesAxis" xlink:to="imc_InventoriesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDomain_0" xlink:href="imc-20210630.xsd#imc_InventoriesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="imc_InventoriesAxis" xlink:to="imc_InventoriesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RawMaterialsAndStoresMember" xlink:href="imc-20210630.xsd#imc_RawMaterialsAndStoresMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDomain" xlink:to="imc_RawMaterialsAndStoresMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WorkInProgressMember" xlink:href="imc-20210630.xsd#imc_WorkInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDomain" xlink:to="imc_WorkInProgressMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_FinishedGoodsMember" xlink:href="imc-20210630.xsd#imc_FinishedGoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDomain" xlink:to="imc_FinishedGoodsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="ifrs-full_Inventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="ifrs-full_NoncurrentInventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesNet" xlink:href="imc-20210630.xsd#imc_InventoriesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="imc_InventoriesNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsubsidiariesTable">
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:to="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ImmuronLimitedMember" xlink:href="imc-20210630.xsd#imc_ImmuronLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="imc_ImmuronLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ImmuronIncMember" xlink:href="imc-20210630.xsd#imc_ImmuronIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="imc_ImmuronIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AnadisEPSPtyLtdMember" xlink:href="imc-20210630.xsd#imc_AnadisEPSPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="imc_AnadisEPSPtyLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IMCCanadaLtdMember" xlink:href="imc-20210630.xsd#imc_IMCCanadaLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="imc_IMCCanadaLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ParentEntityAbstract" xlink:href="imc-20210630.xsd#imc_ParentEntityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:to="imc_ParentEntityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ParentEntityAbstract" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ParentEntityAbstract" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_Accruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfProvisionForSalesReturnsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Provisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_Provisions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable">
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_RightofuseAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable">
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:to="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:href="imc-20210630.xsd#imc_DepreciationChargeOfRightOfUseAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:to="imc_DepreciationChargeOfRightOfUseAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_CashOutflowForLeases" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsharecapitalTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfShareCapitalAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AmountOfOrdinaryShares" xlink:href="imc-20210630.xsd#imc_AmountOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfShareCapitalAbstract" xlink:to="imc_AmountOfOrdinaryShares" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofordinarysharesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfOrdinarySharesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOrdinarySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_OrdinaryShare" xlink:href="imc-20210630.xsd#imc_OrdinaryShare"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGzFqsHpjKaw6JeH5cpcRaX+2rR4hSiNdMw=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_OrdinaryShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfEquityToOrdinaryvalue" xlink:href="imc-20210630.xsd#imc_IssueOfEquityToOrdinaryvalue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_IssueOfEquityToOrdinaryvalue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssuePursuantToAdsPublicOfferingShares" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOfferingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_IssuePursuantToAdsPublicOfferingShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssuePursuantToAdsPublicOffering" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_IssuePursuantToAdsPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueInLieuOfPaymentForServicesShares" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServicesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_IssueInLieuOfPaymentForServicesShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueInLieuOfPaymentForServices" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_IssueInLieuOfPaymentForServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_ExerciseOfNasdaqWarrantsShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_ExerciseOfNasdaqWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_ExerciseOfRepresentativeWarrantShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrant" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_ExerciseOfRepresentativeWarrant" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrants1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ExerciseOfRepresentativeWarrants1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrant1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ExerciseOfRepresentativeWarrant1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering1" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOption" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered20201113"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ProceedsFromIssuedSharesAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedSharesAtADSPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ProceedsFromIssuedSharesAtADSPublicOffering" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ProceedsFromIssuedAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedAtADSPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ProceedsFromIssuedAtADSPublicOffering" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringValueReclassifyToStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_BusinessAcquisitionCostOfTransactionCost" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_BusinessAcquisitionCostOfTransactionCost" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofotherreservesTable">
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="imc_OtherReservesDetailsScheduleofotherreservesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ForeignCurrencyTranslationMember" xlink:href="imc-20210630.xsd#imc_ForeignCurrencyTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="imc_ForeignCurrencyTranslationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="ifrs-full_OtherReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwners" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwners" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TransferToShareCapitalinDollars" xlink:href="imc-20210630.xsd#imc_TransferToShareCapitalinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_TransferToShareCapitalinDollars" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_SharebasedPaymentExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsIssuedexpensed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsIssuedexpensed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_OptionsAndWarrantsIssuedexpensed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_OptionsAndWarrantsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_OptionsAndWarrantsForfeited" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsLapsed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsLapsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_OptionsAndWarrantsLapsed" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CurrencyTranslationDifferences" xlink:href="imc-20210630.xsd#imc_CurrencyTranslationDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="imc_CurrencyTranslationDifferences" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="imc-20210630.xsd#imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriodShares" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriodShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsTwoShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwoShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_IssueOfRepresentativeWarrantsTwoShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsTwo" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_IssueOfRepresentativeWarrantsTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_ExerciseOfRepresentativeWarrantsShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_ExerciseOfRepresentativeWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsSharesOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ExerciseOfRepresentativeWarrantsSharesOne" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ExerciseOfESOPUnlistedOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptionsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ExerciseOfESOPUnlistedOptionsValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_LapseOfUnexercisedOptionsOne" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsValue" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_LapseOfUnexercisedOptionsValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsThreeShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThreeShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_IssueOfRepresentativeWarrantsThreeShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsThree" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_IssueOfRepresentativeWarrantsThree" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptionsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptionsValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsSharesOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_IssueOfRepresentativeWarrantsSharesOne" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_IssueOfRepresentativeWarrantsOne" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable">
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentResearchAndDevelopmentMember" xlink:href="imc-20210630.xsd#imc_SegmentResearchAndDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="imc_SegmentResearchAndDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentHyperImmuneProductsMember" xlink:href="imc-20210630.xsd#imc_SegmentHyperImmuneProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="imc_SegmentHyperImmuneProductsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherMember" xlink:href="imc-20210630.xsd#imc_OtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="imc_OtherMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_HyperimmuneProductsRevenue" xlink:href="imc-20210630.xsd#imc_HyperimmuneProductsRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="imc_HyperimmuneProductsRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_CostOfSales" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_GrossProfit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherGainsLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GeneralAndAdministrativeExpenses" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="imc_GeneralAndAdministrativeExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SellingAndMarketingExpenses" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="imc_SellingAndMarketingExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_AssetsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentAssets" xlink:href="imc-20210630.xsd#imc_SegmentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AssetsAbstract" xlink:to="imc_SegmentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_LiabilitiesAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentLiabilities" xlink:href="imc-20210630.xsd#imc_SegmentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="imc_SegmentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_Liabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinformationongeographicalregionsTable">
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_MajorProductLinesAxis" xlink:href="imc-20210630.xsd#imc_MajorProductLinesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="imc_MajorProductLinesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_MajorProductLinesDomain" xlink:href="imc-20210630.xsd#imc_MajorProductLinesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="imc_MajorProductLinesAxis" xlink:to="imc_MajorProductLinesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_MajorProductLinesDomain_0" xlink:href="imc-20210630.xsd#imc_MajorProductLinesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="imc_MajorProductLinesAxis" xlink:to="imc_MajorProductLinesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TravelanMember" xlink:href="imc-20210630.xsd#imc_TravelanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_MajorProductLinesDomain" xlink:to="imc_TravelanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ProtectynMember" xlink:href="imc-20210630.xsd#imc_ProtectynMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_MajorProductLinesDomain" xlink:to="imc_ProtectynMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_AU" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherCountriesMember" xlink:href="imc-20210630.xsd#imc_OtherCountriesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="imc_OtherCountriesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="ifrs-full_Revenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFromExternalCustomers" xlink:href="imc-20210630.xsd#imc_RevenueFromExternalCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="imc_RevenueFromExternalCustomers" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentRevenue" xlink:href="imc-20210630.xsd#imc_SegmentRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="imc_SegmentRevenue" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmajorcustomersTable">
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofmajorcustomersTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerAMember" xlink:href="imc-20210630.xsd#imc_CustomerAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerBMember" xlink:href="imc-20210630.xsd#imc_CustomerBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerCMember" xlink:href="imc-20210630.xsd#imc_CustomerCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerDMember" xlink:href="imc-20210630.xsd#imc_CustomerDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerDMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerEMember" xlink:href="imc-20210630.xsd#imc_CustomerEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerEMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerFMember" xlink:href="imc-20210630.xsd#imc_CustomerFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerFMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerGMember" xlink:href="imc-20210630.xsd#imc_CustomerGMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerGMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerHMember" xlink:href="imc-20210630.xsd#imc_CustomerHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerHMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerIMember" xlink:href="imc-20210630.xsd#imc_CustomerIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="imc_CustomerIMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFormContractWithCustomer" xlink:href="imc-20210630.xsd#imc_RevenueFormContractWithCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:to="imc_RevenueFormContractWithCustomer" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AdjustmentsForAbstract" xlink:href="imc-20210630.xsd#imc_AdjustmentsForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLoss" xlink:to="imc_AdjustmentsForAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AdjustmentsForDistributionCosts" xlink:href="imc-20210630.xsd#imc_AdjustmentsForDistributionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_AdjustmentsForDistributionCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_ExpectedCreditLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LeaveProvisionExpense" xlink:href="imc-20210630.xsd#imc_LeaveProvisionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_LeaveProvisionExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedPaymentsExpense" xlink:href="imc-20210630.xsd#imc_ShareBasedPaymentsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_ShareBasedPaymentsExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLoss" xlink:to="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfOutstandingShareOption" xlink:href="imc-20210630.xsd#imc_NumberOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_NumberOfOutstandingShareOption" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable">
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="ifrs-full_CreationDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateOneMember" xlink:href="imc-20210630.xsd#imc_GrantDateOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTwoMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateThreeMember" xlink:href="imc-20210630.xsd#imc_GrantDateThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateFourMember" xlink:href="imc-20210630.xsd#imc_GrantDateFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateFiveMember" xlink:href="imc-20210630.xsd#imc_GrantDateFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateSixMember" xlink:href="imc-20210630.xsd#imc_GrantDateSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateSevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateEightMember" xlink:href="imc-20210630.xsd#imc_GrantDateEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateEightMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateNineMember" xlink:href="imc-20210630.xsd#imc_GrantDateNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateNineMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTenMember" xlink:href="imc-20210630.xsd#imc_GrantDateTenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateTenMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateElevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateElevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateElevenMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTwelveMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwelveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="imc_GrantDateTwelveMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePrice" xlink:href="imc-20210630.xsd#imc_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareOptionsOutstanding" xlink:href="imc-20210630.xsd#imc_ShareOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ShareOptionsOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareOptionsPerShare" xlink:href="imc-20210630.xsd#imc_ShareOptionsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ShareOptionsPerShare" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0">
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceOneMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="imc_ExercisePriceOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceTwoMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="imc_ExercisePriceTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceSixteenMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="imc_ExercisePriceSixteenMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_ExercisePriceShareOptionsGranted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ExercisePriceShareOptionsGranted1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfInstrumentOtherEquityInstrumentGranted" xlink:href="imc-20210630.xsd#imc_NumberOfInstrumentOtherEquityInstrumentGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_NumberOfInstrumentOtherEquityInstrumentGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageSharePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_WeightedAverageSharePriceShareOptionsGranted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_WeightedAverageSharePriceShareOptionsGranted1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ValuePerShareOptionsGranted" xlink:href="imc-20210630.xsd#imc_ValuePerShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_ValuePerShareOptionsGranted" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsIssuedUnderESOP" xlink:href="imc-20210630.xsd#imc_OptionsIssuedUnderESOP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="imc_OptionsIssuedUnderESOP" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsToDirectors" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsToDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="imc_SharebasedPaymentsToDirectors" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TotalExpenses" xlink:href="imc-20210630.xsd#imc_TotalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="imc_TotalExpenses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:href="imc-20210630.xsd#imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofforeigncurrencyriskTable">
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_TradeReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofexchangeratesTable">
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfExchangeRatesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_ImpactOnLossForPeriods" xlink:href="imc-20210630.xsd#imc_ImpactOnLossForPeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfExchangeRatesAbstract" xlink:to="imc_ImpactOnLossForPeriods" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ImpactOnOtherComponentOfEquity" xlink:href="imc-20210630.xsd#imc_ImpactOnOtherComponentOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ScheduleOfExchangeRatesAbstract" xlink:to="imc_ImpactOnOtherComponentOfEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradereceivablesTable">
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="ifrs-full_PastDueStatusAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsCategoryMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_TradeReceivablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_CurrentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_LaterThanThreeMonthsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedCreditLossRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedCreditLossRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="ifrs-full_ExpectedCreditLossRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrossCarryingAmount" xlink:href="imc-20210630.xsd#imc_GrossCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="imc_GrossCarryingAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LossAllowance" xlink:href="imc-20210630.xsd#imc_LossAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="imc_LossAllowance" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable">
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="ifrs-full_MaturityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="ifrs-full_PastDueStatusAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ContractualCashFlowsMember" xlink:href="imc-20210630.xsd#imc_ContractualCashFlowsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="imc_ContractualCashFlowsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_CarryingAssetsLiabilitiesMember" xlink:href="imc-20210630.xsd#imc_CarryingAssetsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="imc_CarryingAssetsLiabilitiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TradeAndOtherPayable" xlink:href="imc-20210630.xsd#imc_TradeAndOtherPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="imc_TradeAndOtherPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_PlantAndEquipmentMember" xlink:href="imc-20210630.xsd#imc_PlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="imc_PlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_FixturesAndFittingsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_RightofuseAssetsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RepresentativesWarrants" xlink:href="imc-20210630.xsd#imc_RepresentativesWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_RepresentativesWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShareCapital" xlink:href="imc-20210630.xsd#imc_ShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_ShareCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AssistancePackages" xlink:href="imc-20210630.xsd#imc_AssistancePackages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_AssistancePackages" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:href="imc-20210630.xsd#imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_FinishedGoods" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RawMaterials" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_RawMaterials" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NonCurrentRawMaterials" xlink:href="imc-20210630.xsd#imc_NonCurrentRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_NonCurrentRawMaterials" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RAndDTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_RAndDTaxConcessionRefund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_RAndDTaxConcessionRefund" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AdditionalRAndDTaxReceived" xlink:href="imc-20210630.xsd#imc_AdditionalRAndDTaxReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_AdditionalRAndDTaxReceived" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/RevenueandotherincomeDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomeOfResearchAndDevelopment" xlink:href="imc-20210630.xsd#imc_OtherIncomeOfResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="imc_OtherIncomeOfResearchAndDevelopment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_AdditionalOtherIncome" xlink:href="imc-20210630.xsd#imc_AdditionalOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="imc_AdditionalOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GovernmentAssistancePackages" xlink:href="imc-20210630.xsd#imc_GovernmentAssistancePackages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="imc_GovernmentAssistancePackages" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentsGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentsGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="imc_ResearchAndDevelopmentsGrants" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="imc_ContingentLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_ContingentLiabilitiesAbstract" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InformationAboutNatureOfLesseesLeasingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapitalDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_PaymentForServices" xlink:href="imc-20210630.xsd#imc_PaymentForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="imc_PaymentForServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_IssuanceOfOrdinarySharesDescription" xlink:href="imc-20210630.xsd#imc_IssuanceOfOrdinarySharesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="imc_IssuanceOfOrdinarySharesDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReservesDetails">
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_OtherReservesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TitlesOfIndividualAxis" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_OtherReservesDetailsTable" xlink:to="imc_TitlesOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TitlesOfIndividualDomain" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="imc_TitlesOfIndividualAxis" xlink:to="imc_TitlesOfIndividualDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TitlesOfIndividualDomain_0" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="imc_TitlesOfIndividualAxis" xlink:to="imc_TitlesOfIndividualDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DrJerryKanellosMember" xlink:href="imc-20210630.xsd#imc_DrJerryKanellosMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TitlesOfIndividualDomain" xlink:to="imc_DrJerryKanellosMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_MrRichardJBermanMember" xlink:href="imc-20210630.xsd#imc_MrRichardJBermanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TitlesOfIndividualDomain" xlink:to="imc_MrRichardJBermanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_DrGarySJacobMember" xlink:href="imc-20210630.xsd#imc_DrGarySJacobMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TitlesOfIndividualDomain" xlink:to="imc_DrGarySJacobMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReserveMaturityDateDescription" xlink:href="imc-20210630.xsd#imc_OtherReserveMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_OtherReserveMaturityDateDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesUnlistedOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_NumberOfSharesUnlistedOption" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_UnlistedOptionExercisable" xlink:href="imc-20210630.xsd#imc_UnlistedOptionExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_UnlistedOptionExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ESOPOptionsIssued" xlink:href="imc-20210630.xsd#imc_ESOPOptionsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_ESOPOptionsIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsGranted" xlink:href="imc-20210630.xsd#imc_OptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_OptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluedAtGrantDate" xlink:href="imc-20210630.xsd#imc_RevaluedAtGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_RevaluedAtGrantDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfShareholdersApprovedValue" xlink:href="imc-20210630.xsd#imc_RevaluationOfShareholdersApprovedValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_RevaluationOfShareholdersApprovedValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationFinancialsAmount" xlink:href="imc-20210630.xsd#imc_RevaluationFinancialsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_RevaluationFinancialsAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseOfSharesOwed" xlink:href="imc-20210630.xsd#imc_ExpenseOfSharesOwed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_ExpenseOfSharesOwed" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSegment" xlink:href="imc-20210630.xsd#imc_NumberOfSegment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="imc_NumberOfSegment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_PercentageOfEntityRevenue" xlink:href="imc-20210630.xsd#imc_PercentageOfEntityRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="imc_PercentageOfEntityRevenue" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_OptionGrantedDescription" xlink:href="imc-20210630.xsd#imc_OptionGrantedDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="imc_OptionGrantedDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationFinancialsAmount" xlink:href="imc-20210630.xsd#imc_RevaluationFinancialsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="imc_RevaluationFinancialsAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SharesIssuedToDirectorsForTheDirectorFees" xlink:href="imc-20210630.xsd#imc_SharesIssuedToDirectorsForTheDirectorFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="imc_SharesIssuedToDirectorsForTheDirectorFees" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_RelatedPartyTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TypesOfArrangementsAxis" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="imc_RelatedPartyTransactionsDetailsTable" xlink:to="imc_TypesOfArrangementsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TypesOfArrangementsDomain" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="imc_TypesOfArrangementsAxis" xlink:to="imc_TypesOfArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_TypesOfArrangementsDomain_0" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="imc_TypesOfArrangementsAxis" xlink:to="imc_TypesOfArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_ShortTermFundingAgreementsMember" xlink:href="imc-20210630.xsd#imc_ShortTermFundingAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_TypesOfArrangementsDomain" xlink:to="imc_ShortTermFundingAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_WattleLaboratoriesPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="imc_WattleLaboratoriesPtyLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_GrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_GrandlodgeCapitalPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="imc_GrandlodgeCapitalPtyLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_RentalExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_LeaseRenewed" xlink:href="imc-20210630.xsd#imc_LeaseRenewed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_LeaseRenewed" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WarehousingDistributionAndInvoicingServices" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndInvoicingServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_WarehousingDistributionAndInvoicingServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_SharesIssuedPricePerShare1" xlink:href="imc-20210630.xsd#imc_SharesIssuedPricePerShare1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_SharesIssuedPricePerShare1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_WarehousingDistributionAndServicesFees" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndServicesFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_WarehousingDistributionAndServicesFees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="imc_OrdinarySharesIssued" xlink:href="imc-20210630.xsd#imc_OrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_OrdinarySharesIssued" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails">
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="imc_PercentageOfForeignExchangeRates" xlink:href="imc-20210630.xsd#imc_PercentageOfForeignExchangeRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_PercentageOfForeignExchangeRates" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immuron.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>imc-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:37 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Operating profit/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_FinanceCostsNet" xlink:href="imc-20210630.xsd#imc_FinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="imc_FinanceCostsNet_lbl" xml:lang="en-US">Finance costs - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinanceCostsNet" xlink:to="imc_FinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss Before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Loss from continuing operations before income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss after income tax expense for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Net Loss for the Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total Comprehensive Loss for the Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Total comprehensive loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total Non-Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total Non-Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Liabilities_lbl0" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US">NET ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">TOTAL EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ConsolidatedStatementOfChangesInEquityAbstract" xlink:href="imc-20210630.xsd#imc_ConsolidatedStatementOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ConsolidatedStatementOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statement of Changes in Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ConsolidatedStatementOfChangesInEquityAbstract" xlink:to="imc_ConsolidatedStatementOfChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_EquityBalance" xlink:href="imc-20210630.xsd#imc_EquityBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_EquityBalance_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EquityBalance" xlink:to="imc_EquityBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_EquityBalance_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EquityBalance" xlink:to="imc_EquityBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used In)/From Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows From Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and Cash Equivalents at the End of the Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of significant accounting policies [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfRevenueTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of revenue [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfRevenueTextBlockAbstract" xlink:to="imc_DisclosureOfRevenueTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfRevenueAndOtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfRevenueAndOtherIncomeAbstract_lbl" xml:lang="en-US">Schedule of revenue and other income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="imc_ScheduleOfRevenueAndOtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl" xml:lang="en-US">Total Revenue from Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomeFromNonOperatingActivities" xlink:href="imc-20210630.xsd#imc_OtherIncomeFromNonOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imc_OtherIncomeFromNonOperatingActivities_lbl" xml:lang="en-US">Total Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_OtherIncomeFromNonOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherGainsLosses_lbl" xml:lang="en-US">Total Other Gains/(Losses) &#8211; Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherGainsLosses_lbl0" xml:lang="en-US">Other gains/(losses) &#8211; net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfExpensesByNatureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of expenses by nature [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfExpensesByNatureTextBlockAbstract" xlink:to="imc_DisclosureOfExpensesByNatureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfExpensesAbstract_lbl" xml:lang="en-US">Schedule of expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfExpensesAbstract" xlink:to="imc_ScheduleOfExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Total selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfIncomeTaxTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of income tax [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="imc_DisclosureOfIncomeTaxTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract_lbl" xml:lang="en-US">Schedule of unused tax losses for which no deferred tax asset recognized [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:to="imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfIncomeTaxBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfIncomeTaxBenefitAbstract_lbl" xml:lang="en-US">Schedule of income tax benefit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfIncomeTaxBenefitAbstract" xlink:to="imc_ScheduleOfIncomeTaxBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of information about key management personnel [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:to="imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfKeyManagementPersonnelCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract_lbl" xml:lang="en-US">Schedule of key management personnel compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:to="imc_ScheduleOfKeyManagementPersonnelCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Total Key Management Personnel Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfEarningsPerShareTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of earnings per share [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfEarningsPerShareTextBlockAbstract" xlink:to="imc_DisclosureOfEarningsPerShareTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBasicAndDilutedLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of basic and diluted loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="imc_ScheduleOfBasicAndDilutedLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCashExplanatoryAbstract_lbl" xml:lang="en-US">Disclosure Of Cash Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashExplanatoryAbstract" xlink:to="imc_DisclosureOfCashExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfBalancesUnderCashAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBalancesUnderCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfBalancesUnderCashAbstract_lbl" xml:lang="en-US">Schedule of balances under cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfBalancesUnderCashAbstract" xlink:to="imc_ScheduleOfBalancesUnderCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Total Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of trade and other receivables [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:to="imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTradeAndOtherReceivablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfTradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Schedule of trade and other receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTradeAndOtherReceivablesAbstract" xlink:to="imc_ScheduleOfTradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl" xml:lang="en-US">Total Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_TradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInventoriesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfInventoriesTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of inventories [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfInventoriesTextBlockAbstract" xlink:to="imc_DisclosureOfInventoriesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfInventoriesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfInventoriesAbstract_lbl" xml:lang="en-US">Schedule of inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfInventoriesAbstract" xlink:to="imc_ScheduleOfInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesAxis" xlink:href="imc-20210630.xsd#imc_InventoriesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_InventoriesAxis_lbl" xml:lang="en-US">Inventories [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesAxis" xlink:to="imc_InventoriesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesAbstract" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ControlledEntitiesAbstract_lbl" xml:lang="en-US">Controlled Entities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesAbstract" xlink:to="imc_ControlledEntitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfSubsidiariesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfSubsidiariesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfSubsidiariesAbstract_lbl" xml:lang="en-US">Schedule of subsidiaries [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfSubsidiariesAbstract" xlink:to="imc_ScheduleOfSubsidiariesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US">Subsidiaries [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of trade and other payables [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfTradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of trade and other payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="imc_ScheduleOfTradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract_lbl" xml:lang="en-US">Disclosure Of Provision For Sales Returns Explantory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:to="imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfProvisionForSalesReturnsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfProvisionForSalesReturnsAbstract_lbl" xml:lang="en-US">Schedule of provision for sales returns [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="imc_ScheduleOfProvisionForSalesReturnsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Provisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US">Carrying amount at the start of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Provisions_lbl0" xml:lang="en-US">Carrying amount at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_ContingentLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ContingentLiabilitiesAbstract_lbl" xml:lang="en-US">Contingent Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ContingentLiabilitiesAbstract" xlink:to="imc_ContingentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfLeasesTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of leases [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfLeasesTextBlockAbstract" xlink:to="imc_DisclosureOfLeasesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract_lbl" xml:lang="en-US">Schedule of amounts relating to leases in balance sheet [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract" xlink:to="imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract_lbl" xml:lang="en-US">Schedule of profit or loss amounts relating to leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract" xlink:to="imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of classes of share capital [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfShareCapitalAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of share capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfShareCapitalAbstract" xlink:to="imc_ScheduleOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfOrdinarySharesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOrdinarySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfOrdinarySharesAbstract_lbl" xml:lang="en-US">Schedule of ordinary shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfOrdinarySharesAbstract" xlink:to="imc_ScheduleOfOrdinarySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OrdinaryShare" xlink:href="imc-20210630.xsd#imc_OrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_OrdinaryShare_lbl" xml:lang="en-US">Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinaryShare" xlink:to="imc_OrdinaryShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_OrdinaryShare_lbl0" xml:lang="en-US">Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinaryShare" xlink:to="imc_OrdinaryShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfEquityToOrdinaryvalue" xlink:href="imc-20210630.xsd#imc_IssueOfEquityToOrdinaryvalue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_IssueOfEquityToOrdinaryvalue_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfEquityToOrdinaryvalue" xlink:to="imc_IssueOfEquityToOrdinaryvalue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_IssueOfEquityToOrdinaryvalue_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfEquityToOrdinaryvalue" xlink:to="imc_IssueOfEquityToOrdinaryvalue_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfReservesWithinEquityTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of reserves within equity [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="imc_DisclosureOfReservesWithinEquityTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfOtherReservesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOtherReservesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfOtherReservesAbstract_lbl" xml:lang="en-US">Schedule of other reserves [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfOtherReservesAbstract" xlink:to="imc_ScheduleOfOtherReservesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl1" xml:lang="en-US">Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl1"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract_lbl" xml:lang="en-US">Schedule of movements in options and warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="imc-20210630.xsd#imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl" xml:lang="en-US">Balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0" xml:lang="en-US">Balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract_lbl" xml:lang="en-US">Schedule of segment information for the reportable segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract" xlink:to="imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfInformationOnGeographicalRegionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInformationOnGeographicalRegionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfInformationOnGeographicalRegionsAbstract_lbl" xml:lang="en-US">Schedule of information on geographical regions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfInformationOnGeographicalRegionsAbstract" xlink:to="imc_ScheduleOfInformationOnGeographicalRegionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_MajorProductLinesAxis" xlink:href="imc-20210630.xsd#imc_MajorProductLinesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_MajorProductLinesAxis_lbl" xml:lang="en-US">Major Product Lines [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MajorProductLinesAxis" xlink:to="imc_MajorProductLinesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfMajorCustomersAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMajorCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfMajorCustomersAbstract_lbl" xml:lang="en-US">Schedule of major customers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfMajorCustomersAbstract" xlink:to="imc_ScheduleOfMajorCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US">Major customers [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryAbstract_lbl" xml:lang="en-US">Disclosure Of Cash Flow Information Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:to="imc_DisclosureOfCashFlowInformationExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of cash flow from operations with loss after income tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:to="imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of share-based payment arrangements [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Schedule of movement in number of stock options outstanding and weighted average exercise price [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl" xml:lang="en-US">Average exercise price per share option, As at 1 July</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl0" xml:lang="en-US">Average exercise price per share option, As at 30 June</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfOutstandingShareOption" xlink:href="imc-20210630.xsd#imc_NumberOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="imc_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Number of options, As at 1 July</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfOutstandingShareOption" xlink:to="imc_NumberOfOutstandingShareOption_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="imc_NumberOfOutstandingShareOption_lbl0" xml:lang="en-US">Number of options, As at 30 June</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfOutstandingShareOption" xlink:to="imc_NumberOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfGrantedValuationOfOptionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfGrantedValuationOfOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfGrantedValuationOfOptionsAbstract_lbl" xml:lang="en-US">Schedule of granted valuation of options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfGrantedValuationOfOptionsAbstract" xlink:to="imc_ScheduleOfGrantedValuationOfOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract_lbl" xml:lang="en-US">Schedule of total expenses arising from share-based payment transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfRelatedPartyTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of related party [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="imc_DisclosureOfRelatedPartyTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Schedule of information about other related party transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract" xlink:to="imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of outstanding balances transactions between related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:to="imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of financial risk management [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="imc_DisclosureOfFinancialRiskManagementTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfForeignCurrencyRiskAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfForeignCurrencyRiskAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfForeignCurrencyRiskAbstract_lbl" xml:lang="en-US">Schedule of foreign currency risk [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfForeignCurrencyRiskAbstract" xlink:to="imc_ScheduleOfForeignCurrencyRiskAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfExchangeRatesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExchangeRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfExchangeRatesAbstract_lbl" xml:lang="en-US">Schedule of exchange rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfExchangeRatesAbstract" xlink:to="imc_ScheduleOfExchangeRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTradeReceivablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfTradeReceivablesAbstract_lbl" xml:lang="en-US">Schedule of trade receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTradeReceivablesAbstract" xlink:to="imc_ScheduleOfTradeReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xml:lang="en-US">Categories of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PastDueStatusAxis_lbl" xml:lang="en-US">Past due status [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfContractualUndiscountedCashFlowsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfContractualUndiscountedCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfContractualUndiscountedCashFlowsAbstract_lbl" xml:lang="en-US">Schedule of contractual undiscounted cash flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfContractualUndiscountedCashFlowsAbstract" xlink:to="imc_ScheduleOfContractualUndiscountedCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract_lbl" xml:lang="en-US">Disclosure of events after reporting period [text block] [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:to="imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCompanyDetailsExplanatoryAbstract_lbl" xml:lang="en-US">Disclosure Of Company Details Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:to="imc_DisclosureOfCompanyDetailsExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US">Revenue from contracts with customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CostOfFinance" xlink:href="imc-20210630.xsd#imc_CostOfFinance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CostOfFinance_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CostOfFinance" xlink:to="imc_CostOfFinance_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US">Items that may be reclassified to profit or loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Exchange differences on translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_BasicAndDilutedEarningsLossPerShare" xlink:href="imc-20210630.xsd#imc_BasicAndDilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US">Basic/Diluted Loss per Share (in cents per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BasicAndDilutedEarningsLossPerShare" xlink:to="imc_BasicAndDilutedEarningsLossPerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_BasicAndDilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Basic/Diluted loss per share (in cents)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BasicAndDilutedEarningsLossPerShare" xlink:to="imc_BasicAndDilutedEarningsLossPerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Inventories Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoriesTotal_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US">Provision for sales returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligation" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_EmployeeBenefitObligation_lbl" xml:lang="en-US">Employee benefit obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligation" xlink:to="imc_EmployeeBenefitObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeBenefitObligationNonCurrent" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligationNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_EmployeeBenefitObligationNonCurrent_lbl" xml:lang="en-US">Employee benefit obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligationNonCurrent" xlink:to="imc_EmployeeBenefitObligationNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherComprehensiveIncomeLossForPeriod" xlink:href="imc-20210630.xsd#imc_OtherComprehensiveIncomeLossForPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherComprehensiveIncomeLossForPeriod_lbl" xml:lang="en-US">Other comprehensive income for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherComprehensiveIncomeLossForPeriod" xlink:to="imc_OtherComprehensiveIncomeLossForPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_lbl" xml:lang="en-US">Transactions with owners in their capacity as owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Shares issued, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsIssuedExpensed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsIssuedExpensed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsOrWarrantsIssuedExpensed_lbl" xml:lang="en-US">Options/warrants issued/expensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsIssuedExpensed" xlink:to="imc_OptionsOrWarrantsIssuedExpensed_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsOrWarrantsExercised_lbl" xml:lang="en-US">Options/warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsExercised" xlink:to="imc_OptionsOrWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionswarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionswarrantsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionswarrantsForfeited_lbl" xml:lang="en-US">Options/warrants forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionswarrantsForfeited" xlink:to="imc_OptionswarrantsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ChangeInAccountingPolicy" xlink:href="imc-20210630.xsd#imc_ChangeInAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ChangeInAccountingPolicy_lbl" xml:lang="en-US">Change in accounting policy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ChangeInAccountingPolicy" xlink:to="imc_ChangeInAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RestatedTotalEquityAt1July2019" xlink:href="imc-20210630.xsd#imc_RestatedTotalEquityAt1July2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RestatedTotalEquityAt1July2019_lbl" xml:lang="en-US">Revised total equity at 1 July 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RestatedTotalEquityAt1July2019" xlink:to="imc_RestatedTotalEquityAt1July2019_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0_lbl" xml:lang="en-US">Transactions with owners in their capacity as owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionIssuedInPriorPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluationOfOptionIssuedInPriorPeriod_lbl" xml:lang="en-US">Re-valuation of options issued in prior period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionIssuedInPriorPeriod" xlink:to="imc_RevaluationOfOptionIssuedInPriorPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeShareSchemesValueOfEmployee" xlink:href="imc-20210630.xsd#imc_EmployeeShareSchemesValueOfEmployee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_EmployeeShareSchemesValueOfEmployee_lbl" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeShareSchemesValueOfEmployee" xlink:to="imc_EmployeeShareSchemesValueOfEmployee_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00_lbl" xml:lang="en-US">Transactions with owners in their capacity as owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringPeriodValueIssuedToDirectors" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringPeriodValueIssuedToDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl" xml:lang="en-US">Shares issued to directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringPeriodValueIssuedToDirectors" xlink:to="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferToShareCapital" xlink:href="imc-20210630.xsd#imc_TransferToShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferToShareCapital_lbl" xml:lang="en-US">Transfer to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapital" xlink:to="imc_TransferToShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows Related to Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl" xml:lang="en-US">Receipts from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_PaymentsToSuppliersForGoodsAndService" xlink:href="imc-20210630.xsd#imc_PaymentsToSuppliersForGoodsAndService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_PaymentsToSuppliersForGoodsAndService_lbl" xml:lang="en-US">Payments to suppliers and employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PaymentsToSuppliersForGoodsAndService" xlink:to="imc_PaymentsToSuppliersForGoodsAndService_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Other - R&amp;D tax concession refund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US">Government grants and other grants received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Related to Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Related to Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issues of securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Proceeds from borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of sales of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_SharebasedPaymentsExpenses_lbl" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsExpenses" xlink:to="imc_SharebasedPaymentsExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IncomeFinance" xlink:href="imc-20210630.xsd#imc_IncomeFinance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_IncomeFinance_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IncomeFinance" xlink:to="imc_IncomeFinance_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsOrWarrantsForteitedLapsed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsForteitedLapsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_OptionsOrWarrantsForteitedLapsed_lbl" xml:lang="en-US">Options/warrants forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsForteitedLapsed" xlink:to="imc_OptionsOrWarrantsForteitedLapsed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Payment for purchases of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CapitalCost" xlink:href="imc-20210630.xsd#imc_CapitalCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_CapitalCost_lbl" xml:lang="en-US">Capital raising costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CapitalCost" xlink:to="imc_CapitalCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Principal elements of lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest and other costs of finance paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ReservesMember" xlink:href="imc-20210630.xsd#imc_ReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ReservesMember_lbl" xml:lang="en-US">Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReservesMember" xlink:to="imc_ReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AccumulatedLossesMember" xlink:href="imc-20210630.xsd#imc_AccumulatedLossesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AccumulatedLossesMember_lbl" xml:lang="en-US">Accumulated Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccumulatedLossesMember" xlink:to="imc_AccumulatedLossesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US">Revenue and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl" xml:lang="en-US">Schedule of revenue and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFromOperatingActivitiesAbstract" xlink:href="imc-20210630.xsd#imc_RevenueFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevenueFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Revenue from Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFromOperatingActivitiesAbstract" xlink:to="imc_RevenueFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AustralianFederalRdTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_AustralianFederalRdTaxConcessionRefund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AustralianFederalRdTaxConcessionRefund_lbl" xml:lang="en-US">Australian Federal R&amp;D Tax Concession Refund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AustralianFederalRdTaxConcessionRefund" xlink:to="imc_AustralianFederalRdTaxConcessionRefund_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherGovernmentAssistanceIncome" xlink:href="imc-20210630.xsd#imc_OtherGovernmentAssistanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherGovernmentAssistanceIncome_lbl" xml:lang="en-US">COVID-19 government assistance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherGovernmentAssistanceIncome" xlink:to="imc_OtherGovernmentAssistanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ResearchAndDevelopmentGrants_lbl" xml:lang="en-US">R&amp;D grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentGrants" xlink:to="imc_ResearchAndDevelopmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomes" xlink:href="imc-20210630.xsd#imc_OtherIncomes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherIncomes_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomes" xlink:to="imc_OtherIncomes_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherGainsLossesNetAbstract" xlink:href="imc-20210630.xsd#imc_OtherGainsLossesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherGainsLossesNetAbstract_lbl" xml:lang="en-US">Other Gains/(Losses) &#8211; Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherGainsLossesNetAbstract" xlink:to="imc_OtherGainsLossesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NetForeignExchangeGainLoss" xlink:href="imc-20210630.xsd#imc_NetForeignExchangeGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NetForeignExchangeGainLoss_lbl" xml:lang="en-US">Net foreign exchange gains/(losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NetForeignExchangeGainLoss" xlink:to="imc_NetForeignExchangeGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US">Schedule of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GeneralAndAdministrativeExpensesAbstract" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_GeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AccountingAndAudit" xlink:href="imc-20210630.xsd#imc_AccountingAndAudit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AccountingAndAudit_lbl" xml:lang="en-US">Accounting and audit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccountingAndAudit" xlink:to="imc_AccountingAndAudit_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_BadDebts" xlink:href="imc-20210630.xsd#imc_BadDebts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_BadDebts_lbl" xml:lang="en-US">Bad debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BadDebts" xlink:to="imc_BadDebts_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ConsultingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ConsultingExpenses_lbl" xml:lang="en-US">Consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ConsultingExpenses" xlink:to="imc_ConsultingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEmployeeExpense_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEmployeeExpense" xlink:to="ifrs-full_OtherEmployeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExpectedCreditLosses_lbl" xml:lang="en-US">Expected credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpectedCreditLosses" xlink:to="imc_ExpectedCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US">Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InvestorRelationsExpenses" xlink:href="imc-20210630.xsd#imc_InvestorRelationsExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_InvestorRelationsExpenses_lbl" xml:lang="en-US">Investor relations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InvestorRelationsExpenses" xlink:to="imc_InvestorRelationsExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LegalExpenses" xlink:href="imc-20210630.xsd#imc_LegalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LegalExpenses_lbl" xml:lang="en-US">Legal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LegalExpenses" xlink:to="imc_LegalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ListingAndShareRegistry" xlink:href="imc-20210630.xsd#imc_ListingAndShareRegistry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ListingAndShareRegistry_lbl" xml:lang="en-US">Listing and share registry</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ListingAndShareRegistry" xlink:to="imc_ListingAndShareRegistry_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UtilitiesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UtilitiesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UtilitiesExpense_lbl" xml:lang="en-US">Occupancy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UtilitiesExpense" xlink:to="ifrs-full_UtilitiesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SuperannuationExpenses" xlink:href="imc-20210630.xsd#imc_SuperannuationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SuperannuationExpenses_lbl" xml:lang="en-US">Superannuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SuperannuationExpenses" xlink:to="imc_SuperannuationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US">Travel and entertainment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentExpensesAbstract" xlink:to="imc_ResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentConsultingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses_lbl" xml:lang="en-US">Consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentConsultingExpenses" xlink:to="imc_ResearchAndDevelopmentConsultingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyDevelopmentAndProjectManagementExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense_lbl" xml:lang="en-US">Project research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:to="ifrs-full_PropertyDevelopmentAndProjectManagementExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SellingAndMarketingExpensesAbstract" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SellingAndMarketingExpensesAbstract_lbl" xml:lang="en-US">Selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="imc_SellingAndMarketingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingExpense_lbl" xml:lang="en-US">Selling</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingExpense" xlink:to="ifrs-full_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_MarketingExpenses" xlink:href="imc-20210630.xsd#imc_MarketingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_MarketingExpenses_lbl" xml:lang="en-US">Marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MarketingExpenses" xlink:to="imc_MarketingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DistributionCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DistributionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DistributionCosts_lbl" xml:lang="en-US">Distribution costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DistributionCosts" xlink:to="ifrs-full_DistributionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">Income Tax Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock_lbl" xml:lang="en-US">Schedule of unused tax losses for which no deferred tax asset recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" xlink:to="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US">Unused tax losses for which no deferred tax asset has been recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US">Potential tax benefit @ 26% (2020: 27.5%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfIncomeTaxBenefitExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxBenefitExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl" xml:lang="en-US">Schedule of income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfIncomeTaxBenefitExplanatory" xlink:to="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Tax at the Australian tax rate of 26% (2020: 27.5%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:href="imc-20210630.xsd#imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_lbl" xml:lang="en-US">Tax effect of amounts which are not deductible (taxable) in calculating taxable income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:to="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectofResearchAndDevelopmentTaxIncentive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl" xml:lang="en-US">R&amp;D tax incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl" xml:lang="en-US">Accounting expenditure subject to R&amp;D tax incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfShareBasedPayments" xlink:href="imc-20210630.xsd#imc_TaxEffectOfShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectOfShareBasedPayments_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfShareBasedPayments" xlink:to="imc_TaxEffectOfShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" xlink:href="imc-20210630.xsd#imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses_lbl" xml:lang="en-US">Net impact of other amounts not deductible (taxable)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" xlink:to="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TaxEffectOfTaxPayable" xlink:href="imc-20210630.xsd#imc_TaxEffectOfTaxPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TaxEffectOfTaxPayable_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfTaxPayable" xlink:to="imc_TaxEffectOfTaxPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:href="imc-20210630.xsd#imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Tax losses and other timing differences for which no deferred tax asset is recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:to="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Key Management Personnel Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl" xml:lang="en-US">Schedule of key management personnel compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:to="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_KeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_KeyManagementPersonnelCompensationAbstract_lbl" xml:lang="en-US">Key Management Personnel Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="imc_KeyManagementPersonnelCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl" xml:lang="en-US">Other short-term benefits, including consulting services by KMP and their related entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:to="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US">Post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl" xml:lang="en-US">Long-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share-based payment expenses to KMP and their related entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:to="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_lbl" xml:lang="en-US">a) Net loss used in the calculation of basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageNumberOfShares" xlink:href="imc-20210630.xsd#imc_WeightedAverageNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageNumberOfShares_lbl" xml:lang="en-US">b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageNumberOfShares" xlink:to="imc_WeightedAverageNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfCashExplanatory_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashExplanatory" xlink:to="imc_DisclosureOfCashExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutCashExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutCashExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DetailedInformationAboutCashExplanatory_lbl" xml:lang="en-US">Schedule of balances under cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutCashExplanatory" xlink:to="imc_DetailedInformationAboutCashExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAbstract_lbl" xml:lang="en-US">Cash at Bank and in hand:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CashAtBankAndInHand" xlink:href="imc-20210630.xsd#imc_CashAtBankAndInHand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CashAtBankAndInHand_lbl" xml:lang="en-US">Cash at bank and in hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashAtBankAndInHand" xlink:to="imc_CashAtBankAndInHand_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">Schedule of trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:to="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LossOnAllowanceTradeReceivables" xlink:href="imc-20210630.xsd#imc_LossOnAllowanceTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LossOnAllowanceTradeReceivables_lbl" xml:lang="en-US">Loss allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LossOnAllowanceTradeReceivables" xlink:to="imc_LossOnAllowanceTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets_lbl" xml:lang="en-US">Accrued income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:to="ifrs-full_AccruedIncomeOtherThanContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DetailedInformationAboutInventoriesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DetailedInformationAboutInventoriesExplanatory_lbl" xml:lang="en-US">Schedule of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutInventoriesExplanatory" xlink:to="imc_DetailedInformationAboutInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentInventories_lbl" xml:lang="en-US">Inventories Non- current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentInventories" xlink:to="ifrs-full_NoncurrentInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesNet" xlink:href="imc-20210630.xsd#imc_InventoriesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_InventoriesNet_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesNet" xlink:to="imc_InventoriesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ControlledEntitiesTextBlock_lbl" xml:lang="en-US">Controlled Entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesTextBlock" xlink:to="imc_ControlledEntitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfSubsidiariesExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfSubsidiariesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ScheduleOfSubsidiariesExplanatory_lbl" xml:lang="en-US">Schedule of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfSubsidiariesExplanatory" xlink:to="imc_ScheduleOfSubsidiariesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ParentEntityAbstract" xlink:href="imc-20210630.xsd#imc_ParentEntityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ParentEntityAbstract_lbl" xml:lang="en-US">Parent Entity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ParentEntityAbstract" xlink:to="imc_ParentEntityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl" xml:lang="en-US">Country of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Percentage of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SubsidiariesOfImmuronLimitedAbstract" xlink:href="imc-20210630.xsd#imc_SubsidiariesOfImmuronLimitedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SubsidiariesOfImmuronLimitedAbstract_lbl" xml:lang="en-US">Subsidiaries of Immuron Limited:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SubsidiariesOfImmuronLimitedAbstract" xlink:to="imc_SubsidiariesOfImmuronLimitedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Trade and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl" xml:lang="en-US">Schedule of trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:to="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl" xml:lang="en-US">Provision for Sales Returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantory" xlink:to="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfSalesReturnProvisionExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfSalesReturnProvisionExplantory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfSalesReturnProvisionExplantory_lbl" xml:lang="en-US">Schedule of provision for sales returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfSalesReturnProvisionExplantory" xlink:to="imc_DisclosureOfSalesReturnProvisionExplantory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl" xml:lang="en-US">Sales return provision recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xml:lang="en-US">Amounts transferred from non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ContingentLiabilitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ContingentLiabilitiesTextBlock_lbl" xml:lang="en-US">Contingent liabilities and Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ContingentLiabilitiesTextBlock" xlink:to="imc_ContingentLiabilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfAmountsRecognizedinBalanceSheet" xlink:href="imc-20210630.xsd#imc_ScheduleOfAmountsRecognizedinBalanceSheet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ScheduleOfAmountsRecognizedinBalanceSheet_lbl" xml:lang="en-US">Schedule of amounts relating to leases in balance sheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfAmountsRecognizedinBalanceSheet" xlink:to="imc_ScheduleOfAmountsRecognizedinBalanceSheet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl" xml:lang="en-US">Right-of-use assets1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Lease liabilities2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Total lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases" xlink:href="imc-20210630.xsd#imc_ScheduleOfProfitOrLossAmountsRelatedToLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases_lbl" xml:lang="en-US">Schedule of profit or loss amounts relating to leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases" xlink:to="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:href="imc-20210630.xsd#imc_DepreciationChargeOfRightOfUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DepreciationChargeOfRightOfUseAssetsAbstract_lbl" xml:lang="en-US">Depreciation charge of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="imc_DepreciationChargeOfRightOfUseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US">Depreciation charge of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expense (included in finance cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Finance cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Expense relating to short-term leases (included in other expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0" xml:lang="en-US">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Expense relating to variable lease payments not included in lease liabilities (included in other expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash paid for principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">Schedule of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OrdinarySharesAbstract" xlink:href="imc-20210630.xsd#imc_OrdinarySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OrdinarySharesAbstract_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinarySharesAbstract" xlink:to="imc_OrdinarySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Ordinary shares, Fully paid, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_AmountOfOrdinaryShares" xlink:href="imc-20210630.xsd#imc_AmountOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AmountOfOrdinaryShares_lbl" xml:lang="en-US">Ordinary shares, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AmountOfOrdinaryShares" xlink:to="imc_AmountOfOrdinaryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="imc_AmountOfOrdinaryShares_lbl0" xml:lang="en-US">Ordinary shares, Fully paid, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AmountOfOrdinaryShares" xlink:to="imc_AmountOfOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfOrdinarySharesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfOrdinarySharesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfOrdinarySharesExplanatory_lbl" xml:lang="en-US">Schedule of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfOrdinarySharesExplanatory" xlink:to="imc_DisclosureOfOrdinarySharesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl" xml:lang="en-US">Issue at $0.16 in lieu of payment for services (2018-11-22)1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl" xml:lang="en-US">Issue at $0.16 in lieu of payment for services (2018-11-22)1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ProceedsFromIssuedSharesAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedSharesAtADSPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedSharesAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ProceedsFromIssuedAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedAtADSPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ProceedsFromIssuedAtADSPublicOffering_lbl" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedAtADSPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl" xml:lang="en-US">Reclassify exercised options from reserves to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:to="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringValueReclassifyToStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl" xml:lang="en-US">Reclassify exercised options from reserves to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:to="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl" xml:lang="en-US">Transaction costs arising on representative warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl" xml:lang="en-US">Transaction costs arising on representative warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares_lbl" xml:lang="en-US">Less: Transaction costs arising on share issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" xlink:to="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_BusinessAcquisitionCostOfTransactionCost" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_BusinessAcquisitionCostOfTransactionCost_lbl" xml:lang="en-US">Less: Transaction costs arising on share issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BusinessAcquisitionCostOfTransactionCost" xlink:to="imc_BusinessAcquisitionCostOfTransactionCost_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssuePursuantToAdsPublicOfferingShares" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOfferingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssuePursuantToAdsPublicOfferingShares_lbl" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOfferingShares" xlink:to="imc_IssuePursuantToAdsPublicOfferingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssuePursuantToAdsPublicOffering" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssuePursuantToAdsPublicOffering_lbl" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_IssuePursuantToAdsPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueInLieuOfPaymentForServicesShares" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServicesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueInLieuOfPaymentForServicesShares_lbl" xml:lang="en-US">Issue at A$0.16 in lieu of payment for services (2019-11-12)1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServicesShares" xlink:to="imc_IssueInLieuOfPaymentForServicesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueInLieuOfPaymentForServices" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueInLieuOfPaymentForServices_lbl" xml:lang="en-US">Issue at A$0.16 in lieu of payment for services (2019-11-12)1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServices" xlink:to="imc_IssueInLieuOfPaymentForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrantsShares_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants (2020-06-23)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsShares" xlink:to="imc_ExerciseOfNasdaqWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrants_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants (2020-06-23)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrants" xlink:to="imc_ExerciseOfNasdaqWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrantShares_lbl" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantShares" xlink:to="imc_ExerciseOfRepresentativeWarrantShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrant" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrant_lbl" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant" xlink:to="imc_ExerciseOfRepresentativeWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrants1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrants1_lbl" xml:lang="en-US">Exercise of representative warrants (2020-07-02)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrants1" xlink:to="imc_ExerciseOfRepresentativeWarrants1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrant1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrant1_lbl" xml:lang="en-US">Exercise of representative warrants (2020-07-02)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_ExerciseOfRepresentativeWarrant1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering_lbl" xml:lang="en-US">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS047PursuantToADSPublicOffering" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering1" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl" xml:lang="en-US">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS047PursuantToADSPublicOffering1" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOption_lbl" xml:lang="en-US">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAt050OnExerciseOfESOPUnlistedOption" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl" xml:lang="en-US">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants_lbl" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrants" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant_lbl" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrant" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions_lbl" xml:lang="en-US">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl" xml:lang="en-US">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl" xml:lang="en-US">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl" xml:lang="en-US">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered20201113"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl" xml:lang="en-US">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl" xml:lang="en-US">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl" xml:lang="en-US">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl" xml:lang="en-US">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationOtherReserve" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOtherReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfDetailedInformationOtherReserve_lbl" xml:lang="en-US">Schedule of other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOtherReserve" xlink:to="imc_DisclosureOfDetailedInformationOtherReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CurrencyTranslationDifferences" xlink:href="imc-20210630.xsd#imc_CurrencyTranslationDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CurrencyTranslationDifferences_lbl" xml:lang="en-US">Currency translation differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CurrencyTranslationDifferences" xlink:to="imc_CurrencyTranslationDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwners" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl" xml:lang="en-US">Transactions with owners in their capacity as owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwners" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsIssuedexpensed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsIssuedexpensed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsAndWarrantsIssuedexpensed_lbl" xml:lang="en-US">Options and warrants issued/expensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsIssuedexpensed" xlink:to="imc_OptionsAndWarrantsIssuedexpensed_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsAndWarrantsExercised_lbl" xml:lang="en-US">Options and warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsExercised" xlink:to="imc_OptionsAndWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsLapsed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsLapsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsAndWarrantsLapsed_lbl" xml:lang="en-US">Options and warrants lapsed/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsLapsed" xlink:to="imc_OptionsAndWarrantsLapsed_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SharebasedPaymentExpenses_lbl" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentExpenses" xlink:to="imc_SharebasedPaymentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl" xml:lang="en-US">Re-valuation of options issued in prior period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl0" xml:lang="en-US">Re-valuation of options issued in prior period (2019-11-06) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="imc_TransferToShareCapitalinDollars" xlink:href="imc-20210630.xsd#imc_TransferToShareCapitalinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TransferToShareCapitalinDollars_lbl" xml:lang="en-US">Transfer to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapitalinDollars" xlink:to="imc_TransferToShareCapitalinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsAndWarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsAndWarrantsForfeited_lbl" xml:lang="en-US">Options and warrants forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsForfeited" xlink:to="imc_OptionsAndWarrantsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl" xml:lang="en-US">Schedule of movements in options and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:to="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2018-07-13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2018-07-13) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2018-11-26)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2018-11-26) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl" xml:lang="en-US">Lapse of ESOP unlisted options at $0.50 (2018-10-01)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl" xml:lang="en-US">Lapse of ESOP unlisted options at $0.50 (2018-10-01) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2019-02-11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.50 (2019-02-11) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl" xml:lang="en-US">Lapse of unlisted options at $0.57 (2019-02-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl" xml:lang="en-US">Lapse of unlisted options at $0.57 (2019-02-24) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl" xml:lang="en-US">Lapse of unlisted options at $1.892 (2019-02-28)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl" xml:lang="en-US">Lapse of unlisted options at $1.892 (2019-02-28) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl" xml:lang="en-US">Lapse of unlisted options at $0.30 (2019-05-28)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl" xml:lang="en-US">Lapse of unlisted options at $0.30 (2019-05-28) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl" xml:lang="en-US">Reclassify exercised options from reserves to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl" xml:lang="en-US">Reclassify exercised options from reserves to share capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl" xml:lang="en-US">Reclassify lapsed options from reserves to accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl" xml:lang="en-US">Reclassify lapsed options from reserves to accumulated losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsSharesOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsSharesOne_lbl" xml:lang="en-US">Issue of representative warrants (2019-05-23)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsSharesOne" xlink:to="imc_IssueOfRepresentativeWarrantsSharesOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsOne_lbl" xml:lang="en-US">Issue of representative warrants (2019-05-23) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsOne" xlink:to="imc_IssueOfRepresentativeWarrantsOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriodShares" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriodShares_lbl" xml:lang="en-US">Re-valuation of options issued in prior period (2019-11-06)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriodShares" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsTwoShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwoShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsTwoShares_lbl" xml:lang="en-US">Issue of representative warrants (2019-07-16)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsTwoShares" xlink:to="imc_IssueOfRepresentativeWarrantsTwoShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsTwo" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsTwo_lbl" xml:lang="en-US">Issue of representative warrants (2019-07-16) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsTwo" xlink:to="imc_IssueOfRepresentativeWarrantsTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares_lbl" xml:lang="en-US">Lapse of unexercised options at $0.50 (2019-11-27)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFive_lbl" xml:lang="en-US">Lapse of unexercised options at $0.50 (2019-11-27) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFive" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFive_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares_lbl" xml:lang="en-US">Lapse of unexercised options at $0.55 (2019-11-30)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive_lbl" xml:lang="en-US">Lapse of unexercised options at $0.55 (2019-11-30) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne_lbl" xml:lang="en-US">Lapse of unexercised options at $0.50 (2020-06-30)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne_lbl" xml:lang="en-US">Lapse of unexercised options at $0.50 (2020-06-30) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrantsShares_lbl" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantsShares" xlink:to="imc_ExerciseOfRepresentativeWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrants_lbl" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrants" xlink:to="imc_ExerciseOfRepresentativeWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsSharesOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfRepresentativeWarrantsSharesOne_lbl" xml:lang="en-US">Exercise of representative warrants (2020-07-2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantsSharesOne" xlink:to="imc_ExerciseOfRepresentativeWarrantsSharesOne_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US">Exercise of representative warrants (2020-07-2) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfESOPUnlistedOptions_lbl" xml:lang="en-US">Exercise of ESOP unlisted options at $0.50 (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfESOPUnlistedOptions" xlink:to="imc_ExerciseOfESOPUnlistedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptionsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfESOPUnlistedOptionsValue_lbl" xml:lang="en-US">Exercise of ESOP unlisted options at $0.50 (2020-07-24) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfESOPUnlistedOptionsValue" xlink:to="imc_ExerciseOfESOPUnlistedOptionsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne_lbl" xml:lang="en-US">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsOne_lbl" xml:lang="en-US">Lapse of unexercised options (2020-09-25)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsOne" xlink:to="imc_LapseOfUnexercisedOptionsOne_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LapseOfUnexercisedOptionsValue" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LapseOfUnexercisedOptionsValue_lbl" xml:lang="en-US">Lapse of unexercised options (2020-09-25) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsValue" xlink:to="imc_LapseOfUnexercisedOptionsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsThreeShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThreeShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsThreeShares_lbl" xml:lang="en-US">Issue of representative warrants at US$23.44 per 40 options (2020-07-24)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsThreeShares" xlink:to="imc_IssueOfRepresentativeWarrantsThreeShares_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssueOfRepresentativeWarrantsThree" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssueOfRepresentativeWarrantsThree_lbl" xml:lang="en-US">Issue of representative warrants at US$23.44 per 40 options (2020-07-24) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsThree" xlink:to="imc_IssueOfRepresentativeWarrantsThree_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.12 (2020-10-29)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree_lbl" xml:lang="en-US">Issue of ESOP unlisted options at $0.12 (2020-10-29) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptions_lbl" xml:lang="en-US">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashlessExerciseOfESOPUnlistedOptions" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptionsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptionsValue_lbl" xml:lang="en-US">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashlessExerciseOfESOPUnlistedOptionsValue" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptionsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital_lbl" xml:lang="en-US">Reclassify share-based payments expenses from reserves to share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue_lbl" xml:lang="en-US">Reclassify share-based payments expenses from reserves to share capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosuresOfProductsAndServicesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosuresOfProductsAndServicesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosuresOfProductsAndServicesExplanatory_lbl" xml:lang="en-US">Schedule of segment information for the reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosuresOfProductsAndServicesExplanatory" xlink:to="imc_DisclosuresOfProductsAndServicesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_HyperimmuneProductsRevenue" xlink:href="imc-20210630.xsd#imc_HyperimmuneProductsRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_HyperimmuneProductsRevenue_lbl" xml:lang="en-US">Hyperimmune products revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_HyperimmuneProductsRevenue" xlink:to="imc_HyperimmuneProductsRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SellingAndMarketingExpenses" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SellingAndMarketingExpenses_lbl" xml:lang="en-US">Selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SellingAndMarketingExpenses" xlink:to="imc_SellingAndMarketingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Profit/(loss) for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentAssets" xlink:href="imc-20210630.xsd#imc_SegmentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SegmentAssets_lbl" xml:lang="en-US">Segment assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentAssets" xlink:to="imc_SegmentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AssetsAbstract0" xlink:href="imc-20210630.xsd#imc_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AssetsAbstract0_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssetsAbstract0" xlink:to="imc_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LiabilitiesAbstract0" xlink:href="imc-20210630.xsd#imc_LiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LiabilitiesAbstract0_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LiabilitiesAbstract0" xlink:to="imc_LiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AssetsAbstract00" xlink:href="imc-20210630.xsd#imc_AssetsAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AssetsAbstract00_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssetsAbstract00" xlink:to="imc_AssetsAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LiabilitiesAbstract00" xlink:href="imc-20210630.xsd#imc_LiabilitiesAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LiabilitiesAbstract00_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LiabilitiesAbstract00" xlink:to="imc_LiabilitiesAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl" xml:lang="en-US">Schedule of information on geographical regions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Hyperimmune products revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFromExternalCustomers" xlink:href="imc-20210630.xsd#imc_RevenueFromExternalCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevenueFromExternalCustomers_lbl" xml:lang="en-US">Revenue from external customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFromExternalCustomers" xlink:to="imc_RevenueFromExternalCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentRevenue" xlink:href="imc-20210630.xsd#imc_SegmentRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SegmentRevenue_lbl" xml:lang="en-US">Segment revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentRevenue" xlink:to="imc_SegmentRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_lbl" xml:lang="en-US">Schedule of major customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevenueFormContractWithCustomer" xlink:href="imc-20210630.xsd#imc_RevenueFormContractWithCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevenueFormContractWithCustomer_lbl" xml:lang="en-US">Total revenue for major customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFormContractWithCustomer" xlink:to="imc_RevenueFormContractWithCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl" xml:lang="en-US">Cash Flow Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:to="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl" xml:lang="en-US">Schedule of reconciliation of cash flow from operations with loss after income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:to="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AdjustmentsForAbstract" xlink:href="imc-20210630.xsd#imc_AdjustmentsForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AdjustmentsForAbstract_lbl" xml:lang="en-US">Adjustments for</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_AdjustmentsForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AdjustmentsForDistributionCosts" xlink:href="imc-20210630.xsd#imc_AdjustmentsForDistributionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AdjustmentsForDistributionCosts_lbl" xml:lang="en-US">Distribution costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdjustmentsForDistributionCosts" xlink:to="imc_AdjustmentsForDistributionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeaveProvisionExpense" xlink:href="imc-20210630.xsd#imc_LeaveProvisionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LeaveProvisionExpense_lbl" xml:lang="en-US">Leave provision expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaveProvisionExpense" xlink:to="imc_LeaveProvisionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedPaymentsExpense" xlink:href="imc-20210630.xsd#imc_ShareBasedPaymentsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareBasedPaymentsExpense_lbl" xml:lang="en-US">Share-based payments (income)/expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedPaymentsExpense" xlink:to="imc_ShareBasedPaymentsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US">Unrealized net foreign currency gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US">Add decrease in trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Add (increase) / decrease in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Add (increase) / decrease in other operating assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Add (decrease) / increase in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">Share-based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory_lbl" xml:lang="en-US">Schedule of movement in number of stock options outstanding and weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" xlink:to="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl" xml:lang="en-US">Average exercise price per share option, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl" xml:lang="en-US">Average exercise price per share option, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Number of options, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:to="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1_lbl" xml:lang="en-US">Average exercise price per share option, Forfeited/lapsed during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Number of options,Forfeited/lapsed during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" xlink:to="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl" xml:lang="en-US">Average exercise price per share option, Vested and exercisable at 30 June</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options,Vested and exercisable at 30 June</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfDeemedValuationOfOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl" xml:lang="en-US">Schedule of granted valuation of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:to="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl" xml:lang="en-US">Expiry date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePrice" xlink:href="imc-20210630.xsd#imc_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePrice" xlink:to="imc_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareOptionsOutstanding" xlink:href="imc-20210630.xsd#imc_ShareOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareOptionsOutstanding_lbl" xml:lang="en-US">Share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareOptionsOutstanding" xlink:to="imc_ShareOptionsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareOptionsPerShare" xlink:href="imc-20210630.xsd#imc_ShareOptionsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareOptionsPerShare_lbl" xml:lang="en-US">Share options price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareOptionsPerShare" xlink:to="imc_ShareOptionsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate_lbl" xml:lang="en-US">Grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_ExercisePriceShareOptionsGranted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExercisePriceShareOptionsGranted1_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceShareOptionsGranted1" xlink:to="imc_ExercisePriceShareOptionsGranted1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfInstrumentOtherEquityInstrumentGranted" xlink:href="imc-20210630.xsd#imc_NumberOfInstrumentOtherEquityInstrumentGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfInstrumentOtherEquityInstrumentGranted_lbl" xml:lang="en-US">No. of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfInstrumentOtherEquityInstrumentGranted" xlink:to="imc_NumberOfInstrumentOtherEquityInstrumentGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WeightedAverageSharePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_WeightedAverageSharePriceShareOptionsGranted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl" xml:lang="en-US">Share price at grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageSharePriceShareOptionsGranted1" xlink:to="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk- free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ValuePerShareOptionsGranted" xlink:href="imc-20210630.xsd#imc_ValuePerShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ValuePerShareOptionsGranted_lbl" xml:lang="en-US">Fair value at grant date per option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValuePerShareOptionsGranted" xlink:to="imc_ValuePerShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions_lbl" xml:lang="en-US">Schedule of total expenses arising from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" xlink:to="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsIssuedUnderESOP" xlink:href="imc-20210630.xsd#imc_OptionsIssuedUnderESOP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsIssuedUnderESOP_lbl" xml:lang="en-US">Options issued under ESOP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsIssuedUnderESOP" xlink:to="imc_OptionsIssuedUnderESOP_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsToDirectors" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsToDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SharebasedPaymentsToDirectors_lbl" xml:lang="en-US">Share-based payments to directors2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsToDirectors" xlink:to="imc_SharebasedPaymentsToDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TotalExpenses" xlink:href="imc-20210630.xsd#imc_TotalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TotalExpenses_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TotalExpenses" xlink:to="imc_TotalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl" xml:lang="en-US">Schedule of information about other related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:to="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US">Amounts settled in cash or shares for goods and services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl0" xml:lang="en-US">Amounts settled in cash or shares during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl1" xml:lang="en-US">Current payables (purchases of goods and services)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US">Purchases of various goods and services from entities controlled by key management personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:href="imc-20210630.xsd#imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl" xml:lang="en-US">Other transactions with key management personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:to="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">Schedule of outstanding balances transactions between related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl" xml:lang="en-US">Entities controlled by key management personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl" xml:lang="en-US">Schedule of foreign currency risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:to="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US">Total exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfExchangerateTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfExchangerateTableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfExchangerateTableExplanatory_lbl" xml:lang="en-US">Schedule of exchange rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfExchangerateTableExplanatory" xlink:to="imc_DisclosureOfExchangerateTableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ImpactOnLossForPeriods" xlink:href="imc-20210630.xsd#imc_ImpactOnLossForPeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ImpactOnLossForPeriods_lbl" xml:lang="en-US">Impact on loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImpactOnLossForPeriods" xlink:to="imc_ImpactOnLossForPeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ImpactOnOtherComponentOfEquity" xlink:href="imc-20210630.xsd#imc_ImpactOnOtherComponentOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ImpactOnOtherComponentOfEquity_lbl" xml:lang="en-US">Impact on other components of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImpactOnOtherComponentOfEquity" xlink:to="imc_ImpactOnOtherComponentOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl" xml:lang="en-US">Schedule of trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedCreditLossRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedCreditLossRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedCreditLossRate_lbl" xml:lang="en-US">Expected credit loss rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedCreditLossRate" xlink:to="ifrs-full_ExpectedCreditLossRate_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrossCarryingAmount" xlink:href="imc-20210630.xsd#imc_GrossCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrossCarryingAmount_lbl" xml:lang="en-US">Gross carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrossCarryingAmount" xlink:to="imc_GrossCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LossAllowance" xlink:href="imc-20210630.xsd#imc_LossAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LossAllowance_lbl" xml:lang="en-US">Loss allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LossAllowance" xlink:to="imc_LossAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl" xml:lang="en-US">Schedule of contractual undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TradeAndOtherPayable" xlink:href="imc-20210630.xsd#imc_TradeAndOtherPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TradeAndOtherPayable_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TradeAndOtherPayable" xlink:to="imc_TradeAndOtherPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_At30June2020Abstract" xlink:href="imc-20210630.xsd#imc_At30June2020Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_At30June2020Abstract_lbl" xml:lang="en-US">At 30 June 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_At30June2020Abstract" xlink:to="imc_At30June2020Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Events occurring after the Reporting Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DisclosureOfCompanyDetailsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DisclosureOfCompanyDetailsExplanatory_lbl" xml:lang="en-US">Company Details</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCompanyDetailsExplanatory" xlink:to="imc_DisclosureOfCompanyDetailsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ImpairmentLoss_lbl" xml:lang="en-US">Net impairment losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GeneralAndAdministrativeExpenses" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GeneralAndAdministrativeExpenses" xlink:to="imc_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentLiabilities" xlink:href="imc-20210630.xsd#imc_SegmentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imc_SegmentLiabilities_lbl" xml:lang="en-US">Segment liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentLiabilities" xlink:to="imc_SegmentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RawMaterialsAndStoresMember" xlink:href="imc-20210630.xsd#imc_RawMaterialsAndStoresMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RawMaterialsAndStoresMember_lbl" xml:lang="en-US">Raw materials and stores (Colostrum) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RawMaterialsAndStoresMember" xlink:to="imc_RawMaterialsAndStoresMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WorkInProgressMember" xlink:href="imc-20210630.xsd#imc_WorkInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WorkInProgressMember_lbl" xml:lang="en-US">Work in progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WorkInProgressMember" xlink:to="imc_WorkInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinishedGoodsMember" xlink:href="imc-20210630.xsd#imc_FinishedGoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_FinishedGoodsMember_lbl" xml:lang="en-US">Finished goods (Travelan and Protectyn) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinishedGoodsMember" xlink:to="imc_FinishedGoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ImmuronLimitedMember" xlink:href="imc-20210630.xsd#imc_ImmuronLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ImmuronLimitedMember_lbl" xml:lang="en-US">Immuron Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImmuronLimitedMember" xlink:to="imc_ImmuronLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ImmuronIncMember" xlink:href="imc-20210630.xsd#imc_ImmuronIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ImmuronIncMember_lbl" xml:lang="en-US">Immuron Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImmuronIncMember" xlink:to="imc_ImmuronIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AnadisEPSPtyLtdMember" xlink:href="imc-20210630.xsd#imc_AnadisEPSPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AnadisEPSPtyLtdMember_lbl" xml:lang="en-US">Anadis EPS Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AnadisEPSPtyLtdMember" xlink:to="imc_AnadisEPSPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IMCCanadaLtdMember" xlink:href="imc-20210630.xsd#imc_IMCCanadaLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IMCCanadaLtdMember_lbl" xml:lang="en-US">IMC Canada Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IMCCanadaLtdMember" xlink:to="imc_IMCCanadaLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Properties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Properties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Share-based payments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ForeignCurrencyTranslationMember" xlink:href="imc-20210630.xsd#imc_ForeignCurrencyTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ForeignCurrencyTranslationMember_lbl" xml:lang="en-US">Foreign currency translation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ForeignCurrencyTranslationMember" xlink:to="imc_ForeignCurrencyTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentResearchAndDevelopmentMember" xlink:href="imc-20210630.xsd#imc_SegmentResearchAndDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SegmentResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentResearchAndDevelopmentMember" xlink:to="imc_SegmentResearchAndDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentHyperImmuneProductsMember" xlink:href="imc-20210630.xsd#imc_SegmentHyperImmuneProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SegmentHyperImmuneProductsMember_lbl" xml:lang="en-US">HyperImmune Products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentHyperImmuneProductsMember" xlink:to="imc_SegmentHyperImmuneProductsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherMember" xlink:href="imc-20210630.xsd#imc_OtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherMember" xlink:to="imc_OtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TravelanMember" xlink:href="imc-20210630.xsd#imc_TravelanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TravelanMember_lbl" xml:lang="en-US">Travelan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TravelanMember" xlink:to="imc_TravelanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_AU_lbl" xml:lang="en-US">Australia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherCountriesMember" xlink:href="imc-20210630.xsd#imc_OtherCountriesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherCountriesMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherCountriesMember" xlink:to="imc_OtherCountriesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ProtectynMember" xlink:href="imc-20210630.xsd#imc_ProtectynMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ProtectynMember_lbl" xml:lang="en-US">Protectyn [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProtectynMember" xlink:to="imc_ProtectynMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerAMember" xlink:href="imc-20210630.xsd#imc_CustomerAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerAMember" xlink:to="imc_CustomerAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerBMember" xlink:href="imc-20210630.xsd#imc_CustomerBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerBMember" xlink:to="imc_CustomerBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerCMember" xlink:href="imc-20210630.xsd#imc_CustomerCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerCMember" xlink:to="imc_CustomerCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerDMember" xlink:href="imc-20210630.xsd#imc_CustomerDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerDMember" xlink:to="imc_CustomerDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerEMember" xlink:href="imc-20210630.xsd#imc_CustomerEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerEMember_lbl" xml:lang="en-US">Customer E [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerEMember" xlink:to="imc_CustomerEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerFMember" xlink:href="imc-20210630.xsd#imc_CustomerFMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerFMember_lbl" xml:lang="en-US">Customer F [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerFMember" xlink:to="imc_CustomerFMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerGMember" xlink:href="imc-20210630.xsd#imc_CustomerGMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerGMember_lbl" xml:lang="en-US">Customer G [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerGMember" xlink:to="imc_CustomerGMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerHMember" xlink:href="imc-20210630.xsd#imc_CustomerHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerHMember_lbl" xml:lang="en-US">Customer H [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerHMember" xlink:to="imc_CustomerHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CustomerIMember" xlink:href="imc-20210630.xsd#imc_CustomerIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CustomerIMember_lbl" xml:lang="en-US">Customer I [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerIMember" xlink:to="imc_CustomerIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_EmployeeStockOption1Member" xlink:href="imc-20210630.xsd#imc_EmployeeStockOption1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_EmployeeStockOption1Member_lbl" xml:lang="en-US">ESOP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeStockOption1Member" xlink:to="imc_EmployeeStockOption1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateOneMember" xlink:href="imc-20210630.xsd#imc_GrantDateOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateOneMember_lbl" xml:lang="en-US">2012-06-29 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateOneMember" xlink:to="imc_GrantDateOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTwoMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateTwoMember_lbl" xml:lang="en-US">2012-06-29 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTwoMember" xlink:to="imc_GrantDateTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateThreeMember" xlink:href="imc-20210630.xsd#imc_GrantDateThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateThreeMember_lbl" xml:lang="en-US">2017-06-13 (warrants) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateThreeMember" xlink:to="imc_GrantDateThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateFourMember" xlink:href="imc-20210630.xsd#imc_GrantDateFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateFourMember_lbl" xml:lang="en-US">2018-03-15 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateFourMember" xlink:to="imc_GrantDateFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateFiveMember" xlink:href="imc-20210630.xsd#imc_GrantDateFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateFiveMember_lbl" xml:lang="en-US">2017-06-09 (warrants) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateFiveMember" xlink:to="imc_GrantDateFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateSixMember" xlink:href="imc-20210630.xsd#imc_GrantDateSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateSixMember_lbl" xml:lang="en-US">2018-03-15 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateSixMember" xlink:to="imc_GrantDateSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateSevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateSevenMember_lbl" xml:lang="en-US">2019-05-23 (warrants) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateSevenMember" xlink:to="imc_GrantDateSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateEightMember" xlink:href="imc-20210630.xsd#imc_GrantDateEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateEightMember_lbl" xml:lang="en-US">2019-07-16 (warrants) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateEightMember" xlink:to="imc_GrantDateEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateNineMember" xlink:href="imc-20210630.xsd#imc_GrantDateNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateNineMember_lbl" xml:lang="en-US">2018-07-13 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateNineMember" xlink:to="imc_GrantDateNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTenMember" xlink:href="imc-20210630.xsd#imc_GrantDateTenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateTenMember_lbl" xml:lang="en-US">2019-11-06 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTenMember" xlink:to="imc_GrantDateTenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateElevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateElevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateElevenMember_lbl" xml:lang="en-US">2020-10-29 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateElevenMember" xlink:to="imc_GrantDateElevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrantDateTwelveMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwelveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrantDateTwelveMember_lbl" xml:lang="en-US">2020-07-24 (warrants) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTwelveMember" xlink:to="imc_GrantDateTwelveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceOneMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceOneMember" xlink:to="imc_ExercisePriceOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceTwoMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceTwoMember" xlink:to="imc_ExercisePriceTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExercisePriceSixteenMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExercisePriceSixteenMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceSixteenMember" xlink:to="imc_ExercisePriceSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember_lbl" xml:lang="en-US">Rental of an office suite from Wattle Laboratories Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" xlink:to="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember_lbl" xml:lang="en-US">Services rendered by Grandlodge Capital Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember" xlink:to="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_CAD_lbl" xml:lang="en-US">CAD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">ILS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US">Trade Receivables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentMember_lbl" xml:lang="en-US">Current [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentMember" xlink:to="ifrs-full_CurrentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xml:lang="en-US">1-30 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember_lbl" xml:lang="en-US">31-60 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" xlink:to="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember_lbl" xml:lang="en-US">61-90 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanThreeMonthsMember" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanThreeMonthsMember_lbl" xml:lang="en-US">91-120 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeMonthsMember" xlink:to="ifrs-full_LaterThanThreeMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">121+ [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_lbl" xml:lang="en-US">Less than 6 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_lbl" xml:lang="en-US">6 - 12 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US">Between 1 and 2 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US">Between 2 and 5 Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US">Over 5 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ContractualCashFlowsMember" xlink:href="imc-20210630.xsd#imc_ContractualCashFlowsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ContractualCashFlowsMember_lbl" xml:lang="en-US">Total contractual cash flows [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ContractualCashFlowsMember" xlink:to="imc_ContractualCashFlowsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_CarryingAssetsLiabilitiesMember" xlink:href="imc-20210630.xsd#imc_CarryingAssetsLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_CarryingAssetsLiabilitiesMember_lbl" xml:lang="en-US">Carrying amount (assets)/ liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CarryingAssetsLiabilitiesMember" xlink:to="imc_CarryingAssetsLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TitlesOfIndividualAxis" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TitlesOfIndividualAxis_lbl" xml:lang="en-US">Titles Of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TitlesOfIndividualAxis" xlink:to="imc_TitlesOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TypesOfArrangementsAxis" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_TypesOfArrangementsAxis_lbl" xml:lang="en-US">Types of arrangements [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TypesOfArrangementsAxis" xlink:to="imc_TypesOfArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RepresentativesWarrants" xlink:href="imc-20210630.xsd#imc_RepresentativesWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RepresentativesWarrants_lbl" xml:lang="en-US">Representative warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RepresentativesWarrants" xlink:to="imc_RepresentativesWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShareCapital" xlink:href="imc-20210630.xsd#imc_ShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShareCapital_lbl" xml:lang="en-US">Share capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareCapital" xlink:to="imc_ShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AssistancePackages" xlink:href="imc-20210630.xsd#imc_AssistancePackages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AssistancePackages_lbl" xml:lang="en-US">Assistance packages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssistancePackages" xlink:to="imc_AssistancePackages_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:href="imc-20210630.xsd#imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:to="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RawMaterials" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterials" xlink:to="ifrs-full_RawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NonCurrentRawMaterials" xlink:href="imc-20210630.xsd#imc_NonCurrentRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NonCurrentRawMaterials_lbl" xml:lang="en-US">Raw materials non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NonCurrentRawMaterials" xlink:to="imc_NonCurrentRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RAndDTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_RAndDTaxConcessionRefund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RAndDTaxConcessionRefund_lbl" xml:lang="en-US">Other income R&amp;D tax concession refund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RAndDTaxConcessionRefund" xlink:to="imc_RAndDTaxConcessionRefund_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AdditionalRAndDTaxReceived" xlink:href="imc-20210630.xsd#imc_AdditionalRAndDTaxReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AdditionalRAndDTaxReceived_lbl" xml:lang="en-US">Additional R&amp;D fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalRAndDTaxReceived" xlink:to="imc_AdditionalRAndDTaxReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherIncomeOfResearchAndDevelopment" xlink:href="imc-20210630.xsd#imc_OtherIncomeOfResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherIncomeOfResearchAndDevelopment_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeOfResearchAndDevelopment" xlink:to="imc_OtherIncomeOfResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_AdditionalOtherIncome" xlink:href="imc-20210630.xsd#imc_AdditionalOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_AdditionalOtherIncome_lbl" xml:lang="en-US">Additional other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalOtherIncome" xlink:to="imc_AdditionalOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GovernmentAssistancePackages" xlink:href="imc-20210630.xsd#imc_GovernmentAssistancePackages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GovernmentAssistancePackages_lbl" xml:lang="en-US">Government assistance packages</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGxuwsX9YeYfsaxB1g3aFgV8hkFfiO2LJPI=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GovernmentAssistancePackages" xlink:to="imc_GovernmentAssistancePackages_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ResearchAndDevelopmentsGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentsGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ResearchAndDevelopmentsGrants_lbl" xml:lang="en-US">R&amp;D grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentsGrants" xlink:to="imc_ResearchAndDevelopmentsGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_lbl" xml:lang="en-US">Contingent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InformationAboutNatureOfLesseesLeasingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities_lbl" xml:lang="en-US">Lease, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" xlink:to="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_PaymentForServices" xlink:href="imc-20210630.xsd#imc_PaymentForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_PaymentForServices_lbl" xml:lang="en-US">Payment for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PaymentForServices" xlink:to="imc_PaymentForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">New fully paid ordinary per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_IssuanceOfOrdinarySharesDescription" xlink:href="imc-20210630.xsd#imc_IssuanceOfOrdinarySharesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_IssuanceOfOrdinarySharesDescription_lbl" xml:lang="en-US">Issuance of ordinary shares, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuanceOfOrdinarySharesDescription" xlink:to="imc_IssuanceOfOrdinarySharesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReserveMaturityDateDescription" xlink:href="imc-20210630.xsd#imc_OtherReserveMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OtherReserveMaturityDateDescription_lbl" xml:lang="en-US">Maturity date, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReserveMaturityDateDescription" xlink:to="imc_OtherReserveMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSharesUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesUnlistedOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSharesUnlistedOption_lbl" xml:lang="en-US">Number of shares unlisted option (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesUnlistedOption" xlink:to="imc_NumberOfSharesUnlistedOption_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_UnlistedOptionExercisable" xlink:href="imc-20210630.xsd#imc_UnlistedOptionExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_UnlistedOptionExercisable_lbl" xml:lang="en-US">Unlisted option exercisable per shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UnlistedOptionExercisable" xlink:to="imc_UnlistedOptionExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ESOPOptionsIssued" xlink:href="imc-20210630.xsd#imc_ESOPOptionsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ESOPOptionsIssued_lbl" xml:lang="en-US">ESOP options issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ESOPOptionsIssued" xlink:to="imc_ESOPOptionsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionsGranted" xlink:href="imc-20210630.xsd#imc_OptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionsGranted_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsGranted" xlink:to="imc_OptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluedAtGrantDate" xlink:href="imc-20210630.xsd#imc_RevaluedAtGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluedAtGrantDate_lbl" xml:lang="en-US">Grant date, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluedAtGrantDate" xlink:to="imc_RevaluedAtGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationOfShareholdersApprovedValue" xlink:href="imc-20210630.xsd#imc_RevaluationOfShareholdersApprovedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluationOfShareholdersApprovedValue_lbl" xml:lang="en-US">Revaluation of options value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfShareholdersApprovedValue" xlink:to="imc_RevaluationOfShareholdersApprovedValue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RevaluationFinancialsAmount" xlink:href="imc-20210630.xsd#imc_RevaluationFinancialsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_RevaluationFinancialsAmount_lbl" xml:lang="en-US">Revaluation financials amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationFinancialsAmount" xlink:to="imc_RevaluationFinancialsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ExpenseOfSharesOwed" xlink:href="imc-20210630.xsd#imc_ExpenseOfSharesOwed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ExpenseOfSharesOwed_lbl" xml:lang="en-US">Value of shares owed (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseOfSharesOwed" xlink:to="imc_ExpenseOfSharesOwed_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_NumberOfSegment" xlink:href="imc-20210630.xsd#imc_NumberOfSegment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_NumberOfSegment_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSegment" xlink:to="imc_NumberOfSegment_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_PercentageOfEntityRevenue" xlink:href="imc-20210630.xsd#imc_PercentageOfEntityRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_PercentageOfEntityRevenue_lbl" xml:lang="en-US">Percentage of total revenue for major customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PercentageOfEntityRevenue" xlink:to="imc_PercentageOfEntityRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OptionGrantedDescription" xlink:href="imc-20210630.xsd#imc_OptionGrantedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OptionGrantedDescription_lbl" xml:lang="en-US">Option granted, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionGrantedDescription" xlink:to="imc_OptionGrantedDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharesIssuedToDirectorsForTheDirectorFees" xlink:href="imc-20210630.xsd#imc_SharesIssuedToDirectorsForTheDirectorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SharesIssuedToDirectorsForTheDirectorFees_lbl" xml:lang="en-US">Shares issued to directors for the director fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharesIssuedToDirectorsForTheDirectorFees" xlink:to="imc_SharesIssuedToDirectorsForTheDirectorFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeaseRenewed" xlink:href="imc-20210630.xsd#imc_LeaseRenewed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_LeaseRenewed_lbl" xml:lang="en-US">Lease renewed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaseRenewed" xlink:to="imc_LeaseRenewed_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WarehousingDistributionAndInvoicingServices" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndInvoicingServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WarehousingDistributionAndInvoicingServices_lbl" xml:lang="en-US">Warehousing, distribution and invoicing services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndInvoicingServices" xlink:to="imc_WarehousingDistributionAndInvoicingServices_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharesIssuedPricePerShare1" xlink:href="imc-20210630.xsd#imc_SharesIssuedPricePerShare1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_SharesIssuedPricePerShare1_lbl" xml:lang="en-US">Share issued price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharesIssuedPricePerShare1" xlink:to="imc_SharesIssuedPricePerShare1_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WarehousingDistributionAndServicesFees" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndServicesFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WarehousingDistributionAndServicesFees_lbl" xml:lang="en-US">Warehousing distribution and services fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndServicesFees" xlink:to="imc_WarehousingDistributionAndServicesFees_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OrdinarySharesIssued" xlink:href="imc-20210630.xsd#imc_OrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinarySharesIssued" xlink:to="imc_OrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_PercentageOfForeignExchangeRates" xlink:href="imc-20210630.xsd#imc_PercentageOfForeignExchangeRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_PercentageOfForeignExchangeRates_lbl" xml:lang="en-US">Percentage of USD/AUD exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PercentageOfForeignExchangeRates" xlink:to="imc_PercentageOfForeignExchangeRates_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForBasisOfPresentation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl" xml:lang="en-US">Basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:to="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US">Government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl" xml:lang="en-US">AASB Interpretation 23 Uncertainty over Income Tax Treatments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl" xml:lang="en-US">Investments and other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:to="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl" xml:lang="en-US">Contributed equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl" xml:lang="en-US">Rounding of amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl" xml:lang="en-US">Goods and services tax (GST)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:to="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_PlantAndEquipmentMember" xlink:href="imc-20210630.xsd#imc_PlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_PlantAndEquipmentMember_lbl" xml:lang="en-US">Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PlantAndEquipmentMember" xlink:to="imc_PlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl" xml:lang="en-US">Furniture, fittings and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US">Right-of-use assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DrJerryKanellosMember" xlink:href="imc-20210630.xsd#imc_DrJerryKanellosMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DrJerryKanellosMember_lbl" xml:lang="en-US">Dr. Jerry Kanellos [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DrJerryKanellosMember" xlink:to="imc_DrJerryKanellosMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_MrRichardJBermanMember" xlink:href="imc-20210630.xsd#imc_MrRichardJBermanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_MrRichardJBermanMember_lbl" xml:lang="en-US">Mr. Richard J. Berman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MrRichardJBermanMember" xlink:to="imc_MrRichardJBermanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_DrGarySJacobMember" xlink:href="imc-20210630.xsd#imc_DrGarySJacobMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_DrGarySJacobMember_lbl" xml:lang="en-US">Dr. Gary S. Jacob [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DrGarySJacobMember" xlink:to="imc_DrGarySJacobMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ShortTermFundingAgreementsMember" xlink:href="imc-20210630.xsd#imc_ShortTermFundingAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_ShortTermFundingAgreementsMember_lbl" xml:lang="en-US">Short-term Funding Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShortTermFundingAgreementsMember" xlink:to="imc_ShortTermFundingAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_WattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_WattleLaboratoriesPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_WattleLaboratoriesPtyLtdMember_lbl" xml:lang="en-US">Wattle Laboratories Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WattleLaboratoriesPtyLtdMember" xlink:to="imc_WattleLaboratoriesPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_GrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_GrandlodgeCapitalPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imc_GrandlodgeCapitalPtyLtdMember_lbl" xml:lang="en-US">Grandlodge Capital Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrandlodgeCapitalPtyLtdMember" xlink:to="imc_GrandlodgeCapitalPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsTablesTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsTablesTable_lbl" xml:lang="en-US">Share-based Payments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsTablesTable" xlink:to="imc_SharebasedPaymentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsTablesLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsTablesLineItems_lbl" xml:lang="en-US">Share-based Payments (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsTablesLineItems" xlink:to="imc_SharebasedPaymentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDomain" xlink:href="imc-20210630.xsd#imc_InventoriesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InventoriesDomain_lbl" xml:lang="en-US">Inventories [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesDomain" xlink:to="imc_InventoriesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDetailsScheduleofinventoriesTable" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InventoriesDetailsScheduleofinventoriesTable_lbl" xml:lang="en-US">Inventories (Details) - Schedule of inventories [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesDetailsScheduleofinventoriesTable" xlink:to="imc_InventoriesDetailsScheduleofinventoriesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InventoriesDetailsScheduleofinventoriesLineItems_lbl" xml:lang="en-US">Inventories (Details) - Schedule of inventories [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="imc_InventoriesDetailsScheduleofinventoriesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US">Entity&apos;s total for subsidiaries [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable_lbl" xml:lang="en-US">Controlled Entities (Details) - Schedule of subsidiaries [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:to="imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems_lbl" xml:lang="en-US">Controlled Entities (Details) - Schedule of subsidiaries [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:to="imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of amounts relating to leases in balance sheet [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:to="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of profit or loss amounts relating to leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:to="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of profit or loss amounts relating to leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:to="imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesTable_lbl" xml:lang="en-US">Other Reserves (Details) - Schedule of other reserves [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesTable" xlink:to="imc_OtherReservesDetailsScheduleofotherreservesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherReservesDetailsScheduleofotherreservesLineItems_lbl" xml:lang="en-US">Other Reserves (Details) - Schedule of other reserves [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="imc_OtherReservesDetailsScheduleofotherreservesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsMember_lbl" xml:lang="en-US">Segments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsMember" xlink:to="ifrs-full_SegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of segment information for the reportable segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:to="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_MajorProductLinesDomain" xlink:href="imc-20210630.xsd#imc_MajorProductLinesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_MajorProductLinesDomain_lbl" xml:lang="en-US">MajorProductLines [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MajorProductLinesDomain" xlink:to="imc_MajorProductLinesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US">Geographical areas [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of information on geographical regions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US">Customers [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersTable_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of major customers [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:to="imc_SegmentReportingDetailsScheduleofmajorcustomersTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems_lbl" xml:lang="en-US">Segment Reporting (Details) - Schedule of major customers [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:to="imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable_lbl" xml:lang="en-US">Share-based Payments (Details) - Schedule of granted valuation of options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems_lbl" xml:lang="en-US">Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of information about other related party transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:to="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PastDueStatusMember_lbl" xml:lang="en-US">Past due status [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PastDueStatusMember" xlink:to="ifrs-full_PastDueStatusMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsCategoryMember_lbl" xml:lang="en-US">Financial assets, category [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsCategoryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US">Aggregated time bands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems_lbl" xml:lang="en-US">Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="imc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="imc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TitlesOfIndividualDomain" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TitlesOfIndividualDomain_lbl" xml:lang="en-US">TitlesOfIndividual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TitlesOfIndividualDomain" xlink:to="imc_TitlesOfIndividualDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherReservesDetailsTable_lbl" xml:lang="en-US">Other Reserves (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReservesDetailsTable" xlink:to="imc_OtherReservesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_OtherReservesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherReservesDetailsLineItems_lbl" xml:lang="en-US">Other Reserves (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReservesDetailsLineItems" xlink:to="imc_OtherReservesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_TypesOfArrangementsDomain" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TypesOfArrangementsDomain_lbl" xml:lang="en-US">TypesOfArrangements [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TypesOfArrangementsDomain" xlink:to="imc_TypesOfArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RelatedPartyTransactionsDetailsTable" xlink:to="imc_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="imc_RelatedPartyTransactionsDetailsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RelatedPartyTransactionsDetailsLineItems" xlink:to="imc_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AccountingAndAudit_lbl0" xml:lang="en-US">The amount of accounting and audit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccountingAndAudit" xlink:to="imc_AccountingAndAudit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AdditionalOtherIncome_lbl0" xml:lang="en-US">Additional other income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalOtherIncome" xlink:to="imc_AdditionalOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AdditionalRAndDTaxReceived_lbl0" xml:lang="en-US">Additional research and developement tax received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalRAndDTaxReceived" xlink:to="imc_AdditionalRAndDTaxReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AdjustmentsForDistributionCosts_lbl0" xml:lang="en-US">The amount of adjustments for costs relating to the distribution of goods and services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdjustmentsForDistributionCosts" xlink:to="imc_AdjustmentsForDistributionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AmountOfOrdinaryShares_lbl1" xml:lang="en-US">Amount of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AmountOfOrdinaryShares" xlink:to="imc_AmountOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AssistancePackages_lbl0" xml:lang="en-US">Assistance packages.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssistancePackages" xlink:to="imc_AssistancePackages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_BadDebts_lbl0" xml:lang="en-US">The amount of bad debts expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BadDebts" xlink:to="imc_BadDebts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_BasicAndDilutedEarningsLossPerShare_lbl1" xml:lang="en-US">The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BasicAndDilutedEarningsLossPerShare" xlink:to="imc_BasicAndDilutedEarningsLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_BusinessAcquisitionCostOfTransactionCost_lbl0" xml:lang="en-US">The cash outflow for share issue by cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BusinessAcquisitionCostOfTransactionCost" xlink:to="imc_BusinessAcquisitionCostOfTransactionCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CapitalCost_lbl0" xml:lang="en-US">Represents the information of capital raising cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CapitalCost" xlink:to="imc_CapitalCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CashAtBankAndInHand_lbl0" xml:lang="en-US">The amount of cash on hand and demand deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashAtBankAndInHand" xlink:to="imc_CashAtBankAndInHand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ChangeInAccountingPolicy_lbl0" xml:lang="en-US">Change in accounting policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ChangeInAccountingPolicy" xlink:to="imc_ChangeInAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ConsultingExpenses_lbl0" xml:lang="en-US">The amount of consultinf expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ConsultingExpenses" xlink:to="imc_ConsultingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ControlledEntitiesTextBlock_lbl0" xml:lang="en-US">It represents as a controlled entities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesTextBlock" xlink:to="imc_ControlledEntitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CurrencyTranslationDifferences_lbl0" xml:lang="en-US">Amount of currency translation differences for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CurrencyTranslationDifferences" xlink:to="imc_CurrencyTranslationDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">The amount of tax expense or income not recognized relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:to="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for uncertainty over income tax treatments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for basis of presentation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:to="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl0" xml:lang="en-US">Represents the information of description of accounting policy for equity policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl0" xml:lang="en-US">Represents the information of description of accounting policy for goods and services tax explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:to="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for investments and other financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:to="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl0" xml:lang="en-US">The description of the entity rounding of amounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DetailedInformationAboutCashExplanatory_lbl0" xml:lang="en-US">The disclosure of cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutCashExplanatory" xlink:to="imc_DetailedInformationAboutCashExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DetailedInformationAboutInventoriesExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information about inventories.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutInventoriesExplanatory" xlink:to="imc_DetailedInformationAboutInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information about trade and other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:to="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfCashExplanatory_lbl0" xml:lang="en-US">The disclosure of cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashExplanatory" xlink:to="imc_DisclosureOfCashExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl0" xml:lang="en-US">Represents the information of disclosure of cash flow information explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:to="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfCompanyDetailsExplanatory_lbl0" xml:lang="en-US">The disclosure of company details.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCompanyDetailsExplanatory" xlink:to="imc_DisclosureOfCompanyDetailsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl0" xml:lang="en-US">The disclosure of detailed information about movements in options and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:to="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Represents disclosure of detailed information of related party edxplanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:to="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfDetailedInformationOtherReserve_lbl0" xml:lang="en-US">The disclosure of detailed information about other reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOtherReserve" xlink:to="imc_DisclosureOfDetailedInformationOtherReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Represents the information of disclosure of details of earnings per share explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:to="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfExchangerateTableExplanatory_lbl0" xml:lang="en-US">Detail dislcosure of exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfExchangerateTableExplanatory" xlink:to="imc_DisclosureOfExchangerateTableExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl0" xml:lang="en-US">Dislcosure of financial assets and liabilities are subject to foreign currency risk.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:to="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl0" xml:lang="en-US">Represents information related to disclosure of income tax benefit explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfIncomeTaxBenefitExplanatory" xlink:to="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl0" xml:lang="en-US">Disclosure of information about other related party transactions explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:to="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl0" xml:lang="en-US">The entire disclosure for provision for sales returns.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantory" xlink:to="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl0" xml:lang="en-US">Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:to="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfSalesReturnProvisionExplantory_lbl0" xml:lang="en-US">The disclosure of transactions between the entity sales return provision.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfSalesReturnProvisionExplantory" xlink:to="imc_DisclosureOfSalesReturnProvisionExplantory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about trade and other current payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:to="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl0" xml:lang="en-US">The detail disclosure of trade and other payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl0" xml:lang="en-US">The detail disclosure of trade and other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_DisclosuresOfProductsAndServicesExplanatory_lbl0" xml:lang="en-US">The disclosure of the entity&apos;s products and services. [Refer: Products and services [member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosuresOfProductsAndServicesExplanatory" xlink:to="imc_DisclosuresOfProductsAndServicesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ESOPOptionsIssued_lbl0" xml:lang="en-US">ESOP options issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ESOPOptionsIssued" xlink:to="imc_ESOPOptionsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_EmployeeBenefitObligation_lbl0" xml:lang="en-US">Represents information related to employee benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligation" xlink:to="imc_EmployeeBenefitObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_EmployeeBenefitObligationNonCurrent_lbl0" xml:lang="en-US">Represents information related to non current employee benefit obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligationNonCurrent" xlink:to="imc_EmployeeBenefitObligationNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_EmployeeShareSchemesValueOfEmployee_lbl0" xml:lang="en-US">Employee share schemes - value of employee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeShareSchemesValueOfEmployee" xlink:to="imc_EmployeeShareSchemesValueOfEmployee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_EquityBalance_lbl1" xml:lang="en-US">It represents as a equity balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EquityBalance" xlink:to="imc_EquityBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExerciseOfNasdaqWarrants_lbl0" xml:lang="en-US">Exercise of NASDAQ Warrants (2020-06-23).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrants" xlink:to="imc_ExerciseOfNasdaqWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExerciseOfNasdaqWarrantsShares_lbl0" xml:lang="en-US">Exercise of NASDAQ Warrants (2020-06-23), shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsShares" xlink:to="imc_ExerciseOfNasdaqWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExerciseOfRepresentativeWarrant_lbl0" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant" xlink:to="imc_ExerciseOfRepresentativeWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExerciseOfRepresentativeWarrant1_lbl0" xml:lang="en-US">Exercise of representative warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_ExerciseOfRepresentativeWarrant1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExerciseOfRepresentativeWarrantShares_lbl0" xml:lang="en-US">Exercise of representative warrants (2020-06-15, 2020-06-22), shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantShares" xlink:to="imc_ExerciseOfRepresentativeWarrantShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExercisePriceShareOptionsGranted1_lbl0" xml:lang="en-US">&quot; The exercise price of share options granted.&quot;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceShareOptionsGranted1" xlink:to="imc_ExercisePriceShareOptionsGranted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExpectedCreditLosses_lbl0" xml:lang="en-US">The amount of expected credit losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpectedCreditLosses" xlink:to="imc_ExpectedCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl0" xml:lang="en-US">Stock issued at value in lieu of payment for services1.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl0" xml:lang="en-US">Stock issued at shares in lieu of payment for services1.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_FinanceCostsNet_lbl0" xml:lang="en-US">The net amount of costs associated with financing activities of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinanceCostsNet" xlink:to="imc_FinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">The amount of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GeneralAndAdministrativeExpenses" xlink:to="imc_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_GovernmentAssistancePackages_lbl0" xml:lang="en-US">Government assistance packages.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GovernmentAssistancePackages" xlink:to="imc_GovernmentAssistancePackages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_InventoriesNet_lbl0" xml:lang="en-US">The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesNet" xlink:to="imc_InventoriesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_InvestorRelationsExpenses_lbl0" xml:lang="en-US">The amount of investor relation expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InvestorRelationsExpenses" xlink:to="imc_InvestorRelationsExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl0" xml:lang="en-US">Issue at $0.50 on exercise of ESOP unlisted options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl0" xml:lang="en-US">Issue at A$0.08 in lieu of cash for services rendered.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl0" xml:lang="en-US">Issue at A$0.08 in lieu of cash for services rendered.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl0" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl0" xml:lang="en-US">Issue at US$0.25 on exercise of NASDAQ Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl0" xml:lang="en-US">Issue at US$0.47 pursuant to ADS public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS047PursuantToADSPublicOffering1" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueInLieuOfPaymentForServices_lbl0" xml:lang="en-US">Issue at $0.16 in lieu of payment for services (2019-11-12).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServices" xlink:to="imc_IssueInLieuOfPaymentForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssueInLieuOfPaymentForServicesShares_lbl0" xml:lang="en-US">Issue at $0.16 in lieu of payment for services (2019-11-12), shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServicesShares" xlink:to="imc_IssueInLieuOfPaymentForServicesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssuePursuantToAdsPublicOffering_lbl0" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-07-19).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_IssuePursuantToAdsPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IssuePursuantToAdsPublicOfferingShares_lbl0" xml:lang="en-US">Issue at US$0.10 pursuant to ADS public offering (2019-07-19), shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOfferingShares" xlink:to="imc_IssuePursuantToAdsPublicOfferingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl0" xml:lang="en-US">The amount of compensation to key management personnel in the form of other short-term employee benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:to="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_LeaseRenewed_lbl0" xml:lang="en-US">Lease renewed date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaseRenewed" xlink:to="imc_LeaseRenewed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_LeaveProvisionExpense_lbl0" xml:lang="en-US">The amount of leave provision expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaveProvisionExpense" xlink:to="imc_LeaveProvisionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_LegalExpenses_lbl0" xml:lang="en-US">The amount of legal expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LegalExpenses" xlink:to="imc_LegalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ListingAndShareRegistry_lbl0" xml:lang="en-US">The amount of listing and share registry.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ListingAndShareRegistry" xlink:to="imc_ListingAndShareRegistry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_MarketingExpenses_lbl0" xml:lang="en-US">The amount of expense relating to the marketing and selling of goods or services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MarketingExpenses" xlink:to="imc_MarketingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NetForeignExchangeGainLoss_lbl0" xml:lang="en-US">The net gain loss arising from foreign exchange differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NetForeignExchangeGainLoss" xlink:to="imc_NetForeignExchangeGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NonCurrentRawMaterials_lbl0" xml:lang="en-US">Represents information related to non current raw materials.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NonCurrentRawMaterials" xlink:to="imc_NonCurrentRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSegment_lbl0" xml:lang="en-US">It represents as a number of segment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSegment" xlink:to="imc_NumberOfSegment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl0" xml:lang="en-US">The number of share options exercised in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:to="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl0" xml:lang="en-US">The number of shares issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl0" xml:lang="en-US">The number of shares issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl0" xml:lang="en-US">The number of shares issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl0" xml:lang="en-US">The number of shares lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl0" xml:lang="en-US">The number of shares lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl0" xml:lang="en-US">The number of share lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl0" xml:lang="en-US">The number of shares lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl0" xml:lang="en-US">The number of shares reclassify lapsed options from reserves to accumulated losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl0" xml:lang="en-US">The number of shares reclassify exercised options from reserves to share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfSharesUnlistedOption_lbl0" xml:lang="en-US">The number of shares unlisted option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesUnlistedOption" xlink:to="imc_NumberOfSharesUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl0" xml:lang="en-US">The number of value lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl0" xml:lang="en-US">The number of value lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl0" xml:lang="en-US">The number of value lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl0" xml:lang="en-US">The number of value reclassify lapsed options from reserves to accumulated losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl0" xml:lang="en-US">The number of value reclassify exercised options from reserves to share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionGrantedDescription_lbl0" xml:lang="en-US">Option granted, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionGrantedDescription" xlink:to="imc_OptionGrantedDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsAndWarrantsForfeited_lbl0" xml:lang="en-US">Options and warrants forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsForfeited" xlink:to="imc_OptionsAndWarrantsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsAndWarrantsLapsed_lbl0" xml:lang="en-US">Amount of Options and warrants lapsed for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsLapsed" xlink:to="imc_OptionsAndWarrantsLapsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsGranted_lbl0" xml:lang="en-US">Options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsGranted" xlink:to="imc_OptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsOrWarrantsExercised_lbl0" xml:lang="en-US">The increase (decrease) in equity resulting from the exercise of options/warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsExercised" xlink:to="imc_OptionsOrWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsOrWarrantsForteitedLapsed_lbl0" xml:lang="en-US">The increase (decrease) in equity resulting from options/warrants forteited/lapsed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsForteitedLapsed" xlink:to="imc_OptionsOrWarrantsForteitedLapsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionsOrWarrantsIssuedExpensed_lbl0" xml:lang="en-US">Amount of options or warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsIssuedExpensed" xlink:to="imc_OptionsOrWarrantsIssuedExpensed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OptionswarrantsForfeited_lbl0" xml:lang="en-US">Options/warrants forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionswarrantsForfeited" xlink:to="imc_OptionswarrantsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinarySharesIssued" xlink:to="imc_OrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OtherComprehensiveIncomeLossForPeriod_lbl0" xml:lang="en-US">Other comprehensive income (loss) for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherComprehensiveIncomeLossForPeriod" xlink:to="imc_OtherComprehensiveIncomeLossForPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OtherGovernmentAssistanceIncome_lbl0" xml:lang="en-US">Other government assistance income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherGovernmentAssistanceIncome" xlink:to="imc_OtherGovernmentAssistanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OtherIncomeFromNonOperatingActivities_lbl0" xml:lang="en-US">Represents other income from non operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_OtherIncomeFromNonOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OtherIncomeOfResearchAndDevelopment_lbl0" xml:lang="en-US">Other income of research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeOfResearchAndDevelopment" xlink:to="imc_OtherIncomeOfResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl0" xml:lang="en-US">The amounts recognised as expense other transactions with key management personnel.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:to="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ProceedsFromIssuedAtADSPublicOffering_lbl0" xml:lang="en-US">Amount issued at pursuant to ADS public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedAtADSPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl0" xml:lang="en-US">Shares issued at pursuant to ADS public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedSharesAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_RAndDTaxConcessionRefund_lbl0" xml:lang="en-US">Represent RAndD tax Concession refund.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RAndDTaxConcessionRefund" xlink:to="imc_RAndDTaxConcessionRefund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_RepresentativesWarrants_lbl0" xml:lang="en-US">Representative warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RepresentativesWarrants" xlink:to="imc_RepresentativesWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses_lbl0" xml:lang="en-US">Research and development consulting expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentConsultingExpenses" xlink:to="imc_ResearchAndDevelopmentConsultingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ResearchAndDevelopmentGrants_lbl0" xml:lang="en-US">Research and development grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentGrants" xlink:to="imc_ResearchAndDevelopmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ResearchAndDevelopmentsGrants_lbl0" xml:lang="en-US">Research and development grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentsGrants" xlink:to="imc_ResearchAndDevelopmentsGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_RevaluationFinancialsAmount_lbl0" xml:lang="en-US">Revaluation financials amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationFinancialsAmount" xlink:to="imc_RevaluationFinancialsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_RevenueFromExternalCustomers_lbl0" xml:lang="en-US">The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFromExternalCustomers" xlink:to="imc_RevenueFromExternalCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl0" xml:lang="en-US">Schedule of deemed valuation of options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:to="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ScheduleOfSubsidiariesExplanatory_lbl0" xml:lang="en-US">Schedule of subsidiaries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfSubsidiariesExplanatory" xlink:to="imc_ScheduleOfSubsidiariesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SegmentAssets_lbl0" xml:lang="en-US">Represents the information of segment assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentAssets" xlink:to="imc_SegmentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SegmentLiabilities_lbl0" xml:lang="en-US">Represents the information of segment liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentLiabilities" xlink:to="imc_SegmentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SegmentRevenue_lbl0" xml:lang="en-US">Segment revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentRevenue" xlink:to="imc_SegmentRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SellingAndMarketingExpenses_lbl0" xml:lang="en-US">The amount of expense relating to the marketing and selling of goods or services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SellingAndMarketingExpenses" xlink:to="imc_SellingAndMarketingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl0" xml:lang="en-US">Date the equity-based award expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ShareBasedPaymentsExpense_lbl0" xml:lang="en-US">Represents the information of share based payments expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedPaymentsExpense" xlink:to="imc_ShareBasedPaymentsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ShareCapital_lbl0" xml:lang="en-US">Share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareCapital" xlink:to="imc_ShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ShareOptionsPerShare_lbl0" xml:lang="en-US">Share options per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareOptionsPerShare" xlink:to="imc_ShareOptionsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SharebasedPaymentsExpenses_lbl0" xml:lang="en-US">Share-based payment expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsExpenses" xlink:to="imc_SharebasedPaymentsExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SharesIssuedPricePerShare1_lbl0" xml:lang="en-US">Per share or per unit amount of equity securities issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharesIssuedPricePerShare1" xlink:to="imc_SharesIssuedPricePerShare1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl0" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by directors and founders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringPeriodValueIssuedToDirectors" xlink:to="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of share options reclassify to the exercised options from reserves to share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:to="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl0" xml:lang="en-US">Value of stock issued as a reclassify by the exercise of stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:to="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SuperannuationExpenses_lbl0" xml:lang="en-US">The amount of superannuation expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SuperannuationExpenses" xlink:to="imc_SuperannuationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl0" xml:lang="en-US">The amount representing the accounting expenditure subject to research and development tax incentive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TaxEffectOfShareBasedPayments_lbl0" xml:lang="en-US">The amount representing the share-based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfShareBasedPayments" xlink:to="imc_TaxEffectOfShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl0" xml:lang="en-US">The amount that represents the research and development tax incentive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TradeAndOtherPayable_lbl0" xml:lang="en-US">The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TradeAndOtherPayable" xlink:to="imc_TradeAndOtherPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl0" xml:lang="en-US">Transaction costs arising on representative warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl0" xml:lang="en-US">Transaction costs arising on representative warrants issued, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl0" xml:lang="en-US">Amount of Transactions with owners in their capacity as owners for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwners" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl0" xml:lang="en-US">Transfer from reserves on cashless exercise of ESOP unlisted options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl0" xml:lang="en-US">Transfer from reserves on cashless exercise of ESOP unlisted options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl0" xml:lang="en-US">Transfer from reserves on exercise of ESOP unlisted options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl0" xml:lang="en-US">Transfer from reserves on exercise of NASDAQ Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl0" xml:lang="en-US">Transfer from reserves on exercise of NASDAQ Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferToShareCapital_lbl0" xml:lang="en-US">Equity impact of the value of new stock transfer during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapital" xlink:to="imc_TransferToShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TransferToShareCapitalinDollars_lbl0" xml:lang="en-US">Transfer to share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapitalinDollars" xlink:to="imc_TransferToShareCapitalinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_UnlistedOptionExercisable_lbl0" xml:lang="en-US">Unlisted option exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UnlistedOptionExercisable" xlink:to="imc_UnlistedOptionExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl0" xml:lang="en-US">Represents the information of useful lives or depreciation rates property plant and equipment period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:to="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl0" xml:lang="en-US">The number of value issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl0" xml:lang="en-US">The number of value issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl0" xml:lang="en-US">The number of value issue of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl0" xml:lang="en-US">The number of value lapse of unlisted options for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValuePerShareOptionsGranted_lbl0" xml:lang="en-US">The value per share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValuePerShareOptionsGranted" xlink:to="imc_ValuePerShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl1" xml:lang="en-US">Number of value reserved for issue under options and contracts for sale of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WarehousingDistributionAndInvoicingServices_lbl0" xml:lang="en-US">The amount of warehousing, distribution and invoicing services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndInvoicingServices" xlink:to="imc_WarehousingDistributionAndInvoicingServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WarehousingDistributionAndServicesFees_lbl0" xml:lang="en-US">The amount of warehousing, distribution and services fes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndServicesFees" xlink:to="imc_WarehousingDistributionAndServicesFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl0" xml:lang="en-US">The weighted average exercise price of share options exercisable in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl0" xml:lang="en-US">The weighted average exercise price of share options exercised in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl0" xml:lang="en-US">The weighted average exercise price of share options granted in a share-based payment arrangement.&amp;amp;amp;amp;#160;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl1" xml:lang="en-US">The weighted average exercise price of share options outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageNumberOfShares_lbl0" xml:lang="en-US">Represents weighted average number of Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageNumberOfShares" xlink:to="imc_WeightedAverageNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl0" xml:lang="en-US">The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageSharePriceShareOptionsGranted1" xlink:to="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_TypesOfArrangementsAxis_lbl0" xml:lang="en-US">Types of arrangements [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TypesOfArrangementsAxis" xlink:to="imc_TypesOfArrangementsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AccumulatedLossesMember_lbl0" xml:lang="en-US">Represents information related to accumulated losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccumulatedLossesMember" xlink:to="imc_AccumulatedLossesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_AnadisEPSPtyLtdMember_lbl0" xml:lang="en-US">Represents the information of anadis ePSPty ltd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AnadisEPSPtyLtdMember" xlink:to="imc_AnadisEPSPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CustomerAMember_lbl0" xml:lang="en-US">Represents the information related to customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerAMember" xlink:to="imc_CustomerAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CustomerBMember_lbl0" xml:lang="en-US">Represents the information related to customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerBMember" xlink:to="imc_CustomerBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CustomerCMember_lbl0" xml:lang="en-US">Represents the information related to customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerCMember" xlink:to="imc_CustomerCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CustomerDMember_lbl0" xml:lang="en-US">Represents the information related to customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerDMember" xlink:to="imc_CustomerDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_CustomerEMember_lbl0" xml:lang="en-US">Represents the information related to customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerEMember" xlink:to="imc_CustomerEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_EmployeeStockOption1Member_lbl0" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeStockOption1Member" xlink:to="imc_EmployeeStockOption1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_IMCCanadaLtdMember_lbl0" xml:lang="en-US">Represents information related to IMC canada ttd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IMCCanadaLtdMember" xlink:to="imc_IMCCanadaLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ImmuronIncMember_lbl0" xml:lang="en-US">Represents the information of Ifrs statement lineItems.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImmuronIncMember" xlink:to="imc_ImmuronIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_PlantAndEquipmentMember_lbl0" xml:lang="en-US">Represents the information of plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PlantAndEquipmentMember" xlink:to="imc_PlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ReservesMember_lbl0" xml:lang="en-US">Represents information related to reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReservesMember" xlink:to="imc_ReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SegmentHyperImmuneProductsMember_lbl0" xml:lang="en-US">Represents the information of segment hyperImmune products.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentHyperImmuneProductsMember" xlink:to="imc_SegmentHyperImmuneProductsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_SegmentResearchAndDevelopmentMember_lbl0" xml:lang="en-US">Represents the information of segment research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentResearchAndDevelopmentMember" xlink:to="imc_SegmentResearchAndDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_ShortTermFundingAgreementsMember_lbl0" xml:lang="en-US">Represents the information of short term funding agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShortTermFundingAgreementsMember" xlink:to="imc_ShortTermFundingAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imc_WattleLaboratoriesPtyLtdMember_lbl0" xml:lang="en-US">Represents the information of wattle laboratories Pty Ltd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WattleLaboratoriesPtyLtdMember" xlink:to="imc_WattleLaboratoriesPtyLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl1" xml:lang="en-US">DetailedInformationAboutTradeAndOtherReceivablesExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:to="imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue_lbl0" xml:lang="en-US">ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NonCurrentRawMaterials_lbl1" xml:lang="en-US">NonCurrentRawMaterials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NonCurrentRawMaterials" xlink:to="imc_NonCurrentRawMaterials_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl1" xml:lang="en-US">NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:to="imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevenueFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">RevenueFromOperatingActivitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFromOperatingActivitiesAbstract" xlink:to="imc_RevenueFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExercisePriceTwoMember_lbl0" xml:lang="en-US">ExercisePriceTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceTwoMember" xlink:to="imc_ExercisePriceTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl1" xml:lang="en-US">TransferFromReservesOnExerciseOfESOPUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl1" xml:lang="en-US">TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl1" xml:lang="en-US">KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:to="imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerDMember_lbl1" xml:lang="en-US">CustomerDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerDMember" xlink:to="imc_CustomerDMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RAndDTaxConcessionRefund_lbl1" xml:lang="en-US">RAndDTaxConcessionRefund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RAndDTaxConcessionRefund" xlink:to="imc_RAndDTaxConcessionRefund_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_PlantAndEquipmentMember_lbl1" xml:lang="en-US">PlantAndEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PlantAndEquipmentMember" xlink:to="imc_PlantAndEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectOfShareBasedPayments_lbl1" xml:lang="en-US">TaxEffectOfShareBasedPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfShareBasedPayments" xlink:to="imc_TaxEffectOfShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValuePerShareOptionsGranted_lbl1" xml:lang="en-US">ValuePerShareOptionsGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValuePerShareOptionsGranted" xlink:to="imc_ValuePerShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DrGarySJacobMember_lbl0" xml:lang="en-US">DrGarySJacobMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DrGarySJacobMember" xlink:to="imc_DrGarySJacobMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl1" xml:lang="en-US">NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateNineMember_lbl0" xml:lang="en-US">GrantDateNineMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateNineMember" xlink:to="imc_GrantDateNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_MajorProductLinesAxis_lbl0" xml:lang="en-US">MajorProductLinesAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MajorProductLinesAxis" xlink:to="imc_MajorProductLinesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsOrWarrantsExercised_lbl1" xml:lang="en-US">OptionsOrWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsExercised" xlink:to="imc_OptionsOrWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentResearchAndDevelopmentMember_lbl1" xml:lang="en-US">SegmentResearchAndDevelopmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentResearchAndDevelopmentMember" xlink:to="imc_SegmentResearchAndDevelopmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ProtectynMember_lbl0" xml:lang="en-US">ProtectynMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProtectynMember" xlink:to="imc_ProtectynMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsOne_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsOne" xlink:to="imc_LapseOfUnexercisedOptionsOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions_lbl0" xml:lang="en-US">TransferFromReservesOnExerciseOfESOPUnlistedOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions" xlink:to="imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptionsValue_lbl0" xml:lang="en-US">CashlessExerciseOfESOPUnlistedOptionsValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashlessExerciseOfESOPUnlistedOptionsValue" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptionsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_KeyManagementPersonnelCompensationAbstract_lbl0" xml:lang="en-US">KeyManagementPersonnelCompensationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_KeyManagementPersonnelCompensationAbstract" xlink:to="imc_KeyManagementPersonnelCompensationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_PercentageOfEntityRevenue_lbl0" xml:lang="en-US">PercentageOfEntityRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PercentageOfEntityRevenue" xlink:to="imc_PercentageOfEntityRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IMCCanadaLtdMember_lbl1" xml:lang="en-US">IMCCanadaLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IMCCanadaLtdMember" xlink:to="imc_IMCCanadaLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfESOPUnlistedOptions_lbl0" xml:lang="en-US">ExerciseOfESOPUnlistedOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfESOPUnlistedOptions" xlink:to="imc_ExerciseOfESOPUnlistedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherIncomeFromNonOperatingActivities_lbl1" xml:lang="en-US">OtherIncomeFromNonOperatingActivities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeFromNonOperatingActivities" xlink:to="imc_OtherIncomeFromNonOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl1" xml:lang="en-US">NumberOfValueIssueLapseOfUnlistedOptionThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ConsultingExpenses_lbl1" xml:lang="en-US">ConsultingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ConsultingExpenses" xlink:to="imc_ConsultingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateOneMember_lbl0" xml:lang="en-US">GrantDateOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateOneMember" xlink:to="imc_GrantDateOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CashAtBankAndInHand_lbl1" xml:lang="en-US">CashAtBankAndInHand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashAtBankAndInHand" xlink:to="imc_CashAtBankAndInHand_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateTenMember_lbl0" xml:lang="en-US">GrantDateTenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTenMember" xlink:to="imc_GrantDateTenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NetForeignExchangeGainLoss_lbl1" xml:lang="en-US">NetForeignExchangeGainLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NetForeignExchangeGainLoss" xlink:to="imc_NetForeignExchangeGainLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionswarrantsForfeited_lbl1" xml:lang="en-US">OptionswarrantsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionswarrantsForfeited" xlink:to="imc_OptionswarrantsForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSegment_lbl1" xml:lang="en-US">NumberOfSegment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSegment" xlink:to="imc_NumberOfSegment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions_lbl0" xml:lang="en-US">ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" xlink:to="imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl1" xml:lang="en-US">TransactionCostsArisingOnRepresentativeWarrantsIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LossAllowance_lbl0" xml:lang="en-US">LossAllowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LossAllowance" xlink:to="imc_LossAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectOfTaxPayable_lbl0" xml:lang="en-US">TaxEffectOfTaxPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfTaxPayable" xlink:to="imc_TaxEffectOfTaxPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_MrRichardJBermanMember_lbl0" xml:lang="en-US">MrRichardJBermanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MrRichardJBermanMember" xlink:to="imc_MrRichardJBermanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerIMember_lbl0" xml:lang="en-US">CustomerIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerIMember" xlink:to="imc_CustomerIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherGovernmentAssistanceIncome_lbl1" xml:lang="en-US">OtherGovernmentAssistanceIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherGovernmentAssistanceIncome" xlink:to="imc_OtherGovernmentAssistanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl1" xml:lang="en-US">NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentRevenue_lbl1" xml:lang="en-US">SegmentRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentRevenue" xlink:to="imc_SegmentRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrant1_lbl1" xml:lang="en-US">ExerciseOfRepresentativeWarrant1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant1" xlink:to="imc_ExerciseOfRepresentativeWarrant1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfDetailedInformationOtherReserve_lbl1" xml:lang="en-US">DisclosureOfDetailedInformationOtherReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOtherReserve" xlink:to="imc_DisclosureOfDetailedInformationOtherReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl1" xml:lang="en-US">OtherTransactionsWithKeyManagementRelatedPartyTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:to="imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LiabilitiesAbstract0_lbl0" xml:lang="en-US">LiabilitiesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LiabilitiesAbstract0" xlink:to="imc_LiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssuePursuantToAdsPublicOfferingShares_lbl1" xml:lang="en-US">IssuePursuantToAdsPublicOfferingShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOfferingShares" xlink:to="imc_IssuePursuantToAdsPublicOfferingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentExpenses_lbl0" xml:lang="en-US">SharebasedPaymentExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentExpenses" xlink:to="imc_SharebasedPaymentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharesIssuedToDirectorsForTheDirectorFees_lbl0" xml:lang="en-US">SharesIssuedToDirectorsForTheDirectorFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharesIssuedToDirectorsForTheDirectorFees" xlink:to="imc_SharesIssuedToDirectorsForTheDirectorFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl1" xml:lang="en-US">TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluedAtGrantDate_lbl0" xml:lang="en-US">RevaluedAtGrantDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluedAtGrantDate" xlink:to="imc_RevaluedAtGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RawMaterialsAndStoresMember_lbl0" xml:lang="en-US">RawMaterialsAndStoresMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RawMaterialsAndStoresMember" xlink:to="imc_RawMaterialsAndStoresMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock_lbl0" xml:lang="en-US">DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" xlink:to="imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsGranted_lbl1" xml:lang="en-US">OptionsGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsGranted" xlink:to="imc_OptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl1" xml:lang="en-US">DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:to="imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrandlodgeCapitalPtyLtdMember_lbl0" xml:lang="en-US">GrandlodgeCapitalPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrandlodgeCapitalPtyLtdMember" xlink:to="imc_GrandlodgeCapitalPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ChangeInAccountingPolicy_lbl1" xml:lang="en-US">ChangeInAccountingPolicy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ChangeInAccountingPolicy" xlink:to="imc_ChangeInAccountingPolicy_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl1" xml:lang="en-US">IssueAtUS025OnExerciseOfNASDAQWarrant1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfOutstandingShareOption_lbl1" xml:lang="en-US">NumberOfOutstandingShareOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfOutstandingShareOption" xlink:to="imc_NumberOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares_lbl0" xml:lang="en-US">BusinessAcquisitionCostOfTransactionCostToIssuedAtShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" xlink:to="imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_PaymentForServices_lbl0" xml:lang="en-US">PaymentForServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PaymentForServices" xlink:to="imc_PaymentForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ResearchAndDevelopmentConsultingExpenses_lbl1" xml:lang="en-US">ResearchAndDevelopmentConsultingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentConsultingExpenses" xlink:to="imc_ResearchAndDevelopmentConsultingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AustralianFederalRdTaxConcessionRefund_lbl0" xml:lang="en-US">AustralianFederalRdTaxConcessionRefund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AustralianFederalRdTaxConcessionRefund" xlink:to="imc_AustralianFederalRdTaxConcessionRefund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl1" xml:lang="en-US">DisclosureOfDetailedInformationOfRelatedPartyExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:to="imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentAssets_lbl1" xml:lang="en-US">SegmentAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentAssets" xlink:to="imc_SegmentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsAndWarrantsExercised_lbl0" xml:lang="en-US">OptionsAndWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsExercised" xlink:to="imc_OptionsAndWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsAndWarrantsIssuedexpensed_lbl0" xml:lang="en-US">OptionsAndWarrantsIssuedexpensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsIssuedexpensed" xlink:to="imc_OptionsAndWarrantsIssuedexpensed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_At30June2020Abstract_lbl0" xml:lang="en-US">At30June2020Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_At30June2020Abstract" xlink:to="imc_At30June2020Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExercisePriceOneMember_lbl0" xml:lang="en-US">ExercisePriceOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceOneMember" xlink:to="imc_ExercisePriceOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCompanyDetailsExplanatory_lbl1" xml:lang="en-US">DisclosureOfCompanyDetailsExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCompanyDetailsExplanatory" xlink:to="imc_DisclosureOfCompanyDetailsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl1" xml:lang="en-US">NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_EquityBalance_lbl2" xml:lang="en-US">EquityBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EquityBalance" xlink:to="imc_EquityBalance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueInLieuOfPaymentForServices_lbl1" xml:lang="en-US">IssueInLieuOfPaymentForServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServices" xlink:to="imc_IssueInLieuOfPaymentForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl1" xml:lang="en-US">UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:to="imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ESOPOptionsIssued_lbl1" xml:lang="en-US">ESOPOptionsIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ESOPOptionsIssued" xlink:to="imc_ESOPOptionsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl1" xml:lang="en-US">IssueAtUS025OnExerciseOfNASDAQWarrants1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrants_lbl0" xml:lang="en-US">ExerciseOfRepresentativeWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrants" xlink:to="imc_ExerciseOfRepresentativeWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AdditionalRAndDTaxReceived_lbl1" xml:lang="en-US">AdditionalRAndDTaxReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalRAndDTaxReceived" xlink:to="imc_AdditionalRAndDTaxReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GovernmentAssistancePackages_lbl1" xml:lang="en-US">GovernmentAssistancePackages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GovernmentAssistancePackages" xlink:to="imc_GovernmentAssistancePackages_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExpectedCreditLosses_lbl1" xml:lang="en-US">ExpectedCreditLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpectedCreditLosses" xlink:to="imc_ExpectedCreditLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfInstrumentOtherEquityInstrumentGranted_lbl0" xml:lang="en-US">NumberOfInstrumentOtherEquityInstrumentGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfInstrumentOtherEquityInstrumentGranted" xlink:to="imc_NumberOfInstrumentOtherEquityInstrumentGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCashExplanatory_lbl1" xml:lang="en-US">DisclosureOfCashExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashExplanatory" xlink:to="imc_DisclosureOfCashExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AccumulatedLossesMember_lbl1" xml:lang="en-US">AccumulatedLossesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccumulatedLossesMember" xlink:to="imc_AccumulatedLossesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateEightMember_lbl0" xml:lang="en-US">GrantDateEightMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateEightMember" xlink:to="imc_GrantDateEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl1" xml:lang="en-US">NumberOfSharesIssueLapseOfUnlistedOptionThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00_lbl0" xml:lang="en-US">TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriodShares_lbl0" xml:lang="en-US">RevaluationOfOptionsIssuedInPriorPeriodShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriodShares" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses_lbl0" xml:lang="en-US">TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" xlink:to="imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0_lbl0" xml:lang="en-US">TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueInLieuOfPaymentForServicesShares_lbl1" xml:lang="en-US">IssueInLieuOfPaymentForServicesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueInLieuOfPaymentForServicesShares" xlink:to="imc_IssueInLieuOfPaymentForServicesShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_HyperimmuneProductsRevenue_lbl0" xml:lang="en-US">HyperimmuneProductsRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_HyperimmuneProductsRevenue" xlink:to="imc_HyperimmuneProductsRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RepresentativesWarrants_lbl1" xml:lang="en-US">RepresentativesWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RepresentativesWarrants" xlink:to="imc_RepresentativesWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl1" xml:lang="en-US">DisclosureOfTradeAndOtherPayablesTableExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherPayablesTableExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrants1_lbl0" xml:lang="en-US">ExerciseOfRepresentativeWarrants1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrants1" xlink:to="imc_ExerciseOfRepresentativeWarrants1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrantsShares_lbl0" xml:lang="en-US">ExerciseOfRepresentativeWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantsShares" xlink:to="imc_ExerciseOfRepresentativeWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsOrWarrantsIssuedExpensed_lbl1" xml:lang="en-US">OptionsOrWarrantsIssuedExpensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsIssuedExpensed" xlink:to="imc_OptionsOrWarrantsIssuedExpensed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsExpenses_lbl1" xml:lang="en-US">SharebasedPaymentsExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsExpenses" xlink:to="imc_SharebasedPaymentsExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl1" xml:lang="en-US">WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsAndWarrantsForfeited_lbl1" xml:lang="en-US">OptionsAndWarrantsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsForfeited" xlink:to="imc_OptionsAndWarrantsForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ParentEntityAbstract_lbl0" xml:lang="en-US">ParentEntityAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ParentEntityAbstract" xlink:to="imc_ParentEntityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_lbl0" xml:lang="en-US">TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract" xlink:to="imc_TaxEffectOfAmountsWhichAreNotDeductibleTaxableInCalculatingTaxableIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl1" xml:lang="en-US">ScheduleOfDeemedValuationOfOptionsExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:to="imc_ScheduleOfDeemedValuationOfOptionsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareOptionsPerShare_lbl1" xml:lang="en-US">ShareOptionsPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareOptionsPerShare" xlink:to="imc_ShareOptionsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DetailedInformationAboutInventoriesExplanatory_lbl1" xml:lang="en-US">DetailedInformationAboutInventoriesExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutInventoriesExplanatory" xlink:to="imc_DetailedInformationAboutInventoriesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RestatedTotalEquityAt1July2019_lbl0" xml:lang="en-US">RestatedTotalEquityAt1July2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RestatedTotalEquityAt1July2019" xlink:to="imc_RestatedTotalEquityAt1July2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ImpactOnLossForPeriods_lbl0" xml:lang="en-US">ImpactOnLossForPeriods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImpactOnLossForPeriods" xlink:to="imc_ImpactOnLossForPeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerGMember_lbl0" xml:lang="en-US">CustomerGMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerGMember" xlink:to="imc_CustomerGMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluationOfShareholdersApprovedValue_lbl0" xml:lang="en-US">RevaluationOfShareholdersApprovedValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfShareholdersApprovedValue" xlink:to="imc_RevaluationOfShareholdersApprovedValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DepreciationChargeOfRightOfUseAssetsAbstract_lbl0" xml:lang="en-US">DepreciationChargeOfRightOfUseAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="imc_DepreciationChargeOfRightOfUseAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrantsShares_lbl1" xml:lang="en-US">ExerciseOfNasdaqWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsShares" xlink:to="imc_ExerciseOfNasdaqWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl1" xml:lang="en-US">WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferToShareCapitalinDollars_lbl1" xml:lang="en-US">TransferToShareCapitalinDollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapitalinDollars" xlink:to="imc_TransferToShareCapitalinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsOrWarrantsForteitedLapsed_lbl1" xml:lang="en-US">OptionsOrWarrantsForteitedLapsed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsOrWarrantsForteitedLapsed" xlink:to="imc_OptionsOrWarrantsForteitedLapsed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AssetsAbstract0_lbl0" xml:lang="en-US">AssetsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssetsAbstract0" xlink:to="imc_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl1" xml:lang="en-US">StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:to="imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl1" xml:lang="en-US">DisclosureOfTradeAndOtherReceivablesTableExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:to="imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfAmountsRecognizedinBalanceSheet_lbl0" xml:lang="en-US">ScheduleOfAmountsRecognizedinBalanceSheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfAmountsRecognizedinBalanceSheet" xlink:to="imc_ScheduleOfAmountsRecognizedinBalanceSheet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfESOPUnlistedOptionsValue_lbl0" xml:lang="en-US">ExerciseOfESOPUnlistedOptionsValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfESOPUnlistedOptionsValue" xlink:to="imc_ExerciseOfESOPUnlistedOptionsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US">GeneralAndAdministrativeExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GeneralAndAdministrativeExpenses" xlink:to="imc_GeneralAndAdministrativeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl1" xml:lang="en-US">TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:to="imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrantShares_lbl1" xml:lang="en-US">ExerciseOfRepresentativeWarrantShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantShares" xlink:to="imc_ExerciseOfRepresentativeWarrantShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFiveOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsSharesOne_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsSharesOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsSharesOne" xlink:to="imc_IssueOfRepresentativeWarrantsSharesOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateElevenMember_lbl0" xml:lang="en-US">GrantDateElevenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateElevenMember" xlink:to="imc_GrantDateElevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_UnlistedOptionExercisable_lbl1" xml:lang="en-US">UnlistedOptionExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_UnlistedOptionExercisable" xlink:to="imc_UnlistedOptionExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:to="imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_PaymentsToSuppliersForGoodsAndService_lbl0" xml:lang="en-US">PaymentsToSuppliersForGoodsAndService</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PaymentsToSuppliersForGoodsAndService" xlink:to="imc_PaymentsToSuppliersForGoodsAndService_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateFiveMember_lbl0" xml:lang="en-US">GrantDateFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateFiveMember" xlink:to="imc_GrantDateFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_EmployeeStockOption1Member_lbl1" xml:lang="en-US">EmployeeStockOption1Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeStockOption1Member" xlink:to="imc_EmployeeStockOption1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExercisePriceSixteenMember_lbl0" xml:lang="en-US">ExercisePriceSixteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceSixteenMember" xlink:to="imc_ExercisePriceSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl1" xml:lang="en-US">DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:to="imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WarehousingDistributionAndServicesFees_lbl1" xml:lang="en-US">WarehousingDistributionAndServicesFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndServicesFees" xlink:to="imc_WarehousingDistributionAndServicesFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">NumberOfShareOptionExercisableInSharebasedPaymentArrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ReservesMember_lbl1" xml:lang="en-US">ReservesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReservesMember" xlink:to="imc_ReservesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions_lbl0" xml:lang="en-US">ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrants_lbl0" xml:lang="en-US">IssueAtUS025OnExerciseOfNASDAQWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrants" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IncomeFinance_lbl0" xml:lang="en-US">IncomeFinance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IncomeFinance" xlink:to="imc_IncomeFinance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl1" xml:lang="en-US">ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerHMember_lbl0" xml:lang="en-US">CustomerHMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerHMember" xlink:to="imc_CustomerHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_EmployeeBenefitObligationNonCurrent_lbl1" xml:lang="en-US">EmployeeBenefitObligationNonCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligationNonCurrent" xlink:to="imc_EmployeeBenefitObligationNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl1" xml:lang="en-US">DisclosureOfCashFlowInformationExplanatoryTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:to="imc_DisclosureOfCashFlowInformationExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharebasedPaymentsToDirectors_lbl0" xml:lang="en-US">SharebasedPaymentsToDirectors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharebasedPaymentsToDirectors" xlink:to="imc_SharebasedPaymentsToDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_BadDebts_lbl1" xml:lang="en-US">BadDebts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BadDebts" xlink:to="imc_BadDebts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareOptionsOutstanding_lbl0" xml:lang="en-US">ShareOptionsOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareOptionsOutstanding" xlink:to="imc_ShareOptionsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrossCarryingAmount_lbl0" xml:lang="en-US">GrossCarryingAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrossCarryingAmount" xlink:to="imc_GrossCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherMember_lbl0" xml:lang="en-US">OtherMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherMember" xlink:to="imc_OtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InventoriesAxis_lbl0" xml:lang="en-US">InventoriesAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesAxis" xlink:to="imc_InventoriesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ImpactOnOtherComponentOfEquity_lbl0" xml:lang="en-US">ImpactOnOtherComponentOfEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImpactOnOtherComponentOfEquity" xlink:to="imc_ImpactOnOtherComponentOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS025OnExerciseOfNASDAQWarrant_lbl0" xml:lang="en-US">IssueAtUS025OnExerciseOfNASDAQWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS025OnExerciseOfNASDAQWarrant" xlink:to="imc_IssueAtUS025OnExerciseOfNASDAQWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareBasedPaymentsExpense_lbl1" xml:lang="en-US">ShareBasedPaymentsExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedPaymentsExpense" xlink:to="imc_ShareBasedPaymentsExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerEMember_lbl1" xml:lang="en-US">CustomerEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerEMember" xlink:to="imc_CustomerEMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherReserveMaturityDateDescription_lbl0" xml:lang="en-US">OtherReserveMaturityDateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherReserveMaturityDateDescription" xlink:to="imc_OtherReserveMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SellingAndMarketingExpensesAbstract_lbl0" xml:lang="en-US">SellingAndMarketingExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SellingAndMarketingExpensesAbstract" xlink:to="imc_SellingAndMarketingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl1" xml:lang="en-US">NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SellingAndMarketingExpenses_lbl1" xml:lang="en-US">SellingAndMarketingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SellingAndMarketingExpenses" xlink:to="imc_SellingAndMarketingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageNumberOfShares_lbl1" xml:lang="en-US">WeightedAverageNumberOfShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageNumberOfShares" xlink:to="imc_WeightedAverageNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">ChangeInOperatingAssetsAndLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="imc_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl1" xml:lang="en-US">NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl1" xml:lang="en-US">TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:to="imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl1" xml:lang="en-US">TaxEffectofResearchAndDevelopmentTaxIncentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:to="imc_TaxEffectofResearchAndDevelopmentTaxIncentive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WarehousingDistributionAndInvoicingServices_lbl1" xml:lang="en-US">WarehousingDistributionAndInvoicingServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WarehousingDistributionAndInvoicingServices" xlink:to="imc_WarehousingDistributionAndInvoicingServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfSubsidiariesExplanatory_lbl1" xml:lang="en-US">ScheduleOfSubsidiariesExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfSubsidiariesExplanatory" xlink:to="imc_ScheduleOfSubsidiariesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsIssuedUnderESOP_lbl0" xml:lang="en-US">OptionsIssuedUnderESOP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsIssuedUnderESOP" xlink:to="imc_OptionsIssuedUnderESOP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember_lbl0" xml:lang="en-US">ServicesRenderedByGrandlodgeCapitalPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember" xlink:to="imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl1" xml:lang="en-US">TransferFromReservesOnExerciseOfNASDAQWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl1" xml:lang="en-US">DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:to="imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareCapital_lbl1" xml:lang="en-US">ShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareCapital" xlink:to="imc_ShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_BasicAndDilutedEarningsLossPerShare_lbl2" xml:lang="en-US">BasicAndDilutedEarningsLossPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BasicAndDilutedEarningsLossPerShare" xlink:to="imc_BasicAndDilutedEarningsLossPerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_EmployeeShareSchemesValueOfEmployee_lbl1" xml:lang="en-US">EmployeeShareSchemesValueOfEmployee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeShareSchemesValueOfEmployee" xlink:to="imc_EmployeeShareSchemesValueOfEmployee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TitlesOfIndividualAxis_lbl0" xml:lang="en-US">TitlesOfIndividualAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TitlesOfIndividualAxis" xlink:to="imc_TitlesOfIndividualAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosuresOfProductsAndServicesExplanatory_lbl1" xml:lang="en-US">DisclosuresOfProductsAndServicesExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosuresOfProductsAndServicesExplanatory" xlink:to="imc_DisclosuresOfProductsAndServicesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement_lbl0" xml:lang="en-US">NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" xlink:to="imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_PercentageOfForeignExchangeRates_lbl0" xml:lang="en-US">PercentageOfForeignExchangeRates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_PercentageOfForeignExchangeRates" xlink:to="imc_PercentageOfForeignExchangeRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl1" xml:lang="en-US">NumberOfSharesIssueLapseOfUnlistedOptionTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsThreeShares_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsThreeShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsThreeShares" xlink:to="imc_IssueOfRepresentativeWarrantsThreeShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl1" xml:lang="en-US">ProceedsFromIssuedSharesAtADSPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedSharesAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedSharesAtADSPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ImmuronLimitedMember_lbl0" xml:lang="en-US">ImmuronLimitedMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImmuronLimitedMember" xlink:to="imc_ImmuronLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LossOnAllowanceTradeReceivables_lbl0" xml:lang="en-US">LossOnAllowanceTradeReceivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LossOnAllowanceTradeReceivables" xlink:to="imc_LossOnAllowanceTradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrant_lbl1" xml:lang="en-US">ExerciseOfRepresentativeWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrant" xlink:to="imc_ExerciseOfRepresentativeWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsValue_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsValue" xlink:to="imc_LapseOfUnexercisedOptionsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl1" xml:lang="en-US">WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesUnlistedOption_lbl1" xml:lang="en-US">NumberOfSharesUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesUnlistedOption" xlink:to="imc_NumberOfSharesUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionGrantedDescription_lbl1" xml:lang="en-US">OptionGrantedDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionGrantedDescription" xlink:to="imc_OptionGrantedDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TravelanMember_lbl0" xml:lang="en-US">TravelanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TravelanMember" xlink:to="imc_TravelanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:to="imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl1" xml:lang="en-US">NumberOfSharesIssueLapseOfUnlistedOptionOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueLapseOfUnlistedOptionOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherIncomeOfResearchAndDevelopment_lbl1" xml:lang="en-US">OtherIncomeOfResearchAndDevelopment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomeOfResearchAndDevelopment" xlink:to="imc_OtherIncomeOfResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl1" xml:lang="en-US">ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssuePursuantToAdsPublicOffering_lbl1" xml:lang="en-US">IssuePursuantToAdsPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuePursuantToAdsPublicOffering" xlink:to="imc_IssuePursuantToAdsPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrants_lbl1" xml:lang="en-US">ExerciseOfNasdaqWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrants" xlink:to="imc_ExerciseOfNasdaqWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateTwelveMember_lbl0" xml:lang="en-US">GrantDateTwelveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTwelveMember" xlink:to="imc_GrantDateTwelveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl1" xml:lang="en-US">DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:to="imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFiveShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl1" xml:lang="en-US">ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:to="imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OrdinarySharesIssued_lbl1" xml:lang="en-US">OrdinarySharesIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinarySharesIssued" xlink:to="imc_OrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherIncomes_lbl0" xml:lang="en-US">OtherIncomes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherIncomes" xlink:to="imc_OtherIncomes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl1" xml:lang="en-US">NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:to="imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExercisePriceShareOptionsGranted1_lbl1" xml:lang="en-US">ExercisePriceShareOptionsGranted1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePriceShareOptionsGranted1" xlink:to="imc_ExercisePriceShareOptionsGranted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TradeAndOtherPayable_lbl1" xml:lang="en-US">TradeAndOtherPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TradeAndOtherPayable" xlink:to="imc_TradeAndOtherPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl1" xml:lang="en-US">StockIssuedDuringValueReclassifyToStockOptionsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:to="imc_StockIssuedDuringValueReclassifyToStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl1" xml:lang="en-US">RevaluationOfOptionsIssuedInPriorPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="imc_RevaluationOfOptionsIssuedInPriorPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl1" xml:lang="en-US">TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:to="imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherComprehensiveIncomeLossForPeriod_lbl1" xml:lang="en-US">OtherComprehensiveIncomeLossForPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherComprehensiveIncomeLossForPeriod" xlink:to="imc_OtherComprehensiveIncomeLossForPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherCountriesMember_lbl0" xml:lang="en-US">OtherCountriesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherCountriesMember" xlink:to="imc_OtherCountriesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TypesOfArrangementsAxis_lbl1" xml:lang="en-US">TypesOfArrangementsAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TypesOfArrangementsAxis" xlink:to="imc_TypesOfArrangementsAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl1" xml:lang="en-US">ValueIssuedEmployeeStockOwnershipPlanUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne_lbl0" xml:lang="en-US">ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering_lbl0" xml:lang="en-US">IssueAtUS047PursuantToADSPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS047PursuantToADSPublicOffering" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl1" xml:lang="en-US">ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:to="imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WorkInProgressMember_lbl0" xml:lang="en-US">WorkInProgressMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WorkInProgressMember" xlink:to="imc_WorkInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ResearchAndDevelopmentGrants_lbl1" xml:lang="en-US">ResearchAndDevelopmentGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentGrants" xlink:to="imc_ResearchAndDevelopmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluationOfOptionIssuedInPriorPeriod_lbl0" xml:lang="en-US">RevaluationOfOptionIssuedInPriorPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationOfOptionIssuedInPriorPeriod" xlink:to="imc_RevaluationOfOptionIssuedInPriorPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory_lbl0" xml:lang="en-US">DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" xlink:to="imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfSalesReturnProvisionExplantory_lbl1" xml:lang="en-US">DisclosureOfSalesReturnProvisionExplantory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfSalesReturnProvisionExplantory" xlink:to="imc_DisclosureOfSalesReturnProvisionExplantory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFive_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFive" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AssetsAbstract00_lbl0" xml:lang="en-US">AssetsAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssetsAbstract00" xlink:to="imc_AssetsAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl1" xml:lang="en-US">TransactionsWithOwnersInTheirCapacityAsOwners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwners" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwners_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InventoriesNet_lbl1" xml:lang="en-US">InventoriesNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InventoriesNet" xlink:to="imc_InventoriesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl1" xml:lang="en-US">WeightedAverageSharePriceShareOptionsGranted1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageSharePriceShareOptionsGranted1" xlink:to="imc_WeightedAverageSharePriceShareOptionsGranted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SharesIssuedPricePerShare1_lbl1" xml:lang="en-US">SharesIssuedPricePerShare1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SharesIssuedPricePerShare1" xlink:to="imc_SharesIssuedPricePerShare1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ContingentLiabilitiesTextBlock_lbl0" xml:lang="en-US">ContingentLiabilitiesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ContingentLiabilitiesTextBlock" xlink:to="imc_ContingentLiabilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl2" xml:lang="en-US">WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerFMember_lbl0" xml:lang="en-US">CustomerFMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerFMember" xlink:to="imc_CustomerFMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfEquityToOrdinaryvalue_lbl1" xml:lang="en-US">IssueOfEquityToOrdinaryvalue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfEquityToOrdinaryvalue" xlink:to="imc_IssueOfEquityToOrdinaryvalue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeaveProvisionExpense_lbl1" xml:lang="en-US">LeaveProvisionExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaveProvisionExpense" xlink:to="imc_LeaveProvisionExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ContractualCashFlowsMember_lbl0" xml:lang="en-US">ContractualCashFlowsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ContractualCashFlowsMember" xlink:to="imc_ContractualCashFlowsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CashlessExerciseOfESOPUnlistedOptions_lbl0" xml:lang="en-US">CashlessExerciseOfESOPUnlistedOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CashlessExerciseOfESOPUnlistedOptions" xlink:to="imc_CashlessExerciseOfESOPUnlistedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl1" xml:lang="en-US">DisclosureOfDetailsOfEarningsPerShareExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:to="imc_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OrdinarySharesAbstract_lbl0" xml:lang="en-US">OrdinarySharesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinarySharesAbstract" xlink:to="imc_OrdinarySharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfExchangerateTableExplanatory_lbl1" xml:lang="en-US">DisclosureOfExchangerateTableExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfExchangerateTableExplanatory" xlink:to="imc_DisclosureOfExchangerateTableExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevaluationFinancialsAmount_lbl1" xml:lang="en-US">RevaluationFinancialsAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevaluationFinancialsAmount" xlink:to="imc_RevaluationFinancialsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CurrencyTranslationDifferences_lbl1" xml:lang="en-US">CurrencyTranslationDifferences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CurrencyTranslationDifferences" xlink:to="imc_CurrencyTranslationDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl1" xml:lang="en-US">NumberOfValueIssueLapseOfUnlistedOptionOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerAMember_lbl1" xml:lang="en-US">CustomerAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerAMember" xlink:to="imc_CustomerAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AdditionalOtherIncome_lbl1" xml:lang="en-US">AdditionalOtherIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdditionalOtherIncome" xlink:to="imc_AdditionalOtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateSixMember_lbl0" xml:lang="en-US">GrantDateSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateSixMember" xlink:to="imc_GrantDateSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl1" xml:lang="en-US">DisclosureOfDetailedInformationMovementsInOptionsAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:to="imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AssistancePackages_lbl1" xml:lang="en-US">AssistancePackages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AssistancePackages" xlink:to="imc_AssistancePackages_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl1" xml:lang="en-US">NumberOfValueIssueLapseOfUnlistedOptionTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:to="imc_NumberOfValueIssueLapseOfUnlistedOptionTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AmountOfOrdinaryShares_lbl2" xml:lang="en-US">AmountOfOrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AmountOfOrdinaryShares" xlink:to="imc_AmountOfOrdinaryShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:to="imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl1" xml:lang="en-US">DisclosureOfProvisionForSalesReturnsExplantory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfProvisionForSalesReturnsExplantory" xlink:to="imc_DisclosureOfProvisionForSalesReturnsExplantory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_MarketingExpenses_lbl1" xml:lang="en-US">MarketingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_MarketingExpenses" xlink:to="imc_MarketingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ListingAndShareRegistry_lbl1" xml:lang="en-US">ListingAndShareRegistry</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ListingAndShareRegistry" xlink:to="imc_ListingAndShareRegistry_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CostOfFinance_lbl0" xml:lang="en-US">CostOfFinance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CostOfFinance" xlink:to="imc_CostOfFinance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShortTermFundingAgreementsMember_lbl1" xml:lang="en-US">ShortTermFundingAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShortTermFundingAgreementsMember" xlink:to="imc_ShortTermFundingAgreementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssuanceOfOrdinarySharesDescription_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssuanceOfOrdinarySharesDescription" xlink:to="imc_IssuanceOfOrdinarySharesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital_lbl0" xml:lang="en-US">ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" xlink:to="imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ForeignCurrencyTranslationMember_lbl0" xml:lang="en-US">ForeignCurrencyTranslationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ForeignCurrencyTranslationMember" xlink:to="imc_ForeignCurrencyTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LegalExpenses_lbl1" xml:lang="en-US">LegalExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LegalExpenses" xlink:to="imc_LegalExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfOrdinarySharesExplanatory_lbl0" xml:lang="en-US">DisclosureOfOrdinarySharesExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfOrdinarySharesExplanatory" xlink:to="imc_DisclosureOfOrdinarySharesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerBMember_lbl1" xml:lang="en-US">CustomerBMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerBMember" xlink:to="imc_CustomerBMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinishedGoodsMember_lbl0" xml:lang="en-US">FinishedGoodsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinishedGoodsMember" xlink:to="imc_FinishedGoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LeaseRenewed_lbl1" xml:lang="en-US">LeaseRenewed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LeaseRenewed" xlink:to="imc_LeaseRenewed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_InvestorRelationsExpenses_lbl1" xml:lang="en-US">InvestorRelationsExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_InvestorRelationsExpenses" xlink:to="imc_InvestorRelationsExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AdjustmentsForDistributionCosts_lbl1" xml:lang="en-US">AdjustmentsForDistributionCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdjustmentsForDistributionCosts" xlink:to="imc_AdjustmentsForDistributionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_BusinessAcquisitionCostOfTransactionCost_lbl1" xml:lang="en-US">BusinessAcquisitionCostOfTransactionCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_BusinessAcquisitionCostOfTransactionCost" xlink:to="imc_BusinessAcquisitionCostOfTransactionCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ResearchAndDevelopmentsGrants_lbl1" xml:lang="en-US">ResearchAndDevelopmentsGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentsGrants" xlink:to="imc_ResearchAndDevelopmentsGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AnadisEPSPtyLtdMember_lbl1" xml:lang="en-US">AnadisEPSPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AnadisEPSPtyLtdMember" xlink:to="imc_AnadisEPSPtyLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree_lbl0" xml:lang="en-US">ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DetailedInformationAboutCashExplanatory_lbl1" xml:lang="en-US">DetailedInformationAboutCashExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DetailedInformationAboutCashExplanatory" xlink:to="imc_DetailedInformationAboutCashExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1_lbl0" xml:lang="en-US">WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" xlink:to="imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOption_lbl0" xml:lang="en-US">IssueAt050OnExerciseOfESOPUnlistedOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAt050OnExerciseOfESOPUnlistedOption" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AccountingAndAudit_lbl1" xml:lang="en-US">AccountingAndAudit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AccountingAndAudit" xlink:to="imc_AccountingAndAudit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentHyperImmuneProductsMember_lbl1" xml:lang="en-US">SegmentHyperImmuneProductsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentHyperImmuneProductsMember" xlink:to="imc_SegmentHyperImmuneProductsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CarryingAssetsLiabilitiesMember_lbl0" xml:lang="en-US">CarryingAssetsLiabilitiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CarryingAssetsLiabilitiesMember" xlink:to="imc_CarryingAssetsLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl1" xml:lang="en-US">IssueAt050OnExerciseOfESOPUnlistedOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:to="imc_IssueAt050OnExerciseOfESOPUnlistedOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SegmentLiabilities_lbl1" xml:lang="en-US">SegmentLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SegmentLiabilities" xlink:to="imc_SegmentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransferToShareCapital_lbl1" xml:lang="en-US">TransferToShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransferToShareCapital" xlink:to="imc_TransferToShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl1" xml:lang="en-US">NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CapitalCost_lbl1" xml:lang="en-US">CapitalCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CapitalCost" xlink:to="imc_CapitalCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl1" xml:lang="en-US">IssueAtUS047PursuantToADSPublicOffering1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtUS047PursuantToADSPublicOffering1" xlink:to="imc_IssueAtUS047PursuantToADSPublicOffering1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForEquityPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueIssuedToDirectors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_StockIssuedDuringPeriodValueIssuedToDirectors" xlink:to="imc_StockIssuedDuringPeriodValueIssuedToDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares_lbl0" xml:lang="en-US">ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree_lbl0" xml:lang="en-US">NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ControlledEntitiesTextBlock_lbl1" xml:lang="en-US">ControlledEntitiesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ControlledEntitiesTextBlock" xlink:to="imc_ControlledEntitiesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfRepresentativeWarrantsSharesOne_lbl0" xml:lang="en-US">ExerciseOfRepresentativeWarrantsSharesOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfRepresentativeWarrantsSharesOne" xlink:to="imc_ExerciseOfRepresentativeWarrantsSharesOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SubsidiariesOfImmuronLimitedAbstract_lbl0" xml:lang="en-US">SubsidiariesOfImmuronLimitedAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SubsidiariesOfImmuronLimitedAbstract" xlink:to="imc_SubsidiariesOfImmuronLimitedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevenueFormContractWithCustomer_lbl0" xml:lang="en-US">RevenueFormContractWithCustomer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFormContractWithCustomer" xlink:to="imc_RevenueFormContractWithCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_SuperannuationExpenses_lbl1" xml:lang="en-US">SuperannuationExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_SuperannuationExpenses" xlink:to="imc_SuperannuationExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateTwoMember_lbl0" xml:lang="en-US">GrantDateTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateTwoMember" xlink:to="imc_GrantDateTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateSevenMember_lbl0" xml:lang="en-US">GrantDateSevenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateSevenMember" xlink:to="imc_GrantDateSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:to="imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RevenueFromExternalCustomers_lbl1" xml:lang="en-US">RevenueFromExternalCustomers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RevenueFromExternalCustomers" xlink:to="imc_RevenueFromExternalCustomers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">NumberOfShareOptionGrantedInSharebasedPaymentArrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases_lbl0" xml:lang="en-US">ScheduleOfProfitOrLossAmountsRelatedToLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases" xlink:to="imc_ScheduleOfProfitOrLossAmountsRelatedToLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExpenseOfSharesOwed_lbl0" xml:lang="en-US">ExpenseOfSharesOwed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExpenseOfSharesOwed" xlink:to="imc_ExpenseOfSharesOwed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ProceedsFromIssuedAtADSPublicOffering_lbl1" xml:lang="en-US">ProceedsFromIssuedAtADSPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ProceedsFromIssuedAtADSPublicOffering" xlink:to="imc_ProceedsFromIssuedAtADSPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ImmuronIncMember_lbl1" xml:lang="en-US">ImmuronIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ImmuronIncMember" xlink:to="imc_ImmuronIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl2" xml:lang="en-US">ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">ResearchAndDevelopmentExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ResearchAndDevelopmentExpensesAbstract" xlink:to="imc_ResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember_lbl0" xml:lang="en-US">RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" xlink:to="imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsTwo_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsTwo" xlink:to="imc_IssueOfRepresentativeWarrantsTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_WattleLaboratoriesPtyLtdMember_lbl1" xml:lang="en-US">WattleLaboratoriesPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_WattleLaboratoriesPtyLtdMember" xlink:to="imc_WattleLaboratoriesPtyLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne_lbl0" xml:lang="en-US">ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" xlink:to="imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl1" xml:lang="en-US">IssueAtA008InLieuOfCashForServicesRendered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl1" xml:lang="en-US">NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:to="imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_CustomerCMember_lbl1" xml:lang="en-US">CustomerCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_CustomerCMember" xlink:to="imc_CustomerCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateThreeMember_lbl0" xml:lang="en-US">GrantDateThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateThreeMember" xlink:to="imc_GrantDateThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OrdinaryShare_lbl1" xml:lang="en-US">OrdinaryShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OrdinaryShare" xlink:to="imc_OrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl1" xml:lang="en-US">ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:to="imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive_lbl0" xml:lang="en-US">LapseOfUnexercisedOptionsAtZeroPointFiveFive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive" xlink:to="imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OtherGainsLossesNetAbstract_lbl0" xml:lang="en-US">OtherGainsLossesNetAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OtherGainsLossesNetAbstract" xlink:to="imc_OtherGainsLossesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GrantDateFourMember_lbl0" xml:lang="en-US">GrantDateFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GrantDateFourMember" xlink:to="imc_GrantDateFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_FinanceCostsNet_lbl1" xml:lang="en-US">FinanceCostsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_FinanceCostsNet" xlink:to="imc_FinanceCostsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl1" xml:lang="en-US">IssueAtA008InLieuOfCashForServicesRendered20201113</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:to="imc_IssueAtA008InLieuOfCashForServicesRendered20201113_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_GeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">GeneralAndAdministrativeExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_GeneralAndAdministrativeExpensesAbstract" xlink:to="imc_GeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TotalExpenses_lbl0" xml:lang="en-US">TotalExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TotalExpenses" xlink:to="imc_TotalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ExercisePrice_lbl0" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ExercisePrice" xlink:to="imc_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl1" xml:lang="en-US">DescriptionOfAccountingPolicyForBasisOfPresentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:to="imc_DescriptionOfAccountingPolicyForBasisOfPresentation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DrJerryKanellosMember_lbl0" xml:lang="en-US">DrJerryKanellosMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DrJerryKanellosMember" xlink:to="imc_DrJerryKanellosMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_OptionsAndWarrantsLapsed_lbl1" xml:lang="en-US">OptionsAndWarrantsLapsed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_OptionsAndWarrantsLapsed" xlink:to="imc_OptionsAndWarrantsLapsed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_lbl0" xml:lang="en-US">TransactionsWithOwnersInTheirCapacityAsOwnersAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsTwoShares_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsTwoShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsTwoShares" xlink:to="imc_IssueOfRepresentativeWarrantsTwoShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_EmployeeBenefitObligation_lbl1" xml:lang="en-US">EmployeeBenefitObligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_EmployeeBenefitObligation" xlink:to="imc_EmployeeBenefitObligation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl1" xml:lang="en-US">DisclosureOfIncomeTaxBenefitExplanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_DisclosureOfIncomeTaxBenefitExplanatory" xlink:to="imc_DisclosureOfIncomeTaxBenefitExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_LiabilitiesAbstract00_lbl0" xml:lang="en-US">LiabilitiesAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_LiabilitiesAbstract00" xlink:to="imc_LiabilitiesAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" xlink:to="imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsOne_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsOne" xlink:to="imc_IssueOfRepresentativeWarrantsOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_IssueOfRepresentativeWarrantsThree_lbl0" xml:lang="en-US">IssueOfRepresentativeWarrantsThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_IssueOfRepresentativeWarrantsThree" xlink:to="imc_IssueOfRepresentativeWarrantsThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imc_AdjustmentsForAbstract_lbl0" xml:lang="en-US">AdjustmentsForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imc_AdjustmentsForAbstract" xlink:to="imc_AdjustmentsForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember_lbl0" xml:lang="en-US">Not later than three months [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanThreeMonthsMember" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl0" xml:lang="en-US">Revenue and other operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoriesTotal_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl0" xml:lang="en-US">Current provisions for employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl0" xml:lang="en-US">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CAD_lbl0" xml:lang="en-US">Canada, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl0" xml:lang="en-US">Component of Operating Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_lbl0" xml:lang="en-US">Disclosure of major customers [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl1" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl0" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, other long-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Classes of cash receipts from operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl1" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0" xml:lang="en-US">Description of accounting policy for government grants [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0" xml:lang="en-US">Expense from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl1" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl0" xml:lang="en-US">Expenses by nature [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAbstract_lbl0" xml:lang="en-US">Cash [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetAssetsLiabilities_lbl0" xml:lang="en-US">Assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl0" xml:lang="en-US">Payments to suppliers for goods and services and to and on behalf of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_lbl0" xml:lang="en-US">Estimated financial effect of contingent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of general and administrative expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterials_lbl0" xml:lang="en-US">Current raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterials" xlink:to="ifrs-full_RawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl1" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of reserves within equity [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets_lbl0" xml:lang="en-US">Accrued income other than contract assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:to="ifrs-full_AccruedIncomeOtherThanContractAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Repayments of borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities_lbl0" xml:lang="en-US">Information about nature of lessee&apos;s leasing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" xlink:to="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl0" xml:lang="en-US">Travel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl0" xml:lang="en-US">Adjustments for provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl0" xml:lang="en-US">Receipts from sales of goods and rendering of services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_lbl0" xml:lang="en-US">Later than six months and not later than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl1" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl0" xml:lang="en-US">Country of incorporation of subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of significant accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl0" xml:lang="en-US">Gross lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl1" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UtilitiesExpense_lbl0" xml:lang="en-US">Utilities expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UtilitiesExpense" xlink:to="ifrs-full_UtilitiesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl2" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl0" xml:lang="en-US">Revenue [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl0" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense_lbl0" xml:lang="en-US">Property development and project management expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:to="ifrs-full_PropertyDevelopmentAndProjectManagementExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl0" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl0" xml:lang="en-US">AUSTRALIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl1" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssetsMember_lbl0" xml:lang="en-US">Right-of-use assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl0" xml:lang="en-US">Revenue from contracts with customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherGainsLosses_lbl1" xml:lang="en-US">Other gains (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl1" xml:lang="en-US">Depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_lbl0" xml:lang="en-US">Later than three months and not later than six months [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl0" xml:lang="en-US">Adjustments for finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl0" xml:lang="en-US">Depreciation, right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl0" xml:lang="en-US">Disclosure of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl0" xml:lang="en-US">Later than one month and not later than two months [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl0" xml:lang="en-US">Disclosure of geographical areas [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl0" xml:lang="en-US">Trade and other current payables [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Interest received, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl0" xml:lang="en-US">Adjustments for finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl0" xml:lang="en-US">Income from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Other comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl0" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_TradeAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl1" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl0" xml:lang="en-US">Fixtures and fittings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl1" xml:lang="en-US">Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl0" xml:lang="en-US">Not later than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl1" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanThreeMonthsMember_lbl0" xml:lang="en-US">Later than three months [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeMonthsMember" xlink:to="ifrs-full_LaterThanThreeMonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Provisions_lbl1" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEmployeeExpense_lbl0" xml:lang="en-US">Other employee expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEmployeeExpense" xlink:to="ifrs-full_OtherEmployeeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl2" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl0" xml:lang="en-US">Issue of convertible instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for trading income and expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_lbl0" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl0" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingExpense_lbl0" xml:lang="en-US">Selling expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingExpense" xlink:to="ifrs-full_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl0" xml:lang="en-US">Trade and other current receivables [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl0" xml:lang="en-US">Key management personnel compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Lease liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl0" xml:lang="en-US">Trade and other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl0" xml:lang="en-US">Current tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl0" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLoss_lbl0" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl0" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedCreditLossRate_lbl0" xml:lang="en-US">Expected credit loss rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedCreditLossRate" xlink:to="ifrs-full_ExpectedCreditLossRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentInventories_lbl0" xml:lang="en-US">Non-current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentInventories" xlink:to="ifrs-full_NoncurrentInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl0" xml:lang="en-US">Other current financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl0" xml:lang="en-US">Later than one year and not later than five years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentMember_lbl0" xml:lang="en-US">Current [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentMember" xlink:to="ifrs-full_CurrentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivablesMember_lbl0" xml:lang="en-US">Trade receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Other inflows (outflows) of cash, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0" xml:lang="en-US">Disclosure of financial risk management [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl0" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl0" xml:lang="en-US">Purchases of goods, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl0" xml:lang="en-US">Later than five years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl1" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DistributionCosts_lbl0" xml:lang="en-US">Distribution costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DistributionCosts" xlink:to="ifrs-full_DistributionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl0" xml:lang="en-US">Later than one year and not later than three years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember_lbl0" xml:lang="en-US">Later than two months and not later than three months [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" xlink:to="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>imc-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Oct 29 00:56:37 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedIncomeStatement" roleURI="http://immuron.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedBalanceSheet" roleURI="http://immuron.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareholdersEquityType2or3" roleURI="http://immuron.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ConsolidatedCashFlow" roleURI="http://immuron.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immuron.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Revenueandotherincome" roleURI="http://immuron.com/role/Revenueandotherincome"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Expenses" roleURI="http://immuron.com/role/Expenses"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_IncomeTaxBenefit" roleURI="http://immuron.com/role/IncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_KeyManagementPersonnelCompensation" roleURI="http://immuron.com/role/KeyManagementPersonnelCompensation"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LossperShare" roleURI="http://immuron.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Cash" roleURI="http://immuron.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherReceivables" roleURI="http://immuron.com/role/TradeandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Inventories" roleURI="http://immuron.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ControlledEntities" roleURI="http://immuron.com/role/ControlledEntities"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherPayables" roleURI="http://immuron.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ProvisionforSalesReturns" roleURI="http://immuron.com/role/ProvisionforSalesReturns"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ContingentliabilitiesandCommitments" roleURI="http://immuron.com/role/ContingentliabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_Leases" roleURI="http://immuron.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapital" roleURI="http://immuron.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReserves" roleURI="http://immuron.com/role/OtherReserves"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReporting" roleURI="http://immuron.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashFlowInformation" roleURI="http://immuron.com/role/CashFlowInformation"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPayments" roleURI="http://immuron.com/role/SharebasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactions" roleURI="http://immuron.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPolicies" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_EventsoccurringaftertheReportingDate" roleURI="http://immuron.com/role/EventsoccurringaftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CompanyDetails" roleURI="http://immuron.com/role/CompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_AccountingPoliciesByPolicy" roleURI="http://immuron.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RevenueandotherincomeTables" roleURI="http://immuron.com/role/RevenueandotherincomeTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ExpensesTables" roleURI="http://immuron.com/role/ExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_IncomeTaxBenefitTables" roleURI="http://immuron.com/role/IncomeTaxBenefitTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_KeyManagementPersonnelCompensationTables" roleURI="http://immuron.com/role/KeyManagementPersonnelCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LossperShareTables" roleURI="http://immuron.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashTables" roleURI="http://immuron.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherReceivablesTables" roleURI="http://immuron.com/role/TradeandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_InventoriesTables" roleURI="http://immuron.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ControlledEntitiesTables" roleURI="http://immuron.com/role/ControlledEntitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_TradeandOtherPayablesTables" roleURI="http://immuron.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ProvisionforSalesReturnsTables" roleURI="http://immuron.com/role/ProvisionforSalesReturnsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LeasesTables" roleURI="http://immuron.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapitalTables" roleURI="http://immuron.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReservesTables" roleURI="http://immuron.com/role/OtherReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReportingTables" roleURI="http://immuron.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_CashFlowInformationTables" roleURI="http://immuron.com/role/CashFlowInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPaymentsTables" roleURI="http://immuron.com/role/SharebasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactionsTables" roleURI="http://immuron.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPoliciesTables" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofrevenueandotherincomeTable" roleURI="http://immuron.com/role/ScheduleofrevenueandotherincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofexpensesTable" roleURI="http://immuron.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable" roleURI="http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofincometaxbenefitTable" roleURI="http://immuron.com/role/ScheduleofincometaxbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofkeymanagementpersonnelcompensationTable" roleURI="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofbasicanddilutedlosspershareTable" roleURI="http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofbalancesundercashTable" roleURI="http://immuron.com/role/ScheduleofbalancesundercashTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherreceivablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinventoriesTable" roleURI="http://immuron.com/role/ScheduleofinventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsubsidiariesTable" roleURI="http://immuron.com/role/ScheduleofsubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradeandotherpayablesTable" roleURI="http://immuron.com/role/ScheduleoftradeandotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofprovisionforsalesreturnsTable" roleURI="http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofamountsrelatingtoleasesinbalancesheetTable" roleURI="http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofprofitorlossamountsrelatingtoleasesTable" roleURI="http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsharecapitalTable" roleURI="http://immuron.com/role/ScheduleofsharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofordinarysharesTable" roleURI="http://immuron.com/role/ScheduleofordinarysharesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofotherreservesTable" roleURI="http://immuron.com/role/ScheduleofotherreservesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmovementsinoptionsandwarrantsTable" roleURI="http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofsegmentinformationforthereportablesegmentsTable" roleURI="http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinformationongeographicalregionsTable" roleURI="http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmajorcustomersTable" roleURI="http://immuron.com/role/ScheduleofmajorcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable" roleURI="http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable" roleURI="http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofgrantedvaluationofoptionsTable" roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofgrantedvaluationofoptionsTable0" roleURI="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable" roleURI="http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofinformationaboutotherrelatedpartytransactionsTable" roleURI="http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable" roleURI="http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofforeigncurrencyriskTable" roleURI="http://immuron.com/role/ScheduleofforeigncurrencyriskTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofexchangeratesTable" roleURI="http://immuron.com/role/ScheduleofexchangeratesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleoftradereceivablesTable" roleURI="http://immuron.com/role/ScheduleoftradereceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ScheduleofcontractualundiscountedcashflowsTable" roleURI="http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RevenueandotherincomeDetails" roleURI="http://immuron.com/role/RevenueandotherincomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ContingentliabilitiesandCommitmentsDetails" roleURI="http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_LeasesDetails" roleURI="http://immuron.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_ShareCapitalDetails" roleURI="http://immuron.com/role/ShareCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_OtherReservesDetails" roleURI="http://immuron.com/role/OtherReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SegmentReportingDetails" roleURI="http://immuron.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_SharebasedPaymentsDetails" roleURI="http://immuron.com/role/SharebasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_RelatedPartyTransactionsDetails" roleURI="http://immuron.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#imc_r_FinancialRiskManagementObjectivesandPoliciesDetails" roleURI="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="imc-20210630.xsd#DocumentAndEntityInformation" roleURI="http://immuron.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherGainsLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="SharebasedPaymentsExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeFinance" xlink:href="imc-20210630.xsd#imc_IncomeFinance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="IncomeFinance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="CostOfFinance" xlink:href="imc-20210630.xsd#imc_CostOfFinance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="CostOfFinance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceCostsNet" xlink:href="imc-20210630.xsd#imc_FinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfFinance" xlink:to="FinanceCostsNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfFinance" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfFinance" xlink:to="ifrs-full_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfFinance" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedEarningsLossPerShare" xlink:href="imc-20210630.xsd#imc_BasicAndDilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="BasicAndDilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InventoriesTotal" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitObligation" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="EmployeeBenefitObligation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitObligationNonCurrent" xlink:href="imc-20210630.xsd#imc_EmployeeBenefitObligationNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="EmployeeBenefitObligationNonCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Liabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NetAssetsLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementOfChangesInEquityAbstract" xlink:href="imc-20210630.xsd#imc_ConsolidatedStatementOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReservesMember" xlink:href="imc-20210630.xsd#imc_ReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ReservesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedLossesMember" xlink:href="imc-20210630.xsd#imc_AccumulatedLossesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="AccumulatedLossesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="EquityBalance" xlink:href="imc-20210630.xsd#imc_EquityBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="EquityBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossForPeriod" xlink:href="imc-20210630.xsd#imc_OtherComprehensiveIncomeLossForPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="OtherComprehensiveIncomeLossForPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsOrWarrantsIssuedExpensed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsIssuedExpensed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="OptionsOrWarrantsIssuedExpensed" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsOrWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="OptionsOrWarrantsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsOrWarrantsForteitedLapsed" xlink:href="imc-20210630.xsd#imc_OptionsOrWarrantsForteitedLapsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="OptionsOrWarrantsForteitedLapsed" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuedToDirectors" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringPeriodValueIssuedToDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="StockIssuedDuringPeriodValueIssuedToDirectors" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferToShareCapital" xlink:href="imc-20210630.xsd#imc_TransferToShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="TransferToShareCapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionswarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionswarrantsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="OptionswarrantsForfeited" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfOptionIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionIssuedInPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="RevaluationOfOptionIssuedInPriorPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeShareSchemesValueOfEmployee" xlink:href="imc-20210630.xsd#imc_EmployeeShareSchemesValueOfEmployee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="EmployeeShareSchemesValueOfEmployee" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityBalance_0" xlink:href="imc-20210630.xsd#imc_EquityBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsWithOwnersInTheirCapacityAsOwnersAbstract" xlink:to="EquityBalance_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInAccountingPolicy" xlink:href="imc-20210630.xsd#imc_ChangeInAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ChangeInAccountingPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestatedTotalEquityAt1July2019" xlink:href="imc-20210630.xsd#imc_RestatedTotalEquityAt1July2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="RestatedTotalEquityAt1July2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsToSuppliersForGoodsAndService" xlink:href="imc-20210630.xsd#imc_PaymentsToSuppliersForGoodsAndService"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="PaymentsToSuppliersForGoodsAndService" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalCost" xlink:href="imc-20210630.xsd#imc_CapitalCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="CapitalCost" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/Revenueandotherincome">
    <loc xlink:type="locator" xlink:label="DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/Expenses">
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesByNatureTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfExpensesByNatureTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/IncomeTaxBenefit">
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/KeyManagementPersonnelCompensation">
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="DisclosureOfEarningsPerShareTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEarningsPerShareTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/Cash">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCashExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashExplanatoryAbstract" xlink:to="DisclosureOfCashExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherReceivables">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="DisclosureOfInventoriesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInventoriesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInventoriesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ControlledEntities">
    <loc xlink:type="locator" xlink:label="ControlledEntitiesAbstract" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ControlledEntitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ControlledEntitiesAbstract" xlink:to="ControlledEntitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherPayables">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ProvisionforSalesReturns">
    <loc xlink:type="locator" xlink:label="DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfProvisionForSalesReturnsExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:to="DisclosureOfProvisionForSalesReturnsExplantory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ContingentliabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesTextBlock" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesAbstract" xlink:to="ContingentLiabilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/Leases">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:label="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReserves">
    <loc xlink:type="locator" xlink:label="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/CashFlowInformation">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCashFlowInformationExplanatoryTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:to="DisclosureOfCashFlowInformationExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPayments">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/EventsoccurringaftertheReportingDate">
    <loc xlink:type="locator" xlink:label="DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEventsAfterReportingPeriodTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/CompanyDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCompanyDetailsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfCompanyDetailsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompanyDetailsExplanatoryAbstract" xlink:to="DisclosureOfCompanyDetailsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForBasisOfPresentation" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForBasisOfPresentation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForBasisOfPresentation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForEquityPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForEquityPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/RevenueandotherincomeTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ExpensesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesByNatureTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfExpensesByNatureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfExpensesByNatureTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/IncomeTaxBenefitTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxBenefitExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfIncomeTaxBenefitExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfIncomeTaxTextBlockAbstract" xlink:to="DisclosureOfIncomeTaxBenefitExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/KeyManagementPersonnelCompensationTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract" xlink:to="DisclosureOfDetailedInformationOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfEarningsPerShareTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEarningsPerShareTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEarningsPerShareTextBlockAbstract" xlink:to="DisclosureOfDetailsOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DetailedInformationAboutCashExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutCashExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashExplanatoryAbstract" xlink:to="DetailedInformationAboutCashExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DetailedInformationAboutTradeAndOtherReceivablesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherReceivablesTextBlockAbstract" xlink:to="DetailedInformationAboutTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfInventoriesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfInventoriesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DetailedInformationAboutInventoriesExplanatory" xlink:href="imc-20210630.xsd#imc_DetailedInformationAboutInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInventoriesTextBlockAbstract" xlink:to="DetailedInformationAboutInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ControlledEntitiesTables">
    <loc xlink:type="locator" xlink:label="ControlledEntitiesAbstract" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfSubsidiariesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ControlledEntitiesAbstract" xlink:to="ScheduleOfSubsidiariesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/TradeandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTradeAndOtherPayablesTextBlockAbstract" xlink:to="DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ProvisionforSalesReturnsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSalesReturnProvisionExplantory" xlink:href="imc-20210630.xsd#imc_DisclosureOfSalesReturnProvisionExplantory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfProvisionForSalesReturnsExplantoryAbstract" xlink:to="DisclosureOfSalesReturnProvisionExplantory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsRecognizedinBalanceSheet" xlink:href="imc-20210630.xsd#imc_ScheduleOfAmountsRecognizedinBalanceSheet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ScheduleOfAmountsRecognizedinBalanceSheet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitOrLossAmountsRelatedToLeases" xlink:href="imc-20210630.xsd#imc_ScheduleOfProfitOrLossAmountsRelatedToLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ScheduleOfProfitOrLossAmountsRelatedToLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOrdinarySharesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfOrdinarySharesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="DisclosureOfOrdinarySharesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReservesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationOtherReserve" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationOtherReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="DisclosureOfDetailedInformationOtherReserve" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" xlink:href="imc-20210630.xsd#imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="DisclosureOfDetailedInformationMovementsInOptionsAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosuresOfProductsAndServicesExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosuresOfProductsAndServicesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="DisclosuresOfProductsAndServicesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/CashFlowInformationTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfCashFlowInformationExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashFlowInformationExplanatoryAbstract" xlink:to="DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsTablesTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsTablesLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="SharebasedPaymentsTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsTablesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockOption1Member" xlink:href="imc-20210630.xsd#imc_EmployeeStockOption1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="EmployeeStockOption1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsTablesTable" xlink:to="SharebasedPaymentsTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsTablesLineItems" xlink:to="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDeemedValuationOfOptionsExplanatory" xlink:href="imc-20210630.xsd#imc_ScheduleOfDeemedValuationOfOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsTablesLineItems" xlink:to="ScheduleOfDeemedValuationOfOptionsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsTablesLineItems" xlink:to="ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExchangerateTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfExchangerateTableExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="DisclosureOfExchangerateTableExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherReceivablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="DisclosureOfTradeAndOtherReceivablesTableExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherPayablesTableExplanatory" xlink:href="imc-20210630.xsd#imc_DisclosureOfTradeAndOtherPayablesTableExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="DisclosureOfTradeAndOtherPayablesTableExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofrevenueandotherincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfRevenueAndOtherIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueFromOperatingActivitiesAbstract" xlink:href="imc-20210630.xsd#imc_RevenueFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="RevenueFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromOperatingActivitiesAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AustralianFederalRdTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_AustralianFederalRdTaxConcessionRefund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="AustralianFederalRdTaxConcessionRefund" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherGovernmentAssistanceIncome" xlink:href="imc-20210630.xsd#imc_OtherGovernmentAssistanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="OtherGovernmentAssistanceIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="ResearchAndDevelopmentGrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomes" xlink:href="imc-20210630.xsd#imc_OtherIncomes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="OtherIncomes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeFromNonOperatingActivities" xlink:href="imc-20210630.xsd#imc_OtherIncomeFromNonOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="OtherIncomeFromNonOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherGainsLossesNetAbstract" xlink:href="imc-20210630.xsd#imc_OtherGainsLossesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="OtherGainsLossesNetAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetForeignExchangeGainLoss" xlink:href="imc-20210630.xsd#imc_NetForeignExchangeGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherGainsLossesNetAbstract" xlink:to="NetForeignExchangeGainLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherGainsLossesNetAbstract" xlink:to="ifrs-full_ImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueAndOtherIncomeAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesAbstract" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="GeneralAndAdministrativeExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingAndAudit" xlink:href="imc-20210630.xsd#imc_AccountingAndAudit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="AccountingAndAudit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BadDebts" xlink:href="imc-20210630.xsd#imc_BadDebts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="BadDebts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ConsultingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ConsultingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_OtherEmployeeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ExpectedCreditLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_InsuranceExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsExpenses" xlink:href="imc-20210630.xsd#imc_InvestorRelationsExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="InvestorRelationsExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalExpenses" xlink:href="imc-20210630.xsd#imc_LegalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="LegalExpenses" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ListingAndShareRegistry" xlink:href="imc-20210630.xsd#imc_ListingAndShareRegistry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ListingAndShareRegistry" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UtilitiesExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UtilitiesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_UtilitiesExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuperannuationExpenses" xlink:href="imc-20210630.xsd#imc_SuperannuationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="SuperannuationExpenses" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_TravelExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="ResearchAndDevelopmentExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentConsultingExpenses" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentConsultingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentConsultingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyDevelopmentAndProjectManagementExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_PropertyDevelopmentAndProjectManagementExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="SellingAndMarketingExpensesAbstract" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="SellingAndMarketingExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketingExpenses" xlink:href="imc-20210630.xsd#imc_MarketingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingAndMarketingExpensesAbstract" xlink:to="MarketingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DistributionCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DistributionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_DistributionCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingAndMarketingExpensesAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofincometaxbenefitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxBenefitAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfIncomeTaxBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectofResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectofResearchAndDevelopmentTaxIncentive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="TaxEffectofResearchAndDevelopmentTaxIncentive" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" xlink:href="imc-20210630.xsd#imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfShareBasedPayments" xlink:href="imc-20210630.xsd#imc_TaxEffectOfShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="TaxEffectOfShareBasedPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" xlink:href="imc-20210630.xsd#imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfTaxPayable" xlink:href="imc-20210630.xsd#imc_TaxEffectOfTaxPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="TaxEffectOfTaxPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" xlink:href="imc-20210630.xsd#imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfKeyManagementPersonnelCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationAbstract" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:to="KeyManagementPersonnelCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" xlink:href="imc-20210630.xsd#imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="KeyManagementPersonnelCompensationAbstract" xlink:to="KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="KeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfKeyManagementPersonnelCompensationAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBasicAndDilutedLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedEarningsLossPerShare" xlink:href="imc-20210630.xsd#imc_BasicAndDilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="BasicAndDilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfShares" xlink:href="imc-20210630.xsd#imc_WeightedAverageNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerShareAbstract" xlink:to="WeightedAverageNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofbalancesundercashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesUnderCashAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfBalancesUnderCashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesUnderCashAbstract" xlink:to="ifrs-full_CashAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAtBankAndInHand" xlink:href="imc-20210630.xsd#imc_CashAtBankAndInHand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="CashAtBankAndInHand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherreceivablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherReceivablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnAllowanceTradeReceivables" xlink:href="imc-20210630.xsd#imc_LossOnAllowanceTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="LossOnAllowanceTradeReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeOtherThanContractAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccruedIncomeOtherThanContractAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_AccruedIncomeOtherThanContractAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinventoriesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoriesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="InventoriesDetailsScheduleofinventoriesTable" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesTable"/>
    <loc xlink:type="locator" xlink:label="InventoriesDetailsScheduleofinventoriesLineItems" xlink:href="imc-20210630.xsd#imc_InventoriesDetailsScheduleofinventoriesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="InventoriesDetailsScheduleofinventoriesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="InventoriesAxis" xlink:href="imc-20210630.xsd#imc_InventoriesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleofinventoriesTable" xlink:to="InventoriesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoriesDomain" xlink:href="imc-20210630.xsd#imc_InventoriesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAxis" xlink:to="InventoriesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RawMaterialsAndStoresMember" xlink:href="imc-20210630.xsd#imc_RawMaterialsAndStoresMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAxis" xlink:to="RawMaterialsAndStoresMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkInProgressMember" xlink:href="imc-20210630.xsd#imc_WorkInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAxis" xlink:to="WorkInProgressMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinishedGoodsMember" xlink:href="imc-20210630.xsd#imc_FinishedGoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAxis" xlink:to="FinishedGoodsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleofinventoriesTable" xlink:to="InventoriesDetailsScheduleofinventoriesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="ifrs-full_Inventories" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="ifrs-full_NoncurrentInventories" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoriesNet" xlink:href="imc-20210630.xsd#imc_InventoriesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleofinventoriesLineItems" xlink:to="InventoriesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsubsidiariesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable"/>
    <loc xlink:type="locator" xlink:label="ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:href="imc-20210630.xsd#imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubsidiariesAbstract" xlink:to="ControlledEntitiesDetailsScheduleofsubsidiariesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ImmuronLimitedMember" xlink:href="imc-20210630.xsd#imc_ImmuronLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ImmuronLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImmuronIncMember" xlink:href="imc-20210630.xsd#imc_ImmuronIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ImmuronIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnadisEPSPtyLtdMember" xlink:href="imc-20210630.xsd#imc_AnadisEPSPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="AnadisEPSPtyLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IMCCanadaLtdMember" xlink:href="imc-20210630.xsd#imc_IMCCanadaLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="IMCCanadaLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ControlledEntitiesDetailsScheduleofsubsidiariesTable" xlink:to="ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ParentEntityAbstract" xlink:href="imc-20210630.xsd#imc_ParentEntityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ControlledEntitiesDetailsScheduleofsubsidiariesLineItems" xlink:to="ParentEntityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ParentEntityAbstract" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ParentEntityAbstract" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradeandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProvisionForSalesReturnsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfProvisionForSalesReturnsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Provisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_Provisions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Provisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionForSalesReturnsAbstract" xlink:to="ifrs-full_Provisions_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract" xlink:to="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable" xlink:to="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_RightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:href="imc-20210630.xsd#imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract" xlink:to="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable" xlink:to="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:href="imc-20210630.xsd#imc_DepreciationChargeOfRightOfUseAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems" xlink:to="DepreciationChargeOfRightOfUseAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepreciationChargeOfRightOfUseAssetsAbstract" xlink:to="ifrs-full_CashOutflowForLeases" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsharecapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfOrdinaryShares" xlink:href="imc-20210630.xsd#imc_AmountOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="AmountOfOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfOrdinaryShares_0" xlink:href="imc-20210630.xsd#imc_AmountOfOrdinaryShares"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZlqtFB48Q4g+vDsrz/J+txP+YnQqdt84sBHw2d8eU6Gzi7iEHBQKr9q64s0PJMi+w5vjjovZ/8c/ypAyxVH44jeNG4gaeNFipfVD82eU0dXhH2mhR8c/hDENfta4A4c65eempJXG7euhbC1DYaNw2BmRQ2WSA7nGzowo5AdcvYvDW/V4Y0Yzj09eVZFtaZteU=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="AmountOfOrdinaryShares_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofordinarysharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOrdinarySharesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOrdinarySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShare" xlink:href="imc-20210630.xsd#imc_OrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="OrdinaryShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfEquityToOrdinaryvalue" xlink:href="imc-20210630.xsd#imc_IssueOfEquityToOrdinaryvalue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="IssueOfEquityToOrdinaryvalue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuePursuantToAdsPublicOfferingShares" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOfferingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="IssuePursuantToAdsPublicOfferingShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuePursuantToAdsPublicOffering" xlink:href="imc-20210630.xsd#imc_IssuePursuantToAdsPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="IssuePursuantToAdsPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueInLieuOfPaymentForServicesShares" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServicesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="IssueInLieuOfPaymentForServicesShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueInLieuOfPaymentForServices" xlink:href="imc-20210630.xsd#imc_IssueInLieuOfPaymentForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="IssueInLieuOfPaymentForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="ExerciseOfNasdaqWarrantsShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="ExerciseOfNasdaqWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrantShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="ExerciseOfRepresentativeWarrantShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrant" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuePursuantToAdsPublicOffering" xlink:to="ExerciseOfRepresentativeWarrant" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrants1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ExerciseOfRepresentativeWarrants1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrant1" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrant1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ExerciseOfRepresentativeWarrant1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS047PursuantToADSPublicOffering" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS047PursuantToADSPublicOffering" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS047PursuantToADSPublicOffering1" xlink:href="imc-20210630.xsd#imc_IssueAtUS047PursuantToADSPublicOffering1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS047PursuantToADSPublicOffering1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAt050OnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAt050OnExerciseOfESOPUnlistedOption" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAt050OnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_IssueAt050OnExerciseOfESOPUnlistedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAt050OnExerciseOfESOPUnlistedOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS025OnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS025OnExerciseOfNASDAQWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS025OnExerciseOfNASDAQWarrants1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrants1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS025OnExerciseOfNASDAQWarrants1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS025OnExerciseOfNASDAQWarrant" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS025OnExerciseOfNASDAQWarrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtUS025OnExerciseOfNASDAQWarrant1" xlink:href="imc-20210630.xsd#imc_IssueAtUS025OnExerciseOfNASDAQWarrant1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtUS025OnExerciseOfNASDAQWarrant1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnExerciseOfESOPUnlistedOptions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnExerciseOfESOPUnlistedOption" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfESOPUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnExerciseOfESOPUnlistedOption" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnExerciseOfNASDAQWarrants" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnExerciseOfNASDAQWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnExerciseOfNASDAQWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtA008InLieuOfCashForServicesRendered20201113" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered20201113"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtA008InLieuOfCashForServicesRendered20201113" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueAtA008InLieuOfCashForServicesRendered" xlink:href="imc-20210630.xsd#imc_IssueAtA008InLieuOfCashForServicesRendered"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="IssueAtA008InLieuOfCashForServicesRendered" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExerciseOfRepresentativeWarrant1" xlink:to="TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" xlink:href="imc-20210630.xsd#imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuedSharesAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedSharesAtADSPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ProceedsFromIssuedSharesAtADSPublicOffering" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuedAtADSPublicOffering" xlink:href="imc-20210630.xsd#imc_ProceedsFromIssuedAtADSPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="ProceedsFromIssuedAtADSPublicOffering" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringValueReclassifyToStockOptionsExercised" xlink:href="imc-20210630.xsd#imc_StockIssuedDuringValueReclassifyToStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="StockIssuedDuringValueReclassifyToStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionCostsArisingOnRepresentativeWarrantsIssued" xlink:href="imc-20210630.xsd#imc_TransactionCostsArisingOnRepresentativeWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="TransactionCostsArisingOnRepresentativeWarrantsIssued" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="BusinessAcquisitionCostOfTransactionCostToIssuedAtShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionCostOfTransactionCost" xlink:href="imc-20210630.xsd#imc_BusinessAcquisitionCostOfTransactionCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="BusinessAcquisitionCostOfTransactionCost" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShare_0" xlink:href="imc-20210630.xsd#imc_OrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="OrdinaryShare_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfEquityToOrdinaryvalue_0" xlink:href="imc-20210630.xsd#imc_IssueOfEquityToOrdinaryvalue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinarySharesAbstract" xlink:to="IssueOfEquityToOrdinaryvalue_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofotherreservesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherReservesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOtherReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReservesDetailsScheduleofotherreservesTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesTable"/>
    <loc xlink:type="locator" xlink:label="OtherReservesDetailsScheduleofotherreservesLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsScheduleofotherreservesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReservesAbstract" xlink:to="OtherReservesDetailsScheduleofotherreservesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationMember" xlink:href="imc-20210630.xsd#imc_ForeignCurrencyTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ForeignCurrencyTranslationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesTable" xlink:to="OtherReservesDetailsScheduleofotherreservesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="ifrs-full_OtherReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithOwnersInTheirCapacityAsOwners" xlink:href="imc-20210630.xsd#imc_TransactionsWithOwnersInTheirCapacityAsOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="TransactionsWithOwnersInTheirCapacityAsOwners" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransferToShareCapitalinDollars" xlink:href="imc-20210630.xsd#imc_TransferToShareCapitalinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="TransferToShareCapitalinDollars" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentExpenses" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="SharebasedPaymentExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsAndWarrantsIssuedexpensed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsIssuedexpensed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="OptionsAndWarrantsIssuedexpensed" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsAndWarrantsExercised" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="OptionsAndWarrantsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsAndWarrantsForfeited" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="OptionsAndWarrantsForfeited" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsAndWarrantsLapsed" xlink:href="imc-20210630.xsd#imc_OptionsAndWarrantsLapsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="OptionsAndWarrantsLapsed" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfOptionsIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="RevaluationOfOptionsIssuedInPriorPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="ifrs-full_OtherReserves_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CurrencyTranslationDifferences" xlink:href="imc-20210630.xsd#imc_CurrencyTranslationDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsScheduleofotherreservesLineItems" xlink:to="CurrencyTranslationDifferences" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="imc-20210630.xsd#imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfOptionsIssuedInPriorPeriodShares" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="RevaluationOfOptionsIssuedInPriorPeriodShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfOptionsIssuedInPriorPeriod" xlink:href="imc-20210630.xsd#imc_RevaluationOfOptionsIssuedInPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="RevaluationOfOptionsIssuedInPriorPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsTwoShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwoShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="IssueOfRepresentativeWarrantsTwoShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsTwo" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="IssueOfRepresentativeWarrantsTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFiveShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFiveFive" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFiveFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsAtZeroPointFiveOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="LapseOfUnexercisedOptionsAtZeroPointFiveOne" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrantsShares" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="ExerciseOfRepresentativeWarrantsShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrants" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfOptionsIssuedInPriorPeriod" xlink:to="ExerciseOfRepresentativeWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfRepresentativeWarrantsSharesOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ExerciseOfRepresentativeWarrantsSharesOne" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ifrs-full_IssueOfConvertibleInstruments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ExerciseOfESOPUnlistedOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_ExerciseOfESOPUnlistedOptionsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ExerciseOfESOPUnlistedOptionsValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" xlink:href="imc-20210630.xsd#imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsOne" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="LapseOfUnexercisedOptionsOne" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LapseOfUnexercisedOptionsValue" xlink:href="imc-20210630.xsd#imc_LapseOfUnexercisedOptionsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="LapseOfUnexercisedOptionsValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsThreeShares" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThreeShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="IssueOfRepresentativeWarrantsThreeShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsThree" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="IssueOfRepresentativeWarrantsThree" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfESOPUnlistedOptions" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="CashlessExerciseOfESOPUnlistedOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfESOPUnlistedOptionsValue" xlink:href="imc-20210630.xsd#imc_CashlessExerciseOfESOPUnlistedOptionsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="CashlessExerciseOfESOPUnlistedOptionsValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" xlink:href="imc-20210630.xsd#imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueIssuedEmployeeStockOwnershipPlanUnlistedOption" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" xlink:href="imc-20210630.xsd#imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueLapseOfUnlistedOptionOne" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfValueIssueLapseOfUnlistedOptionOne" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfValueIssueLapseOfUnlistedOptionOne" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueLapseOfUnlistedOptionTwo" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfValueIssueLapseOfUnlistedOptionTwo" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfValueIssueLapseOfUnlistedOptionTwo" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfSharesIssueLapseOfUnlistedOptionThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesIssueLapseOfUnlistedOptionThree" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfValueIssueLapseOfUnlistedOptionThree" xlink:href="imc-20210630.xsd#imc_NumberOfValueIssueLapseOfUnlistedOptionThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfValueIssueLapseOfUnlistedOptionThree" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" xlink:href="imc-20210630.xsd#imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsSharesOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsSharesOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="IssueOfRepresentativeWarrantsSharesOne" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfRepresentativeWarrantsOne" xlink:href="imc-20210630.xsd#imc_IssueOfRepresentativeWarrantsOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="IssueOfRepresentativeWarrantsOne" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_0" xlink:href="imc-20210630.xsd#imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsAndWarrantsAbstract" xlink:to="ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentInformationForTheReportableSegmentsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentInformationForTheReportableSegmentsAbstract" xlink:to="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SegmentResearchAndDevelopmentMember" xlink:href="imc-20210630.xsd#imc_SegmentResearchAndDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="SegmentResearchAndDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SegmentHyperImmuneProductsMember" xlink:href="imc-20210630.xsd#imc_SegmentHyperImmuneProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="SegmentHyperImmuneProductsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherMember" xlink:href="imc-20210630.xsd#imc_OtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OtherMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable" xlink:to="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="HyperimmuneProductsRevenue" xlink:href="imc-20210630.xsd#imc_HyperimmuneProductsRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="HyperimmuneProductsRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherGainsLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="imc-20210630.xsd#imc_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="GeneralAndAdministrativeExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="SellingAndMarketingExpenses" xlink:href="imc-20210630.xsd#imc_SellingAndMarketingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="SellingAndMarketingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_AssetsAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SegmentAssets" xlink:href="imc-20210630.xsd#imc_SegmentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="SegmentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_LiabilitiesAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SegmentLiabilities" xlink:href="imc-20210630.xsd#imc_SegmentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="SegmentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems" xlink:to="ifrs-full_Liabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinformationongeographicalregionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationOnGeographicalRegionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInformationOnGeographicalRegionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationOnGeographicalRegionsAbstract" xlink:to="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="MajorProductLinesAxis" xlink:href="imc-20210630.xsd#imc_MajorProductLinesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="MajorProductLinesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MajorProductLinesDomain" xlink:href="imc-20210630.xsd#imc_MajorProductLinesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorProductLinesAxis" xlink:to="MajorProductLinesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TravelanMember" xlink:href="imc-20210630.xsd#imc_TravelanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorProductLinesAxis" xlink:to="TravelanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProtectynMember" xlink:href="imc-20210630.xsd#imc_ProtectynMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorProductLinesAxis" xlink:to="ProtectynMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_AU" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCountriesMember" xlink:href="imc-20210630.xsd#imc_OtherCountriesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="OtherCountriesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsTable" xlink:to="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueFromExternalCustomers" xlink:href="imc-20210630.xsd#imc_RevenueFromExternalCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="RevenueFromExternalCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SegmentRevenue" xlink:href="imc-20210630.xsd#imc_SegmentRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems" xlink:to="SegmentRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmajorcustomersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomersAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMajorCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersTable"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:href="imc-20210630.xsd#imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMajorCustomersAbstract" xlink:to="SegmentReportingDetailsScheduleofmajorcustomersTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorCustomersMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerAMember" xlink:href="imc-20210630.xsd#imc_CustomerAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerBMember" xlink:href="imc-20210630.xsd#imc_CustomerBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerCMember" xlink:href="imc-20210630.xsd#imc_CustomerCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerDMember" xlink:href="imc-20210630.xsd#imc_CustomerDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerDMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerEMember" xlink:href="imc-20210630.xsd#imc_CustomerEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerEMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerFMember" xlink:href="imc-20210630.xsd#imc_CustomerFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerFMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerGMember" xlink:href="imc-20210630.xsd#imc_CustomerGMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerGMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerHMember" xlink:href="imc-20210630.xsd#imc_CustomerHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerHMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerIMember" xlink:href="imc-20210630.xsd#imc_CustomerIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="CustomerIMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofmajorcustomersTable" xlink:to="SegmentReportingDetailsScheduleofmajorcustomersLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RevenueFormContractWithCustomer" xlink:href="imc-20210630.xsd#imc_RevenueFormContractWithCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDetailsScheduleofmajorcustomersLineItems" xlink:to="RevenueFormContractWithCustomer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForAbstract" xlink:href="imc-20210630.xsd#imc_AdjustmentsForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLoss" xlink:to="AdjustmentsForAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForDistributionCosts" xlink:href="imc-20210630.xsd#imc_AdjustmentsForDistributionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="AdjustmentsForDistributionCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedCreditLosses" xlink:href="imc-20210630.xsd#imc_ExpectedCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ExpectedCreditLosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LeaveProvisionExpense" xlink:href="imc-20210630.xsd#imc_LeaveProvisionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="LeaveProvisionExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsExpense" xlink:href="imc-20210630.xsd#imc_ShareBasedPaymentsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ShareBasedPaymentsExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLoss" xlink:to="ChangeInOperatingAssetsAndLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption" xlink:href="imc-20210630.xsd#imc_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfOutstandingShareOption" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_0" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption_0" xlink:href="imc-20210630.xsd#imc_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfOutstandingShareOption_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" xlink:href="imc-20210630.xsd#imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="imc-20210630.xsd#imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract" xlink:to="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGrantedValuationOfOptionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfGrantedValuationOfOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGrantedValuationOfOptionsAbstract" xlink:to="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="ifrs-full_CreationDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GrantDateOneMember" xlink:href="imc-20210630.xsd#imc_GrantDateOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateTwoMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateThreeMember" xlink:href="imc-20210630.xsd#imc_GrantDateThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateFourMember" xlink:href="imc-20210630.xsd#imc_GrantDateFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateFiveMember" xlink:href="imc-20210630.xsd#imc_GrantDateFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateSixMember" xlink:href="imc-20210630.xsd#imc_GrantDateSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateSevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateEightMember" xlink:href="imc-20210630.xsd#imc_GrantDateEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateEightMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateNineMember" xlink:href="imc-20210630.xsd#imc_GrantDateNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateNineMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateTenMember" xlink:href="imc-20210630.xsd#imc_GrantDateTenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateTenMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateElevenMember" xlink:href="imc-20210630.xsd#imc_GrantDateElevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateElevenMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateTwelveMember" xlink:href="imc-20210630.xsd#imc_GrantDateTwelveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrantDateTwelveMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="imc-20210630.xsd#imc_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsOutstanding" xlink:href="imc-20210630.xsd#imc_ShareOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ShareOptionsOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsPerShare" xlink:href="imc-20210630.xsd#imc_ShareOptionsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ShareOptionsPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfGrantedValuationOfOptionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfGrantedValuationOfOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGrantedValuationOfOptionsAbstract" xlink:to="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOneMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceTwoMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSixteenMember" xlink:href="imc-20210630.xsd#imc_ExercisePriceSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceSixteenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable" xlink:to="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" xlink:href="imc-20210630.xsd#imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_ExercisePriceShareOptionsGranted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ExercisePriceShareOptionsGranted1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfInstrumentOtherEquityInstrumentGranted" xlink:href="imc-20210630.xsd#imc_NumberOfInstrumentOtherEquityInstrumentGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="NumberOfInstrumentOtherEquityInstrumentGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharePriceShareOptionsGranted1" xlink:href="imc-20210630.xsd#imc_WeightedAverageSharePriceShareOptionsGranted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="WeightedAverageSharePriceShareOptionsGranted1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuePerShareOptionsGranted" xlink:href="imc-20210630.xsd#imc_ValuePerShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems" xlink:to="ValuePerShareOptionsGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionsIssuedUnderESOP" xlink:href="imc-20210630.xsd#imc_OptionsIssuedUnderESOP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="OptionsIssuedUnderESOP" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentsToDirectors" xlink:href="imc-20210630.xsd#imc_SharebasedPaymentsToDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="SharebasedPaymentsToDirectors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalExpenses" xlink:href="imc-20210630.xsd#imc_TotalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract" xlink:to="TotalExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesRenderedByGrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ServicesRenderedByGrandlodgeCapitalPtyLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable" xlink:to="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherTransactionsWithKeyManagementRelatedPartyTransactions" xlink:href="imc-20210630.xsd#imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems" xlink:to="OtherTransactionsWithKeyManagementRelatedPartyTransactions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofforeigncurrencyriskTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfForeignCurrencyRiskAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfForeignCurrencyRiskAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfForeignCurrencyRiskAbstract" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CAD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_TradeReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofexchangeratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExchangeRatesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpactOnLossForPeriods" xlink:href="imc-20210630.xsd#imc_ImpactOnLossForPeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExchangeRatesAbstract" xlink:to="ImpactOnLossForPeriods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpactOnOtherComponentOfEquity" xlink:href="imc-20210630.xsd#imc_ImpactOnOtherComponentOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExchangeRatesAbstract" xlink:to="ImpactOnOtherComponentOfEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleoftradereceivablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeReceivablesAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfTradeReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeReceivablesAbstract" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="ifrs-full_PastDueStatusAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_CurrentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_LaterThanThreeMonthsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_TradeReceivablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedCreditLossRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedCreditLossRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="ifrs-full_ExpectedCreditLossRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossCarryingAmount" xlink:href="imc-20210630.xsd#imc_GrossCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="GrossCarryingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossAllowance" xlink:href="imc-20210630.xsd#imc_LossAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems" xlink:to="LossAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfContractualUndiscountedCashFlowsAbstract" xlink:href="imc-20210630.xsd#imc_ScheduleOfContractualUndiscountedCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:href="imc-20210630.xsd#imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualUndiscountedCashFlowsAbstract" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="ifrs-full_MaturityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="ifrs-full_PastDueStatusAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PastDueStatusMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PastDueStatusMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractualCashFlowsMember" xlink:href="imc-20210630.xsd#imc_ContractualCashFlowsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ContractualCashFlowsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarryingAssetsLiabilitiesMember" xlink:href="imc-20210630.xsd#imc_CarryingAssetsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="CarryingAssetsLiabilitiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable" xlink:to="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherPayable" xlink:href="imc-20210630.xsd#imc_TradeAndOtherPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="TradeAndOtherPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantAccountingPoliciesTextBlockAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PlantAndEquipmentMember" xlink:href="imc-20210630.xsd#imc_PlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_FixturesAndFittingsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_RightofuseAssetsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="RepresentativesWarrants" xlink:href="imc-20210630.xsd#imc_RepresentativesWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RepresentativesWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapital" xlink:href="imc-20210630.xsd#imc_ShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssistancePackages" xlink:href="imc-20210630.xsd#imc_AssistancePackages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AssistancePackages" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" xlink:href="imc-20210630.xsd#imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_FinishedGoods" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RawMaterials" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_RawMaterials" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentRawMaterials" xlink:href="imc-20210630.xsd#imc_NonCurrentRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="NonCurrentRawMaterials" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RAndDTaxConcessionRefund" xlink:href="imc-20210630.xsd#imc_RAndDTaxConcessionRefund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RAndDTaxConcessionRefund" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalRAndDTaxReceived" xlink:href="imc-20210630.xsd#imc_AdditionalRAndDTaxReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AdditionalRAndDTaxReceived" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/RevenueandotherincomeDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfRevenueTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRevenueTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeOfResearchAndDevelopment" xlink:href="imc-20210630.xsd#imc_OtherIncomeOfResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="OtherIncomeOfResearchAndDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOtherIncome" xlink:href="imc-20210630.xsd#imc_AdditionalOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="AdditionalOtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAssistancePackages" xlink:href="imc-20210630.xsd#imc_GovernmentAssistancePackages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="GovernmentAssistancePackages" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentsGrants" xlink:href="imc-20210630.xsd#imc_ResearchAndDevelopmentsGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRevenueTextBlockAbstract" xlink:to="ResearchAndDevelopmentsGrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesAbstract" xlink:href="imc-20210630.xsd#imc_ContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesAbstract" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfLeasesTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfLeasesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InformationAboutNatureOfLesseesLeasingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfLeasesTextBlockAbstract" xlink:to="ifrs-full_InformationAboutNatureOfLesseesLeasingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/ShareCapitalDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="PaymentForServices" xlink:href="imc-20210630.xsd#imc_PaymentForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="PaymentForServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesDescription" xlink:href="imc-20210630.xsd#imc_IssuanceOfOrdinarySharesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTextBlockAbstract" xlink:to="IssuanceOfOrdinarySharesDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/OtherReservesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfReservesWithinEquityTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReservesDetailsTable" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OtherReservesDetailsLineItems" xlink:href="imc-20210630.xsd#imc_OtherReservesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfReservesWithinEquityTextBlockAbstract" xlink:to="OtherReservesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="TitlesOfIndividualAxis" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsTable" xlink:to="TitlesOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TitlesOfIndividualDomain" xlink:href="imc-20210630.xsd#imc_TitlesOfIndividualDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitlesOfIndividualAxis" xlink:to="TitlesOfIndividualDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrJerryKanellosMember" xlink:href="imc-20210630.xsd#imc_DrJerryKanellosMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitlesOfIndividualAxis" xlink:to="DrJerryKanellosMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrRichardJBermanMember" xlink:href="imc-20210630.xsd#imc_MrRichardJBermanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitlesOfIndividualAxis" xlink:to="MrRichardJBermanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrGarySJacobMember" xlink:href="imc-20210630.xsd#imc_DrGarySJacobMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitlesOfIndividualAxis" xlink:to="DrGarySJacobMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsTable" xlink:to="OtherReservesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="OtherReserveMaturityDateDescription" xlink:href="imc-20210630.xsd#imc_OtherReserveMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="OtherReserveMaturityDateDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesUnlistedOption" xlink:href="imc-20210630.xsd#imc_NumberOfSharesUnlistedOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="NumberOfSharesUnlistedOption" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnlistedOptionExercisable" xlink:href="imc-20210630.xsd#imc_UnlistedOptionExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="UnlistedOptionExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ESOPOptionsIssued" xlink:href="imc-20210630.xsd#imc_ESOPOptionsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="ESOPOptionsIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsGranted" xlink:href="imc-20210630.xsd#imc_OptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="OptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluedAtGrantDate" xlink:href="imc-20210630.xsd#imc_RevaluedAtGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="RevaluedAtGrantDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfShareholdersApprovedValue" xlink:href="imc-20210630.xsd#imc_RevaluationOfShareholdersApprovedValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="RevaluationOfShareholdersApprovedValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationFinancialsAmount" xlink:href="imc-20210630.xsd#imc_RevaluationFinancialsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="RevaluationFinancialsAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseOfSharesOwed" xlink:href="imc-20210630.xsd#imc_ExpenseOfSharesOwed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReservesDetailsLineItems" xlink:to="ExpenseOfSharesOwed" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSegment" xlink:href="imc-20210630.xsd#imc_NumberOfSegment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="NumberOfSegment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfEntityRevenue" xlink:href="imc-20210630.xsd#imc_PercentageOfEntityRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfEntitysOperatingSegmentsTextBlockAbstract" xlink:to="PercentageOfEntityRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/SharebasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionGrantedDescription" xlink:href="imc-20210630.xsd#imc_OptionGrantedDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="OptionGrantedDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationFinancialsAmount" xlink:href="imc-20210630.xsd#imc_RevaluationFinancialsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="RevaluationFinancialsAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedToDirectorsForTheDirectorFees" xlink:href="imc-20210630.xsd#imc_SharesIssuedToDirectorsForTheDirectorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract" xlink:to="SharesIssuedToDirectorsForTheDirectorFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfRelatedPartyTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfRelatedPartyTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="imc-20210630.xsd#imc_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRelatedPartyTextBlockAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WattleLaboratoriesPtyLtdMember" xlink:href="imc-20210630.xsd#imc_WattleLaboratoriesPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="WattleLaboratoriesPtyLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrandlodgeCapitalPtyLtdMember" xlink:href="imc-20210630.xsd#imc_GrandlodgeCapitalPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="GrandlodgeCapitalPtyLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfArrangementsAxis" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="TypesOfArrangementsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfArrangementsDomain" xlink:href="imc-20210630.xsd#imc_TypesOfArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfArrangementsAxis" xlink:to="TypesOfArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShortTermFundingAgreementsMember" xlink:href="imc-20210630.xsd#imc_ShortTermFundingAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfArrangementsAxis" xlink:to="ShortTermFundingAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_RentalExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseRenewed" xlink:href="imc-20210630.xsd#imc_LeaseRenewed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="LeaseRenewed" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarehousingDistributionAndInvoicingServices" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndInvoicingServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="WarehousingDistributionAndInvoicingServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedPricePerShare1" xlink:href="imc-20210630.xsd#imc_SharesIssuedPricePerShare1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="SharesIssuedPricePerShare1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarehousingDistributionAndServicesFees" xlink:href="imc-20210630.xsd#imc_WarehousingDistributionAndServicesFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="WarehousingDistributionAndServicesFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssued" xlink:href="imc-20210630.xsd#imc_OrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="OrdinarySharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:href="imc-20210630.xsd#imc_DisclosureOfFinancialRiskManagementTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="PercentageOfForeignExchangeRates" xlink:href="imc-20210630.xsd#imc_PercentageOfForeignExchangeRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialRiskManagementTextBlockAbstract" xlink:to="PercentageOfForeignExchangeRates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immuron.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="imc-20210630.xsd#imc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>f20f2021_immuronlimited_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:imc="http://immuron.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imc-20210630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:AccumulatedLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imc:PlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">imc:PlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:RawMaterialsAndStoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:RawMaterialsAndStoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:WorkInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:WorkInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:InventoriesAxis">imc:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:ImmuronIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:AnadisEPSPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:AnadisEPSPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:IMCCanadaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">imc:IMCCanadaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrJerryKanellosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-13</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:MrRichardJBermanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-26</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrGarySJacobMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-11</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TitlesOfIndividualAxis">imc:DrGarySJacobMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">imc:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:SegmentHyperImmuneProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">imc:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:TravelanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:MajorProductLinesAxis">imc:ProtectynMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">imc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">imc:CustomerIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">imc:EmployeeStockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">imc:GrantDateTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">imc:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TypesOfArrangementsAxis">imc:ShortTermFundingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="imc:TypesOfArrangementsAxis">imc:ShortTermFundingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:WattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:GrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">imc:ServicesRenderedByGrandlodgeCapitalPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:ContractualCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:CarryingAssetsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:ContractualCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001660046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">imc:CarryingAssetsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="audPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:AUD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">000-38104</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">IMMURON LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">Level 3, 62 Lygon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Carlton South</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">3053</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">AU</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Dr. Jerry Kanellos</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1">Level 3, 62 Lygon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1">Carlton South</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1">3053</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1">AU</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1">61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">3 9822 7735</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">American Depositary Shares,   each representing 40 Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">IMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">227246596</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:DocumentAccountingStandard contextRef="c0">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c0" decimals="0" unitRef="aud">145776</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c3" decimals="0" unitRef="aud">2518566</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c4" decimals="0" unitRef="aud">2387426</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales contextRef="c0" decimals="0" unitRef="aud">51071</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c3" decimals="0" unitRef="aud">688836</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="0" unitRef="aud">667371</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="0" unitRef="aud">94705</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c3" decimals="0" unitRef="aud">1829730</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c4" decimals="0" unitRef="aud">1720055</ifrs-full:GrossProfit>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" unitRef="aud">617110</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c3" decimals="0" unitRef="aud">473674</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c4" decimals="0" unitRef="aud">532050</ifrs-full:OtherIncome>
    <ifrs-full:OtherGainsLosses contextRef="c0" decimals="0" unitRef="aud">-1342293</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c3" decimals="0" unitRef="aud">11335</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c4" decimals="0" unitRef="aud">38413</ifrs-full:OtherGainsLosses>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="aud">3978679</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c3" decimals="0" unitRef="aud">3703990</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="aud">3694306</ifrs-full:GeneralAndAdministrativeExpense>
    <imc:SharebasedPaymentsExpenses contextRef="c0" decimals="0" unitRef="aud">2116013</imc:SharebasedPaymentsExpenses>
    <imc:SharebasedPaymentsExpenses contextRef="c3" decimals="0" unitRef="aud">-533912</imc:SharebasedPaymentsExpenses>
    <imc:SharebasedPaymentsExpenses contextRef="c4" decimals="0" unitRef="aud">1343500</imc:SharebasedPaymentsExpenses>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="aud">1367054</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" unitRef="aud">1178685</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="aud">1044528</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="0" unitRef="aud">287684</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c3" decimals="0" unitRef="aud">871551</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="0" unitRef="aud">864644</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="0" unitRef="aud">-8379908</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c3" decimals="0" unitRef="aud">-2905575</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="0" unitRef="aud">-4656460</ifrs-full:ProfitLossFromOperatingActivities>
    <imc:IncomeFinance contextRef="c0" decimals="0" unitRef="aud">-9204</imc:IncomeFinance>
    <imc:IncomeFinance contextRef="c4" decimals="0" unitRef="aud">-39</imc:IncomeFinance>
    <imc:CostOfFinance contextRef="c0" decimals="0" unitRef="aud">-13761</imc:CostOfFinance>
    <imc:CostOfFinance contextRef="c3" decimals="0" unitRef="aud">-21631</imc:CostOfFinance>
    <imc:FinanceCostsNet contextRef="c0" decimals="0" unitRef="aud">4557</imc:FinanceCostsNet>
    <imc:FinanceCostsNet contextRef="c3" decimals="0" unitRef="aud">21631</imc:FinanceCostsNet>
    <imc:FinanceCostsNet contextRef="c4" decimals="0" unitRef="aud">-39</imc:FinanceCostsNet>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c0" decimals="0" unitRef="aud">-14953</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c3" decimals="0" unitRef="aud">102938</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c4" decimals="0" unitRef="aud">61846</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" unitRef="aud">-8399418</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" unitRef="aud">-2824268</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" unitRef="aud">-4594575</ifrs-full:ComprehensiveIncome>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c0" decimals="2" unitRef="audPershares">-3.79</imc:BasicAndDilutedEarningsLossPerShare>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c3" decimals="2" unitRef="audPershares">-1.66</imc:BasicAndDilutedEarningsLossPerShare>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c4" decimals="2" unitRef="audPershares">-3.22</imc:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" unitRef="aud">25047281</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" unitRef="aud">3250468</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c2" decimals="0" unitRef="aud">334707</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c5" decimals="0" unitRef="aud">327689</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c2" decimals="0" unitRef="aud">292532</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c5" decimals="0" unitRef="aud">797690</ifrs-full:Inventories>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="0" unitRef="aud">78258</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c5" decimals="0" unitRef="aud">33194</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="0" unitRef="aud">25752778</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="0" unitRef="aud">4409041</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="0" unitRef="aud">33741</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="aud">70773</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:InventoriesTotal contextRef="c2" decimals="0" unitRef="aud">1266587</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal contextRef="c5" decimals="0" unitRef="aud">1722349</ifrs-full:InventoriesTotal>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="0" unitRef="aud">1300328</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="0" unitRef="aud">1793122</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="0" unitRef="aud">27053106</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="0" unitRef="aud">6202163</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="0" unitRef="aud">758494</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="0" unitRef="aud">384397</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits contextRef="c2" decimals="0" unitRef="aud">213024</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <imc:EmployeeBenefitObligation contextRef="c2" decimals="0" unitRef="aud">129837</imc:EmployeeBenefitObligation>
    <imc:EmployeeBenefitObligation contextRef="c5" decimals="0" unitRef="aud">89838</imc:EmployeeBenefitObligation>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="0" unitRef="aud">20498</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c5" decimals="0" unitRef="aud">42176</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="0" unitRef="aud">1121853</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="0" unitRef="aud">516411</ifrs-full:CurrentLiabilities>
    <imc:EmployeeBenefitObligationNonCurrent contextRef="c2" decimals="0" unitRef="aud">36196</imc:EmployeeBenefitObligationNonCurrent>
    <imc:EmployeeBenefitObligationNonCurrent contextRef="c5" decimals="0" unitRef="aud">22910</imc:EmployeeBenefitObligationNonCurrent>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c5" decimals="0" unitRef="aud">18929</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c2" decimals="0" unitRef="aud">36196</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c5" decimals="0" unitRef="aud">41839</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c2" decimals="0" unitRef="aud">1158049</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c5" decimals="0" unitRef="aud">558250</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c2" decimals="0" unitRef="aud">25895057</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c5" decimals="0" unitRef="aud">5643913</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="0" unitRef="aud">88361303</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c5" decimals="0" unitRef="aud">62426991</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="c2" decimals="0" unitRef="aud">3466642</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c5" decimals="0" unitRef="aud">1133345</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="0" unitRef="aud">-65932888</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="0" unitRef="aud">-57916423</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c2" decimals="0" unitRef="aud">25895057</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="0" unitRef="aud">5643913</ifrs-full:Equity>
    <imc:EquityBalance contextRef="c6" decimals="0" unitRef="aud">58237314</imc:EquityBalance>
    <imc:EquityBalance contextRef="c7" decimals="0" unitRef="aud">3096308</imc:EquityBalance>
    <imc:EquityBalance contextRef="c8" decimals="0" unitRef="aud">-52894272</imc:EquityBalance>
    <imc:EquityBalance contextRef="c9" decimals="0" unitRef="aud">8439350</imc:EquityBalance>
    <ifrs-full:ProfitLoss contextRef="c12" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLoss>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c11" decimals="0" unitRef="aud">61846</imc:OtherComprehensiveIncomeLossForPeriod>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c4" decimals="0" unitRef="aud">61846</imc:OtherComprehensiveIncomeLossForPeriod>
    <ifrs-full:ComprehensiveIncome contextRef="c11" decimals="0" unitRef="aud">61846</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c12" decimals="0" unitRef="aud">-4656421</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" unitRef="aud">-4594575</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c10" decimals="0" unitRef="aud">2052461</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c4" decimals="0" unitRef="aud">2052461</ifrs-full:IssueOfEquity>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c11" decimals="0" unitRef="aud">1453900</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c4" decimals="0" unitRef="aud">1453900</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionsOrWarrantsExercised contextRef="c10" decimals="0" unitRef="aud">100</imc:OptionsOrWarrantsExercised>
    <imc:OptionsOrWarrantsExercised contextRef="c11" decimals="0" unitRef="aud">-100</imc:OptionsOrWarrantsExercised>
    <imc:OptionswarrantsForfeited contextRef="c11" decimals="0" unitRef="aud">-311635</imc:OptionswarrantsForfeited>
    <imc:OptionswarrantsForfeited contextRef="c12" decimals="0" unitRef="aud">311635</imc:OptionswarrantsForfeited>
    <imc:EquityBalance contextRef="c13" decimals="0" unitRef="aud">60289875</imc:EquityBalance>
    <imc:EquityBalance contextRef="c14" decimals="0" unitRef="aud">4300319</imc:EquityBalance>
    <imc:EquityBalance contextRef="c15" decimals="0" unitRef="aud">-57239058</imc:EquityBalance>
    <imc:EquityBalance contextRef="c16" decimals="0" unitRef="aud">7351136</imc:EquityBalance>
    <imc:ChangeInAccountingPolicy contextRef="c12" decimals="0" unitRef="aud">-1479</imc:ChangeInAccountingPolicy>
    <imc:ChangeInAccountingPolicy contextRef="c4" decimals="0" unitRef="aud">-1479</imc:ChangeInAccountingPolicy>
    <imc:RestatedTotalEquityAt1July2019 contextRef="c10" decimals="0" unitRef="aud">60289875</imc:RestatedTotalEquityAt1July2019>
    <imc:RestatedTotalEquityAt1July2019 contextRef="c11" decimals="0" unitRef="aud">4300319</imc:RestatedTotalEquityAt1July2019>
    <imc:RestatedTotalEquityAt1July2019 contextRef="c12" decimals="0" unitRef="aud">-57239058</imc:RestatedTotalEquityAt1July2019>
    <imc:RestatedTotalEquityAt1July2019 contextRef="c4" decimals="0" unitRef="aud">7351136</imc:RestatedTotalEquityAt1July2019>
    <ifrs-full:ProfitLoss contextRef="c19" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLoss>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c18" decimals="0" unitRef="aud">102938</imc:OtherComprehensiveIncomeLossForPeriod>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c3" decimals="0" unitRef="aud">102938</imc:OtherComprehensiveIncomeLossForPeriod>
    <ifrs-full:ComprehensiveIncome contextRef="c18" decimals="0" unitRef="aud">102938</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c19" decimals="0" unitRef="aud">-2927206</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" unitRef="aud">-2824268</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c17" decimals="0" unitRef="aud">1652436</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c3" decimals="0" unitRef="aud">1652436</ifrs-full:IssueOfEquity>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c17" decimals="0" unitRef="aud">484680</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c18" decimals="0" unitRef="aud">-484680</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionswarrantsForfeited contextRef="c18" decimals="0" unitRef="aud">-2251320</imc:OptionswarrantsForfeited>
    <imc:OptionswarrantsForfeited contextRef="c19" decimals="0" unitRef="aud">2251320</imc:OptionswarrantsForfeited>
    <imc:RevaluationOfOptionIssuedInPriorPeriod contextRef="c18" decimals="0" unitRef="aud">-607000</imc:RevaluationOfOptionIssuedInPriorPeriod>
    <imc:RevaluationOfOptionIssuedInPriorPeriod contextRef="c3" decimals="0" unitRef="aud">-607000</imc:RevaluationOfOptionIssuedInPriorPeriod>
    <imc:EmployeeShareSchemesValueOfEmployee contextRef="c18" decimals="0" unitRef="aud">73088</imc:EmployeeShareSchemesValueOfEmployee>
    <imc:EmployeeShareSchemesValueOfEmployee contextRef="c3" decimals="0" unitRef="aud">73088</imc:EmployeeShareSchemesValueOfEmployee>
    <imc:EquityBalance contextRef="c20" decimals="0" unitRef="aud">62426991</imc:EquityBalance>
    <imc:EquityBalance contextRef="c21" decimals="0" unitRef="aud">1133345</imc:EquityBalance>
    <imc:EquityBalance contextRef="c22" decimals="0" unitRef="aud">-57916423</imc:EquityBalance>
    <imc:EquityBalance contextRef="c5" decimals="0" unitRef="aud">5643913</imc:EquityBalance>
    <ifrs-full:ProfitLoss contextRef="c25" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLoss>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c24" decimals="0" unitRef="aud">-14953</imc:OtherComprehensiveIncomeLossForPeriod>
    <imc:OtherComprehensiveIncomeLossForPeriod contextRef="c0" decimals="0" unitRef="aud">-14953</imc:OtherComprehensiveIncomeLossForPeriod>
    <ifrs-full:ComprehensiveIncome contextRef="c24" decimals="0" unitRef="aud">-14953</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c25" decimals="0" unitRef="aud">-8384465</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" unitRef="aud">-8399418</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c23" decimals="0" unitRef="aud">24386005</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c0" decimals="0" unitRef="aud">24386005</ifrs-full:IssueOfEquity>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c24" decimals="0" unitRef="aud">3003060</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionsOrWarrantsIssuedExpensed contextRef="c0" decimals="0" unitRef="aud">3003060</imc:OptionsOrWarrantsIssuedExpensed>
    <imc:OptionsOrWarrantsExercised contextRef="c23" decimals="0" unitRef="aud">1329307</imc:OptionsOrWarrantsExercised>
    <imc:OptionsOrWarrantsExercised contextRef="c24" decimals="0" unitRef="aud">-213722</imc:OptionsOrWarrantsExercised>
    <imc:OptionsOrWarrantsExercised contextRef="c0" decimals="0" unitRef="aud">1115585</imc:OptionsOrWarrantsExercised>
    <imc:OptionsOrWarrantsForteitedLapsed contextRef="c24" decimals="0" unitRef="aud">368000</imc:OptionsOrWarrantsForteitedLapsed>
    <imc:OptionsOrWarrantsForteitedLapsed contextRef="c25" decimals="0" unitRef="aud">-368000</imc:OptionsOrWarrantsForteitedLapsed>
    <imc:StockIssuedDuringPeriodValueIssuedToDirectors contextRef="c23" decimals="0" unitRef="aud">145912</imc:StockIssuedDuringPeriodValueIssuedToDirectors>
    <imc:StockIssuedDuringPeriodValueIssuedToDirectors contextRef="c0" decimals="0" unitRef="aud">145912</imc:StockIssuedDuringPeriodValueIssuedToDirectors>
    <imc:TransferToShareCapital contextRef="c23" decimals="0" unitRef="aud">73088</imc:TransferToShareCapital>
    <imc:TransferToShareCapital contextRef="c24" decimals="0" unitRef="aud">-73088</imc:TransferToShareCapital>
    <imc:EquityBalance contextRef="c26" decimals="0" unitRef="aud">88361303</imc:EquityBalance>
    <imc:EquityBalance contextRef="c27" decimals="0" unitRef="aud">3466642</imc:EquityBalance>
    <imc:EquityBalance contextRef="c28" decimals="0" unitRef="aud">-65932888</imc:EquityBalance>
    <imc:EquityBalance contextRef="c2" decimals="0" unitRef="aud">25895057</imc:EquityBalance>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices contextRef="c0" decimals="0" unitRef="aud">192185</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices contextRef="c3" decimals="0" unitRef="aud">2914614</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices contextRef="c4" decimals="0" unitRef="aud">2619477</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <imc:PaymentsToSuppliersForGoodsAndService contextRef="c0" decimals="0" unitRef="aud">-4865633</imc:PaymentsToSuppliersForGoodsAndService>
    <imc:PaymentsToSuppliersForGoodsAndService contextRef="c3" decimals="0" unitRef="aud">-6748674</imc:PaymentsToSuppliersForGoodsAndService>
    <imc:PaymentsToSuppliersForGoodsAndService contextRef="c4" decimals="0" unitRef="aud">-5608262</imc:PaymentsToSuppliersForGoodsAndService>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities contextRef="c0" decimals="0" unitRef="aud">358280</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities contextRef="c3" decimals="0" unitRef="aud">531828</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities contextRef="c4" decimals="0" unitRef="aud">1190206</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c0" decimals="0" unitRef="aud">236421</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c3" decimals="0" unitRef="aud">154904</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="aud">-4078747</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c3" decimals="0" unitRef="aud">-3147328</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="aud">-1798579</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c0" decimals="0" unitRef="aud">6630</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c3" decimals="0" unitRef="aud">864</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c4" decimals="0" unitRef="aud">2047</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c0" decimals="0" unitRef="aud">9204</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c4" decimals="0" unitRef="aud">39</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="aud">2574</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c3" decimals="0" unitRef="aud">-864</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="aud">-2008</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="0" unitRef="aud">29281421</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c3" decimals="0" unitRef="aud">1957164</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c4" decimals="0" unitRef="aud">2894238</ifrs-full:ProceedsFromIssuingShares>
    <imc:CapitalCost contextRef="c0" decimals="0" unitRef="aud">2746871</imc:CapitalCost>
    <imc:CapitalCost contextRef="c3" decimals="0" unitRef="aud">374728</imc:CapitalCost>
    <imc:CapitalCost contextRef="c4" decimals="0" unitRef="aud">825055</imc:CapitalCost>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c0" decimals="0" unitRef="aud">212794</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c0" decimals="0" unitRef="aud">212794</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c3" decimals="0" unitRef="aud">366655</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="0" unitRef="aud">40607</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c3" decimals="0" unitRef="aud">41390</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c0" decimals="0" unitRef="aud">13761</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c3" decimals="0" unitRef="aud">17439</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="aud">26480182</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c3" decimals="0" unitRef="aud">1156952</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="aud">2069183</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="0" unitRef="aud">22404009</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c3" decimals="0" unitRef="aud">-1991240</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="0" unitRef="aud">268596</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" unitRef="aud">3250468</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c16" decimals="0" unitRef="aud">5119887</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c9" decimals="0" unitRef="aud">4727430</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="0" unitRef="aud">-607196</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c3" decimals="0" unitRef="aud">121821</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="0" unitRef="aud">123861</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" unitRef="aud">25047281</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" unitRef="aud">3250468</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c16" decimals="0" unitRef="aud">5119887</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 1. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Corporate Information&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial report of Immuron Limited
(&#x201c;the Company&#x201d;) for the year ended June 30, 2021, 2020 and 2019 was authorized for issue in accordance with a resolution of
the Directors on October 29, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Immuron Limited is a listed public company limited
by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and The
NASDAQ Capital Market (&#x201c;NASDAQ&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s principal activity is oral
immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment
and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting
travelers&#x2019; diarrhea and Protectyn an OTC immune supplement for GI tract and liver health.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;These general purpose financial statements
have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards
Board and the &lt;i&gt;Corporations Act 2001&lt;/i&gt;. Immuron Limited is a for-profit entity for the purpose of preparing the financial statements.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Compliance with
                                            IFRS&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The consolidated financial statements
of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Historical cost
                                            convention&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The financial statements have been prepared on a historical
cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0"/&gt;
    &lt;td style="width: 0.25in; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Significant
    estimates and judgements&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Going concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;The group is in a position to meet future commitments in the current
business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs
for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not
include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of
liabilities that might be necessary should the group not continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Judgement has been exercised in considering
the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration
extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group
operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that
COVID-19 will continue to have on sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This note provides a list of the significant
accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed
in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial
statements are for the group consisting of Immuron Limited and its subsidiaries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(iv) New standards and interpretations not
yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There are no standards that are not yet effective
and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future
transactions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(v)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revision of immaterial error&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;During the year ended June 2020 the following immaterial
error corrections were identified.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Representative warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Immuron Limited raised capital in June
2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for
at the time of these capital raisings.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Management has undertaken an assessment of the impact of this and concluded
this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and
the related notes included herein to include the representative warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Reserves as of 30 June 2017 has been
revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share
capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Reserves as of 30 June 2019 has been revised to increase by A$110,400
for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a summary of the material accounting
policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless
otherwise stated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Principles of consolidation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Subsidiaries are all entities (including
structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from
the date that control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The acquisition method of accounting
is used to account for business combinations by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Intercompany transactions, balances
and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to
ensure consistency with the policies adopted by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive
management team consisting of the CEO and COO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Functional and
                                            presentation currency&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Items included in the financial statements
of each of the group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#x2018;the functional currency&#x2019;). The consolidated financial statements are presented in Australian dollar (&#x201c;A$&#x201d; or
&#x201c;$&#x201d;), which is Immuron Limited&#x2019;s functional and presentation currency.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Transactions
                                            and balances&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Foreign currency transactions are translated
into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at
year end exchange rates are generally recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Foreign exchange gains and losses that
relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs.
All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income
on a net basis within other gains/(losses).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Non-monetary items that are measured
at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation
differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation
differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit
or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair
value through other comprehensive income are recognized in other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Group companies&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The results and financial position
of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from
the presentation currency are translated into the presentation currency as follows:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;assets and liabilities for each
                                            consolidated balance sheet presented are translated at the closing rate at the date of that
                                            consolidated balance sheet;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;income and expenses for each consolidated statement of
                         profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at
                         average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates
                         prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions);
                         and&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;all resulting exchange differences are recognized in other comprehensive income.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;On consolidation, exchange differences
arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated
as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming
part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or
loss on sale.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sale
                                            of hyperimmune products&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying
the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction
price to the performance obligations and recognising revenue when performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided
where this is outlined in a customer agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financing
                                            components&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The group does
not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment
by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Government grants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Grants from the government are recognized
at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached
conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value of other grants&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;The group&#x2019;s other grant income
consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable
assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the
group has recognized A$154,904 in assistance packages.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Income tax&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The income tax expense or credit for
the period is the tax payable on the current period&#x2019;s taxable income based on the applicable income tax rate for each jurisdiction
adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The current income tax charge is calculated
on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and
its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns
with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate
on the basis of amounts expected to be paid to the tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Deferred income tax is provided in full,
using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts
in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition
of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Deferred tax assets are recognized only
if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Current and deferred tax is recognized
in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this
case, the tax is also recognized in other comprehensive income or directly in equity, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="width: 0; font-size: 10pt"/&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(h)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;AASB Interpretation 23 Uncertainty over Income Tax Treatments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;Interpretation 23 requires the assessment of whether the effect of
uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses,
unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax
treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity
determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes
in facts and circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The group has adopted Interpretation 23 from 1 July 2019, based on
an assessment of whether it is &#x2018;probable&#x2019; that a taxation authority will accept an uncertain tax treatment. This assessment
takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group&#x2019;s
books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment
used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority
will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending
on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation
23 in this reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;The accounting policies for the group's leases are explained in note
14(iii).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(j)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Impairment of assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;An impairment loss is recognized for
the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s
fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels
for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups
of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal
of the impairment at the end of each reporting period.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(k)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;For the purpose of presentation in
the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings
in current liabilities in the consolidated balance sheet.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(l)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Trade receivables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Trade receivables are recognized initially
at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for
a description of the group&#x2019;s impairment policies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Classification
                                            as trade receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Trade receivables are amounts due from
customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days
and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional
unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with
the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method. Details about the group&#x2019;s impairment policies and the calculation of the loss allowance are provided below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Accrued receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;These amounts primarily comprise receivables
from the Australian Taxation Office in relation to the R&amp;amp;D tax incentive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Fair value
                                            of trade and other receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Due to the short-term nature of the
current receivables, their carrying amount is considered to be the same as their fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iv)&lt;/i&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Impairment
                                            and risk exposure&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Information about the impairment of
trade receivables and the group&#x2019;s exposure to credit risk and foreign currency risk can be found in note 21.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(m)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Raw materials and stores, work in progress and finished
goods&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Raw materials and stores, work in progress
and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate
proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are
assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting
rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs
of completion and the estimated costs necessary to make the sale.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(n)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Investments and other financial assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Classification&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The group classifies its financial assets in the following
measurement categories:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;those to be measured
                                            subsequently at fair value (either through other comprehensive income or through profit or
                                            loss); and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;those to be measured
                                            at amortised cost.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
classification depends on the group&#x2019;s business model for managing the financial assets and the contractual terms of the cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For assets measured at fair value, gains and
losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held
for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for
the equity investment at fair value through other comprehensive income (FVOCI).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Recognition
                                            and derecognition&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Regular way purchases and sales of
financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has
transferred substantially all the risks and rewards of ownership.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Measurement&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;At initial recognition, the group measures
a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction
costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL
are expensed in profit or loss.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iv)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Impairment&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The group assesses on a forward looking
basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends
on whether there has been a significant increase in credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;For
                                            trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires
                                            expected lifetime losses to be recognized from initial recognition of the receivables, see
                                            note 21(b) for further details.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(v)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Income recognition
                                            Interest income&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Interest income is recognized using
the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being
the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount
as interest income. Interest income on impaired loans is recognized using the original effective interest rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(o)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Property, plant and equipment is stated
at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Subsequent costs are included in the
asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits
associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component
accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during
the reporting period in which they are incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Depreciation is calculated using the
straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or,
in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Plant and equipment	2 - 5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Furniture, fittings and equipment	3 - 15 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Right-of-use assets	3 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The assets&#x2019; residual values and
useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;An asset&#x2019;s carrying amount is
written down immediately to its recoverable amount if the asset&#x2019;s carrying amount is greater than its estimated recoverable amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Gains and losses on disposals are determined
by comparing proceeds with carrying amount. These are included in profit or loss.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(p)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Research and development&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Expenditure on research activities,
undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated
statement of profit or loss and other comprehensive income as an expense when it is incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Expenditure on development activities,
being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved
products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is
technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development
and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other
comprehensive income as an expense as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(q)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Trade and other payables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;These amounts represent liabilities
for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually
paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12
months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using
the effective interest method.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(r)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Short-term obligations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Liabilities for wages and salaries,
including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after
the end of the period in which the employees render the related service are recognized in respect of employees&#x2019; services up to
the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as current employee benefit obligations in the balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Other long-term
                                            employee benefit obligations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;In some countries, the group also has
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the
period in which the employees render the related service. These obligations are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit
method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Consideration is given to expected
future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using
market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as
possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions
are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The obligations are presented as current
liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after
the reporting period, regardless of when the actual settlement is expected to occur.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Share-based
                                            payments&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Share-based compensation benefits are
provided to employees via the &#x2018;executive share and option plan&#x2019; (ESOP). Information relating to these schemes is set out
in note 19.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Employee options&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The fair value of options granted under
the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined
by reference to the fair value of the options granted:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;including
                                            any market performance conditions (e.g. the company&#x2019;s share price);&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;-&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;excluding
                                            the impact of any service and non-market performance vesting conditions (e.g. profitability,
                                            sales growth targets and remaining an employee of the company over a specified time period);
                                            and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;-&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;including the impact of any non-vesting conditions (e.g. the
                   requirement for employees to save or holdings shares for a specific period of time).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The total expense is recognized over
the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period,
the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.
It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(s)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Contributed equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Ordinary shares are classified as equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Incremental costs directly attributable
to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(t)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Basic loss per
                                            share&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Basic loss per share is calculated by dividing:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;the loss attributable to owners
                                            of the company, excluding any costs of servicing equity other than ordinary shares&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;by the weighted average number of ordinary shares outstanding during the financial
                         year, adjusted for bonus elements in ordinary shares issued during the year.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Diluted loss
                                            per share&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Diluted loss per share adjusts the figures used in the determination
of basic loss per share to take into account:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;the after
                                            income tax effect of interest and other financing costs associated with dilutive potential
                                            ordinary shares, and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the weighted average
                                            number of additional ordinary shares that would have been outstanding assuming the conversion
                                            of all dilutive potential ordinary shares.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(u)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Rounding of amounts&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The company is of a kind referred to
in ASIC Legislative Instrument 2016/191, relating to the &#x2018;rounding off&#x2019; of amounts in the financial statements. Amounts in
the financial statements have been rounded off in accordance with the instrument to the nearest dollar.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(v)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Goods and services tax (GST)&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Revenues, expenses and assets are recognized
net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized
as part of the cost of acquisition of the asset or as part of the expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Receivables and payables are stated
inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the consolidated balance sheet.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Cash flows are presented on a gross
basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the
taxation authority, are presented as operating cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Critical Accounting Estimates and Judgments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management evaluates estimates and judgments
incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable
expectation of future events and are based on current trends and economic data, obtained both internally and externally.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Share-based payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The value attributed to share options and remunerations
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value of volatility of the price of the underlying shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value of options granted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Impairment of inventories&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The provision for impairment of inventories assessment
requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience,
the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed
on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability
study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There was a $328,833 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-58"&gt;Nil&lt;/span&gt;) finished goods
impairment and a $430,932 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-59"&gt;Nil&lt;/span&gt;) raw materials impairment of inventories recognised during year ended 30 June 2021 for inventory
obsolescence in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Inventory split&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended 30 June 2021, management
performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials
relating to Colostrum will be consumed within 12 months from reporting date (2020: &lt;span style="-sec-ix-hidden: hidden-fact-60"&gt;Nil&lt;/span&gt;); the remaining balance of A$1,266,587 (2020:
A$1,722,349) was estimated to be consumed beyond 12 months.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Provision for employee benefits&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Provision for employee benefits represents amounts
accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual
leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the
required period of service. Refer to note 1(q) for policies on provisions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;R&amp;amp;D tax incentive&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s research and development activities
are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities
and expenditure to determine which are likely to be eligible under the incentive scheme.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended June 30, 2021 the Group has
recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&amp;amp;D tax incentive on
a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055
in current financial year as part of the R&amp;amp;D claim for financial year ended 30 June 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value measurement hierarchy&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the financial statements requires
management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually
evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases
its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the
related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the convertible notes classified
as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs
that required significant adjustments based on unobservable inputs.&lt;/p&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <imc:DescriptionOfAccountingPolicyForBasisOfPresentation contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;These general purpose financial statements
have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards
Board and the &lt;i&gt;Corporations Act 2001&lt;/i&gt;. Immuron Limited is a for-profit entity for the purpose of preparing the financial statements.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Compliance with
                                            IFRS&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The consolidated financial statements
of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Historical cost
                                            convention&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The financial statements have been prepared on a historical
cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0"/&gt;
    &lt;td style="width: 0.25in; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Significant
    estimates and judgements&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Going concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;The group is in a position to meet future commitments in the current
business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs
for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not
include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of
liabilities that might be necessary should the group not continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Judgement has been exercised in considering
the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration
extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group
operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that
COVID-19 will continue to have on sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This note provides a list of the significant
accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed
in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial
statements are for the group consisting of Immuron Limited and its subsidiaries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(iv) New standards and interpretations not
yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There are no standards that are not yet effective
and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future
transactions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(v)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revision of immaterial error&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;During the year ended June 2020 the following immaterial
error corrections were identified.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Representative warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Immuron Limited raised capital in June
2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for
at the time of these capital raisings.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Management has undertaken an assessment of the impact of this and concluded
this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and
the related notes included herein to include the representative warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Reserves as of 30 June 2017 has been
revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share
capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Reserves as of 30 June 2019 has been revised to increase by A$110,400
for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a summary of the material accounting
policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless
otherwise stated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForBasisOfPresentation>
    <imc:RepresentativesWarrants contextRef="c29" decimals="0" unitRef="usd">489586</imc:RepresentativesWarrants>
    <imc:ShareCapital contextRef="c29" decimals="0" unitRef="usd">1220000</imc:ShareCapital>
    <imc:RepresentativesWarrants contextRef="c16" decimals="0" unitRef="usd">110400</imc:RepresentativesWarrants>
    <imc:ShareCapital contextRef="c16" decimals="0" unitRef="usd">800000</imc:ShareCapital>
    <imc:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Principles of consolidation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Subsidiaries are all entities (including
structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from
the date that control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The acquisition method of accounting
is used to account for business combinations by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Intercompany transactions, balances
and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to
ensure consistency with the policies adopted by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive
management team consisting of the CEO and COO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Functional and
                                            presentation currency&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Items included in the financial statements
of each of the group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#x2018;the functional currency&#x2019;). The consolidated financial statements are presented in Australian dollar (&#x201c;A$&#x201d; or
&#x201c;$&#x201d;), which is Immuron Limited&#x2019;s functional and presentation currency.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Transactions
                                            and balances&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Foreign currency transactions are translated
into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at
year end exchange rates are generally recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Foreign exchange gains and losses that
relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs.
All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income
on a net basis within other gains/(losses).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Non-monetary items that are measured
at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation
differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation
differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit
or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair
value through other comprehensive income are recognized in other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Group companies&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The results and financial position
of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from
the presentation currency are translated into the presentation currency as follows:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;assets and liabilities for each
                                            consolidated balance sheet presented are translated at the closing rate at the date of that
                                            consolidated balance sheet;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;income and expenses for each consolidated statement of
                         profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at
                         average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates
                         prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions);
                         and&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;all resulting exchange differences are recognized in other comprehensive income.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;On consolidation, exchange differences
arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated
as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming
part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or
loss on sale.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sale
                                            of hyperimmune products&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying
the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction
price to the performance obligations and recognising revenue when performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided
where this is outlined in a customer agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financing
                                            components&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The group does
not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment
by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Government grants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Grants from the government are recognized
at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached
conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value of other grants&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;The group&#x2019;s other grant income
consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable
assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the
group has recognized A$154,904 in assistance packages.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <imc:AssistancePackages contextRef="c0" decimals="0" unitRef="aud">154904</imc:AssistancePackages>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Income tax&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The income tax expense or credit for
the period is the tax payable on the current period&#x2019;s taxable income based on the applicable income tax rate for each jurisdiction
adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The current income tax charge is calculated
on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and
its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns
with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate
on the basis of amounts expected to be paid to the tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Deferred income tax is provided in full,
using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts
in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition
of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Deferred tax assets are recognized only
if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Current and deferred tax is recognized
in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this
case, the tax is also recognized in other comprehensive income or directly in equity, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <imc:DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="width: 0; font-size: 10pt"/&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(h)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;AASB Interpretation 23 Uncertainty over Income Tax Treatments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;Interpretation 23 requires the assessment of whether the effect of
uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses,
unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax
treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity
determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes
in facts and circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The group has adopted Interpretation 23 from 1 July 2019, based on
an assessment of whether it is &#x2018;probable&#x2019; that a taxation authority will accept an uncertain tax treatment. This assessment
takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group&#x2019;s
books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment
used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority
will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending
on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation
23 in this reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;</imc:DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;The accounting policies for the group's leases are explained in note
14(iii)</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(j)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Impairment of assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;An impairment loss is recognized for
the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s
fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels
for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups
of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal
of the impairment at the end of each reporting period.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(k)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;For the purpose of presentation in
the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings
in current liabilities in the consolidated balance sheet.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(l)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Trade receivables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Trade receivables are recognized initially
at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for
a description of the group&#x2019;s impairment policies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Classification
                                            as trade receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Trade receivables are amounts due from
customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days
and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional
unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with
the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method. Details about the group&#x2019;s impairment policies and the calculation of the loss allowance are provided below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Accrued receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;These amounts primarily comprise receivables
from the Australian Taxation Office in relation to the R&amp;amp;D tax incentive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Fair value
                                            of trade and other receivables&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Due to the short-term nature of the
current receivables, their carrying amount is considered to be the same as their fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iv)&lt;/i&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Impairment
                                            and risk exposure&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Information about the impairment of
trade receivables and the group&#x2019;s exposure to credit risk and foreign currency risk can be found in note 21.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(m)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Raw materials and stores, work in progress and finished
goods&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Raw materials and stores, work in progress
and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate
proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are
assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting
rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs
of completion and the estimated costs necessary to make the sale.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <imc:DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(n)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Investments and other financial assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Classification&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The group classifies its financial assets in the following
measurement categories:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;those to be measured
                                            subsequently at fair value (either through other comprehensive income or through profit or
                                            loss); and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;those to be measured
                                            at amortised cost.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
classification depends on the group&#x2019;s business model for managing the financial assets and the contractual terms of the cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For assets measured at fair value, gains and
losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held
for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for
the equity investment at fair value through other comprehensive income (FVOCI).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Recognition
                                            and derecognition&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Regular way purchases and sales of
financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has
transferred substantially all the risks and rewards of ownership.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Measurement&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;At initial recognition, the group measures
a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction
costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL
are expensed in profit or loss.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iv)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Impairment&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The group assesses on a forward looking
basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends
on whether there has been a significant increase in credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;For
                                            trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires
                                            expected lifetime losses to be recognized from initial recognition of the receivables, see
                                            note 21(b) for further details.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(v)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Income recognition
                                            Interest income&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Interest income is recognized using
the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being
the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount
as interest income. Interest income on impaired loans is recognized using the original effective interest rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(o)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Property, plant and equipment is stated
at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Subsequent costs are included in the
asset&#x2019;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits
associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component
accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during
the reporting period in which they are incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Depreciation is calculated using the
straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or,
in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Plant and equipment	2 - 5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Furniture, fittings and equipment	3 - 15 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;Right-of-use assets	3 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The assets&#x2019; residual values and
useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;An asset&#x2019;s carrying amount is
written down immediately to its recoverable amount if the asset&#x2019;s carrying amount is greater than its estimated recoverable amount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Gains and losses on disposals are determined
by comparing proceeds with carrying amount. These are included in profit or loss.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod contextRef="c30">P2Y</imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod>
    <imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod contextRef="c31">P5Y</imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod>
    <imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod contextRef="c32">P3Y</imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod>
    <imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod contextRef="c33">P15Y</imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod>
    <imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod contextRef="c34">P3Y</imc:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(p)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Intangible assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Research and development&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Expenditure on research activities,
undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated
statement of profit or loss and other comprehensive income as an expense when it is incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Expenditure on development activities,
being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved
products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is
technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development
and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other
comprehensive income as an expense as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(q)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Trade and other payables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;These amounts represent liabilities
for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually
paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12
months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using
the effective interest method.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(r)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Short-term obligations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Liabilities for wages and salaries,
including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after
the end of the period in which the employees render the related service are recognized in respect of employees&#x2019; services up to
the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as current employee benefit obligations in the balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Other long-term
                                            employee benefit obligations&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;In some countries, the group also has
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the
period in which the employees render the related service. These obligations are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit
method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Consideration is given to expected
future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using
market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as
possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions
are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The obligations are presented as current
liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after
the reporting period, regardless of when the actual settlement is expected to occur.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Share-based
                                            payments&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Share-based compensation benefits are
provided to employees via the &#x2018;executive share and option plan&#x2019; (ESOP). Information relating to these schemes is set out
in note 19.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&lt;i&gt;Employee options&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The fair value of options granted under
the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined
by reference to the fair value of the options granted:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;including
                                            any market performance conditions (e.g. the company&#x2019;s share price);&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;-&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;excluding
                                            the impact of any service and non-market performance vesting conditions (e.g. profitability,
                                            sales growth targets and remaining an employee of the company over a specified time period);
                                            and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;-&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;including the impact of any non-vesting conditions (e.g. the
                   requirement for employees to save or holdings shares for a specific period of time).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;The total expense is recognized over
the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period,
the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.
It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <imc:DescriptionOfAccountingPolicyForEquityPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(s)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Contributed equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Ordinary shares are classified as equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"&gt;Incremental costs directly attributable
to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForEquityPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(t)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Basic loss per
                                            share&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Basic loss per share is calculated by dividing:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;the loss attributable to owners
                                            of the company, excluding any costs of servicing equity other than ordinary shares&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td/&gt;&lt;td&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding-right: 1.3pt"&gt;by the weighted average number of ordinary shares outstanding during the financial
                         year, adjusted for bonus elements in ordinary shares issued during the year.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;i&gt;Diluted loss
                                            per share&lt;/i&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Diluted loss per share adjusts the figures used in the determination
of basic loss per share to take into account:&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.3pt"&gt;the after
                                            income tax effect of interest and other financing costs associated with dilutive potential
                                            ordinary shares, and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;the weighted average
                                            number of additional ordinary shares that would have been outstanding assuming the conversion
                                            of all dilutive potential ordinary shares.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <imc:DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(u)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Rounding of amounts&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;The company is of a kind referred to
in ASIC Legislative Instrument 2016/191, relating to the &#x2018;rounding off&#x2019; of amounts in the financial statements. Amounts in
the financial statements have been rounded off in accordance with the instrument to the nearest dollar.&lt;/p&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock>
    <imc:DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;(v)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Goods and services tax (GST)&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;Revenues, expenses and assets are recognized
net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized
as part of the cost of acquisition of the asset or as part of the expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Receivables and payables are stated
inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the consolidated balance sheet.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"&gt;Cash flows are presented on a gross
basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the
taxation authority, are presented as operating cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Critical Accounting Estimates and Judgments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management evaluates estimates and judgments
incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable
expectation of future events and are based on current trends and economic data, obtained both internally and externally.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Share-based payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The value attributed to share options and remunerations
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value of volatility of the price of the underlying shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value of options granted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Impairment of inventories&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The provision for impairment of inventories assessment
requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience,
the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed
on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability
study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There was a $328,833 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-58"&gt;Nil&lt;/span&gt;) finished goods
impairment and a $430,932 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-59"&gt;Nil&lt;/span&gt;) raw materials impairment of inventories recognised during year ended 30 June 2021 for inventory
obsolescence in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Inventory split&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended 30 June 2021, management
performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials
relating to Colostrum will be consumed within 12 months from reporting date (2020: &lt;span style="-sec-ix-hidden: hidden-fact-60"&gt;Nil&lt;/span&gt;); the remaining balance of A$1,266,587 (2020:
A$1,722,349) was estimated to be consumed beyond 12 months.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Provision for employee benefits&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Provision for employee benefits represents amounts
accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual
leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the
required period of service. Refer to note 1(q) for policies on provisions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;R&amp;amp;D tax incentive&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s research and development activities
are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities
and expenditure to determine which are likely to be eligible under the incentive scheme.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended June 30, 2021 the Group has
recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&amp;amp;D tax incentive on
a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055
in current financial year as part of the R&amp;amp;D claim for financial year ended 30 June 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value measurement hierarchy&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of the financial statements requires
management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually
evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases
its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the
related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the convertible notes classified
as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs
that required significant adjustments based on unobservable inputs.&lt;/p&gt;</imc:DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory>
    <ifrs-full:FinishedGoods contextRef="c2" decimals="0" unitRef="aud">328833</ifrs-full:FinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" unitRef="usd">430932</us-gaap:InventoryRawMaterials>
    <imc:NonCurrentRawMaterials contextRef="c2" decimals="0" unitRef="aud">1266587</imc:NonCurrentRawMaterials>
    <imc:NonCurrentRawMaterials contextRef="c5" decimals="0" unitRef="aud">1722349</imc:NonCurrentRawMaterials>
    <imc:RAndDTaxConcessionRefund contextRef="c0" decimals="0" unitRef="aud">306154</imc:RAndDTaxConcessionRefund>
    <imc:RAndDTaxConcessionRefund contextRef="c3" decimals="0" unitRef="aud">308225</imc:RAndDTaxConcessionRefund>
    <imc:AdditionalRAndDTaxReceived contextRef="c3" decimals="0" unitRef="aud">50055</imc:AdditionalRAndDTaxReceived>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2. Revenue and other income&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Revenue from Operating Activities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Revenue from contracts with customers&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Revenue from Operating Activities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Other Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australian Federal R&amp;amp;D Tax Concession Refund&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;356,209&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;COVID-19 government assistance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;161,600&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D grants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;74,821&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;24,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;617,110&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;473,674&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;532,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Other Gains/(Losses) &#x2013; Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net foreign exchange gains/(losses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(582,528&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net impairment losses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(759,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Gains/(Losses) &#x2013; Net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,342,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sale
                                            of hyperimmune products&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Revenue arises mainly from the sale of products in the hyperimmune
category. To determine whether to recognise revenue, the group follows the process of identifying the contract with a customer, identifying
the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising
revenue when performance obligations are satisfied.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Revenue from the sale of hyperimmune products is recognised when or
as the group transfers control of the assets to the customer.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There is no variable consideration or significant cost to obtain the
contract. There is no warranties and no refunds. Returns are provided where this is outlined in a customer agreement.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
                                            value of R&amp;amp;D tax incentive&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The group's research and development (R&amp;amp;D) activities are eligible
under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine
which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of
the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2021, the group has
included an item in other income of $306,154 (2020: $308,225) to recognise income over the year necessary to match the R&amp;amp;D tax incentive
on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional $50,055
in current financial year as part of the R&amp;amp;D claim for financial year ended 30 June 2020.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
                                            value of COVID-19 government assistance and R&amp;amp;D grants&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The group's other grant income is recognised when compliance with
the conditions attached to the grant have been determined and the group has ascertained the grant will be received.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For the year ended 30 June 2021, the group has recognised $161,600
(2020: $154,904) in the COVID-19 government assistance packages and a $74,821 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-65"&gt;Nil&lt;/span&gt;) R&amp;amp;D grant from the Henry M Jackson Foundation.&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Revenue from Operating Activities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Revenue from contracts with customers&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Revenue from Operating Activities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Other Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australian Federal R&amp;amp;D Tax Concession Refund&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;356,209&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;COVID-19 government assistance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;161,600&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D grants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;74,821&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;24,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Income&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;617,110&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;473,674&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;532,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Other Gains/(Losses) &#x2013; Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net foreign exchange gains/(losses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(582,528&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net impairment losses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(759,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Gains/(Losses) &#x2013; Net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,342,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c0" decimals="0" unitRef="aud">145776</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c3" decimals="0" unitRef="aud">2518566</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c4" decimals="0" unitRef="aud">2387426</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c0" decimals="0" unitRef="aud">145776</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c3" decimals="0" unitRef="aud">2518566</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c4" decimals="0" unitRef="aud">2387426</ifrs-full:RevenueAndOperatingIncome>
    <imc:AustralianFederalRdTaxConcessionRefund contextRef="c0" decimals="0" unitRef="aud">356209</imc:AustralianFederalRdTaxConcessionRefund>
    <imc:AustralianFederalRdTaxConcessionRefund contextRef="c3" decimals="0" unitRef="aud">308225</imc:AustralianFederalRdTaxConcessionRefund>
    <imc:AustralianFederalRdTaxConcessionRefund contextRef="c4" decimals="0" unitRef="aud">531005</imc:AustralianFederalRdTaxConcessionRefund>
    <imc:OtherGovernmentAssistanceIncome contextRef="c0" decimals="0" unitRef="aud">161600</imc:OtherGovernmentAssistanceIncome>
    <imc:OtherGovernmentAssistanceIncome contextRef="c3" decimals="0" unitRef="aud">154904</imc:OtherGovernmentAssistanceIncome>
    <imc:ResearchAndDevelopmentGrants contextRef="c0" decimals="0" unitRef="aud">74821</imc:ResearchAndDevelopmentGrants>
    <imc:OtherIncomes contextRef="c0" decimals="0" unitRef="aud">24480</imc:OtherIncomes>
    <imc:OtherIncomes contextRef="c3" decimals="0" unitRef="aud">10545</imc:OtherIncomes>
    <imc:OtherIncomes contextRef="c4" decimals="0" unitRef="aud">1045</imc:OtherIncomes>
    <imc:OtherIncomeFromNonOperatingActivities contextRef="c0" decimals="0" unitRef="aud">617110</imc:OtherIncomeFromNonOperatingActivities>
    <imc:OtherIncomeFromNonOperatingActivities contextRef="c3" decimals="0" unitRef="aud">473674</imc:OtherIncomeFromNonOperatingActivities>
    <imc:OtherIncomeFromNonOperatingActivities contextRef="c4" decimals="0" unitRef="aud">532050</imc:OtherIncomeFromNonOperatingActivities>
    <imc:NetForeignExchangeGainLoss contextRef="c0" decimals="0" unitRef="aud">-582528</imc:NetForeignExchangeGainLoss>
    <imc:NetForeignExchangeGainLoss contextRef="c3" decimals="0" unitRef="aud">11335</imc:NetForeignExchangeGainLoss>
    <imc:NetForeignExchangeGainLoss contextRef="c4" decimals="0" unitRef="aud">51807</imc:NetForeignExchangeGainLoss>
    <ifrs-full:ImpairmentLoss contextRef="c0" decimals="0" unitRef="aud">759765</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss contextRef="c4" decimals="0" unitRef="aud">13394</ifrs-full:ImpairmentLoss>
    <ifrs-full:OtherGainsLosses contextRef="c0" decimals="0" unitRef="aud">-1342293</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c3" decimals="0" unitRef="aud">11335</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c4" decimals="0" unitRef="aud">38413</ifrs-full:OtherGainsLosses>
    <imc:OtherIncomeOfResearchAndDevelopment contextRef="c0" decimals="0" unitRef="aud">306154</imc:OtherIncomeOfResearchAndDevelopment>
    <imc:OtherIncomeOfResearchAndDevelopment contextRef="c3" decimals="0" unitRef="aud">308225</imc:OtherIncomeOfResearchAndDevelopment>
    <imc:AdditionalOtherIncome contextRef="c3" decimals="0" unitRef="aud">50055</imc:AdditionalOtherIncome>
    <imc:GovernmentAssistancePackages contextRef="c0" decimals="0" unitRef="aud">161600</imc:GovernmentAssistancePackages>
    <imc:GovernmentAssistancePackages contextRef="c3" decimals="0" unitRef="aud">154904</imc:GovernmentAssistancePackages>
    <imc:ResearchAndDevelopmentsGrants contextRef="c0" decimals="0" unitRef="aud">74821</imc:ResearchAndDevelopmentsGrants>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3. Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
                                            2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;30 June &lt;br/&gt;2020&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;30 June &lt;br/&gt;2019&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounting and audit&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;547,055&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;389,798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;496,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Bad debts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,472&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Consulting&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;126,215&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,474&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;43,662&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,775,809&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,531,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,599,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected credit losses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,991&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;341,202&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;469,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;307,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Investor relations&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;38,568&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Legal&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;205,722&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Listing and share registry&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;292,113&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Occupancy&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Superannuation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;41,964&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Travel and entertainment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,398&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;589,554&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;278,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;151,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,978,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,703,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,694,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Consulting&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,006,086&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Project research and development&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;360,968&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;915,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,367,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,178,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,044,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Selling&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;25,858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Marketing&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;90,652&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Distribution costs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;171,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;236,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;209,739&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
                                            2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;30 June &lt;br/&gt;2020&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;30 June &lt;br/&gt;2019&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounting and audit&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;547,055&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;389,798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;496,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Bad debts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,472&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Consulting&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;126,215&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,474&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;43,662&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,775,809&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,531,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,599,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected credit losses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,991&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;341,202&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;469,844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;307,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Investor relations&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;38,568&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Legal&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;205,722&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Listing and share registry&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;292,113&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Occupancy&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Superannuation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;41,964&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Travel and entertainment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,398&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;589,554&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;278,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;151,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,978,679&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,703,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,694,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Consulting&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,006,086&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Project research and development&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;360,968&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;915,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,367,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,178,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,044,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Selling&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;25,858&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Marketing&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;90,652&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Distribution costs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;171,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;236,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;209,739&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <imc:AccountingAndAudit contextRef="c0" decimals="0" unitRef="aud">547055</imc:AccountingAndAudit>
    <imc:AccountingAndAudit contextRef="c3" decimals="0" unitRef="aud">389798</imc:AccountingAndAudit>
    <imc:AccountingAndAudit contextRef="c4" decimals="0" unitRef="aud">496983</imc:AccountingAndAudit>
    <imc:BadDebts contextRef="c0" decimals="0" unitRef="aud">5472</imc:BadDebts>
    <imc:BadDebts contextRef="c3" decimals="0" unitRef="aud">26983</imc:BadDebts>
    <imc:BadDebts contextRef="c4" decimals="0" unitRef="aud">50429</imc:BadDebts>
    <imc:ConsultingExpenses contextRef="c0" decimals="0" unitRef="aud">126215</imc:ConsultingExpenses>
    <imc:ConsultingExpenses contextRef="c3" decimals="0" unitRef="aud">181474</imc:ConsultingExpenses>
    <imc:ConsultingExpenses contextRef="c4" decimals="0" unitRef="aud">243508</imc:ConsultingExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c0" decimals="0" unitRef="aud">43662</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c3" decimals="0" unitRef="aud">44056</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c4" decimals="0" unitRef="aud">5287</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c0" decimals="0" unitRef="aud">1775809</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c3" decimals="0" unitRef="aud">1531037</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c4" decimals="0" unitRef="aud">1599023</ifrs-full:OtherEmployeeExpense>
    <imc:ExpectedCreditLosses contextRef="c0" decimals="0" unitRef="aud">-30055</imc:ExpectedCreditLosses>
    <imc:ExpectedCreditLosses contextRef="c3" decimals="0" unitRef="aud">-3991</imc:ExpectedCreditLosses>
    <imc:ExpectedCreditLosses contextRef="c4" decimals="0" unitRef="aud">34046</imc:ExpectedCreditLosses>
    <ifrs-full:InsuranceExpense contextRef="c0" decimals="0" unitRef="aud">341202</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c3" decimals="0" unitRef="aud">469844</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c4" decimals="0" unitRef="aud">307757</ifrs-full:InsuranceExpense>
    <imc:InvestorRelationsExpenses contextRef="c0" decimals="0" unitRef="aud">38568</imc:InvestorRelationsExpenses>
    <imc:InvestorRelationsExpenses contextRef="c3" decimals="0" unitRef="aud">197839</imc:InvestorRelationsExpenses>
    <imc:InvestorRelationsExpenses contextRef="c4" decimals="0" unitRef="aud">128415</imc:InvestorRelationsExpenses>
    <imc:LegalExpenses contextRef="c0" decimals="0" unitRef="aud">205722</imc:LegalExpenses>
    <imc:LegalExpenses contextRef="c3" decimals="0" unitRef="aud">184382</imc:LegalExpenses>
    <imc:LegalExpenses contextRef="c4" decimals="0" unitRef="aud">171145</imc:LegalExpenses>
    <imc:ListingAndShareRegistry contextRef="c0" decimals="0" unitRef="aud">292113</imc:ListingAndShareRegistry>
    <imc:ListingAndShareRegistry contextRef="c3" decimals="0" unitRef="aud">212236</imc:ListingAndShareRegistry>
    <imc:ListingAndShareRegistry contextRef="c4" decimals="0" unitRef="aud">186013</imc:ListingAndShareRegistry>
    <ifrs-full:UtilitiesExpense contextRef="c3" decimals="0" unitRef="aud">51973</ifrs-full:UtilitiesExpense>
    <ifrs-full:UtilitiesExpense contextRef="c4" decimals="0" unitRef="aud">105606</ifrs-full:UtilitiesExpense>
    <imc:SuperannuationExpenses contextRef="c0" decimals="0" unitRef="aud">41964</imc:SuperannuationExpenses>
    <imc:SuperannuationExpenses contextRef="c3" decimals="0" unitRef="aud">48877</imc:SuperannuationExpenses>
    <imc:SuperannuationExpenses contextRef="c4" decimals="0" unitRef="aud">55176</imc:SuperannuationExpenses>
    <ifrs-full:TravelExpense contextRef="c0" decimals="0" unitRef="aud">1398</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c3" decimals="0" unitRef="aud">91347</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c4" decimals="0" unitRef="aud">159911</ifrs-full:TravelExpense>
    <ifrs-full:OtherExpenseByNature contextRef="c0" decimals="0" unitRef="aud">589554</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c3" decimals="0" unitRef="aud">278135</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c4" decimals="0" unitRef="aud">151007</ifrs-full:OtherExpenseByNature>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="aud">3978679</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c3" decimals="0" unitRef="aud">3703990</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="aud">3694306</us-gaap:GeneralAndAdministrativeExpense>
    <imc:ResearchAndDevelopmentConsultingExpenses contextRef="c0" decimals="0" unitRef="aud">1006086</imc:ResearchAndDevelopmentConsultingExpenses>
    <imc:ResearchAndDevelopmentConsultingExpenses contextRef="c3" decimals="0" unitRef="aud">262720</imc:ResearchAndDevelopmentConsultingExpenses>
    <imc:ResearchAndDevelopmentConsultingExpenses contextRef="c4" decimals="0" unitRef="aud">430996</imc:ResearchAndDevelopmentConsultingExpenses>
    <ifrs-full:PropertyDevelopmentAndProjectManagementExpense contextRef="c0" decimals="0" unitRef="aud">360968</ifrs-full:PropertyDevelopmentAndProjectManagementExpense>
    <ifrs-full:PropertyDevelopmentAndProjectManagementExpense contextRef="c3" decimals="0" unitRef="aud">915965</ifrs-full:PropertyDevelopmentAndProjectManagementExpense>
    <ifrs-full:PropertyDevelopmentAndProjectManagementExpense contextRef="c4" decimals="0" unitRef="aud">613532</ifrs-full:PropertyDevelopmentAndProjectManagementExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="aud">1367054</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" unitRef="aud">1178685</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="aud">1044528</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingExpense contextRef="c0" decimals="0" unitRef="aud">25858</ifrs-full:SellingExpense>
    <ifrs-full:SellingExpense contextRef="c3" decimals="0" unitRef="aud">340046</ifrs-full:SellingExpense>
    <ifrs-full:SellingExpense contextRef="c4" decimals="0" unitRef="aud">277478</ifrs-full:SellingExpense>
    <imc:MarketingExpenses contextRef="c0" decimals="0" unitRef="aud">90652</imc:MarketingExpenses>
    <imc:MarketingExpenses contextRef="c3" decimals="0" unitRef="aud">295261</imc:MarketingExpenses>
    <imc:MarketingExpenses contextRef="c4" decimals="0" unitRef="aud">377427</imc:MarketingExpenses>
    <ifrs-full:DistributionCosts contextRef="c0" decimals="0" unitRef="aud">171174</ifrs-full:DistributionCosts>
    <ifrs-full:DistributionCosts contextRef="c3" decimals="0" unitRef="aud">236244</ifrs-full:DistributionCosts>
    <ifrs-full:DistributionCosts contextRef="c4" decimals="0" unitRef="aud">209739</ifrs-full:DistributionCosts>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="0" unitRef="aud">287684</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c3" decimals="0" unitRef="aud">871551</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="0" unitRef="aud">864644</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 4. Income Tax Benefit&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
                                            2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
    June &lt;br/&gt;2020&lt;br/&gt; A$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Unused tax losses for which no deferred tax asset has been recognised&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;44,178,579&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;40,018,956&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Potential tax benefit @ 26% (2020: 27.5%)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,486,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,005,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Numerical reconciliation of income tax expense
to prima facie tax payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
    June&lt;br/&gt; 2020&lt;br/&gt; A$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loss from continuing operations before income tax expense&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Tax at the Australian tax rate of 26% (2020: 27.5%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(2,179,961&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(804,982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax effect of amounts which are not deductible (taxable) in calculating taxable income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax incentive&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(92,614&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(84,762&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounting expenditure subject to R&amp;amp;D tax incentive&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;212,907&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;550,163&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(146,826&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net impact of other amounts not deductible (taxable)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;428,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,678&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,081,502&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860,393&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax losses and other timing differences for which no deferred tax asset is recognised&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,081,502&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
                                            2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
    June &lt;br/&gt;2020&lt;br/&gt; A$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Unused tax losses for which no deferred tax asset has been recognised&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;44,178,579&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;40,018,956&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Potential tax benefit @ 26% (2020: 27.5%)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,486,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,005,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c2" decimals="0" unitRef="aud">44178579</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c5" decimals="0" unitRef="aud">40018956</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c0" decimals="0" unitRef="aud">11486431</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c3" decimals="0" unitRef="aud">11005213</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <imc:DisclosureOfIncomeTaxBenefitExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
    June&lt;br/&gt; 2020&lt;br/&gt; A$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loss from continuing operations before income tax expense&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Tax at the Australian tax rate of 26% (2020: 27.5%)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(2,179,961&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(804,982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax effect of amounts which are not deductible (taxable) in calculating taxable income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax incentive&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(92,614&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(84,762&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounting expenditure subject to R&amp;amp;D tax incentive&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;212,907&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;550,163&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(146,826&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net impact of other amounts not deductible (taxable)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;428,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,678&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,081,502&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860,393&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax losses and other timing differences for which no deferred tax asset is recognised&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,081,502&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DisclosureOfIncomeTaxBenefitExplanatory>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c0" decimals="0" unitRef="aud">-2179961</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c3" decimals="0" unitRef="aud">-804982</ifrs-full:CurrentTaxExpenseIncome>
    <imc:TaxEffectofResearchAndDevelopmentTaxIncentive contextRef="c0" decimals="0" unitRef="aud">-92614</imc:TaxEffectofResearchAndDevelopmentTaxIncentive>
    <imc:TaxEffectofResearchAndDevelopmentTaxIncentive contextRef="c3" decimals="0" unitRef="aud">-84762</imc:TaxEffectofResearchAndDevelopmentTaxIncentive>
    <imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive contextRef="c0" decimals="0" unitRef="aud">212907</imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive>
    <imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive contextRef="c3" decimals="0" unitRef="aud">194855</imc:TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive>
    <imc:TaxEffectOfShareBasedPayments contextRef="c0" decimals="0" unitRef="aud">550163</imc:TaxEffectOfShareBasedPayments>
    <imc:TaxEffectOfShareBasedPayments contextRef="c3" decimals="0" unitRef="aud">-146826</imc:TaxEffectOfShareBasedPayments>
    <imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses contextRef="c0" decimals="0" unitRef="aud">428003</imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses>
    <imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses contextRef="c3" decimals="0" unitRef="aud">-18678</imc:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses>
    <imc:TaxEffectOfTaxPayable contextRef="c0" decimals="0" unitRef="aud">-1081502</imc:TaxEffectOfTaxPayable>
    <imc:TaxEffectOfTaxPayable contextRef="c3" decimals="0" unitRef="aud">-860393</imc:TaxEffectOfTaxPayable>
    <imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss contextRef="c0" decimals="0" unitRef="aud">1081502</imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss>
    <imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss contextRef="c3" decimals="0" unitRef="aud">860393</imc:DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5. Key Management Personnel Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This note details the nature and amount of remuneration
for each Director of Immuron Limited, and for the Key Management Personnel.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Directors of Immuron Limited during the year
ended June 30, 2021 were:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following persons held office as Directors
of Immuron Limited during the financial year:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Dr Roger Aston, Independent Non-Executive
Chairman&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Mr Peter Anastasiou, Executive Vice
Chairman (resigned on 24 September 2021)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Mr Daniel Pollock, Independent Non-Executive
Director&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Mr Stephen Anastasiou, Independent
Non-Executive Director&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Prof. Ravi Savarirayan, Independent
Non-Executive Director&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following persons held office as Key Management
Personnel of Immuron Limited during the financial year ended June 30, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Dr Jerry Kanellos, Chief Operating
Officer and Chief Executive Officer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate compensation made to Directors
and Other Key Management Personnel of the Company is set out below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Key Management Personnel Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 9pt"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;450,002&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;867,054&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;952,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Other short-term benefits, including consulting services by KMP and their related entities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,603,747&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Post-employment benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,869&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,213&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Long-term benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,610&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Share-based payment expenses to KMP and their related entities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,116,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,296,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total Key Management Personnel Compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,205,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;972,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,284,758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Key Management Personnel Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 9pt"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;450,002&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;867,054&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;952,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Other short-term benefits, including consulting services by KMP and their related entities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,603,747&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Post-employment benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,869&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,213&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Long-term benefits&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,610&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Share-based payment expenses to KMP and their related entities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,116,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,296,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total Key Management Personnel Compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,205,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;972,965&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,284,758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="0" unitRef="aud">450002</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c3" decimals="0" unitRef="aud">867054</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c4" decimals="0" unitRef="aud">952406</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities contextRef="c0" decimals="0" unitRef="aud">1603747</imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c0" decimals="0" unitRef="aud">27869</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c3" decimals="0" unitRef="aud">29213</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c4" decimals="0" unitRef="aud">32300</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c0" decimals="0" unitRef="aud">8220</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c3" decimals="0" unitRef="aud">3610</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c4" decimals="0" unitRef="aud">3652</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="0" unitRef="aud">2116012</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c3" decimals="0" unitRef="aud">73088</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c4" decimals="0" unitRef="aud">1296400</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c0" decimals="0" unitRef="aud">4205850</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c3" decimals="0" unitRef="aud">972965</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c4" decimals="0" unitRef="aud">2284758</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 6. Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Basic/Diluted loss per share (in cents)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3.79&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;a) Net loss used in the calculation of basic and diluted loss
    per share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;8,384,465&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,927,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,656,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;b) Weighted average number of ordinary shares outstanding
    during the period used in the calculation of basic and diluted loss per share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;221,062,229&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,393,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,740,535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is currently in a loss making position
and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company&#x2019;s options and warrants
and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <imc:DisclosureOfDetailsOfEarningsPerShareExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Basic/Diluted loss per share (in cents)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3.79&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;a) Net loss used in the calculation of basic and diluted loss
    per share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;8,384,465&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,927,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,656,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;b) Weighted average number of ordinary shares outstanding
    during the period used in the calculation of basic and diluted loss per share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;221,062,229&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,393,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,740,535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfDetailsOfEarningsPerShareExplanatory>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c0" decimals="2" unitRef="audPershares">-3.79</imc:BasicAndDilutedEarningsLossPerShare>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c3" decimals="2" unitRef="audPershares">-1.66</imc:BasicAndDilutedEarningsLossPerShare>
    <imc:BasicAndDilutedEarningsLossPerShare contextRef="c4" decimals="2" unitRef="audPershares">-3.22</imc:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c0" decimals="0" unitRef="aud">8384465</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c3" decimals="0" unitRef="aud">2927206</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c4" decimals="0" unitRef="aud">4656421</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <imc:WeightedAverageNumberOfShares contextRef="c0" decimals="0" unitRef="shares">221062229</imc:WeightedAverageNumberOfShares>
    <imc:WeightedAverageNumberOfShares contextRef="c3" decimals="0" unitRef="shares">176393354</imc:WeightedAverageNumberOfShares>
    <imc:WeightedAverageNumberOfShares contextRef="c4" decimals="0" unitRef="shares">144740535</imc:WeightedAverageNumberOfShares>
    <imc:DisclosureOfCashExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 7. Cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cash at Bank and in hand:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cash at bank and in hand&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,047,281&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,250,468&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Cash&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,047,281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,250,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DisclosureOfCashExplanatory>
    <imc:DetailedInformationAboutCashExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cash at Bank and in hand:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cash at bank and in hand&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,047,281&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,250,468&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Cash&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,047,281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,250,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DetailedInformationAboutCashExplanatory>
    <imc:CashAtBankAndInHand contextRef="c2" decimals="0" unitRef="aud">25047281</imc:CashAtBankAndInHand>
    <imc:CashAtBankAndInHand contextRef="c5" decimals="0" unitRef="aud">3250468</imc:CashAtBankAndInHand>
    <ifrs-full:Cash contextRef="c2" decimals="0" unitRef="aud">25047281</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c5" decimals="0" unitRef="aud">3250468</ifrs-full:Cash>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 8. Trade and Other Receivables&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Trade receivables*&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;28,553&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Accrued income**&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total Trade and Other Receivables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;334,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;327,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All trade receivables are non-interest bearing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;**&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;amp;D tax concession for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Trade receivables*&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;28,553&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Accrued income**&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total Trade and Other Receivables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;334,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;327,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All trade receivables are non-interest bearing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;**&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;amp;D tax concession for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory>
    <ifrs-full:TradeReceivables contextRef="c2" decimals="0" id="ix_2_fact" unitRef="aud">28553</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c5" decimals="0" id="ix_3_fact" unitRef="aud">49519</ifrs-full:TradeReceivables>
    <imc:LossOnAllowanceTradeReceivables contextRef="c5" decimals="0" unitRef="aud">-30055</imc:LossOnAllowanceTradeReceivables>
    <ifrs-full:AccruedIncomeOtherThanContractAssets contextRef="c2" decimals="0" id="ix_0_fact" unitRef="aud">306154</ifrs-full:AccruedIncomeOtherThanContractAssets>
    <ifrs-full:AccruedIncomeOtherThanContractAssets contextRef="c5" decimals="0" id="ix_1_fact" unitRef="aud">308225</ifrs-full:AccruedIncomeOtherThanContractAssets>
    <ifrs-full:TradeAndOtherReceivables contextRef="c2" decimals="0" unitRef="aud">334707</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables contextRef="c5" decimals="0" unitRef="aud">327689</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 9. Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30 June&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June &lt;br/&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Non-&lt;br/&gt; current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Non-&lt;br/&gt; current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Raw materials and stores (Colostrum)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Work in progress&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Finished goods (Travelan and Protectyn)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;680,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;680,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,559,119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;797,690&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,520,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <imc:DetailedInformationAboutInventoriesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30 June&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June &lt;br/&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Non-&lt;br/&gt; current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Non-&lt;br/&gt; current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Raw materials and stores (Colostrum)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Work in progress&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Finished goods (Travelan and Protectyn)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;680,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;680,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;292,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,266,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,559,119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;797,690&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,722,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,520,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DetailedInformationAboutInventoriesExplanatory>
    <ifrs-full:NoncurrentInventories contextRef="c35" decimals="0" unitRef="aud">1266587</ifrs-full:NoncurrentInventories>
    <imc:InventoriesNet contextRef="c35" decimals="0" unitRef="aud">1266587</imc:InventoriesNet>
    <ifrs-full:NoncurrentInventories contextRef="c36" decimals="0" unitRef="aud">1722349</ifrs-full:NoncurrentInventories>
    <imc:InventoriesNet contextRef="c36" decimals="0" unitRef="aud">1722349</imc:InventoriesNet>
    <ifrs-full:Inventories contextRef="c38" decimals="0" unitRef="aud">117576</ifrs-full:Inventories>
    <imc:InventoriesNet contextRef="c38" decimals="0" unitRef="aud">117576</imc:InventoriesNet>
    <ifrs-full:Inventories contextRef="c39" decimals="0" unitRef="aud">292532</ifrs-full:Inventories>
    <imc:InventoriesNet contextRef="c39" decimals="0" unitRef="aud">292532</imc:InventoriesNet>
    <ifrs-full:Inventories contextRef="c40" decimals="0" unitRef="aud">680114</ifrs-full:Inventories>
    <imc:InventoriesNet contextRef="c40" decimals="0" unitRef="aud">680114</imc:InventoriesNet>
    <ifrs-full:Inventories contextRef="c2" decimals="0" unitRef="aud">292532</ifrs-full:Inventories>
    <ifrs-full:NoncurrentInventories contextRef="c2" decimals="0" unitRef="aud">1266587</ifrs-full:NoncurrentInventories>
    <imc:InventoriesNet contextRef="c2" decimals="0" unitRef="aud">1559119</imc:InventoriesNet>
    <ifrs-full:Inventories contextRef="c5" decimals="0" unitRef="aud">797690</ifrs-full:Inventories>
    <ifrs-full:NoncurrentInventories contextRef="c5" decimals="0" unitRef="aud">1722349</ifrs-full:NoncurrentInventories>
    <imc:InventoriesNet contextRef="c5" decimals="0" unitRef="aud">2520039</imc:InventoriesNet>
    <imc:ControlledEntitiesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 10. Controlled Entities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries at 30 June 2021
are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the
Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or
registration is also their principal place of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Percentage
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ownership&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Country of Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Parent Entity:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Immuron Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Subsidiaries of Immuron Limited:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;Immuron Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USA&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Anadis EPS Pty Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;IMC Canada Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</imc:ControlledEntitiesTextBlock>
    <imc:ScheduleOfSubsidiariesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Percentage
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ownership&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Country of Incorporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Parent Entity:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Immuron Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-decoration: underline; text-align: left"&gt;Subsidiaries of Immuron Limited:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;Immuron Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USA&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Anadis EPS Pty Ltd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;IMC Canada Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</imc:ScheduleOfSubsidiariesExplanatory>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="c41">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="c43">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c43" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c44" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="c45">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c45" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c46" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="c47">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c47" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c48" decimals="2" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 11. Trade and Other Payables&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
 2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
 2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;106,893&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;157,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;625,980&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;758,494&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;384,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
 2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;br/&gt;
 2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;106,893&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;157,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;625,980&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;758,494&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;384,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="0" unitRef="aud">106893</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="0" unitRef="aud">157644</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:Accruals contextRef="c2" decimals="0" unitRef="aud">625980</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c5" decimals="0" unitRef="aud">210734</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c2" decimals="0" unitRef="aud">25621</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c5" decimals="0" unitRef="aud">16019</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c2" decimals="0" unitRef="aud">758494</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c5" decimals="0" unitRef="aud">384397</ifrs-full:TradeAndOtherPayables>
    <imc:DisclosureOfProvisionForSalesReturnsExplantory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 12. Provision for Sales Returns&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&lt;b&gt;Sales return provision due to the ongoing COVID-19 pandemic&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Carrying amount at the start of the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Sales return provision recognised&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;213,024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amounts transferred from non-current&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at the end of the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;213,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The sales return provision has been assessed by management based on
external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled
in the next year.&lt;/p&gt;</imc:DisclosureOfProvisionForSalesReturnsExplantory>
    <imc:DisclosureOfSalesReturnProvisionExplantory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&lt;b&gt;Sales return provision due to the ongoing COVID-19 pandemic&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Carrying amount at the start of the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Sales return provision recognised&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;213,024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amounts transferred from non-current&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at the end of the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;213,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfSalesReturnProvisionExplantory>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c0" decimals="0" unitRef="aud">213024</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:Provisions contextRef="c2" decimals="0" unitRef="aud">213024</ifrs-full:Provisions>
    <imc:ContingentLiabilitiesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 13. Contingent liabilities and Commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group had no contingent liabilities or commitments
at June 30, 2021 (2020: &lt;span style="-sec-ix-hidden: hidden-fact-84"&gt;Nil&lt;/span&gt;).&lt;/p&gt;</imc:ContingentLiabilitiesTextBlock>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c2" decimals="0" unitRef="usd">0</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 14. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amounts
    recognized in the balance sheet&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The balance sheet shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
                                            June&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2020&lt;br/&gt;
                                            A$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Right-of-use assets&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;Properties&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,471&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;58,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lease liabilities&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,929&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"&gt;Included in the line item &#x2018;property, plant and equipment&#x2019; in the consolidated balance sheet.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"&gt;Included in the line items &#x2018;other current liabilities&#x2019; and &#x2018;other non-current liabilities&#x2019; in the consolidated balance sheet.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amounts
    recognized in the statement of profit or loss&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The statement of profit or loss shows the following amounts relating
to leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2020&lt;br/&gt;
    A$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold"&gt;Depreciation charge of right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt"&gt;Properties&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,624&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;38,729&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,729&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Interest expense (included in finance cost)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,152&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to short-term leases (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to variable lease payments not included in lease liabilities (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash paid for principal payments&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;40,607&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total finance cash outflow for leases in 2021 was A$1,152.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total finance cash outflow for leases in 2020 was A$4,192.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;The
    group&#x2019;s leasing activities and how these are accounted for&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2019, the group entered into a three-year
commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option
for a further 3 years by written request to the landlord before 31 December 2021. There is no variability and no covenants included in
the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Leases are recognized as a right-of-use asset
and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated
between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant
periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter
of the asset&#x2019;s useful life and the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Assets and liabilities arising from a lease are
initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
&lt;tr&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fixed
    payments (including in-substance fixed payments), less any lease incentives receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;variable
    lease payment that are based on an index or a rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;amounts
    expected to be payable by the lessee under residual value guarantees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;payments
    of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The lease payments are discounted using the interest
rate implicit in the lease, if that rate can be determined, or the group&#x2019;s incremental borrowing rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Right-of-use assets are measured at cost comprising the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
&lt;tr&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    amount of the initial measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any
    lease payments made at or before the commencement date, less any lease incentives received&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any
    initial direct costs, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-right: 12.75pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restoration
    costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Payments associated with short-term leases and
leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with
a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <imc:ScheduleOfAmountsRecognizedinBalanceSheet contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;30
                                            June&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt;
                                            A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;30
                                            June&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2020&lt;br/&gt;
                                            A$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Right-of-use assets&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt"&gt;Properties&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,471&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;58,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lease liabilities&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,929&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"&gt;Included in the line item &#x2018;property, plant and equipment&#x2019; in the consolidated balance sheet.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%"&gt;Included in the line items &#x2018;other current liabilities&#x2019; and &#x2018;other non-current liabilities&#x2019; in the consolidated balance sheet.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:ScheduleOfAmountsRecognizedinBalanceSheet>
    <ifrs-full:RightofuseAssets contextRef="c49" decimals="0" id="ix_4_fact" unitRef="aud">19471</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c50" decimals="0" id="ix_5_fact" unitRef="aud">58095</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="0" id="ix_6_fact" unitRef="aud">19471</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c5" decimals="0" id="ix_7_fact" unitRef="aud">58095</ifrs-full:RightofuseAssets>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="0" id="ix_8_fact" unitRef="aud">20498</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c5" decimals="0" id="ix_9_fact" unitRef="aud">42176</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c5" decimals="0" id="ix_10_fact" unitRef="aud">18929</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="0" id="ix_11_fact" unitRef="aud">20498</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="0" id="ix_12_fact" unitRef="aud">61105</ifrs-full:LeaseLiabilities>
    <imc:ScheduleOfProfitOrLossAmountsRelatedToLeases contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;2020&lt;br/&gt;
    A$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold"&gt;Depreciation charge of right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt"&gt;Properties&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,624&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;38,729&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;38,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,729&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Interest expense (included in finance cost)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,152&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to short-term leases (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expense relating to variable lease payments not included in lease liabilities (included in other expenses)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash paid for principal payments&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;40,607&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:ScheduleOfProfitOrLossAmountsRelatedToLeases>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c51" decimals="0" unitRef="aud">38624</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c52" decimals="0" unitRef="aud">38729</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c0" decimals="0" unitRef="aud">38624</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c3" decimals="0" unitRef="aud">38729</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="0" unitRef="aud">1152</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c3" decimals="0" unitRef="aud">4192</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases contextRef="c0" decimals="0" unitRef="aud">40607</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c3" decimals="0" unitRef="aud">41390</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="0" unitRef="aud">1152</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c3" decimals="0" unitRef="aud">4192</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InformationAboutNatureOfLesseesLeasingActivities contextRef="c0">In January 2019, the group entered into a three-year
commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option
for a further 3 years by written request to the landlord before 31 December 2021.</ifrs-full:InformationAboutNatureOfLesseesLeasingActivities>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 15. Share capital&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify; padding-bottom: 1.5pt"&gt;Fully paid&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Movements in ordinary
    shares:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Details&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Balance at 30 June 2018&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;142,778,206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;58,237,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at $0.16 in lieu
    of payment for services (2018-11-22)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,678&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at US$0.10 pursuant
    to ADS public offering (2019-05-30)&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,894,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Reclassify exercised options from reserves to share capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction costs arising
    on representative warrants issued&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(825,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Balance at 30 June 2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Issue at US$0.10 pursuant to ADS public offering (2019-07-19)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,565,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,926,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at A$0.16 in lieu
    of payment for services (2019-11-12)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Exercise of NASDAQ Warrants (2020-06-23)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Exercise of representative warrants (2020-06-15, 2020-06-22)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;974,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Transaction costs arising on representative warrants issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,454&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(374,728&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify"&gt;Balance at 30 June 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%"&gt;Exercise of representative warrants (2020-07-02)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.47 pursuant to ADS public offering (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,666,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,165,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,008,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,051,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,779,831&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at 30 June 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Notes&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#x2019;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#x2019;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary
    shares&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary shares entitle the holder to participate
in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On a show of hands every holder of ordinary shares
present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary shares have no par value and the Company
does not have a limited amount of authorized capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="text-decoration:underline"&gt;Options&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Information relating to options, including details
of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set
out in notes 15 and 18.&lt;/p&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify; padding-bottom: 1.5pt"&gt;Fully paid&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesIssued contextRef="c2" decimals="0" unitRef="shares">227246596</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c5" decimals="0" unitRef="shares">178279566</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c16" decimals="0" unitRef="shares">163215706</ifrs-full:NumberOfSharesIssued>
    <imc:AmountOfOrdinaryShares contextRef="c2" decimals="0" unitRef="aud">88361303</imc:AmountOfOrdinaryShares>
    <imc:AmountOfOrdinaryShares contextRef="c5" decimals="0" unitRef="aud">62426991</imc:AmountOfOrdinaryShares>
    <imc:AmountOfOrdinaryShares contextRef="c16" decimals="0" unitRef="aud">60289875</imc:AmountOfOrdinaryShares>
    <ifrs-full:NumberOfSharesIssued contextRef="c2" decimals="0" unitRef="shares">227246596</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c5" decimals="0" unitRef="shares">178279566</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c16" decimals="0" unitRef="shares">163215706</ifrs-full:NumberOfSharesIssued>
    <imc:AmountOfOrdinaryShares contextRef="c2" decimals="0" unitRef="aud">88361303</imc:AmountOfOrdinaryShares>
    <imc:AmountOfOrdinaryShares contextRef="c5" decimals="0" unitRef="aud">62426991</imc:AmountOfOrdinaryShares>
    <imc:AmountOfOrdinaryShares contextRef="c16" decimals="0" unitRef="aud">60289875</imc:AmountOfOrdinaryShares>
    <imc:DisclosureOfOrdinarySharesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Details&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Balance at 30 June 2018&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;142,778,206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;58,237,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at $0.16 in lieu
    of payment for services (2018-11-22)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,678&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at US$0.10 pursuant
    to ADS public offering (2019-05-30)&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,894,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Reclassify exercised options from reserves to share capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction costs arising
    on representative warrants issued&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(825,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Balance at 30 June 2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;163,215,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;60,289,875&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Issue at US$0.10 pursuant to ADS public offering (2019-07-19)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,565,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,926,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue at A$0.16 in lieu
    of payment for services (2019-11-12)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Exercise of NASDAQ Warrants (2020-06-23)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Exercise of representative warrants (2020-06-15, 2020-06-22)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;974,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"&gt;Transaction costs arising on representative warrants issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,454&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(374,728&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify"&gt;Balance at 30 June 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;178,279,566&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;62,426,991&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%"&gt;Exercise of representative warrants (2020-07-02)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.47 pursuant to ADS public offering (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,666,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,165,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,008,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,051,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Transaction costs arising on share issues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,779,831&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at 30 June 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,246,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;88,361,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#x2019;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#x2019;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfOrdinarySharesExplanatory>
    <imc:OrdinaryShare contextRef="c9" decimals="0" unitRef="shares">142778206</imc:OrdinaryShare>
    <imc:IssueOfEquityToOrdinaryvalue contextRef="c9" decimals="0" unitRef="usd">58237314</imc:IssueOfEquityToOrdinaryvalue>
    <imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1
      contextRef="c4"
      decimals="0"
      id="ix_15_fact"
      unitRef="shares">437500</imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1>
    <imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1 contextRef="c4" decimals="0" id="ix_16_fact" unitRef="usd">93678</imc:ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1>
    <imc:ProceedsFromIssuedSharesAtADSPublicOffering
      contextRef="c4"
      decimals="0"
      id="ix_13_fact"
      unitRef="shares">20000000</imc:ProceedsFromIssuedSharesAtADSPublicOffering>
    <imc:ProceedsFromIssuedAtADSPublicOffering contextRef="c4" decimals="0" id="ix_14_fact" unitRef="usd">2894238</imc:ProceedsFromIssuedAtADSPublicOffering>
    <imc:StockIssuedDuringValueReclassifyToStockOptionsExercised contextRef="c4" decimals="0" unitRef="usd">100</imc:StockIssuedDuringValueReclassifyToStockOptionsExercised>
    <imc:TransactionCostsArisingOnRepresentativeWarrantsIssued contextRef="c4" decimals="0" unitRef="usd">-110400</imc:TransactionCostsArisingOnRepresentativeWarrantsIssued>
    <imc:BusinessAcquisitionCostOfTransactionCost contextRef="c4" decimals="0" unitRef="usd">-825055</imc:BusinessAcquisitionCostOfTransactionCost>
    <imc:OrdinaryShare contextRef="c16" decimals="0" unitRef="shares">163215706</imc:OrdinaryShare>
    <imc:IssueOfEquityToOrdinaryvalue contextRef="c16" decimals="0" unitRef="usd">60289875</imc:IssueOfEquityToOrdinaryvalue>
    <imc:IssuePursuantToAdsPublicOfferingShares contextRef="c3" decimals="0" unitRef="shares">13565200</imc:IssuePursuantToAdsPublicOfferingShares>
    <imc:IssuePursuantToAdsPublicOffering contextRef="c3" decimals="0" unitRef="usd">1926186</imc:IssuePursuantToAdsPublicOffering>
    <imc:IssueInLieuOfPaymentForServicesShares
      contextRef="c3"
      decimals="0"
      id="ix_17_fact"
      unitRef="shares">437500</imc:IssueInLieuOfPaymentForServicesShares>
    <imc:IssueInLieuOfPaymentForServices contextRef="c3" decimals="0" id="ix_18_fact" unitRef="usd">100978</imc:IssueInLieuOfPaymentForServices>
    <imc:ExerciseOfNasdaqWarrantsShares contextRef="c3" decimals="0" unitRef="shares">86240</imc:ExerciseOfNasdaqWarrantsShares>
    <imc:ExerciseOfNasdaqWarrants contextRef="c3" decimals="0" unitRef="usd">72</imc:ExerciseOfNasdaqWarrants>
    <imc:ExerciseOfRepresentativeWarrantShares contextRef="c3" decimals="0" unitRef="shares">974920</imc:ExerciseOfRepresentativeWarrantShares>
    <imc:ExerciseOfRepresentativeWarrant contextRef="c3" decimals="0" unitRef="usd">540062</imc:ExerciseOfRepresentativeWarrant>
    <imc:TransactionCostsArisingOnRepresentativeWarrantsIssued contextRef="c3" decimals="0" unitRef="usd">-55454</imc:TransactionCostsArisingOnRepresentativeWarrantsIssued>
    <imc:BusinessAcquisitionCostOfTransactionCost contextRef="c3" decimals="0" unitRef="usd">-374728</imc:BusinessAcquisitionCostOfTransactionCost>
    <imc:OrdinaryShare contextRef="c5" decimals="0" unitRef="shares">178279566</imc:OrdinaryShare>
    <imc:IssueOfEquityToOrdinaryvalue contextRef="c5" decimals="0" unitRef="usd">62426991</imc:IssueOfEquityToOrdinaryvalue>
    <imc:ExerciseOfRepresentativeWarrants1 contextRef="c0" decimals="0" unitRef="shares">5720</imc:ExerciseOfRepresentativeWarrants1>
    <imc:IssueAtUS047PursuantToADSPublicOffering contextRef="c0" decimals="0" unitRef="shares">42666720</imc:IssueAtUS047PursuantToADSPublicOffering>
    <imc:IssueAtUS047PursuantToADSPublicOffering1 contextRef="c0" decimals="0" unitRef="usd">28165836</imc:IssueAtUS047PursuantToADSPublicOffering1>
    <imc:IssueAt050OnExerciseOfESOPUnlistedOption contextRef="c0" decimals="0" unitRef="shares">100000</imc:IssueAt050OnExerciseOfESOPUnlistedOption>
    <imc:IssueAt050OnExerciseOfESOPUnlistedOptions contextRef="c0" decimals="0" unitRef="usd">50000</imc:IssueAt050OnExerciseOfESOPUnlistedOptions>
    <imc:IssueAtUS025OnExerciseOfNASDAQWarrants contextRef="c0" decimals="0" unitRef="shares">3008000</imc:IssueAtUS025OnExerciseOfNASDAQWarrants>
    <imc:IssueAtUS025OnExerciseOfNASDAQWarrants1 contextRef="c0" decimals="0" unitRef="usd">1051626</imc:IssueAtUS025OnExerciseOfNASDAQWarrants1>
    <imc:IssueAtUS025OnExerciseOfNASDAQWarrant contextRef="c0" decimals="0" unitRef="shares">40000</imc:IssueAtUS025OnExerciseOfNASDAQWarrant>
    <imc:IssueAtUS025OnExerciseOfNASDAQWarrant1 contextRef="c0" decimals="0" unitRef="usd">13959</imc:IssueAtUS025OnExerciseOfNASDAQWarrant1>
    <imc:TransferFromReservesOnExerciseOfESOPUnlistedOption contextRef="c0" decimals="0" unitRef="usd">15700</imc:TransferFromReservesOnExerciseOfESOPUnlistedOption>
    <imc:TransferFromReservesOnExerciseOfNASDAQWarrants contextRef="c0" decimals="0" unitRef="usd">1012</imc:TransferFromReservesOnExerciseOfNASDAQWarrants>
    <imc:IssueAtA008InLieuOfCashForServicesRendered20201113 contextRef="c0" decimals="0" unitRef="shares">2737500</imc:IssueAtA008InLieuOfCashForServicesRendered20201113>
    <imc:IssueAtA008InLieuOfCashForServicesRendered contextRef="c0" decimals="0" unitRef="usd">219000</imc:IssueAtA008InLieuOfCashForServicesRendered>
    <imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209 contextRef="c0" decimals="0" unitRef="shares">409090</imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209>
    <imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions contextRef="c0" decimals="0" unitRef="usd">197010</imc:TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions>
    <imc:BusinessAcquisitionCostOfTransactionCost contextRef="c0" decimals="0" unitRef="usd">-3779831</imc:BusinessAcquisitionCostOfTransactionCost>
    <imc:OrdinaryShare contextRef="c2" decimals="0" unitRef="shares">227246596</imc:OrdinaryShare>
    <imc:IssueOfEquityToOrdinaryvalue contextRef="c2" decimals="0" unitRef="usd">88361303</imc:IssueOfEquityToOrdinaryvalue>
    <imc:PaymentForServices contextRef="c0" decimals="0" unitRef="aud">70000</imc:PaymentForServices>
    <ifrs-full:ParValuePerShare contextRef="c2" decimals="2" unitRef="audPershares">0.16</ifrs-full:ParValuePerShare>
    <imc:IssuanceOfOrdinarySharesDescription contextRef="c53">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</imc:IssuanceOfOrdinarySharesDescription>
    <ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 16. Other reserves&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table shows a breakdown of the
consolidated statement of financial position line item &#x2018;other reserves&#x2019; and the movements in these reserves during the year.
A description of the nature and purpose of each reserve is provided below the table.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Foreign currency translation&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: justify"&gt;At 1 July 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"/&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,139,625&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(43,317&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,096,308&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,453,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,453,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Options and warrants lapsed/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(311,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(311,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;At 30 June 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,281,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;18,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,300,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Notes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Foreign currency translation&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;At
    1 July 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,281,790&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;18,529&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,300,319&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(484,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(484,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants lapsed/expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,251,320&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,251,320&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Re-valuation of options issued in prior period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;16(iii)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;At 30 June 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,011,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;121,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,133,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Foreign currency translation&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;At 1 July 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,011,878&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;121,467&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,133,345&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transfer to share capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options and warrants exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(213,722&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(213,722&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options and warrants forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(368,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(368,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;At 30 June 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,360,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;106,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,466,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Nature
    and purpose of other reserves&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Share-based payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The share-based payment reserve records items
recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency translation&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Exchange differences arising on translation of
foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve
within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Movements
    in options and warrants:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Details&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;br/&gt;
&#160;A$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2018&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;72,569,180&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3,139,625&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2018-07-13)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;204,100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2018-11-26)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;164,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of ESOP unlisted options at $0.50 (2018-10-01)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,050,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(98,385&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2019-02-11)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;975,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $0.57 (2019-02-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(185,601&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $1.892 (2019-02-28)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15,380&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,173&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $0.30 (2019-05-28)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(140,056&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,390&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify exercised options from reserves to share capital&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify lapsed options from reserves to accumulated losses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,086&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants (2019-05-23)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;800,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;79,463,744&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4,281,790&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Re-valuation of options issued in prior period (2019-11-06)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(607,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants (2019-07-16)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;542,600&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55,454&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.50 (2019-11-27)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,625,532&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,086,920&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.55 (2019-11-30)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(25,289,894&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.50 (2020-06-30)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(164,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(218,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of representative warrants (2020-06-15, 2020-06-22)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,065,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(540,062&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;42,807,118&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;938,790&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of representative warrants (2020-07-2)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,640&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of ESOP unlisted options at $0.50 (2020-07-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15,700&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,048,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,012&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options (2020-09-25)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(368,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants at US$23.44 per 40 options (2020-07-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,560,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,032,960&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.12 (2020-10-29)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,970,100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(900,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(197,010&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify share-based payments expenses from reserves to share capital&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(73,088&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;45,309,478&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3,360,128&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On 13 July 2018, the Company issued Dr. Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On 26 November 2018, the Company issued Mr. Richard
J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021. During
the 2019 annual general meeting, the shareholders approved the issuance of the options to Richard Berman.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On 11 February 2019, the Company issued Dr. Gary
S. Jacob 5,000,000 unlisted options exercisable at $0.50. These options were subsequently forfeited on September 25, 2020, being 6 months
after his resignation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Given the shareholders' approval at the AGM held
on 29 October 2020, a total of 9,000,000 ESOP Options were issued to directors on 13 November 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revaluation
                                            of options issued in prior period&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options granted to Dr Gary Jacob on 11 February 2019 and valued at
$975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date
6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
                                            payment expenses&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Due to the ongoing crisis of COVID-19, the groups
directors decided to forgo cash payments of their director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that
value. In prior year, no shares were issued to directors, however the expense of the shares owed to them was A$73,088. As at 30 June
2021, shares have been issued to directors given the shareholders' approval at the AGM held on 29 October 2020.&lt;/p&gt;</ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory>
    <imc:DisclosureOfDetailedInformationOtherReserve contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Foreign currency translation&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: justify"&gt;At 1 July 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"/&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,139,625&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(43,317&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,096,308&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;61,846&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,453,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,453,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Options and warrants lapsed/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(311,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(311,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;At 30 June 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,281,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;18,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,300,319&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Notes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Foreign currency translation&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;At
    1 July 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,281,790&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;18,529&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,300,319&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(484,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(484,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options and warrants lapsed/expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,251,320&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,251,320&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Re-valuation of options issued in prior period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;16(iii)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;At 30 June 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,011,878&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;121,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,133,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share-based payments&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Foreign currency translation&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total other reserves&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;At 1 July 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,011,878&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;121,467&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,133,345&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Currency translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other comprehensive income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Transactions with owners in their capacity as owners&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transfer to share capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Options and warrants issued/expensed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options and warrants exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;16(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(213,722&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(213,722&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options and warrants forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(368,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(368,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;At 30 June 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,360,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;106,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,466,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfDetailedInformationOtherReserve>
    <ifrs-full:OtherReserves contextRef="c60" decimals="0" unitRef="aud">3139625</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c61" decimals="0" unitRef="aud">-43317</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c9" decimals="0" unitRef="aud">3096308</ifrs-full:OtherReserves>
    <imc:CurrencyTranslationDifferences contextRef="c63" decimals="0" unitRef="aud">61846</imc:CurrencyTranslationDifferences>
    <imc:CurrencyTranslationDifferences contextRef="c4" decimals="0" unitRef="aud">61846</imc:CurrencyTranslationDifferences>
    <ifrs-full:OtherComprehensiveIncome contextRef="c63" decimals="0" unitRef="aud">61846</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c4" decimals="0" unitRef="aud">61846</ifrs-full:OtherComprehensiveIncome>
    <imc:OptionsAndWarrantsIssuedexpensed contextRef="c62" decimals="0" unitRef="aud">1453900</imc:OptionsAndWarrantsIssuedexpensed>
    <imc:OptionsAndWarrantsIssuedexpensed contextRef="c4" decimals="0" unitRef="aud">1453900</imc:OptionsAndWarrantsIssuedexpensed>
    <imc:OptionsAndWarrantsExercised contextRef="c62" decimals="0" unitRef="aud">-100</imc:OptionsAndWarrantsExercised>
    <imc:OptionsAndWarrantsExercised contextRef="c4" decimals="0" unitRef="aud">-100</imc:OptionsAndWarrantsExercised>
    <imc:OptionsAndWarrantsLapsed contextRef="c62" decimals="0" unitRef="aud">-311635</imc:OptionsAndWarrantsLapsed>
    <imc:OptionsAndWarrantsLapsed contextRef="c4" decimals="0" unitRef="aud">-311635</imc:OptionsAndWarrantsLapsed>
    <ifrs-full:OtherReserves contextRef="c64" decimals="0" unitRef="aud">4281790</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c65" decimals="0" unitRef="aud">18529</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c16" decimals="0" unitRef="aud">4300319</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c64" decimals="0" unitRef="aud">4281790</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c65" decimals="0" unitRef="aud">18529</ifrs-full:OtherReserves>
    <imc:CurrencyTranslationDifferences contextRef="c67" decimals="0" unitRef="aud">102938</imc:CurrencyTranslationDifferences>
    <ifrs-full:OtherComprehensiveIncome contextRef="c67" decimals="0" unitRef="aud">102938</ifrs-full:OtherComprehensiveIncome>
    <imc:SharebasedPaymentExpenses contextRef="c66" decimals="0" unitRef="aud">73088</imc:SharebasedPaymentExpenses>
    <imc:OptionsAndWarrantsIssuedexpensed contextRef="c66" decimals="0" unitRef="aud">-484680</imc:OptionsAndWarrantsIssuedexpensed>
    <imc:OptionsAndWarrantsLapsed contextRef="c66" decimals="0" unitRef="aud">-2251320</imc:OptionsAndWarrantsLapsed>
    <imc:RevaluationOfOptionsIssuedInPriorPeriod contextRef="c66" decimals="0" unitRef="aud">-607000</imc:RevaluationOfOptionsIssuedInPriorPeriod>
    <ifrs-full:OtherReserves contextRef="c68" decimals="0" unitRef="aud">1011878</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c69" decimals="0" unitRef="aud">121467</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c68" decimals="0" unitRef="aud">1011878</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c69" decimals="0" unitRef="aud">121467</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c5" decimals="0" unitRef="aud">1133345</ifrs-full:OtherReserves>
    <imc:CurrencyTranslationDifferences contextRef="c71" decimals="0" unitRef="aud">-14953</imc:CurrencyTranslationDifferences>
    <imc:CurrencyTranslationDifferences contextRef="c0" decimals="0" unitRef="aud">-14953</imc:CurrencyTranslationDifferences>
    <ifrs-full:OtherComprehensiveIncome contextRef="c71" decimals="0" unitRef="aud">-14953</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="0" unitRef="aud">-14953</ifrs-full:OtherComprehensiveIncome>
    <imc:TransferToShareCapitalinDollars contextRef="c70" decimals="0" unitRef="aud">-73088</imc:TransferToShareCapitalinDollars>
    <imc:TransferToShareCapitalinDollars contextRef="c0" decimals="0" unitRef="aud">-73088</imc:TransferToShareCapitalinDollars>
    <imc:OptionsAndWarrantsIssuedexpensed contextRef="c70" decimals="0" unitRef="aud">3003060</imc:OptionsAndWarrantsIssuedexpensed>
    <imc:OptionsAndWarrantsIssuedexpensed contextRef="c0" decimals="0" unitRef="aud">3003060</imc:OptionsAndWarrantsIssuedexpensed>
    <imc:OptionsAndWarrantsExercised contextRef="c70" decimals="0" unitRef="aud">-213722</imc:OptionsAndWarrantsExercised>
    <imc:OptionsAndWarrantsExercised contextRef="c0" decimals="0" unitRef="aud">-213722</imc:OptionsAndWarrantsExercised>
    <imc:OptionsAndWarrantsForfeited contextRef="c70" decimals="0" unitRef="aud">-368000</imc:OptionsAndWarrantsForfeited>
    <imc:OptionsAndWarrantsForfeited contextRef="c0" decimals="0" unitRef="aud">-368000</imc:OptionsAndWarrantsForfeited>
    <ifrs-full:OtherReserves contextRef="c72" decimals="0" unitRef="aud">3360128</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c73" decimals="0" unitRef="aud">106514</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c2" decimals="0" unitRef="aud">3466642</ifrs-full:OtherReserves>
    <imc:DisclosureOfDetailedInformationMovementsInOptionsAndWarrants contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Details&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;br/&gt;
&#160;A$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2018&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;72,569,180&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3,139,625&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2018-07-13)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;204,100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2018-11-26)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;164,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of ESOP unlisted options at $0.50 (2018-10-01)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,050,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(98,385&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.50 (2019-02-11)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;975,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $0.57 (2019-02-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(185,601&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $1.892 (2019-02-28)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15,380&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,173&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unlisted options at $0.30 (2019-05-28)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(140,056&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,390&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify exercised options from reserves to share capital&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify lapsed options from reserves to accumulated losses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,086&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants (2019-05-23)&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;800,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;79,463,744&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4,281,790&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Re-valuation of options issued in prior period (2019-11-06)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(607,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants (2019-07-16)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;542,600&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55,454&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.50 (2019-11-27)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,625,532&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,086,920&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.55 (2019-11-30)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(25,289,894&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options at $0.50 (2020-06-30)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(164,400&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(218,800&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(72&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of representative warrants (2020-06-15, 2020-06-22)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,065,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(540,062&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;42,807,118&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;938,790&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of representative warrants (2020-07-2)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,640&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of ESOP unlisted options at $0.50 (2020-07-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15,700&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,048,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,012&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lapse of unexercised options (2020-09-25)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(368,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of representative warrants at US$23.44 per 40 options (2020-07-24)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,560,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,032,960&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of ESOP unlisted options at $0.12 (2020-10-29)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,970,100&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(900,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(197,010&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassify share-based payments expenses from reserves to share capital&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(73,088&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance at 30 June 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;45,309,478&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3,360,128&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfDetailedInformationMovementsInOptionsAndWarrants>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c9" decimals="0" unitRef="shares">72569180</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c9" decimals="0" unitRef="aud">3139625</imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption contextRef="c4" decimals="0" unitRef="shares">1300000</imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption>
    <imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOption contextRef="c4" decimals="0" unitRef="aud">204100</imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOption>
    <imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne contextRef="c4" decimals="0" unitRef="shares">2000000</imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne>
    <imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne contextRef="c4" decimals="0" unitRef="aud">164400</imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne>
    <imc:NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption contextRef="c4" decimals="0" unitRef="shares">-1050000</imc:NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption>
    <imc:ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption contextRef="c4" decimals="0" unitRef="aud">-98385</imc:ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption>
    <imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo contextRef="c4" decimals="0" unitRef="shares">5000000</imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo>
    <imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo contextRef="c4" decimals="0" unitRef="aud">975000</imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo>
    <imc:NumberOfSharesIssueLapseOfUnlistedOptionOne contextRef="c4" decimals="0" unitRef="shares">-1000000</imc:NumberOfSharesIssueLapseOfUnlistedOptionOne>
    <imc:NumberOfValueIssueLapseOfUnlistedOptionOne contextRef="c4" decimals="0" unitRef="aud">-185601</imc:NumberOfValueIssueLapseOfUnlistedOptionOne>
    <imc:NumberOfSharesIssueLapseOfUnlistedOptionTwo contextRef="c4" decimals="0" unitRef="shares">-15380</imc:NumberOfSharesIssueLapseOfUnlistedOptionTwo>
    <imc:NumberOfValueIssueLapseOfUnlistedOptionTwo contextRef="c4" decimals="0" unitRef="aud">-1173</imc:NumberOfValueIssueLapseOfUnlistedOptionTwo>
    <imc:NumberOfSharesIssueLapseOfUnlistedOptionThree contextRef="c4" decimals="0" unitRef="shares">-140056</imc:NumberOfSharesIssueLapseOfUnlistedOptionThree>
    <imc:NumberOfValueIssueLapseOfUnlistedOptionThree contextRef="c4" decimals="0" unitRef="aud">-13390</imc:NumberOfValueIssueLapseOfUnlistedOptionThree>
    <imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital contextRef="c4" decimals="0" unitRef="aud">-100</imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital>
    <imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses contextRef="c4" decimals="0" unitRef="aud">-13086</imc:NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses>
    <imc:IssueOfRepresentativeWarrantsSharesOne contextRef="c4" decimals="0" unitRef="shares">800000</imc:IssueOfRepresentativeWarrantsSharesOne>
    <imc:IssueOfRepresentativeWarrantsOne contextRef="c4" decimals="0" unitRef="aud">110400</imc:IssueOfRepresentativeWarrantsOne>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c16" decimals="0" unitRef="shares">79463744</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c16" decimals="0" unitRef="aud">4281790</imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:RevaluationOfOptionsIssuedInPriorPeriod contextRef="c3" decimals="0" unitRef="aud">-607000</imc:RevaluationOfOptionsIssuedInPriorPeriod>
    <imc:IssueOfRepresentativeWarrantsTwoShares contextRef="c3" decimals="0" unitRef="shares">542600</imc:IssueOfRepresentativeWarrantsTwoShares>
    <imc:IssueOfRepresentativeWarrantsTwo contextRef="c3" decimals="0" unitRef="aud">55454</imc:IssueOfRepresentativeWarrantsTwo>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFiveShares contextRef="c3" decimals="0" unitRef="shares">-7625532</imc:LapseOfUnexercisedOptionsAtZeroPointFiveShares>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFive contextRef="c3" decimals="0" unitRef="aud">-2086920</imc:LapseOfUnexercisedOptionsAtZeroPointFive>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares contextRef="c3" decimals="0" unitRef="shares">-25289894</imc:LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne contextRef="c3" decimals="0" unitRef="shares">-2000000</imc:LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFiveOne contextRef="c3" decimals="0" unitRef="aud">-164400</imc:LapseOfUnexercisedOptionsAtZeroPointFiveOne>
    <imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares contextRef="c3" decimals="0" unitRef="shares">-218800</imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares>
    <imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions contextRef="c3" decimals="0" unitRef="aud">-72</imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions>
    <imc:ExerciseOfRepresentativeWarrantsShares contextRef="c3" decimals="0" unitRef="shares">-2065000</imc:ExerciseOfRepresentativeWarrantsShares>
    <imc:ExerciseOfRepresentativeWarrants contextRef="c3" decimals="0" unitRef="aud">-540062</imc:ExerciseOfRepresentativeWarrants>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c5" decimals="0" unitRef="shares">42807118</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c5" decimals="0" unitRef="aud">938790</imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:ExerciseOfRepresentativeWarrantsSharesOne contextRef="c0" decimals="0" unitRef="shares">-9640</imc:ExerciseOfRepresentativeWarrantsSharesOne>
    <imc:ExerciseOfESOPUnlistedOptions contextRef="c0" decimals="0" unitRef="shares">-100000</imc:ExerciseOfESOPUnlistedOptions>
    <imc:ExerciseOfESOPUnlistedOptionsValue contextRef="c0" decimals="0" unitRef="aud">-15700</imc:ExerciseOfESOPUnlistedOptionsValue>
    <imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne contextRef="c0" decimals="0" unitRef="shares">-3048000</imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne>
    <imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne contextRef="c0" decimals="0" unitRef="aud">-1012</imc:ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne>
    <imc:LapseOfUnexercisedOptionsOne contextRef="c0" decimals="0" unitRef="shares">-5000000</imc:LapseOfUnexercisedOptionsOne>
    <imc:LapseOfUnexercisedOptionsValue contextRef="c0" decimals="0" unitRef="aud">-368000</imc:LapseOfUnexercisedOptionsValue>
    <imc:IssueOfRepresentativeWarrantsThreeShares contextRef="c0" decimals="0" unitRef="shares">2560000</imc:IssueOfRepresentativeWarrantsThreeShares>
    <imc:IssueOfRepresentativeWarrantsThree contextRef="c0" decimals="0" unitRef="aud">1032960</imc:IssueOfRepresentativeWarrantsThree>
    <imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree contextRef="c0" decimals="0" unitRef="shares">9000000</imc:NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree>
    <imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree contextRef="c0" decimals="0" unitRef="aud">1970100</imc:ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree>
    <imc:CashlessExerciseOfESOPUnlistedOptions contextRef="c0" decimals="0" unitRef="shares">-900000</imc:CashlessExerciseOfESOPUnlistedOptions>
    <imc:CashlessExerciseOfESOPUnlistedOptionsValue contextRef="c0" decimals="0" unitRef="aud">-197010</imc:CashlessExerciseOfESOPUnlistedOptionsValue>
    <imc:ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue contextRef="c0" decimals="0" unitRef="aud">-73088</imc:ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c2" decimals="0" unitRef="shares">45309478</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="c2" decimals="0" unitRef="aud">3360128</imc:ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <imc:OtherReserveMaturityDateDescription contextRef="c54">Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021.</imc:OtherReserveMaturityDateDescription>
    <imc:NumberOfSharesUnlistedOption contextRef="c54" decimals="0" unitRef="shares">1000000</imc:NumberOfSharesUnlistedOption>
    <imc:UnlistedOptionExercisable contextRef="c54" decimals="2" unitRef="usdPershares">0.5</imc:UnlistedOptionExercisable>
    <imc:OtherReserveMaturityDateDescription contextRef="c55">On 26 November 2018, the Company issued Mr. Richard
J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021.</imc:OtherReserveMaturityDateDescription>
    <imc:NumberOfSharesUnlistedOption contextRef="c55" decimals="0" unitRef="shares">2000000</imc:NumberOfSharesUnlistedOption>
    <imc:UnlistedOptionExercisable contextRef="c55" decimals="2" unitRef="usdPershares">0.5</imc:UnlistedOptionExercisable>
    <imc:NumberOfSharesUnlistedOption contextRef="c56" decimals="0" unitRef="shares">5000000</imc:NumberOfSharesUnlistedOption>
    <imc:UnlistedOptionExercisable contextRef="c56" decimals="2" unitRef="usdPershares">0.5</imc:UnlistedOptionExercisable>
    <imc:ESOPOptionsIssued contextRef="c57" decimals="0" unitRef="usd">9000000</imc:ESOPOptionsIssued>
    <imc:OptionsGranted contextRef="c58" decimals="0" unitRef="usd">975000</imc:OptionsGranted>
    <imc:RevaluedAtGrantDate contextRef="c58">In line with IFRS 2, these were re-measured at grant date
6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.</imc:RevaluedAtGrantDate>
    <imc:RevaluationOfShareholdersApprovedValue contextRef="c58" decimals="0" unitRef="usd">368000</imc:RevaluationOfShareholdersApprovedValue>
    <imc:RevaluationFinancialsAmount contextRef="c59" decimals="0" unitRef="usd">607000</imc:RevaluationFinancialsAmount>
    <imc:ExpenseOfSharesOwed contextRef="c2" decimals="0" unitRef="aud">73088</imc:ExpenseOfSharesOwed>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 17. Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Description of segments and principal activities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group has identified its operating segments
based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the
allocation of resources.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management considers the business from both a
product and a geographic perspective and has identified two reportable segments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development (R&amp;amp;D): income and
expenses directly attributable to the group&#x2019;s R&amp;amp;D projects performed in Australia, Israel and United States.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Hyperimmune products: income and expenses directly
attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Financial breakdown&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The segment information for the reportable segments
for the year ended June 30, 2021 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;94,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;94,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;617,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(759,765&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(582,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,342,293&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,978,679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,978,679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,116,013&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,116,013&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,367,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,367,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(936,024&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(928,264&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(6,515,620&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(8,379,908&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,761&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,761&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(936,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(928,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(6,520,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,587,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,159,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,053,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,587,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,159,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;27,053,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;284,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;629,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,158,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;243,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;284,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;629,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,158,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The segment information for the reportable segments
for the year ended June 30, 2020 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(688,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(688,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,829,730&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,829,730&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;473,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,170,078&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,170,078&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,178,685&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,178,685&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(870,460&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;968,724&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(3,003,839&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(2,905,575&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(870,460&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;968,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(3,025,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,539,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,354,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,202,163&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,539,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,354,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,202,163&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;426,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;558,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;30,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;426,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;558,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The segment information for the reportable segments
for the year ended June 30, 2019 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(667,371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(667,371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,720,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,720,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,037,806&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,037,806&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,044,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,044,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(513,523&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;843,062&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,985,999&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,656,460&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(513,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;843,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,985,960&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,656,421&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;531,828&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,705,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,324,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,561,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;531,828&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,705,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,324,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;8,561,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;221,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;797,155&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,210,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;221,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;191,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;797,155&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,210,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Information on geographical regions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group derives revenue from the transfer of
hyperimmune products at a point in time in the following major product lines and geographical regions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hyperimmune
    products revenue&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,308&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,639&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;50,181&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,308&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,639&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;50,181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;1.&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Returns are provided where outlined in a customer&#x2019;s agreement.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,240,393&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;926,325&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;301,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;49,933&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,240,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;926,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;301,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;49,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Segment revenue&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,162,628&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,016,468&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;149,283&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;58,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,162,628&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,016,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;149,283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,683&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Information on major customers:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended June 30, 2021, 2020 and
2019, the Company had the following major customers in the hyperimmune product segment with revenues amounting to 10 percent or more
of total group revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;41,040&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,563&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer C&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;25,319&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer D&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,214&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;462,490&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer E&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;22,886&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer F&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;442,916&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer G&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;438,065&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer H&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;327,559&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Customer I&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;140,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,898,982&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,015,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <imc:NumberOfSegment contextRef="c2" decimals="0" unitRef="pure">2</imc:NumberOfSegment>
    <imc:DisclosuresOfProductsAndServicesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;94,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;94,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;617,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(759,765&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(582,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,342,293&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,978,679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,978,679&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,116,013&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,116,013&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,367,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,367,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(287,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(936,024&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(928,264&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(6,515,620&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(8,379,908&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,761&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,761&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(936,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(928,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(6,520,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,587,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,159,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,053,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;306,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,587,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;25,159,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;27,053,106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;284,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;629,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,158,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;243,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;284,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;629,827&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,158,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(688,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(688,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,829,730&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,829,730&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;473,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,170,078&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,170,078&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,178,685&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,178,685&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(870,460&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;968,724&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(3,003,839&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(2,905,575&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(870,460&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;968,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(3,025,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,539,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,354,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,202,163&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,539,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,354,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,202,163&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;426,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;558,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;30,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;426,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;558,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Research and development&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Hyperimmune products&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales of goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(667,371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(667,371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,720,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,720,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other gains/(losses) &#x2013; net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,037,806&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,037,806&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,044,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,044,528&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(864,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating profit/(loss)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(513,523&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;843,062&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,985,999&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,656,460&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Profit/(loss) for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(513,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;843,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,985,960&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,656,421&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;531,828&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,705,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,324,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,561,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;531,828&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,705,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,324,489&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;8,561,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Segment liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;221,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;797,155&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,210,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;221,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;191,836&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;797,155&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,210,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosuresOfProductsAndServicesExplanatory>
    <imc:HyperimmuneProductsRevenue contextRef="c75" decimals="0" unitRef="aud">145776</imc:HyperimmuneProductsRevenue>
    <imc:HyperimmuneProductsRevenue contextRef="c0" decimals="0" unitRef="aud">145776</imc:HyperimmuneProductsRevenue>
    <ifrs-full:CostOfSales contextRef="c75" decimals="0" unitRef="aud">51071</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c0" decimals="0" unitRef="aud">51071</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c75" decimals="0" unitRef="aud">94705</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c0" decimals="0" unitRef="aud">94705</ifrs-full:GrossProfit>
    <ifrs-full:OtherIncome contextRef="c74" decimals="0" unitRef="aud">431030</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c75" decimals="0" unitRef="aud">24480</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c76" decimals="0" unitRef="aud">161600</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" unitRef="aud">617110</ifrs-full:OtherIncome>
    <ifrs-full:OtherGainsLosses contextRef="c75" decimals="0" unitRef="aud">-759765</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c76" decimals="0" unitRef="aud">-582528</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c0" decimals="0" unitRef="aud">-1342293</ifrs-full:OtherGainsLosses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c76" decimals="0" unitRef="aud">3978679</imc:GeneralAndAdministrativeExpenses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c0" decimals="0" unitRef="aud">3978679</imc:GeneralAndAdministrativeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c76" decimals="0" unitRef="aud">-2116013</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c0" decimals="0" unitRef="aud">-2116013</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c74" decimals="0" unitRef="aud">1367054</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="aud">1367054</ifrs-full:ResearchAndDevelopmentExpense>
    <imc:SellingAndMarketingExpenses contextRef="c75" decimals="0" unitRef="aud">-287684</imc:SellingAndMarketingExpenses>
    <imc:SellingAndMarketingExpenses contextRef="c0" decimals="0" unitRef="aud">-287684</imc:SellingAndMarketingExpenses>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c74" decimals="0" unitRef="aud">-936024</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c75" decimals="0" unitRef="aud">-928264</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c76" decimals="0" unitRef="aud">-6515620</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="0" unitRef="aud">-8379908</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c76" decimals="0" unitRef="aud">9204</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="0" unitRef="aud">9204</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c76" decimals="0" unitRef="aud">13761</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="0" unitRef="aud">13761</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c74" decimals="0" unitRef="aud">-936024</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c75" decimals="0" unitRef="aud">-928264</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c76" decimals="0" unitRef="aud">-6520177</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <imc:SegmentAssets contextRef="c77" decimals="0" unitRef="aud">306154</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c78" decimals="0" unitRef="aud">1587672</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c79" decimals="0" unitRef="aud">25159280</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c2" decimals="0" unitRef="aud">27053106</imc:SegmentAssets>
    <ifrs-full:Assets contextRef="c77" decimals="0" unitRef="aud">306154</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c78" decimals="0" unitRef="aud">1587672</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c79" decimals="0" unitRef="aud">25159280</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c2" decimals="0" unitRef="aud">27053106</ifrs-full:Assets>
    <imc:SegmentLiabilities contextRef="c77" decimals="0" unitRef="aud">-243565</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c78" decimals="0" unitRef="aud">-284657</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c79" decimals="0" unitRef="aud">-629827</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c2" decimals="0" unitRef="aud">-1158049</imc:SegmentLiabilities>
    <ifrs-full:Liabilities contextRef="c77" decimals="0" unitRef="aud">243565</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c78" decimals="0" unitRef="aud">284657</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c79" decimals="0" unitRef="aud">629827</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c2" decimals="0" unitRef="aud">1158049</ifrs-full:Liabilities>
    <imc:HyperimmuneProductsRevenue contextRef="c81" decimals="0" unitRef="aud">2518566</imc:HyperimmuneProductsRevenue>
    <imc:HyperimmuneProductsRevenue contextRef="c3" decimals="0" unitRef="aud">2518566</imc:HyperimmuneProductsRevenue>
    <ifrs-full:CostOfSales contextRef="c81" decimals="0" unitRef="aud">688836</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c3" decimals="0" unitRef="aud">688836</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c81" decimals="0" unitRef="aud">1829730</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c3" decimals="0" unitRef="aud">1829730</ifrs-full:GrossProfit>
    <ifrs-full:OtherIncome contextRef="c80" decimals="0" unitRef="aud">308225</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c81" decimals="0" unitRef="aud">10545</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c82" decimals="0" unitRef="aud">154904</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c3" decimals="0" unitRef="aud">473674</ifrs-full:OtherIncome>
    <ifrs-full:OtherGainsLosses contextRef="c82" decimals="0" unitRef="aud">11335</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c3" decimals="0" unitRef="aud">11335</ifrs-full:OtherGainsLosses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c82" decimals="0" unitRef="aud">3170078</imc:GeneralAndAdministrativeExpenses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c3" decimals="0" unitRef="aud">3170078</imc:GeneralAndAdministrativeExpenses>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c80" decimals="0" unitRef="aud">1178685</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" unitRef="aud">1178685</ifrs-full:ResearchAndDevelopmentExpense>
    <imc:SellingAndMarketingExpenses contextRef="c81" decimals="0" unitRef="aud">-871551</imc:SellingAndMarketingExpenses>
    <imc:SellingAndMarketingExpenses contextRef="c3" decimals="0" unitRef="aud">-871551</imc:SellingAndMarketingExpenses>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c80" decimals="0" unitRef="aud">-870460</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c81" decimals="0" unitRef="aud">968724</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c82" decimals="0" unitRef="aud">-3003839</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c3" decimals="0" unitRef="aud">-2905575</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c82" decimals="0" unitRef="aud">21631</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c3" decimals="0" unitRef="aud">21631</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c80" decimals="0" unitRef="aud">-870460</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c81" decimals="0" unitRef="aud">968724</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c82" decimals="0" unitRef="aud">-3025470</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <imc:SegmentAssets contextRef="c83" decimals="0" unitRef="aud">308225</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c84" decimals="0" unitRef="aud">2539503</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c85" decimals="0" unitRef="aud">3354435</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c5" decimals="0" unitRef="aud">6202163</imc:SegmentAssets>
    <ifrs-full:Assets contextRef="c83" decimals="0" unitRef="aud">308225</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c84" decimals="0" unitRef="aud">2539503</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c85" decimals="0" unitRef="aud">3354435</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="0" unitRef="aud">6202163</ifrs-full:Assets>
    <imc:SegmentLiabilities contextRef="c83" decimals="0" unitRef="aud">-101092</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c84" decimals="0" unitRef="aud">-30377</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c85" decimals="0" unitRef="aud">-426781</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c5" decimals="0" unitRef="aud">-558250</imc:SegmentLiabilities>
    <ifrs-full:Liabilities contextRef="c83" decimals="0" unitRef="aud">101092</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c84" decimals="0" unitRef="aud">30377</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c85" decimals="0" unitRef="aud">426781</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c5" decimals="0" unitRef="aud">558250</ifrs-full:Liabilities>
    <imc:HyperimmuneProductsRevenue contextRef="c87" decimals="0" unitRef="aud">2387426</imc:HyperimmuneProductsRevenue>
    <imc:HyperimmuneProductsRevenue contextRef="c4" decimals="0" unitRef="aud">2387426</imc:HyperimmuneProductsRevenue>
    <ifrs-full:CostOfSales contextRef="c87" decimals="0" unitRef="aud">667371</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="0" unitRef="aud">667371</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c87" decimals="0" unitRef="aud">1720055</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c4" decimals="0" unitRef="aud">1720055</ifrs-full:GrossProfit>
    <ifrs-full:OtherIncome contextRef="c86" decimals="0" unitRef="aud">531005</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c87" decimals="0" unitRef="aud">1045</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c4" decimals="0" unitRef="aud">532050</ifrs-full:OtherIncome>
    <ifrs-full:OtherGainsLosses contextRef="c87" decimals="0" unitRef="aud">-13394</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c88" decimals="0" unitRef="aud">51807</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c4" decimals="0" unitRef="aud">38413</ifrs-full:OtherGainsLosses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c88" decimals="0" unitRef="aud">5037806</imc:GeneralAndAdministrativeExpenses>
    <imc:GeneralAndAdministrativeExpenses contextRef="c4" decimals="0" unitRef="aud">5037806</imc:GeneralAndAdministrativeExpenses>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c86" decimals="0" unitRef="aud">1044528</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="aud">1044528</ifrs-full:ResearchAndDevelopmentExpense>
    <imc:SellingAndMarketingExpenses contextRef="c87" decimals="0" unitRef="aud">-864644</imc:SellingAndMarketingExpenses>
    <imc:SellingAndMarketingExpenses contextRef="c4" decimals="0" unitRef="aud">-864644</imc:SellingAndMarketingExpenses>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c86" decimals="0" unitRef="aud">-513523</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c87" decimals="0" unitRef="aud">843062</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c88" decimals="0" unitRef="aud">-4985999</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="0" unitRef="aud">-4656460</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c88" decimals="0" unitRef="aud">39</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="0" unitRef="aud">39</ifrs-full:FinanceIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c86" decimals="0" unitRef="aud">-513523</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c87" decimals="0" unitRef="aud">843062</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c88" decimals="0" unitRef="aud">-4985960</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c4" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <imc:SegmentAssets contextRef="c89" decimals="0" unitRef="aud">531828</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c90" decimals="0" unitRef="aud">2705330</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c91" decimals="0" unitRef="aud">5324489</imc:SegmentAssets>
    <imc:SegmentAssets contextRef="c16" decimals="0" unitRef="aud">8561647</imc:SegmentAssets>
    <ifrs-full:Assets contextRef="c89" decimals="0" unitRef="aud">531828</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c90" decimals="0" unitRef="aud">2705330</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c91" decimals="0" unitRef="aud">5324489</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c16" decimals="0" unitRef="aud">8561647</ifrs-full:Assets>
    <imc:SegmentLiabilities contextRef="c89" decimals="0" unitRef="aud">-221520</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c90" decimals="0" unitRef="aud">-191836</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c91" decimals="0" unitRef="aud">-797155</imc:SegmentLiabilities>
    <imc:SegmentLiabilities contextRef="c16" decimals="0" unitRef="aud">-1210511</imc:SegmentLiabilities>
    <ifrs-full:Liabilities contextRef="c89" decimals="0" unitRef="aud">221520</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c90" decimals="0" unitRef="aud">191836</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c91" decimals="0" unitRef="aud">797155</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c16" decimals="0" unitRef="aud">1210511</ifrs-full:Liabilities>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hyperimmune
    products revenue&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,308&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,639&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;50,181&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,308&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;101,639&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;50,181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Hyperimmune products revenue&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,240,393&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;926,325&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;301,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;49,933&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,240,393&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;926,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;301,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;49,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,518,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Travelan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Protectyn&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;United States&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Australia&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Segment revenue&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,162,628&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,016,468&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;149,283&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;58,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,162,628&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,016,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;149,283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,683&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,387,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:Revenue contextRef="c92" decimals="0" id="ix_19_fact" unitRef="aud">-10308</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c93" decimals="0" id="ix_20_fact" unitRef="aud">4264</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c94" decimals="0" id="ix_21_fact" unitRef="aud">101639</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c95" decimals="0" id="ix_22_fact" unitRef="aud">50181</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c0" decimals="0" id="ix_23_fact" unitRef="aud">145776</ifrs-full:Revenue>
    <imc:RevenueFromExternalCustomers contextRef="c92" decimals="0" unitRef="aud">-10308</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c93" decimals="0" unitRef="aud">4264</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c94" decimals="0" unitRef="aud">101639</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c95" decimals="0" unitRef="aud">50181</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c0" decimals="0" unitRef="aud">145776</imc:RevenueFromExternalCustomers>
    <ifrs-full:Revenue contextRef="c97" decimals="0" unitRef="aud">1240393</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c98" decimals="0" unitRef="aud">926325</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c99" decimals="0" unitRef="aud">301915</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c100" decimals="0" unitRef="aud">49933</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c3" decimals="0" unitRef="aud">2518566</ifrs-full:Revenue>
    <imc:RevenueFromExternalCustomers contextRef="c97" decimals="0" unitRef="aud">1240393</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c98" decimals="0" unitRef="aud">926325</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c99" decimals="0" unitRef="aud">301915</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c100" decimals="0" unitRef="aud">49933</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c3" decimals="0" unitRef="aud">2518566</imc:RevenueFromExternalCustomers>
    <imc:SegmentRevenue contextRef="c102" decimals="0" unitRef="aud">1162628</imc:SegmentRevenue>
    <imc:SegmentRevenue contextRef="c103" decimals="0" unitRef="aud">1016468</imc:SegmentRevenue>
    <imc:SegmentRevenue contextRef="c104" decimals="0" unitRef="aud">149283</imc:SegmentRevenue>
    <imc:SegmentRevenue contextRef="c105" decimals="0" unitRef="aud">58683</imc:SegmentRevenue>
    <imc:SegmentRevenue contextRef="c106" decimals="0" unitRef="aud">364</imc:SegmentRevenue>
    <imc:SegmentRevenue contextRef="c4" decimals="0" unitRef="aud">2387426</imc:SegmentRevenue>
    <imc:RevenueFromExternalCustomers contextRef="c102" decimals="0" unitRef="aud">1162628</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c103" decimals="0" unitRef="aud">1016468</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c104" decimals="0" unitRef="aud">149283</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c105" decimals="0" unitRef="aud">58683</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c106" decimals="0" unitRef="aud">364</imc:RevenueFromExternalCustomers>
    <imc:RevenueFromExternalCustomers contextRef="c4" decimals="0" unitRef="aud">2387426</imc:RevenueFromExternalCustomers>
    <imc:PercentageOfEntityRevenue contextRef="c0" decimals="2" unitRef="pure">0.10</imc:PercentageOfEntityRevenue>
    <imc:PercentageOfEntityRevenue contextRef="c3" decimals="2" unitRef="pure">0.10</imc:PercentageOfEntityRevenue>
    <imc:PercentageOfEntityRevenue contextRef="c4" decimals="2" unitRef="pure">0.10</imc:PercentageOfEntityRevenue>
    <ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;41,040&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,563&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer C&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;25,319&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer D&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,214&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;462,490&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer E&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;22,886&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer F&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;442,916&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer G&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;438,065&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Customer H&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;327,559&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Customer I&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;227,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;140,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,898,982&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,015,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory>
    <imc:RevenueFormContractWithCustomer contextRef="c107" decimals="0" unitRef="aud">41040</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c110" decimals="0" unitRef="aud">27563</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c113" decimals="0" unitRef="aud">25319</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c116" decimals="0" unitRef="aud">23214</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c117" decimals="0" unitRef="aud">462490</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c118" decimals="0" unitRef="aud">611920</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c119" decimals="0" unitRef="aud">22886</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c123" decimals="0" unitRef="aud">442916</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c124" decimals="0" unitRef="aud">228661</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c126" decimals="0" unitRef="aud">438065</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c127" decimals="0" unitRef="aud">659637</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c129" decimals="0" unitRef="aud">327559</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c130" decimals="0" unitRef="aud">266111</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c132" decimals="0" unitRef="aud">227952</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c133" decimals="0" unitRef="aud">249522</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c0" decimals="0" unitRef="aud">140022</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c3" decimals="0" unitRef="aud">1898982</imc:RevenueFormContractWithCustomer>
    <imc:RevenueFormContractWithCustomer contextRef="c4" decimals="0" unitRef="aud">2015851</imc:RevenueFormContractWithCustomer>
    <imc:DisclosureOfCashFlowInformationExplanatoryTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 18. Cash Flow Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reconciliation of cash
    flow from operations with loss after income tax&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2019&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold; text-align: justify"&gt;Net Loss for the Year&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,656,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Adjustments for&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;43,662&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Distribution costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Expected credit losses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,991&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Finance costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;13,761&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Finance income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(9,204&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Leave provision expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;53,610&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Share-based payments (income)/expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,116,013&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(533,912&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Unrealized net foreign currency gains&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;592,243&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,883&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(62,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Change in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add decrease in trade and other receivables&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,037&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;680,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add (increase) / decrease in inventories&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;960,920&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,635&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add (increase) / decrease in other operating assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(45,065&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Add (decrease) / increase in trade and other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;586,796&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(362,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;426,271&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,078,747&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,147,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,798,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-cash financing and
    investing activities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;See note 19 for details regarding issues of options
to employees and for details surrounding the issue of shares to suppliers.&lt;/p&gt;</imc:DisclosureOfCashFlowInformationExplanatoryTextBlock>
    <imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2021&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;30 June&lt;br/&gt; 2019&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-weight: bold; text-align: justify"&gt;Net Loss for the Year&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;(8,384,465&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,927,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,656,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Adjustments for&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Depreciation expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;43,662&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Distribution costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Expected credit losses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,991&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Finance costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;13,761&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Finance income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(9,204&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Leave provision expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;53,610&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Share-based payments (income)/expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,116,013&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(533,912&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Unrealized net foreign currency gains&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;592,243&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,883&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(62,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Change in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add decrease in trade and other receivables&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,037&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;680,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add (increase) / decrease in inventories&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;960,920&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,635&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Add (increase) / decrease in other operating assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(45,065&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Add (decrease) / increase in trade and other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;586,796&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(362,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;426,271&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(4,078,747&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,147,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,798,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" unitRef="aud">-8384465</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" unitRef="aud">-2927206</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" unitRef="aud">-4656421</ifrs-full:ProfitLoss>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c0" decimals="0" unitRef="aud">43662</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c3" decimals="0" unitRef="aud">44056</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c4" decimals="0" unitRef="aud">5287</ifrs-full:DepreciationAndAmortisationExpense>
    <imc:AdjustmentsForDistributionCosts contextRef="c3" decimals="0" unitRef="aud">70000</imc:AdjustmentsForDistributionCosts>
    <imc:AdjustmentsForDistributionCosts contextRef="c4" decimals="0" unitRef="aud">70000</imc:AdjustmentsForDistributionCosts>
    <imc:ExpectedCreditLosses contextRef="c0" decimals="0" unitRef="aud">-30055</imc:ExpectedCreditLosses>
    <imc:ExpectedCreditLosses contextRef="c3" decimals="0" unitRef="aud">-3991</imc:ExpectedCreditLosses>
    <imc:ExpectedCreditLosses contextRef="c4" decimals="0" unitRef="aud">34046</imc:ExpectedCreditLosses>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c0" decimals="0" unitRef="aud">13761</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c3" decimals="0" unitRef="aud">21631</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c0" decimals="0" unitRef="aud">9204</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c4" decimals="0" unitRef="aud">39</ifrs-full:AdjustmentsForFinanceIncome>
    <imc:LeaveProvisionExpense contextRef="c0" decimals="0" unitRef="aud">53610</imc:LeaveProvisionExpense>
    <imc:LeaveProvisionExpense contextRef="c3" decimals="0" unitRef="aud">19717</imc:LeaveProvisionExpense>
    <imc:LeaveProvisionExpense contextRef="c4" decimals="0" unitRef="aud">4580</imc:LeaveProvisionExpense>
    <imc:ShareBasedPaymentsExpense contextRef="c0" decimals="0" unitRef="aud">2116013</imc:ShareBasedPaymentsExpense>
    <imc:ShareBasedPaymentsExpense contextRef="c3" decimals="0" unitRef="aud">-533912</imc:ShareBasedPaymentsExpense>
    <imc:ShareBasedPaymentsExpense contextRef="c4" decimals="0" unitRef="aud">1343500</imc:ShareBasedPaymentsExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c0" decimals="0" unitRef="aud">592243</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c3" decimals="0" unitRef="aud">-18883</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c4" decimals="0" unitRef="aud">-62015</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c0" decimals="0" unitRef="aud">23037</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c3" decimals="0" unitRef="aud">641236</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c4" decimals="0" unitRef="aud">680337</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="0" unitRef="aud">960920</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c3" decimals="0" unitRef="aud">-113635</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c4" decimals="0" unitRef="aud">263365</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c0" decimals="0" unitRef="aud">-45065</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c3" decimals="0" unitRef="aud">16096</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c4" decimals="0" unitRef="aud">92510</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="0" unitRef="aud">586796</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c3" decimals="0" unitRef="aud">-362437</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="0" unitRef="aud">426271</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="aud">-4078747</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c3" decimals="0" unitRef="aud">-3147328</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="aud">-1798579</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c3">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 19. Share-based Payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Executive share and
    option plan&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The establishment of the &#x2018;executive share
and option plan&#x2019; (ESOP) was approved by shareholders at the 2017 annual general meeting. The plan is designed to provide long-term
incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board&#x2019;s
discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued to Dr Gary Jacob expire within
6 months upon his resignation without good reason or termination. All other options issued expire upon departure from the company if
they are determined to be a &#x2018;bad leaver&#x2019;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Set out below are summaries of all listed and
unlisted options, including those issued under ESOP:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;As at 1 July&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,569,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted during the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;11,560,000&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;542,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised during the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.23&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,057,640&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/lapsed during the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(36,774,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,205,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;As at 30 June&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Vested and exercisable at 30 June&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Share options outstanding at the end of the year
have the following expiry date and exercise prices:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry&lt;br/&gt; date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;Grant date&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(A$ unless stated otherwise)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;30 June&lt;br/&gt;
 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;2012-06-29&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2021-11-30&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.944&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2012-06-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-01-17&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2017-06-13 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-06-13&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,493,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,541,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,897,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,897,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2017-06-09 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-06-08&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.3125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.585&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2019-05-23 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-05-23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2019-07-16 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-07-16&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2018-07-13&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2021-07-01&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2019-11-06&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-02-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2020-10-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-04-14&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;2020-07-24 (warrants)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2025-07-21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.5859&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,560,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted average remaining contractual life of options outstanding at end of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;i&gt;Fair value of options granted&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The model inputs for options granted under ESOP
during the year ended June 30, 2021 included:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Expiry date&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise price &lt;br/&gt;
(A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected volatility&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend yield&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free interest rate&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
 at grant&lt;br/&gt;
 date per&lt;br/&gt;
 option
    &lt;br/&gt;
(A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%"&gt;2020-07-24&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2025-07-21&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,560,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.4035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2020-10-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-04-14&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,560,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The model inputs for options granted under ESOP
during the year ended June 30, 2020 included:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
    price&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of&lt;br/&gt;
    options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
    volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt;
    yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free&lt;br/&gt;
    interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
    at grant&lt;br/&gt;
    date per&lt;br/&gt;
    option&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;2019-11-06&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;2024-02-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%"&gt;5,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.0736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The model inputs for options granted under ESOP
during the year ended June 30, 2019 included:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
    price&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of&lt;br/&gt;
    options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
    volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt;
    yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free&lt;br/&gt;
    interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
    at grant&lt;br/&gt;
    date per&lt;br/&gt;
    option&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;2018-07-13&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;2021-07-01&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.1570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-11-26&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2020-06-30&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0822&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2019-02-11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2024-02-11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.69&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;8,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The expected life of the options is based on
historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption
that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expenses arising from
    share-based payment transactions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total expenses arising from share-based payment
transactions recognized during the period were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;sup&gt;1&lt;/sup&gt;&lt;br/&gt;
    A$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Options issued under ESOP&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,970,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payments to directors&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,116,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(533,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;1.&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Options granted to a former managing director on 11 February 2019 and
valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at
grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June
2020 financials.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;2.&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <imc:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory contextRef="c134">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Average exercise price per share
    option (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;As at 1 July&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,569,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted during the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;11,560,000&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;542,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised during the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.23&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(4,057,640&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/lapsed during the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(36,774,386&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,205,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;As at 30 June&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Vested and exercisable at 30 June&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,463,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c5" decimals="2" unitRef="audPershares">0.4</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c5" decimals="0" unitRef="shares">42807118</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c16" decimals="2" unitRef="audPershares">0.46</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c16" decimals="0" unitRef="shares">79463744</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c9" decimals="2" unitRef="audPershares">0.45</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c9" decimals="0" unitRef="shares">72569180</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1 contextRef="c0" decimals="2" unitRef="audPershares">0.28</imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement contextRef="c0" decimals="0" unitRef="shares">11560000</imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1 contextRef="c3" decimals="2" unitRef="audPershares">0.18</imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement contextRef="c3" decimals="0" unitRef="shares">542600</imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1 contextRef="c4" decimals="2" unitRef="audPershares">0.47</imc:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement contextRef="c4" decimals="0" unitRef="shares">9100000</imc:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1 contextRef="c0" decimals="2" unitRef="audPershares">0.23</imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement contextRef="c0" decimals="0" unitRef="shares">-4057640</imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1 contextRef="c3" decimals="2" unitRef="audPershares">0.18</imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement contextRef="c3" decimals="0" unitRef="shares">-424840</imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1 contextRef="c0" decimals="2" unitRef="audPershares">0.5</imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement contextRef="c0" decimals="0" unitRef="shares">-5000000</imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1 contextRef="c3" decimals="2" unitRef="audPershares">0.52</imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement contextRef="c3" decimals="0" unitRef="shares">-36774386</imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1 contextRef="c4" decimals="2" unitRef="audPershares">0.53</imc:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement contextRef="c4" decimals="0" unitRef="shares">-2205436</imc:NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c2" decimals="2" unitRef="audPershares">0.31</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c2" decimals="0" unitRef="shares">45309478</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c5" decimals="2" unitRef="audPershares">0.4</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c5" decimals="0" unitRef="shares">42807118</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1 contextRef="c16" decimals="2" unitRef="audPershares">0.46</imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1>
    <imc:NumberOfOutstandingShareOption contextRef="c16" decimals="0" unitRef="shares">79463744</imc:NumberOfOutstandingShareOption>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1 contextRef="c0" decimals="2" unitRef="audPershares">0.31</imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement contextRef="c2" decimals="0" unitRef="shares">45309478</imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1 contextRef="c3" decimals="2" unitRef="audPershares">0.4</imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement contextRef="c5" decimals="0" unitRef="shares">42807118</imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1 contextRef="c4" decimals="2" unitRef="audPershares">0.46</imc:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1>
    <imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement contextRef="c16" decimals="0" unitRef="shares">79463744</imc:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <imc:ScheduleOfDeemedValuationOfOptionsExplanatory contextRef="c3">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry&lt;br/&gt; date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;Grant date&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(A$ unless stated otherwise)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;30 June&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;30 June&lt;br/&gt;
 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;2012-06-29&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2021-11-30&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.944&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2012-06-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-01-17&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2017-06-13 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-06-13&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,493,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,541,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,897,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,897,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2017-06-09 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2022-06-08&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.3125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023-03-15&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.585&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,510&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2019-05-23 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-05-23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2019-07-16 (warrants)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-07-16&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.125&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2018-07-13&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2021-07-01&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2019-11-06&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-02-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2020-10-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-04-14&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;2020-07-24 (warrants)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2025-07-21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD 0.5859&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,560,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,309,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,807,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Weighted average remaining contractual life of options outstanding at end of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:ScheduleOfDeemedValuationOfOptionsExplanatory>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c135">2021-11-30</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c135">1.944</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c135" decimals="0" unitRef="shares">14493</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c136" decimals="0" unitRef="shares">14493</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c137">2022-01-17</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c137">1.876</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c137" decimals="0" unitRef="shares">29668</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c138" decimals="0" unitRef="shares">29668</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c139">2022-06-13</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c139">USD 0.25</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c139" decimals="0" unitRef="shares">24493200</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c140" decimals="0" unitRef="shares">27541200</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c141">2023-03-15</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c141">0.468</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c141" decimals="0" unitRef="shares">7897647</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c142" decimals="0" unitRef="shares">7897647</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c143">2022-06-08</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c143">USD 0.3125</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c143" decimals="0" unitRef="shares">198240</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c144" decimals="0" unitRef="shares">198240</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c145">2023-03-15</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c145">0.585</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c145" decimals="0" unitRef="shares">526510</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c146" decimals="0" unitRef="shares">526510</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c147">2024-05-23</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c147">USD 0.125</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c147" decimals="0" unitRef="shares">173600</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c148" decimals="0" unitRef="shares">181600</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c149">2024-07-16</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c149">USD 0.125</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c149" decimals="0" unitRef="shares">116120</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c150" decimals="0" unitRef="shares">117760</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c151">2021-07-01</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c151">0.500</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c151" decimals="0" unitRef="shares">1200000</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c152" decimals="0" unitRef="shares">1300000</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c153">2024-02-10</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c153">0.500</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c154" decimals="0" unitRef="shares">5000000</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c155">2024-04-14</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c155">0.12</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c155" decimals="0" unitRef="shares">8100000</imc:ShareOptionsOutstanding>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c157">2025-07-21</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePrice contextRef="c157">USD 0.5859</imc:ExercisePrice>
    <imc:ShareOptionsOutstanding contextRef="c157" decimals="0" unitRef="shares">2560000</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c0" decimals="0" unitRef="shares">45309478</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsOutstanding contextRef="c3" decimals="0" unitRef="shares">42807118</imc:ShareOptionsOutstanding>
    <imc:ShareOptionsPerShare contextRef="c0" decimals="2" unitRef="usdPershares">1.58</imc:ShareOptionsPerShare>
    <imc:ShareOptionsPerShare contextRef="c3" decimals="2" unitRef="usdPershares">2.28</imc:ShareOptionsPerShare>
    <imc:ScheduleOfDeemedValuationOfOptionsExplanatory contextRef="c134">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Expiry date&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise price &lt;br/&gt;
(A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected volatility&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend yield&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free interest rate&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
 at grant&lt;br/&gt;
 date per&lt;br/&gt;
 option
    &lt;br/&gt;
(A$)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%"&gt;2020-07-24&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2025-07-21&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,560,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.4035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2020-10-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2024-04-14&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,560,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
    price&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of&lt;br/&gt;
    options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
    volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt;
    yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free&lt;br/&gt;
    interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
    at grant&lt;br/&gt;
    date per&lt;br/&gt;
    option&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;2019-11-06&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;2024-02-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%"&gt;5,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.0736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
    price&lt;br/&gt;
 (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of&lt;br/&gt;
    options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
    volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt;
    yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk- free&lt;br/&gt;
    interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;br/&gt;
    at grant&lt;br/&gt;
    date per&lt;br/&gt;
    option&lt;br/&gt;
    (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%"&gt;2018-07-13&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;2021-07-01&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.1570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;2018-11-26&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2020-06-30&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0822&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2019-02-11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2024-02-11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.69&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;8,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:ScheduleOfDeemedValuationOfOptionsExplanatory>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c159">2020-07-24</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c159">2025-07-21</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c159" decimals="2" unitRef="audPershares">0.83</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c159" decimals="0" unitRef="shares">2560000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c159" decimals="2" unitRef="audPershares">0.5</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c159" decimals="4" unitRef="pure">1.2793</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c159" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c159" decimals="4" unitRef="pure">0.0043</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c159" decimals="4" unitRef="audPershares">0.4035</imc:ValuePerShareOptionsGranted>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c160">2020-10-29</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c160">2024-04-14</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c160" decimals="2" unitRef="audPershares">0.12</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c160" decimals="0" unitRef="shares">9000000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c160" decimals="2" unitRef="audPershares">0.25</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c160" decimals="4" unitRef="pure">1.427</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c160" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c160" decimals="4" unitRef="pure">0.0013</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c160" decimals="4" unitRef="audPershares">0.2189</imc:ValuePerShareOptionsGranted>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c0" decimals="0" unitRef="shares">11560000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c161">2019-11-06</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c161">2024-02-10</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c161" decimals="2" unitRef="audPershares">0.5</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c161" decimals="0" unitRef="shares">5000000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c161" decimals="2" unitRef="audPershares">0.15</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c161" decimals="2" unitRef="pure">0.98</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c161" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c161" decimals="4" unitRef="pure">0.0088</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c161" decimals="4" unitRef="audPershares">0.0736</imc:ValuePerShareOptionsGranted>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c3" decimals="0" unitRef="shares">5000000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c162">2018-07-13</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c162">2021-07-01</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c162" decimals="2" unitRef="audPershares">0.5</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c162" decimals="0" unitRef="shares">1300000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c162" decimals="2" unitRef="audPershares">0.32</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c162" decimals="4" unitRef="pure">0.92</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c162" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c162" decimals="4" unitRef="pure">0.0209</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c162" decimals="4" unitRef="audPershares">0.157</imc:ValuePerShareOptionsGranted>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c163">2018-11-26</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c163">2020-06-30</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c163" decimals="2" unitRef="audPershares">0.5</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c163" decimals="0" unitRef="shares">2000000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c163" decimals="2" unitRef="audPershares">0.34</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c163" decimals="4" unitRef="pure">0.92</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c163" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c163" decimals="4" unitRef="pure">0.0202</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c163" decimals="4" unitRef="audPershares">0.0822</imc:ValuePerShareOptionsGranted>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate contextRef="c164">2019-02-11</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate>
    <imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1 contextRef="c164">2024-02-11</imc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1>
    <imc:ExercisePriceShareOptionsGranted1 contextRef="c164" decimals="2" unitRef="audPershares">0.5</imc:ExercisePriceShareOptionsGranted1>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c164" decimals="0" unitRef="shares">5000000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:WeightedAverageSharePriceShareOptionsGranted1 contextRef="c164" decimals="2" unitRef="audPershares">0.29</imc:WeightedAverageSharePriceShareOptionsGranted1>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c164" decimals="4" unitRef="pure">1</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c164" decimals="4" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c164" decimals="4" unitRef="pure">0.0169</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <imc:ValuePerShareOptionsGranted contextRef="c164" decimals="4" unitRef="audPershares">0.195</imc:ValuePerShareOptionsGranted>
    <imc:NumberOfInstrumentOtherEquityInstrumentGranted contextRef="c4" decimals="0" unitRef="shares">8300000</imc:NumberOfInstrumentOtherEquityInstrumentGranted>
    <imc:ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions contextRef="c3">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;sup&gt;1&lt;/sup&gt;&lt;br/&gt;
    A$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;br/&gt; A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Options issued under ESOP&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,970,100&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(607,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payments to directors&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;145,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,116,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(533,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,343,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions>
    <imc:OptionsIssuedUnderESOP contextRef="c0" decimals="0" unitRef="aud">1970100</imc:OptionsIssuedUnderESOP>
    <imc:OptionsIssuedUnderESOP contextRef="c3" decimals="0" id="ix_26_fact" unitRef="aud">-607000</imc:OptionsIssuedUnderESOP>
    <imc:OptionsIssuedUnderESOP contextRef="c4" decimals="0" unitRef="aud">1343500</imc:OptionsIssuedUnderESOP>
    <imc:SharebasedPaymentsToDirectors contextRef="c0" decimals="0" id="ix_24_fact" unitRef="aud">145913</imc:SharebasedPaymentsToDirectors>
    <imc:SharebasedPaymentsToDirectors contextRef="c3" decimals="0" id="ix_25_fact" unitRef="aud">73088</imc:SharebasedPaymentsToDirectors>
    <imc:TotalExpenses contextRef="c0" decimals="0" unitRef="aud">2116013</imc:TotalExpenses>
    <imc:TotalExpenses contextRef="c3" decimals="0" id="ix_27_fact" unitRef="aud">-533912</imc:TotalExpenses>
    <imc:TotalExpenses contextRef="c4" decimals="0" unitRef="aud">1343500</imc:TotalExpenses>
    <imc:OptionGrantedDescription contextRef="c0">Options granted to a former managing director on 11 February 2019 and
valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at
grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June
2020 financials.</imc:OptionGrantedDescription>
    <imc:RevaluationFinancialsAmount contextRef="c0" decimals="0" unitRef="usd">607000</imc:RevaluationFinancialsAmount>
    <imc:SharesIssuedToDirectorsForTheDirectorFees contextRef="c0" decimals="0" unitRef="usd">145913</imc:SharesIssuedToDirectorsForTheDirectorFees>
    <imc:SharesIssuedToDirectorsForTheDirectorFees contextRef="c3" decimals="0" unitRef="usd">73088</imc:SharesIssuedToDirectorsForTheDirectorFees>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 20. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Interests in subsidiaries are set out in note
10.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Transactions with other
    related parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following transactions occurred with related
parties:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amounts settled in cash or shares for goods
    and services&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchases of various
    goods and services from entities controlled by key management personnel (i)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;110,607&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;142,347&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;147,636&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;i&gt;Purchases from entities controlled by key
    management personnel&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group acquired the following goods and services
from entities that are controlled by members of the group&#x2019;s key management personnel:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;rental of an office suite
    (Wattle Laboratories Pty Ltd); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective January 2016, we executed a Lease Agreement
with Wattle Laboratories Pty Ltd, (&#x201c;Wattle&#x201d;), an entity part-owned and operated by our non-executive directors, Mr. Peter
Anastasiou (a director resigned on 24 September 2021) and Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities
for our operations at a rental rate of A$38,940 per year, payable in monthly installments. The rental agreement is subject to annual rental
increases, and effective January 2017, the annual rent was increased to A$39,525. The lease is for a three-year term with an additional
three-year option period. The lease may be terminated by either party upon six months&#x2019; written notice. During the fiscal years ended
June 30, 2019, 2020 and 2021, we paid Wattle A$53,958, A$41,369 and A$40,607 (excluding Goods and Services Tax), respectively. The lease
was renewed, commencing January 1, 2019 for three years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warehousing, distribution
    and invoicing services (Grandlodge Capital Pty Ltd).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Grandlodge Capital Pty Ltd is an entity part-owned
and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on 24 September 2021) and
Mr. David Plush are also owners of Grandlodge, and its associated entities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Commenced on June 1, 2013, Grandlodge provides
warehousing, distribution and invoicing services for our products for A$70,000 per year. The terms of the agreement were to have fees
payable in new fully paid ordinary shares in Immuron Limited as a set price of A$0.16 per share. The fair value of the equity instrument
has been assessed and accounted for in accordance with IFRS 2 Share Based Payments in the 2020 financial statements. During the 2020 financial
year, the fees of A$100,978 equivalent were repaid by issuance of 437,500 ordinary shares based on their fair value. During the 2019 financial
year, the fees of A$93,678 equivalent were repaid by issuance of 437,500 ordinary shares based on based on their fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Grandlodge is reimbursed in cash for all reasonable
costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to
an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written
notice of the termination of the agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;A new
agreement commenced on July 1, 2020. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing
services for Immuron's products for $70,000 per annum. The terms of the agreement were to have fees payable in cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Aggregate amounts of each of the above types
of other transactions with key management personnel of Immuron Limited:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;Amounts settled in cash or shares during the period&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Rental of an office suite from Wattle Laboratories
    Pty Ltd&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;40,607&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,369&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,958&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Services rendered by Grandlodge Capital
    Pty Ltd&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;100,978&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;93,678&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,607&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;142,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;147,636&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding balances
    arising from sales/purchases of goods and services&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following balances are outstanding at the
end of the reporting period in relation to transactions with related parties:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Current payables (purchases of goods and services)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Entities controlled by key management personnel&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amounts settled in cash or shares for goods
    and services&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchases of various
    goods and services from entities controlled by key management personnel (i)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;110,607&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;142,347&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;147,636&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;Amounts settled in cash or shares during the period&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Rental of an office suite from Wattle Laboratories
    Pty Ltd&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;40,607&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,369&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,958&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Services rendered by Grandlodge Capital
    Pty Ltd&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;100,978&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;93,678&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,607&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;142,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;147,636&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c0" decimals="0" id="ix_28_fact" unitRef="aud">110607</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c3" decimals="0" id="ix_29_fact" unitRef="aud">142347</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c4" decimals="0" id="ix_30_fact" unitRef="aud">147636</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:RentalExpense contextRef="c165" decimals="0" unitRef="aud">38940</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c166" decimals="0" unitRef="aud">39525</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c167" decimals="0" unitRef="aud">53958</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c168" decimals="0" unitRef="aud">41369</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c169" decimals="0" unitRef="aud">40607</ifrs-full:RentalExpense>
    <imc:LeaseRenewed contextRef="c169">2019-01-01</imc:LeaseRenewed>
    <imc:WarehousingDistributionAndInvoicingServices contextRef="c170" decimals="0" unitRef="aud">70000</imc:WarehousingDistributionAndInvoicingServices>
    <imc:SharesIssuedPricePerShare1 contextRef="c171" decimals="2" unitRef="audPershares">0.16</imc:SharesIssuedPricePerShare1>
    <imc:WarehousingDistributionAndServicesFees contextRef="c172" decimals="0" unitRef="aud">100978</imc:WarehousingDistributionAndServicesFees>
    <imc:OrdinarySharesIssued contextRef="c172" decimals="0" unitRef="shares">437500</imc:OrdinarySharesIssued>
    <imc:WarehousingDistributionAndServicesFees contextRef="c173" decimals="0" unitRef="aud">93678</imc:WarehousingDistributionAndServicesFees>
    <imc:OrdinarySharesIssued contextRef="c173" decimals="0" unitRef="shares">437500</imc:OrdinarySharesIssued>
    <imc:WarehousingDistributionAndInvoicingServices contextRef="c174" decimals="0" unitRef="usd">70000</imc:WarehousingDistributionAndInvoicingServices>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c175" decimals="0" unitRef="aud">40607</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c176" decimals="0" unitRef="aud">41369</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c177" decimals="0" unitRef="aud">53958</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c178" decimals="0" unitRef="aud">70000</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c179" decimals="0" unitRef="aud">100978</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c180" decimals="0" unitRef="aud">93678</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c0" decimals="0" unitRef="aud">110607</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c3" decimals="0" unitRef="aud">142347</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions contextRef="c4" decimals="0" unitRef="aud">147636</imc:OtherTransactionsWithKeyManagementRelatedPartyTransactions>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Current payables (purchases of goods and services)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Entities controlled by key management personnel&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees contextRef="c0" decimals="0" unitRef="aud">70000</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 21. Financial Risk Management Objectives
and Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This note explains the Group&#x2019;s exposure
to financial risks and how these risks could affect the Group&#x2019;s future financial performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s risk management is predominantly
controlled by the Board. The Board monitors the Group&#x2019;s financial risk management policies and exposures and approves substantial
financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Risk Management Policy&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 36.85pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Board is responsible for overseeing the establishment
and implementation of the risk management system, and reviews and assesses the effectiveness of the Company&#x2019;s implementation of
that system on a regular basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Board and Senior Management identify the
general areas of risk and their impact on the activities of the Company, with Management performing a regular review of:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.1pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the major risks that occur
    within the business; the degree of risk involved;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the current approach to
    managing the risk; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if appropriate, determine:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any inadequacies of the
    current approach; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;possible new approaches
    that more efficiently and effectively address the risk.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management report risks identified to the Board
through the monthly Operations Report.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company seeks to ensure that its exposure
to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(a) Market risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Foreign exchange risk&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group undertakes certain transactions denominated
in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign exchange rate risk arises from financial
assets and financial liabilities denominated in a currency that is not the group's functional currency. Exposure to foreign currency
risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange
rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency
of the group including United States dollar (USD), Canadian dollar (CAD) and Israeli Shekel (ILS). This risk is measured using sensitivity
analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Exposure&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group&#x2019;s exposure to foreign currency
risk at the end of the reporting period, expressed in Australian dollars, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;USD&lt;br/&gt;
    $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;CAD&lt;br/&gt;
    $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;USD&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;CAD&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;ILS&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,742,688&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;108,688&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,954,589&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;107,605&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,801&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;45,591&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Trade payables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;43,466&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total exposure&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,785,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,030,126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;109,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Sensitivity&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As shown in the table above, the Group is primarily
exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD
denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial
statements into AUD.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Group has conducted a sensitivity analysis
of its exposure to foreign currency risk. The Group is currently materially exposed to the United States dollar (USD). The sensitivity
analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement
in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to
is listed below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD: 4.9% (2020: 3.3%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Impact
    on loss for&lt;br/&gt;
 the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Impact
    on other components&lt;br/&gt;
 of equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;USD/AUD exchange rate &#x2013; change by 4.9% (2020:
    3.3%)&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;136,467&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99,994&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,219&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,035&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holding
    all other variables constant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss is more sensitive to movements in the AUD/USD
exchange rates in 2021 than 2020 because of the increased amount of USD denominated cash and cash equivalents and the increased variability
of the AUD/USD exchange rate. Equity is more sensitive to movements in the AUD/USD exchange rates in 2021 than 2020 because of the increased
size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group's exposure to other foreign
exchange movements is not material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(b) Credit risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Exposure to credit risk relating to financial
assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the
group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk management&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Credit risk is managed through the maintenance
of procedures (such as the utilisation of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures
against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible
that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for
impairment. Credit terms are normally 30 days from the invoice date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Risk is also minimised through investing surplus
funds in financial institutions that maintain a high credit rating.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Security&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For some trade receivables the group may obtain
security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default
under the terms of the agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment of financial
    assets&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group has one type of financial asset subject
to the expected credit loss model:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;trade
                                            receivables for sales of inventory&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;While cash and cash equivalents are also subject
to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Trade receivables&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The group applies the IFRS 9 simplified approach
to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To measure the expected credit losses, trade
receivables assets have been grouped based on shared credit risk characteristics and the days past due.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The expected loss rates are based on the payment
profiles of sales over a period of 60 months before June 30, 2021 and the corresponding historical credit losses experienced within this
period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting
the ability of the customers to settle the receivables.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On that basis, the loss allowance as at June
30, 2021 was determined as follows for trade receivables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Days past due&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Current&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;1-30&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;31-60&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;61-90&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;91-120&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;121+&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;30 June 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; text-align: left"&gt;Expected credit loss rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;13.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;21.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;34.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;53.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On that basis, the loss allowance as at June
30, 2020 was determined as follows for trade receivables:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;30 June 2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1-30&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31-60&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;61-90&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;91-120&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;121+&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Expected credit loss rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;8.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;23.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;38.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,380&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,852&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,721&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade receivables are written off when there
is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the
failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater
than 121 days past due.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Impairment losses on trade receivables are presented
as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same
line item.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Previous accounting policy for impairment
of trade receivables&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the prior year, the impairment of trade receivables
was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing
the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that
an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognized in
a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following indicators were
present:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;significant financial difficulties
    of the debtor;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;probability that the debtor
    will enter bankruptcy or financial reorganization; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;default or late payments
    (more than 121 days overdue).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Receivables for which an impairment provision
was recognized were written off against the provision when there was no expectation of recovering additional cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Liquidity risk arises from the possibility that
the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The
group manages this risk through the following mechanisms:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;preparing forward looking
    cash flow analyses in relation to its operating, investing and financing activities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;obtaining funding from
    a variety of sources;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;maintaining a reputable
    credit profile;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;managing credit risk related
    to financial assets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;investing cash and cash
    equivalents and deposits at call with major financial institutions; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;comparing the maturity
    profile of financial liabilities with the realisation profile of financial assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Maturities of financial liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tables below analyze the group&#x2019;s financial
liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual
discounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Contractual maturities of financial liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Less than 6 months&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;6 - 12 months&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Between 1 and 2 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Between 2 and 5 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Over 5 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total contractual cash flows&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount (assets)/ liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;At 30 June 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;At 30 June 2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;194,553&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;USD&lt;br/&gt;
    $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;CAD&lt;br/&gt;
    $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;USD&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;CAD&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;ILS&lt;br/&gt; $&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,742,688&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;108,688&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,954,589&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;107,605&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,801&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;45,591&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Trade payables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;43,466&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Total exposure&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,785,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,030,126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;109,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;41,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory>
    <ifrs-full:CashAndCashEquivalents contextRef="c181" decimals="0" unitRef="usd">2742688</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c182" decimals="0" unitRef="cad">108688</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c183" decimals="0" unitRef="usd">2954589</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c184" decimals="0" unitRef="cad">107605</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeReceivables contextRef="c181" decimals="0" unitRef="usd">23801</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c183" decimals="0" unitRef="usd">45591</ifrs-full:TradeReceivables>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c181" decimals="0" unitRef="usd">18556</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c182" decimals="0" unitRef="cad">43466</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c183" decimals="0" unitRef="usd">29946</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c184" decimals="0" unitRef="cad">1923</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c185" decimals="0" unitRef="ils">41771</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c181" decimals="0" unitRef="usd">2785045</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c182" decimals="0" unitRef="cad">152154</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c183" decimals="0" unitRef="usd">3030126</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c184" decimals="0" unitRef="cad">109528</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c185" decimals="0" unitRef="ils">41771</ifrs-full:OtherCurrentFinancialLiabilities>
    <imc:PercentageOfForeignExchangeRates contextRef="c0" decimals="3" unitRef="pure">0.049</imc:PercentageOfForeignExchangeRates>
    <imc:PercentageOfForeignExchangeRates contextRef="c3" decimals="3" unitRef="pure">0.033</imc:PercentageOfForeignExchangeRates>
    <imc:DisclosureOfExchangerateTableExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Impact
    on loss for&lt;br/&gt;
 the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Impact
    on other components&lt;br/&gt;
 of equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;br/&gt;
    A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;br/&gt; A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;USD/AUD exchange rate &#x2013; change by 4.9% (2020:
    3.3%)&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;136,467&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99,994&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,219&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,035&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfExchangerateTableExplanatory>
    <imc:ImpactOnLossForPeriods contextRef="c2" decimals="0" unitRef="aud">136467</imc:ImpactOnLossForPeriods>
    <imc:ImpactOnLossForPeriods contextRef="c5" decimals="0" unitRef="aud">99994</imc:ImpactOnLossForPeriods>
    <imc:ImpactOnOtherComponentOfEquity contextRef="c2" decimals="0" unitRef="aud">5219</imc:ImpactOnOtherComponentOfEquity>
    <imc:ImpactOnOtherComponentOfEquity contextRef="c5" decimals="0" unitRef="aud">4035</imc:ImpactOnOtherComponentOfEquity>
    <imc:DisclosureOfTradeAndOtherReceivablesTableExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Days past due&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Current&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;1-30&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;31-60&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;61-90&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;91-120&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;121+&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;30 June 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; text-align: left"&gt;Expected credit loss rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;13.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;21.88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;34.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;53.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;30 June 2020&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Current&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1-30&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31-60&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;61-90&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;91-120&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;121+&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; A$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Expected credit loss rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;8.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;23.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;38.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross carrying amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss allowance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,380&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,852&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;23,721&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;30,055&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</imc:DisclosureOfTradeAndOtherReceivablesTableExplanatory>
    <ifrs-full:ExpectedCreditLossRate contextRef="c186" decimals="4" unitRef="pure">0</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c187" decimals="4" unitRef="pure">0</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c188" decimals="4" unitRef="pure">0.1307</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c189" decimals="4" unitRef="pure">0.2188</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c190" decimals="4" unitRef="pure">0.3409</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c191" decimals="4" unitRef="pure">0.5358</ifrs-full:ExpectedCreditLossRate>
    <imc:GrossCarryingAmount contextRef="c186" decimals="0" unitRef="aud">23801</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c187" decimals="0" unitRef="aud">4752</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c192" decimals="0" unitRef="aud">28553</imc:GrossCarryingAmount>
    <ifrs-full:ExpectedCreditLossRate contextRef="c193" decimals="4" unitRef="pure">0.006</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c194" decimals="4" unitRef="pure">0.0806</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c195" decimals="4" unitRef="pure">0</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c196" decimals="4" unitRef="pure">0.2335</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c197" decimals="4" unitRef="pure">0.383</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate contextRef="c198" decimals="4" unitRef="pure">1</ifrs-full:ExpectedCreditLossRate>
    <imc:GrossCarryingAmount contextRef="c193" decimals="0" unitRef="aud">2820</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c194" decimals="0" unitRef="aud">1055</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c196" decimals="0" unitRef="aud">14476</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c197" decimals="0" unitRef="aud">7447</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c198" decimals="0" unitRef="aud">23721</imc:GrossCarryingAmount>
    <imc:GrossCarryingAmount contextRef="c199" decimals="0" unitRef="aud">49519</imc:GrossCarryingAmount>
    <imc:LossAllowance contextRef="c193" decimals="0" unitRef="aud">17</imc:LossAllowance>
    <imc:LossAllowance contextRef="c194" decimals="0" unitRef="aud">85</imc:LossAllowance>
    <imc:LossAllowance contextRef="c196" decimals="0" unitRef="aud">3380</imc:LossAllowance>
    <imc:LossAllowance contextRef="c197" decimals="0" unitRef="aud">2852</imc:LossAllowance>
    <imc:LossAllowance contextRef="c198" decimals="0" unitRef="aud">23721</imc:LossAllowance>
    <imc:LossAllowance contextRef="c199" decimals="0" unitRef="aud">30055</imc:LossAllowance>
    <imc:DisclosureOfTradeAndOtherPayablesTableExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Contractual maturities of financial liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Less than 6 months&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;6 - 12 months&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Between 1 and 2 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Between 2 and 5 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Over 5 years&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total contractual cash flows&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount (assets)/ liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;At 30 June 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;132,514&lt;/td&gt;&lt;td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,498&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;153,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;At 30 June 2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,663&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;194,553&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;237,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</imc:DisclosureOfTradeAndOtherPayablesTableExplanatory>
    <imc:TradeAndOtherPayable contextRef="c200" decimals="0" unitRef="aud">132514</imc:TradeAndOtherPayable>
    <imc:TradeAndOtherPayable contextRef="c205" decimals="0" unitRef="aud">132514</imc:TradeAndOtherPayable>
    <imc:TradeAndOtherPayable contextRef="c206" decimals="0" unitRef="aud">132514</imc:TradeAndOtherPayable>
    <ifrs-full:GrossLeaseLiabilities contextRef="c200" decimals="0" unitRef="aud">20498</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c205" decimals="0" unitRef="aud">20498</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c206" decimals="0" unitRef="aud">20498</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c200" decimals="0" unitRef="aud">153012</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c205" decimals="0" unitRef="aud">153012</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c206" decimals="0" unitRef="aud">153012</ifrs-full:FinancialLiabilities>
    <imc:TradeAndOtherPayable contextRef="c207" decimals="0" unitRef="aud">173663</imc:TradeAndOtherPayable>
    <imc:TradeAndOtherPayable contextRef="c212" decimals="0" unitRef="aud">173663</imc:TradeAndOtherPayable>
    <imc:TradeAndOtherPayable contextRef="c213" decimals="0" unitRef="aud">173663</imc:TradeAndOtherPayable>
    <ifrs-full:GrossLeaseLiabilities contextRef="c207" decimals="0" unitRef="aud">20890</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c208" decimals="0" unitRef="aud">21286</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c209" decimals="0" unitRef="aud">21286</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c212" decimals="0" unitRef="aud">63462</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c213" decimals="0" unitRef="aud">63462</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c207" decimals="0" unitRef="aud">194553</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c208" decimals="0" unitRef="aud">21286</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c209" decimals="0" unitRef="aud">21286</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c212" decimals="0" unitRef="aud">237125</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c213" decimals="0" unitRef="aud">237125</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 22. Events occurring after the Reporting
Date&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, Immuron identified a transformational
COVID-19 asset, for which it entered a binding contract to acquire. The company&#x2019;s securities were placed in suspension by the Australian
Securities Exchange (ASX) until the company met the requirements set out by the Exchange. Unfortunately, after filing an ASX In-Principal
Advice Application and subsequent lengthy discussions and exchanges with the ASX, Immuron was unable to satisfy the ASX that the combined
group, following the proposed acquisition, would meet the requirements of the Listing Rules. Ultimately the ASX has an absolute discretion
whether to approve such a major acquisition. Immuron is now unable to satisfy the pre-conditions for this proposed acquisition due to
the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On 23 September 2021, as a result of the company
not proceeding with the major transaction the ASX has lifted the suspension and the company's securities have now re-commenced trading
on the ASX and NASDAQ official list.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On 24 September 2021, Mr Peter Anastasiou resigned
as a director of the company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;No other matter or circumstance has occurred
subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those
operations or the state of affairs of the group or economic entity in subsequent financial years.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <imc:DisclosureOfCompanyDetailsExplanatory contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 23. Company Details&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;The registered office of the Company is:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 3, 62 Lygon Street, Carlton,
Victoria, Australia 3053.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;The principal place of business of the Company
is:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Unit 10, 25-37 Chapman Street, Blackburn,
Victoria, Australia 3130.&lt;/p&gt;</imc:DisclosureOfCompanyDetailsExplanatory>
    <imc:IncomeFinance
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:CostOfFinance
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-2"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c10"
      id="hidden-fact-7"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c11"
      id="hidden-fact-8"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c10"
      id="hidden-fact-9"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c12"
      id="hidden-fact-10"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c10"
      id="hidden-fact-11"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c11"
      id="hidden-fact-12"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c12"
      id="hidden-fact-13"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c10"
      id="hidden-fact-14"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsExercised
      contextRef="c12"
      id="hidden-fact-16"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsExercised
      contextRef="c4"
      id="hidden-fact-17"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionswarrantsForfeited
      contextRef="c10"
      id="hidden-fact-18"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionswarrantsForfeited
      contextRef="c4"
      id="hidden-fact-19"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ChangeInAccountingPolicy
      contextRef="c10"
      id="hidden-fact-20"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ChangeInAccountingPolicy
      contextRef="c11"
      id="hidden-fact-21"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c17"
      id="hidden-fact-24"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c19"
      id="hidden-fact-25"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c17"
      id="hidden-fact-26"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c18"
      id="hidden-fact-27"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c19"
      id="hidden-fact-28"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c19"
      id="hidden-fact-29"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c3"
      id="hidden-fact-30"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionswarrantsForfeited
      contextRef="c17"
      id="hidden-fact-31"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionswarrantsForfeited
      contextRef="c3"
      id="hidden-fact-32"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevaluationOfOptionIssuedInPriorPeriod
      contextRef="c17"
      id="hidden-fact-33"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevaluationOfOptionIssuedInPriorPeriod
      contextRef="c19"
      id="hidden-fact-34"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:EmployeeShareSchemesValueOfEmployee
      contextRef="c17"
      id="hidden-fact-35"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:EmployeeShareSchemesValueOfEmployee
      contextRef="c19"
      id="hidden-fact-36"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c23"
      id="hidden-fact-37"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      id="hidden-fact-38"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c23"
      id="hidden-fact-39"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherComprehensiveIncomeLossForPeriod
      contextRef="c25"
      id="hidden-fact-40"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c23"
      id="hidden-fact-41"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c24"
      id="hidden-fact-42"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c25"
      id="hidden-fact-43"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c23"
      id="hidden-fact-44"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsIssuedExpensed
      contextRef="c25"
      id="hidden-fact-45"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsExercised
      contextRef="c25"
      id="hidden-fact-46"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsForteitedLapsed
      contextRef="c23"
      id="hidden-fact-47"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsOrWarrantsForteitedLapsed
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:StockIssuedDuringPeriodValueIssuedToDirectors
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:StockIssuedDuringPeriodValueIssuedToDirectors
      contextRef="c25"
      id="hidden-fact-50"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransferToShareCapital
      contextRef="c25"
      id="hidden-fact-51"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransferToShareCapital
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="c4"
      id="hidden-fact-53"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities
      contextRef="c3"
      id="hidden-fact-54"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="c3"
      id="hidden-fact-55"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="c4"
      id="hidden-fact-56"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="c4"
      id="hidden-fact-57"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinishedGoods
      contextRef="c5"
      id="hidden-fact-58"
      unitRef="aud"
      xsi:nil="true"/>
    <us-gaap:InventoryRawMaterials
      contextRef="c5"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RawMaterials
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OtherGovernmentAssistanceIncome
      contextRef="c4"
      id="hidden-fact-61"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ResearchAndDevelopmentGrants
      contextRef="c3"
      id="hidden-fact-62"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ResearchAndDevelopmentGrants
      contextRef="c4"
      id="hidden-fact-63"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLoss
      contextRef="c3"
      id="hidden-fact-64"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ResearchAndDevelopmentsGrants
      contextRef="c3"
      id="hidden-fact-65"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:UtilitiesExpense
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-68"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities
      contextRef="c3"
      id="hidden-fact-69"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities
      contextRef="c4"
      id="hidden-fact-70"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossOnAllowanceTradeReceivables
      contextRef="c2"
      id="hidden-fact-71"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:Inventories
      contextRef="c35"
      id="hidden-fact-72"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:Inventories
      contextRef="c36"
      id="hidden-fact-73"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:Inventories
      contextRef="c37"
      id="hidden-fact-74"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentInventories
      contextRef="c37"
      id="hidden-fact-75"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:InventoriesNet
      contextRef="c37"
      id="hidden-fact-76"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentInventories
      contextRef="c38"
      id="hidden-fact-77"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentInventories
      contextRef="c39"
      id="hidden-fact-78"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentInventories
      contextRef="c40"
      id="hidden-fact-79"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c41"
      id="hidden-fact-80"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c42"
      id="hidden-fact-81"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:Provisions
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="c5"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c2"
      id="hidden-fact-85"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c3"
      id="hidden-fact-87"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c3"
      id="hidden-fact-89"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="c0"
      id="hidden-fact-90"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="c3"
      id="hidden-fact-91"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised
      contextRef="c4"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares
      contextRef="c4"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares
      contextRef="c4"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares
      contextRef="c3"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares
      contextRef="c3"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:ExerciseOfRepresentativeWarrant1
      contextRef="c0"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <imc:TransferFromReservesOnExerciseOfESOPUnlistedOptions
      contextRef="c0"
      id="hidden-fact-98"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729
      contextRef="c0"
      id="hidden-fact-99"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:BusinessAcquisitionCostOfTransactionCostToIssuedAtShares
      contextRef="c0"
      id="hidden-fact-100"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:CurrencyTranslationDifferences
      contextRef="c62"
      id="hidden-fact-101"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c62"
      id="hidden-fact-102"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c62"
      id="hidden-fact-103"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c63"
      id="hidden-fact-104"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c4"
      id="hidden-fact-105"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsIssuedexpensed
      contextRef="c63"
      id="hidden-fact-106"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsExercised
      contextRef="c63"
      id="hidden-fact-107"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsLapsed
      contextRef="c63"
      id="hidden-fact-108"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:CurrencyTranslationDifferences
      contextRef="c66"
      id="hidden-fact-109"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c66"
      id="hidden-fact-110"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c66"
      id="hidden-fact-111"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c67"
      id="hidden-fact-112"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SharebasedPaymentExpenses
      contextRef="c67"
      id="hidden-fact-113"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsIssuedexpensed
      contextRef="c67"
      id="hidden-fact-114"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsLapsed
      contextRef="c67"
      id="hidden-fact-115"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevaluationOfOptionsIssuedInPriorPeriod
      contextRef="c67"
      id="hidden-fact-116"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:CurrencyTranslationDifferences
      contextRef="c70"
      id="hidden-fact-117"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c70"
      id="hidden-fact-118"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c70"
      id="hidden-fact-119"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransactionsWithOwnersInTheirCapacityAsOwners
      contextRef="c71"
      id="hidden-fact-120"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TransferToShareCapitalinDollars
      contextRef="c71"
      id="hidden-fact-121"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsIssuedexpensed
      contextRef="c71"
      id="hidden-fact-122"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsExercised
      contextRef="c71"
      id="hidden-fact-123"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:OptionsAndWarrantsForfeited
      contextRef="c71"
      id="hidden-fact-124"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital
      contextRef="c4"
      id="hidden-fact-125"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses
      contextRef="c4"
      id="hidden-fact-126"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:RevaluationOfOptionsIssuedInPriorPeriodShares
      contextRef="c3"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:LapseOfUnexercisedOptionsAtZeroPointFiveFive
      contextRef="c3"
      id="hidden-fact-128"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="c0"
      id="hidden-fact-129"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital
      contextRef="c0"
      id="hidden-fact-130"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c74"
      id="hidden-fact-131"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c76"
      id="hidden-fact-132"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c74"
      id="hidden-fact-133"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c76"
      id="hidden-fact-134"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c74"
      id="hidden-fact-135"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c76"
      id="hidden-fact-136"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c74"
      id="hidden-fact-137"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c74"
      id="hidden-fact-138"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c75"
      id="hidden-fact-139"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="c74"
      id="hidden-fact-140"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="c75"
      id="hidden-fact-141"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c75"
      id="hidden-fact-142"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c76"
      id="hidden-fact-143"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c74"
      id="hidden-fact-144"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c76"
      id="hidden-fact-145"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c74"
      id="hidden-fact-146"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c75"
      id="hidden-fact-147"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c74"
      id="hidden-fact-148"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c75"
      id="hidden-fact-149"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c74"
      id="hidden-fact-150"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c75"
      id="hidden-fact-151"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c76"
      id="hidden-fact-152"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-153"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c80"
      id="hidden-fact-154"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c82"
      id="hidden-fact-155"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c80"
      id="hidden-fact-156"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c82"
      id="hidden-fact-157"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c80"
      id="hidden-fact-158"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c82"
      id="hidden-fact-159"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c80"
      id="hidden-fact-160"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c81"
      id="hidden-fact-161"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c80"
      id="hidden-fact-162"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c81"
      id="hidden-fact-163"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c81"
      id="hidden-fact-164"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c82"
      id="hidden-fact-165"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c80"
      id="hidden-fact-166"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c82"
      id="hidden-fact-167"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c80"
      id="hidden-fact-168"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c81"
      id="hidden-fact-169"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c82"
      id="hidden-fact-170"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c3"
      id="hidden-fact-171"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c80"
      id="hidden-fact-172"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c81"
      id="hidden-fact-173"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c80"
      id="hidden-fact-174"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c81"
      id="hidden-fact-175"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c82"
      id="hidden-fact-176"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-177"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c86"
      id="hidden-fact-178"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:HyperimmuneProductsRevenue
      contextRef="c88"
      id="hidden-fact-179"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c86"
      id="hidden-fact-180"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c88"
      id="hidden-fact-181"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c86"
      id="hidden-fact-182"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c88"
      id="hidden-fact-183"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c88"
      id="hidden-fact-184"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherGainsLosses
      contextRef="c86"
      id="hidden-fact-185"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c86"
      id="hidden-fact-186"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GeneralAndAdministrativeExpenses
      contextRef="c87"
      id="hidden-fact-187"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c87"
      id="hidden-fact-188"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c88"
      id="hidden-fact-189"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c86"
      id="hidden-fact-190"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:SellingAndMarketingExpenses
      contextRef="c88"
      id="hidden-fact-191"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c86"
      id="hidden-fact-192"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c87"
      id="hidden-fact-193"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c96"
      id="hidden-fact-194"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFromExternalCustomers
      contextRef="c96"
      id="hidden-fact-195"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c101"
      id="hidden-fact-196"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFromExternalCustomers
      contextRef="c101"
      id="hidden-fact-197"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c108"
      id="hidden-fact-198"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c109"
      id="hidden-fact-199"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c111"
      id="hidden-fact-200"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c112"
      id="hidden-fact-201"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c114"
      id="hidden-fact-202"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c115"
      id="hidden-fact-203"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c120"
      id="hidden-fact-204"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c121"
      id="hidden-fact-205"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c122"
      id="hidden-fact-206"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c125"
      id="hidden-fact-207"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c128"
      id="hidden-fact-208"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:RevenueFormContractWithCustomer
      contextRef="c131"
      id="hidden-fact-209"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:AdjustmentsForDistributionCosts
      contextRef="c0"
      id="hidden-fact-210"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="c3"
      id="hidden-fact-211"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1
      contextRef="c4"
      id="hidden-fact-212"
      unitRef="audPershares"
      xsi:nil="true"/>
    <imc:NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement
      contextRef="c4"
      id="hidden-fact-213"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:ShareOptionsOutstanding
      contextRef="c153"
      id="hidden-fact-214"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:ShareOptionsOutstanding
      contextRef="c156"
      id="hidden-fact-215"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:ShareOptionsOutstanding
      contextRef="c158"
      id="hidden-fact-216"
      unitRef="shares"
      xsi:nil="true"/>
    <imc:SharebasedPaymentsToDirectors
      contextRef="c4"
      id="hidden-fact-217"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees
      contextRef="c3"
      id="hidden-fact-218"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees
      contextRef="c4"
      id="hidden-fact-219"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="c182"
      id="hidden-fact-220"
      unitRef="cad"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="c184"
      id="hidden-fact-221"
      unitRef="cad"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="c185"
      id="hidden-fact-222"
      unitRef="ils"
      xsi:nil="true"/>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="c192"
      id="hidden-fact-223"
      unitRef="pure"
      xsi:nil="true"/>
    <imc:GrossCarryingAmount
      contextRef="c188"
      id="hidden-fact-224"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GrossCarryingAmount
      contextRef="c189"
      id="hidden-fact-225"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GrossCarryingAmount
      contextRef="c190"
      id="hidden-fact-226"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:GrossCarryingAmount
      contextRef="c191"
      id="hidden-fact-227"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c186"
      id="hidden-fact-228"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c187"
      id="hidden-fact-229"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c188"
      id="hidden-fact-230"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c189"
      id="hidden-fact-231"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c190"
      id="hidden-fact-232"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c191"
      id="hidden-fact-233"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c192"
      id="hidden-fact-234"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="c199"
      id="hidden-fact-235"
      unitRef="pure"
      xsi:nil="true"/>
    <imc:GrossCarryingAmount
      contextRef="c195"
      id="hidden-fact-236"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:LossAllowance
      contextRef="c195"
      id="hidden-fact-237"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c201"
      id="hidden-fact-238"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c202"
      id="hidden-fact-239"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c203"
      id="hidden-fact-240"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c204"
      id="hidden-fact-241"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c201"
      id="hidden-fact-242"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c202"
      id="hidden-fact-243"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c203"
      id="hidden-fact-244"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c204"
      id="hidden-fact-245"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c201"
      id="hidden-fact-246"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c202"
      id="hidden-fact-247"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c203"
      id="hidden-fact-248"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c204"
      id="hidden-fact-249"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c208"
      id="hidden-fact-250"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c209"
      id="hidden-fact-251"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c210"
      id="hidden-fact-252"
      unitRef="aud"
      xsi:nil="true"/>
    <imc:TradeAndOtherPayable
      contextRef="c211"
      id="hidden-fact-253"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c210"
      id="hidden-fact-254"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c211"
      id="hidden-fact-255"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c210"
      id="hidden-fact-256"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c211"
      id="hidden-fact-257"
      unitRef="aud"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001660046</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;D tax concession for the year.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trade receivables are non-interest bearing.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in the line item &#x2018;property, plant and equipment&#x2019; in the consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-85"
          xlink:label="hidden-fact-85"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in the line items &#x2018;other current liabilities&#x2019; and &#x2018;other non-current liabilities&#x2019; in the consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-85"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#x2019;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#x2019;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-194"
          xlink:label="hidden-fact-194"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Returns are provided where outlined in a customer&#x2019;s agreement.
</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-194"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-217"
          xlink:label="hidden-fact-217"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.
</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-217"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.
</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Purchases from entities controlled by key management personnel</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695262520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMURON LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">227,246,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001660046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-38104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level 3, 62 Lygon Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlton South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares,
each representing 40 Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level 3, 62 Lygon Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlton South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dr. Jerry Kanellos<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3 9822 7735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696263656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 145,776<span></span>
</td>
<td class="nump">$ 2,518,566<span></span>
</td>
<td class="nump">$ 2,387,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of Goods Sold</a></td>
<td class="num">(51,071)<span></span>
</td>
<td class="num">(688,836)<span></span>
</td>
<td class="num">(667,371)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">94,705<span></span>
</td>
<td class="nump">1,829,730<span></span>
</td>
<td class="nump">1,720,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other Income</a></td>
<td class="nump">617,110<span></span>
</td>
<td class="nump">473,674<span></span>
</td>
<td class="nump">532,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains/(losses) &#8211; net</a></td>
<td class="num">(1,342,293)<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">38,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(3,978,679)<span></span>
</td>
<td class="num">(3,703,990)<span></span>
</td>
<td class="num">(3,694,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsExpenses', window );">Share-based payment expenses</a></td>
<td class="num">(2,116,013)<span></span>
</td>
<td class="nump">533,912<span></span>
</td>
<td class="num">(1,343,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(1,367,054)<span></span>
</td>
<td class="num">(1,178,685)<span></span>
</td>
<td class="num">(1,044,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="num">(287,684)<span></span>
</td>
<td class="num">(871,551)<span></span>
</td>
<td class="num">(864,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(8,379,908)<span></span>
</td>
<td class="num">(2,905,575)<span></span>
</td>
<td class="num">(4,656,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IncomeFinance', window );">Finance income</a></td>
<td class="nump">9,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CostOfFinance', window );">Finance expenses</a></td>
<td class="num">(13,761)<span></span>
</td>
<td class="num">(21,631)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinanceCostsNet', window );">Finance costs - net</a></td>
<td class="num">(4,557)<span></span>
</td>
<td class="num">(21,631)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss Before Income Tax</a></td>
<td class="num">(8,384,465)<span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income Tax Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the Period</a></td>
<td class="num">(8,384,465)<span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="num">(14,953)<span></span>
</td>
<td class="nump">102,938<span></span>
</td>
<td class="nump">61,846<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total Comprehensive Loss for the Period</a></td>
<td class="num">$ (8,399,418)<span></span>
</td>
<td class="num">$ (2,824,268)<span></span>
</td>
<td class="num">$ (4,594,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_BasicAndDilutedEarningsLossPerShare', window );">Basic/Diluted Loss per Share (in cents per share) (in Dollars per share)</a></td>
<td class="num">$ (3.79)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (3.22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CostOfFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CostOfFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_FinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_FinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IncomeFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IncomeFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based payment expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696550328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Financial Position - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,047,281<span></span>
</td>
<td class="nump">$ 3,250,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">334,707<span></span>
</td>
<td class="nump">327,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">292,532<span></span>
</td>
<td class="nump">797,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">78,258<span></span>
</td>
<td class="nump">33,194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total Current Assets</a></td>
<td class="nump">25,752,778<span></span>
</td>
<td class="nump">4,409,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Plant and equipment</a></td>
<td class="nump">33,741<span></span>
</td>
<td class="nump">70,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Inventories</a></td>
<td class="nump">1,266,587<span></span>
</td>
<td class="nump">1,722,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total Non-Current Assets</a></td>
<td class="nump">1,300,328<span></span>
</td>
<td class="nump">1,793,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,053,106<span></span>
</td>
<td class="nump">6,202,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">758,494<span></span>
</td>
<td class="nump">384,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Provision for sales returns</a></td>
<td class="nump">213,024<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EmployeeBenefitObligation', window );">Employee benefit obligations</a></td>
<td class="nump">129,837<span></span>
</td>
<td class="nump">89,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">42,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total Current Liabilities</a></td>
<td class="nump">1,121,853<span></span>
</td>
<td class="nump">516,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EmployeeBenefitObligationNonCurrent', window );">Employee benefit obligations</a></td>
<td class="nump">36,196<span></span>
</td>
<td class="nump">22,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,929<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total Non-Current Liabilities</a></td>
<td class="nump">36,196<span></span>
</td>
<td class="nump">41,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">1,158,049<span></span>
</td>
<td class="nump">558,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">NET ASSETS</a></td>
<td class="nump">25,895,057<span></span>
</td>
<td class="nump">5,643,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">88,361,303<span></span>
</td>
<td class="nump">62,426,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">3,466,642<span></span>
</td>
<td class="nump">1,133,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(65,932,888)<span></span>
</td>
<td class="num">(57,916,423)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">TOTAL EQUITY</a></td>
<td class="nump">$ 25,895,057<span></span>
</td>
<td class="nump">$ 5,643,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG63<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_EmployeeBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to employee benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_EmployeeBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_EmployeeBenefitObligationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to non current employee benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_EmployeeBenefitObligationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696499304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Equity - AUD ($)<br></strong></div></th>
<th class="th"><div>Issued Capital</div></th>
<th class="th"><div>Reserves</div></th>
<th class="th"><div>Accumulated Losses</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EquityBalance', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 58,237,314<span></span>
</td>
<td class="nump">$ 3,096,308<span></span>
</td>
<td class="num">$ (52,894,272)<span></span>
</td>
<td class="nump">$ 8,439,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherComprehensiveIncomeLossForPeriod', window );">Other comprehensive income for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,846<span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
<td class="num">(4,594,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued, net of costs</a></td>
<td class="nump">2,052,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,052,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsIssuedExpensed', window );">Options/warrants issued/expensed</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,453,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,453,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsExercised', window );">Options/warrants exercised</a></td>
<td class="nump">100<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionswarrantsForfeited', window );">Options/warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(311,635)<span></span>
</td>
<td class="nump">311,635<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EquityBalance', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">60,289,875<span></span>
</td>
<td class="nump">4,300,319<span></span>
</td>
<td class="num">(57,239,058)<span></span>
</td>
<td class="nump">7,351,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ChangeInAccountingPolicy', window );">Change in accounting policy</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,479)<span></span>
</td>
<td class="num">(1,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RestatedTotalEquityAt1July2019', window );">Revised total equity at 1 July 2019</a></td>
<td class="nump">60,289,875<span></span>
</td>
<td class="nump">4,300,319<span></span>
</td>
<td class="num">(57,239,058)<span></span>
</td>
<td class="nump">7,351,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherComprehensiveIncomeLossForPeriod', window );">Other comprehensive income for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">102,938<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">102,938<span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
<td class="num">(2,824,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued, net of costs</a></td>
<td class="nump">1,652,436<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,652,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsIssuedExpensed', window );">Options/warrants issued/expensed</a></td>
<td class="nump">484,680<span></span>
</td>
<td class="num">(484,680)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionswarrantsForfeited', window );">Options/warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,251,320)<span></span>
</td>
<td class="nump">2,251,320<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionIssuedInPriorPeriod', window );">Re-valuation of options issued in prior period</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EmployeeShareSchemesValueOfEmployee', window );">Share-based payment expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,088<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">73,088<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EquityBalance', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">62,426,991<span></span>
</td>
<td class="nump">1,133,345<span></span>
</td>
<td class="num">(57,916,423)<span></span>
</td>
<td class="nump">5,643,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss after income tax expense for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,384,465)<span></span>
</td>
<td class="num">(8,384,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherComprehensiveIncomeLossForPeriod', window );">Other comprehensive income for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(14,953)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(14,953)<span></span>
</td>
<td class="num">(8,384,465)<span></span>
</td>
<td class="num">(8,399,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract', window );"><strong>Transactions with owners in their capacity as owners</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued, net of costs</a></td>
<td class="nump">24,386,005<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,386,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsIssuedExpensed', window );">Options/warrants issued/expensed</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,003,060<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,003,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsExercised', window );">Options/warrants exercised</a></td>
<td class="nump">1,329,307<span></span>
</td>
<td class="num">(213,722)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,115,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsOrWarrantsForteitedLapsed', window );">Options/warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(368,000)<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_StockIssuedDuringPeriodValueIssuedToDirectors', window );">Shares issued to directors</a></td>
<td class="nump">145,912<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">145,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferToShareCapital', window );">Transfer to share capital</a></td>
<td class="nump">73,088<span></span>
</td>
<td class="num">(73,088)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_EquityBalance', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 88,361,303<span></span>
</td>
<td class="nump">$ 3,466,642<span></span>
</td>
<td class="num">$ (65,932,888)<span></span>
</td>
<td class="nump">$ 25,895,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ChangeInAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ChangeInAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_EmployeeShareSchemesValueOfEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee share schemes - value of employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_EmployeeShareSchemesValueOfEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_EquityBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a equity balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_EquityBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsOrWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options/warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsOrWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsOrWarrantsForteitedLapsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from options/warrants forteited/lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsOrWarrantsForteitedLapsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsOrWarrantsIssuedExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of options or warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsOrWarrantsIssuedExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionswarrantsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options/warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionswarrantsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherComprehensiveIncomeLossForPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income (loss) for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherComprehensiveIncomeLossForPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RestatedTotalEquityAt1July2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RestatedTotalEquityAt1July2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationOfOptionIssuedInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationOfOptionIssuedInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_StockIssuedDuringPeriodValueIssuedToDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by directors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_StockIssuedDuringPeriodValueIssuedToDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock transfer during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696679832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract', window );"><strong>Cash flows Related to Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices', window );">Receipts from customers</a></td>
<td class="nump">$ 192,185<span></span>
</td>
<td class="nump">$ 2,914,614<span></span>
</td>
<td class="nump">$ 2,619,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_PaymentsToSuppliersForGoodsAndService', window );">Payments to suppliers and employees</a></td>
<td class="num">(4,865,633)<span></span>
</td>
<td class="num">(6,748,674)<span></span>
</td>
<td class="num">(5,608,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities', window );">Other - R&amp;D tax concession refund</a></td>
<td class="nump">358,280<span></span>
</td>
<td class="nump">531,828<span></span>
</td>
<td class="nump">1,190,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Government grants and other grants received</a></td>
<td class="nump">236,421<span></span>
</td>
<td class="nump">154,904<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net Cash Flows Used In Operating Activities</a></td>
<td class="num">(4,078,747)<span></span>
</td>
<td class="num">(3,147,328)<span></span>
</td>
<td class="num">(1,798,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Related to Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Payment for purchases of plant and equipment</a></td>
<td class="num">(6,630)<span></span>
</td>
<td class="num">(864)<span></span>
</td>
<td class="num">(2,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">9,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net Cash Flows (Used In)/From Investing Activities</a></td>
<td class="nump">2,574<span></span>
</td>
<td class="num">(864)<span></span>
</td>
<td class="num">(2,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Related to Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issues of securities</a></td>
<td class="nump">29,281,421<span></span>
</td>
<td class="nump">1,957,164<span></span>
</td>
<td class="nump">2,894,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CapitalCost', window );">Capital raising costs</a></td>
<td class="num">(2,746,871)<span></span>
</td>
<td class="num">(374,728)<span></span>
</td>
<td class="num">(825,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="nump">212,794<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(212,794)<span></span>
</td>
<td class="num">(366,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal elements of lease payments</a></td>
<td class="num">(40,607)<span></span>
</td>
<td class="num">(41,390)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest and other costs of finance paid</a></td>
<td class="num">(13,761)<span></span>
</td>
<td class="num">(17,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net Cash Flows From Financing Activities</a></td>
<td class="nump">26,480,182<span></span>
</td>
<td class="nump">1,156,952<span></span>
</td>
<td class="nump">2,069,183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">22,404,009<span></span>
</td>
<td class="num">(1,991,240)<span></span>
</td>
<td class="nump">268,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">3,250,468<span></span>
</td>
<td class="nump">5,119,887<span></span>
</td>
<td class="nump">4,727,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(607,196)<span></span>
</td>
<td class="nump">121,821<span></span>
</td>
<td class="nump">123,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and Cash Equivalents at the End of the Year</a></td>
<td class="nump">$ 25,047,281<span></span>
</td>
<td class="nump">$ 3,250,468<span></span>
</td>
<td class="nump">$ 5,119,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 14<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of goods and rendering of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CapitalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of capital raising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CapitalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_PaymentsToSuppliersForGoodsAndService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_PaymentsToSuppliersForGoodsAndService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692327832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract', window );"><strong>Disclosure of significant accounting policies [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporate Information</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial report of Immuron Limited
(&#8220;the Company&#8221;) for the year ended June 30, 2021, 2020 and 2019 was authorized for issue in accordance with a resolution of
the Directors on October 29, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited is a listed public company limited
by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and The
NASDAQ Capital Market (&#8220;NASDAQ&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s principal activity is oral
immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment
and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting
travelers&#8217; diarrhea and Protectyn an OTC immune supplement for GI tract and liver health.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of preparation</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These general purpose financial statements
have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards
Board and the <i>Corporations Act 2001</i>. Immuron Limited is a for-profit entity for the purpose of preparing the financial statements.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Compliance with
                                            IFRS</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The consolidated financial statements
of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Historical cost
                                            convention</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The financial statements have been prepared on a historical
cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Significant
    estimates and judgements</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Going concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group is in a position to meet future commitments in the current
business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs
for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not
include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of
liabilities that might be necessary should the group not continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>COVID-19</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Judgement has been exercised in considering
the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration
extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group
operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that
COVID-19 will continue to have on sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note provides a list of the significant
accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed
in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial
statements are for the group consisting of Immuron Limited and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(iv) New standards and interpretations not
yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no standards that are not yet effective
and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future
transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(v)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revision of immaterial error</i></span></td></tr>
  </table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">During the year ended June 2020 the following immaterial
error corrections were identified.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Representative warrants</i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Immuron Limited raised capital in June
2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for
at the time of these capital raisings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Management has undertaken an assessment of the impact of this and concluded
this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and
the related notes included herein to include the representative warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Reserves as of 30 June 2017 has been
revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share
capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Reserves as of 30 June 2019 has been revised to increase by A$110,400
for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Summary of significant accounting policies</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material accounting
policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless
otherwise stated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(b)</b></td><td style="text-align: justify"><b>Principles of consolidation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>(i) Subsidiaries</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Subsidiaries are all entities (including
structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from
the date that control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The acquisition method of accounting
is used to account for business combinations by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Intercompany transactions, balances
and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to
ensure consistency with the policies adopted by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(c)</b></td><td style="text-align: justify"><b>Segment reporting</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive
management team consisting of the CEO and COO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(d)</b></td><td style="text-align: justify"><b>Foreign currency translation</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Functional and
                                            presentation currency</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Items included in the financial statements
of each of the group&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#8216;the functional currency&#8217;). The consolidated financial statements are presented in Australian dollar (&#8220;A$&#8221; or
&#8220;$&#8221;), which is Immuron Limited&#8217;s functional and presentation currency.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Transactions
                                            and balances</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign currency transactions are translated
into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at
year end exchange rates are generally recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign exchange gains and losses that
relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs.
All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income
on a net basis within other gains/(losses).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Non-monetary items that are measured
at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation
differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation
differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit
or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair
value through other comprehensive income are recognized in other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Group companies</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The results and financial position
of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from
the presentation currency are translated into the presentation currency as follows:</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">assets and liabilities for each
                                            consolidated balance sheet presented are translated at the closing rate at the date of that
                                            consolidated balance sheet;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">income and expenses for each consolidated statement of
                         profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at
                         average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates
                         prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions);
                         and</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="text-align: justify; padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">all resulting exchange differences are recognized in other comprehensive income.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">On consolidation, exchange differences
arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated
as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming
part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or
loss on sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(e)</b></td><td style="text-align: justify"><b>Revenue recognition</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale
                                            of hyperimmune products</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying
the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction
price to the performance obligations and recognising revenue when performance obligations are satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided
where this is outlined in a customer agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
                                            components</i></span></td>
</tr></table><p style="margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The group does
not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment
by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.</span></p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(f)</b></td><td style="text-align: justify"><b>Government grants</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Grants from the government are recognized
at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached
conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Fair value of other grants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group&#8217;s other grant income
consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable
assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the
group has recognized A$154,904 in assistance packages.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(g)</b></td><td style="text-align: justify"><b>Income tax</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The income tax expense or credit for
the period is the tax payable on the current period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction
adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The current income tax charge is calculated
on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and
its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns
with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate
on the basis of amounts expected to be paid to the tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred income tax is provided in full,
using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts
in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition
of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred tax assets are recognized only
if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Current and deferred tax is recognized
in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this
case, the tax is also recognized in other comprehensive income or directly in equity, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; "> <td style="width: 0; font-size: 10pt"/> <td style="width: 0.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(h)</b></span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AASB Interpretation 23 Uncertainty over Income Tax Treatments</b></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Interpretation 23 requires the assessment of whether the effect of
uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses,
unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax
treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity
determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes
in facts and circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The group has adopted Interpretation 23 from 1 July 2019, based on
an assessment of whether it is &#8216;probable&#8217; that a taxation authority will accept an uncertain tax treatment. This assessment
takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group&#8217;s
books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment
used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority
will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending
on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation
23 in this reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(i)</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The accounting policies for the group's leases are explained in note
14(iii).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(j)</b></td><td style="text-align: justify"><b>Impairment of assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">An impairment loss is recognized for
the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s
fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels
for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups
of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal
of the impairment at the end of each reporting period.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(k)</b></td><td style="text-align: justify"><b>Cash and cash equivalents</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For the purpose of presentation in
the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings
in current liabilities in the consolidated balance sheet.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(l)</b></td><td style="text-align: justify"><b>Trade receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are recognized initially
at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for
a description of the group&#8217;s impairment policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification
                                            as trade receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are amounts due from
customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days
and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional
unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with
the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method. Details about the group&#8217;s impairment policies and the calculation of the loss allowance are provided below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Accrued receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">These amounts primarily comprise receivables
from the Australian Taxation Office in relation to the R&amp;D tax incentive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Fair value
                                            of trade and other receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Due to the short-term nature of the
current receivables, their carrying amount is considered to be the same as their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Impairment
                                            and risk exposure</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Information about the impairment of
trade receivables and the group&#8217;s exposure to credit risk and foreign currency risk can be found in note 21.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(m)</b></td><td style="text-align: justify"><b>Inventories</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Raw materials and stores, work in progress and finished
goods</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Raw materials and stores, work in progress
and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate
proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are
assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting
rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs
of completion and the estimated costs necessary to make the sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(n)</b></td><td style="text-align: justify"><b>Investments and other financial assets</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The group classifies its financial assets in the following
measurement categories:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            subsequently at fair value (either through other comprehensive income or through profit or
                                            loss); and</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            at amortised cost.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
classification depends on the group&#8217;s business model for managing the financial assets and the contractual terms of the cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For assets measured at fair value, gains and
losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held
for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for
the equity investment at fair value through other comprehensive income (FVOCI).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Recognition
                                            and derecognition</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Regular way purchases and sales of
financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has
transferred substantially all the risks and rewards of ownership.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Measurement</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">At initial recognition, the group measures
a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction
costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL
are expensed in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="text-align: justify"><i>Impairment</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The group assesses on a forward looking
basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends
on whether there has been a significant increase in credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For
                                            trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires
                                            expected lifetime losses to be recognized from initial recognition of the receivables, see
                                            note 21(b) for further details.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>(v)</i></td><td style="text-align: justify"><i>Income recognition
                                            Interest income</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Interest income is recognized using
the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being
the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount
as interest income. Interest income on impaired loans is recognized using the original effective interest rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(o)</b></td><td style="text-align: justify"><b>Property, plant and equipment</b></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Property, plant and equipment is stated
at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Subsequent costs are included in the
asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits
associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component
accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during
the reporting period in which they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Depreciation is calculated using the
straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or,
in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">Plant and equipment	2 - 5 years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">Furniture, fittings and equipment	3 - 15 years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">Right-of-use assets	3 years</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The assets&#8217; residual values and
useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">An asset&#8217;s carrying amount is
written down immediately to its recoverable amount if the asset&#8217;s carrying amount is greater than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Gains and losses on disposals are determined
by comparing proceeds with carrying amount. These are included in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(p)</b></td><td style="text-align: justify"><b>Intangible assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Research and development</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on research activities,
undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated
statement of profit or loss and other comprehensive income as an expense when it is incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on development activities,
being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved
products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is
technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development
and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other
comprehensive income as an expense as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(q)</b></td><td style="text-align: justify"><b>Trade and other payables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These amounts represent liabilities
for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually
paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12
months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using
the effective interest method.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(r)</b></td><td style="text-align: justify"><b>Employee benefits</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Short-term obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Liabilities for wages and salaries,
including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after
the end of the period in which the employees render the related service are recognized in respect of employees&#8217; services up to
the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as current employee benefit obligations in the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Other long-term
                                            employee benefit obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">In some countries, the group also has
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the
period in which the employees render the related service. These obligations are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit
method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Consideration is given to expected
future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using
market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as
possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions
are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The obligations are presented as current
liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after
the reporting period, regardless of when the actual settlement is expected to occur.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Share-based
                                            payments</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Share-based compensation benefits are
provided to employees via the &#8216;executive share and option plan&#8217; (ESOP). Information relating to these schemes is set out
in note 19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Employee options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The fair value of options granted under
the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined
by reference to the fair value of the options granted:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td style="padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">including
                                            any market performance conditions (e.g. the company&#8217;s share price);</p></td></tr>
<tr style="vertical-align: top">
<td/><td>-</td><td style="text-align: justify; padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">excluding
                                            the impact of any service and non-market performance vesting conditions (e.g. profitability,
                                            sales growth targets and remaining an employee of the company over a specified time period);
                                            and</p></td></tr>
<tr style="vertical-align: top">
<td/><td>-</td><td style="text-align: justify; padding-right: 1.3pt">including the impact of any non-vesting conditions (e.g. the
                   requirement for employees to save or holdings shares for a specific period of time).</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The total expense is recognized over
the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period,
the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.
It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(s)</b></td><td style="text-align: justify"><b>Contributed equity</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Ordinary shares are classified as equity.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Incremental costs directly attributable
to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(t)</b></td><td style="text-align: justify"><b>Loss per share</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Basic loss per
                                            share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Basic loss per share is calculated by dividing:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">the loss attributable to owners
                                            of the company, excluding any costs of servicing equity other than ordinary shares</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">by the weighted average number of ordinary shares outstanding during the financial
                         year, adjusted for bonus elements in ordinary shares issued during the year.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Diluted loss
                                            per share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Diluted loss per share adjusts the figures used in the determination
of basic loss per share to take into account:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">the after
                                            income tax effect of interest and other financing costs associated with dilutive potential
                                            ordinary shares, and</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the weighted average
                                            number of additional ordinary shares that would have been outstanding assuming the conversion
                                            of all dilutive potential ordinary shares.</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(u)</b></td><td style="text-align: justify"><b>Rounding of amounts</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The company is of a kind referred to
in ASIC Legislative Instrument 2016/191, relating to the &#8216;rounding off&#8217; of amounts in the financial statements. Amounts in
the financial statements have been rounded off in accordance with the instrument to the nearest dollar.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(v)</b></td><td style="text-align: justify"><b>Goods and services tax (GST)</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Revenues, expenses and assets are recognized
net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized
as part of the cost of acquisition of the asset or as part of the expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Receivables and payables are stated
inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the consolidated balance sheet.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Cash flows are presented on a gross
basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the
taxation authority, are presented as operating cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Critical Accounting Estimates and Judgments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management evaluates estimates and judgments
incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable
expectation of future events and are based on current trends and economic data, obtained both internally and externally.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Share-based payments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value attributed to share options and remunerations
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value of volatility of the price of the underlying shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value of options granted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of inventories</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for impairment of inventories assessment
requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience,
the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed
on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability
study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was a $328,833 (2020: <span style="-sec-ix-hidden: hidden-fact-58">Nil</span>) finished goods
impairment and a $430,932 (2020: <span style="-sec-ix-hidden: hidden-fact-59">Nil</span>) raw materials impairment of inventories recognised during year ended 30 June 2021 for inventory
obsolescence in the consolidated statement of profit or loss and other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Inventory split</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended 30 June 2021, management
performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials
relating to Colostrum will be consumed within 12 months from reporting date (2020: <span style="-sec-ix-hidden: hidden-fact-60">Nil</span>); the remaining balance of A$1,266,587 (2020:
A$1,722,349) was estimated to be consumed beyond 12 months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provision for employee benefits</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provision for employee benefits represents amounts
accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual
leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the
required period of service. Refer to note 1(q) for policies on provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>R&amp;D tax incentive</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s research and development activities
are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities
and expenditure to determine which are likely to be eligible under the incentive scheme.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2021 the Group has
recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&amp;D tax incentive on
a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055
in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value measurement hierarchy</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements requires
management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually
evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases
its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the
related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the convertible notes classified
as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs
that required significant adjustments based on unobservable inputs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692798296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfRevenueTextBlockAbstract', window );"><strong>Disclosure of revenue [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue and other income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. Revenue and other income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue from Operating Activities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Revenue from contracts with customers</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,518,566</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Revenue from Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,387,426</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australian Federal R&amp;D Tax Concession Refund</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">356,209</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">COVID-19 government assistance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">161,600</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">74,821</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">24,480</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">617,110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">473,674</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">532,050</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Gains/(Losses) &#8211; Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net foreign exchange gains/(losses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(582,528</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,807</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impairment losses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(759,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Gains/(Losses) &#8211; Net</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,342,293</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,335</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,413</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale
                                            of hyperimmune products</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue arises mainly from the sale of products in the hyperimmune
category. To determine whether to recognise revenue, the group follows the process of identifying the contract with a customer, identifying
the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognising
revenue when performance obligations are satisfied.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue from the sale of hyperimmune products is recognised when or
as the group transfers control of the assets to the customer.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no variable consideration or significant cost to obtain the
contract. There is no warranties and no refunds. Returns are provided where this is outlined in a customer agreement.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
                                            value of R&amp;D tax incentive</i></span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The group's research and development (R&amp;D) activities are eligible
under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine
which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of
the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2021, the group has
included an item in other income of $306,154 (2020: $308,225) to recognise income over the year necessary to match the R&amp;D tax incentive
on a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional $50,055
in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
                                            value of COVID-19 government assistance and R&amp;D grants</i></span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The group's other grant income is recognised when compliance with
the conditions attached to the grant have been determined and the group has ascertained the grant will be received.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the year ended 30 June 2021, the group has recognised $161,600
(2020: $154,904) in the COVID-19 government assistance packages and a $74,821 (2020: <span style="-sec-ix-hidden: hidden-fact-65">Nil</span>) R&amp;D grant from the Henry M Jackson Foundation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfRevenueTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfRevenueTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692644264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfExpensesByNatureTextBlockAbstract', window );"><strong>Disclosure of expenses by nature [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2020<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">General and administrative expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounting and audit</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">547,055</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">389,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">496,983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bad debts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,472</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">126,215</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,474</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,508</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">43,662</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,775,809</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,531,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,599,023</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(30,055</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,991</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">341,202</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">307,757</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investor relations</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">38,568</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Legal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">205,722</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Listing and share registry</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">292,113</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,013</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Occupancy</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,973</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,606</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Superannuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">41,964</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel and entertainment</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,398</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,911</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">589,554</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">278,135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,978,679</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,703,990</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,694,306</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,006,086</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Project research and development</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360,968</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">915,965</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,367,054</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,178,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,044,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Selling</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,858</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,478</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Marketing</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">90,652</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,427</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Distribution costs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">171,174</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">236,244</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">209,739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">287,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">871,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">864,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfExpensesByNatureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfExpensesByNatureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690864504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Benefit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfIncomeTaxTextBlockAbstract', window );"><strong>Disclosure of income tax [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax Benefit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. Income Tax Benefit</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">30
    June <br/>2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Unused tax losses for which no deferred tax asset has been recognised</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">44,178,579</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">40,018,956</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Potential tax benefit @ 26% (2020: 27.5%)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,486,431</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,005,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Numerical reconciliation of income tax expense
to prima facie tax payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-style: normal; font-weight: normal">30
    June<br/> 2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss from continuing operations before income tax expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(8,384,465</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,927,206</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tax at the Australian tax rate of 26% (2020: 27.5%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,179,961</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(804,982</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax effect of amounts which are not deductible (taxable) in calculating taxable income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(92,614</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84,762</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting expenditure subject to R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">212,907</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">550,163</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(146,826</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impact of other amounts not deductible (taxable)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">428,003</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,678</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,081,502</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860,393</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax losses and other timing differences for which no deferred tax asset is recognised</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,081,502</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfIncomeTaxTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfIncomeTaxTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690988648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract', window );"><strong>Disclosure of information about key management personnel [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Key Management Personnel Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. Key Management Personnel Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note details the nature and amount of remuneration
for each Director of Immuron Limited, and for the Key Management Personnel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Directors of Immuron Limited during the year
ended June 30, 2021 were:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following persons held office as Directors
of Immuron Limited during the financial year:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Dr Roger Aston, Independent Non-Executive
Chairman</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Peter Anastasiou, Executive Vice
Chairman (resigned on 24 September 2021)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Daniel Pollock, Independent Non-Executive
Director</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Mr Stephen Anastasiou, Independent
Non-Executive Director</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Prof. Ravi Savarirayan, Independent
Non-Executive Director</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following persons held office as Key Management
Personnel of Immuron Limited during the financial year ended June 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Dr Jerry Kanellos, Chief Operating
Officer and Chief Executive Officer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate compensation made to Directors
and Other Key Management Personnel of the Company is set out below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Key Management Personnel Compensation</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Short-term employee benefits</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">450,002</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">867,054</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">952,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Other short-term benefits, including consulting services by KMP and their related entities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,603,747</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Post-employment benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">27,869</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">29,213</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Long-term benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">8,220</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,610</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,652</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Share-based payment expenses to KMP and their related entities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,116,012</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">73,088</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,296,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Key Management Personnel Compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,205,850</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">972,965</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,284,758</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690864504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEarningsPerShareTextBlockAbstract', window );"><strong>Disclosure of earnings per share [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6. Loss per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic/Diluted loss per share (in cents)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3.79</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.22</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">a) Net loss used in the calculation of basic and diluted loss
    per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">8,384,465</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,927,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,656,421</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">b) Weighted average number of ordinary shares outstanding
    during the period used in the calculation of basic and diluted loss per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">221,062,229</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,393,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,740,535</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently in a loss making position
and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company&#8217;s options and warrants
and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEarningsPerShareTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEarningsPerShareTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692653096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashExplanatoryAbstract', window );"><strong>Disclosure Of Cash Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashExplanatory', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. Cash</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Cash at Bank and in hand:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Cash at bank and in hand</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,047,281</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,250,468</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Cash</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,047,281</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,250,468</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690833368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract', window );"><strong>Disclosure of trade and other receivables [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and Other Receivables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8. Trade and Other Receivables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Trade receivables*</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">28,553</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49,519</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,055</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued income**</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Trade and Other Receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">334,707</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327,689</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trade receivables are non-interest bearing.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;D tax concession for the year.</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692680472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfInventoriesTextBlockAbstract', window );"><strong>Disclosure of inventories [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9. Inventories</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30 June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">30 June <br/>2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Raw materials and stores (Colostrum)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">1,266,587</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">1,266,587</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,722,349</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,722,349</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Work in progress</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,576</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Finished goods (Travelan and Protectyn)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,266,587</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,559,119</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">797,690</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,722,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,520,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfInventoriesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfInventoriesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690902200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Controlled Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ControlledEntitiesAbstract', window );"><strong>Controlled Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ControlledEntitiesTextBlock', window );">Controlled Entities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10. Controlled Entities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries at 30 June 2021
are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the
Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or
registration is also their principal place of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Percentage
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Ownership</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Country of Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Parent Entity:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Immuron Limited</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Subsidiaries of Immuron Limited:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Immuron Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Anadis EPS Pty Ltd</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">IMC Canada Ltd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ControlledEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ControlledEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ControlledEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a controlled entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ControlledEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692277896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract', window );"><strong>Disclosure of trade and other payables [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and Other Payables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11. Trade and Other Payables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Trade payables</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">106,893</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157,644</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">625,980</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,621</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,019</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">758,494</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">384,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692346696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Sales Returns<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract', window );"><strong>Disclosure Of Provision For Sales Returns Explantory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfProvisionForSalesReturnsExplantory', window );">Provision for Sales Returns</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12. Provision for Sales Returns</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"><b>Sales return provision due to the ongoing COVID-19 pandemic</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carrying amount at the start of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Sales return provision recognised</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">213,024</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts transferred from non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Carrying amount at the end of the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">213,024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The sales return provision has been assessed by management based on
external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled
in the next year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfProvisionForSalesReturnsExplantory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for provision for sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfProvisionForSalesReturnsExplantory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692256808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ContingentLiabilitiesAbstract', window );"><strong>Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ContingentLiabilitiesTextBlock', window );">Contingent liabilities and Commitments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 13. Contingent liabilities and Commitments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group had no contingent liabilities or commitments
at June 30, 2021 (2020: <span style="-sec-ix-hidden: hidden-fact-84">Nil</span>).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ContingentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ContingentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690908088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfLeasesTextBlockAbstract', window );"><strong>Disclosure of leases [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 14. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts
    recognized in the balance sheet</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The balance sheet shows the following amounts relating to leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">30
                                            June</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
                                            A$</span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right-of-use assets<sup>1</sup></b></span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,471</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">58,095</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,471</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease liabilities<sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">20,498</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,929</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">1.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%">Included in the line item &#8216;property, plant and equipment&#8217; in the consolidated balance sheet.</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">2.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%">Included in the line items &#8216;other current liabilities&#8217; and &#8216;other non-current liabilities&#8217; in the consolidated balance sheet.</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts
    recognized in the statement of profit or loss</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of profit or loss shows the following amounts relating
to leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
    A$</span></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold">Depreciation charge of right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,624</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">38,729</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,624</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,729</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense (included in finance cost)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,152</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to variable lease payments not included in lease liabilities (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash paid for principal payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">40,607</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,390</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total finance cash outflow for leases in 2021 was A$1,152.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total finance cash outflow for leases in 2020 was A$4,192.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    group&#8217;s leasing activities and how these are accounted for</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2019, the group entered into a three-year
commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option
for a further 3 years by written request to the landlord before 31 December 2021. There is no variability and no covenants included in
the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases are recognized as a right-of-use asset
and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated
between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant
periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter
of the asset&#8217;s useful life and the lease term on a straight-line basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities arising from a lease are
initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fixed
    payments (including in-substance fixed payments), less any lease incentives receivable</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variable
    lease payment that are based on an index or a rate</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
    expected to be payable by the lessee under residual value guarantees</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.</span></td></tr>
</table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The lease payments are discounted using the interest
rate implicit in the lease, if that rate can be determined, or the group&#8217;s incremental borrowing rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right-of-use assets are measured at cost comprising the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 0.25in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of the initial measurement of lease liability</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    lease payments made at or before the commencement date, less any lease incentives received</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    initial direct costs, and</span></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; padding-right: 12.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restoration
    costs.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments associated with short-term leases and
leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with
a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfLeasesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfLeasesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690718472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract', window );"><strong>Disclosure of classes of share capital [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15. Share capital</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Ordinary shares</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; padding-bottom: 1.5pt">Fully paid</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">178,279,566</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">163,215,706</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">62,426,991</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">60,289,875</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,279,566</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">163,215,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,426,991</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,289,875</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Movements in ordinary
    shares:</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Details</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2018</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">142,778,206</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">58,237,314</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at $0.16 in lieu
    of payment for services (2018-11-22)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,678</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at US$0.10 pursuant
    to ADS public offering (2019-05-30)<sup>2</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,894,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Reclassify exercised options from reserves to share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs arising
    on representative warrants issued<sup>3</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(110,400</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(825,055</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">163,215,706</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">60,289,875</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,565,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,926,186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at A$0.16 in lieu
    of payment for services (2019-11-12)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,978</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of NASDAQ Warrants (2020-06-23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of representative warrants (2020-06-15, 2020-06-22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">974,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540,062</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Transaction costs arising on representative warrants issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,454</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(374,728</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify">Balance at 30 June 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">178,279,566</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">62,426,991</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%">Exercise of representative warrants (2020-07-02)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,666,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,165,836</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,008,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,051,626</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,012</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,779,831</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance at 30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Notes</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#8217;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#8217;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Ordinary
    shares</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares entitle the holder to participate
in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a show of hands every holder of ordinary shares
present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares have no par value and the Company
does not have a limited amount of authorized capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td><span style="text-decoration:underline">Options</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information relating to options, including details
of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set
out in notes 15 and 18.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692351176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfReservesWithinEquityTextBlockAbstract', window );"><strong>Disclosure of reserves within equity [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory', window );">Other reserves</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16. Other reserves</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows a breakdown of the
consolidated statement of financial position line item &#8216;other reserves&#8217; and the movements in these reserves during the year.
A description of the nature and purpose of each reserve is provided below the table.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify">At 1 July 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%"/><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,139,625</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(43,317</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,096,308</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">61,846</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">61,846</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Options and warrants lapsed/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,635</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,635</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,281,790</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,529</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,300,319</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At
    1 July 2019</b></span></td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,281,790</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">18,529</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,300,319</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,938</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,088</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,088</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(484,680</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(484,680</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants lapsed/expired</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,251,320</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,251,320</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Re-valuation of options issued in prior period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">16(iii)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,011,878</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">121,467</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,133,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-based payments<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign currency translation<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total other reserves<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">At 1 July 2020</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,011,878</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">121,467</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,133,345</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,953</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transfer to share capital</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,088</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,088</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,003,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,003,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213,722</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Options and warrants forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">At 30 June 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,360,128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">106,514</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,466,642</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Nature
    and purpose of other reserves</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The share-based payment reserve records items
recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency translation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exchange differences arising on translation of
foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve
within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Movements
    in options and warrants:</span></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Details</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
&#160;A$</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2018</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 11%; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>72,569,180</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,139,625</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-07-13)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204,100</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-11-26)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of ESOP unlisted options at $0.50 (2018-10-01)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,050,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,385</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2019-02-11)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">975,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.57 (2019-02-24)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(185,601</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $1.892 (2019-02-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,380</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,173</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.30 (2019-05-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(140,056</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,390</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify exercised options from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify lapsed options from reserves to accumulated losses</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,086</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-05-23)<sup>1</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2019</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>79,463,744</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,281,790</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-valuation of options issued in prior period (2019-11-06)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iii)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(607,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-07-16)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">542,600</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,454</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2019-11-27)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,625,532</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,086,920</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.55 (2019-11-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,289,894</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2020-06-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,400</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(218,800</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(72</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-06-15, 2020-06-22)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,065,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(540,062</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2020</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,807,118</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>938,790</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-07-2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,640</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of ESOP unlisted options at $0.50 (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,700</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,048,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,012</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options (2020-09-25)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(368,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants at US$23.44 per 40 options (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,560,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,032,960</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.12 (2020-10-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,970,100</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(900,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(197,010</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify share-based payments expenses from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iv)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,088</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>45,309,478</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,360,128</b></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 13 July 2018, the Company issued Dr. Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 26 November 2018, the Company issued Mr. Richard
J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021. During
the 2019 annual general meeting, the shareholders approved the issuance of the options to Richard Berman.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 11 February 2019, the Company issued Dr. Gary
S. Jacob 5,000,000 unlisted options exercisable at $0.50. These options were subsequently forfeited on September 25, 2020, being 6 months
after his resignation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the shareholders' approval at the AGM held
on 29 October 2020, a total of 9,000,000 ESOP Options were issued to directors on 13 November 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revaluation
                                            of options issued in prior period</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options granted to Dr Gary Jacob on 11 February 2019 and valued at
$975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date
6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
                                            payment expenses</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the ongoing crisis of COVID-19, the groups
directors decided to forgo cash payments of their director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that
value. In prior year, no shares were issued to directors, however the expense of the shares owed to them was A$73,088. As at 30 June
2021, shares have been issued to directors given the shareholders' approval at the AGM held on 29 October 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reserves within equity. [Refer: Other reserves [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfReservesWithinEquityTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfReservesWithinEquityTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692068632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract', window );"><strong>Disclosure of entity's operating segments [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Segment Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of segments and principal activities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group has identified its operating segments
based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the
allocation of resources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management considers the business from both a
product and a geographic perspective and has identified two reportable segments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development (R&amp;D): income and
expenses directly attributable to the group&#8217;s R&amp;D projects performed in Australia, Israel and United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hyperimmune products: income and expenses directly
attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial breakdown</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2021 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">145,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">145,776</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">94,705</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">94,705</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617,110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(759,765</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(582,528</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,342,293</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,978,679</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,978,679</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,116,013</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,116,013</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,367,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,367,054</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(287,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(287,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(936,024</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(928,264</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,515,620</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,379,908</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,761</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,761</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(936,024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(928,264</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,520,177</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,384,465</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,587,672</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,159,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,053,106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,587,672</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,159,280</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,053,106</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">284,657</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">629,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">243,565</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">284,657</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">629,827</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,158,049</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2020 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,829,730</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,829,730</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,674</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,170,078</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,170,078</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,178,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,178,685</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(870,460</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">968,724</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3,003,839</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,905,575</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,631</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,631</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(870,460</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">968,724</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,025,470</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,927,206</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,539,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,354,435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,202,163</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,539,503</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,354,435</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,202,163</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,377</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">426,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">558,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,092</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">30,377</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">426,781</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">558,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment information for the reportable segments
for the year ended June 30, 2019 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,720,055</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,720,055</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532,050</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,394</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,807</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,037,806</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,037,806</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,044,528</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,044,528</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(864,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(864,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(513,523</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">843,062</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,985,999</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,656,460</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(513,523</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">843,062</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,985,960</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,656,421</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">531,828</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,705,330</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,324,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,561,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">531,828</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,705,330</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,324,489</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,561,647</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">221,520</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">191,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">797,155</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,210,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">221,520</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">191,836</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">797,155</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,210,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Information on geographical regions:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group derives revenue from the transfer of
hyperimmune products at a point in time in the following major product lines and geographical regions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyperimmune
    products revenue<sup>1</sup></span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,308</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,264</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,639</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,181</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,308</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,264</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,639</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,181</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>1.</sup></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Returns are provided where outlined in a customer&#8217;s agreement.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Hyperimmune products revenue</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,240,393</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">926,325</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">301,915</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">49,933</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,240,393</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">926,325</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">301,915</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">49,933</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Segment revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,162,628</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,016,468</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">149,283</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">58,683</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,162,628</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,016,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">149,283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,683</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Information on major customers:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended June 30, 2021, 2020 and
2019, the Company had the following major customers in the hyperimmune product segment with revenues amounting to 10 percent or more
of total group revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Customer A</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">41,040</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">27,563</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer C</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,319</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer D</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,214</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">462,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer E</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">22,886</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer F</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">442,916</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,661</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer G</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">438,065</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer H</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">327,559</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266,111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Customer I</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,952</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249,522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">140,022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,898,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,015,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692794344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashFlowInformationExplanatoryAbstract', window );"><strong>Disclosure Of Cash Flow Information Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashFlowInformationExplanatoryTextBlock', window );">Cash Flow Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 18. Cash Flow Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation of cash
    flow from operations with loss after income tax</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: justify">Net Loss for the Year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(8,384,465</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,927,206</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,656,421</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Adjustments for</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Depreciation expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">43,662</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Distribution costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(30,055</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,991</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Finance costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,761</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Finance income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,204</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Leave provision expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">53,610</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Share-based payments (income)/expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,116,013</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(533,912</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,343,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Unrealized net foreign currency gains</p></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">592,243</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,883</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(62,015</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add decrease in trade and other receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,037</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">680,337</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in inventories</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">960,920</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,635</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in other operating assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(45,065</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,510</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Add (decrease) / increase in trade and other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">586,796</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362,437</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">426,271</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,078,747</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,147,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,798,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-cash financing and
    investing activities</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See note 19 for details regarding issues of options
to employees and for details surrounding the issue of shares to suppliers.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashFlowInformationExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashFlowInformationExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashFlowInformationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of disclosure of cash flow information explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashFlowInformationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505827319448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract', window );"><strong>Disclosure of share-based payment arrangements [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 19. Share-based Payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive share and
    option plan</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The establishment of the &#8216;executive share
and option plan&#8217; (ESOP) was approved by shareholders at the 2017 annual general meeting. The plan is designed to provide long-term
incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board&#8217;s
discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued to Dr Gary Jacob expire within
6 months upon his resignation without good reason or termination. All other options issued expire upon departure from the company if
they are determined to be a &#8216;bad leaver&#8217;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set out below are summaries of all listed and
unlisted options, including those issued under ESOP:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; text-indent: -9pt; padding-left: 9pt">As at 1 July</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">0.40</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">42,807,118</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79,463,744</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">72,569,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.28</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">11,560,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">542,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.23</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,057,640</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/lapsed during the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">0.50</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,774,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,205,436</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">As at 30 June</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">0.31</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">45,309,478</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,807,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,463,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at 30 June</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.31</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">45,309,478</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,807,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,463,744</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share options outstanding at the end of the year
have the following expiry date and exercise prices:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry<br/> date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/> price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Grant date</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(A$ unless stated otherwise)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">30 June<br/>
 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">30 June<br/>
 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">2012-06-29</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2021-11-30</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.944</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,493</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2012-06-29</td><td>&#160;</td>
    <td style="text-align: center">2022-01-17</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,668</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-13 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2022-06-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,493,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,541,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center">2023-03-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,897,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,897,647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-09 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2022-06-08</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.3125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,240</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center">2023-03-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.585</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,510</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2019-05-23 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2024-05-23</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-07-16 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2024-07-16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2018-07-13</td><td>&#160;</td>
    <td style="text-align: center">2021-07-01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-11-06</td><td>&#160;</td>
    <td style="text-align: center">2024-02-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2020-10-29</td><td>&#160;</td>
    <td style="text-align: center">2024-04-14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">2020-07-24 (warrants)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2025-07-21</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.5859</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,560,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,309,478</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,807,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average remaining contractual life of options outstanding at end of period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><i>(i)</i></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><i>Fair value of options granted</i></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2021 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiry date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend yield</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free interest rate</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
 at grant<br/>
 date per<br/>
 option
    <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%">2020-07-24</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2025-07-21</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,560,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">127.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.4035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2020-10-29</td><td>&#160;</td>
    <td style="text-align: center">2024-04-14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,560,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2020 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">2019-11-06</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2024-02-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%">5,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.0736</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model inputs for options granted under ESOP
during the year ended June 30, 2019 included:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">2018-07-13</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2021-07-01</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.09</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.1570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>2018-11-26</td><td>&#160;</td>
    <td style="text-align: right">2020-06-30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.02</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0822</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2019-02-11</td><td>&#160;</td>
    <td style="text-align: right">2024-02-11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.69</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1950</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,300,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected life of the options is based on
historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption
that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses arising from
    share-based payment transactions</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total expenses arising from share-based payment
transactions recognized during the period were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020<sup>1</sup><br/>
    A$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options issued under ESOP</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,970,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(607,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,343,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payments to directors<sup>2</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,913</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,116,013</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(533,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,343,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>1.</sup></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Options granted to a former managing director on 11 February 2019 and
valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at
grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June
2020 financials.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>2.</sup></td><td style="text-align: justify">Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690828216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfRelatedPartyTextBlockAbstract', window );"><strong>Disclosure of related party [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 20. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests in subsidiaries are set out in note
10.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions with other
    related parties</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following transactions occurred with related
parties:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; font: italic 10pt Times New Roman, Times, Serif; text-align: left">Amounts settled in cash or shares for goods
    and services</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchases of various
    goods and services from entities controlled by key management personnel (i)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">110,607</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">142,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">147,636</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><i>(i)</i></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><i>Purchases from entities controlled by key
    management personnel</i></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group acquired the following goods and services
from entities that are controlled by members of the group&#8217;s key management personnel:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rental of an office suite
    (Wattle Laboratories Pty Ltd); and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January 2016, we executed a Lease Agreement
with Wattle Laboratories Pty Ltd, (&#8220;Wattle&#8221;), an entity part-owned and operated by our non-executive directors, Mr. Peter
Anastasiou (a director resigned on 24 September 2021) and Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities
for our operations at a rental rate of A$38,940 per year, payable in monthly installments. The rental agreement is subject to annual rental
increases, and effective January 2017, the annual rent was increased to A$39,525. The lease is for a three-year term with an additional
three-year option period. The lease may be terminated by either party upon six months&#8217; written notice. During the fiscal years ended
June 30, 2019, 2020 and 2021, we paid Wattle A$53,958, A$41,369 and A$40,607 (excluding Goods and Services Tax), respectively. The lease
was renewed, commencing January 1, 2019 for three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warehousing, distribution
    and invoicing services (Grandlodge Capital Pty Ltd).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge Capital Pty Ltd is an entity part-owned
and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on 24 September 2021) and
Mr. David Plush are also owners of Grandlodge, and its associated entities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commenced on June 1, 2013, Grandlodge provides
warehousing, distribution and invoicing services for our products for A$70,000 per year. The terms of the agreement were to have fees
payable in new fully paid ordinary shares in Immuron Limited as a set price of A$0.16 per share. The fair value of the equity instrument
has been assessed and accounted for in accordance with IFRS 2 Share Based Payments in the 2020 financial statements. During the 2020 financial
year, the fees of A$100,978 equivalent were repaid by issuance of 437,500 ordinary shares based on their fair value. During the 2019 financial
year, the fees of A$93,678 equivalent were repaid by issuance of 437,500 ordinary shares based on based on their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grandlodge is reimbursed in cash for all reasonable
costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to
an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written
notice of the termination of the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A new
agreement commenced on July 1, 2020. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing
services for Immuron's products for $70,000 per annum. The terms of the agreement were to have fees payable in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate amounts of each of the above types
of other transactions with key management personnel of Immuron Limited:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Amounts settled in cash or shares during the period</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Rental of an office suite from Wattle Laboratories
    Pty Ltd</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,607</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">41,369</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">53,958</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Services rendered by Grandlodge Capital
    Pty Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">100,978</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">93,678</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">110,607</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">142,347</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">147,636</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding balances
    arising from sales/purchases of goods and services</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following balances are outstanding at the
end of the reporting period in relation to transactions with related parties:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Current payables (purchases of goods and services)</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Entities controlled by key management personnel</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfRelatedPartyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfRelatedPartyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692202328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract', window );"><strong>Disclosure of financial risk management [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial Risk Management Objectives and Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 21. Financial Risk Management Objectives
and Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note explains the Group&#8217;s exposure
to financial risks and how these risks could affect the Group&#8217;s future financial performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s risk management is predominantly
controlled by the Board. The Board monitors the Group&#8217;s financial risk management policies and exposures and approves substantial
financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Risk Management Policy</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 36.85pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is responsible for overseeing the establishment
and implementation of the risk management system, and reviews and assesses the effectiveness of the Company&#8217;s implementation of
that system on a regular basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board and Senior Management identify the
general areas of risk and their impact on the activities of the Company, with Management performing a regular review of:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.1pt 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the major risks that occur
    within the business; the degree of risk involved;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the current approach to
    managing the risk; and</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if appropriate, determine:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any inadequacies of the
    current approach; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possible new approaches
    that more efficiently and effectively address the risk.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management report risks identified to the Board
through the monthly Operations Report.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company seeks to ensure that its exposure
to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.9pt 0pt 0; text-align: justify; "><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Market risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Foreign exchange risk</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group undertakes certain transactions denominated
in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign exchange rate risk arises from financial
assets and financial liabilities denominated in a currency that is not the group's functional currency. Exposure to foreign currency
risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange
rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency
of the group including United States dollar (USD), Canadian dollar (CAD) and Israeli Shekel (ILS). This risk is measured using sensitivity
analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exposure</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s exposure to foreign currency
risk at the end of the reporting period, expressed in Australian dollars, was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">USD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">ILS<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,742,688</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">108,688</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,954,589</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">107,605</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,801</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Trade payables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">18,556</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">43,466</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,946</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,923</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,771</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,785,045</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">152,154</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,030,126</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">109,528</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,771</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As shown in the table above, the Group is primarily
exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD
denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial
statements into AUD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has conducted a sensitivity analysis
of its exposure to foreign currency risk. The Group is currently materially exposed to the United States dollar (USD). The sensitivity
analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement
in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to
is listed below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">USD: 4.9% (2020: 3.3%)</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on loss for<br/>
 the period</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on other components<br/>
 of equity</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">USD/AUD exchange rate &#8211; change by 4.9% (2020:
    3.3%)</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">136,467</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">99,994</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,219</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,035</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holding
    all other variables constant</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss is more sensitive to movements in the AUD/USD
exchange rates in 2021 than 2020 because of the increased amount of USD denominated cash and cash equivalents and the increased variability
of the AUD/USD exchange rate. Equity is more sensitive to movements in the AUD/USD exchange rates in 2021 than 2020 because of the increased
size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group's exposure to other foreign
exchange movements is not material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Credit risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exposure to credit risk relating to financial
assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the
group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk management</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is managed through the maintenance
of procedures (such as the utilisation of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures
against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible
that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for
impairment. Credit terms are normally 30 days from the invoice date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk is also minimised through investing surplus
funds in financial institutions that maintain a high credit rating.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Security</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For some trade receivables the group may obtain
security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default
under the terms of the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment of financial
    assets</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group has one type of financial asset subject
to the expected credit loss model:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
                                            receivables for sales of inventory</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While cash and cash equivalents are also subject
to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Trade receivables</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The group applies the IFRS 9 simplified approach
to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To measure the expected credit losses, trade
receivables assets have been grouped based on shared credit risk characteristics and the days past due.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected loss rates are based on the payment
profiles of sales over a period of 60 months before June 30, 2021 and the corresponding historical credit losses experienced within this
period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting
the ability of the customers to settle the receivables.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On that basis, the loss allowance as at June
30, 2021 was determined as follows for trade receivables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Days past due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Current</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">1-30</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">31-60</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">61-90</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">91-120</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">121+</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">13.07</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">21.88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">34.09</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">53.58</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On that basis, the loss allowance as at June
30, 2020 was determined as follows for trade receivables:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Days past due</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">30 June 2020</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1-30<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-60<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">61-90<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">91-120<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">121+<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">8.06</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">23.35</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">38.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,519</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">17</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">85</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,380</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,852</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,721</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">30,055</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade receivables are written off when there
is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the
failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater
than 121 days past due.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment losses on trade receivables are presented
as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same
line item.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Previous accounting policy for impairment
of trade receivables</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the prior year, the impairment of trade receivables
was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing
the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that
an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognized in
a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following indicators were
present:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant financial difficulties
    of the debtor;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">probability that the debtor
    will enter bankruptcy or financial reorganization; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">default or late payments
    (more than 121 days overdue).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receivables for which an impairment provision
was recognized were written off against the provision when there was no expectation of recovering additional cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity risk</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk arises from the possibility that
the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The
group manages this risk through the following mechanisms:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing forward looking
    cash flow analyses in relation to its operating, investing and financing activities;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining funding from
    a variety of sources;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a reputable
    credit profile;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing credit risk related
    to financial assets;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investing cash and cash
    equivalents and deposits at call with major financial institutions; and</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">comparing the maturity
    profile of financial liabilities with the realisation profile of financial assets.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Maturities of financial liabilities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below analyze the group&#8217;s financial
liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual
discounted cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Contractual maturities of financial liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Less than 6 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6 - 12 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 1 and 2 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 2 and 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Over 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total contractual cash flows</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount (assets)/ liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">At 30 June 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">At 30 June 2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,890</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,462</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,462</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">194,553</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">237,125</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">237,125</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfFinancialRiskManagementTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692124856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events occurring after the Reporting Date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract', window );"><strong>Disclosure of events after reporting period [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events occurring after the Reporting Date</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 22. Events occurring after the Reporting
Date</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, Immuron identified a transformational
COVID-19 asset, for which it entered a binding contract to acquire. The company&#8217;s securities were placed in suspension by the Australian
Securities Exchange (ASX) until the company met the requirements set out by the Exchange. Unfortunately, after filing an ASX In-Principal
Advice Application and subsequent lengthy discussions and exchanges with the ASX, Immuron was unable to satisfy the ASX that the combined
group, following the proposed acquisition, would meet the requirements of the Listing Rules. Ultimately the ASX has an absolute discretion
whether to approve such a major acquisition. Immuron is now unable to satisfy the pre-conditions for this proposed acquisition due to
the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 23 September 2021, as a result of the company
not proceeding with the major transaction the ASX has lifted the suspension and the company's securities have now re-commenced trading
on the ASX and NASDAQ official list.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On 24 September 2021, Mr Peter Anastasiou resigned
as a director of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No other matter or circumstance has occurred
subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those
operations or the state of affairs of the group or economic entity in subsequent financial years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690914488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCompanyDetailsExplanatoryAbstract', window );"><strong>Disclosure Of Company Details Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCompanyDetailsExplanatory', window );">Company Details</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 23. Company Details</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The registered office of the Company is:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3, 62 Lygon Street, Carlton,
Victoria, Australia 3053.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The principal place of business of the Company
is:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Unit 10, 25-37 Chapman Street, Blackburn,
Victoria, Australia 3130.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCompanyDetailsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of company details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCompanyDetailsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCompanyDetailsExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCompanyDetailsExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505773419080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForBasisOfPresentation', window );">Basis of preparation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of preparation</b></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These general purpose financial statements
have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards
Board and the <i>Corporations Act 2001</i>. Immuron Limited is a for-profit entity for the purpose of preparing the financial statements.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Compliance with
                                            IFRS</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The consolidated financial statements
of the Immuron Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Historical cost
                                            convention</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The financial statements have been prepared on a historical
cost basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0"/>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Significant
    estimates and judgements</i></span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Going concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group is in a position to meet future commitments in the current
business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs
for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not
include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of
liabilities that might be necessary should the group not continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>COVID-19</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Judgement has been exercised in considering
the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration
extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group
operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date it is unknown the prolonged effect that
COVID-19 will continue to have on sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This note provides a list of the significant
accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed
in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial
statements are for the group consisting of Immuron Limited and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(iv) New standards and interpretations not
yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no standards that are not yet effective
and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future
transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(v)</i></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revision of immaterial error</i></span></td></tr>
  </table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">During the year ended June 2020 the following immaterial
error corrections were identified.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Representative warrants</i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Immuron Limited raised capital in June
2017 and May 2019, representative warrants were included as part of these public offerings. These were not identified and accounted for
at the time of these capital raisings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Management has undertaken an assessment of the impact of this and concluded
this to be an immaterial error. This has been corrected in the prior year by restating prior period financial statements presented and
the related notes included herein to include the representative warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Reserves as of 30 June 2017 has been
revised to increase by A$489,586 for the June 2017 representative warrants (1,220,000 options) with a corresponding decrease in share
capital of the same amount. The impact of the 2017 revision has been also reflected in the 30 June 2018 and 30 June 2019 years presented.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Reserves as of 30 June 2019 has been revised to increase by A$110,400
for the May 2019 representative warrants (800,000 options) with a corresponding decrease in share capital of the same amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Summary of significant accounting policies</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material accounting
policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless
otherwise stated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<i>&#160;</i></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(b)</b></td><td style="text-align: justify"><b>Principles of consolidation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>(i) Subsidiaries</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Subsidiaries are all entities (including
structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable
returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from
the date that control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The acquisition method of accounting
is used to account for business combinations by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Intercompany transactions, balances
and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to
ensure consistency with the policies adopted by the group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(c)</b></td><td style="text-align: justify"><b>Segment reporting</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive
management team consisting of the CEO and COO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(d)</b></td><td style="text-align: justify"><b>Foreign currency translation</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Functional and
                                            presentation currency</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Items included in the financial statements
of each of the group&#8217;s entities are measured using the currency of the primary economic environment in which the entity operates
(&#8216;the functional currency&#8217;). The consolidated financial statements are presented in Australian dollar (&#8220;A$&#8221; or
&#8220;$&#8221;), which is Immuron Limited&#8217;s functional and presentation currency.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Transactions
                                            and balances</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign currency transactions are translated
into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at
year end exchange rates are generally recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Foreign exchange gains and losses that
relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs.
All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income
on a net basis within other gains/(losses).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Non-monetary items that are measured
at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation
differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation
differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit
or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair
value through other comprehensive income are recognized in other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Group companies</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The results and financial position
of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from
the presentation currency are translated into the presentation currency as follows:</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">assets and liabilities for each
                                            consolidated balance sheet presented are translated at the closing rate at the date of that
                                            consolidated balance sheet;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">income and expenses for each consolidated statement of
                         profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at
                         average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates
                         prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions);
                         and</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="text-align: justify; padding-right: 1.3pt"><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">all resulting exchange differences are recognized in other comprehensive income.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">On consolidation, exchange differences
arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated
as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming
part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or
loss on sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(e)</b></td><td style="text-align: justify"><b>Revenue recognition</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale
                                            of hyperimmune products</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying
the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction
price to the performance obligations and recognising revenue when performance obligations are satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the sale of hyperimmune products is recognized when or as the group transfers control of the assets to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no variable consideration or significant cost to obtain the contract. There are no warranties and no refunds. Returns are provided
where this is outlined in a customer agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
                                            components</i></span></td>
</tr></table><p style="margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The group does
not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment
by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.</span></p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(f)</b></td><td style="text-align: justify"><b>Government grants</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Grants from the government are recognized
at their fair value where there is a reasonable assurance that the grant will be received and the group will comply with all attached
conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><i>Fair value of other grants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">The group&#8217;s other grant income
consists of grants received by the group with relation to COVID-19. Grants are recognized as other income when the group is reasonable
assured that it will comply with the conditions attaching to it and the grant will be received. For the year ended 30 June 2020, the
group has recognized A$154,904 in assistance packages.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(g)</b></td><td style="text-align: justify"><b>Income tax</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The income tax expense or credit for
the period is the tax payable on the current period&#8217;s taxable income based on the applicable income tax rate for each jurisdiction
adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The current income tax charge is calculated
on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and
its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns
with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate
on the basis of amounts expected to be paid to the tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred income tax is provided in full,
using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts
in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition
of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Deferred tax assets are recognized only
if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Current and deferred tax is recognized
in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this
case, the tax is also recognized in other comprehensive income or directly in equity, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock', window );">AASB Interpretation 23 Uncertainty over Income Tax Treatments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; "> <td style="width: 0; font-size: 10pt"/> <td style="width: 0.25in; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(h)</b></span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AASB Interpretation 23 Uncertainty over Income Tax Treatments</b></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Interpretation 23 requires the assessment of whether the effect of
uncertainty over income tax treatments should be included in the determination of taxable profit (tax loss), tax bases, unused tax losses,
unused tax credits and tax rates. The Interpretation outlines the requirements to determine whether an entity considers uncertain tax
treatments separately, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity
determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes
in facts and circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The group has adopted Interpretation 23 from 1 July 2019, based on
an assessment of whether it is &#8216;probable&#8217; that a taxation authority will accept an uncertain tax treatment. This assessment
takes into account that for certain jurisdictions in which the group operates, a local tax authority may seek to open a group&#8217;s
books as far back as inception of the group. Where it is probable, the group has determined tax balances consistently with the tax treatment
used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority
will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending
on which method is expected to better predict the resolution of the uncertainty). There has been no impact from the adoption of Interpretation
23 in this reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(i)</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>The accounting policies for the group's leases are explained in note
14(iii)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(j)</b></td><td style="text-align: justify"><b>Impairment of assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">An impairment loss is recognized for
the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s
fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels
for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups
of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal
of the impairment at the end of each reporting period.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(k)</b></td><td style="text-align: justify"><b>Cash and cash equivalents</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For the purpose of presentation in
the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts
of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings
in current liabilities in the consolidated balance sheet.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory', window );">Trade receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(l)</b></td><td style="text-align: justify"><b>Trade receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are recognized initially
at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. See note 21(b) for
a description of the group&#8217;s impairment policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification
                                            as trade receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Trade receivables are amounts due from
customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days
and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional
unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with
the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method. Details about the group&#8217;s impairment policies and the calculation of the loss allowance are provided below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Accrued receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">These amounts primarily comprise receivables
from the Australian Taxation Office in relation to the R&amp;D tax incentive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Fair value
                                            of trade and other receivables</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Due to the short-term nature of the
current receivables, their carrying amount is considered to be the same as their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Impairment
                                            and risk exposure</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Information about the impairment of
trade receivables and the group&#8217;s exposure to credit risk and foreign currency risk can be found in note 21.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(m)</b></td><td style="text-align: justify"><b>Inventories</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Raw materials and stores, work in progress and finished
goods</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Raw materials and stores, work in progress
and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate
proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are
assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting
rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs
of completion and the estimated costs necessary to make the sale.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets', window );">Investments and other financial assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(n)</b></td><td style="text-align: justify"><b>Investments and other financial assets</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Classification</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The group classifies its financial assets in the following
measurement categories:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            subsequently at fair value (either through other comprehensive income or through profit or
                                            loss); and</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">those to be measured
                                            at amortised cost.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
classification depends on the group&#8217;s business model for managing the financial assets and the contractual terms of the cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For assets measured at fair value, gains and
losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held
for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for
the equity investment at fair value through other comprehensive income (FVOCI).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Recognition
                                            and derecognition</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Regular way purchases and sales of
financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has
transferred substantially all the risks and rewards of ownership.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Measurement</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">At initial recognition, the group measures
a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction
costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL
are expensed in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iv)</i></td><td style="text-align: justify"><i>Impairment</i></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The group assesses on a forward looking
basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends
on whether there has been a significant increase in credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">For
                                            trade receivables, the group applies the simplified approach permitted by IFRS 9, which requires
                                            expected lifetime losses to be recognized from initial recognition of the receivables, see
                                            note 21(b) for further details.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>(v)</i></td><td style="text-align: justify"><i>Income recognition
                                            Interest income</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Interest income is recognized using
the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being
the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount
as interest income. Interest income on impaired loans is recognized using the original effective interest rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(o)</b></td><td style="text-align: justify"><b>Property, plant and equipment</b></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Property, plant and equipment is stated
at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify"><span style="font-size: 7pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Subsequent costs are included in the
asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits
associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component
accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during
the reporting period in which they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Depreciation is calculated using the
straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or,
in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">Plant and equipment	2 - 5 years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">Furniture, fittings and equipment	3 - 15 years</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">Right-of-use assets	3 years</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The assets&#8217; residual values and
useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">An asset&#8217;s carrying amount is
written down immediately to its recoverable amount if the asset&#8217;s carrying amount is greater than its estimated recoverable amount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Gains and losses on disposals are determined
by comparing proceeds with carrying amount. These are included in profit or loss.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(p)</b></td><td style="text-align: justify"><b>Intangible assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Research and development</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on research activities,
undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated
statement of profit or loss and other comprehensive income as an expense when it is incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Expenditure on development activities,
being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved
products or services before the start of commercial production or use, is capitalised if it is probable that the product or service is
technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development
and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other
comprehensive income as an expense as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory', window );">Trade and other payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(q)</b></td><td style="text-align: justify"><b>Trade and other payables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">These amounts represent liabilities
for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually
paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12
months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortised cost using
the effective interest method.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(r)</b></td><td style="text-align: justify"><b>Employee benefits</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Short-term obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Liabilities for wages and salaries,
including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after
the end of the period in which the employees render the related service are recognized in respect of employees&#8217; services up to
the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as current employee benefit obligations in the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Other long-term
                                            employee benefit obligations</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">In some countries, the group also has
liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the
period in which the employees render the related service. These obligations are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit
method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Consideration is given to expected
future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using
market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as
possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions
are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The obligations are presented as current
liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after
the reporting period, regardless of when the actual settlement is expected to occur.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(iii)</i></td><td style="text-align: justify"><i>Share-based
                                            payments</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Share-based compensation benefits are
provided to employees via the &#8216;executive share and option plan&#8217; (ESOP). Information relating to these schemes is set out
in note 19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0"><i>Employee options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The fair value of options granted under
the ESOP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined
by reference to the fair value of the options granted:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td style="padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">including
                                            any market performance conditions (e.g. the company&#8217;s share price);</p></td></tr>
<tr style="vertical-align: top">
<td/><td>-</td><td style="text-align: justify; padding-right: 1.3pt"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">excluding
                                            the impact of any service and non-market performance vesting conditions (e.g. profitability,
                                            sales growth targets and remaining an employee of the company over a specified time period);
                                            and</p></td></tr>
<tr style="vertical-align: top">
<td/><td>-</td><td style="text-align: justify; padding-right: 1.3pt">including the impact of any non-vesting conditions (e.g. the
                   requirement for employees to save or holdings shares for a specific period of time).</td></tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">The total expense is recognized over
the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period,
the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.
It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock', window );">Contributed equity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(s)</b></td><td style="text-align: justify"><b>Contributed equity</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Ordinary shares are classified as equity.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1.3pt 0pt 0">Incremental costs directly attributable
to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(t)</b></td><td style="text-align: justify"><b>Loss per share</b></td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Basic loss per
                                            share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Basic loss per share is calculated by dividing:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="padding-right: 1.3pt">the loss attributable to owners
                                            of the company, excluding any costs of servicing equity other than ordinary shares</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="padding-right: 1.3pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td/><td>&#9679;</td><td style="padding-right: 1.3pt">by the weighted average number of ordinary shares outstanding during the financial
                         year, adjusted for bonus elements in ordinary shares issued during the year.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Diluted loss
                                            per share</i></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Diluted loss per share adjusts the figures used in the determination
of basic loss per share to take into account:</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 1.3pt">the after
                                            income tax effect of interest and other financing costs associated with dilutive potential
                                            ordinary shares, and</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the weighted average
                                            number of additional ordinary shares that would have been outstanding assuming the conversion
                                            of all dilutive potential ordinary shares.</td>
</tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock', window );">Rounding of amounts</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(u)</b></td><td style="text-align: justify"><b>Rounding of amounts</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">The company is of a kind referred to
in ASIC Legislative Instrument 2016/191, relating to the &#8216;rounding off&#8217; of amounts in the financial statements. Amounts in
the financial statements have been rounded off in accordance with the instrument to the nearest dollar.</p><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory', window );">Goods and services tax (GST)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><b>(v)</b></td><td style="text-align: justify"><b>Goods and services tax (GST)</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">Revenues, expenses and assets are recognized
net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized
as part of the cost of acquisition of the asset or as part of the expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0; text-align: justify">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Receivables and payables are stated
inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the consolidated balance sheet.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 0">Cash flows are presented on a gross
basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the
taxation authority, are presented as operating cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Critical Accounting Estimates and Judgments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management evaluates estimates and judgments
incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable
expectation of future events and are based on current trends and economic data, obtained both internally and externally.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Share-based payments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value attributed to share options and remunerations
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value of volatility of the price of the underlying shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value of options granted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The assessed fair value of options at grant date
was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security
price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate
for the term of the security and certain probability assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of inventories</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for impairment of inventories assessment
requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience,
the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed
on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability
study was completed in September 2019 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was a $328,833 (2020: <span style="-sec-ix-hidden: hidden-fact-58">Nil</span>) finished goods
impairment and a $430,932 (2020: <span style="-sec-ix-hidden: hidden-fact-59">Nil</span>) raw materials impairment of inventories recognised during year ended 30 June 2021 for inventory
obsolescence in the consolidated statement of profit or loss and other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Inventory split</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended 30 June 2021, management
performed an assessment of its raw materials and utilisation within 12 months from reporting date. Management determined no raw materials
relating to Colostrum will be consumed within 12 months from reporting date (2020: <span style="-sec-ix-hidden: hidden-fact-60">Nil</span>); the remaining balance of A$1,266,587 (2020:
A$1,722,349) was estimated to be consumed beyond 12 months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provision for employee benefits</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provision for employee benefits represents amounts
accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual
leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the
required period of service. Refer to note 1(q) for policies on provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>R&amp;D tax incentive</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s research and development activities
are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities
and expenditure to determine which are likely to be eligible under the incentive scheme.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2021 the Group has
recorded other income of A$306,154 (2020: A$308,225) to recognise income over the year necessary to match the R&amp;D tax incentive on
a systematic basis with the costs that they are intended to compensate. Furthermore, the group subsequently received additional A$50,055
in current financial year as part of the R&amp;D claim for financial year ended 30 June 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value measurement hierarchy</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements requires
management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually
evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases
its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events,
management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the
related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the convertible notes classified
as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs
that required significant adjustments based on unobservable inputs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for trading income and expense. [Refer: Trading income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 46<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for uncertainty over income tax treatments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForBasisOfPresentation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForBasisOfPresentation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of description of accounting policy for equity policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of description of accounting policy for goods and services tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for investments and other financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity rounding of amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692048776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfRevenueTextBlockAbstract', window );"><strong>Disclosure of revenue [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Schedule of revenue and other income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Revenue from Operating Activities</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Revenue from contracts with customers</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,518,566</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Revenue from Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,387,426</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Australian Federal R&amp;D Tax Concession Refund</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">356,209</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">COVID-19 government assistance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">161,600</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">74,821</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">24,480</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">617,110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">473,674</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">532,050</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Other Gains/(Losses) &#8211; Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net foreign exchange gains/(losses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(582,528</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,807</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impairment losses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(759,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Gains/(Losses) &#8211; Net</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,342,293</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,335</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,413</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfRevenueTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfRevenueTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692303320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfExpensesByNatureTextBlockAbstract', window );"><strong>Disclosure of expenses by nature [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">Schedule of expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2020<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>30 June <br/>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">General and administrative expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounting and audit</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">547,055</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">389,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">496,983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bad debts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,472</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">126,215</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,474</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,508</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">43,662</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,775,809</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,531,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,599,023</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(30,055</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,991</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">341,202</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">307,757</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investor relations</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">38,568</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Legal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">205,722</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Listing and share registry</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">292,113</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,013</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Occupancy</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,973</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,606</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Superannuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">41,964</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel and entertainment</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,398</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,911</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">589,554</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">278,135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,978,679</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,703,990</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,694,306</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consulting</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,006,086</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Project research and development</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">360,968</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">915,965</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,367,054</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,178,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,044,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Selling</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,858</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,478</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Marketing</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">90,652</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,427</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Distribution costs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">171,174</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">236,244</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">209,739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">287,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">871,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">864,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfExpensesByNatureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfExpensesByNatureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505691990616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Benefit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfIncomeTaxTextBlockAbstract', window );"><strong>Disclosure of income tax [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock', window );">Schedule of unused tax losses for which no deferred tax asset recognized</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June<br/>
                                            2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">30
    June <br/>2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Unused tax losses for which no deferred tax asset has been recognised</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">44,178,579</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">40,018,956</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Potential tax benefit @ 26% (2020: 27.5%)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,486,431</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,005,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfIncomeTaxBenefitExplanatory', window );">Schedule of income tax benefit</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-style: normal; font-weight: normal">30
    June<br/> 2020<br/> A$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss from continuing operations before income tax expense</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(8,384,465</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,927,206</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tax at the Australian tax rate of 26% (2020: 27.5%)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,179,961</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(804,982</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax effect of amounts which are not deductible (taxable) in calculating taxable income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(92,614</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84,762</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting expenditure subject to R&amp;D tax incentive</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">212,907</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">550,163</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(146,826</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net impact of other amounts not deductible (taxable)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">428,003</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,678</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,081,502</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860,393</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax losses and other timing differences for which no deferred tax asset is recognised</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,081,502</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,393</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfIncomeTaxBenefitExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to disclosure of income tax benefit explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfIncomeTaxBenefitExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfIncomeTaxTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfIncomeTaxTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690837656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract', window );"><strong>Disclosure of information about key management personnel [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory', window );">Schedule of key management personnel compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Key Management Personnel Compensation</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Short-term employee benefits</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">450,002</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">867,054</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">952,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Other short-term benefits, including consulting services by KMP and their related entities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,603,747</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Post-employment benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">27,869</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">29,213</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Long-term benefits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">8,220</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,610</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,652</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Share-based payment expenses to KMP and their related entities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,116,012</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">73,088</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,296,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Key Management Personnel Compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,205,850</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">972,965</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,284,758</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents disclosure of detailed information of related party edxplanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690876776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEarningsPerShareTextBlockAbstract', window );"><strong>Disclosure of earnings per share [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfDetailsOfEarningsPerShareExplanatory', window );">Schedule of basic and diluted loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2019</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic/Diluted loss per share (in cents)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3.79</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.22</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">a) Net loss used in the calculation of basic and diluted loss
    per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">8,384,465</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,927,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,656,421</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">b) Weighted average number of ordinary shares outstanding
    during the period used in the calculation of basic and diluted loss per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">221,062,229</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,393,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,740,535</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfDetailsOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of disclosure of details of earnings per share explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfDetailsOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEarningsPerShareTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEarningsPerShareTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692345032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashExplanatoryAbstract', window );"><strong>Disclosure Of Cash Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DetailedInformationAboutCashExplanatory', window );">Schedule of balances under cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Cash at Bank and in hand:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Cash at bank and in hand</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,047,281</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,250,468</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Cash</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,047,281</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,250,468</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DetailedInformationAboutCashExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DetailedInformationAboutCashExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692068632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract', window );"><strong>Disclosure of trade and other receivables [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory', window );">Schedule of trade and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">30 June<br/> 2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Trade receivables*</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">28,553</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49,519</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,055</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued income**</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Trade and Other Receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">334,707</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327,689</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trade receivables are non-interest bearing.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;D tax concession for the year.</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690804536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfInventoriesTextBlockAbstract', window );"><strong>Disclosure of inventories [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DetailedInformationAboutInventoriesExplanatory', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30 June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">30 June <br/>2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> current<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Raw materials and stores (Colostrum)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">1,266,587</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">1,266,587</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,722,349</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,722,349</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Work in progress</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,576</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Finished goods (Travelan and Protectyn)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">292,532</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,266,587</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,559,119</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">797,690</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,722,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,520,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DetailedInformationAboutInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DetailedInformationAboutInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfInventoriesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfInventoriesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693266280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Controlled Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ControlledEntitiesAbstract', window );"><strong>Controlled Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfSubsidiariesExplanatory', window );">Schedule of subsidiaries</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Percentage
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Ownership</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Country of Incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"><span style="text-decoration:underline">Parent Entity:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Immuron Limited</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Subsidiaries of Immuron Limited:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Immuron Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Anadis EPS Pty Ltd</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">IMC Canada Ltd.</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ControlledEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ControlledEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692250264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract', window );"><strong>Disclosure of trade and other payables [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock', window );">Schedule of trade and other payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30
                                            June<br/>
 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Trade payables</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">106,893</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157,644</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">625,980</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,621</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,019</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">758,494</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">384,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade and other current payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690850824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Sales Returns (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract', window );"><strong>Disclosure Of Provision For Sales Returns Explantory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfSalesReturnProvisionExplantory', window );">Schedule of provision for sales returns</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"><b>Sales return provision due to the ongoing COVID-19 pandemic</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carrying amount at the start of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Sales return provision recognised</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">213,024</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts transferred from non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Carrying amount at the end of the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">213,024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfSalesReturnProvisionExplantory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity sales return provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfSalesReturnProvisionExplantory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690829656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfLeasesTextBlockAbstract', window );"><strong>Disclosure of leases [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfAmountsRecognizedinBalanceSheet', window );">Schedule of amounts relating to leases in balance sheet</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>30
                                            June</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021<br/>
                                            A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">30
                                            June</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
                                            A$</span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right-of-use assets<sup>1</sup></b></span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,471</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">58,095</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,471</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease liabilities<sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Current</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">20,498</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,929</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">1.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%">Included in the line item &#8216;property, plant and equipment&#8217; in the consolidated balance sheet.</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%"><span style="font-style: normal; font-weight: normal">2.</span></td> <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 98%">Included in the line items &#8216;other current liabilities&#8217; and &#8216;other non-current liabilities&#8217; in the consolidated balance sheet.</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfProfitOrLossAmountsRelatedToLeases', window );">Schedule of profit or loss amounts relating to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-style: normal; font-weight: normal">2020<br/>
    A$</span></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold">Depreciation charge of right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Properties</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,624</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">38,729</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,624</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,729</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense (included in finance cost)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,152</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expense relating to variable lease payments not included in lease liabilities (included in other expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash paid for principal payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">40,607</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,390</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfLeasesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfLeasesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfAmountsRecognizedinBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfAmountsRecognizedinBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfProfitOrLossAmountsRelatedToLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfProfitOrLossAmountsRelatedToLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692675720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract', window );"><strong>Disclosure of classes of share capital [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Ordinary shares</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; padding-bottom: 1.5pt">Fully paid</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">178,279,566</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">163,215,706</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">62,426,991</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">60,289,875</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,279,566</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">163,215,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,426,991</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,289,875</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfOrdinarySharesExplanatory', window );">Schedule of ordinary shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Details</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2018</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">142,778,206</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">58,237,314</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at $0.16 in lieu
    of payment for services (2018-11-22)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,678</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at US$0.10 pursuant
    to ADS public offering (2019-05-30)<sup>2</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,894,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Reclassify exercised options from reserves to share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs arising
    on representative warrants issued<sup>3</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(110,400</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(825,055</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance at 30 June 2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">163,215,706</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">60,289,875</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,565,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,926,186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue at A$0.16 in lieu
    of payment for services (2019-11-12)<sup>1</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,978</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of NASDAQ Warrants (2020-06-23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Exercise of representative warrants (2020-06-15, 2020-06-22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">974,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540,062</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Transaction costs arising on representative warrants issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,454</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(374,728</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify">Balance at 30 June 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">178,279,566</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">62,426,991</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%">Exercise of representative warrants (2020-07-02)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,666,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,165,836</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,008,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,051,626</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,012</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: Transaction costs arising on share issues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,779,831</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance at 30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,246,596</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,361,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#8217;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#8217;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top"> <td style="padding: 0; text-align: justify; text-indent: 0; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="padding: 0; text-align: justify; text-indent: 0; width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfOrdinarySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfOrdinarySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692268536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfReservesWithinEquityTextBlockAbstract', window );"><strong>Disclosure of reserves within equity [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfDetailedInformationOtherReserve', window );">Schedule of other reserves</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify">At 1 July 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%"/><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,139,625</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(43,317</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,096,308</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">61,846</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">61,846</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Options and warrants lapsed/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,635</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(311,635</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,281,790</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,529</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,300,319</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-based payments<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation<br/>
    A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total other reserves<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At
    1 July 2019</b></span></td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,281,790</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">18,529</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,300,319</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,938</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,088</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,088</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(484,680</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(484,680</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options and warrants lapsed/expired</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,251,320</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,251,320</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Re-valuation of options issued in prior period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">16(iii)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">At 30 June 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,011,878</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">121,467</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,133,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-based payments<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign currency translation<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total other reserves<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">At 1 July 2020</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,011,878</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">121,467</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,133,345</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Currency translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,953</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transfer to share capital</td><td>&#160;</td>
    <td style="text-align: center">16(iv)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,088</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,088</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Options and warrants issued/expensed</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,003,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,003,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options and warrants exercised</td><td>&#160;</td>
    <td style="text-align: center">16(ii)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213,722</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Options and warrants forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">At 30 June 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,360,128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">106,514</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,466,642</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants', window );">Schedule of movements in options and warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Details</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of options</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
&#160;A$</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2018</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 11%; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>72,569,180</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,139,625</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-07-13)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204,100</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2018-11-26)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of ESOP unlisted options at $0.50 (2018-10-01)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,050,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,385</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.50 (2019-02-11)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">975,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.57 (2019-02-24)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(185,601</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $1.892 (2019-02-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,380</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,173</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unlisted options at $0.30 (2019-05-28)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(140,056</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,390</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify exercised options from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify lapsed options from reserves to accumulated losses</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,086</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-05-23)<sup>1</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,400</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2019</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>79,463,744</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,281,790</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-valuation of options issued in prior period (2019-11-06)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iii)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(607,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants (2019-07-16)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">542,600</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,454</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2019-11-27)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,625,532</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,086,920</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.55 (2019-11-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,289,894</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options at $0.50 (2020-06-30)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,400</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(218,800</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(72</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-06-15, 2020-06-22)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,065,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(540,062</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2020</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,807,118</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>938,790</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of representative warrants (2020-07-2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,640</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of ESOP unlisted options at $0.50 (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,700</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,048,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,012</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lapse of unexercised options (2020-09-25)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(368,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of representative warrants at US$23.44 per 40 options (2020-07-24)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,560,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,032,960</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of ESOP unlisted options at $0.12 (2020-10-29)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,970,100</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(900,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(197,010</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify share-based payments expenses from reserves to share capital</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16(iv)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,088</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at 30 June 2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>45,309,478</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,360,128</b></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about movements in options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfDetailedInformationOtherReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about other reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfDetailedInformationOtherReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfReservesWithinEquityTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfReservesWithinEquityTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690620856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract', window );"><strong>Disclosure of entity's operating segments [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosuresOfProductsAndServicesExplanatory', window );">Schedule of segment information for the reportable segments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">145,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">145,776</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">94,705</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">94,705</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617,110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(759,765</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(582,528</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,342,293</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,978,679</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,978,679</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,116,013</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,116,013</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,367,054</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,367,054</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(287,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(287,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(936,024</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(928,264</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,515,620</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,379,908</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,761</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,761</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(936,024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(928,264</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,520,177</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,384,465</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,587,672</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,159,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,053,106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">306,154</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,587,672</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,159,280</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,053,106</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">284,657</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">629,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">243,565</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">284,657</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">629,827</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,158,049</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,566</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(688,836</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,829,730</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,829,730</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,674</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,335</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,170,078</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,170,078</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,178,685</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,178,685</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(870,460</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">968,724</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(3,003,839</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,905,575</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,631</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,631</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(870,460</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">968,724</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,025,470</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,927,206</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,539,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,354,435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,202,163</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,225</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,539,503</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,354,435</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,202,163</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,377</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">426,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">558,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,092</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">30,377</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">426,781</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">558,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Research and development</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Hyperimmune products</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Hyperimmune products revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,387,426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales of goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,720,055</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,720,055</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532,050</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other gains/(losses) &#8211; net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,394</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,807</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,037,806</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,037,806</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,044,528</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,044,528</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling and marketing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(864,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(864,644</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating profit/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(513,523</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">843,062</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,985,999</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,656,460</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Profit/(loss) for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(513,523</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">843,062</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,985,960</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,656,421</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">531,828</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,705,330</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,324,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,561,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">531,828</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,705,330</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,324,489</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,561,647</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Segment liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">221,520</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">191,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">797,155</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,210,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">221,520</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">191,836</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">797,155</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,210,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Schedule of information on geographical regions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>2021</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyperimmune
    products revenue<sup>1</sup></span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,308</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,264</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,639</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,181</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,308</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,264</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,639</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,181</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,776</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Hyperimmune products revenue</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,240,393</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">926,325</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">301,915</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">49,933</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,240,393</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">926,325</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">301,915</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">49,933</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,518,566</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Travelan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Protectyn</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">United States</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Australia</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-bottom: 1.5pt">Segment revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,162,628</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,016,468</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">149,283</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">58,683</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from external customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,162,628</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,016,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">149,283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,683</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,387,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory', window );">Schedule of major customers</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Customer A</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">41,040</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">27,563</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer C</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,319</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer D</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,214</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">462,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer E</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">22,886</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer F</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">442,916</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,661</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer G</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">438,065</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Customer H</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">327,559</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266,111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Customer I</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">227,952</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249,522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">140,022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,898,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,015,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of major customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosuresOfProductsAndServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's products and services. [Refer: Products and services [member].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosuresOfProductsAndServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692224312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfCashFlowInformationExplanatoryAbstract', window );"><strong>Disclosure Of Cash Flow Information Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory', window );">Schedule of reconciliation of cash flow from operations with loss after income tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2021<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2020<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">30 June<br/> 2019<br/> A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: justify">Net Loss for the Year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(8,384,465</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,927,206</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,656,421</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Adjustments for</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Depreciation expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">43,662</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Distribution costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Expected credit losses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(30,055</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,991</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Finance costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,761</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Finance income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,204</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Leave provision expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">53,610</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,580</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Share-based payments (income)/expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,116,013</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(533,912</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,343,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Unrealized net foreign currency gains</p></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">592,243</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,883</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(62,015</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add decrease in trade and other receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,037</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">680,337</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in inventories</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">960,920</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,635</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Add (increase) / decrease in other operating assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(45,065</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,510</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Add (decrease) / increase in trade and other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">586,796</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362,437</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">426,271</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,078,747</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,147,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,798,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfCashFlowInformationExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfCashFlowInformationExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692928792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsTablesLineItems', window );"><strong>Share-based Payments (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfDeemedValuationOfOptionsExplanatory', window );">Schedule of granted valuation of options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry<br/> date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/> price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Grant date</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(A$ unless stated otherwise)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">30 June<br/>
 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">30 June<br/>
 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">2012-06-29</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2021-11-30</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.944</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,493</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2012-06-29</td><td>&#160;</td>
    <td style="text-align: center">2022-01-17</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,668</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-13 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2022-06-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,493,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,541,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center">2023-03-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,897,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,897,647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2017-06-09 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2022-06-08</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.3125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,240</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2018-03-15</td><td>&#160;</td>
    <td style="text-align: center">2023-03-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.585</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,510</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2019-05-23 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2024-05-23</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-07-16 (warrants)</td><td>&#160;</td>
    <td style="text-align: center">2024-07-16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.125</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2018-07-13</td><td>&#160;</td>
    <td style="text-align: center">2021-07-01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2019-11-06</td><td>&#160;</td>
    <td style="text-align: center">2024-02-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2020-10-29</td><td>&#160;</td>
    <td style="text-align: center">2024-04-14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">2020-07-24 (warrants)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2025-07-21</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 0.5859</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,560,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,309,478</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,807,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average remaining contractual life of options outstanding at end of period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions', window );">Schedule of total expenses arising from share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020<sup>1</sup><br/>
    A$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019<br/> A$</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Options issued under ESOP</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,970,100</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(607,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,343,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payments to directors<sup>2</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">145,913</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,116,013</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(533,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,343,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imc_EmployeeStockOption1Member', window );">ESOP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsTablesLineItems', window );"><strong>Share-based Payments (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory', window );">Schedule of movement in number of stock options outstanding and weighted average exercise price</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average exercise price per share
    option (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; text-indent: -9pt; padding-left: 9pt">As at 1 July</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">0.40</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">42,807,118</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79,463,744</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">72,569,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.28</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">11,560,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">542,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.23</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,057,640</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/lapsed during the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">0.50</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,774,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,205,436</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">As at 30 June</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">0.31</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">45,309,478</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,807,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,463,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at 30 June</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.31</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">45,309,478</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,807,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,463,744</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfDeemedValuationOfOptionsExplanatory', window );">Schedule of granted valuation of options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiry date</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend yield</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free interest rate</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
 at grant<br/>
 date per<br/>
 option
    <br/>
(A$)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%">2020-07-24</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2025-07-21</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,560,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">127.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.4035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>2020-10-29</td><td>&#160;</td>
    <td style="text-align: center">2024-04-14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,560,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Grant date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">2019-11-06</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2024-02-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; width: 9%">5,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.0736</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
    price<br/>
 (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of<br/>
    options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
    volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dividend<br/>
    yield</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk- free<br/>
    interest rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value<br/>
    at grant<br/>
    date per<br/>
    option<br/>
    (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%">2018-07-13</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2021-07-01</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.09</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.1570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>2018-11-26</td><td>&#160;</td>
    <td style="text-align: right">2020-06-30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.02</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0822</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2019-02-11</td><td>&#160;</td>
    <td style="text-align: right">2024-02-11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.69</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1950</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,300,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfDeemedValuationOfOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of deemed valuation of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfDeemedValuationOfOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imc_EmployeeStockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=imc_EmployeeStockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692666600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfRelatedPartyTextBlockAbstract', window );"><strong>Disclosure of related party [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory', window );">Schedule of information about other related party transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; font: italic 10pt Times New Roman, Times, Serif; text-align: left">Amounts settled in cash or shares for goods
    and services</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchases of various
    goods and services from entities controlled by key management personnel (i)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-style: normal; font-weight: normal">110,607</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">142,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">147,636</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019<br/>
    A$</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Amounts settled in cash or shares during the period</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Rental of an office suite from Wattle Laboratories
    Pty Ltd</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,607</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">41,369</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">53,958</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Services rendered by Grandlodge Capital
    Pty Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">100,978</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">93,678</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">110,607</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">142,347</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">147,636</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of outstanding balances transactions between related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Current payables (purchases of goods and services)</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left">Entities controlled by key management personnel</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">70,000</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about other related party transactions explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfRelatedPartyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfRelatedPartyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505838228456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract', window );"><strong>Disclosure of financial risk management [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory', window );">Schedule of foreign currency risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/>
    $</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">USD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">CAD<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">ILS<br/> $</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,742,688</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">108,688</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,954,589</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">107,605</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23,801</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Trade payables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">18,556</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">43,466</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,946</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,923</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,771</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,785,045</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">152,154</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,030,126</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">109,528</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,771</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfExchangerateTableExplanatory', window );">Schedule of exchange rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on loss for<br/>
 the period</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Impact
    on other components<br/>
 of equity</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021<br/>
    A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2020<br/> A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left">USD/AUD exchange rate &#8211; change by 4.9% (2020:
    3.3%)</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">136,467</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">99,994</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,219</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,035</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory', window );">Schedule of trade receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Days past due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Current</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">1-30</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">31-60</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">61-90</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">91-120</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">121+</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">30 June 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">13.07</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">21.88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">34.09</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">53.58</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Days past due</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">30 June 2020</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1-30<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-60<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">61-90<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">91-120<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">121+<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Expected credit loss rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">8.06</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">23.35</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">38.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,519</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss allowance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">17</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">85</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,380</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,852</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23,721</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">30,055</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfTradeAndOtherPayablesTableExplanatory', window );">Schedule of contractual undiscounted cash flows</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Contractual maturities of financial liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Less than 6 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6 - 12 months</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 1 and 2 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Between 2 and 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Over 5 years</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total contractual cash flows</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount (assets)/ liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">At 30 June 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 7%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">132,514</td><td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,498</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">153,012</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">At 30 June 2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,663</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,890</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,462</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,462</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">194,553</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,286</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">237,125</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">237,125</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfExchangerateTableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail dislcosure of exchange rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfExchangerateTableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dislcosure of financial assets and liabilities are subject to foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfFinancialRiskManagementTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherPayablesTableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The detail disclosure of trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherPayablesTableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The detail disclosure of trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693308584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RepresentativesWarrants', window );">Representative warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,400<span></span>
</td>
<td class="nump">$ 489,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareCapital', window );">Share capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AssistancePackages', window );">Assistance packages</a></td>
<td class="nump">$ 154,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">328,833<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NonCurrentRawMaterials', window );">Raw materials non-current</a></td>
<td class="nump">1,266,587<span></span>
</td>
<td class="nump">1,722,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RAndDTaxConcessionRefund', window );">Other income R&amp;D tax concession refund</a></td>
<td class="nump">$ 306,154<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AdditionalRAndDTaxReceived', window );">Additional R&amp;D fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imc_PlantAndEquipmentMember', window );">Plant and Equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imc_PlantAndEquipmentMember', window );">Plant and Equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture, fittings and equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture, fittings and equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AdditionalRAndDTaxReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional research and developement tax received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AdditionalRAndDTaxReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AssistancePackages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assistance packages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AssistancePackages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NonCurrentRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to non current raw materials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NonCurrentRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RAndDTaxConcessionRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent RAndD tax Concession refund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RAndDTaxConcessionRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RepresentativesWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Representative warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RepresentativesWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of useful lives or depreciation rates property plant and equipment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imc_PlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=imc_PlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505700905016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfRevenueTextBlockAbstract', window );"><strong>Disclosure of revenue [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherIncomeOfResearchAndDevelopment', window );">Other income</a></td>
<td class="nump">$ 306,154<span></span>
</td>
<td class="nump">$ 308,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AdditionalOtherIncome', window );">Additional other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GovernmentAssistancePackages', window );">Government assistance packages</a></td>
<td class="nump">161,600<span></span>
</td>
<td class="nump">154,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ResearchAndDevelopmentsGrants', window );">R&amp;D grant</a></td>
<td class="nump">$ 74,821<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AdditionalOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AdditionalOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfRevenueTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfRevenueTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_GovernmentAssistancePackages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government assistance packages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_GovernmentAssistancePackages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherIncomeOfResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income of research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherIncomeOfResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ResearchAndDevelopmentsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ResearchAndDevelopmentsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692848792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income (Details) - Schedule of revenue and other income - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromOperatingActivitiesAbstract', window );"><strong>Revenue from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 145,776<span></span>
</td>
<td class="nump">$ 2,518,566<span></span>
</td>
<td class="nump">$ 2,387,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Total Revenue from Operating Activities</a></td>
<td class="nump">145,776<span></span>
</td>
<td class="nump">2,518,566<span></span>
</td>
<td class="nump">2,387,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AustralianFederalRdTaxConcessionRefund', window );">Australian Federal R&amp;D Tax Concession Refund</a></td>
<td class="nump">356,209<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
<td class="nump">531,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherGovernmentAssistanceIncome', window );">COVID-19 government assistance</a></td>
<td class="nump">161,600<span></span>
</td>
<td class="nump">154,904<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ResearchAndDevelopmentGrants', window );">R&amp;D grants</a></td>
<td class="nump">74,821<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherIncomes', window );">Other income</a></td>
<td class="nump">24,480<span></span>
</td>
<td class="nump">10,545<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherIncomeFromNonOperatingActivities', window );">Total Other Income</a></td>
<td class="nump">617,110<span></span>
</td>
<td class="nump">473,674<span></span>
</td>
<td class="nump">532,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherGainsLossesNetAbstract', window );"><strong>Other Gains/(Losses) &#8211; Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NetForeignExchangeGainLoss', window );">Net foreign exchange gains/(losses)</a></td>
<td class="num">(582,528)<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">51,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Net impairment losses</a></td>
<td class="num">(759,765)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,394)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Total Other Gains/(Losses) &#8211; Net</a></td>
<td class="num">$ (1,342,293)<span></span>
</td>
<td class="nump">$ 11,335<span></span>
</td>
<td class="nump">$ 38,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2021-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2021-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AustralianFederalRdTaxConcessionRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AustralianFederalRdTaxConcessionRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NetForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain loss arising from foreign exchange differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NetForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherGainsLossesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherGainsLossesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherGovernmentAssistanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other government assistance income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherGovernmentAssistanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherIncomeFromNonOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents other income from non operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherIncomeFromNonOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherIncomes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherIncomes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevenueFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevenueFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695598536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses (Details) - Schedule of expenses - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AccountingAndAudit', window );">Accounting and audit</a></td>
<td class="nump">$ 547,055<span></span>
</td>
<td class="nump">$ 389,798<span></span>
</td>
<td class="nump">$ 496,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_BadDebts', window );">Bad debts</a></td>
<td class="nump">5,472<span></span>
</td>
<td class="nump">26,983<span></span>
</td>
<td class="nump">50,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ConsultingExpenses', window );">Consulting</a></td>
<td class="nump">126,215<span></span>
</td>
<td class="nump">181,474<span></span>
</td>
<td class="nump">243,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation</a></td>
<td class="nump">43,662<span></span>
</td>
<td class="nump">44,056<span></span>
</td>
<td class="nump">5,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Employee benefits</a></td>
<td class="nump">1,775,809<span></span>
</td>
<td class="nump">1,531,037<span></span>
</td>
<td class="nump">1,599,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExpectedCreditLosses', window );">Expected credit losses</a></td>
<td class="num">(30,055)<span></span>
</td>
<td class="num">(3,991)<span></span>
</td>
<td class="nump">34,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance</a></td>
<td class="nump">341,202<span></span>
</td>
<td class="nump">469,844<span></span>
</td>
<td class="nump">307,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InvestorRelationsExpenses', window );">Investor relations</a></td>
<td class="nump">38,568<span></span>
</td>
<td class="nump">197,839<span></span>
</td>
<td class="nump">128,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LegalExpenses', window );">Legal</a></td>
<td class="nump">205,722<span></span>
</td>
<td class="nump">184,382<span></span>
</td>
<td class="nump">171,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ListingAndShareRegistry', window );">Listing and share registry</a></td>
<td class="nump">292,113<span></span>
</td>
<td class="nump">212,236<span></span>
</td>
<td class="nump">186,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UtilitiesExpense', window );">Occupancy</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">51,973<span></span>
</td>
<td class="nump">105,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SuperannuationExpenses', window );">Superannuation</a></td>
<td class="nump">41,964<span></span>
</td>
<td class="nump">48,877<span></span>
</td>
<td class="nump">55,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel and entertainment</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">91,347<span></span>
</td>
<td class="nump">159,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other</a></td>
<td class="nump">589,554<span></span>
</td>
<td class="nump">278,135<span></span>
</td>
<td class="nump">151,007<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">3,978,679<span></span>
</td>
<td class="nump">3,703,990<span></span>
</td>
<td class="nump">3,694,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ResearchAndDevelopmentConsultingExpenses', window );">Consulting</a></td>
<td class="nump">1,006,086<span></span>
</td>
<td class="nump">262,720<span></span>
</td>
<td class="nump">430,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyDevelopmentAndProjectManagementExpense', window );">Project research and development</a></td>
<td class="nump">360,968<span></span>
</td>
<td class="nump">915,965<span></span>
</td>
<td class="nump">613,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,367,054<span></span>
</td>
<td class="nump">1,178,685<span></span>
</td>
<td class="nump">1,044,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SellingAndMarketingExpensesAbstract', window );"><strong>Selling and marketing expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingExpense', window );">Selling</a></td>
<td class="nump">25,858<span></span>
</td>
<td class="nump">340,046<span></span>
</td>
<td class="nump">277,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MarketingExpenses', window );">Marketing</a></td>
<td class="nump">90,652<span></span>
</td>
<td class="nump">295,261<span></span>
</td>
<td class="nump">377,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DistributionCosts', window );">Distribution costs</a></td>
<td class="nump">171,174<span></span>
</td>
<td class="nump">236,244<span></span>
</td>
<td class="nump">209,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Total selling and marketing expenses</a></td>
<td class="nump">$ 287,684<span></span>
</td>
<td class="nump">$ 871,551<span></span>
</td>
<td class="nump">$ 864,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to the distribution of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 5<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyDevelopmentAndProjectManagementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from property development and project management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyDevelopmentAndProjectManagementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from travel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UtilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UtilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AccountingAndAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accounting and audit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AccountingAndAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_BadDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of bad debts expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_BadDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ConsultingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consultinf expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ConsultingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InvestorRelationsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investor relation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InvestorRelationsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LegalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of legal expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LegalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ListingAndShareRegistry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of listing and share registry.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ListingAndShareRegistry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_MarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_MarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ResearchAndDevelopmentConsultingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development consulting expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ResearchAndDevelopmentConsultingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SellingAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SellingAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SuperannuationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of superannuation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SuperannuationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692995256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract', window );"><strong>Schedule of unused tax losses for which no deferred tax asset recognized [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset has been recognised</a></td>
<td class="nump">$ 44,178,579<span></span>
</td>
<td class="nump">$ 40,018,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Potential tax benefit @ 26% (2020: 27.5%)</a></td>
<td class="nump">$ 11,486,431<span></span>
</td>
<td class="nump">$ 11,005,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505839866360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Benefit (Details) - Schedule of income tax benefit - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfIncomeTaxBenefitAbstract', window );"><strong>Schedule of income tax benefit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss from continuing operations before income tax expense</a></td>
<td class="num">$ (8,384,465)<span></span>
</td>
<td class="num">$ (2,927,206)<span></span>
</td>
<td class="num">$ (4,656,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Tax at the Australian tax rate of 26% (2020: 27.5%)</a></td>
<td class="num">(2,179,961)<span></span>
</td>
<td class="num">(804,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TaxEffectofResearchAndDevelopmentTaxIncentive', window );">R&amp;D tax incentive</a></td>
<td class="num">(92,614)<span></span>
</td>
<td class="num">(84,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive', window );">Accounting expenditure subject to R&amp;D tax incentive</a></td>
<td class="nump">212,907<span></span>
</td>
<td class="nump">194,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TaxEffectOfShareBasedPayments', window );">Share-based payments</a></td>
<td class="nump">550,163<span></span>
</td>
<td class="num">(146,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses', window );">Net impact of other amounts not deductible (taxable)</a></td>
<td class="nump">428,003<span></span>
</td>
<td class="num">(18,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TaxEffectOfTaxPayable', window );">Subtotal</a></td>
<td class="num">(1,081,502)<span></span>
</td>
<td class="num">(860,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss', window );">Tax losses and other timing differences for which no deferred tax asset is recognised</a></td>
<td class="nump">1,081,502<span></span>
</td>
<td class="nump">860,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income not recognized relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfIncomeTaxBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfIncomeTaxBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount representing the accounting expenditure subject to research and development tax incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TaxEffectOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount representing the share-based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TaxEffectOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TaxEffectOfTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TaxEffectOfTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TaxEffectofResearchAndDevelopmentTaxIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the research and development tax incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TaxEffectofResearchAndDevelopmentTaxIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695271608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_KeyManagementPersonnelCompensationAbstract', window );"><strong>Key Management Personnel Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">$ 450,002<span></span>
</td>
<td class="nump">$ 867,054<span></span>
</td>
<td class="nump">$ 952,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities', window );">Other short-term benefits, including consulting services by KMP and their related entities</a></td>
<td class="nump">1,603,747<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">27,869<span></span>
</td>
<td class="nump">29,213<span></span>
</td>
<td class="nump">32,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Long-term benefits</a></td>
<td class="nump">8,220<span></span>
</td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payment expenses to KMP and their related entities</a></td>
<td class="nump">2,116,012<span></span>
</td>
<td class="nump">73,088<span></span>
</td>
<td class="nump">1,296,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total Key Management Personnel Compensation</a></td>
<td class="nump">$ 4,205,850<span></span>
</td>
<td class="nump">$ 972,965<span></span>
</td>
<td class="nump">$ 2,284,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_KeyManagementPersonnelCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_KeyManagementPersonnelCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other short-term employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696739544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Details) - Schedule of basic and diluted loss per share - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfBasicAndDilutedLossPerShareAbstract', window );"><strong>Schedule of basic and diluted loss per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_BasicAndDilutedEarningsLossPerShare', window );">Basic/Diluted loss per share (in cents)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 3.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects', window );">a) Net loss used in the calculation of basic and diluted loss per share</a></td>
<td class="nump">$ 8,384,465<span></span>
</td>
<td class="nump">$ 2,927,206<span></span>
</td>
<td class="nump">$ 4,656,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageNumberOfShares', window );">b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share</a></td>
<td class="nump">221,062,229<span></span>
</td>
<td class="nump">176,393,354<span></span>
</td>
<td class="nump">144,740,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfBasicAndDilutedLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfBasicAndDilutedLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents weighted average number of Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692329800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash (Details) - Schedule of balances under cash - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash at Bank and in hand:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CashAtBankAndInHand', window );">Cash at bank and in hand</a></td>
<td class="nump">$ 25,047,281<span></span>
</td>
<td class="nump">$ 3,250,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Total Cash</a></td>
<td class="nump">$ 25,047,281<span></span>
</td>
<td class="nump">$ 3,250,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CashAtBankAndInHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CashAtBankAndInHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693125160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables (Details) - Schedule of trade and other receivables - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract', window );"><strong>Current</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 28,553<span></span>
</td>
<td class="nump">$ 49,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossOnAllowanceTradeReceivables', window );">Loss allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(30,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccruedIncomeOtherThanContractAssets', window );">Accrued income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">306,154<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Total Trade and Other Receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 334,707<span></span>
</td>
<td class="nump">$ 327,689<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trade receivables are non-interest bearing.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primarily comprises of receivables from the Australian Tax Office in relation to R&amp;D tax concession for the year.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccruedIncomeOtherThanContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing income that has been earned but is not yet a receivable, other than contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccruedIncomeOtherThanContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LossOnAllowanceTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LossOnAllowanceTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695768152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - Schedule of inventories - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesDetailsScheduleofinventoriesLineItems', window );"><strong>Inventories (Details) - Schedule of inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories Current</a></td>
<td class="nump">$ 292,532<span></span>
</td>
<td class="nump">$ 797,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentInventories', window );">Inventories Non- current</a></td>
<td class="nump">1,266,587<span></span>
</td>
<td class="nump">1,722,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesNet', window );">Net</a></td>
<td class="nump">1,559,119<span></span>
</td>
<td class="nump">2,520,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesAxis=imc_RawMaterialsAndStoresMember', window );">Raw materials and stores (Colostrum) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesDetailsScheduleofinventoriesLineItems', window );"><strong>Inventories (Details) - Schedule of inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentInventories', window );">Inventories Non- current</a></td>
<td class="nump">1,266,587<span></span>
</td>
<td class="nump">1,722,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesNet', window );">Net</a></td>
<td class="nump">1,266,587<span></span>
</td>
<td class="nump">1,722,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesAxis=imc_WorkInProgressMember', window );">Work in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesDetailsScheduleofinventoriesLineItems', window );"><strong>Inventories (Details) - Schedule of inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories Current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">117,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentInventories', window );">Inventories Non- current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesNet', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">117,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesAxis=imc_FinishedGoodsMember', window );">Finished goods (Travelan and Protectyn) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesDetailsScheduleofinventoriesLineItems', window );"><strong>Inventories (Details) - Schedule of inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories Current</a></td>
<td class="nump">292,532<span></span>
</td>
<td class="nump">680,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentInventories', window );">Inventories Non- current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_InventoriesNet', window );">Net</a></td>
<td class="nump">$ 292,532<span></span>
</td>
<td class="nump">$ 680,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InventoriesDetailsScheduleofinventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InventoriesDetailsScheduleofinventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InventoriesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InventoriesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InventoriesAxis=imc_RawMaterialsAndStoresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InventoriesAxis=imc_RawMaterialsAndStoresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InventoriesAxis=imc_WorkInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InventoriesAxis=imc_WorkInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_InventoriesAxis=imc_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_InventoriesAxis=imc_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505823398792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Controlled Entities (Details) - Schedule of subsidiaries<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronLimitedMember', window );">Immuron Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ParentEntityAbstract', window );"><strong>Parent Entity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of Incorporation</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronIncMember', window );">Immuron Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ParentEntityAbstract', window );"><strong>Parent Entity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of Incorporation</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_AnadisEPSPtyLtdMember', window );">Anadis EPS Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ParentEntityAbstract', window );"><strong>Parent Entity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of Incorporation</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_IMCCanadaLtdMember', window );">IMC Canada Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ParentEntityAbstract', window );"><strong>Parent Entity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of Incorporation</a></td>
<td class="text">Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 19B<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ParentEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ParentEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_ImmuronIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_AnadisEPSPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_AnadisEPSPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_IMCCanadaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imc_IMCCanadaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695667640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables (Details) - Schedule of trade and other payables - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 106,893<span></span>
</td>
<td class="nump">$ 157,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued expenses</a></td>
<td class="nump">625,980<span></span>
</td>
<td class="nump">210,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">25,621<span></span>
</td>
<td class="nump">16,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">$ 758,494<span></span>
</td>
<td class="nump">$ 384,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692162888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Sales Returns (Details) - Schedule of provision for sales returns<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfProvisionForSalesReturnsAbstract', window );"><strong>Schedule of provision for sales returns [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at the start of the year</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Sales return provision recognised</a></td>
<td class="nump">213,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Amounts transferred from non-current</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at the end of the year</a></td>
<td class="nump">$ 213,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfProvisionForSalesReturnsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfProvisionForSalesReturnsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690903288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingent liabilities and Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ContingentLiabilitiesAbstract', window );"><strong>Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 86<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505690947864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfLeasesTextBlockAbstract', window );"><strong>Disclosure of leases [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Finance cash outflow for leases</a></td>
<td class="nump">$ 1,152<span></span>
</td>
<td class="nump">$ 4,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InformationAboutNatureOfLesseesLeasingActivities', window );">Lease, description</a></td>
<td class="text">In January 2019, the group entered into a three-year
commercial lease in Blackburn North. The lease is for the use of warehousing and office facilities. This lease includes an extension option
for a further 3 years by written request to the landlord before 31 December 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InformationAboutNatureOfLesseesLeasingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about the nature of the lessee's leasing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 59<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_59_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InformationAboutNatureOfLesseesLeasingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfLeasesTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfLeasesTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505691055304">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of amounts relating to leases in balance sheet - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems', window );"><strong>Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 19,471<span></span>
</td>
<td class="nump">$ 58,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">42,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">61,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Properties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems', window );"><strong>Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 19,471<span></span>
</td>
<td class="nump">$ 58,095<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in the line item &#8216;property, plant and equipment&#8217; in the consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in the line items &#8216;other current liabilities&#8217; and &#8216;other non-current liabilities&#8217; in the consolidated balance sheet.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696249496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of profit or loss amounts relating to leases - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DepreciationChargeOfRightOfUseAssetsAbstract', window );"><strong>Depreciation charge of right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">$ 38,624<span></span>
</td>
<td class="nump">$ 38,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense (included in finance cost)</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases (included in other expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities', window );">Expense relating to variable lease payments not included in lease liabilities (included in other expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal payments</a></td>
<td class="nump">40,607<span></span>
</td>
<td class="nump">41,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Properties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DepreciationChargeOfRightOfUseAssetsAbstract', window );"><strong>Depreciation charge of right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">$ 38,624<span></span>
</td>
<td class="nump">$ 38,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DepreciationChargeOfRightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DepreciationChargeOfRightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692073672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract', window );"><strong>Disclosure of classes of share capital [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_PaymentForServices', window );">Payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">New fully paid ordinary per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssuanceOfOrdinarySharesDescription', window );">Issuance of ordinary shares, description</a></td>
<td class="text">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssuanceOfOrdinarySharesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssuanceOfOrdinarySharesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_PaymentForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_PaymentForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505932507896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital (Details) - Schedule of share capital - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfShareCapitalAbstract', window );"><strong>Schedule of share capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares</a></td>
<td class="nump">227,246,596<span></span>
</td>
<td class="nump">178,279,566<span></span>
</td>
<td class="nump">163,215,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AmountOfOrdinaryShares', window );">Ordinary shares, value</a></td>
<td class="nump">$ 88,361,303<span></span>
</td>
<td class="nump">$ 62,426,991<span></span>
</td>
<td class="nump">$ 60,289,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares, Fully paid, shares</a></td>
<td class="nump">227,246,596<span></span>
</td>
<td class="nump">178,279,566<span></span>
</td>
<td class="nump">163,215,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AmountOfOrdinaryShares', window );">Ordinary shares, Fully paid, value</a></td>
<td class="nump">$ 88,361,303<span></span>
</td>
<td class="nump">$ 62,426,991<span></span>
</td>
<td class="nump">$ 60,289,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AmountOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AmountOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694011976">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Details) - Schedule of ordinary shares - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfOrdinarySharesAbstract', window );"><strong>Schedule of ordinary shares [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OrdinaryShare', window );">Balance, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178,279,566<span></span>
</td>
<td class="nump">163,215,706<span></span>
</td>
<td class="nump">142,778,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfEquityToOrdinaryvalue', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 62,426,991<span></span>
</td>
<td class="nump">$ 60,289,875<span></span>
</td>
<td class="nump">$ 58,237,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssuePursuantToAdsPublicOfferingShares', window );">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,565,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssuePursuantToAdsPublicOffering', window );">Issue at US$0.10 pursuant to ADS public offering (2019-07-19)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,926,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueInLieuOfPaymentForServicesShares', window );">Issue at A$0.16 in lieu of payment for services (2019-11-12)1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueInLieuOfPaymentForServices', window );">Issue at A$0.16 in lieu of payment for services (2019-11-12)1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrantsShares', window );">Exercise of NASDAQ Warrants (2020-06-23)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrants', window );">Exercise of NASDAQ Warrants (2020-06-23)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrantShares', window );">Exercise of representative warrants (2020-06-15, 2020-06-22)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrant', window );">Exercise of representative warrants (2020-06-15, 2020-06-22)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrants1', window );">Exercise of representative warrants (2020-07-02)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrant1', window );">Exercise of representative warrants (2020-07-02)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS047PursuantToADSPublicOffering', window );">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,666,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS047PursuantToADSPublicOffering1', window );">Issue at US$0.47 pursuant to ADS public offering (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 28,165,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAt050OnExerciseOfESOPUnlistedOption', window );">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAt050OnExerciseOfESOPUnlistedOptions', window );">Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrants', window );">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrants1', window );">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,051,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrant', window );">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrant1', window );">Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions', window );">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnExerciseOfESOPUnlistedOption', window );">Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729', window );">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnExerciseOfNASDAQWarrants', window );">Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtA008InLieuOfCashForServicesRendered20201113', window );">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,737,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueAtA008InLieuOfCashForServicesRendered', window );">Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209', window );">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">409,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions', window );">Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 197,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1', window );">Issue at $0.16 in lieu of payment for services (2018-11-22)1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1', window );">Issue at $0.16 in lieu of payment for services (2018-11-22)1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ProceedsFromIssuedSharesAtADSPublicOffering', window );">Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ProceedsFromIssuedAtADSPublicOffering', window );">Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,894,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised', window );">Reclassify exercised options from reserves to share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_StockIssuedDuringValueReclassifyToStockOptionsExercised', window );">Reclassify exercised options from reserves to share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares', window );">Transaction costs arising on representative warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionCostsArisingOnRepresentativeWarrantsIssued', window );">Transaction costs arising on representative warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,454)<span></span>
</td>
<td class="num">$ (110,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares', window );">Less: Transaction costs arising on share issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_BusinessAcquisitionCostOfTransactionCost', window );">Less: Transaction costs arising on share issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,779,831)<span></span>
</td>
<td class="num">$ (374,728)<span></span>
</td>
<td class="num">$ (825,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OrdinaryShare', window );">Balance, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,246,596<span></span>
</td>
<td class="nump">178,279,566<span></span>
</td>
<td class="nump">163,215,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfEquityToOrdinaryvalue', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 88,361,303<span></span>
</td>
<td class="nump">$ 62,426,991<span></span>
</td>
<td class="nump">$ 60,289,875<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr Peter (resigned 24 September 2021) and Mr Stephen Anastasiou are
directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and
expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution
and invoicing services for Immuron Limited&#8217;s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary
shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited&#8217;s shares price at the commencement of
the agreement. The above amount is the fair value of the equity instrument.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On 30 May 2019, 500,000 American Depository Shares (ADS) were issued at US$4.00 each. Each ADS is equivalent to 40 ordinary shares, i.e. 20,000,000 at US$0.10 each (A$0.1447).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_BusinessAcquisitionCostOfTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue by cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_BusinessAcquisitionCostOfTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of NASDAQ Warrants (2020-06-23).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of NASDAQ Warrants (2020-06-23), shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of representative warrants (2020-06-15, 2020-06-22).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrant1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of representative warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrant1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of representative warrants (2020-06-15, 2020-06-22), shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrants1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrants1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued at value in lieu of payment for services1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued at shares in lieu of payment for services1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAt050OnExerciseOfESOPUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAt050OnExerciseOfESOPUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAt050OnExerciseOfESOPUnlistedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at $0.50 on exercise of ESOP unlisted options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAt050OnExerciseOfESOPUnlistedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtA008InLieuOfCashForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at A$0.08 in lieu of cash for services rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtA008InLieuOfCashForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtA008InLieuOfCashForServicesRendered20201113">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at A$0.08 in lieu of cash for services rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtA008InLieuOfCashForServicesRendered20201113</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS025OnExerciseOfNASDAQWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrant1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at US$0.25 on exercise of NASDAQ Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS025OnExerciseOfNASDAQWarrant1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS025OnExerciseOfNASDAQWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS025OnExerciseOfNASDAQWarrants1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at US$0.25 on exercise of NASDAQ Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS025OnExerciseOfNASDAQWarrants1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS047PursuantToADSPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS047PursuantToADSPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueAtUS047PursuantToADSPublicOffering1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at US$0.47 pursuant to ADS public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueAtUS047PursuantToADSPublicOffering1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueInLieuOfPaymentForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at $0.16 in lieu of payment for services (2019-11-12).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueInLieuOfPaymentForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueInLieuOfPaymentForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at $0.16 in lieu of payment for services (2019-11-12), shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueInLieuOfPaymentForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfEquityToOrdinaryvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfEquityToOrdinaryvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssuePursuantToAdsPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at US$0.10 pursuant to ADS public offering (2019-07-19).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssuePursuantToAdsPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssuePursuantToAdsPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue at US$0.10 pursuant to ADS public offering (2019-07-19), shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssuePursuantToAdsPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ProceedsFromIssuedAtADSPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount issued at pursuant to ADS public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ProceedsFromIssuedAtADSPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ProceedsFromIssuedSharesAtADSPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued at pursuant to ADS public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ProceedsFromIssuedSharesAtADSPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfOrdinarySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfOrdinarySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options reclassify to the exercised options from reserves to share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_StockIssuedDuringValueReclassifyToStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a reclassify by the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_StockIssuedDuringValueReclassifyToStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransactionCostsArisingOnRepresentativeWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs arising on representative warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransactionCostsArisingOnRepresentativeWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs arising on representative warrants issued, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from reserves on cashless exercise of ESOP unlisted options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from reserves on cashless exercise of ESOP unlisted options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnExerciseOfESOPUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from reserves on exercise of ESOP unlisted options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnExerciseOfESOPUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnExerciseOfNASDAQWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from reserves on exercise of NASDAQ Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnExerciseOfNASDAQWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer from reserves on exercise of NASDAQ Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693949800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Reserves (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 11, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 13, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 26, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsLineItems', window );"><strong>Other Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ESOPOptionsIssued', window );">ESOP options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationFinancialsAmount', window );">Revaluation financials amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExpenseOfSharesOwed', window );">Value of shares owed (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TitlesOfIndividualAxis=imc_DrJerryKanellosMember', window );">Dr. Jerry Kanellos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsLineItems', window );"><strong>Other Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReserveMaturityDateDescription', window );">Maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jerry Kanellos, Chief Operating Officer of Immuron Limited, 1,000,000 unlisted options exercisable at $0.50 on or before 1 July 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesUnlistedOption', window );">Number of shares unlisted option (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UnlistedOptionExercisable', window );">Unlisted option exercisable per shares (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TitlesOfIndividualAxis=imc_MrRichardJBermanMember', window );">Mr. Richard J. Berman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsLineItems', window );"><strong>Other Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReserveMaturityDateDescription', window );">Maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On 26 November 2018, the Company issued Mr. Richard
J. Berman, a Non-Executive Director of Immuron Limited, 2,000,000 unlisted options exercisable at $0.50 on or before June 30, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesUnlistedOption', window );">Number of shares unlisted option (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UnlistedOptionExercisable', window );">Unlisted option exercisable per shares (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TitlesOfIndividualAxis=imc_DrGarySJacobMember', window );">Dr. Gary S. Jacob [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsLineItems', window );"><strong>Other Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesUnlistedOption', window );">Number of shares unlisted option (in Shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_UnlistedOptionExercisable', window );">Unlisted option exercisable per shares (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsGranted', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluedAtGrantDate', window );">Grant date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In line with IFRS 2, these were re-measured at grant date
6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfShareholdersApprovedValue', window );">Revaluation of options value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ESOPOptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ESOP options issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ESOPOptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExpenseOfSharesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExpenseOfSharesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares unlisted option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherReserveMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherReserveMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherReservesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherReservesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationFinancialsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation financials amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationFinancialsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationOfShareholdersApprovedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationOfShareholdersApprovedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluedAtGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluedAtGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_UnlistedOptionExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unlisted option exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_UnlistedOptionExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TitlesOfIndividualAxis=imc_DrJerryKanellosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TitlesOfIndividualAxis=imc_DrJerryKanellosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TitlesOfIndividualAxis=imc_MrRichardJBermanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TitlesOfIndividualAxis=imc_MrRichardJBermanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TitlesOfIndividualAxis=imc_DrGarySJacobMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TitlesOfIndividualAxis=imc_DrGarySJacobMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694637800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Reserves (Details) - Schedule of other reserves - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsScheduleofotherreservesLineItems', window );"><strong>Other Reserves (Details) - Schedule of other reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">$ 1,133,345<span></span>
</td>
<td class="nump">$ 4,300,319<span></span>
</td>
<td class="nump">$ 3,096,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(14,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwners', window );">Transactions with owners in their capacity as owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferToShareCapitalinDollars', window );">Transfer to share capital</a></td>
<td class="num">(73,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsIssuedexpensed', window );">Options and warrants issued/expensed</a></td>
<td class="nump">3,003,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,453,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsExercised', window );">Options and warrants exercised</a></td>
<td class="num">(213,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsForfeited', window );">Options and warrants forfeited</a></td>
<td class="num">(368,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsLapsed', window );">Options and warrants lapsed/expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(311,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionsIssuedInPriorPeriod', window );">Re-valuation of options issued in prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">3,466,642<span></span>
</td>
<td class="nump">1,133,345<span></span>
</td>
<td class="nump">4,300,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">(14,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Share-based payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsScheduleofotherreservesLineItems', window );"><strong>Other Reserves (Details) - Schedule of other reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">1,011,878<span></span>
</td>
<td class="nump">4,281,790<span></span>
</td>
<td class="nump">3,139,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwners', window );">Transactions with owners in their capacity as owners</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferToShareCapitalinDollars', window );">Transfer to share capital</a></td>
<td class="num">(73,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentExpenses', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsIssuedexpensed', window );">Options and warrants issued/expensed</a></td>
<td class="nump">3,003,060<span></span>
</td>
<td class="num">(484,680)<span></span>
</td>
<td class="nump">1,453,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsExercised', window );">Options and warrants exercised</a></td>
<td class="num">(213,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsForfeited', window );">Options and warrants forfeited</a></td>
<td class="num">(368,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsLapsed', window );">Options and warrants lapsed/expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,251,320)<span></span>
</td>
<td class="num">(311,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionsIssuedInPriorPeriod', window );">Re-valuation of options issued in prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">3,360,128<span></span>
</td>
<td class="nump">1,011,878<span></span>
</td>
<td class="nump">4,281,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=imc_ForeignCurrencyTranslationMember', window );">Foreign currency translation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherReservesDetailsScheduleofotherreservesLineItems', window );"><strong>Other Reserves (Details) - Schedule of other reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">121,467<span></span>
</td>
<td class="nump">18,529<span></span>
</td>
<td class="num">(43,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(14,953)<span></span>
</td>
<td class="nump">102,938<span></span>
</td>
<td class="nump">61,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransactionsWithOwnersInTheirCapacityAsOwners', window );">Transactions with owners in their capacity as owners</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TransferToShareCapitalinDollars', window );">Transfer to share capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentExpenses', window );">Share-based payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsIssuedexpensed', window );">Options and warrants issued/expensed</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsExercised', window );">Options and warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsForfeited', window );">Options and warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsAndWarrantsLapsed', window );">Options and warrants lapsed/expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionsIssuedInPriorPeriod', window );">Re-valuation of options issued in prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Balance</a></td>
<td class="nump">106,514<span></span>
</td>
<td class="nump">121,467<span></span>
</td>
<td class="nump">18,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="num">$ (14,953)<span></span>
</td>
<td class="nump">$ 102,938<span></span>
</td>
<td class="nump">$ 61,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CurrencyTranslationDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency translation differences for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CurrencyTranslationDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsAndWarrantsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options and warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsAndWarrantsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsAndWarrantsIssuedexpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsAndWarrantsIssuedexpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsAndWarrantsLapsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Options and warrants lapsed for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsAndWarrantsLapsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherReservesDetailsScheduleofotherreservesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherReservesDetailsScheduleofotherreservesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationOfOptionsIssuedInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationOfOptionsIssuedInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransactionsWithOwnersInTheirCapacityAsOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Transactions with owners in their capacity as owners for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransactionsWithOwnersInTheirCapacityAsOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TransferToShareCapitalinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer to share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TransferToShareCapitalinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=imc_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=imc_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694366664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Reserves (Details) - Schedule of movements in options and warrants - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract', window );"><strong>Schedule of movements in options and warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Balance</a></td>
<td class="nump">42,807,118<span></span>
</td>
<td class="nump">79,463,744<span></span>
</td>
<td class="nump">72,569,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Balance (in Dollars)</a></td>
<td class="nump">$ 938,790<span></span>
</td>
<td class="nump">$ 4,281,790<span></span>
</td>
<td class="nump">$ 3,139,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionsIssuedInPriorPeriodShares', window );">Re-valuation of options issued in prior period (2019-11-06)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationOfOptionsIssuedInPriorPeriod', window );">Re-valuation of options issued in prior period (2019-11-06) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (607,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsTwoShares', window );">Issue of representative warrants (2019-07-16)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsTwo', window );">Issue of representative warrants (2019-07-16) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares', window );">Lapse of unexercised options at $0.50 (2019-11-27)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,625,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFive', window );">Lapse of unexercised options at $0.50 (2019-11-27) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,086,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares', window );">Lapse of unexercised options at $0.55 (2019-11-30)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,289,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive', window );">Lapse of unexercised options at $0.55 (2019-11-30) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne', window );">Lapse of unexercised options at $0.50 (2020-06-30)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne', window );">Lapse of unexercised options at $0.50 (2020-06-30) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (164,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares', window );">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(218,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions', window );">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrantsShares', window );">Exercise of representative warrants (2020-06-15, 2020-06-22)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,065,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrants', window );">Exercise of representative warrants (2020-06-15, 2020-06-22) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (540,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfRepresentativeWarrantsSharesOne', window );">Exercise of representative warrants (2020-07-2)</a></td>
<td class="num">(9,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Exercise of representative warrants (2020-07-2) (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfESOPUnlistedOptions', window );">Exercise of ESOP unlisted options at $0.50 (2020-07-24)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfESOPUnlistedOptionsValue', window );">Exercise of ESOP unlisted options at $0.50 (2020-07-24) (in Dollars)</a></td>
<td class="num">$ (15,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne', window );">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)</a></td>
<td class="num">(3,048,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne', window );">Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (in Dollars)</a></td>
<td class="num">$ (1,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsOne', window );">Lapse of unexercised options (2020-09-25)</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LapseOfUnexercisedOptionsValue', window );">Lapse of unexercised options (2020-09-25) (in Dollars)</a></td>
<td class="num">$ (368,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsThreeShares', window );">Issue of representative warrants at US$23.44 per 40 options (2020-07-24)</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsThree', window );">Issue of representative warrants at US$23.44 per 40 options (2020-07-24) (in Dollars)</a></td>
<td class="nump">$ 1,032,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree', window );">Issue of ESOP unlisted options at $0.12 (2020-10-29)</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree', window );">Issue of ESOP unlisted options at $0.12 (2020-10-29) (in Dollars)</a></td>
<td class="nump">$ 1,970,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CashlessExerciseOfESOPUnlistedOptions', window );">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)</a></td>
<td class="num">(900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_CashlessExerciseOfESOPUnlistedOptionsValue', window );">Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (in Dollars)</a></td>
<td class="num">$ (197,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital', window );">Reclassify share-based payments expenses from reserves to share capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue', window );">Reclassify share-based payments expenses from reserves to share capital (in Dollars)</a></td>
<td class="num">$ (73,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption', window );">Issue of ESOP unlisted options at $0.50 (2018-07-13)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption', window );">Issue of ESOP unlisted options at $0.50 (2018-07-13) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne', window );">Issue of ESOP unlisted options at $0.50 (2018-11-26)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne', window );">Issue of ESOP unlisted options at $0.50 (2018-11-26) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption', window );">Lapse of ESOP unlisted options at $0.50 (2018-10-01)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,050,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption', window );">Lapse of ESOP unlisted options at $0.50 (2018-10-01) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo', window );">Issue of ESOP unlisted options at $0.50 (2019-02-11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo', window );">Issue of ESOP unlisted options at $0.50 (2019-02-11) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionOne', window );">Lapse of unlisted options at $0.57 (2019-02-24)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfValueIssueLapseOfUnlistedOptionOne', window );">Lapse of unlisted options at $0.57 (2019-02-24) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (185,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo', window );">Lapse of unlisted options at $1.892 (2019-02-28)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfValueIssueLapseOfUnlistedOptionTwo', window );">Lapse of unlisted options at $1.892 (2019-02-28) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionThree', window );">Lapse of unlisted options at $0.30 (2019-05-28)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfValueIssueLapseOfUnlistedOptionThree', window );">Lapse of unlisted options at $0.30 (2019-05-28) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital', window );">Reclassify exercised options from reserves to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital', window );">Reclassify exercised options from reserves to share capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses', window );">Reclassify lapsed options from reserves to accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses', window );">Reclassify lapsed options from reserves to accumulated losses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsSharesOne', window );">Issue of representative warrants (2019-05-23)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_IssueOfRepresentativeWarrantsOne', window );">Issue of representative warrants (2019-05-23) (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Balance</a></td>
<td class="nump">45,309,478<span></span>
</td>
<td class="nump">42,807,118<span></span>
</td>
<td class="nump">79,463,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Balance (in Dollars)</a></td>
<td class="nump">$ 3,360,128<span></span>
</td>
<td class="nump">$ 938,790<span></span>
</td>
<td class="nump">$ 4,281,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CashlessExerciseOfESOPUnlistedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CashlessExerciseOfESOPUnlistedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_CashlessExerciseOfESOPUnlistedOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_CashlessExerciseOfESOPUnlistedOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfESOPUnlistedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfESOPUnlistedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfESOPUnlistedOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfESOPUnlistedOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExerciseOfRepresentativeWarrantsSharesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExerciseOfRepresentativeWarrantsSharesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsSharesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsSharesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsThreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsThreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_IssueOfRepresentativeWarrantsTwoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_IssueOfRepresentativeWarrantsTwoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LapseOfUnexercisedOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LapseOfUnexercisedOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueLapseOfUnlistedOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueLapseOfUnlistedOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reclassify lapsed options from reserves to accumulated losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reclassify exercised options from reserves to share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfValueIssueLapseOfUnlistedOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfValueIssueLapseOfUnlistedOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfValueIssueLapseOfUnlistedOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfValueIssueLapseOfUnlistedOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfValueIssueLapseOfUnlistedOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfValueIssueLapseOfUnlistedOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value reclassify lapsed options from reserves to accumulated losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value reclassify exercised options from reserves to share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationOfOptionsIssuedInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationOfOptionsIssuedInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationOfOptionsIssuedInPriorPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationOfOptionsIssuedInPriorPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value issue of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of value lapse of unlisted options for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of value reserved for issue under options and contracts for sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692194856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract', window );"><strong>Disclosure of entity's operating segments [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfSegment', window );">Number of segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_PercentageOfEntityRevenue', window );">Percentage of total revenue for major customer</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a number of segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_PercentageOfEntityRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_PercentageOfEntityRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505688943192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of segment information for the reportable segments - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_HyperimmuneProductsRevenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">$ 145,776<span></span>
</td>
<td class="nump">$ 2,518,566<span></span>
</td>
<td class="nump">$ 2,387,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales of goods</a></td>
<td class="num">(51,071)<span></span>
</td>
<td class="num">(688,836)<span></span>
</td>
<td class="num">(667,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">94,705<span></span>
</td>
<td class="nump">1,829,730<span></span>
</td>
<td class="nump">1,720,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">617,110<span></span>
</td>
<td class="nump">473,674<span></span>
</td>
<td class="nump">532,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains/(losses) &#8211; net</a></td>
<td class="num">(1,342,293)<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">38,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="num">(3,978,679)<span></span>
</td>
<td class="num">(3,170,078)<span></span>
</td>
<td class="num">(5,037,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based payment expenses</a></td>
<td class="num">(2,116,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(1,367,054)<span></span>
</td>
<td class="num">(1,178,685)<span></span>
</td>
<td class="num">(1,044,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SellingAndMarketingExpenses', window );">Selling and marketing expenses</a></td>
<td class="num">(287,684)<span></span>
</td>
<td class="num">(871,551)<span></span>
</td>
<td class="num">(864,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="num">(8,379,908)<span></span>
</td>
<td class="num">(2,905,575)<span></span>
</td>
<td class="num">(4,656,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">9,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">(13,761)<span></span>
</td>
<td class="num">(21,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/(loss) for the year</a></td>
<td class="num">(8,384,465)<span></span>
</td>
<td class="num">(2,927,206)<span></span>
</td>
<td class="num">(4,656,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentAssets', window );">Segment assets</a></td>
<td class="nump">27,053,106<span></span>
</td>
<td class="nump">6,202,163<span></span>
</td>
<td class="nump">8,561,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">27,053,106<span></span>
</td>
<td class="nump">6,202,163<span></span>
</td>
<td class="nump">8,561,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentLiabilities', window );">Segment liabilities</a></td>
<td class="nump">1,158,049<span></span>
</td>
<td class="nump">558,250<span></span>
</td>
<td class="nump">1,210,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,158,049<span></span>
</td>
<td class="nump">558,250<span></span>
</td>
<td class="nump">1,210,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=imc_SegmentResearchAndDevelopmentMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_HyperimmuneProductsRevenue', window );">Hyperimmune products revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales of goods</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">431,030<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
<td class="nump">531,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains/(losses) &#8211; net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based payment expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(1,367,054)<span></span>
</td>
<td class="num">(1,178,685)<span></span>
</td>
<td class="num">(1,044,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SellingAndMarketingExpenses', window );">Selling and marketing expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="num">(936,024)<span></span>
</td>
<td class="num">(870,460)<span></span>
</td>
<td class="num">(513,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/(loss) for the year</a></td>
<td class="num">(936,024)<span></span>
</td>
<td class="num">(870,460)<span></span>
</td>
<td class="num">(513,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentAssets', window );">Segment assets</a></td>
<td class="nump">306,154<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
<td class="nump">531,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">306,154<span></span>
</td>
<td class="nump">308,225<span></span>
</td>
<td class="nump">531,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentLiabilities', window );">Segment liabilities</a></td>
<td class="nump">243,565<span></span>
</td>
<td class="nump">101,092<span></span>
</td>
<td class="nump">221,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">243,565<span></span>
</td>
<td class="nump">101,092<span></span>
</td>
<td class="nump">221,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=imc_SegmentHyperImmuneProductsMember', window );">HyperImmune Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_HyperimmuneProductsRevenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">145,776<span></span>
</td>
<td class="nump">2,518,566<span></span>
</td>
<td class="nump">2,387,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales of goods</a></td>
<td class="num">(51,071)<span></span>
</td>
<td class="num">(688,836)<span></span>
</td>
<td class="num">(667,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">94,705<span></span>
</td>
<td class="nump">1,829,730<span></span>
</td>
<td class="nump">1,720,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">24,480<span></span>
</td>
<td class="nump">10,545<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains/(losses) &#8211; net</a></td>
<td class="num">(759,765)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based payment expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SellingAndMarketingExpenses', window );">Selling and marketing expenses</a></td>
<td class="num">(287,684)<span></span>
</td>
<td class="num">(871,551)<span></span>
</td>
<td class="num">(864,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="num">(928,264)<span></span>
</td>
<td class="nump">968,724<span></span>
</td>
<td class="nump">843,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/(loss) for the year</a></td>
<td class="num">(928,264)<span></span>
</td>
<td class="nump">968,724<span></span>
</td>
<td class="nump">843,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentAssets', window );">Segment assets</a></td>
<td class="nump">1,587,672<span></span>
</td>
<td class="nump">2,539,503<span></span>
</td>
<td class="nump">2,705,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">1,587,672<span></span>
</td>
<td class="nump">2,539,503<span></span>
</td>
<td class="nump">2,705,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentLiabilities', window );">Segment liabilities</a></td>
<td class="nump">284,657<span></span>
</td>
<td class="nump">30,377<span></span>
</td>
<td class="nump">191,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">284,657<span></span>
</td>
<td class="nump">30,377<span></span>
</td>
<td class="nump">191,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=imc_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_HyperimmuneProductsRevenue', window );">Hyperimmune products revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales of goods</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">161,600<span></span>
</td>
<td class="nump">154,904<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains/(losses) &#8211; net</a></td>
<td class="num">(582,528)<span></span>
</td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">51,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="num">(3,978,679)<span></span>
</td>
<td class="num">(3,170,078)<span></span>
</td>
<td class="num">(5,037,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based payment expenses</a></td>
<td class="num">(2,116,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SellingAndMarketingExpenses', window );">Selling and marketing expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="num">(6,515,620)<span></span>
</td>
<td class="num">(3,003,839)<span></span>
</td>
<td class="num">(4,985,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">9,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">(13,761)<span></span>
</td>
<td class="num">(21,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/(loss) for the year</a></td>
<td class="num">(6,520,177)<span></span>
</td>
<td class="num">(3,025,470)<span></span>
</td>
<td class="num">(4,985,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentAssets', window );">Segment assets</a></td>
<td class="nump">25,159,280<span></span>
</td>
<td class="nump">3,354,435<span></span>
</td>
<td class="nump">5,324,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">25,159,280<span></span>
</td>
<td class="nump">3,354,435<span></span>
</td>
<td class="nump">5,324,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentLiabilities', window );">Segment liabilities</a></td>
<td class="nump">629,827<span></span>
</td>
<td class="nump">426,781<span></span>
</td>
<td class="nump">797,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 629,827<span></span>
</td>
<td class="nump">$ 426,781<span></span>
</td>
<td class="nump">$ 797,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_HyperimmuneProductsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_HyperimmuneProductsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of segment assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of segment liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SellingAndMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SellingAndMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=imc_SegmentResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=imc_SegmentResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=imc_SegmentHyperImmuneProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=imc_SegmentHyperImmuneProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=imc_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=imc_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695363160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of information on geographical regions - AUD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">$ 145,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,518,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="nump">145,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,518,566<span></span>
</td>
<td class="nump">$ 2,387,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,387,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MajorProductLinesAxis=imc_TravelanMember', window );">Travelan [Member] | Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="num">(10,308)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,240,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="num">(10,308)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,240,393<span></span>
</td>
<td class="nump">1,162,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MajorProductLinesAxis=imc_TravelanMember', window );">Travelan [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">926,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">926,325<span></span>
</td>
<td class="nump">1,016,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MajorProductLinesAxis=imc_TravelanMember', window );">Travelan [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">101,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">301,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="nump">101,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">301,915<span></span>
</td>
<td class="nump">149,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MajorProductLinesAxis=imc_ProtectynMember', window );">Protectyn [Member] | Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="nump">50,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="nump">50,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49,933<span></span>
</td>
<td class="nump">58,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_MajorProductLinesAxis=imc_ProtectynMember', window );">Protectyn [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems', window );"><strong>Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Hyperimmune products revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFromExternalCustomers', window );">Revenue from external customers</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentRevenue', window );">Segment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Returns are provided where outlined in a customer&#8217;s agreement.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevenueFromExternalCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevenueFromExternalCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_MajorProductLinesAxis=imc_TravelanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_MajorProductLinesAxis=imc_TravelanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=imc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=imc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_MajorProductLinesAxis=imc_ProtectynMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_MajorProductLinesAxis=imc_ProtectynMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693970536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of major customers - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">$ 140,022<span></span>
</td>
<td class="nump">$ 1,898,982<span></span>
</td>
<td class="nump">$ 2,015,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerAMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">41,040<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerBMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">27,563<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerCMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">25,319<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerDMember', window );">Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">23,214<span></span>
</td>
<td class="nump">462,490<span></span>
</td>
<td class="nump">611,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerEMember', window );">Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="nump">22,886<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerFMember', window );">Customer F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">442,916<span></span>
</td>
<td class="nump">228,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerGMember', window );">Customer G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">438,065<span></span>
</td>
<td class="nump">659,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerHMember', window );">Customer H [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">327,559<span></span>
</td>
<td class="nump">266,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=imc_CustomerIMember', window );">Customer I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems', window );"><strong>Segment Reporting (Details) - Schedule of major customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevenueFormContractWithCustomer', window );">Total revenue for major customers</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 227,952<span></span>
</td>
<td class="nump">$ 249,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevenueFormContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevenueFormContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=imc_CustomerIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=imc_CustomerIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693906152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract', window );"><strong>Schedule of reconciliation of cash flow from operations with loss after income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net Loss for the Year</a></td>
<td class="num">$ (8,384,465)<span></span>
</td>
<td class="num">$ (2,927,206)<span></span>
</td>
<td class="num">$ (4,656,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AdjustmentsForAbstract', window );"><strong>Adjustments for</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="nump">43,662<span></span>
</td>
<td class="nump">44,056<span></span>
</td>
<td class="nump">5,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_AdjustmentsForDistributionCosts', window );">Distribution costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExpectedCreditLosses', window );">Expected credit losses</a></td>
<td class="num">(30,055)<span></span>
</td>
<td class="num">(3,991)<span></span>
</td>
<td class="nump">34,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance costs</a></td>
<td class="nump">13,761<span></span>
</td>
<td class="nump">21,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(9,204)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LeaveProvisionExpense', window );">Leave provision expense</a></td>
<td class="nump">53,610<span></span>
</td>
<td class="nump">19,717<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedPaymentsExpense', window );">Share-based payments (income)/expenses</a></td>
<td class="nump">2,116,013<span></span>
</td>
<td class="num">(533,912)<span></span>
</td>
<td class="nump">1,343,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized net foreign currency gains</a></td>
<td class="nump">592,243<span></span>
</td>
<td class="num">(18,883)<span></span>
</td>
<td class="num">(62,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ChangeInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Add decrease in trade and other receivables</a></td>
<td class="nump">23,037<span></span>
</td>
<td class="nump">641,236<span></span>
</td>
<td class="nump">680,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Add (increase) / decrease in inventories</a></td>
<td class="nump">960,920<span></span>
</td>
<td class="num">(113,635)<span></span>
</td>
<td class="nump">263,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Add (increase) / decrease in other operating assets</a></td>
<td class="num">(45,065)<span></span>
</td>
<td class="nump">16,096<span></span>
</td>
<td class="nump">92,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Add (decrease) / increase in trade and other payables</a></td>
<td class="nump">586,796<span></span>
</td>
<td class="num">(362,437)<span></span>
</td>
<td class="nump">426,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Total</a></td>
<td class="num">$ (4,078,747)<span></span>
</td>
<td class="num">$ (3,147,328)<span></span>
</td>
<td class="num">$ (1,798,579)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AdjustmentsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AdjustmentsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_AdjustmentsForDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments for costs relating to the distribution of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_AdjustmentsForDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ChangeInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ChangeInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LeaveProvisionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of leave provision expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LeaveProvisionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareBasedPaymentsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information of share based payments expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareBasedPaymentsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696122904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract', window );"><strong>Disclosure of share-based payment arrangements [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionGrantedDescription', window );">Option granted, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options granted to a former managing director on 11 February 2019 and
valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at
grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June
2020 financials.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RevaluationFinancialsAmount', window );">Revaluation financials amount</a></td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharesIssuedToDirectorsForTheDirectorFees', window );">Shares issued to directors for the director fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,913<span></span>
</td>
<td class="nump">$ 73,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionGrantedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option granted, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionGrantedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RevaluationFinancialsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation financials amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RevaluationFinancialsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharesIssuedToDirectorsForTheDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharesIssuedToDirectorsForTheDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505700939352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract', window );"><strong>Schedule of movement in number of stock options outstanding and weighted average exercise price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1', window );">Average exercise price per share option, As at 1 July</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfOutstandingShareOption', window );">Number of options, As at 1 July</a></td>
<td class="nump">42,807,118<span></span>
</td>
<td class="nump">79,463,744<span></span>
</td>
<td class="nump">72,569,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1', window );">Average exercise price per share option, Granted during the year</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement', window );">Number of options, Granted during the year</a></td>
<td class="nump">11,560,000<span></span>
</td>
<td class="nump">542,600<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1', window );">Average exercise price per share option, Exercised during the year</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement', window );">Number of options, Exercised during the year</a></td>
<td class="num">(4,057,640)<span></span>
</td>
<td class="num">(424,840)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1', window );">Average exercise price per share option, Forfeited/lapsed during the year</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement', window );">Number of options,Forfeited/lapsed during the year</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(36,774,386)<span></span>
</td>
<td class="num">(2,205,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1', window );">Average exercise price per share option, As at 30 June</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfOutstandingShareOption', window );">Number of options, As at 30 June</a></td>
<td class="nump">45,309,478<span></span>
</td>
<td class="nump">42,807,118<span></span>
</td>
<td class="nump">79,463,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1', window );">Average exercise price per share option, Vested and exercisable at 30 June</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement', window );">Number of options,Vested and exercisable at 30 June</a></td>
<td class="nump">45,309,478<span></span>
</td>
<td class="nump">42,807,118<span></span>
</td>
<td class="nump">79,463,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement.&amp;amp;amp;amp;#160;</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693749512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Details) - Schedule of granted valuation of options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">45,309,478<span></span>
</td>
<td class="nump">42,807,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsPerShare', window );">Share options price per share (in Dollars per share)</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateOneMember', window );">2012-06-29 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Nov. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">1.944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">14,493<span></span>
</td>
<td class="nump">14,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateTwoMember', window );">2012-06-29 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jan. 17,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">1.876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">29,668<span></span>
</td>
<td class="nump">29,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateThreeMember', window );">2017-06-13 (warrants) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jun. 13,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">USD 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">24,493,200<span></span>
</td>
<td class="nump">27,541,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateFourMember', window );">2018-03-15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Mar. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">0.468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">7,897,647<span></span>
</td>
<td class="nump">7,897,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateFiveMember', window );">2017-06-09 (warrants) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jun.  08,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">USD 0.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">198,240<span></span>
</td>
<td class="nump">198,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateSixMember', window );">2018-03-15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Mar. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">0.585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">526,510<span></span>
</td>
<td class="nump">526,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateSevenMember', window );">2019-05-23 (warrants) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">May 23,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">USD 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">173,600<span></span>
</td>
<td class="nump">181,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateEightMember', window );">2019-07-16 (warrants) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jul. 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">USD 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">116,120<span></span>
</td>
<td class="nump">117,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateNineMember', window );">2018-07-13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jul.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">0.500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateTenMember', window );">2019-11-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Feb. 10,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">0.500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateElevenMember', window );">2020-10-29 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Apr. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=imc_GrantDateTwelveMember', window );">2020-07-24 (warrants) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jul. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePrice', window );">Exercise price</a></td>
<td class="text">USD 0.5859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareOptionsOutstanding', window );">Share options</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareOptionsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share options per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareOptionsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=imc_GrantDateTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=imc_GrantDateTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694789272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Details) - Schedule of granted valuation of options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfInstrumentOtherEquityInstrumentGranted', window );">No. of options</a></td>
<td class="nump">11,560,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate', window );">Grant date</a></td>
<td class="text">Jul. 24,  2020<span></span>
</td>
<td class="text">Nov.  06,  2019<span></span>
</td>
<td class="text">Jul. 13,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Jul. 21,  2025<span></span>
</td>
<td class="text">Feb. 10,  2024<span></span>
</td>
<td class="text">Jul.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePriceShareOptionsGranted1', window );">Exercise price</a></td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfInstrumentOtherEquityInstrumentGranted', window );">No. of options</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageSharePriceShareOptionsGranted1', window );">Share price at grant date</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">127.93%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk- free interest rate</a></td>
<td class="nump">0.43%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValuePerShareOptionsGranted', window );">Fair value at grant date per option</a></td>
<td class="nump">$ 0.4035<span></span>
</td>
<td class="nump">$ 0.0736<span></span>
</td>
<td class="nump">$ 0.157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate', window );">Grant date</a></td>
<td class="text">Oct. 29,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 26,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">Apr. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePriceShareOptionsGranted1', window );">Exercise price</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfInstrumentOtherEquityInstrumentGranted', window );">No. of options</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageSharePriceShareOptionsGranted1', window );">Share price at grant date</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">142.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk- free interest rate</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValuePerShareOptionsGranted', window );">Fair value at grant date per option</a></td>
<td class="nump">$ 0.2189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceSixteenMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems', window );"><strong>Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate', window );">Grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 11,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 11,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ExercisePriceShareOptionsGranted1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_NumberOfInstrumentOtherEquityInstrumentGranted', window );">No. of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WeightedAverageSharePriceShareOptionsGranted1', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk- free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ValuePerShareOptionsGranted', window );">Fair value at grant date per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ExercisePriceShareOptionsGranted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>" The exercise price of share options granted."</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ExercisePriceShareOptionsGranted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_NumberOfInstrumentOtherEquityInstrumentGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_NumberOfInstrumentOtherEquityInstrumentGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ValuePerShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value per share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ValuePerShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WeightedAverageSharePriceShareOptionsGranted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WeightedAverageSharePriceShareOptionsGranted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=imc_ExercisePriceSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505696453400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions - AUD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract', window );"><strong>Schedule of total expenses arising from share-based payment transactions [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OptionsIssuedUnderESOP', window );">Options issued under ESOP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,970,100<span></span>
</td>
<td colspan="2" class="num">$ (607,000)<span></span>
</td>
<td class="nump">$ 1,343,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharebasedPaymentsToDirectors', window );">Share-based payments to directors2</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">145,913<span></span>
</td>
<td colspan="2" class="nump">73,088<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TotalExpenses', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,116,013<span></span>
</td>
<td colspan="2" class="num">$ (533,912)<span></span>
</td>
<td class="nump">$ 1,343,500<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a revaluation of $607,000 in the 30 June 2020 financials.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders' approval at the AGM held on 29 October 2020.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OptionsIssuedUnderESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OptionsIssuedUnderESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharebasedPaymentsToDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharebasedPaymentsToDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TotalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TotalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694428424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>AUD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>AUD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_WattleLaboratoriesPtyLtdMember', window );">Wattle Laboratories Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,607<span></span>
</td>
<td class="nump">$ 41,369<span></span>
</td>
<td class="nump">$ 53,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LeaseRenewed', window );">Lease renewed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_WattleLaboratoriesPtyLtdMember', window );">Wattle Laboratories Pty Ltd [Member] | Short-term Funding Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,525<span></span>
</td>
<td class="nump">$ 38,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_GrandlodgeCapitalPtyLtdMember', window );">Grandlodge Capital Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WarehousingDistributionAndInvoicingServices', window );">Warehousing, distribution and invoicing services</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_SharesIssuedPricePerShare1', window );">Share issued price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_WarehousingDistributionAndServicesFees', window );">Warehousing distribution and services fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,978<span></span>
</td>
<td class="nump">$ 93,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,500<span></span>
</td>
<td class="nump">437,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LeaseRenewed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease renewed date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LeaseRenewed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WarehousingDistributionAndInvoicingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warehousing, distribution and invoicing services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WarehousingDistributionAndInvoicingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_WarehousingDistributionAndServicesFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warehousing, distribution and services fes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_WarehousingDistributionAndServicesFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_WattleLaboratoriesPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imc_WattleLaboratoriesPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TypesOfArrangementsAxis=imc_ShortTermFundingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TypesOfArrangementsAxis=imc_ShortTermFundingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_GrandlodgeCapitalPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imc_GrandlodgeCapitalPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695997944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of information about other related party transactions - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases of various goods and services from entities controlled by key management personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 110,607<span></span>
</td>
<td class="nump">$ 142,347<span></span>
</td>
<td class="nump">$ 147,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions', window );">Other transactions with key management personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110,607<span></span>
</td>
<td class="nump">142,347<span></span>
</td>
<td class="nump">147,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember', window );">Rental of an office suite from Wattle Laboratories Pty Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions', window );">Other transactions with key management personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,607<span></span>
</td>
<td class="nump">41,369<span></span>
</td>
<td class="nump">53,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember', window );">Services rendered by Grandlodge Capital Pty Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions', window );">Other transactions with key management personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 100,978<span></span>
</td>
<td class="nump">$ 93,678<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Purchases from entities controlled by key management personnel</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts recognised as expense other transactions with key management personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692156216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Current payables (purchases of goods and services)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees', window );">Entities controlled by key management personnel</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 14<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505692788536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract', window );"><strong>Disclosure of financial risk management [text block] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_PercentageOfForeignExchangeRates', window );">Percentage of USD/AUD exchange rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_DisclosureOfFinancialRiskManagementTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_DisclosureOfFinancialRiskManagementTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_PercentageOfForeignExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_PercentageOfForeignExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505694809736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,742,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,954,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">23,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">18,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Total exposure</a></td>
<td class="nump">$ 2,785,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,030,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Total exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Total exposure | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 41,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505695803608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ScheduleOfExchangeRatesAbstract', window );"><strong>Schedule of exchange rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ImpactOnLossForPeriods', window );">Impact on loss for the period</a></td>
<td class="nump">$ 136,467<span></span>
</td>
<td class="nump">$ 99,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_ImpactOnOtherComponentOfEquity', window );">Impact on other components of equity</a></td>
<td class="nump">$ 5,219<span></span>
</td>
<td class="nump">$ 4,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ImpactOnLossForPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ImpactOnLossForPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ImpactOnOtherComponentOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ImpactOnOtherComponentOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_ScheduleOfExchangeRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_ScheduleOfExchangeRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693986232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables - Trade Receivables [Member] - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 28,553<span></span>
</td>
<td class="nump">$ 49,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember', window );">Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 23,801<span></span>
</td>
<td class="nump">$ 2,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember', window );">1-30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 4,752<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember', window );">31-60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">13.07%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanThreeMonthsMember', window );">61-90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">21.88%<span></span>
</td>
<td class="nump">23.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsMember', window );">91-120 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">34.09%<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneYearMember', window );">121+ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">Expected credit loss rate</a></td>
<td class="nump">53.58%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_LossAllowance', window );">Loss allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedCreditLossRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20D&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedCreditLossRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_GrossCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_GrossCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_LossAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_LossAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505693557656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">Less than 6 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="nump">$ 132,514<span></span>
</td>
<td class="nump">$ 173,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">20,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">153,012<span></span>
</td>
<td class="nump">194,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=imc_ContractualCashFlowsMember', window );">Total contractual cash flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="nump">132,514<span></span>
</td>
<td class="nump">173,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">63,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">153,012<span></span>
</td>
<td class="nump">237,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=imc_CarryingAssetsLiabilitiesMember', window );">Carrying amount (assets)/ liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="nump">132,514<span></span>
</td>
<td class="nump">173,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">20,498<span></span>
</td>
<td class="nump">63,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">153,012<span></span>
</td>
<td class="nump">237,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">6 - 12 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 2 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between 2 and 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Over 5 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems', window );"><strong>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imc_TradeAndOtherPayable', window );">Trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imc_TradeAndOtherPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imc_TradeAndOtherPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=imc_ContractualCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=imc_ContractualCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=imc_CarryingAssetsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=imc_CarryingAssetsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(0NROD^M/VA15C>,CT)KD5>/.\[67!H ?+\10K]^, NTM]J+?P%02P,$%
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M8+9PU=FI<>!E:,0[*O%9*UPEO7:8:^P?B!%U"ZN!XQ29;RLC-N84@:84?9Y
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MOJ*DX3"[J30C_D$K5**W^:2%DJ$?;L54)9'](]'[3 0!O]1(8A6R.,8\]N%
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M"VE]F_@J-QVX2?-%F$1GH&$5)DE.>1J'490';S__]N'=J_B,MOI&FA;-Q9&
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MM&S_6.'N*@UOP/I&8UP97MC X39\^5]02P,$%     @ 53)=4W&,"G8Y!
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M%.JX($/R^O#(]X7U#U$ZK]@>G]!^K3;:65''DO,2I>%*@L;=@BR'LU7BXT/
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M@\F8@&Y6J#&LJL+8;I5U2Q"NA?OJH/8!SK]3KE>MX1-TW['T-U!+ P04
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MJ*P#G:\DM:%5;(!N/\]^ U!+ P04    " !5,EU3-%[NER #  #<!@  &0
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MM![ ]UO#8],)WL'P0YO_ E!+ P04    " !5,EU3-D(U$VT"   X!0  &0
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M;2A,@#[?<5W3WC$7#,,R^PM02P,$%     @ 53)=4V21C"[? @  8@8  !D
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MD_D+NGRCS.*V$XW5'2\;1:2]=]9TO'SF_#\P[)5^D1<^0(A\):XC&+G&+R?
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MC4$\K\![G2L.S]$[;F^T3 O:G%@=ST<LQAJ$OHE]D62ZG0D$XS+(G2TA&J'
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M%3CDZ ">YQ:OO/4%*6@_0%W_!5!+ P04    " !5,EU3\WO2I;L'  "N$@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM6-MRV\@1?<=7="E;*;,*
M) $0!$FOI"K:\FZ<\D6QO-F'K7T8 D-Q8@"#Q0Q$*5^?TS,@12JF8M?F02(N
MTP>GNT_W-'"^U>T7LY'2TGU5UN;B;&-M\W(\-OE&5L*,="-KW%GKMA(6I^WM
MV#2M%(4SJLIQ$D79N!*J/KL\=]>NV\MSW=E2U?*Z)=-5E6@?7LE2;R_.XK/=
MA4_J=F/YPOCRO!&W\D;:7YKK%F?C/4JA*ED;I6MJY?KB;!F_?)7R>K?@GTIN
MS<$QL2<KK;_PR=OBXBQB0K*4N64$@9\[^5J6)0.!QA\]YMG^D6QX>+Q#_\GY
M#E]6PLC7NOQ5%79S<38_HT*N15?:3WK[-]G[,V6\7)?&_:>M7YM-SBCOC-55
M;PP&E:K]K[COXW!@,(].&"2]0>)X^P<YEE?"BLOS5F^IY=5 XP/GJK,&.55S
M4FYLB[L*=O;R9B-:2:]%HZPHS\<6D'QCG/?FK[QY<L(\3NB]KNW&T)NZD,4Q
MP!A<]H22':%7R;.(?^_J$4VBD)(HB9_!F^P=G#B\R0F\*V7R4IL.7NHUY:4P
M1AH^-,[SW'M.OUEY;VE5ZOS+[_3;<F5L"\'\_@R!=$\@=0329R.<GX[P\^8?
MM)443T=TA!-P=#A$$?[%"SH^#3ZVA:I18]Y)$_S4E>4#-4(5E"2S,$FS<+K(
M*)[-PV2V"*<9CK-)F,33<!9E-)^'DRP.)]&$LB1,DRQ<+&+*HC"9+\+Y;!K\
M7T!>J '$<R=1XM:0JDGWK //^F5P):U0I:$/7;62[3YIACYKCL$K48HZER0L
M!$,0CF3OYQ2G23AC5F QQ<]D%D[B-'AK3.<6_Q"-XHP?6"K9!4!MQ .3(/0X
M,K*]4SF>\8*QAG$\3)(!Q90"91I%M)B$V6S^"/;+#<-%U'2MZ41M ZMI>76#
M\U6I<G!>RU;5MPYN,8RFPTDTH 1$PRAR?Y2$\T4*EO/@DW3Z5.L'DO>RS961
M!>F&VY>A=:LKM$'F!W9XRK& __J7>1(G/U(<1<'G5M1&^+:7:X/HBE89L A<
M)VT8I;:"^R%M18O5G #VJ*#)'NE%'$=A"H*#X)TTYB6=A"5<\&P<B'F$F"?3
M,)I. ?'U9"V.)',@CI/QI>?C.QO&"Z1K CE.(8"(XG !Z<7S[!%R^>T"6+
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M.3<:EPDMP/RU153V'=I@^!WG[+]02P,$%     @ 53)=4P8 6*1@!   SP@
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M\2+C3SM]##EG(+C(7N#+#X[FD2__!M]KY=K>N)U%^'D-S[H-;^['7FKIC7V
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M$G3=-/^5PL[-('9(T*)#9(.D3><[@>1:(N?-CWF8Y @MUW1O92P_A_07N'*
M;Q-^)FBUN</!NK<C6:=A9@Q$-]NZW-KS16/4-]RO7)/I"R@*)B8X.0]69]9G
M6I0\#&&U+5\TY 7W7:.@_K9&E$Z#KHS+^Y#ONX,)CI Q!ZM-6__K> [P!?M&
MTJ6&\0VQF0YRW(UR=Z;D0[S!>Y=Y1$T*.UV@IW"#!%PZ34*T.<'D2B7PC!E[
MC3!<*K 8Z3$+EP@,-&H1D@ :G9 ZKXB:UBQ)L!<?T>2'J7U( %3,*3/LP-9.
MM&(SO;B RZ&%8R_E2O<TV-L<0$.N#<V*(OK1,K>./]P@#+VY!5UC>&_+&E9V
MFC+]ZI\@3(=.[S[<G8UHYNQUR^B.R=X'L-<O/UXC.(DLG-<2@$9V4M#]&1T>
M3-+) AGGB[2SJ.-R#5>'*]D^ZZ$[(7N,.#1.CY)%8:-X0,2!M.DN*0A@L-2Q
MM+:B3:2=!_&<78(F!+6AW&Z4;0S)\^REP8OW/[V^G/&E:U,V6O5[,S%M)<NZ
M<M:!;3:*E<)LV>@&+D,@18Z&6DMR;,H&+<9$48W7-U9>CP%S65'G['@4):<-
M!T@[Y*VD;"<7.P?&AL;I^&#2S."+*!&]UL?1,FIF6EFFIUO6'WDW_G\HP&0;
MB.NL,K7QWT?O&J;:BU=OV99:'I@4>?H]Q'!>$T?S^VY6SR?7VHB2C;V\-\PV
MP.Z&>_PZ_C]PX:[%#^#NSX6W0B.^#&OD&JC1/,].W'7<L.C4WEZ2KU37J9U]
MW<*:4A, ]M=*=<."#AC_-7GV;U!+ P04    " !5,EU3KH.J(QL(   I%
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MC\_=3F_/HN^_.STZ/CU'LDHO<]HM2_R?0S&@HX&/_=\DY4=\DC-CI3<,I%N
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MT?]1@L>AW[K(E&53^B\Q1A*#+BQ=JFW*\(0NZKKUF!U=P%V7F@M2!.$V=.L
M<Z7,Z-6[#Q?G3PY^)A4"QPGA'6TJG5>D(\&1??);:5M(Z!Q-(;FCZ#"47UOM
M>4I_@DGNZD;9[???O<@.GO\2*##8ZJ@YT 88U!B5 TE;K)#0](MAM4TJ%JT4
MQ&AE1\L[M]>W>:7LFNG'Q?+C3]1"A$GF?2BJL?;DWG/B4:<L001A?^V@=R!3
M>F\A+;86>3+;29_#4IN44$N(@?0]N4*"<]T@,8OB1N?@UC1&YZK;0K8 ^U5
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MI]1H>#8)0+>#VQI6U7Y8ULK2Z/EM26\=:A= _ES17^D,1]"_GO/?4$L#!!0
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M-QW8YZ:];V!65FL  'C4@$=N$?1= LA@&J!3.0(@9D1N826 1.50"#21*5<
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MF"R3(M  (&.QAB>-'- .:T#G*N\J/)6SZNX\_3LHRC:2W=5(=B-'.B+WD#.
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M;*2FRN:2.0_F7 Q@E?ZMO0>UL,MB:HJFD6PD;8T1@AYIY2:(R@HM 0IN!:L
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M!!DC.],QMTN.ZC@9_IY:@B'H),F4BP1D;%2 APX4-'9)N$&X1M&[4$ =@XT
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M,HD<T'T/[A=6K;N^MU"6<K6;%O1LH6X%Z'RIE-TM6H+]0SC[!E!+ P04
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M@+ZO%9T'PXM+L/_EL?P"4$L#!!0    ( %4R75,_;R2-&0,  * &   9
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M,QH?0-^76KO=PB?8&_[L#U!+ P04    " !5,EU3B;\(R4X"  #J!   &0
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MY>1G9S=RB](JS=' EP>V%&A.)H$E9*</LA9EWJ#$1U"B&&Z5M!L#7V6.^=\
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M*(N#Z,T<7S[0#H#G1Z5LZSB![BU=_@-02P,$%     @ 53)=4V==L%=S @
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M5YG/<OLSW]GC"!:RTNX7MOW8)!Q!T6DCZ]UD9%"+IK^RAYT.1Q.RX,P$NIM
M'>]^(<?REAEV?:GD%I0=C6CVQIGJ9B,YT5BG+(S"KP+GF>O%ABD.;UDK#*O@
MX@M;5ER/+V<&L>V(6;'#N>EQZ!D<0N&C;,Q&P[NFY.4IP Q)#<SHGMD-?1'Q
MGUTSA3#P@0:4O( 7#I:&#B\\@W<K=%%)W:&Y<@5%Q;3FVMYJ)T&QD^!WPQ\,
M+"M9?/T#?I\OM5$8.7^\0" :"$2.0'1.:DRHLJOX?ZWYG-HO0ME,?:-;5O"K
M$::BYNJ>CZZM3E:L '](#J>/WB=5B@;3KE]:>S]V5?4(+1,E4)KZ-$K\.$^
MI)E/T]R/$[Q/0I^2V$^#!++,#Q/BAT$("?4CFOAY3B )?)KE?I;&WO\#!%Y0
M.1Y4CE^MLCRU^3F=7P1[7N=;;IBH-/S2U4NN!F]J^"+1F=X-JUA3<& &HQ<P
MBKEU0 8DHGYJA4$A8KR$J1^2R'NO=><&?Q=,20*B@4KPSD/4ECUB]3. E1?L
MTJ+ -2XLUH20":5C(! A2AP$D(=^DF8'L%\7%BZ ME.Z8XWQC(3Y[0*?EY4H
MD/.**]&L'5P^">))&(R!(E$_"-P?4#_+(V29>9^Y2Q:Q>@3^P%4A-"]!MK:H
M:E@I6<-.&@VXRFDV??^/C!+Z Y @\+XHUFC6%^-":J.!*:&1A>?JNQ.X,<Q6
M:=@RA:-QB+ 6E1 .2!>$!'Z$!,?>!Z[U&S@+"_BB9^- ] $BH[$?Q#%"/.^L
M_"1JCX+\K+[PLK[IA.3HKA S(L8 "(#X.48_R9(#Y/SU 9#; " G 8 "^SE&
MP+N=AVQ8_C)?W,[_!;_MM;RPU6 2)!,:CB%+,%T#2.G)E'-N&*:B)C# ((,\
MC="4 .((PR:AYYT,_]O)@W_BV(_BZ.]X.$1:*<W.>1@)']>H0S'Z%C'228 "
M8(P@VN1):$3I:T*C1Z'1&+ V)$GBH&CF$XR2+$Q.:D,<6&OY$;UWBT]WT&'-
MTN8H(4]@R2Z98W=YPI'&3Q'/! QBI6,($2)S: 23A_@)3?X&(*9#U'/#K,CC
MO \<E.9)1?EVFR?@\C9X)>(+-N\CO:<[L783>IJP0;9/6-=4,+TYS5;%L1M2
M2+6'M6F+N8<;P2YM*<F=9\YSM9C8DNE7RD P*">!4Q>1<Y0W3Y%V\,VI-,$D
MPOT*ZUY(SJ81.>D=#MN[1Z;P4<$=-VC2!9HCU@T2I1$L>&NXVS?M]#&PIK0C
M%X:W&][ O&':,.SX.R3&O5(H[-ZETFY<S?Z42IC==KZ1%4KK.KB?T*JRDN7Z
MT,G>X; /!G4_?!M/8:ZAQ:49G@;6BG-77;<;46Q0C!J?"JMF@V5UOQ.$=F&/
M/[1"]9^.:X@/[^NZ4_CV@ZB%]42!+;!M%_'VB!,.:.P)HNI702_B+2I3]V;A
MI%+T'L12T2IY+TI7;=#$SOK&AQ(=K<2RLZ,\.T<T]U(4UF]#J-FX>\+'E</T
M!VU!RZXP_:#Y=VF?>;T435=/X<L&0PY6''&VLJM*6'*[_=C3@ WP!D]7JT/#
MN.^KO%WC@R.>*H%QPI";P:61G772;G^SB[II_J&^6CO.4=\MT<,@JMGPP5G.
M?W+EV7>#0YTQP)822S:K98=#A';35DPHN&=5Y_C8-_ROSL:3:%#>SDWVZ!0^
M.3=_9(^N%_"Q>O9ZS=%WHL#@N>6MU +C\A$6/;T+K/!CV/)]_I2[HAA-<1YG
MQ68*[_#7;03(QJZ+1'B_.^ V_*13]4%,^?2X'3OJ.2P<+F@?HBC%J'ZN:YX=
M'0F1]MH=?#4JAWKTI\/A[7"VGO='RL/P_F#^D:DU*@057^'48)IBSZSZPV[_
M8&3K#IA+:?"XZFXWG&%RV@'X?26EV3_8!8;_.%S_!U!+ P04    " !5,EU3
M>3G/@GP&  "L$P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RM6$MO
MVS@0OOM7$$8/#D#')/4ND@!Y=+$MMFTV:;>'H@?&IF.ADN@EJ3CY]SM#R;*2
M.H[;[:$527.^&<Y\,\/P:*7-=[M0RI'[LJCL\7#AW/+U9&*G"U5*>ZB7JH)?
MYMJ4TL'4W$[LTB@Y\T)E,1&,Q9-2YM7PY,BO79J3(UV[(J_4I2&V+DMI'LY4
MH5?'0SY<+USEMPN'"Y.3HZ6\5=?*?5Y>&IA-.I197JK*YKHB1LV/AZ?\]5F$
M^_V&?W*ULKTQP9/<:/T=)V]GQT.&!JE"31TB2/C<J7-5% @$9OS;8@X[E2C8
M'Z_1__!GA[/<2*O.=?$EG[G%\3 =DIF:R[IP5WKUIVK/XPV<ZL+Z_\FJV1N#
MQFEMG2Y;89B7>=5\Y7WKAYY RIX1$*V \'8WBKR5%]+)DR.C5\3@;D##@3^J
MEP;C\@J#<NT,_)J#G#OYZ!;*D"MEE;E3EHP^R9M"V8.CB0-PW#*9MD!G#9!X
M!H@+\EY7;F')FVJF9H\!)F!59YI8FW8F=B*^JZM#$C!*!!-\!U[0'37P>,$S
M>!>YG1;:UD81/0="M4=>Y6Z15T3]6^?N@7QUZMZ1FT)/OW\C7T]OK#- G&\[
MU(>=^M"K#Y]1?PWY-*L+KUQ[KZ]-V.;LG5B8J:_M4D[5\7#9H@Q//F@'Q[E>
M2*/&2-096<H'R!]G"1 8Z%D!H8Q1U?2!P*DJ6TB?&)^TD\43DP:GCG#RKBX>
MP/L\)0'E049C$9%1&-" )^0 UE@6TX"E@_-ML+-\/E>X#$:-2<QI&L;M9]"P
M;JI+L'Z!&7ZG2%[!7/VP]1-"2I_"3:R(7E7*6-A/ "4'& F>P-A)V_XV^+AL
M]LMJ1E;2  0X(;>V5K.)NH>"AM[A-(P"FC$&.KOQ=E%UK\PT1Z$1A_T'(-$,
MMF\OY-(VFG*#,@'G- ZB1JZ;H(\#!DZN%#HY(R$5*:=)Q@A/:21P(6 ,O)T-
M?G-L!YO8[E2[1V Y$S0+TO5W=VB?;OZEX&[Q FF#:@F/1_G= 4F G&D*&IO!
M?H08A6E(X[2-;S?9+\:"BHC30+32O>G@2HWO9%$WWL/L;_$:_7C6I<FU(4L%
MGYD_0IX?D%',$LK6=.LFCVD#"CAE0*DT ;<*X'&<P H/($O#Z'?S9E,37M"[
M!W%&/*19%,#INM%N\FP3^"4">2&PA#A-++H&-^5XX)8]HY8^WO'K\9Y%!8/G
M:R.#?S'6EF[\4FUI94>"!S01HB72>K)=&JYE<Y4[7V7B=$.7;O*$+AS,"6)&
MN< LC&G$0U@)XYC&H2 [VES4M;EH[S97ZCO5D W"H;>8OZWS[83?WODNE)-Y
M84G#]@]U>0/![26:9_/@3!82N$?DH[*;DD30*,XHAUSOVMS@+<85,=Y<?[PD
M-=AAT<G=(1QYQ0XC!O$!B#%+QCPX /YCX42W"Q92:! _"</Y6,0'1""$A^%Q
M2$. ^0N+S?XP;,PX9@EE$6LI,<I2&J38=7[&I&S,!%AU0*+.I"SQXXU)SR$D
M&P01-M:PSAJ>1C1F',S9C<,/TTST@%*4C> D#0KE2? B!CL,NM-$+40(ED2Q
MQX!\R)HJ/2VDM?G\H9>2:YRYT>7FROA#W>BN SV0ID$\CR"GT[JLH33")KB6
MVK8H8K6)^V$RRA.]<A+_?MED_N9$R#R2KBG#F:?,=K9G),D@VZ&DA.&F\?]L
MAVI4 UL9L'7=KA[UJ'VMA[P!B"@4P 9&H@BN86$_G#]&X@D_,642K-B8M30*
ML&I"\P4?TLPWWWW H@U8P% ^ L]D-,U"+*;[VR,@\>(6XA';FS0&:]ZT\HCV
MX?3ZXO1O\F7M$D#Z?/V*,_0R"5FGH0/&0$,_2&G:P";B">(.9S<(D#JD0Q.-
MF7&T-C/"K(@1="MYP)T0IQ1BS*%JPO7-4^<G]"=C5 GU-?1-ZI'HR\6H1?"E
MI.?:B";_U[. FJS] N,,8"$+P[33 1<=\1*56JQL+")T93_\FU[\8EHTEHK@
M$-+S66-#;!%1W.8[90%<IN,]>PT7+1 T"3QIMNDU-$N8;UKGTBX*93=7DSU!
M.99HAN[+>@'*H";P)[71;KN0=G?X%XIM>TGK7\VV\Y63$%H%@X*7I+UKS[9+
MSJ3W@E(J<^O?B2S<1.O*-8\IW6KW%'7:O,!LMC?O6.^EN<W!-86:@R@[3.!"
M8YJWH6;B]-*_Q]QHYW3IAPLE9\K@!OA]KN$:TTY00?= =_(?4$L#!!0    (
M %4R75,2TBS9'0<  #\5   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;*U8;7/;-A+^SE^!T77NW!DDP@L!DCG;,[;3-.E<IQD[O7[H] ,MP1(O%*F2
M4&S_^SX+4I34R+)\[21CX6T7N\ ^SRYX>E\WG]NY<YX]+,JJ/1O-O5^^&8_;
MR=PM\O9UO7059N[J9I%[=)O9N%TV+I\&H44Y5D+8\2(OJM'Y:1C[V)R?UBM?
M%I7[V+!VM5CDS>.E*^O[LY$<K0>NB]G<T\#X_'29S]R-\S\O/S;HC0<MTV+A
MJK:H*]:XN[/1A7QS:6E]6/#?PMVW6VU&GMS6]6?J?)B>C009Y$HW\:0AQ\\7
M=^7*DA3!C-][G:-A2Q+<;J^UOPN^PY?;O'57=?E+,?7SLU$Z8E-WEZ]*?UW?
MOW>]/X;T3>JR#7_9?;?6VA&;K%I?+WIA6+ HJNXW?^C/84L@%4\(J%Y !;N[
MC8*5;W.?GY\V]3UK:#6T42.X&J1A7%'1I=SX!K,%Y/SYC9OAB#V[=LNZ\44U
M8R>?\MO2M=^>CCWTTZKQI-=UV>E23^B2BOU85W[>LN^JJ9ON*AC#L,$ZM;;N
M4AW4^,.J>LVTX$P))0_HTX.W.NC33^A[6[23LFY7C6/U'8/?A7_\5\L0XDT>
MG&^[XVC9K]X]>'9;UI//O[%?+VY;WR" ?CM@0SS8$ <;XJ=.'+B:KLI@0;\=
M*ZH.7A2G:#$_=XAXNA&ZB\&J?5=R<#."])MVF4_<V0B8;5WSQ8W.K]'(F\F<
MY=44$?P%R%P&,]X_XB"*Q6)5.;9LZNEJ@I/X"<8T[%/M\S*B:V 7WPS_H[T2
M#516*\=>,1D;GB1VTXJNZM8'SW/$&#5F=3UML>#$2"X2R;[=;D??-W7;DN:[
MPF,BBWDBS-"(.MN*:E(O'(LUI+1@*N9Q*IBTDELAF)4)EU+T:V?@J79\@B!H
M$>/LG_](E93_9I4C]2>)R7AB#8PX,:GB1J74E%S'BJM,DT&N0JR4X>CR*0!9
M4&00LS#W *:$5BB"*LVS).4VR4C#5B>ZF>>->T5,,F7+_#$<_*ZH@KV6"ZE)
M=*L3/7EQ@SS9:A,N3!P.\M7.0'0#\J,H)W%0\&<78GYK\Q.5)MRFG?"F$_TT
M *2[BNX 85VF89NB]2>92KFRH6FYD89;):B3<IUD/!,XRNA=4>75Q*UOC S,
MN!)Q]W>8GB!(^K.0&A<BPRWTK>A#)^SSA[7I82G^11]WK%LCZ1&'=L!4);A,
MDM[4%,%# 1!=($!\&ZWY,0]=<)'E$F<IN:'#2113!@,P'Q&GZ)PUE\)& 2XO
M%?I/D=\69>$+M]FWW(PAL#4W,$[!2&L29E7&4Y5 KS0I%W'6;_LRF;_$!N(E
M; ! R136V.WV 4:P:<I3;;M@'#I_Y@0)?X!: '^KO<L,6N"^E6%2<!/CQ\2(
MQYC%B<9MQ,<P U0#2-KT/R^A 9D(D%G:T<#0.0[+DE@C-1LL#P-'8#E-$'"F
M9]2A\S264]@66\)L9E.> "HP6 B-8\\Z)LJ$X28Q^X%,^-L#8 46U@' Z];_
M"^#]]@%*<2)Z^P F)>P!]'9Q@.#3&3=",\TU@B'&Q5I(@FNM_C-VCQ%Y#KE2
M(#5EBDH9#:J)E>5)*ID!!)41>V#[C,!?P:S,7H99#<["_MOM0YA%LM'K-#YT
MOL9L M85QFRW=S%K*)LCU^-O3,N,5EAT7!I'JM 9T3OJB%0D3*<\EOIXT!K4
M$0DD;2@$-IWC0"OBN*\<>M . \> UH*GXSX!#YVG06O@JU%4*:1@>F$5.P&Y
MI89G60 ML;[M8+,/M$"VS@ZB[ND- A37&RCY).KH)E.XKZAD WL*AK^A2,L8
MI0#00ISLHNXXD6?S)1@'V9W)3(;4D62H! V%E*),(.6^?/F<##OP!###$\ <
M_038+OWQ?^;J69,OY\4$AC5NAN&]9?_!#?:7_9^:' &;5PS7[?$H?JRBBQ4A
M /ZSGZO"HR"]\;EW:\;8S!YZ WS-(]%7/"(! S 9U8 L#J47$9Q%]!D47R"V
MS0/ANA>Y:^H%D.%=4^$DNI>P:]KC%?U][HK#[GY-FPB6&%;BP9"!N#72AX:5
MF30L1B6L]4[]\YS#+U+VMSF]FR5ZI]<@V_@IK4*=GQ)+2Z(9M&*J:S4S5*@@
M6^**-GGC>5]?IO 0&.T 1GLT&!?Y_T!^@SW[@'=0V7[@K1&S#J7^=*.K?A]V
MP6+*$B*40,/H);T-C-6[HU?T>-!0L#/ZEBD-AD)-B_.+,WKU(D:4V*SX#M3&
MT]3NRKU#-\;C-I,6\SAA*S>3W],D<J? ^\'BN6)ULIE\3]F###094Q8/'+DE
M^8&"$I.9P5L']V>4BB2B6"A%-7J6(H-@!G=L>&KV<^IXZZ,6=,["I[L6I>6J
M\MWWK6%T^#IXT7T4VRSO/BW^F#<SU NL='<0%:\3L&?3?:[K.KY>AD]DM[6'
M Z$Y=_G4-;0 \W<UT-1W:(/AF^GY'U!+ P04    " !5,EU3W%L'M!$$   2
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R-5FUOVS80_NY?<="
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M7F01F.$&&A9.;\/47VF'=TAX;?#2EL8;X/>UUNZX\ %.?P.6?P-02P,$%
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M_1C?+MT,LPUCU;(>("?*XCA:?RYP_I?:'<#]F5)VR[@+NO\HAO\ 4$L#!!0
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M28)%:X+?E:AA@6KT_64"H=?SO)'[LKNNA\-Z@V$P".MA>Z2#FG1@);U88T%
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M0YY]7.$%$E0I@-\74IJ71>F@N9).?P!02P,$%     @ 53)=4P8<]F77!0
M9!<  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULE5C;<MLV$/T5CJ8/
MR4P3 2!X\]B:L:6T3::9>.*D?:9)2&)#$BH(V<G?=WD1*0%+U'FQ2>KL8@^
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M5O+94RT:O+4/W61VUD"_J-MU?] *?BW 3J_>?8<=U(C&>[41.BW*YK7WQGN
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M0%"<!*'!P$8%+([P^.,Q_M@9_[OJ4,H?0GB/D'G; M]&L3W#413$)#%H(+C
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M6"MBXU@44S\P&=@X&E!"Y@KUU =0=R/P16KHNW<_VW\/+&U%]Z$PAY'9(6#
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M]TM*MF)+LANT+S9)G3.<,S,:S70GY*,J #1ZKDJN9DZA=7WMNBHKH*+J2M3
MS9.UD!759BLWKJHET+PA5:5+,([<BC+NS*?-V5+.IV*K2\9A*9':5A65+[=0
MBMW,\9S#P1>V*;0]<.?3FF[@ ?2W>BG-SNVLY*P"KIC@2,)ZYMQXUXO4XAO
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M]+(=CMJ-%G4S+JR$-L-'LRS,/ G2 LSSM1#ZL+$7=!/J_']02P,$%     @
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M+E7/IWICY-IU[(4TT/_=LH"13I4-@/=+*<UN8Q.T_R2,_P!02P,$%     @
M53)=4XCU.Q$3 @  #04  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
MC51A;YLP$/TK)[0/K;0& B3-(H+4))JV29.B9MT^.W $*\9FMBG=OY]M"$K7
M-,L7[+/OO7OOL)VT0AY4B:CAI6)<+;Q2ZWKN^RHKL2)J)&KD9J<0LB+:A'+O
MJUHBR1VH8GX8!%._(I1[:>+6-C)-1*,9Y;B1H)JJ(O+/$IEH%][8.RX\TGVI
M[8*?)C79XQ;U4[V1)O('EIQ6R!45'"06"^]A/%_%-M\E_*38JI,Y6"<[(0XV
M^)HOO, *0H:9M@S$#,^X0L8LD9'QN^?TAI(6>#H_LG]VWHV7'5&X$NP7S76Y
M\&8>Y%B0ANE'T7[!WL_$\F6"*?>%MLN=?/(@:Y0650\V"BK*NY&\]'TX 8SC
M=P!A#PBO!40](')&.V7.UIIHDB92M"!MMF&S$]<;AS9N*+=_<:NEV:4&I],5
M427<K%$3RM0MW,'6G).\80BB,/UAA&>HH.$Y2LAL[AT\/*WAYL-MXFM3W[+X
M65]KV=4*WZGUK>$CB(*/$ ;A^ Q\=3T\> WWC>O!>CA8#QU?=,DZT; D_ "$
MYT YE&:<7^".!N[(<<?_X=[]PWVN:1W3U#'92_><AI,@O@]GID?/I^UYFQC9
MS.ELR'NE-1ZTQA>U_A":,+"*SZF+KU7W-O&\.O_DL-J'XCN1>\H5,"P,,AC=
M3SR0W>7K BUJ=WYW0IO;X*:E>:]0V@2S7PBACX&]$L,+F/X%4$L#!!0    (
M %4R75/S\'H9-0,  $0)   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;)U6VX[;-A#]%4(HB@3HKF1=?(MMP!<4;9$@B]VD?0CZ0$LCFPA%*B1E[_Y]
MAI164;RRL,B+38[F')X9DC-<G*7ZJH\ ACP67.BE=S2FG/N^3H]04'TK2Q#X
M)9>JH :GZN#K4@'-'*C@?A@$8[^@3'BKA;/=J=5"5H8S 7>*Z*HHJ'K: )?G
MI3?RG@WW[' TUN"O%B4]P .8S^6=PIG?LF2L *&9%$1!OO36H_EN9OV=P[\,
MSKHS)C:2O91?[>3O;.D%5A!P2(UEH/AW@BUP;HE0QK>&TVN7M,#N^)G]3Q<[
MQK*G&K:2_\<R<UQZ4X]DD-.*FWMY_@N:>!++ETJNW2\Y-[Z!1])*&UDT8%10
M,%'_T\<F#Z\!A T@O ",XBN J %$KP7$#2!VF:E#<7G844-7"R7/1%EO9+,#
METR'QO"9L-O^8!1^98@SJT^*9D"HR,A'<P1%[B$%=J)[#IJ\V8&AC.NWY(8\
MX'G+*@Y$YL2T&.DPJH.Y(>O/._+FM[<+WZ \NXB?-E*VM93PBI1_*G%+HN /
M$@;AJ >^>ST\^!GN8U+:S(1M9D+'%UWAVU9*@3 #3%'+%#FF>##'G2SU!+<9
MIO@R^K\OH35H[$#V@I]6X31)HH5_ZN;MI5<\2T:SUNNGH.(VJ'A0T7NI-:$<
MRP85*?2)&\3;<C;7)4UAZ6&]TJ!.X*U(W[;7/$E'_DT4!$G2KS]I]2>#^M=I
MJBK("!.I+/KT;X;Q7\+>'4E>B(V"\2B)+[:DSVT:AE=B&K<QC8</FC24DX$K
MW:=X_.)T1%$\"287BGO<PLEX>N443;P+P[0-8?H+!WTS#%ISWA2E;BFB"HB0
MXH8) WC"#-D#54P<;@>N]*R5.?N%W=\,@^X4P];*^!/!(U<JIE$DEM.NYES)
M@N"ND366?D4YHX)\HH_D8YZS%/"PHC>GKF,:2>Y_IT7Y;D<,>J02KZ%VW1@?
M X[C">/M#=;O](L"U,'U78T4E3!U!6BM;6O?N!9X:9_,MY,>^V8ZWT[[[+/Y
MUCT1_!_+UN^+#U0=F-"$0XX2@ML)W@U5]^QZ8F3INMA>&NR);GC$9PXHZX#?
M<RG-\\0NT#Z<5M\!4$L#!!0    ( %4R75,9)^DE9 ,  %H/   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;,57WV_:,!#^5ZQH#ZNT-K%#$E(!TD8U
MK=,V5>U^/$Q[<,D!UA*;V0:Z_W[GD"6PAHRV2'V!.+G[[CO[SI\]6"O]T\P!
M++DK<FF&WMS:Q;GOF\D<"F[.U (D?IDJ77"+0SWSS4(#STJG(O=9$,1^P87T
M1H/RW94>#=32YD+"E29F611<_WX#N5H//>K]?7$M9G/K7OBCP8+/X ;LE\65
MQI%?HV2B &F$DD3#=.B]IN=C%CB'TN*K@+79>B8NE5NE?KK!93;T L<(<IA8
M!\'Q;P5CR'.'A#Q^5:!>'=,Y;C__17];)H_)W'(#8Y5_$YF=#[V^1S*8\F5N
MK]7Z'50)10YOHG)3_I+UQC;&B).EL:JHG'%<"+GYYW?51&PYT-X>!U8YL$,=
MPLHA+!/=,"O3NN"6CP9:K8EVUHCF'LJY*;TQ&R'=,MY8C5\%^MG1I5R!M$H+
M,.3E!5@N<G-"3LD-UDNVS(&H*1%;-J?D]9<+\O+%R<"W&-Z!^),JU)M-*+8G
MU/NE/"-A\(JP@-$6]_'A[L&NNX])UYFS.G-6XH5'ROS[!P0@EQ8*\Z,C?%B'
M#\OPO0/"CY=:XZ!M2C<@<0GB6G(U8BF+0C;P5]M3=]\L29,X#6JS'8Z]FF/O
M8(Z?E#S%@MQ+=(,4;3&@+(ZC?O(/TQ:[A+&PE[93C6JJ42?53]#**KH?+8I2
M2M-_6-VW8Q'NA.$>5G'-*NYD=<W7V*P6M."Y(5QF!!M:NX+#;4<9JY?%"?G^
M$8I;T%U%E=3QDN>HZ7X=OG^,FNX$<;IU;A9\ D,/A<F 7H$W(FW[Q=-Q=K),
MZRS3HW5%>F!7M-AU=04-FNT]>$Q?5%[_)]9FV,EL2WAH)[-O*.]8C&2AU0S7
MQQS2![39W.FS[.ZTV=[I4?;W;I0'-$,%M+-0-(F2>,\Z-1I CR<"W5 /R>;I
M0+OI-CI"'R4DW5X/R:Q%DKK6J9$:VJTU;X44> [,R$RI#(O^L^8KR+DL9>=*
M*XL'Y]_R(+FAC=[09Q$<VB@./8KD5"@[ M]VCFJQB_L!I;T]J]-H!CV>:'1#
M/:36G@ZT>[1N9(<]2G8JK_\>9UOL6I?!W[KXN%OG1ZYG0AJ2PQ0=@[,$%U)O
M+G*;@56+\BYTJRS>K,K'.5Y^03L#_#Y5V"?5P%VOZNOTZ ]02P,$%     @
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M<*)%!3$=RPK, N>E$85Z;,.BD-:"Y"5L&.)U46#V\02$-@O#-HX#+_D^$VK
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M'9@*D/,II>+844](_X\1_0=02P,$%     @ 53)=4ZHBO%J) @  D@8  !D
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MF1=<US4:+IALRT(N,)>,K_/&*/BBC:L&\(V(NE,;*NB9&QNN<<L,5KJQ0JV
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MKSMLV4%9 US?2&D. _N!^D_ _#]02P,$%     @ 53)=4Z6U<[]S P  Q0L
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M<U)@.>85*?6;#1<%5GHJMJZL!,&9)17,A9Z'W +3TDD3^^Q>I FO%:,EN1=
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M(@'B6"3UFB8!G-AM][#;2]=WO0^+^\!(=,R>7GRB%&_^?8>48]D6Q3A;;[!
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M4[476G6 8:\A.0V2F$&23N"BP(U(7^1:5L/T?8'2[@KL0G'<%]&6%;&=%M\
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M1CNH)]#])>=J?Z%? ^3ONH;_ 5!+ P04    " !5,EU3^.SXV@T&  "#(@
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M6-\KW+<@$S#(#@IEV'_72LTL"3R/J;!$$S#1QK[*%I[70(GH\RP":"9V3I#
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M9 7+PQ6)YX05!O+^@E+Q?%($4!/R\?]02P,$%     @ 53)=4W @S.L7!0
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M08,V<]$XLY$&^D5MXOZ@);PM0$[/%TQMT0>(/OI8MUEDHG&UY)H5I;I&4_0
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M*>";N_=.QP)TJ2-TZ3%+.1$<'SG6&K>O$)!+K<@=#WT^)*\=ZE) +CTSY%)
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M>LB*(DNJQ862<Z7+ //]8Y85VY5R!\W,N.E_4$L#!!0    ( %4R75.:)RT
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M5Q",NT#GN=9X-%R ]ET=_@502P,$%     @ 53)=4P..X#*T P  (P\  !D
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MMP!*7+)6V%NU^8Y=/B/'5RAA_#]L.M\H@*(U5M4=F!347.Z^;-O580\P3 \
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M+S) ?0:HC_/R(9/JA<7Q^R3V\L\T2:(HCK$5G4R\"B;8NL4QO/ULF#;PP.)
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M?E+O8?PZEN'6\[W&Y_\DU>/EN^7V^.OR^R*^+U97G.O[BN'I+U!+ P04
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ 53)=4P"O!5D !@  @AL  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %4R75-RL(5XQP4   T6   8
M              " @4,.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !5,EU3'EXEG2,%  !Z%   &               @(% %   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 53)=4ZD(69@,!P
M02H  !@              ("!F1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( %4R75-\M;U;[@4  .$6   8              " @=L@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !5,EU3]@E.
MGN,J  #*A0  &               @('_)@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ 53)=4V[F88R.!@  &0\  !@
M ("!&%(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %4R
M75-QC IV.00  "((   8              " @=Q8  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !5,EU3FC(DJ=(#   #"   &
M        @(%+70  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ 53)=4[6RC UK!   20H  !D              ("!4V$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !5,EU33$&Y=TL#   3!P
M&0              @('U90  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( %4R75/'8\@ . (  -,$   9              " @7=I  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 53)=4^K1]57,
M @  ] 4  !D              ("!YFL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !5,EU3@<&B.ZL"  "K!0  &0
M@('I;@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %4R
M75,T7NZ7( ,  -P&   9              " @<MQ  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ 53)=4S9"-1-M @  . 4  !D
M         ("!(G4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !5,EU39)&,+M\"  !B!@  &0              @('&=P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %4R75-"7%DM& (  /$$
M   9              " @=QZ  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ 53)=4\&\6ZIH!P  C!(  !D              ("!*WT
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !5,EU3\WO2
MI;L'  "N$@  &0              @('*A   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( %4R75-SFHR75PH  /,<   9
M  " @;R,  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M53)=4W;\DM80"0  TQD  !D              ("!2I<  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !5,EU3!@!8I& $  #/"   &0
M            @(&1H   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( %4R75,.S933]0D  $$9   9              " @2BE  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 53)=4ZZ#JB,;"
M*10  !D              ("!5*\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !5,EU3:/UA>RH1   )+0  &0              @(&F
MMP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %4R75.+
MEAK7P00  ',*   9              " @0?)  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ 53)=4P:[:,9K @  204  !D
M     ("!_\T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %4R75,_;R2-&0,  * &   9              "
M@9P( 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 53)=
M4T@'!WW. @  _ 4  !D              ("![ L! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !5,EU3B;\(R4X"  #J!   &0
M        @('Q#@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( %4R75-/L<<$T0(  .4%   9              " @781 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 53)=4[[8J16N @  K 4
M !D              ("!?A0! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !5,EU3?-D!-'$"  !7!0  &0              @(%C%P$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %4R75-G7;!7
M<P(  "L%   9              " @0L: 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ 53)=4R:I6U:) @  C04  !D
M ("!M1P! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !5
M,EU3F<=H[)X#  #9"   &0              @(%U'P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %4R75-JF$5CD08  'T0   9
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M970T-BYX;6Q02P$"% ,4    " !5,EU3Z57#/EX#  "R!P  &0
M    @(&H0@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M %4R75.DL;X"# 4  %T,   9              " @3U& 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ 53)=4P\T%NB0!   6!0  !D
M             ("!@$L! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !5,EU3BV#6RK8"  #X!@  &0              @(%'4 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %4R75/XCA06)@0
M )X.   9              " @313 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ 53)=4P8<]F77!0  9!<  !D              ("!
MD5<! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !5,EU3
M$KE6ZYD"  !Q!@  &0              @(&?70$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( %4R75-8?,RV_@,  $H,   9
M      " @6]@ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ 53)=4Y26=$9U P  K0H  !D              ("!I&0! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !5,EU39I"XV_,"   P"
M&0              @(%0: $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( %4R75.(]3L1$P(   T%   9              " @7IK 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 53)=4_/P>ADU
M P  1 D  !D              ("!Q&T! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !5,EU3&2?I)60#  !:#P  &0
M@($P<0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( %4R
M75/-?<0A'0,  ' ,   9              " @<MT 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ 53)=4[8G>2%= @  /08  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( %4R75.EM7._<P,  ,4+   9
M  " @7V& 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M53)=4]X+B97I @  [08  !D              ("!)XH! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !5,EU3H Q3I7\"  "I!P  &0
M            @(%'C0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( %4R75-Z.7LOKP@  $4H   9              " @?V/ 0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ 53)=4UC.:C#P!
M]Q(  !D              ("!XY@! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " !5,EU3^.SXV@T&  "#(@  &0              @($*
MG@$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( %4R75-B
M<_>:=@<  %HJ   9              " @4ZD 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ 53)=4_4N/HYS @  < 8  !D
M     ("!^ZL! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %4R75/&1M4/8@,  )<(   9              "
M@:#( 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ 53)=
M4QZ#<RH>!   \!   !D              ("!.<P! 'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6Q02P$"% ,4    " !5,EU3LE1ZON<%   E)P  &0
M        @(&.T $ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0
M   ( %4R75.:)RT @@4  ,T<   9              " @:S6 0!X;"]W;W)K
M<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ 53)=4VT5-$VR!   : T
M !D              ("!9=P! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q0
M2P$"% ,4    " !5,EU33F7>OK #  #I#   &0              @(%.X0$
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( %4R75,(C![@
MG ,   4-   9              " @37E 0!X;"]W;W)K<VAE971S+W-H965T
M.#0N>&UL4$L! A0#%     @ 53)=4TQ&$4^7 @  508  !D
M ("!".D! 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " !5
M,EU3>++"!U "  !C!0  &0              @('6ZP$ >&PO=V]R:W-H965T
M<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( %4R75,#CN RM ,  ",/   9
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M;',O+G)E;'-02P$"% ,4    " !5,EU3Q3F]%"8&  "[.@  #P
M    @ %' @( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 53)=4^;BI-"@
M @  !34  !H              ( !F@@" 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 53)=4\* #&LZ @  :#,  !,
M ( !<@L" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &( 8@#E&@  W0T"
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>214</ContextCount>
  <ElementCount>515</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statement of Profit or Loss and Other Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statement of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statement of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Revenue and other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/Revenueandotherincome</Role>
      <ShortName>Revenue and other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/Expenses</Role>
      <ShortName>Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Income Tax Benefit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/IncomeTaxBenefit</Role>
      <ShortName>Income Tax Benefit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Key Management Personnel Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/KeyManagementPersonnelCompensation</Role>
      <ShortName>Key Management Personnel Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Trade and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/TradeandOtherReceivables</Role>
      <ShortName>Trade and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Controlled Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ControlledEntities</Role>
      <ShortName>Controlled Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/TradeandOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Provision for Sales Returns</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ProvisionforSalesReturns</Role>
      <ShortName>Provision for Sales Returns</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Contingent liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ContingentliabilitiesandCommitments</Role>
      <ShortName>Contingent liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Other Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/OtherReserves</Role>
      <ShortName>Other Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/CashFlowInformation</Role>
      <ShortName>Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Financial Risk Management Objectives and Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies</Role>
      <ShortName>Financial Risk Management Objectives and Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Events occurring after the Reporting Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/EventsoccurringaftertheReportingDate</Role>
      <ShortName>Events occurring after the Reporting Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Company Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/CompanyDetails</Role>
      <ShortName>Company Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://immuron.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Revenue and other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/RevenueandotherincomeTables</Role>
      <ShortName>Revenue and other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/Revenueandotherincome</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ExpensesTables</Role>
      <ShortName>Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/Expenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Income Tax Benefit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/IncomeTaxBenefitTables</Role>
      <ShortName>Income Tax Benefit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/IncomeTaxBenefit</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Key Management Personnel Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/KeyManagementPersonnelCompensationTables</Role>
      <ShortName>Key Management Personnel Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/KeyManagementPersonnelCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/LossperShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/Cash</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Trade and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/TradeandOtherReceivablesTables</Role>
      <ShortName>Trade and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/TradeandOtherReceivables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/Inventories</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Controlled Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ControlledEntitiesTables</Role>
      <ShortName>Controlled Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/ControlledEntities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/TradeandOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/TradeandOtherPayables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Provision for Sales Returns (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ProvisionforSalesReturnsTables</Role>
      <ShortName>Provision for Sales Returns (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/ProvisionforSalesReturns</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/ShareCapital</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Other Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/OtherReservesTables</Role>
      <ShortName>Other Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/OtherReserves</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/SegmentReporting</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/CashFlowInformationTables</Role>
      <ShortName>Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/CashFlowInformation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Share-based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SharebasedPaymentsTables</Role>
      <ShortName>Share-based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPayments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/RelatedPartyTransactions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Financial Risk Management Objectives and Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Revenue and other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/RevenueandotherincomeDetails</Role>
      <ShortName>Revenue and other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/RevenueandotherincomeTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Revenue and other income (Details) - Schedule of revenue and other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofrevenueandotherincomeTable</Role>
      <ShortName>Revenue and other income (Details) - Schedule of revenue and other income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/RevenueandotherincomeTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Expenses (Details) - Schedule of expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofexpensesTable</Role>
      <ShortName>Expenses (Details) - Schedule of expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ExpensesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable</Role>
      <ShortName>Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/IncomeTaxBenefitTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Income Tax Benefit (Details) - Schedule of income tax benefit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofincometaxbenefitTable</Role>
      <ShortName>Income Tax Benefit (Details) - Schedule of income tax benefit</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/IncomeTaxBenefitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable</Role>
      <ShortName>Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/KeyManagementPersonnelCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Loss per Share (Details) - Schedule of basic and diluted loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable</Role>
      <ShortName>Loss per Share (Details) - Schedule of basic and diluted loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/LossperShareTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Cash (Details) - Schedule of balances under cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofbalancesundercashTable</Role>
      <ShortName>Cash (Details) - Schedule of balances under cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/CashTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Trade and Other Receivables (Details) - Schedule of trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleoftradeandotherreceivablesTable</Role>
      <ShortName>Trade and Other Receivables (Details) - Schedule of trade and other receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/TradeandOtherReceivablesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Inventories (Details) - Schedule of inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofinventoriesTable</Role>
      <ShortName>Inventories (Details) - Schedule of inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/InventoriesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Controlled Entities (Details) - Schedule of subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofsubsidiariesTable</Role>
      <ShortName>Controlled Entities (Details) - Schedule of subsidiaries</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ControlledEntitiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Trade and Other Payables (Details) - Schedule of trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleoftradeandotherpayablesTable</Role>
      <ShortName>Trade and Other Payables (Details) - Schedule of trade and other payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/TradeandOtherPayablesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Provision for Sales Returns (Details) - Schedule of provision for sales returns</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable</Role>
      <ShortName>Provision for Sales Returns (Details) - Schedule of provision for sales returns</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ProvisionforSalesReturnsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Contingent liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ContingentliabilitiesandCommitments</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/LeasesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Leases (Details) - Schedule of amounts relating to leases in balance sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable</Role>
      <ShortName>Leases (Details) - Schedule of amounts relating to leases in balance sheet</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/LeasesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Leases (Details) - Schedule of profit or loss amounts relating to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of profit or loss amounts relating to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/LeasesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ShareCapitalDetails</Role>
      <ShortName>Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ShareCapitalTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Share Capital (Details) - Schedule of share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofsharecapitalTable</Role>
      <ShortName>Share Capital (Details) - Schedule of share capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ShareCapitalTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Share Capital (Details) - Schedule of ordinary shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofordinarysharesTable</Role>
      <ShortName>Share Capital (Details) - Schedule of ordinary shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/ShareCapitalTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Other Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/OtherReservesDetails</Role>
      <ShortName>Other Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/OtherReservesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Other Reserves (Details) - Schedule of other reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofotherreservesTable</Role>
      <ShortName>Other Reserves (Details) - Schedule of other reserves</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/OtherReservesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Other Reserves (Details) - Schedule of movements in options and warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable</Role>
      <ShortName>Other Reserves (Details) - Schedule of movements in options and warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/OtherReservesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SegmentReportingTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Segment Reporting (Details) - Schedule of segment information for the reportable segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of segment information for the reportable segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SegmentReportingTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Segment Reporting (Details) - Schedule of information on geographical regions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofinformationongeographicalregionsTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of information on geographical regions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SegmentReportingTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Segment Reporting (Details) - Schedule of major customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofmajorcustomersTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of major customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SegmentReportingTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable</Role>
      <ShortName>Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/CashFlowInformationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Share-based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/SharebasedPaymentsDetails</Role>
      <ShortName>Share-based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPaymentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable</Role>
      <ShortName>Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPaymentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable</Role>
      <ShortName>Share-based Payments (Details) - Schedule of granted valuation of options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPaymentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0</Role>
      <ShortName>Share-based Payments (Details) - Schedule of granted valuation of options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPaymentsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable</Role>
      <ShortName>Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/SharebasedPaymentsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Related Party Transactions (Details) - Schedule of information about other related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of information about other related party transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Financial Risk Management Objectives and Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofforeigncurrencyriskTable</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofexchangeratesTable</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleoftradereceivablesTable</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="f20f2021_immuronlimited.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>089 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable</Role>
      <ShortName>Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="f20f2021_immuronlimited.htm">f20f2021_immuronlimited.htm</File>
    <File>f20f2021ex12-1_immuron.htm</File>
    <File>f20f2021ex12-2_immuron.htm</File>
    <File>f20f2021ex13-1_immuron.htm</File>
    <File>f20f2021ex13-2_immuron.htm</File>
    <File>f20f2021ex23-1_immuron.htm</File>
    <File>imc-20210630.xsd</File>
    <File>imc-20210630_cal.xml</File>
    <File>imc-20210630_def.xml</File>
    <File>imc-20210630_lab.xml</File>
    <File>imc-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2021_immuronlimited.htm": {
   "axisCustom": 4,
   "axisStandard": 17,
   "contextCount": 214,
   "dts": {
    "calculationLink": {
     "local": [
      "imc-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imc-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2021_immuronlimited.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imc-20210630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imc-20210630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "imc-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 694,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://immuron.com/20210630": 136,
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 121,
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 261
   },
   "keyCustom": 254,
   "keyStandard": 261,
   "memberCustom": 52,
   "memberStandard": 26,
   "nsprefix": "imc",
   "nsuri": "http://immuron.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://immuron.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Key Management Personnel Compensation",
     "role": "http://immuron.com/role/KeyManagementPersonnelCompensation",
     "shortName": "Key Management Personnel Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Loss per Share",
     "role": "http://immuron.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCashExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Cash",
     "role": "http://immuron.com/role/Cash",
     "shortName": "Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCashExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Trade and Other Receivables",
     "role": "http://immuron.com/role/TradeandOtherReceivables",
     "shortName": "Trade and Other Receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Inventories",
     "role": "http://immuron.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ControlledEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Controlled Entities",
     "role": "http://immuron.com/role/ControlledEntities",
     "shortName": "Controlled Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ControlledEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Trade and Other Payables",
     "role": "http://immuron.com/role/TradeandOtherPayables",
     "shortName": "Trade and Other Payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfProvisionForSalesReturnsExplantory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Provision for Sales Returns",
     "role": "http://immuron.com/role/ProvisionforSalesReturns",
     "shortName": "Provision for Sales Returns",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfProvisionForSalesReturnsExplantory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ContingentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Contingent liabilities and Commitments",
     "role": "http://immuron.com/role/ContingentliabilitiesandCommitments",
     "shortName": "Contingent liabilities and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ContingentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Leases",
     "role": "http://immuron.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income",
     "role": "http://immuron.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statement of Profit or Loss and Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Share Capital",
     "role": "http://immuron.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Other Reserves",
     "role": "http://immuron.com/role/OtherReserves",
     "shortName": "Other Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Segment Reporting",
     "role": "http://immuron.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCashFlowInformationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Cash Flow Information",
     "role": "http://immuron.com/role/CashFlowInformation",
     "shortName": "Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCashFlowInformationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Share-based Payments",
     "role": "http://immuron.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Related Party Transactions",
     "role": "http://immuron.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Financial Risk Management Objectives and Policies",
     "role": "http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies",
     "shortName": "Financial Risk Management Objectives and Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Events occurring after the Reporting Date",
     "role": "http://immuron.com/role/EventsoccurringaftertheReportingDate",
     "shortName": "Events occurring after the Reporting Date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCompanyDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Company Details",
     "role": "http://immuron.com/role/CompanyDetails",
     "shortName": "Company Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfCompanyDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DescriptionOfAccountingPolicyForBasisOfPresentation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://immuron.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DescriptionOfAccountingPolicyForBasisOfPresentation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Statement of Financial Position",
     "role": "http://immuron.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Statement of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Revenue and other income (Tables)",
     "role": "http://immuron.com/role/RevenueandotherincomeTables",
     "shortName": "Revenue and other income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Expenses (Tables)",
     "role": "http://immuron.com/role/ExpensesTables",
     "shortName": "Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Income Tax Benefit (Tables)",
     "role": "http://immuron.com/role/IncomeTaxBenefitTables",
     "shortName": "Income Tax Benefit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Key Management Personnel Compensation (Tables)",
     "role": "http://immuron.com/role/KeyManagementPersonnelCompensationTables",
     "shortName": "Key Management Personnel Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailsOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Loss per Share (Tables)",
     "role": "http://immuron.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailsOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutCashExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Cash (Tables)",
     "role": "http://immuron.com/role/CashTables",
     "shortName": "Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutCashExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Trade and Other Receivables (Tables)",
     "role": "http://immuron.com/role/TradeandOtherReceivablesTables",
     "shortName": "Trade and Other Receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Inventories (Tables)",
     "role": "http://immuron.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DetailedInformationAboutInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Controlled Entities (Tables)",
     "role": "http://immuron.com/role/ControlledEntitiesTables",
     "shortName": "Controlled Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Trade and Other Payables (Tables)",
     "role": "http://immuron.com/role/TradeandOtherPayablesTables",
     "shortName": "Trade and Other Payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:EquityBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statement of Changes in Equity",
     "role": "http://immuron.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statement of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:EquityBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfSalesReturnProvisionExplantory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Provision for Sales Returns (Tables)",
     "role": "http://immuron.com/role/ProvisionforSalesReturnsTables",
     "shortName": "Provision for Sales Returns (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfSalesReturnProvisionExplantory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfAmountsRecognizedinBalanceSheet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Leases (Tables)",
     "role": "http://immuron.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfAmountsRecognizedinBalanceSheet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Share Capital (Tables)",
     "role": "http://immuron.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailedInformationOtherReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Other Reserves (Tables)",
     "role": "http://immuron.com/role/OtherReservesTables",
     "shortName": "Other Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfDetailedInformationOtherReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosuresOfProductsAndServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Segment Reporting (Tables)",
     "role": "http://immuron.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosuresOfProductsAndServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Cash Flow Information (Tables)",
     "role": "http://immuron.com/role/CashFlowInformationTables",
     "shortName": "Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Share-based Payments (Tables)",
     "role": "http://immuron.com/role/SharebasedPaymentsTables",
     "shortName": "Share-based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://immuron.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Financial Risk Management Objectives and Policies (Tables)",
     "role": "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables",
     "shortName": "Financial Risk Management Objectives and Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c16",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:RepresentativesWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c16",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:RepresentativesWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://immuron.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:OtherIncomeOfResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Revenue and other income (Details)",
     "role": "http://immuron.com/role/RevenueandotherincomeDetails",
     "shortName": "Revenue and other income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:OtherIncomeOfResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Revenue and other income (Details) - Schedule of revenue and other income",
     "role": "http://immuron.com/role/ScheduleofrevenueandotherincomeTable",
     "shortName": "Revenue and other income (Details) - Schedule of revenue and other income",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:RevenueAndOperatingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:AccountingAndAudit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Expenses (Details) - Schedule of expenses",
     "role": "http://immuron.com/role/ScheduleofexpensesTable",
     "shortName": "Expenses (Details) - Schedule of expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:AccountingAndAudit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized",
     "role": "http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable",
     "shortName": "Income Tax Benefit (Details) - Schedule of unused tax losses for which no deferred tax asset recognized",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Income Tax Benefit (Details) - Schedule of income tax benefit",
     "role": "http://immuron.com/role/ScheduleofincometaxbenefitTable",
     "shortName": "Income Tax Benefit (Details) - Schedule of income tax benefit",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfIncomeTaxBenefitExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation",
     "role": "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable",
     "shortName": "Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "imc:BasicAndDilutedEarningsLossPerShare",
      "reportCount": 1,
      "unitRef": "audPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Loss per Share (Details) - Schedule of basic and diluted loss per share",
     "role": "http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable",
     "shortName": "Loss per Share (Details) - Schedule of basic and diluted loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailsOfEarningsPerShareExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DetailedInformationAboutCashExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:CashAtBankAndInHand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Cash (Details) - Schedule of balances under cash",
     "role": "http://immuron.com/role/ScheduleofbalancesundercashTable",
     "shortName": "Cash (Details) - Schedule of balances under cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DetailedInformationAboutCashExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:CashAtBankAndInHand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Trade and Other Receivables (Details) - Schedule of trade and other receivables",
     "role": "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable",
     "shortName": "Trade and Other Receivables (Details) - Schedule of trade and other receivables",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Inventories",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Inventories (Details) - Schedule of inventories",
     "role": "http://immuron.com/role/ScheduleofinventoriesTable",
     "shortName": "Inventories (Details) - Schedule of inventories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DetailedInformationAboutInventoriesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:NoncurrentInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "005 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://immuron.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c41",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Controlled Entities (Details) - Schedule of subsidiaries",
     "role": "http://immuron.com/role/ScheduleofsubsidiariesTable",
     "shortName": "Controlled Entities (Details) - Schedule of subsidiaries",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c41",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Trade and Other Payables (Details) - Schedule of trade and other payables",
     "role": "http://immuron.com/role/ScheduleoftradeandotherpayablesTable",
     "shortName": "Trade and Other Payables (Details) - Schedule of trade and other payables",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfSalesReturnProvisionExplantory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Provision for Sales Returns (Details) - Schedule of provision for sales returns",
     "role": "http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable",
     "shortName": "Provision for Sales Returns (Details) - Schedule of provision for sales returns",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfSalesReturnProvisionExplantory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Contingent liabilities and Commitments (Details)",
     "role": "http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails",
     "shortName": "Contingent liabilities and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfProfitOrLossAmountsRelatedToLeases",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Leases (Details)",
     "role": "http://immuron.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:InformationAboutNatureOfLesseesLeasingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfAmountsRecognizedinBalanceSheet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Leases (Details) - Schedule of amounts relating to leases in balance sheet",
     "role": "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable",
     "shortName": "Leases (Details) - Schedule of amounts relating to leases in balance sheet",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfAmountsRecognizedinBalanceSheet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfProfitOrLossAmountsRelatedToLeases",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Leases (Details) - Schedule of profit or loss amounts relating to leases",
     "role": "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable",
     "shortName": "Leases (Details) - Schedule of profit or loss amounts relating to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfProfitOrLossAmountsRelatedToLeases",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:PaymentForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Share Capital (Details)",
     "role": "http://immuron.com/role/ShareCapitalDetails",
     "shortName": "Share Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:PaymentForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Share Capital (Details) - Schedule of share capital",
     "role": "http://immuron.com/role/ScheduleofsharecapitalTable",
     "shortName": "Share Capital (Details) - Schedule of share capital",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfOrdinarySharesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c5",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:OrdinaryShare",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Share Capital (Details) - Schedule of ordinary shares",
     "role": "http://immuron.com/role/ScheduleofordinarysharesTable",
     "shortName": "Share Capital (Details) - Schedule of ordinary shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfOrdinarySharesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c9",
      "decimals": "0",
      "lang": null,
      "name": "imc:OrdinaryShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Revenue and other income",
     "role": "http://immuron.com/role/Revenueandotherincome",
     "shortName": "Revenue and other income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c57",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ESOPOptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Other Reserves (Details)",
     "role": "http://immuron.com/role/OtherReservesDetails",
     "shortName": "Other Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c57",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ESOPOptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c5",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherReserves",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Other Reserves (Details) - Schedule of other reserves",
     "role": "http://immuron.com/role/ScheduleofotherreservesTable",
     "shortName": "Other Reserves (Details) - Schedule of other reserves",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailedInformationOtherReserve",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c9",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:OtherReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailedInformationMovementsInOptionsAndWarrants",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c5",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Other Reserves (Details) - Schedule of movements in options and warrants",
     "role": "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable",
     "shortName": "Other Reserves (Details) - Schedule of movements in options and warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "imc:DisclosureOfDetailedInformationMovementsInOptionsAndWarrants",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c9",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:NumberOfSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Segment Reporting (Details)",
     "role": "http://immuron.com/role/SegmentReportingDetails",
     "shortName": "Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:NumberOfSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosuresOfProductsAndServicesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:HyperimmuneProductsRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Segment Reporting (Details) - Schedule of segment information for the reportable segments",
     "role": "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable",
     "shortName": "Segment Reporting (Details) - Schedule of segment information for the reportable segments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosuresOfProductsAndServicesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:HyperimmuneProductsRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Segment Reporting (Details) - Schedule of information on geographical regions",
     "role": "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable",
     "shortName": "Segment Reporting (Details) - Schedule of information on geographical regions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:RevenueFormContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Segment Reporting (Details) - Schedule of major customers",
     "role": "http://immuron.com/role/ScheduleofmajorcustomersTable",
     "shortName": "Segment Reporting (Details) - Schedule of major customers",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:RevenueFormContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax",
     "role": "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable",
     "shortName": "Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "imc:AdjustmentsForDistributionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:OptionGrantedDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Share-based Payments (Details)",
     "role": "http://immuron.com/role/SharebasedPaymentsDetails",
     "shortName": "Share-based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imc:OptionGrantedDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1",
      "reportCount": 1,
      "unitRef": "audPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price",
     "role": "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable",
     "shortName": "Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c9",
      "decimals": "2",
      "lang": null,
      "name": "imc:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "audPershares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Expenses",
     "role": "http://immuron.com/role/Expenses",
     "shortName": "Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ShareOptionsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options",
     "role": "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable",
     "shortName": "Share-based Payments (Details) - Schedule of granted valuation of options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ShareOptionsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:NumberOfInstrumentOtherEquityInstrumentGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Share-based Payments (Details) - Schedule of granted valuation of options",
     "role": "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0",
     "shortName": "Share-based Payments (Details) - Schedule of granted valuation of options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfDeemedValuationOfOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:NumberOfInstrumentOtherEquityInstrumentGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:OptionsIssuedUnderESOP",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions",
     "role": "http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable",
     "shortName": "Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:OptionsIssuedUnderESOP",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c169",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "082 - Disclosure - Related Party Transactions (Details)",
     "role": "http://immuron.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c169",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "083 - Disclosure - Related Party Transactions (Details) - Schedule of information about other related party transactions",
     "role": "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable",
     "shortName": "Related Party Transactions (Details) - Schedule of information about other related party transactions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "imc:DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "084 - Disclosure - Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties",
     "role": "http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of outstanding balances transactions between related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "imc:PercentageOfForeignExchangeRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "085 - Disclosure - Financial Risk Management Objectives and Policies (Details)",
     "role": "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails",
     "shortName": "Financial Risk Management Objectives and Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "imc:PercentageOfForeignExchangeRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c181",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "086 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk",
     "role": "http://immuron.com/role/ScheduleofforeigncurrencyriskTable",
     "shortName": "Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c181",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfExchangerateTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ImpactOnLossForPeriods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "087 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates",
     "role": "http://immuron.com/role/ScheduleofexchangeratesTable",
     "shortName": "Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfExchangerateTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:ImpactOnLossForPeriods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherReceivablesTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c192",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:GrossCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "088 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables",
     "role": "http://immuron.com/role/ScheduleoftradereceivablesTable",
     "shortName": "Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherReceivablesTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c192",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:GrossCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Income Tax Benefit",
     "role": "http://immuron.com/role/IncomeTaxBenefit",
     "shortName": "Income Tax Benefit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherPayablesTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c200",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:TradeAndOtherPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "089 - Disclosure - Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows",
     "role": "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable",
     "shortName": "Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "imc:DisclosureOfTradeAndOtherPayablesTableExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_immuronlimited.htm",
      "contextRef": "c200",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "imc:TradeAndOtherPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "aud",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia [Member]"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CAD [Member]"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_ILS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel, New Shekels",
        "terseLabel": "ILS [Member]"
       }
      }
     },
     "localname": "ILS",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://immuron.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_Accruals": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "Accruals",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccruedIncomeOtherThanContractAssets": {
     "auth_ref": [
      "r21",
      "r32"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing income that has been earned but is not yet a receivable, other than contract assets. [Refer: Contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accrued income other than contract assets",
        "terseLabel": "Accrued income"
       }
      }
     },
     "localname": "AccruedIncomeOtherThanContractAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Add (increase) / decrease in inventories"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Add (increase) / decrease in other operating assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Add decrease in trade and other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Finance costs"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedLabel": "Finance income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Add (decrease) / increase in trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Amounts transferred from non-current"
       }
      }
     },
     "localname": "AdjustmentsForProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r107",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Unrealized net foreign currency gains"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r23",
      "r62",
      "r151",
      "r164",
      "r165",
      "r174",
      "r183",
      "r189",
      "r207",
      "r208",
      "r210",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r21",
      "r141",
      "r142",
      "r143",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r169",
      "r180",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [Member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofbalancesundercashTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "totalLabel": "Total Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofbalancesundercashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [abstract]",
        "terseLabel": "Cash at Bank and in hand:"
       }
      }
     },
     "localname": "CashAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofbalancesundercashTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r113",
      "r136"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and Cash Equivalents at the End of the Year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet",
      "http://immuron.com/role/ConsolidatedCashFlow",
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r97",
      "r115"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash Flows Related to Financing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r97",
      "r115"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net Cash Flows (Used In)/From Investing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash Flows Related to Investing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r115"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "terseLabel": "Total",
        "totalLabel": "Net Cash Flows Used In Operating Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow",
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "terseLabel": "Cash paid for principal payments"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails",
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r90",
      "r93",
      "r144",
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable",
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r90",
      "r144",
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable",
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfCashReceiptsFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of cash receipts from operating activities [abstract]",
        "terseLabel": "Cash flows Related to Operating Activities"
       }
      }
     },
     "localname": "ClassesOfCashReceiptsFromOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable",
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r40",
      "r121",
      "r123",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive loss for the period",
        "totalLabel": "Total Comprehensive Loss for the Period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r2",
      "r47"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "negatedLabel": "Cost of Goods Sold",
        "negatedTerseLabel": "Cost of sales of goods"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "auth_ref": [
      "r81",
      "r84",
      "r125",
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary",
        "terseLabel": "Country of Incorporation"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CreationDateAxis": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      }
     },
     "localname": "CreationDateAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r24",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r26",
      "r128",
      "r131"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentMember": {
     "auth_ref": [
      "r178",
      "r190",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a current time band."
       }
      },
      "en-us": {
       "role": {
        "label": "Current [member]",
        "terseLabel": "Current [Member]"
       }
      }
     },
     "localname": "CurrentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions for employee benefits",
        "terseLabel": "Provision for sales returns"
       }
      }
     },
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Tax at the Australian tax rate of 26% (2020: 27.5%)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "terseLabel": "Potential tax benefit @ 26% (2020: 27.5%)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      }
     },
     "localname": "DefaultFinancialStatementsDateMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r47",
      "r138",
      "r193",
      "r200"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable",
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "terseLabel": "Depreciation charge of right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Government grants"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of non-financial assets [text block]",
        "terseLabel": "Impairment of assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other payables [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for trading income and expense. [Refer: Trading income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trading income and expense [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk- free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events occurring after the Reporting Date"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/EventsoccurringaftertheReportingDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/Expenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Financial Risk Management Objectives and Policies"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general and administrative expense [text block]",
        "terseLabel": "Schedule of expenses"
       }
      }
     },
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [text block]",
        "terseLabel": "Schedule of information on geographical regions"
       }
      }
     },
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/IncomeTaxBenefit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block]",
        "terseLabel": "Key Management Personnel Compensation"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/KeyManagementPersonnelCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income (expense) [text block]",
        "terseLabel": "Schedule of revenue and other income"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/RevenueandotherincomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block]",
        "terseLabel": "Other reserves"
       }
      }
     },
     "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/OtherReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenue and other income"
       }
      }
     },
     "localname": "DisclosureOfRevenueExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/Revenueandotherincome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of major customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [text block]",
        "terseLabel": "Schedule of major customers"
       }
      }
     },
     "localname": "DisclosureOfSegmentsMajorCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Schedule of share capital"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and Other Payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/TradeandOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block]",
        "terseLabel": "Trade and Other Receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/TradeandOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]",
        "netLabel": "Current payables (purchases of goods and services)",
        "terseLabel": "Amounts settled in cash or shares for goods and services",
        "verboseLabel": "Amounts settled in cash or shares during the period"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Schedule of outstanding balances transactions between related parties"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DistributionCosts": {
     "auth_ref": [
      "r2",
      "r47"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs relating to the distribution of goods and services."
       }
      },
      "en-us": {
       "role": {
        "label": "Distribution costs",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "DistributionCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r21",
      "r31",
      "r120",
      "r122",
      "r141",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "totalLabel": "TOTAL EQUITY"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable",
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ContingentliabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpectedCreditLossRate": {
     "auth_ref": [
      "r178",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected credit loss rate",
        "terseLabel": "Expected credit loss rate"
       }
      }
     },
     "localname": "ExpectedCreditLossRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions",
        "terseLabel": "Share-based payment expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "terseLabel": "Expense relating to short-term leases (included in other expenses)",
        "verboseLabel": "Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)"
       }
      }
     },
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities",
        "terseLabel": "Expense relating to variable lease payments not included in lease liabilities (included in other expenses)"
       }
      }
     },
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance costs"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinishedGoods": {
     "auth_ref": [
      "r29",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "FinishedGoods",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fixtures and fittings [member]",
        "terseLabel": "Furniture, fittings and equipment [Member]"
       }
      }
     },
     "localname": "FixturesAndFittingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r60",
      "r152",
      "r204",
      "r212"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r60",
      "r152",
      "r204",
      "r212"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r162",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossProfit": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLoss": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss",
        "negatedLabel": "Net impairment losses"
       }
      }
     },
     "localname": "ImpairmentLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r44",
      "r50",
      "r53",
      "r54",
      "r80",
      "r139",
      "r194"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "terseLabel": "Income Tax Expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofincometaxbenefitTable",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers and other changes, other provisions",
        "terseLabel": "Sales return provision recognised"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InformationAboutNatureOfLesseesLeasingActivities": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Information about the nature of the lessee's leasing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Information about nature of lessee's leasing activities",
        "terseLabel": "Lease, description"
       }
      }
     },
     "localname": "InformationAboutNatureOfLesseesLeasingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_InsuranceExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 7.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      },
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "InsuranceExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense (included in finance cost)",
        "verboseLabel": "Finance cash outflow for leases"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/LeasesDetails",
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as financing activities",
        "negatedLabel": "Interest and other costs of finance paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as investing activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r15",
      "r25",
      "r65"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories Current"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet",
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoriesTotal": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesTotal",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of convertible instruments",
        "terseLabel": "Exercise of representative warrants (2020-07-2) (in Dollars)"
       }
      }
     },
     "localname": "IssueOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Shares issued, net of costs"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Issued Capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total Key Management Personnel Compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": 4.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, other long-term employee benefits",
        "terseLabel": "Long-term benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": 5.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based payment expenses to KMP and their related entities"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r164",
      "r165",
      "r183",
      "r188",
      "r191",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "Over 5 years [Member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": {
     "auth_ref": [
      "r11",
      "r178",
      "r190",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than two months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one month and not later than two months [member]",
        "terseLabel": "1-30 [Member]"
       }
      }
     },
     "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r182",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "Between 2 and 5 Years [Member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r183",
      "r187",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than three years [member]",
        "terseLabel": "Between 1 and 2 years [Member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "auth_ref": [
      "r183",
      "r186",
      "r191",
      "r215",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than six months and not later than one year [member]",
        "terseLabel": "6 - 12 months [Member]"
       }
      }
     },
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "auth_ref": [
      "r183",
      "r185",
      "r191",
      "r215",
      "r218"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three months and not later than six months [member]",
        "terseLabel": "Less than 6 months [Member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeMonthsMember": {
     "auth_ref": [
      "r178",
      "r190",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three months [member]",
        "terseLabel": "91-120 [Member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r11",
      "r178",
      "r190",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two months and not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two months and not later than three months [member]",
        "terseLabel": "31-60 [Member]"
       }
      }
     },
     "localname": "LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r21",
      "r141",
      "r142",
      "r143",
      "r195",
      "r199"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "LIABILITIES",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r23",
      "r62",
      "r151",
      "r164",
      "r165",
      "r174",
      "r179",
      "r183",
      "r207",
      "r208",
      "r210",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r11",
      "r124"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets (liabilities)",
        "totalLabel": "NET ASSETS"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r24",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total Non-Current Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-Current Assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentInventories": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current inventories",
        "terseLabel": "Inventories Non- current"
       }
      }
     },
     "localname": "NoncurrentInventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Non-current"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r26",
      "r128",
      "r132"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total Non-Current Liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-Current Liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r22",
      "r164",
      "r165",
      "r183",
      "r191",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "121+ [Member]"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r11",
      "r215",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than three months [member]",
        "terseLabel": "61-90 [Member]"
       }
      }
     },
     "localname": "NotLaterThanThreeMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares, Fully paid, shares"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsharecapitalTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r6",
      "r39",
      "r46",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r27",
      "r46"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translation of foreign operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r20",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "terseLabel": "Total exposure"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEmployeeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other employee expense",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "OtherEmployeeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherExpenseByNature": {
     "auth_ref": [
      "r1",
      "r47"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 14.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other expenses, by nature",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherGainsLosses": {
     "auth_ref": [
      "r1",
      "r2"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      },
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other gains (losses)",
        "terseLabel": "Other gains/(losses) \u2013 net",
        "totalLabel": "Total Other Gains/(Losses) \u2013 Net"
       }
      }
     },
     "localname": "OtherGainsLosses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r1",
      "r2",
      "r79"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "terseLabel": "Other Income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as operating activities",
        "terseLabel": "Other - R&amp;D tax concession refund"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherPayables": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other payables",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet",
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "New fully paid ordinary per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareCapitalDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PastDueStatusAxis": {
     "auth_ref": [
      "r178",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [axis]"
       }
      }
     },
     "localname": "PastDueStatusAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable",
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PastDueStatusMember": {
     "auth_ref": [
      "r178",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [member]"
       }
      }
     },
     "localname": "PastDueStatusMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable",
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Principal elements of lease payments"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to suppliers for goods and services and to and on behalf of employees",
        "terseLabel": "Entities controlled by key management personnel"
       }
      }
     },
     "localname": "PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofoutstandingbalancestransactionsbetweenrelatedpartiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issues of securities"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r38",
      "r105",
      "r121",
      "r123",
      "r128",
      "r195",
      "r197",
      "r209",
      "r214"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Loss after income tax expense for the year",
        "totalLabel": "Loss for the Period",
        "verboseLabel": "Net Loss for the Year"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable",
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share",
        "terseLabel": "a) Net loss used in the calculation of basic and diluted loss per share"
       }
      }
     },
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Profit/(loss) for the year"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r173",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss from continuing operations before income tax expense",
        "totalLabel": "Loss Before Income Tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r45",
      "r87"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "terseLabel": "Operating profit/(loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyDevelopmentAndProjectManagementExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from property development and project management."
       }
      },
      "en-us": {
       "role": {
        "label": "Property development and project management expense",
        "terseLabel": "Project research and development"
       }
      }
     },
     "localname": "PropertyDevelopmentAndProjectManagementExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r58"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r59",
      "r91",
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Properties [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable",
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r82",
      "r85",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Percentage of Ownership"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Provisions": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Provisions",
        "periodEndLabel": "Carrying amount at the end of the year",
        "periodStartLabel": "Carrying amount at the start of the year"
       }
      }
     },
     "localname": "Provisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofprovisionforsalesreturnsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Payment for purchases of plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchases of goods, related party transactions",
        "terseLabel": "Purchases of various goods and services from entities controlled by key management personnel"
       }
      }
     },
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r169",
      "r180",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r169",
      "r180",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RawMaterials": {
     "auth_ref": [
      "r29",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current raw materials",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterials",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of goods and rendering of services."
       }
      },
      "en-us": {
       "role": {
        "label": "Receipts from sales of goods and rendering of services",
        "terseLabel": "Receipts from customers"
       }
      }
     },
     "localname": "ReceiptsFromSalesOfGoodsAndRenderingOfServices",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RentalExpense": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised on rental activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Rental expense",
        "terseLabel": "Rental expense"
       }
      }
     },
     "localname": "RentalExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      },
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses",
        "negatedTerseLabel": "Research and development expenses",
        "totalLabel": "Total research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofexpensesTable",
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Share-based payments [Member]"
       }
      }
     },
     "localname": "ReserveOfSharebasedPaymentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r31",
      "r48"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated losses"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r128",
      "r134",
      "r173",
      "r192",
      "r196",
      "r202",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Hyperimmune products revenue"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue and other operating income",
        "totalLabel": "Total Revenue from Operating Activities"
       }
      }
     },
     "localname": "RevenueAndOperatingIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      },
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "terseLabel": "Government grants and other grants received"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssetsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets [member]",
        "terseLabel": "Right-of-use assets [Member]"
       }
      }
     },
     "localname": "RightofuseAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      },
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Selling and marketing expenses",
        "totalLabel": "Total selling and marketing expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r61",
      "r93",
      "r150",
      "r195",
      "r213"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r61",
      "r93",
      "r150",
      "r201",
      "r213"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SellingExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling expense",
        "terseLabel": "Selling"
       }
      }
     },
     "localname": "SellingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issue under options and contracts for sale of shares",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r83",
      "r86",
      "r140"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r169",
      "r180",
      "r210"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [Member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables [abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r16",
      "r28"
     ],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current receivables [abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherPayables": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable",
      "http://immuron.com/role/ScheduleoftradeandotherpayablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "auth_ref": [
      "r16",
      "r28"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other receivables",
        "totalLabel": "Total Trade and Other Receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivables": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable",
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r11",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]",
        "terseLabel": "Trade Receivables [Member]"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TravelExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 13.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      },
      "en-us": {
       "role": {
        "label": "Travel expense",
        "terseLabel": "Travel and entertainment"
       }
      }
     },
     "localname": "TravelExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses for which no deferred tax asset has been recognised"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofunusedtaxlossesforwhichnodeferredtaxassetrecognizedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UtilitiesExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 11.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased utilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Utilities expense",
        "terseLabel": "Occupancy"
       }
      }
     },
     "localname": "UtilitiesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AccountingAndAudit": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accounting and audit.",
        "label": "AccountingAndAudit",
        "terseLabel": "Accounting and audit"
       }
      }
     },
     "localname": "AccountingAndAudit",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AccumulatedLossesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to accumulated losses.",
        "label": "AccumulatedLossesMember",
        "terseLabel": "Accumulated Losses"
       }
      }
     },
     "localname": "AccumulatedLossesMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_AdditionalOtherIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional other income.",
        "label": "AdditionalOtherIncome",
        "terseLabel": "Additional other income"
       }
      }
     },
     "localname": "AdditionalOtherIncome",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AdditionalRAndDTaxReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional research and developement tax received.",
        "label": "AdditionalRAndDTaxReceived",
        "terseLabel": "Additional R&amp;D fund"
       }
      }
     },
     "localname": "AdditionalRAndDTaxReceived",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AdjustmentsForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AdjustmentsForAbstract",
        "terseLabel": "Adjustments for"
       }
      }
     },
     "localname": "AdjustmentsForAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_AdjustmentsForDistributionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustments for costs relating to the distribution of goods and services.",
        "label": "AdjustmentsForDistributionCosts",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "AdjustmentsForDistributionCosts",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AmountOfOrdinaryShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ordinary shares.",
        "label": "AmountOfOrdinaryShares",
        "terseLabel": "Ordinary shares, value",
        "verboseLabel": "Ordinary shares, Fully paid, value"
       }
      }
     },
     "localname": "AmountOfOrdinaryShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsharecapitalTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AnadisEPSPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of anadis ePSPty ltd.",
        "label": "AnadisEPSPtyLtdMember",
        "terseLabel": "Anadis EPS Pty Ltd [Member]"
       }
      }
     },
     "localname": "AnadisEPSPtyLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_AssistancePackages": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance packages.",
        "label": "AssistancePackages",
        "terseLabel": "Assistance packages"
       }
      }
     },
     "localname": "AssistancePackages",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_AustralianFederalRdTaxConcessionRefund": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 1.0,
       "parentTag": "imc_OtherIncomeFromNonOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AustralianFederalRdTaxConcessionRefund",
        "terseLabel": "Australian Federal R&amp;D Tax Concession Refund"
       }
      }
     },
     "localname": "AustralianFederalRdTaxConcessionRefund",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_BadDebts": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of bad debts expenses.",
        "label": "BadDebts",
        "terseLabel": "Bad debts"
       }
      }
     },
     "localname": "BadDebts",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_BasicAndDilutedEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]",
        "label": "BasicAndDilutedEarningsLossPerShare",
        "negatedLabel": "Basic/Diluted loss per share (in cents)",
        "terseLabel": "Basic/Diluted Loss per Share (in cents per share) (in Dollars per share)"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsLossPerShare",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement",
      "http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_BusinessAcquisitionCostOfTransactionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for share issue by cost.",
        "label": "BusinessAcquisitionCostOfTransactionCost",
        "terseLabel": "Less: Transaction costs arising on share issues"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfTransactionCost",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_BusinessAcquisitionCostOfTransactionCostToIssuedAtShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessAcquisitionCostOfTransactionCostToIssuedAtShares",
        "terseLabel": "Less: Transaction costs arising on share issues"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfTransactionCostToIssuedAtShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_CapitalCost": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of capital raising cost.",
        "label": "CapitalCost",
        "negatedLabel": "Capital raising costs"
       }
      }
     },
     "localname": "CapitalCost",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_CarryingAssetsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CarryingAssetsLiabilitiesMember",
        "terseLabel": "Carrying amount (assets)/ liabilities [Member]"
       }
      }
     },
     "localname": "CarryingAssetsLiabilitiesMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CashAtBankAndInHand": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofbalancesundercashTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_Cash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits.",
        "label": "CashAtBankAndInHand",
        "terseLabel": "Cash at bank and in hand"
       }
      }
     },
     "localname": "CashAtBankAndInHand",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofbalancesundercashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_CashlessExerciseOfESOPUnlistedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashlessExerciseOfESOPUnlistedOptions",
        "terseLabel": "Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09)"
       }
      }
     },
     "localname": "CashlessExerciseOfESOPUnlistedOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_CashlessExerciseOfESOPUnlistedOptionsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CashlessExerciseOfESOPUnlistedOptionsValue",
        "terseLabel": "Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (in Dollars)"
       }
      }
     },
     "localname": "CashlessExerciseOfESOPUnlistedOptionsValue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ChangeInAccountingPolicy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in accounting policy.",
        "label": "ChangeInAccountingPolicy",
        "terseLabel": "Change in accounting policy"
       }
      }
     },
     "localname": "ChangeInAccountingPolicy",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ChangeInOperatingAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangeInOperatingAssetsAndLiabilitiesAbstract",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "ChangeInOperatingAssetsAndLiabilitiesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ConsolidatedStatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Changes in Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementOfChangesInEquityAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ConsultingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consultinf expenses.",
        "label": "ConsultingExpenses",
        "terseLabel": "Consulting"
       }
      }
     },
     "localname": "ConsultingExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ContingentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities [Abstract]"
       }
      }
     },
     "localname": "ContingentLiabilitiesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ContingentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ContingentLiabilitiesTextBlock",
        "terseLabel": "Contingent liabilities and Commitments"
       }
      }
     },
     "localname": "ContingentLiabilitiesTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ContingentliabilitiesandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ContractualCashFlowsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ContractualCashFlowsMember",
        "terseLabel": "Total contractual cash flows [Member]"
       }
      }
     },
     "localname": "ContractualCashFlowsMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ControlledEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Controlled Entities [Abstract]"
       }
      }
     },
     "localname": "ControlledEntitiesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ControlledEntitiesDetailsScheduleofsubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Controlled Entities (Details) - Schedule of subsidiaries [Line Items]"
       }
      }
     },
     "localname": "ControlledEntitiesDetailsScheduleofsubsidiariesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ControlledEntitiesDetailsScheduleofsubsidiariesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Controlled Entities (Details) - Schedule of subsidiaries [Table]"
       }
      }
     },
     "localname": "ControlledEntitiesDetailsScheduleofsubsidiariesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ControlledEntitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a controlled entities.",
        "label": "ControlledEntitiesTextBlock",
        "terseLabel": "Controlled Entities"
       }
      }
     },
     "localname": "ControlledEntitiesTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ControlledEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_CostOfFinance": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "imc_FinanceCostsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CostOfFinance",
        "terseLabel": "Finance expenses"
       }
      }
     },
     "localname": "CostOfFinance",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_CurrencyTranslationDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency translation differences for the period.",
        "label": "CurrencyTranslationDifferences",
        "terseLabel": "Currency translation differences"
       }
      }
     },
     "localname": "CurrencyTranslationDifferences",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to customer.",
        "label": "CustomerAMember",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to customer.",
        "label": "CustomerBMember",
        "terseLabel": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to customer.",
        "label": "CustomerCMember",
        "terseLabel": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to customer.",
        "label": "CustomerDMember",
        "terseLabel": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to customer.",
        "label": "CustomerEMember",
        "terseLabel": "Customer E [Member]"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomerFMember",
        "terseLabel": "Customer F [Member]"
       }
      }
     },
     "localname": "CustomerFMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomerGMember",
        "terseLabel": "Customer G [Member]"
       }
      }
     },
     "localname": "CustomerGMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomerHMember",
        "terseLabel": "Customer H [Member]"
       }
      }
     },
     "localname": "CustomerHMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_CustomerIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomerIMember",
        "terseLabel": "Customer I [Member]"
       }
      }
     },
     "localname": "CustomerIMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tax expense or income not recognized relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss.",
        "label": "DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss",
        "terseLabel": "Tax losses and other timing differences for which no deferred tax asset is recognised"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeUnRecognisedInProfitOrLoss",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_DepreciationChargeOfRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DepreciationChargeOfRightOfUseAssetsAbstract",
        "terseLabel": "Depreciation charge of right-of-use assets"
       }
      }
     },
     "localname": "DepreciationChargeOfRightOfUseAssetsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for uncertainty over income tax treatments.",
        "label": "DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock",
        "terseLabel": "AASB Interpretation 23 Uncertainty over Income Tax Treatments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForAASBInterpretation23UncertaintyOverIncomeTaxTreatmentstextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForBasisOfPresentation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for basis of presentation.",
        "label": "DescriptionOfAccountingPolicyForBasisOfPresentation",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfPresentation",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of description of accounting policy for equity policy.",
        "label": "DescriptionOfAccountingPolicyForEquityPolicyTextBlock",
        "terseLabel": "Contributed equity"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEquityPolicyTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of description of accounting policy for goods and services tax explanatory.",
        "label": "DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory",
        "terseLabel": "Goods and services tax (GST)"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGoodsAndServicesTaxExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for investments and other financial assets.",
        "label": "DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets",
        "terseLabel": "Investments and other financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForInvestmentsOtherFinancialAssets",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.",
        "label": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatoryPolicyTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity rounding of amounts.",
        "label": "DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock",
        "terseLabel": "Rounding of amounts"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRoundingOfAmountsPolicyTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DetailedInformationAboutCashExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of cash.",
        "label": "DetailedInformationAboutCashExplanatory",
        "terseLabel": "Schedule of balances under cash"
       }
      }
     },
     "localname": "DetailedInformationAboutCashExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/CashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DetailedInformationAboutInventoriesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about inventories.",
        "label": "DetailedInformationAboutInventoriesExplanatory",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "DetailedInformationAboutInventoriesExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DetailedInformationAboutTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about trade and other receivables.",
        "label": "DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
        "terseLabel": "Schedule of trade and other receivables"
       }
      }
     },
     "localname": "DetailedInformationAboutTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/TradeandOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfCashExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of cash.",
        "label": "DisclosureOfCashExplanatory",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "DisclosureOfCashExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/Cash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfCashExplanatoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Cash Explanatory [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCashExplanatoryAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfCashFlowInformationExplanatoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Cash Flow Information Explanatory [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCashFlowInformationExplanatoryAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfCashFlowInformationExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of disclosure of cash flow information explanatory.",
        "label": "DisclosureOfCashFlowInformationExplanatoryTextBlock",
        "terseLabel": "Cash Flow Information"
       }
      }
     },
     "localname": "DisclosureOfCashFlowInformationExplanatoryTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/CashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfClassesOfShareCapitalTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfCompanyDetailsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of company details.",
        "label": "DisclosureOfCompanyDetailsExplanatory",
        "terseLabel": "Company Details"
       }
      }
     },
     "localname": "DisclosureOfCompanyDetailsExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/CompanyDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfCompanyDetailsExplanatoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Company Details Explanatory [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompanyDetailsExplanatoryAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfDetailedInformationMovementsInOptionsAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about movements in options and warrants.",
        "label": "DisclosureOfDetailedInformationMovementsInOptionsAndWarrants",
        "terseLabel": "Schedule of movements in options and warrants"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationMovementsInOptionsAndWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfDetailedInformationOfRelatedPartyExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents disclosure of detailed information of related party edxplanatory.",
        "label": "DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
        "terseLabel": "Schedule of key management personnel compensation"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationOfRelatedPartyExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/KeyManagementPersonnelCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfDetailedInformationOtherReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about other reserves.",
        "label": "DisclosureOfDetailedInformationOtherReserve",
        "terseLabel": "Schedule of other reserves"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationOtherReserve",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfDetailsOfEarningsPerShareExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of disclosure of details of earnings per share explanatory.",
        "label": "DisclosureOfDetailsOfEarningsPerShareExplanatory",
        "terseLabel": "Schedule of basic and diluted loss per share"
       }
      }
     },
     "localname": "DisclosureOfDetailsOfEarningsPerShareExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfEarningsPerShareTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEntitysOperatingSegmentsTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfEventsAfterReportingPeriodTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfExchangerateTableExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail dislcosure of exchange rate.",
        "label": "DisclosureOfExchangerateTableExplanatory",
        "terseLabel": "Schedule of exchange rates"
       }
      }
     },
     "localname": "DisclosureOfExchangerateTableExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfExpensesByNatureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dislcosure of financial assets and liabilities are subject to foreign currency risk.",
        "label": "DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
        "terseLabel": "Schedule of foreign currency risk"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesAreSubjectToForeignCurrencyRiskTableExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfFinancialRiskManagementTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfIncomeTaxBenefitExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to disclosure of income tax benefit explanatory.",
        "label": "DisclosureOfIncomeTaxBenefitExplanatory",
        "terseLabel": "Schedule of income tax benefit"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxBenefitExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/IncomeTaxBenefitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfIncomeTaxTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about other related party transactions explanatory.",
        "label": "DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
        "terseLabel": "Schedule of information about other related party transactions"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutOtherRelatedPartyTransactionsExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfInventoriesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfInventoriesTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfLeasesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfLeasesTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory",
        "terseLabel": "Schedule of movement in number of stock options outstanding and weighted average exercise price"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTabularExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfOrdinarySharesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureOfOrdinarySharesExplanatory",
        "terseLabel": "Schedule of ordinary shares"
       }
      }
     },
     "localname": "DisclosureOfOrdinarySharesExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfProvisionForSalesReturnsExplantory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for provision for sales returns.",
        "label": "DisclosureOfProvisionForSalesReturnsExplantory",
        "terseLabel": "Provision for Sales Returns"
       }
      }
     },
     "localname": "DisclosureOfProvisionForSalesReturnsExplantory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ProvisionforSalesReturns"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfProvisionForSalesReturnsExplantoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Provision For Sales Returns Explantory [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfProvisionForSalesReturnsExplantoryAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of disclosure of reconciliation of cash flow from operations with loss after income tax explanatory.",
        "label": "DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory",
        "terseLabel": "Schedule of reconciliation of cash flow from operations with loss after income tax"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/CashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfRelatedPartyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfReservesWithinEquityTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfReservesWithinEquityTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfRevenueTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfRevenueTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfSalesReturnProvisionExplantory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of transactions between the entity sales return provision.",
        "label": "DisclosureOfSalesReturnProvisionExplantory",
        "terseLabel": "Schedule of provision for sales returns"
       }
      }
     },
     "localname": "DisclosureOfSalesReturnProvisionExplantory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ProvisionforSalesReturnsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantAccountingPoliciesTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about trade and other current payables.",
        "label": "DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
        "terseLabel": "Schedule of trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherCurrentPayablesTableTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/TradeandOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfTradeAndOtherPayablesTableExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The detail disclosure of trade and other payables.",
        "label": "DisclosureOfTradeAndOtherPayablesTableExplanatory",
        "terseLabel": "Schedule of contractual undiscounted cash flows"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesTableExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfTradeAndOtherPayablesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfTradeAndOtherReceivablesTableExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The detail disclosure of trade and other receivables.",
        "label": "DisclosureOfTradeAndOtherReceivablesTableExplanatory",
        "terseLabel": "Schedule of trade receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesTableExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosureOfTradeAndOtherReceivablesTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other receivables [text block] [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesTextBlockAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
        "terseLabel": "Schedule of unused tax losses for which no deferred tax asset recognized"
       }
      }
     },
     "localname": "DisclosureOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedTextBlock",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/IncomeTaxBenefitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DisclosuresOfProductsAndServicesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the entity's products and services. [Refer: Products and services [member].",
        "label": "DisclosuresOfProductsAndServicesExplanatory",
        "terseLabel": "Schedule of segment information for the reportable segments"
       }
      }
     },
     "localname": "DisclosuresOfProductsAndServicesExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_DrGarySJacobMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DrGarySJacobMember",
        "terseLabel": "Dr. Gary S. Jacob [Member]"
       }
      }
     },
     "localname": "DrGarySJacobMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_DrJerryKanellosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DrJerryKanellosMember",
        "terseLabel": "Dr. Jerry Kanellos [Member]"
       }
      }
     },
     "localname": "DrJerryKanellosMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ESOPOptionsIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESOP options issued",
        "label": "ESOPOptionsIssued",
        "terseLabel": "ESOP options issued"
       }
      }
     },
     "localname": "ESOPOptionsIssued",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_EmployeeBenefitObligation": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to employee benefit obligation.",
        "label": "EmployeeBenefitObligation",
        "terseLabel": "Employee benefit obligations"
       }
      }
     },
     "localname": "EmployeeBenefitObligation",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_EmployeeBenefitObligationNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to non current employee benefit obligation.",
        "label": "EmployeeBenefitObligationNonCurrent",
        "terseLabel": "Employee benefit obligations"
       }
      }
     },
     "localname": "EmployeeBenefitObligationNonCurrent",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_EmployeeShareSchemesValueOfEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee share schemes - value of employee.",
        "label": "EmployeeShareSchemesValueOfEmployee",
        "terseLabel": "Share-based payment expenses"
       }
      }
     },
     "localname": "EmployeeShareSchemesValueOfEmployee",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_EmployeeStockOption1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "EmployeeStockOption1Member",
        "terseLabel": "ESOP [Member]"
       }
      }
     },
     "localname": "EmployeeStockOption1Member",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_EquityBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a equity balance.",
        "label": "EquityBalance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "EquityBalance",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfESOPUnlistedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfESOPUnlistedOptions",
        "terseLabel": "Exercise of ESOP unlisted options at $0.50 (2020-07-24)"
       }
      }
     },
     "localname": "ExerciseOfESOPUnlistedOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfESOPUnlistedOptionsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfESOPUnlistedOptionsValue",
        "terseLabel": "Exercise of ESOP unlisted options at $0.50 (2020-07-24) (in Dollars)"
       }
      }
     },
     "localname": "ExerciseOfESOPUnlistedOptionsValue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfNasdaqWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of NASDAQ Warrants (2020-06-23).",
        "label": "ExerciseOfNasdaqWarrants",
        "terseLabel": "Exercise of NASDAQ Warrants (2020-06-23)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions",
        "terseLabel": "Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (in Dollars)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne",
        "terseLabel": "Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (in Dollars)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares",
        "terseLabel": "Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne",
        "terseLabel": "Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrantsAtUsdTenPerFortyOptionsSharesOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfNasdaqWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of NASDAQ Warrants (2020-06-23), shares.",
        "label": "ExerciseOfNasdaqWarrantsShares",
        "terseLabel": "Exercise of NASDAQ Warrants (2020-06-23)"
       }
      }
     },
     "localname": "ExerciseOfNasdaqWarrantsShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfRepresentativeWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of representative warrants (2020-06-15, 2020-06-22).",
        "label": "ExerciseOfRepresentativeWarrant",
        "terseLabel": "Exercise of representative warrants (2020-06-15, 2020-06-22)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrant",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfRepresentativeWarrant1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of representative warrants.",
        "label": "ExerciseOfRepresentativeWarrant1",
        "terseLabel": "Exercise of representative warrants (2020-07-02)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrant1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfRepresentativeWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of representative warrants (2020-06-15, 2020-06-22), shares.",
        "label": "ExerciseOfRepresentativeWarrantShares",
        "terseLabel": "Exercise of representative warrants (2020-06-15, 2020-06-22)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrantShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfRepresentativeWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfRepresentativeWarrants",
        "terseLabel": "Exercise of representative warrants (2020-06-15, 2020-06-22) (in Dollars)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExerciseOfRepresentativeWarrants1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfRepresentativeWarrants1",
        "terseLabel": "Exercise of representative warrants (2020-07-02)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrants1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfRepresentativeWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfRepresentativeWarrantsShares",
        "terseLabel": "Exercise of representative warrants (2020-06-15, 2020-06-22)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrantsShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExerciseOfRepresentativeWarrantsSharesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseOfRepresentativeWarrantsSharesOne",
        "terseLabel": "Exercise of representative warrants (2020-07-2)"
       }
      }
     },
     "localname": "ExerciseOfRepresentativeWarrantsSharesOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePrice",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceOneMember",
        "terseLabel": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ExercisePriceShareOptionsGranted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\" The exercise price of share options granted.\"",
        "label": "ExercisePriceShareOptionsGranted1",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_ExercisePriceSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceSixteenMember",
        "terseLabel": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixteenMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceTwoMember",
        "terseLabel": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ExpectedCreditLosses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expected credit losses.",
        "label": "ExpectedCreditLosses",
        "terseLabel": "Expected credit losses"
       }
      }
     },
     "localname": "ExpectedCreditLosses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable",
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued at value in lieu of payment for services1.",
        "label": "ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1",
        "terseLabel": "Issue at $0.16 in lieu of payment for services (2018-11-22)1"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServices1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued at shares in lieu of payment for services1.",
        "label": "ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1",
        "terseLabel": "Issue at $0.16 in lieu of payment for services (2018-11-22)1"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsLieuOfPaymentForServicesThroughShares1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ExpenseOfSharesOwed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ExpenseOfSharesOwed",
        "terseLabel": "Value of shares owed (in Dollars)"
       }
      }
     },
     "localname": "ExpenseOfSharesOwed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_FinanceCostsNet": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of costs associated with financing activities of the entity.",
        "label": "FinanceCostsNet",
        "negatedTotalLabel": "Finance costs - net"
       }
      }
     },
     "localname": "FinanceCostsNet",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Line Items]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of contractual undiscounted cash flows [Table]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofcontractualundiscountedcashflowsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Line Items]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk [Table]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleofforeigncurrencyriskTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Table]"
       }
      }
     },
     "localname": "FinancialRiskManagementObjectivesandPoliciesDetailsScheduleoftradereceivablesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_FinishedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinishedGoodsMember",
        "terseLabel": "Finished goods (Travelan and Protectyn) [Member]"
       }
      }
     },
     "localname": "FinishedGoodsMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ForeignCurrencyTranslationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ForeignCurrencyTranslationMember",
        "terseLabel": "Foreign currency translation [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of general and administrative expenses.",
        "label": "GeneralAndAdministrativeExpenses",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_GeneralAndAdministrativeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GeneralAndAdministrativeExpensesAbstract",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_GovernmentAssistancePackages": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government assistance packages.",
        "label": "GovernmentAssistancePackages",
        "terseLabel": "Government assistance packages"
       }
      }
     },
     "localname": "GovernmentAssistancePackages",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_GrandlodgeCapitalPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrandlodgeCapitalPtyLtdMember",
        "terseLabel": "Grandlodge Capital Pty Ltd [Member]"
       }
      }
     },
     "localname": "GrandlodgeCapitalPtyLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateEightMember",
        "terseLabel": "2019-07-16 (warrants) [Member]"
       }
      }
     },
     "localname": "GrantDateEightMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateElevenMember",
        "terseLabel": "2020-10-29 [Member]"
       }
      }
     },
     "localname": "GrantDateElevenMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateFiveMember",
        "terseLabel": "2017-06-09 (warrants) [Member]"
       }
      }
     },
     "localname": "GrantDateFiveMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateFourMember",
        "terseLabel": "2018-03-15 [Member]"
       }
      }
     },
     "localname": "GrantDateFourMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateNineMember",
        "terseLabel": "2018-07-13 [Member]"
       }
      }
     },
     "localname": "GrantDateNineMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateOneMember",
        "terseLabel": "2012-06-29 [Member]"
       }
      }
     },
     "localname": "GrantDateOneMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateSevenMember",
        "terseLabel": "2019-05-23 (warrants) [Member]"
       }
      }
     },
     "localname": "GrantDateSevenMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateSixMember",
        "terseLabel": "2018-03-15 [Member]"
       }
      }
     },
     "localname": "GrantDateSixMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateTenMember",
        "terseLabel": "2019-11-06 [Member]"
       }
      }
     },
     "localname": "GrantDateTenMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateThreeMember",
        "terseLabel": "2017-06-13 (warrants) [Member]"
       }
      }
     },
     "localname": "GrantDateThreeMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateTwelveMember",
        "terseLabel": "2020-07-24 (warrants) [Member]"
       }
      }
     },
     "localname": "GrantDateTwelveMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrantDateTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateTwoMember",
        "terseLabel": "2012-06-29 [Member]"
       }
      }
     },
     "localname": "GrantDateTwoMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_GrossCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GrossCarryingAmount",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "GrossCarryingAmount",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_HyperimmuneProductsRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "HyperimmuneProductsRevenue",
        "terseLabel": "Hyperimmune products revenue"
       }
      }
     },
     "localname": "HyperimmuneProductsRevenue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IMCCanadaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to IMC canada ttd.",
        "label": "IMCCanadaLtdMember",
        "terseLabel": "IMC Canada Ltd [Member]"
       }
      }
     },
     "localname": "IMCCanadaLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ImmuronIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of Ifrs statement lineItems.",
        "label": "ImmuronIncMember",
        "terseLabel": "Immuron Inc [Member]"
       }
      }
     },
     "localname": "ImmuronIncMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ImmuronLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ImmuronLimitedMember",
        "terseLabel": "Immuron Limited [Member]"
       }
      }
     },
     "localname": "ImmuronLimitedMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ImpactOnLossForPeriods": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ImpactOnLossForPeriods",
        "terseLabel": "Impact on loss for the period"
       }
      }
     },
     "localname": "ImpactOnLossForPeriods",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexchangeratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ImpactOnOtherComponentOfEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ImpactOnOtherComponentOfEquity",
        "terseLabel": "Impact on other components of equity"
       }
      }
     },
     "localname": "ImpactOnOtherComponentOfEquity",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexchangeratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IncomeFinance": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "imc_FinanceCostsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeFinance",
        "negatedLabel": "Finance income"
       }
      }
     },
     "localname": "IncomeFinance",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_InventoriesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InventoriesAxis",
        "terseLabel": "Inventories [axis]"
       }
      }
     },
     "localname": "InventoriesAxis",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_InventoriesDetailsScheduleofinventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories (Details) - Schedule of inventories [Line Items]"
       }
      }
     },
     "localname": "InventoriesDetailsScheduleofinventoriesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_InventoriesDetailsScheduleofinventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories (Details) - Schedule of inventories [Table]"
       }
      }
     },
     "localname": "InventoriesDetailsScheduleofinventoriesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_InventoriesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Domain]"
       }
      }
     },
     "localname": "InventoriesDomain",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_InventoriesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]",
        "label": "InventoriesNet",
        "terseLabel": "Net"
       }
      }
     },
     "localname": "InventoriesNet",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_InvestorRelationsExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 8.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investor relation expenses.",
        "label": "InvestorRelationsExpenses",
        "terseLabel": "Investor relations"
       }
      }
     },
     "localname": "InvestorRelationsExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssuanceOfOrdinarySharesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfOrdinarySharesDescription",
        "terseLabel": "Issuance of ordinary shares, description"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesDescription",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_IssueAt050OnExerciseOfESOPUnlistedOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueAt050OnExerciseOfESOPUnlistedOption",
        "terseLabel": "Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)"
       }
      }
     },
     "localname": "IssueAt050OnExerciseOfESOPUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueAt050OnExerciseOfESOPUnlistedOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at $0.50 on exercise of ESOP unlisted options.",
        "label": "IssueAt050OnExerciseOfESOPUnlistedOptions",
        "terseLabel": "Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)"
       }
      }
     },
     "localname": "IssueAt050OnExerciseOfESOPUnlistedOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueAtA008InLieuOfCashForServicesRendered": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at A$0.08 in lieu of cash for services rendered.",
        "label": "IssueAtA008InLieuOfCashForServicesRendered",
        "terseLabel": "Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)"
       }
      }
     },
     "localname": "IssueAtA008InLieuOfCashForServicesRendered",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueAtA008InLieuOfCashForServicesRendered20201113": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at A$0.08 in lieu of cash for services rendered.",
        "label": "IssueAtA008InLieuOfCashForServicesRendered20201113",
        "terseLabel": "Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)"
       }
      }
     },
     "localname": "IssueAtA008InLieuOfCashForServicesRendered20201113",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueAtUS025OnExerciseOfNASDAQWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueAtUS025OnExerciseOfNASDAQWarrant",
        "terseLabel": "Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)"
       }
      }
     },
     "localname": "IssueAtUS025OnExerciseOfNASDAQWarrant",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueAtUS025OnExerciseOfNASDAQWarrant1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at US$0.25 on exercise of NASDAQ Warrants.",
        "label": "IssueAtUS025OnExerciseOfNASDAQWarrant1",
        "terseLabel": "Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)"
       }
      }
     },
     "localname": "IssueAtUS025OnExerciseOfNASDAQWarrant1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueAtUS025OnExerciseOfNASDAQWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueAtUS025OnExerciseOfNASDAQWarrants",
        "terseLabel": "Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)"
       }
      }
     },
     "localname": "IssueAtUS025OnExerciseOfNASDAQWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueAtUS025OnExerciseOfNASDAQWarrants1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at US$0.25 on exercise of NASDAQ Warrants.",
        "label": "IssueAtUS025OnExerciseOfNASDAQWarrants1",
        "terseLabel": "Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)"
       }
      }
     },
     "localname": "IssueAtUS025OnExerciseOfNASDAQWarrants1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueAtUS047PursuantToADSPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueAtUS047PursuantToADSPublicOffering",
        "terseLabel": "Issue at US$0.47 pursuant to ADS public offering (2020-07-24)"
       }
      }
     },
     "localname": "IssueAtUS047PursuantToADSPublicOffering",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueAtUS047PursuantToADSPublicOffering1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at US$0.47 pursuant to ADS public offering.",
        "label": "IssueAtUS047PursuantToADSPublicOffering1",
        "terseLabel": "Issue at US$0.47 pursuant to ADS public offering (2020-07-24)"
       }
      }
     },
     "localname": "IssueAtUS047PursuantToADSPublicOffering1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueInLieuOfPaymentForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at $0.16 in lieu of payment for services (2019-11-12).",
        "label": "IssueInLieuOfPaymentForServices",
        "terseLabel": "Issue at A$0.16 in lieu of payment for services (2019-11-12)1"
       }
      }
     },
     "localname": "IssueInLieuOfPaymentForServices",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueInLieuOfPaymentForServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at $0.16 in lieu of payment for services (2019-11-12), shares.",
        "label": "IssueInLieuOfPaymentForServicesShares",
        "terseLabel": "Issue at A$0.16 in lieu of payment for services (2019-11-12)1"
       }
      }
     },
     "localname": "IssueInLieuOfPaymentForServicesShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueOfEquityToOrdinaryvalue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfEquityToOrdinaryvalue",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "IssueOfEquityToOrdinaryvalue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueOfRepresentativeWarrantsOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsOne",
        "terseLabel": "Issue of representative warrants (2019-05-23) (in Dollars)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueOfRepresentativeWarrantsSharesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsSharesOne",
        "terseLabel": "Issue of representative warrants (2019-05-23)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsSharesOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueOfRepresentativeWarrantsThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsThree",
        "terseLabel": "Issue of representative warrants at US$23.44 per 40 options (2020-07-24) (in Dollars)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsThree",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueOfRepresentativeWarrantsThreeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsThreeShares",
        "terseLabel": "Issue of representative warrants at US$23.44 per 40 options (2020-07-24)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsThreeShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssueOfRepresentativeWarrantsTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsTwo",
        "terseLabel": "Issue of representative warrants (2019-07-16) (in Dollars)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsTwo",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssueOfRepresentativeWarrantsTwoShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssueOfRepresentativeWarrantsTwoShares",
        "terseLabel": "Issue of representative warrants (2019-07-16)"
       }
      }
     },
     "localname": "IssueOfRepresentativeWarrantsTwoShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_IssuePursuantToAdsPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at US$0.10 pursuant to ADS public offering (2019-07-19).",
        "label": "IssuePursuantToAdsPublicOffering",
        "terseLabel": "Issue at US$0.10 pursuant to ADS public offering (2019-07-19)"
       }
      }
     },
     "localname": "IssuePursuantToAdsPublicOffering",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_IssuePursuantToAdsPublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue at US$0.10 pursuant to ADS public offering (2019-07-19), shares.",
        "label": "IssuePursuantToAdsPublicOfferingShares",
        "terseLabel": "Issue at US$0.10 pursuant to ADS public offering (2019-07-19)"
       }
      }
     },
     "localname": "IssuePursuantToAdsPublicOfferingShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_KeyManagementPersonnelCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KeyManagementPersonnelCompensationAbstract",
        "terseLabel": "Key Management Personnel Compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of other short-term employee benefits.",
        "label": "KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities",
        "terseLabel": "Other short-term benefits, including consulting services by KMP and their related entities"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOtherShorttermBenefitsIncludingConsultingServicesRelatedEntities",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofkeymanagementpersonnelcompensationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFive",
        "terseLabel": "Lapse of unexercised options at $0.50 (2019-11-27) (in Dollars)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFive",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFiveFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFiveFive",
        "terseLabel": "Lapse of unexercised options at $0.55 (2019-11-30) (in Dollars)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFiveFive",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares",
        "terseLabel": "Lapse of unexercised options at $0.55 (2019-11-30)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFiveFiveShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFiveOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFiveOne",
        "terseLabel": "Lapse of unexercised options at $0.50 (2020-06-30) (in Dollars)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFiveOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFiveShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFiveShares",
        "terseLabel": "Lapse of unexercised options at $0.50 (2019-11-27)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFiveShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne",
        "terseLabel": "Lapse of unexercised options at $0.50 (2020-06-30)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsAtZeroPointFiveSharesOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_LapseOfUnexercisedOptionsOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsOne",
        "terseLabel": "Lapse of unexercised options (2020-09-25)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_LapseOfUnexercisedOptionsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LapseOfUnexercisedOptionsValue",
        "terseLabel": "Lapse of unexercised options (2020-09-25) (in Dollars)"
       }
      }
     },
     "localname": "LapseOfUnexercisedOptionsValue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LeaseRenewed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease renewed date.",
        "label": "LeaseRenewed",
        "terseLabel": "Lease renewed"
       }
      }
     },
     "localname": "LeaseRenewed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of amounts relating to leases in balance sheet [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of amounts relating to leases in balance sheet [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofamountsrelatingtoleasesinbalancesheetTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of profit or loss amounts relating to leases [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of profit or loss amounts relating to leases [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofprofitorlossamountsrelatingtoleasesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofprofitorlossamountsrelatingtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_LeaveProvisionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of leave provision expense.",
        "label": "LeaveProvisionExpense",
        "terseLabel": "Leave provision expense"
       }
      }
     },
     "localname": "LeaveProvisionExpense",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LegalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 9.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of legal expenses.",
        "label": "LegalExpenses",
        "terseLabel": "Legal"
       }
      }
     },
     "localname": "LegalExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ListingAndShareRegistry": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 10.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of listing and share registry.",
        "label": "ListingAndShareRegistry",
        "terseLabel": "Listing and share registry"
       }
      }
     },
     "localname": "ListingAndShareRegistry",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LossAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LossAllowance",
        "terseLabel": "Loss allowance"
       }
      }
     },
     "localname": "LossAllowance",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradereceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_LossOnAllowanceTradeReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherReceivables",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LossOnAllowanceTradeReceivables",
        "terseLabel": "Loss allowance"
       }
      }
     },
     "localname": "LossOnAllowanceTradeReceivables",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftradeandotherreceivablesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_MajorProductLinesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MajorProductLinesAxis",
        "terseLabel": "Major Product Lines [Axis]"
       }
      }
     },
     "localname": "MajorProductLinesAxis",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_MajorProductLinesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MajorProductLines [Domain]"
       }
      }
     },
     "localname": "MajorProductLinesDomain",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_MarketingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 2.0,
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services.",
        "label": "MarketingExpenses",
        "terseLabel": "Marketing"
       }
      }
     },
     "localname": "MarketingExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_MrRichardJBermanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MrRichardJBermanMember",
        "terseLabel": "Mr. Richard J. Berman [Member]"
       }
      }
     },
     "localname": "MrRichardJBermanMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_NetForeignExchangeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain loss arising from foreign exchange differences.",
        "label": "NetForeignExchangeGainLoss",
        "terseLabel": "Net foreign exchange gains/(losses)"
       }
      }
     },
     "localname": "NetForeignExchangeGainLoss",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NonCurrentRawMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to non current raw materials.",
        "label": "NonCurrentRawMaterials",
        "terseLabel": "Raw materials non-current"
       }
      }
     },
     "localname": "NonCurrentRawMaterials",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NumberOfInstrumentOtherEquityInstrumentGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfInstrumentOtherEquityInstrumentGranted",
        "terseLabel": "No. of options"
       }
      }
     },
     "localname": "NumberOfInstrumentOtherEquityInstrumentGranted",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfOutstandingShareOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfOutstandingShareOption",
        "periodEndLabel": "Number of options, As at 30 June",
        "periodStartLabel": "Number of options, As at 1 July"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a number of segment.",
        "label": "NumberOfSegment",
        "terseLabel": "Number of segment"
       }
      }
     },
     "localname": "NumberOfSegment",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imc_NumberOfShareOptionExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement",
        "terseLabel": "Number of options,Vested and exercisable at 30 June"
       }
      }
     },
     "localname": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement",
        "terseLabel": "Number of options,Forfeited/lapsed during the year"
       }
      }
     },
     "localname": "NumberOfShareOptionForfeitedInSharebasedPaymentsArrangement",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfShareOptionGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement",
        "terseLabel": "Number of options, Granted during the year"
       }
      }
     },
     "localname": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement.",
        "label": "NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement",
        "terseLabel": "Number of options, Exercised during the year"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentsArrangement",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issue of unlisted options for the period.",
        "label": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2018-07-13)"
       }
      }
     },
     "localname": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issue of unlisted options for the period.",
        "label": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2018-11-26)"
       }
      }
     },
     "localname": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree",
        "terseLabel": "Issue of ESOP unlisted options at $0.12 (2020-10-29)"
       }
      }
     },
     "localname": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionThree",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issue of unlisted options for the period.",
        "label": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2019-02-11)"
       }
      }
     },
     "localname": "NumberOfSharesIssueEmployeeStockOwnershipPlanUnlistedOptionTwo",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares lapse of unlisted options for the period.",
        "label": "NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption",
        "terseLabel": "Lapse of ESOP unlisted options at $0.50 (2018-10-01)"
       }
      }
     },
     "localname": "NumberOfSharesIssueLapseOfEmployeeStockOwnershipPlanUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueLapseOfUnlistedOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares lapse of unlisted options for the period.",
        "label": "NumberOfSharesIssueLapseOfUnlistedOptionOne",
        "terseLabel": "Lapse of unlisted options at $0.57 (2019-02-24)"
       }
      }
     },
     "localname": "NumberOfSharesIssueLapseOfUnlistedOptionOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueLapseOfUnlistedOptionThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share lapse of unlisted options for the period.",
        "label": "NumberOfSharesIssueLapseOfUnlistedOptionThree",
        "terseLabel": "Lapse of unlisted options at $0.30 (2019-05-28)"
       }
      }
     },
     "localname": "NumberOfSharesIssueLapseOfUnlistedOptionThree",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesIssueLapseOfUnlistedOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares lapse of unlisted options for the period.",
        "label": "NumberOfSharesIssueLapseOfUnlistedOptionTwo",
        "terseLabel": "Lapse of unlisted options at $1.892 (2019-02-28)"
       }
      }
     },
     "localname": "NumberOfSharesIssueLapseOfUnlistedOptionTwo",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reclassify lapsed options from reserves to accumulated losses.",
        "label": "NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses",
        "terseLabel": "Reclassify lapsed options from reserves to accumulated losses"
       }
      }
     },
     "localname": "NumberOfSharesReclassifyExcercisedOptionFromReserveToAccumulatedLosses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reclassify exercised options from reserves to share capital.",
        "label": "NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital",
        "terseLabel": "Reclassify exercised options from reserves to share capital"
       }
      }
     },
     "localname": "NumberOfSharesReclassifyExcercisedOptionFromReserveToShareCapital",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfSharesUnlistedOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares unlisted option.",
        "label": "NumberOfSharesUnlistedOption",
        "terseLabel": "Number of shares unlisted option (in Shares)"
       }
      }
     },
     "localname": "NumberOfSharesUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_NumberOfValueIssueLapseOfUnlistedOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value lapse of unlisted options for the period.",
        "label": "NumberOfValueIssueLapseOfUnlistedOptionOne",
        "terseLabel": "Lapse of unlisted options at $0.57 (2019-02-24) (in Dollars)"
       }
      }
     },
     "localname": "NumberOfValueIssueLapseOfUnlistedOptionOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NumberOfValueIssueLapseOfUnlistedOptionThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value lapse of unlisted options for the period.",
        "label": "NumberOfValueIssueLapseOfUnlistedOptionThree",
        "terseLabel": "Lapse of unlisted options at $0.30 (2019-05-28) (in Dollars)"
       }
      }
     },
     "localname": "NumberOfValueIssueLapseOfUnlistedOptionThree",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NumberOfValueIssueLapseOfUnlistedOptionTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value lapse of unlisted options for the period.",
        "label": "NumberOfValueIssueLapseOfUnlistedOptionTwo",
        "terseLabel": "Lapse of unlisted options at $1.892 (2019-02-28) (in Dollars)"
       }
      }
     },
     "localname": "NumberOfValueIssueLapseOfUnlistedOptionTwo",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value reclassify lapsed options from reserves to accumulated losses.",
        "label": "NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses",
        "terseLabel": "Reclassify lapsed options from reserves to accumulated losses (in Dollars)"
       }
      }
     },
     "localname": "NumberOfValuesReclassifyExcercisedOptionFromReserveToAccumulatedLosses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value reclassify exercised options from reserves to share capital.",
        "label": "NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital",
        "terseLabel": "Reclassify exercised options from reserves to share capital (in Dollars)"
       }
      }
     },
     "localname": "NumberOfValuesReclassifyExcercisedOptionFromReserveToShareCapital",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionGrantedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option granted, description.",
        "label": "OptionGrantedDescription",
        "terseLabel": "Option granted, description"
       }
      }
     },
     "localname": "OptionGrantedDescription",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OptionsAndWarrantsExercised",
        "terseLabel": "Options and warrants exercised"
       }
      }
     },
     "localname": "OptionsAndWarrantsExercised",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsAndWarrantsForfeited": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and warrants forfeited.",
        "label": "OptionsAndWarrantsForfeited",
        "terseLabel": "Options and warrants forfeited"
       }
      }
     },
     "localname": "OptionsAndWarrantsForfeited",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsAndWarrantsIssuedexpensed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OptionsAndWarrantsIssuedexpensed",
        "terseLabel": "Options and warrants issued/expensed"
       }
      }
     },
     "localname": "OptionsAndWarrantsIssuedexpensed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsAndWarrantsLapsed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Options and warrants lapsed for the period.",
        "label": "OptionsAndWarrantsLapsed",
        "terseLabel": "Options and warrants lapsed/expired"
       }
      }
     },
     "localname": "OptionsAndWarrantsLapsed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted.",
        "label": "OptionsGranted",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "OptionsGranted",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsIssuedUnderESOP": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OptionsIssuedUnderESOP",
        "terseLabel": "Options issued under ESOP"
       }
      }
     },
     "localname": "OptionsIssuedUnderESOP",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsOrWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options/warrants.",
        "label": "OptionsOrWarrantsExercised",
        "terseLabel": "Options/warrants exercised"
       }
      }
     },
     "localname": "OptionsOrWarrantsExercised",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsOrWarrantsForteitedLapsed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from options/warrants forteited/lapsed.",
        "label": "OptionsOrWarrantsForteitedLapsed",
        "negatedLabel": "Options/warrants forfeited"
       }
      }
     },
     "localname": "OptionsOrWarrantsForteitedLapsed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionsOrWarrantsIssuedExpensed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of options or warrants issued.",
        "label": "OptionsOrWarrantsIssuedExpensed",
        "terseLabel": "Options/warrants issued/expensed"
       }
      }
     },
     "localname": "OptionsOrWarrantsIssuedExpensed",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OptionswarrantsForfeited": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options/warrants forfeited.",
        "label": "OptionswarrantsForfeited",
        "terseLabel": "Options/warrants forfeited"
       }
      }
     },
     "localname": "OptionswarrantsForfeited",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrdinaryShare",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "OrdinaryShare",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_OrdinarySharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares issued.",
        "label": "OrdinarySharesIssued",
        "terseLabel": "Ordinary shares issued (in Shares)"
       }
      }
     },
     "localname": "OrdinarySharesIssued",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_OtherComprehensiveIncomeLossForPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income (loss) for the period.",
        "label": "OtherComprehensiveIncomeLossForPeriod",
        "terseLabel": "Other comprehensive income for the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForPeriod",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherCountriesMember",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_OtherGainsLossesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherGainsLossesNetAbstract",
        "terseLabel": "Other Gains/(Losses) \u2013 Net"
       }
      }
     },
     "localname": "OtherGainsLossesNetAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherGovernmentAssistanceIncome": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 2.0,
       "parentTag": "imc_OtherIncomeFromNonOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other government assistance income.",
        "label": "OtherGovernmentAssistanceIncome",
        "terseLabel": "COVID-19 government assistance"
       }
      }
     },
     "localname": "OtherGovernmentAssistanceIncome",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OtherIncomeFromNonOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other income from non operating activities.",
        "label": "OtherIncomeFromNonOperatingActivities",
        "totalLabel": "Total Other Income"
       }
      }
     },
     "localname": "OtherIncomeFromNonOperatingActivities",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OtherIncomeOfResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income of research and development.",
        "label": "OtherIncomeOfResearchAndDevelopment",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeOfResearchAndDevelopment",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OtherIncomes": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 4.0,
       "parentTag": "imc_OtherIncomeFromNonOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomes",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomes",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherMember",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_OtherReserveMaturityDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherReserveMaturityDateDescription",
        "terseLabel": "Maturity date, description"
       }
      }
     },
     "localname": "OtherReserveMaturityDateDescription",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherReservesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reserves (Details) [Line Items]"
       }
      }
     },
     "localname": "OtherReservesDetailsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherReservesDetailsScheduleofotherreservesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reserves (Details) - Schedule of other reserves [Line Items]"
       }
      }
     },
     "localname": "OtherReservesDetailsScheduleofotherreservesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherReservesDetailsScheduleofotherreservesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reserves (Details) - Schedule of other reserves [Table]"
       }
      }
     },
     "localname": "OtherReservesDetailsScheduleofotherreservesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherReservesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reserves (Details) [Table]"
       }
      }
     },
     "localname": "OtherReservesDetailsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_OtherTransactionsWithKeyManagementRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amounts recognised as expense other transactions with key management personnel.",
        "label": "OtherTransactionsWithKeyManagementRelatedPartyTransactions",
        "terseLabel": "Other transactions with key management personnel"
       }
      }
     },
     "localname": "OtherTransactionsWithKeyManagementRelatedPartyTransactions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ParentEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ParentEntityAbstract",
        "terseLabel": "Parent Entity:"
       }
      }
     },
     "localname": "ParentEntityAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsubsidiariesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_PaymentForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentForServices",
        "terseLabel": "Payment for services"
       }
      }
     },
     "localname": "PaymentForServices",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_PaymentsToSuppliersForGoodsAndService": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentsToSuppliersForGoodsAndService",
        "terseLabel": "Payments to suppliers and employees"
       }
      }
     },
     "localname": "PaymentsToSuppliersForGoodsAndService",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_PercentageOfEntityRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfEntityRevenue",
        "terseLabel": "Percentage of total revenue for major customer"
       }
      }
     },
     "localname": "PercentageOfEntityRevenue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imc_PercentageOfForeignExchangeRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfForeignExchangeRates",
        "terseLabel": "Percentage of USD/AUD exchange rate"
       }
      }
     },
     "localname": "PercentageOfForeignExchangeRates",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/FinancialRiskManagementObjectivesandPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imc_PlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of plant and equipment.",
        "label": "PlantAndEquipmentMember",
        "terseLabel": "Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PlantAndEquipmentMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ProceedsFromIssuedAtADSPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount issued at pursuant to ADS public offering.",
        "label": "ProceedsFromIssuedAtADSPublicOffering",
        "terseLabel": "Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2"
       }
      }
     },
     "localname": "ProceedsFromIssuedAtADSPublicOffering",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ProceedsFromIssuedSharesAtADSPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued at pursuant to ADS public offering.",
        "label": "ProceedsFromIssuedSharesAtADSPublicOffering",
        "terseLabel": "Issue at US$0.10 pursuant to ADS public offering (2019-05-30)2"
       }
      }
     },
     "localname": "ProceedsFromIssuedSharesAtADSPublicOffering",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ProtectynMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProtectynMember",
        "terseLabel": "Protectyn [Member]"
       }
      }
     },
     "localname": "ProtectynMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_RAndDTaxConcessionRefund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent RAndD tax Concession refund.",
        "label": "RAndDTaxConcessionRefund",
        "terseLabel": "Other income R&amp;D tax concession refund"
       }
      }
     },
     "localname": "RAndDTaxConcessionRefund",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RawMaterialsAndStoresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RawMaterialsAndStoresMember",
        "terseLabel": "Raw materials and stores (Colostrum) [Member]"
       }
      }
     },
     "localname": "RawMaterialsAndStoresMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital",
        "terseLabel": "Reclassify share-based payments expenses from reserves to share capital"
       }
      }
     },
     "localname": "ReclassifySharebasedPaymentsExpensesFromReservesToShareCapital",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue",
        "terseLabel": "Reclassify share-based payments expenses from reserves to share capital (in Dollars)"
       }
      }
     },
     "localname": "ReclassifySharebasedPaymentsExpensesFromReservesToShareCapitalValue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of information about other related party transactions [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofinformationaboutotherrelatedpartytransactionsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember",
        "terseLabel": "Rental of an office suite from Wattle Laboratories Pty Ltd [Member]"
       }
      }
     },
     "localname": "RentalOfAnOfficeSuiteFromWattleLaboratoriesPtyLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_RepresentativesWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Representative warrants.",
        "label": "RepresentativesWarrants",
        "terseLabel": "Representative warrants (in Dollars)"
       }
      }
     },
     "localname": "RepresentativesWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ResearchAndDevelopmentConsultingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 1.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development consulting expenses.",
        "label": "ResearchAndDevelopmentConsultingExpenses",
        "terseLabel": "Consulting"
       }
      }
     },
     "localname": "ResearchAndDevelopmentConsultingExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ResearchAndDevelopmentExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ResearchAndDevelopmentExpensesAbstract",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ResearchAndDevelopmentGrants": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable": {
       "order": 3.0,
       "parentTag": "imc_OtherIncomeFromNonOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "ResearchAndDevelopmentGrants",
        "terseLabel": "R&amp;D grants"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ResearchAndDevelopmentsGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "ResearchAndDevelopmentsGrants",
        "terseLabel": "R&amp;D grant"
       }
      }
     },
     "localname": "ResearchAndDevelopmentsGrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RevenueandotherincomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to reserves.",
        "label": "ReservesMember",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "ReservesMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_RestatedTotalEquityAt1July2019": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RestatedTotalEquityAt1July2019",
        "terseLabel": "Revised total equity at 1 July 2019"
       }
      }
     },
     "localname": "RestatedTotalEquityAt1July2019",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevaluationFinancialsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revaluation financials amount.",
        "label": "RevaluationFinancialsAmount",
        "terseLabel": "Revaluation financials amount"
       }
      }
     },
     "localname": "RevaluationFinancialsAmount",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails",
      "http://immuron.com/role/SharebasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevaluationOfOptionIssuedInPriorPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluationOfOptionIssuedInPriorPeriod",
        "terseLabel": "Re-valuation of options issued in prior period"
       }
      }
     },
     "localname": "RevaluationOfOptionIssuedInPriorPeriod",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevaluationOfOptionsIssuedInPriorPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluationOfOptionsIssuedInPriorPeriod",
        "terseLabel": "Re-valuation of options issued in prior period",
        "verboseLabel": "Re-valuation of options issued in prior period (2019-11-06) (in Dollars)"
       }
      }
     },
     "localname": "RevaluationOfOptionsIssuedInPriorPeriod",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable",
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevaluationOfOptionsIssuedInPriorPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluationOfOptionsIssuedInPriorPeriodShares",
        "terseLabel": "Re-valuation of options issued in prior period (2019-11-06)"
       }
      }
     },
     "localname": "RevaluationOfOptionsIssuedInPriorPeriodShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_RevaluationOfShareholdersApprovedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluationOfShareholdersApprovedValue",
        "terseLabel": "Revaluation of options value"
       }
      }
     },
     "localname": "RevaluationOfShareholdersApprovedValue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevaluedAtGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevaluedAtGrantDate",
        "terseLabel": "Grant date, description"
       }
      }
     },
     "localname": "RevaluedAtGrantDate",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_RevenueFormContractWithCustomer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFormContractWithCustomer",
        "terseLabel": "Total revenue for major customers"
       }
      }
     },
     "localname": "RevenueFormContractWithCustomer",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevenueFromExternalCustomers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration.",
        "label": "RevenueFromExternalCustomers",
        "terseLabel": "Revenue from external customers"
       }
      }
     },
     "localname": "RevenueFromExternalCustomers",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_RevenueFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenueFromOperatingActivitiesAbstract",
        "terseLabel": "Revenue from Operating Activities"
       }
      }
     },
     "localname": "RevenueFromOperatingActivitiesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfAmountsRecognizedinBalanceSheet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfAmountsRecognizedinBalanceSheet",
        "terseLabel": "Schedule of amounts relating to leases in balance sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedinBalanceSheet",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amounts relating to leases in balance sheet [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAmountsRelatingToLeasesInBalanceSheetAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfBalancesUnderCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of balances under cash [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBalancesUnderCashAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfBasicAndDilutedLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted loss per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBasicAndDilutedLossPerShareAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfContractualUndiscountedCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contractual undiscounted cash flows [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfContractualUndiscountedCashFlowsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfDeemedValuationOfOptionsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deemed valuation of options.",
        "label": "ScheduleOfDeemedValuationOfOptionsExplanatory",
        "terseLabel": "Schedule of granted valuation of options"
       }
      }
     },
     "localname": "ScheduleOfDeemedValuationOfOptionsExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ScheduleOfExchangeRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of exchange rates [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfExchangeRatesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfExpensesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfForeignCurrencyRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of foreign currency risk [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyRiskAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfGrantedValuationOfOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of granted valuation of options [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfGrantedValuationOfOptionsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfIncomeTaxBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax benefit [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIncomeTaxBenefitAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information about other related party transactions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInformationAboutOtherRelatedPartyTransactionsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfInformationOnGeographicalRegionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information on geographical regions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInformationOnGeographicalRegionsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventories [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoriesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfKeyManagementPersonnelCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of key management personnel compensation [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfKeyManagementPersonnelCompensationAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfMajorCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of major customers [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomersAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of movement in number of stock options outstanding and weighted average exercise price [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMovementInNumberOfStockOptionsOutstandingAndWeightedAverageExercisePriceAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfMovementsInOptionsAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of movements in options and warrants [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMovementsInOptionsAndWarrantsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfOrdinarySharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of ordinary shares [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOrdinarySharesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfOtherReservesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other reserves [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherReservesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding balances transactions between related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOutstandingBalancesTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfProfitOrLossAmountsRelatedToLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfProfitOrLossAmountsRelatedToLeases",
        "terseLabel": "Schedule of profit or loss amounts relating to leases"
       }
      }
     },
     "localname": "ScheduleOfProfitOrLossAmountsRelatedToLeases",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of profit or loss amounts relating to leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfProfitOrLossAmountsRelatingToLeasesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfProvisionForSalesReturnsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provision for sales returns [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfProvisionForSalesReturnsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of cash flow from operations with loss after income tax [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashFlowFromOperationsWithLossAfterIncomeTaxAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfRevenueAndOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of revenue and other income [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRevenueAndOtherIncomeAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfSegmentInformationForTheReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment information for the reportable segments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSegmentInformationForTheReportableSegmentsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share capital [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShareCapitalAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of subsidiaries [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiariesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfSubsidiariesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiaries.",
        "label": "ScheduleOfSubsidiariesExplanatory",
        "terseLabel": "Schedule of subsidiaries"
       }
      }
     },
     "localname": "ScheduleOfSubsidiariesExplanatory",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ControlledEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total expenses arising from share-based payment transactions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTotalExpensesArisingFromShareBasedPaymentTransactionsAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions",
        "terseLabel": "Schedule of total expenses arising from share-based payment transactions"
       }
      }
     },
     "localname": "ScheduleOfTotalExpensesArisingFromSharebasedPaymentTransactions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imc_ScheduleOfTradeAndOtherPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of trade and other payables [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTradeAndOtherPayablesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfTradeAndOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of trade and other receivables [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTradeAndOtherReceivablesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfTradeReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of trade receivables [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTradeReceivablesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unused tax losses for which no deferred tax asset recognized [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfUnusedTaxLossesForWhichNoDeferredTaxAssetRecognizedAbstract",
     "nsuri": "http://immuron.com/20210630",
     "xbrltype": "stringItemType"
    },
    "imc_SegmentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of segment assets.",
        "label": "SegmentAssets",
        "terseLabel": "Segment assets"
       }
      }
     },
     "localname": "SegmentAssets",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SegmentHyperImmuneProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of segment hyperImmune products.",
        "label": "SegmentHyperImmuneProductsMember",
        "terseLabel": "HyperImmune Products [Member]"
       }
      }
     },
     "localname": "SegmentHyperImmuneProductsMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_SegmentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of segment liabilities.",
        "label": "SegmentLiabilities",
        "negatedLabel": "Segment liabilities"
       }
      }
     },
     "localname": "SegmentLiabilities",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofinformationongeographicalregionsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentReportingDetailsScheduleofinformationongeographicalregionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of information on geographical regions [Table]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofinformationongeographicalregionsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentReportingDetailsScheduleofmajorcustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of major customers [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofmajorcustomersLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentReportingDetailsScheduleofmajorcustomersTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of major customers [Table]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofmajorcustomersTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmajorcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting (Details) - Schedule of segment information for the reportable segments [Table]"
       }
      }
     },
     "localname": "SegmentReportingDetailsScheduleofsegmentinformationforthereportablesegmentsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SegmentResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of segment research and development.",
        "label": "SegmentResearchAndDevelopmentMember",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "SegmentResearchAndDevelopmentMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_SegmentRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment revenue.",
        "label": "SegmentRevenue",
        "terseLabel": "Segment revenue"
       }
      }
     },
     "localname": "SegmentRevenue",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SellingAndMarketingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services.",
        "label": "SellingAndMarketingExpenses",
        "terseLabel": "Selling and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofsegmentinformationforthereportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SellingAndMarketingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SellingAndMarketingExpensesAbstract",
        "terseLabel": "Selling and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpensesAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ServicesRenderedByGrandlodgeCapitalPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ServicesRenderedByGrandlodgeCapitalPtyLtdMember",
        "terseLabel": "Services rendered by Grandlodge Capital Pty Ltd [Member]"
       }
      }
     },
     "localname": "ServicesRenderedByGrandlodgeCapitalPtyLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationaboutotherrelatedpartytransactionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate",
        "terseLabel": "Grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantDate",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1",
        "terseLabel": "Expiry date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable",
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_ShareBasedPaymentsExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of share based payments expense.",
        "label": "ShareBasedPaymentsExpense",
        "terseLabel": "Share-based payments (income)/expenses"
       }
      }
     },
     "localname": "ShareBasedPaymentsExpense",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofreconciliationofcashflowfromoperationswithlossafterincometaxTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ShareCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share capital.",
        "label": "ShareCapital",
        "terseLabel": "Share capital (in Dollars)"
       }
      }
     },
     "localname": "ShareCapital",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ShareOptionsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareOptionsOutstanding",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "ShareOptionsOutstanding",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_ShareOptionsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share options per share.",
        "label": "ShareOptionsPerShare",
        "terseLabel": "Share options price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ShareOptionsPerShare",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_SharebasedPaymentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedPaymentExpenses",
        "terseLabel": "Share-based payment expenses"
       }
      }
     },
     "localname": "SharebasedPaymentExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]"
       }
      }
     },
     "localname": "SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable",
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payments (Details) - Schedule of granted valuation of options [Table]"
       }
      }
     },
     "localname": "SharebasedPaymentsDetailsScheduleofgrantedvaluationofoptionsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable",
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SharebasedPaymentsExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment expenses.",
        "label": "SharebasedPaymentsExpenses",
        "negatedLabel": "Share-based payment expenses"
       }
      }
     },
     "localname": "SharebasedPaymentsExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SharebasedPaymentsTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payments (Tables) [Line Items]"
       }
      }
     },
     "localname": "SharebasedPaymentsTablesLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SharebasedPaymentsTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payments (Tables) [Table]"
       }
      }
     },
     "localname": "SharebasedPaymentsTablesTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SharebasedPaymentsToDirectors": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedPaymentsToDirectors",
        "terseLabel": "Share-based payments to directors2"
       }
      }
     },
     "localname": "SharebasedPaymentsToDirectors",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SharesIssuedPricePerShare1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "SharesIssuedPricePerShare1",
        "terseLabel": "Share issued price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_SharesIssuedToDirectorsForTheDirectorFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SharesIssuedToDirectorsForTheDirectorFees",
        "terseLabel": "Shares issued to directors for the director fees"
       }
      }
     },
     "localname": "SharesIssuedToDirectorsForTheDirectorFees",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SharebasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ShortTermFundingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of short term funding agreements.",
        "label": "ShortTermFundingAgreementsMember",
        "terseLabel": "Short-term Funding Agreements [Member]"
       }
      }
     },
     "localname": "ShortTermFundingAgreementsMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_StockIssuedDuringPeriodValueIssuedToDirectors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by directors and founders.",
        "label": "StockIssuedDuringPeriodValueIssuedToDirectors",
        "terseLabel": "Shares issued to directors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedToDirectors",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options reclassify to the exercised options from reserves to share capital.",
        "label": "StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised",
        "terseLabel": "Reclassify exercised options from reserves to share capital"
       }
      }
     },
     "localname": "StockIssuedDuringTheReclassifiedBySharesStockOptionsExercised",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_StockIssuedDuringValueReclassifyToStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a reclassify by the exercise of stock options.",
        "label": "StockIssuedDuringValueReclassifyToStockOptionsExercised",
        "terseLabel": "Reclassify exercised options from reserves to share capital"
       }
      }
     },
     "localname": "StockIssuedDuringValueReclassifyToStockOptionsExercised",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_SuperannuationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": 12.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of superannuation expenses.",
        "label": "SuperannuationExpenses",
        "terseLabel": "Superannuation"
       }
      }
     },
     "localname": "SuperannuationExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount representing the accounting expenditure subject to research and development tax incentive.",
        "label": "TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive",
        "terseLabel": "Accounting expenditure subject to R&amp;D tax incentive"
       }
      }
     },
     "localname": "TaxEffectOfAccountingExpenditureSubjecttoResearchAndDevelopmentTaxIncentive",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses",
        "terseLabel": "Net impact of other amounts not deductible (taxable)"
       }
      }
     },
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLosses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TaxEffectOfShareBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount representing the share-based payments.",
        "label": "TaxEffectOfShareBasedPayments",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "TaxEffectOfShareBasedPayments",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TaxEffectOfTaxPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TaxEffectOfTaxPayable",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "TaxEffectOfTaxPayable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TaxEffectofResearchAndDevelopmentTaxIncentive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the research and development tax incentive.",
        "label": "TaxEffectofResearchAndDevelopmentTaxIncentive",
        "terseLabel": "R&amp;D tax incentive"
       }
      }
     },
     "localname": "TaxEffectofResearchAndDevelopmentTaxIncentive",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofincometaxbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TitlesOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TitlesOfIndividualAxis",
        "terseLabel": "Titles Of Individual [Axis]"
       }
      }
     },
     "localname": "TitlesOfIndividualAxis",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_TitlesOfIndividualDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TitlesOfIndividual [Domain]"
       }
      }
     },
     "localname": "TitlesOfIndividualDomain",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_TotalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalExpenses",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalExpenses",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleoftotalexpensesarisingfromsharebasedpaymenttransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TradeAndOtherPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]",
        "label": "TradeAndOtherPayable",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofcontractualundiscountedcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransactionCostsArisingOnRepresentativeWarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs arising on representative warrants issued.",
        "label": "TransactionCostsArisingOnRepresentativeWarrantsIssued",
        "terseLabel": "Transaction costs arising on representative warrants issued"
       }
      }
     },
     "localname": "TransactionCostsArisingOnRepresentativeWarrantsIssued",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs arising on representative warrants issued, shares.",
        "label": "TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares",
        "terseLabel": "Transaction costs arising on representative warrants issued"
       }
      }
     },
     "localname": "TransactionCostsArisingOnRepresentativeWarrantsIssuedAtShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_TransactionsWithOwnersInTheirCapacityAsOwners": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Transactions with owners in their capacity as owners for the period.",
        "label": "TransactionsWithOwnersInTheirCapacityAsOwners",
        "terseLabel": "Transactions with owners in their capacity as owners"
       }
      }
     },
     "localname": "TransactionsWithOwnersInTheirCapacityAsOwners",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransactionsWithOwnersInTheirCapacityAsOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TransactionsWithOwnersInTheirCapacityAsOwnersAbstract",
        "terseLabel": "Transactions with owners in their capacity as owners"
       }
      }
     },
     "localname": "TransactionsWithOwnersInTheirCapacityAsOwnersAbstract",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from reserves on cashless exercise of ESOP unlisted options.",
        "label": "TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions",
        "terseLabel": "Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)"
       }
      }
     },
     "localname": "TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from reserves on cashless exercise of ESOP unlisted options.",
        "label": "TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209",
        "terseLabel": "Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)"
       }
      }
     },
     "localname": "TransferFromReservesOnCashlessExerciseOfESOPUnlistedOptions20210209",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_TransferFromReservesOnExerciseOfESOPUnlistedOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from reserves on exercise of ESOP unlisted options.",
        "label": "TransferFromReservesOnExerciseOfESOPUnlistedOption",
        "terseLabel": "Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)"
       }
      }
     },
     "localname": "TransferFromReservesOnExerciseOfESOPUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransferFromReservesOnExerciseOfESOPUnlistedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TransferFromReservesOnExerciseOfESOPUnlistedOptions",
        "terseLabel": "Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)"
       }
      }
     },
     "localname": "TransferFromReservesOnExerciseOfESOPUnlistedOptions",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_TransferFromReservesOnExerciseOfNASDAQWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from reserves on exercise of NASDAQ Warrants.",
        "label": "TransferFromReservesOnExerciseOfNASDAQWarrants",
        "terseLabel": "Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)"
       }
      }
     },
     "localname": "TransferFromReservesOnExerciseOfNASDAQWarrants",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from reserves on exercise of NASDAQ Warrants.",
        "label": "TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729",
        "terseLabel": "Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)"
       }
      }
     },
     "localname": "TransferFromReservesOnExerciseOfNASDAQWarrants2020072720200729",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofordinarysharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_TransferToShareCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock transfer during the period.",
        "label": "TransferToShareCapital",
        "terseLabel": "Transfer to share capital"
       }
      }
     },
     "localname": "TransferToShareCapital",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TransferToShareCapitalinDollars": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer to share capital.",
        "label": "TransferToShareCapitalinDollars",
        "terseLabel": "Transfer to share capital"
       }
      }
     },
     "localname": "TransferToShareCapitalinDollars",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofotherreservesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_TravelanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TravelanMember",
        "terseLabel": "Travelan [Member]"
       }
      }
     },
     "localname": "TravelanMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinformationongeographicalregionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_TypesOfArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Types of arrangements [Axis]",
        "label": "TypesOfArrangementsAxis",
        "terseLabel": "Types of arrangements [Axis]"
       }
      }
     },
     "localname": "TypesOfArrangementsAxis",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imc_TypesOfArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypesOfArrangements [Domain]"
       }
      }
     },
     "localname": "TypesOfArrangementsDomain",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_UnlistedOptionExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unlisted option exercisable.",
        "label": "UnlistedOptionExercisable",
        "terseLabel": "Unlisted option exercisable per shares (in Dollars per share)"
       }
      }
     },
     "localname": "UnlistedOptionExercisable",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/OtherReservesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of useful lives or depreciation rates property plant and equipment period.",
        "label": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentPeriod",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value issue of unlisted options for the period.",
        "label": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOption",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2018-07-13) (in Dollars)"
       }
      }
     },
     "localname": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value issue of unlisted options for the period.",
        "label": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2018-11-26) (in Dollars)"
       }
      }
     },
     "localname": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionOne",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree",
        "terseLabel": "Issue of ESOP unlisted options at $0.12 (2020-10-29) (in Dollars)"
       }
      }
     },
     "localname": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionThree",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value issue of unlisted options for the period.",
        "label": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo",
        "terseLabel": "Issue of ESOP unlisted options at $0.50 (2019-02-11) (in Dollars)"
       }
      }
     },
     "localname": "ValueIssuedEmployeeStockOwnershipPlanUnlistedOptionTwo",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of value lapse of unlisted options for the period.",
        "label": "ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption",
        "terseLabel": "Lapse of ESOP unlisted options at $0.50 (2018-10-01) (in Dollars)"
       }
      }
     },
     "localname": "ValueIssuedLapseOfEmployeeStockOwnershipPlanUnlistedOption",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_ValuePerShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value per share options granted.",
        "label": "ValuePerShareOptionsGranted",
        "terseLabel": "Fair value at grant date per option"
       }
      }
     },
     "localname": "ValuePerShareOptionsGranted",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of value reserved for issue under options and contracts for sale of shares.",
        "label": "ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares",
        "periodEndLabel": "Balance (in Dollars)",
        "periodStartLabel": "Balance (in Dollars)"
       }
      }
     },
     "localname": "ValueReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementsinoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_WarehousingDistributionAndInvoicingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warehousing, distribution and invoicing services.",
        "label": "WarehousingDistributionAndInvoicingServices",
        "terseLabel": "Warehousing, distribution and invoicing services"
       }
      }
     },
     "localname": "WarehousingDistributionAndInvoicingServices",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_WarehousingDistributionAndServicesFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warehousing, distribution and services fes.",
        "label": "WarehousingDistributionAndServicesFees",
        "terseLabel": "Warehousing distribution and services fees"
       }
      }
     },
     "localname": "WarehousingDistributionAndServicesFees",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imc_WattleLaboratoriesPtyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of wattle laboratories Pty Ltd.",
        "label": "WattleLaboratoriesPtyLtdMember",
        "terseLabel": "Wattle Laboratories Pty Ltd [Member]"
       }
      }
     },
     "localname": "WattleLaboratoriesPtyLtdMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imc_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement.",
        "label": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1",
        "terseLabel": "Average exercise price per share option, Vested and exercisable at 30 June"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement.",
        "label": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1",
        "terseLabel": "Average exercise price per share option, Exercised during the year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1",
        "terseLabel": "Average exercise price per share option, Forfeited/lapsed during the year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement.&amp;amp;amp;amp;#160;",
        "label": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1",
        "terseLabel": "Average exercise price per share option, Granted during the year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement.",
        "label": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1",
        "periodEndLabel": "Average exercise price per share option, As at 30 June",
        "periodStartLabel": "Average exercise price per share option, As at 1 July"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofmovementinnumberofstockoptionsoutstandingandweightedaverageexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WeightedAverageNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents weighted average number of Shares.",
        "label": "WeightedAverageNumberOfShares",
        "terseLabel": "b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShares",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofbasicanddilutedlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "imc_WeightedAverageSharePriceShareOptionsGranted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted.",
        "label": "WeightedAverageSharePriceShareOptionsGranted1",
        "terseLabel": "Share price at grant date"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted1",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "imc_WorkInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WorkInProgressMember",
        "terseLabel": "Work in progress [Member]"
       }
      }
     },
     "localname": "WorkInProgressMember",
     "nsuri": "http://immuron.com/20210630",
     "presentation": [
      "http://immuron.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofforeigncurrencyriskTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://immuron.com/role/ScheduleofexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "Total general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials (in Dollars)"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofrevenueandotherincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Properties [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofamountsrelatingtoleasesinbalancesheetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuron.com/role/ScheduleofgrantedvaluationofoptionsTable0"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "46",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "59",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_59_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r183": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r184": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r185": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r186": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r187": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r188": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r189": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20D",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r191": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r192": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r194": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r196": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r197": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r198": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r199": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r200": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r201": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r202": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r203": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r204": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r205": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r206": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2021-03-24"
  },
  "r207": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r208": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r209": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r210": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r211": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r212": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r213": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r214": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r215": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r216": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r217": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r218": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r219": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r225": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r226": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r227": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r228": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r229": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r230": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r231": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r232": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r233": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001213900-21-055241-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-055241-xbrl.zip
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MM>A/Y$ F*6XLDDD^P?)"' <P<;N/AEC:Q7.ZFEC<7V+X#SX \R,KKSB._6"
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M8)KGP"$,=LHYUJR+5^KEG9 V"DJLSX8R 82/'X]Q<4  @8()% R+AL5I\&
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M0'/-5$422BHBSVK&N7.J6!%/+HRC(3Q$:G<5W*87G=5Y7=6!+%@&P1!Z*7V
MREYK1-ZOZ/F3AYS3XG(>[H)R'LY3E/-PY\MY. ]1SL/>VN='3PO8Y1^SF\(K
MB^JXI"S "28F ^<)*(<5W1%#=!D5Q;K@ROK145/'Q^AI?/#A:9',=.D5H(_V
MWPZ]O<.FU]QO>?!'PSMJ''B-VC[^T?3V6_M>LU''/_:\VOZAUSIL$,&U_[;O
M'1X=86-IU\\-YQX$*<+,ID"9J8MX?-_T$45&5*=_Z7/]B/X]I#%B6S@/*7K"
M:,5PNNN6NY"JN\E%T^_GXYQ4"H=]IIE[#<P-AM3RCO8:WN'A(0'A".R)HH?H
MN9)Z+=?<PKHT$>P1<'ELJ:YG!F_C8Z&L(6>9VCKZ>28W%><'<H@"@V0%4;8K
M$!!AZ7!O(Z M!=F; 0L5^#E3"0"N<+ *9?"![:D@E&A.<92T2,%C9S.W_'AK
M9=;2DA6GTS+-ESFHSU%W6W \SXD&"0-$#=SLH)*#"WB%?EOMZT?&C<*8L4$@
M93'-(\*X%1U.E*96"I,;Y: X(#4,N*Z8E07\[LE7^59]EY<?DM6&&23L#?6\
MP2!;V)5OUJ=24?1XYLKYFIT#,0["Z;L?C9>N38/_2)X>OO-H_^#HO:GH^8."
MRX7,6=D(&('+W(WB4\,$@Y0X"*4#+.10=+$8IZ7A<[GF<K'F!Z_4^A"ID5N2
M76>2S0(NMY7V0?IZNO(H#82S+%.N0PJ*\([!L*<9L$,5SIP!MF]I>$O#C\]V
MT\Q3E*R\XU0Q3C-?JP)#FO?&09J:LF4FBV)+MUNZ?4RZ]66&$+I(A\>UGXN&
M8=<$*:R&1=D[6]+=DNYCDFZ*MA+AL3DXR9@XZ;/20%;MEB2W)/F8)#F#&[(K
M2M!("C\1P_BPQ%Q1<X00#"J&L*7<+>4^(>7*%+<J2$?& C/^/JM$)8)QDD1$
M'-)+W^.%6[K=TNTCVUU JUFN\J_8^(H'6G_EHI17I:H)&)M\%")=8]=U94SE
M6CHC@1&=1LNK-0^\QF&=@O+HVR8?"WY 'S=8JK2.[DE1;K.J'$:*(6537UT'
MH52M5<:!I)A?*.WPB^I&H[KN)#Z7XK(C-F,I&0I*X>ED!TV8HDQK3'!K>%^I
M<*;PKS#-RZZ:\4-'* 9"'-.,1WGW2T/-%3)@DB>(?;,L_'X(S\8WPBA\.9!*
M[-^<>FS8;JD8"# "'(:M)L GU2#6,Z6JK(J*"$8@D$!?3$PK62Z&FT=V:)?W
M1G+(!\<6J4V1WU![&<U.%G=%UU[G)"@N<,K)66;GZ%UO*<K%UW+Q\2)Y4NGG
M>#."0C,YQ%K((8)#"4"AJV#8XH4SN0Q.UT$,8:0R[:0[#.,>-N,$.HD1"-(/
M PR\*/!A@?"V"OM:\DYEY].4U3P]73%]9KP$8\.UBHL!.\L,V"T&W(X0SH^Q
M=\%5/-0[U6B+[!\J3".N=-0R1QPRM4GJ4SG<N B[(R+6*<C]1OHN0I$ZV_U:
MX]DYP*^27JI@\44#J05=HYS*KE'/-#!X2]CFT1:V.0?;;&YAF^M*VCT#0&$D
MP%!&DE,D$)-$U1= Z%%0VY;^CO8-L@SB+,R ZA8)S?^-M"[A##26@!I#ODR$
MY'E9,.DE=^S:H@M7OEQ 1J,U2@@-4S-'><V*=WD@S^*(P!TDN K!7.I*8.2N
M-U=&?&&S"G)ZF.)W5:6H;5C+C675J"R/5:?52?,!9TMF&F.YT$/ME4Q;+/IJ
M"+10GN)D*")3N0IK#3%%EC,70LK&),L"T39%%P*EXU!FLJZ<72[K$]]4?KWZ
M/LHIUY>%>/2P<2R/"G1?KA_F%+WC"J@1Z=I:<\U)5\6<3LQ*-,MFM%B6Z-+J
M>& >5"I^5U0T5'A '#78;YCX'*%B-F7]A^BS7 D5%TP3D&I\:5.V3J*=0PSN
MNK_%U\@F/%U%5RA\&.O>9(&8&(5Z@U,B7&I4J?59>Q+P8EB)"=6#X.-&333M
M0V9ODLJVK>I84#UVT,L&A-=[U&ZWZ\"T%-I3+65:O9:+S:+7JKWBZ1?55/&-
MUL,U$QM)4([QR#,STW7!8!)/KF]N?4;KZC,R$D"=Y%+I0QK+3%W%&W FB]&8
M=W7A']R? VQI<.UIL$IU0N<*N2UG2&S5$?<MA;T$"BO:+MKJ=L3A\?GN*\S)
M%N@URDDD"R5_-7"[+26^!$JT>GYZ5BE.$UKDJ/C-JJ!)5.(D!G$5!W2'59 U
MCA;<.UN2=4NL6V)=3CFT ]^:8JWF';JEJC?3MY%)U$0S5 6Z+05N*7 Y2*:)
MJ0J@MA2)#S?+8_*#-:2_,(V/I'704\T"LD1$Z4!RV[ARO-#N1;?5);<DN7JF
M2)Y7_LDF/"IPACQQ%$RJ.*$JIR4BKC;CR[*SU*34Z[+/'M5$'&/5.[H OD2O
M$Y\-<JU.4%5PJWHBJ$R2BNX$B]S%P< X8[?G8WL^%HX@%'G4-X=CQL&I]-SI
M#XVKN>8:,Y&)HFVGZ@O7F]J*!UQ!YTMH][>N0<FC4\!H=-VJ_FCHRH='E \W
MQT2\&32)'Z1@Z/6X\!/JW *[XU  9GLPM@=C"2?$>+;EMLZ*6G R2"XDLB^#
MJ\J (::J7 4< BO2Z"EJN-5EMB2Y#$D.Q%7,RC+5YQ5#:5P2B0S&O3Q)&2^8
ME%J2&P5%9?,74>&)F,;)EOJVU+=X!+ =F(^O^V$KA+)2$HJ./ZBY%L*_!%[>
MDM>6O!:.0/>'U7H;"$J4IYK L(I,A>E_][R-+56]!*J*Y##&DKQEH4G((QTN
M9V9F.4$]&_-=B8XF"+4Q?A '2%#3;7(&=1S2'CO0D N'H',#[DAUP]*5>4NU
MI89YYHZE'Q!V<R*R43R$K:&<"BR-;6I:!1&65$:-A\IUXG/R2%6_9KBX09@[
MQL-BE5B/J0\>W&HAG5YH->4.; 8:WPI12?T25..HJO:@:8'ZJ^@%Z^D3LJ#/
M/,*BXCYOKTHZ*&.LJF"%19-P+K$6(?I?8'S74[4".3>D:'&?4-)!3TYCCMK)
M?J8"'D5S>X4U]-&S@&3Y,8ZYP-4)MM=N^]11+],\(DZ<CR=MK^ 0MJ4WY X8
M7M%;"2Y3#8$(RCF1"75)+Y$B/T=#=H("\L>5#;#V%MF6&,W6D$:G@ #NNGKG
M-,Y0U3[3H+89-!LEH&&[WD6@3[-W7.8<"X)8.&>K$J+TG2(393[OII0$925]
M*!;*FT1@;2RBSZD;NG"G@L?=F+M1%-TI)6[H-B=4D._YIG$\>#E/W<C(/MJS
M>3FJ12_7_'1TIK@!-:8%,WZQ\/A%RZA9 +<Y=GI!/-,8W;2+TDU?J_NFT]-]
MB1R6DZ!(CF(/)U1<%M1IW'7/K7XM\'!=F)?V\ LC'J91F26HYLR9A<0.ISI-
MT:]&T<]BVTL9C@2T5EVC0RG\>4W?<[!"9+W1["@4/1F7<7(#;PM*LDAU3V$T
M];GU/FS1 :-3>-\%H912.00U-ZR2K)FC&86%32< O@F!%N.C3A_T5:YQY*7D
MD<<I%?LD"3G:*6KUT^ VANRK6E0,&%N<@.C)Q'>&NE+U*;B<T/^[[ND/<F))
M&P!)0;VN\)#@COG8MQ54 1@G1:&U+LI/I81BUNNI316V\; Z]A8=LQ3X9^ :
MO/CBQ%S,[9T3>LG83H6DL".)LI?,)HF_C +L18<<CK)&B'!\SQ%&?YM-K5;7
M>)HP"B7'(K>/TB=SX5=#=HC/KQ^\QPK_UM:=6%MW"71W&F$V8< I29AA[3G<
MB,VJ=5Y0L@H(4QELKJY*R<N:QII[NZV_(]$8ZEN.=D$O3<>8=DN)Y'Z0CQVT
M=>WYX2")0JUZQECNM[J.,0^>Y0;W(<02Q!5/(\V<NOF1H&C_K5'#K)F08VJ.
MXFV>3O@5=%:Q!/%C:UWK8#^A#;R(F)PR,6E2%=2ETY?:]+#V8* HUB(OI*,?
MD\XD3R8Q&D&F:P 7MP[1!":9#/\7Y679R-"%O)=2,FN)]282J#"RLH6*,MF4
M@P_G+P;C[C_PKAN/TK%AX<[\0FC&>G,);OC7^A.K<-M_<CEN^YL#+A*^5SOT
M&@TJ$=[:JWNU&GVL>X?-(Z_>V%,UP>M>ZZ#E[=5;Y6+>IE&O*D1N)HO/W??J
MK6;5RE2?.[+B6/VAW P,9'/.?SS@5H_(RR9%E\Q^*((Q/#!3"@/VB_5WJUR1
M&Z8NW#(+O5[;IJ'/I:&WMFGH2]'52_/C75)&K2UB3,]G=-=P/174/:-A3%*[
MR+V]=36.4N=!CWL+A(1T*%]CVE2K6IW4HB;CZB4Q.7Y$NL,"RSCQN-.H;E*Y
M\)TFK[>/]7E&(N0^-^8QA88?RBM1&CUQ?EH@[0*;E\.%_-UU+V/U:!K\[8P/
M97@P'U=9HJ!Z*7'NJ711E *1>C+OW[7N=TNNS)F,X(5C5:Y7J[^O.X[!E)FJ
MI;!:2:-]GJB&T]Q^D+"*5"$&K!-D8^3C05&D^H:[J!'P+5K9-.1FVHL7#8MO
MJ6'C<*@#,>OX)!B#V:M(1TVXV0:6ID%"ZH_(XZ&F?;NWJG5F;Z0;R:&@7XTW
MTL$]42M)NOT@C%6S5O)NF$1NRZ^M+K=)8?>Q[>^YB!I'R0YL?JV"5T_<6NT7
MY>I]7 /XIO69L8X?>9F>WXMZ']K87R20G.'$SC/N*ZU;AEC'QZD,"Y7@3,K1
M/Q>:BE2I"PQ&4+(J=_,T34UN+!/U0!Z8']/:3X$A-VPD^M@DM] OP[$NK%VG
MP^-60164,U1[K0KP.(<_J\[7!(8]1@?;#@P%B,$/=+M<;!:/O<2'JH2'=@!Q
M,,RA2B%%NW*WJEWYW! 6T(S5UKSPR6&9,P[>N>0.3$C[&%C(9]1E(HEVK;!+
MPSQLYYO[L?5;@58L* JC+&XSW!_9/#\"ME1!51BI0D"+&R O"G["5U%+*9G,
MY!67=*"JC7Y?P#G*:([M-C[--N:1*?7'FAY;%B!0!@,LE)20(TTDL'G(F29)
MT)<J6U=IAE3!.@Y3*^J^@"*VF[]FFV^J9%Y+\8T1 86Q&D2#T, S0!?'ZJ%]
M @>EIH@8%DC!!*X^;+?!9.CBFZ626MO-7[?-IQH.E)JL\O'$=\^5\%U,9;N
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M<]Y@)'@5Y*).]D/E=+#+E0,!5Q;!XR#"M:164?9&,O0VQ..<&%"9@J[- Z'
M,'34F?,68A"XJYCJ.*9JY78M^+ Z>NRIG@,S<^S!=(TQW:-FNM?8P"Y=^G7-
MP0GK$+FRPPTJN%V$ON<PZCI)C_H5J!Q"RL0N:$SSZ!E$&^V4"@G [TF<#X$[
M]AFV9UJ#!=$.YQS*E]MMY;P:(P ;Y.B\&,JLQUPC*^.%V"FA?0Q04G=(D$5+
M*/ZB2)\G(55ZBO*FCV1(KG3:90Z3*^Q&'FGT VU?(ADSJC?.=")6Z'],YY#9
M*/;ID%&&A8+46OB14N/K&U/^BS;91M#J!GRZ72V)8@R5FE_@]/MNH9;:" N&
M]9H\5TI5**B2Y?\/AN:HH1&HV&2X7!&N0/"""S?*QSUDJ -FJ!*KWX5!.I*^
M:B9&07C,>0K3&!N%I#F.1Z><L;#52XS#5VMOC<ZYN5:"6@N2Q"ICSLK9T8D.
MU0/#FU3][=($L;\8I[0!TT8Y[^=2@9Z#A+1%3[?;X7PZ/N9#;(,F%P!S5*QG
M)MAHI^B_+.'_D8 5JI4F;& :PWG"1SM%!J(JOD=E_ 6W-:(Z&Z(O?(FE&3&N
M&&1YH7'"80@Y*6@6-F.IJ:5]4<V5$@Q21',Z'JN']FMV$=+*B&ZOXF?=D0FI
M1H4K003KUIJZ23!2G*9Z'':1DF@]2_>+,@<QLL#<L]4!6)VP>@OONA=R*"A!
M+>54.9@[/8F:B 5)FIGAX.@&Q.XJ3IH&N#D]+**DF6353*P@J&+E4B7*<"XL
MF=&D3Q=LC'B#!1J)8>$(L:<ZBQ9O](&MQYXSLTB,[D'\CEJ^F^NJ* <HLUBO
M2.D O:P7QOUO&C5O.6"):6EZHL#TRSJHI>3F@G?B[CG4K0%9IFDP6'!2E8Y,
M5(,A=IU3FJ94,RTQ9%/L3JZ :R@KS+UZ_^\C)69$)VOD81A?JX%35J90:4B3
M)."L0NHYH; D070%,D3E&5=09ZEOHX9+FHF9E,=E%0)O246_,!OP_ Z3^#I3
M%0T=#!10I_#5.S/7I4=38YM2,9=2<;!-J7B4'DU/C(PWZLRL"J3PC!4(NO0&
MQ'<J^^B58KBLJECSHU>X5H,:X[YZN<8M8Y"QTN3$VA_'7CP;5C/)P1[I*R8>
M7*'$T=@9.XV!4P*XQV=NM\=445HV42PH-=L9:68G^#DZ;: 4B9C:;E(0/FD<
M13(L_-J%"@1J=)('F4Y#7Z"@ >- U[#1H'FPIAY!Y8H@*=OJGPT%YCQYK>6:
MYZ)!JGW9I?0+6QH3.7N&ENF1((+[WPAZ/ &^+E7[PWD:UWH[ZXI_@71F3=:^
MI&+8SU0KU(P'%%_LF:W<6+HL@ETM!K]T*-D7?AB!D$IV@O$8^U%B^0TP^?.Q
M;<#([W 44O+G+/*N5?B+\$J%_BQ4H9?+>)3_*LZS'<N>1#SNS,Z,E)[-:O:R
M>W3???$<T.0QJ*9S^<JCLJ-C^F8;I(_>&ZR_)$6D5/>80GFEM&;D!VKNY/$7
MY1)&6"Q%6/:H&9RG.9CJ"@4#@7F-@AY!:,FH5M-6$<.J*2LLNJV2TYV%ZTV9
M]X5O;UIQH_;7%=4X O0TFO: Z,'2QZ4X@QQ9F%#Y$PJST:OE]XF(3$?%$@9>
MQ2G(S9TG2^PJ[0R"BDK[YH&>S.4"[ KJ-[:X>OJHQ-,'(*SLNB+N9^T!QIQU
MQI6GTZTL=Y5V7G!%(YESY%.WF7KI+'!!1J5QXU5%;K@O0.;IQ!-69KT%2SR3
MDRE4V3-V*6 .@7([XR]:Z;%<<E=2-S%;Q%8IQ,!#HLI)K%K_<##,/.![TLUT
MG0LL.&&8'C/E2%*<W3%I%-S#TO8:LEL??BHUE61V0BYVSK&&T?5D*6V)&K#J
M2#>JGG@AER0#[4BF?.QEH),U2O*)/(,J+T?,]-:TWHI+QBD5=BTBGG51[7O&
M"]HVQ=;085OJH(I.3;NN7V:7'*,-*0JU+4IGM--%U-99V475 :_YB&0XU<EB
MJ-'.UINS2W $<16<@J)16#*G .);>6^8ZN@CSEYQ87;9523S>NCCI9 $UT/C
MBFP\"4U%)F)MH4]%9N?S*>0)TX@]1U4[C,N@ZK)4.&%%%B#K<@R>.:)\;G2]
M'4/HW%?OVAR@2@8 4IWKF!"=F-H]5C&K4B$35=^,C0]3AL3#_$\$()BB1*SU
M4_8.P9-&4H2HO@C>;K34J!>81@&Q.55X_29BJB./*H-2%R@,J"TN)DTO+1D*
MIK6(3>B.A5KH^*K.?9'?[1?)4'C26>>@TYC2^M!!*)\JATZ?"G:S9? 2Q+B&
ME"1!G #A_Z=2@B,G&*/]#3LP#E*NPUU .#(%2YNP+WM0*9ILE/96L,\M.UGN
MZ+[O&S2;O8*EH.S;F,D:1?8U\<!K%3'NR9!K/1&?K=@V?81B:R^( S'^4$,$
MJ4#93*HOUXQ28#E=ZS21.I8>4?+Y''(0%>T H=#C0A8C\LW.>-6EKIB;&IW;
M43JW)8X,GP3F52J3.L]Y1O$U#W7A" CEQ!4.RSV^60BKG5',H9JH+0EI*3>5
MJ0@<&9R?"A:PM6.:09:67J/JT+*"441L3&$SELQ(# B5+-_LZ3Q05F@462B.
M6"CASSM!NU1#>:[!_  ((^-T6H<*M26HC0 E_EO&("E\%"8*?C?K&233_IN<
MSO@9J;\2^3[Q-Q/6I^H.=NEA2_:\7'YX7KC;=5DZ+N]!11,%@QMU8G:L*RMI
M_1QVZXIZWJ@SE<HHX(X1-E(6M\%:>;-;MN?Z!!2Q?TBLQ?!/ 3^%,4.=@]11
MYQMY$[SA>!3(@=OY+OLY:7'GJ,$^2$1R'<[/@DT[+DH#*X6Q%\2%\XKJG,RH
M;D6,?1#;_N>BI63 K2(B1)U9F&GK5>R$8K1K\3PR_#1*R8A)+EZZJ!)0P0Z-
M>4M&!)WH8G V,)NFIV#9?B4Y$?:=S1?V(RN"WG7.BS]PFJ-@.,(*+789FQE\
MAK8!2K$K=)\E)&2YGC7PC5$P,?$300M6#2/"1A)JS*E!\7/ JV"-F;(D_\JQ
M[ %*8AOK;I"'R@FWD*46.#@-5+-YH%/) ZEG/?  W"DJ56/(0A>[(4A;4=@9
M51^/U?Y(1U-8=PC2F)($N8X*KXZGU$^IC#O'E, WQ8$1"V^K+AJT,U,%/Y4S
MHR[@=DF"!KT5)=*]$ VZQ&0/*!^%^L$IE!DN%JX.D@%,XCO8?K81?4QE#^%K
M7!\PQ-X6##$'ACC<@B'6 KCP(\04Z!UR NO;E\I?:\XU"43C=#3.7(+H6MI,
M 3I3T"DK/J1P4FP,<:B8"G3'/2!C],/K-+V"8;Q8'1/-VY*"XLXK*,"#?7A(
MHJ'=5G%Z[&'@L]2W$F&J=I.+XEC;QC(M'\L$/9PJ6@6:#:HE_X[GPAY&(GA.
M>;R#@" $>12@:1R8*G"FQ\H\ID7+7GLT2"=:LRA)F1(U&0@KHM\=DZ' E24X
M[,?.!J[%I^46EPRBV)GN/T#NZYL(]R9J=3\7".(47>O%/$C>:I6O0!%RGS"M
MII5A[.4F<L)TJ9]K*4>SI!)-,\(?"Q4Y\R>3!S-&@<[9 D7F5_$H+IXI=^;J
M'>) N)_%7)HMNT[0<3LFV>]S9Q=T83JZAG0IYZ>JG/;+LDO^D%Q22[F6S!XY
M94J=;RIX)<CJ+Q\*RT5F0C,9$IUVO_A!B@ER1;X&%\"D[%KIVY7,2[XJITN,
M>F#4R4*E,^]3V9? >H@WS'5OXILPLI/ Z=1P@^J2I7.ENE2;%<>$8&W'FH(=
MS0:^V0EB!X:L(W MDT+Z<4SE1K+4RQDD]NP=,X8TCB-=RB9_KC1,(K)=1%XJ
M/)Q%GQ(&=]G=-U3!OR+S5I?YGX_ID \PDD.A?*S*YWE#-<$7JRJ<W^3039W9
ME@KS:RVYCP-NW93S0":*>_?*#7+R;$3^91WJ]B5B ;EAT^Q#=::+&0?M*/L/
M"+5GI:S-E]+;ELW;5@59- ([_5QU $(@%56H&2QNT(&WY;;D(Y49X;=P]].7
M6-K2VSK3FTE;-0[ZHD$+AMJX$ T+/PSEL6$TQN*U)J.0*RI9V&^[K UB-7;*
M+6C*PM6=J3_ JD@!IS"YLBF?!$2C4]$55;%!JV5I87(HI5&UHM[2_Y;^%](_
M=M+3ME\B@W$/"]R/=95&[(;=5]7OBJ*FE9";.'FTJDO\+S8"7T:;VGFZ\AA?
M1M,4UD]$%ES)JU@X1&1QO02C:,_Q&BMTA#)R8GG=%T+GK(B3:>5H 9I45\<B
MO3D5H71BNWWW0E;U8I5RU1O-+7JC:6W$48BWBGZ8%?N O7_A10S(M_8!]R"=
M[>86S#5WTP#'&''A6;F\@L/9293B$V1DEJ4W&V5@#DR6IU7W![2JO'V.>@]#
M  /@#)E5)20-*'B(P_+C"?4BQ-9VEE/#-)7^81;%#9U68"VBJX =8%7'JIJ3
MZ4H'2A&EXB/<:5<7'QB(JSA1,%"+:Z)"ROU'YX], 4 U.$P.+VIA7MAXI:@>
M.A\KC+!%+6%*UEBYQ)LRQ[8VV%8GN$DGJ&A+J(VP:J+;&EE;@KJIW++E[N5"
M(I@^1_JE[=)&R>=:OG+V02.B:DM?6_JZV6D4<AH#"GL94<"+AD$L3# ,7/AC
M,,^U8;]E9EMBNZO%+$'9-]UEJ)DRUK-5$I)2NU2S)*R5IJKJI7:^UPWQL2WU
M;:GO)NKC(DN:SDQ/=\WL&)&<1XP= 0.-,1"%PQQ]XVRW2G]+:UM:6UBAW<J4
M1RB-2#!^SH2&<%8B("JX#'0(MJH,BZY%)JG>_7C25MEP8%W37NL"@]71QRU%
M;BERT0B*FA=<_X= BMKUAD.Q"CK<ENY^T.O-<X5[@5WU.O"N7)C$K<_<@ __
M[#+.G-6 UUA8LE%[?]'YW*6/]?=OMJ2])>V;!+LJX*@#A-H%:P*0R90@>,8]
MJE R \MQR_Y)F?:3H"=UW7US_98 MP1X$P'.YLH6\3ZC7<Z7W"9WN4OU'!!*
M3_4:?/E7SN4]+<?X-A:]I<";1C!+?2*D-I84SL*16,CO@@.:*B^,?;6J2J0+
M$18)ES"FI&/BJU)DQG0RCB3LH8M5F&0D!P'S6J7ZJCHKH#J4N.M:=!Q:ET2I
MYC91:BY1ZFB;*/4<J\8N0 D4-9&8E5#=("Q(;;)E==FZ*MYU+55-=$>Y;S D
M'&*Z)F4"B]1-*(E 0_Y)[%*Q[0&5>IH@5EU5S< T(7[A#.9W"/2GG$2<_V-5
M'N+(/:R#ZD5%]4"H20!<U\FQDC:\X6M$]9].!P9%%*2,2-9N *HDCD%K]A44
M$'+"+)2K@8<8'>>J0<:U)4UZ#E495 D]>G5*Q9:P"T#UQ+T27GD>B2$C*K.C
M41@<I$IE5C#[4A&+4K*&YQ29.]7])V @DT#A;HPX48/V"^C-S6,7J5XW7:0P
M0,"A IQ@E0C?424X=MUS?I1UI:ILDDG,V19)0/G>H2!\(A7E+Y(A,"P25>#_
M!^6Z\^Q"3!<-FZ P.%&S>]@-8=?]+;Z6U/Q,SJ%HXOE1$S%7#(;,?U-12V$H
MBML," 1G1I2;YKV4&&Y6FJBH2G=A%#%6EAG%UY$J4J*1G5CR+:?U3F:P5[OK
MP'7680P*JT(-_[ 8#W8:$)331(T=,;N\@N/A?LUS.$X6PNRT,2EO7)N&*@?-
M5ANC]VGF43Q9XXWP_H1K]OD!AJ#1K*'#IXL5Z;)TN*^$R-&5I/!0X05TM%%D
MSYUQ3V4CF0/)).&5BG<6+>KLQ$U.U:2D^U(&#+9&XWP\;IZCQV]"2U)5 "W?
M5]G&P/O_[+U_<]M&LB[\/SX%:NOL+;LNI4AVG!]G]Z9*D9VLSHUC7\LYN7O_
M>0LD01$Q"' !0C+WT[_33W?/](  )6?CQ"NQZIR-)9' 8-#3T]/]]/,,TX+&
MZ@;WN:_I9X)KS4QSF])W* ,#KWF::H/1$G4-[4L;H:=%0RE+6 [8=9\\A*D7
M3/-?#_/6PW!O22)O0UP7;4##K>IY5H:N6]/-VA;N[)6I9V(.\=#6%]U[K+DP
MXE&D#E+T&Y?;Q+2/^G8Y>PW[I&YO*4#P&'] NWC#66ZRCVDDZEZ/^/22H<'R
M.J<'!;T86*0>)D+U;8\:;# N29 Y'.2Y-:PP40OTS[J"1#2*O7K.Y_45:$\R
MY?(<X]O!BR725"9&['66AY9SV@&TK]A\@.DRPQK--A_8AMYOB8_7_"3=[<UE
M[[W'"X@;%6$Z&U'L;8,]M^0IH8LC,;Y V_,EUZ ^RNVI[C-SFHV\"H%RYJ7J
M0OUM!^^ZGS83K7J4ZJ!-M)=MQNUQ2#9A_#W=-<8[NCVE(6@)[%:>A*Y'OY!P
M;O.,74R@&YTEE$](^#+"*J569\Z(E7G,!S@9;O\.U3'$WOZDU*=%T#OV. 8;
MZWXG@P;[,U\LN\E8&1HK?EW:S<63-9"<)+7NZ5THBP ZP0J>G[K;]? Z<3=W
M1EVZ-2QR;.Y/6=,L\PR#/3]._UI\0T&;.V*ZN_WUL^(;V_5D-Y[SNEW5Z=MH
MUWF=5<XA-MOWD^2U6Z4;A(CS]/ML!4%'^O<E'K/*K@NWQWU;U*_AO=)P]L[*
M,N)$LDU7>!O[GF"2GLV<SRP1B9TY)^%NO$V^M8YODIX3@;/;W/G6D_1YEOYW
M32G0)H/=PGRWE;LS->!_N\,?\B8G3UJ\3R^JV3'&U)LWFK9[NEHUQH-OU*(M
M4_6U,\*41B?VQ'!B['70K W.Z1%+ST"J7ZR*:@F:M2M: _56NP:],%G@B*94
M1D3 $<1H N4&$[,>VN3OX):7Y!>4\0+LC*3B8%\T&$_H%?>6;^@FF8S0\X5W
MGX^_^9%: Z%CDKC_$\&S>VR0<U=@W'X969?L^:WM]X'G,%J['$5M?-PL]"T
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MF_XH";3S;J@F!7EJ=E[";=,#) Y417YED_3!,.^_80X)V9DS)W.0U$)#O7N
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M/!<4 =B[@X:Z L,<I(@AR5@$F>N"  ;2;(<B=TFO/J5SU6J]89PW1.NR!@
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M 8VT+3-I6%;N%2;. )TC!EB%#*9K9E+'YZM6^96>"<T:C<'[Z<]P#OQ&?9.
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ME<FCI6[=J2S]HAG?%87_^- G>*AACXU :/W!];WFX,@:&48CS:I!A5=ZO@]
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M2>I&7$I&7FYO1M(2D(5J0EGC0C3??4'!EEE%!],^F/9O8]IZ(-G4!"]U7IC
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MG?'CR$M]6ALA<B@@&B2"L8R9_J@#%W2X+:F\)].B7I-T2S;+.X8MZY&!FYD
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MO*O$G(%1O,#<9J6;M#E1S%"QA4/+/K\]"\]RM=WM@[X:SY*P,J543%RMW1&
M2I ,AU:,>,S9HB/+E)E@SAUBRAKE8NRKHV76E3)1N*R;";K+-NGAP[EXS[&"
MOQU54_.5FPVF?^.( [2 +%68^4OO#$PYQ$ HY^*SIEN3$98; ;'A6^[$7X$V
M3K#"4:N@#PB.TY>0U//1P@T? <A^:XJH*.LQI["-DY/<F=!5&JFY>)UMOVC<
M28C6**NFP*1Q.!2"GF3=-12Y2Y9E]SUQARBQNW$['K^UC@3V6L:K;@HF!9.I
M)H$)G4RFAQV<+'T L.T$]LQ$3ZA-+KU_$LQIRS.=N$N&RF(\4*C,RFE.C)[<
M6)YV[H"^P$CX>13048&2Z)*)_ZD1@&:&3L^,Z##O. G#[E:A)79* 0!%<Q27
M/OWJQ(/ ^:7(8=!=EW)145^K#(%?**:2')BDMM3D*.9%?X8L3],JG;BU3/:D
M@"\Z@-'I=,CYP23 _4_&1L=110PPJQO(J8@P=<VWJ1NA4#WN;XL?O8+AG)_>
ML_A('?][;W[A3K.-4>BY>/GRZ/3)YR^&VD[Z[F.HO<2TEK3[6DLVUN5P@\Q@
MB\GO/"T[N_$G<W*V+L#9M%M&,WY!W+V&1E\W@__5.3]%72 A0T/UD:.+D?+(
M4'?1)MS*VP5UXJ>]5GQJ7??LFL#@]+.N?4*"A'.OVOHI?<\[+=IW:F2*FIA\
M[AHGPR%C^[AM7&_1X'3D[MK4<H:UM%=^>#[=9UJKB!M2**?==H0S.HB4:MW6
MRYK;&30[-?3.[C!A(3UK;KZD_YQ^_9D_PW_VWQ?G)Z>?P83XB3WC)(BU7^;E
MU(VORKUIO"8AX_1YO01H)#0QTD[K.XHQ(ABA>S$/*]5^4;E89BL-6F9MF:B1
M;.JE,[YV27D.$EHB\]46T/1R1NEXMY.V*@#];5%K18.254BCV;E?9O->@VMH
M/R6;O*F!6>-<)A Y6,Y<-W;VFVW;I'-QC33MW#"M[6I*XLQ4G@&/ELC/&6NZ
M7+M B;$U D+-(&FYWE!=JF!<G@LZ,I8AQ:=N,:_D5Y@71W*RY8=I<'$63[)S
M-5=7G''V7C+J=?2=BNI*$DU5H]8LSG2_%[V+"ZOS%KPK7"V6XH:=0DEK]><P
MD3D,67BL5#@EBJRH(J@=E03O _L$YDK"7-^SN<FSE0F[(I-QD3&"+Z. ZI[P
M%RB(T@0DIMOJT<75&;^$J^\?>P'2O7O/P_("YY<7;U[Y=0LF/;45>J$#KR +
MRE0S=Y[DLZGL(.Z,]"YL&AJ=[]WIN:9Q^ZZ9W&773.^P:[*E8:2F+7A-TI5S
MNC(2<6@GW&I2?>9.@BMW R1OM\D&YX*C%1$PH9N4[DBGAT<_G!^]O/SLY257
MK@6'2Y %)3FXN#HJS4+":8=MUQ@MY][7:^J?%>;7BK(0?%SISV B+<GLOQM>
M\2(EF+XLRG?I:\::X+DQPI>7;GQ9N6V)KZ?E<V=+RD3<OPB6=DGK9W*$<NOL
MZ9?/S+@%)^!.=7+_9 /7=4SI_7<H4A55EYNV$W>PRL)]"4VM.&5657B7;\/U
M;^F_3CV'-_DI4XHC+ L5> 5@HYR^U!-.Z=78DPR'9^)2M*FF4*_JWP]4RJ:$
M4&DMZ*9OF,F'&N:A#O=SCJ(7OUVS]7%@2PS&;KLHW0+]9\;K*"I7H>A?N)L7
M4-SS21_>8K@0TU57:I*^)@8WU7C>=_O:W&\WC(+Q2J_.NN:]5RO<$2$32;=Q
MM_VE(WX(-'!!.R!=N&,)M.!YC66;Y7'ZD^\.< >6[20=O#32>FYW)3B8&*^F
M&)C<8)(N6:-FEVW-7T0Q-B$U>>VNN 'Z#4'1E.]0IFOP3RDK13TE5E+V/AE8
M$G(<(=;.Z4M/\R:O$EF%-%&8X*H>?!:HU>RF?7#R1M6%\[M:ZU1/QH$*2+OI
MA77KN9^)UI!WF.65X-6CN]H_\G%ZKID9'VM(U!7 <",<+2#Z5E>3,0E:RGD$
M"93PDMG/<N3SYL>SA"'@O5)IAA=SDTV9<01,YCJ;](P"3G11(5K:M]553K?)
M.2=.E]Q0-$I[Y14*M\)RPE%5)<P6E0L*K[I-2H_L-O/\/9*##%?(5G08#LHK
MSL(I&^\.8^Z87*%'@KCPJG]NW=B<HSH[?_'D<8CX^BM48SS VG/-I<EXG,_U
M?!L^YP]-G1UC+:+0F:1)W+L2(5WFD+'+%LO3R#/M_S1*U]"OP=L($4?"NVPL
MD4Q!$+IE>-B:"]1,MY85#,V(<Y2T,Q!],ID=\>7%.5(:P*(HL:UZ3G@L-VA!
M1 "FH(,B;VC!,7;[.[&<?;HIIPN33H(ZIZ:=$CM-B%B^.$%KAUMF5(;QASCI
MN(5KH87M3[01)N&#$Q.\Z)./D)CXX$1.,I;(23]:(H<'>:&#;+L6<O#,M*E4
M'9*LJD-"]P;$/VY&5D7EP7I9^H^.LK0;!J7@Y"\GA97;%0!=YDLU>;1FL%3A
MHD4D+<BTQ[AD'9 ^LPV>!ZYI0#WF6_S(+(=>@+NK!Y6.GM+G503F&@/&>N/)
M%.TU\)BMI@(X>?#LA%[O#,C(%^=_=?OS-\]._OH9_?<QG=2_WOW[U_KWCQ!S
MXG^?GAY_20"$#SKW[L.0/#U@2'8Q)%\=,"2_H?G]KFIN+DX8<L-*$DFTO^Z\
MX)=SRNOUFI8 ?/7G;D,F7_7UZ?'7:7?UV>H'*9:J8^# U/H-H(2CW@SV,!L0
MP=X@./*Q?D*A&X &,[\!C;NW/=Z*KANYJWWN*!U\_*]/DNCQH^/8YU\=?TD3
M<?KLV?'G,A. ANL,8W>S1_6!B?#C'YR+-)Z+Y&RLV(3 6G.D-@OA ;Q9R[LK
M"&[7SN?DTUKW&,T,2T\1S\.(!5P1*B9O$I&NR^.Q @X_VVYJ'?/NJ_L?5YN_
M?/[5R0G/F'^_.&K9D=]B4*BHT[62)\\F)WHY/ +T@4CQK2'];2+S+N8(O^62
M>RX8WD?!<^:?Q1\JCM,S.8%Q^DS"OF25T6F/6W]U4K>X!E?(Z$U>>[&X@8@A
MVK(QS26USBPS%#8A@FIC!7F'Q^%[2CJ>].[E3/_TJQ/ZSI,O3OY,4FT<W*#_
M1)-4#$MGB$O@TN:QV]4VN)##NPK17Q+-+YWF/2EZ/+Z/1(;W<8 $@XYV\.8_
M78XPW="UGQ.X_EQ1:XDGGKH3M@Q&W@>-]1%CNVBQXX\''?B]D!L? TSYH9B#
M75P8&$09C),'J8842HIMPK@<T4Q;U&7))#0 #&4NJ#E:N7$OG0<G[#B<PH\O
MWYSCHG$]%(U@$JP7E21M>K=+VV)CX$V79\BEM>Z>Y9:J4TP#8O!8?!X=1-2)
M-)7;QDAHV>UL-Z3P)GEQ5#]7Y+KL:5#117B"0222<D(=)_8P/4D%=F.1')H3
MP\4H_5.0[[AIBLW&N<*KSBT=\IR^M 9RJ>_JFGMCL<(4<"6[SZ/OGI\]Y@2'
M]!EMZL1F-..A<J.=2%]0<1CT)<65HO[0(>-W;XM',YR/'[:TDU^YM+&+4LR>
M?NO[ 7SYPSTUI @[;O:A5[MTANNF93N)JVZ8.<E[MDGH+Y3S(3?TD-0G,M^2
M$_0R(+[M-CI.!BH+:R%^QC7VR"F^X(YCAH>J;D:BJAB#1V"_5H0W4QZ0'MF=
M25H>$H];%L6T*?(%E]UG'>2Y?=:C:,.^['NAT0V%0@U,Y>+'Y[;?[V'5;"/8
MI0@]2R8\)UZ@T#A."KD9 7BO*H(*O$22BQ ?F&A&4LA7IT6_M6^7&AROV7>P
M(=3JUFH0I!K4E8BA&&K]2_Y+5Q7@:IR1I0/+X=Q?]4MWI3(26 ;?G7UVD:X+
MZ@UW7Z95)5")\:=!=-9V,S*/14=^/53VB@!L84&9#&K5:"[24!M73MQZG@>?
M)DAV!*"^!HB9X.%$#?VF@)U90@"#=>.[:\$2?8B$5%N')\=\DJ9%!'CQB["N
MS.IR UX4R.!YEVRF4E^9/S=D:5-/J4DMOK3OQF353;NQ4>64_&M$^[TQK:R^
M[W"\?U4TAG<5B6 2UL]&UB&6,^!UDP$4/KXCSI=>0V@BXXR]],JFI^DC,JW3
MQQI6TR9,16;Y@*%#6%-K\4QL<II[&IYK+Y'M96HH*,<,NS7!FCT"U'^ G=JK
M:-?RGD:[WK S>U)U/LC957K679&%^J7R_[/W;LUM(\FV\#M^!<*[>X<4'Z0F
MJ7OW3$?(DFQKQK>QY.YO]LL)D 1%M$& &R E<Q[.;S^Y,K,*!1*4J+MD\<0^
MT[)$ G7)RLK+RI7N]<UP?*W-YV\HS,<AF^^92O%*C2P]]Q.)09N<8SRX-N\_
M;4(8[(LEK+<9?JY)B?*\/+/_R/HTL'?9\!N.PFLRR]#<\<P_Z?0SZ1W\>=RF
M>\G4,:[\X]WKD\_O5CW'&JP8.Z7%:+JQZ,NAHA :TKL8:#=S;ZMQ@$S2NS$M
MBI,W^$ &3C)SL2LJ(TOE]IR:O_6%5NA>7:T4TMM],0_$T<CHV$F6=JZ]X,^Q
M%Y@[;Y'V,#=TKTK@B:,[ 2FP H4$G%]C0WA5?M3%3-A_-2&^+7F7\?1M4N9"
M[@S5I68%'.ZP\RP!(IESWHPM6'QE:-X6_6 DQE:IF@#(13;71RDTJ9B+.V-O
M=:QP=YP(B8?Q+LR]*1_OATD/W^&9/Z.ZU>NHMS<:0F0]9DL\M #$4WMHQ@D-
MA#PDS$<I[2E=]HHUJ?*_BQJ8$Y<PE3S,!Q=( 8AI',)D=WJOGJ/O[;KWI^Z^
M$?OJ89VB>1$':J85R^WC'G77])QB.>FS_I?I8U8>NA/_8W@. *(J8YN4!2HD
M?^RV20\669'R%Q/J.YTN*SPT9LB1T:^<3J$/TIG^<4,^3T$EG"B&4SW[PN&(
MZ6,+1J#RXJ8G3!0#33#WE*_@+QGN6MO*63+/:+1:=?2-1<2&>\:]&/M0^L?'
MQ]-&A+F; ]N_@LQ=K_3 '4"J:C!XZ)T2$86WFZ:*+D"S+-2---I65D"ZC5$U
M\,6)=]37%2-C-GT]\6B^Z_ZA#<W3%.Q*NI:?)(S.XY&A1%%LYZ@H-2#?YI9=
MX;5E[WPO?0S]?<>"67G]?A^E,C*.#[BBPWSB'9>$5@HU*TJ5\UE[+JU\.#[\
M\ID<"/ZO,H04)>9'8'RS<34[--EF"6O0! P2*7891#UK<PQT<!92JIT80=S2
M >!(6+!GF+@0Q7>K*8RTU1@R^W6&#%E!DK(PK#D!V]26E"H\2S.IQ^02#+%V
M2L*+(G.1U+VQ\AQ7B(?+)!GNEC'_33;O_7Y-]; G0Q*9AI-?86.5M3MGO#:@
M<PXDG9:-O-.2V=70ZTS)6#9.NMS$!<\"7O!,K[V0FV>4>!>Q"G%,I$?F6#M\
M\:YV_G<<"ZWK#^K[/;;:/W458<U!\UU2200PAJ!#FM.U695D]!TF.5NUO+=5
M9!/)]D56HW-G(J6"R'7+%CB*,M5Q%U$;<1]W-W_F,GPD'/8:/[LA!NLJF6-?
M8X?9\,-X"#.T#W)*4//Q%-@9B$UB,BXXI%XFF)E/L8AFY\ QJ1(:IH WFK_M
M55&&PZ;;RK8:#7\@H>I-_G$UJ%96;_@CEHK0[X83N.%G&9<(20A<TI88//<8
M9(:>\%Q:.(OI+"N,6%."$VT66$#,H.*CIZ?2F1<>."L")H8P2G2(7Y*[##-X
MF&031=Z.>7Q>1%<,F=A2U\GY:O.]'AM4E7TN^BCIEPPR(@DQZP@TSB7/TM"0
M2NB@*W1;&1>LHO$A/CE$-\I0812YNMVP'?HD\9ZCF2Q(4*3>-KVRO-HN]!2J
MTQP$B!;C#G'EO+5E^U8;X_J+M$C!=<W)*Q&J1_#)<<=M]D%D<6>WG1'@G3+Z
MT.?H0PG:'7#T8>7@W?&'U:J\31P\)<LKC@T][EVSL=G8T3:2>+LG;V<TOT-J
MSRL:#I2W$1L]%E*Y<K^SH1+7T0WU15/H9?1!K:GJF"X$L,NT(_3RLLN$9T(M
MP_B<"V ^L]&U8>4"(\ &V&OAX:Z 1_:$?DA'X+J<5IM+/.(L'G%OB4=\HN&L
MT]HKACVK$J;'7JP:4JVM:A+MPIK?R/MW2P^R>MVHP:0N@O.'TK=DHX-+#@>X
MRLF*H77OEE0O-H^&83CTQ<9),#<C6'_/!95U6G[JN,((M+)_>JPT"1]PYQSP
MZ$;Q>(",NV%[?!/G ^XZS!=-FJF+[* O//4F:%7^@5 N+XMM4V'O:LEPD ?2
M90LH,M2$C$=DW(:DW=@CC[H6;L$N47O 3#G(9I9/['%EJ#Q1H]22(P@=@EL.
M#O+WG:RJF2]7.!124*VS:&Z4.<IJ@8K-A<IJZ%JH(ZT92+G$0W5;:W>_ILZ_
MS&D:,F8[1[/S:5=+Z,!]"^1?N6PTN[\B"9T;@T8=RFGLV@_F?0F&+8W50J>O
MGL?@RW;H&#YK-,C_O'EZZ#G10,UN"HG:'':R!Z?W>6+*L)3X$+P"'5Y+X6;3
M;F*D!3F1*#PPT M3)O%4EG/%Q&Y7IR,=EV_CRM>3KZNSP!P;V(.5C[20'J1H
MQI*OJ=!ACE,&R:99NL9Y^CA#'.?3Z4'IL= DYX:9U^F$?RU9F&SHR;,Q,UM/
M.1L\.SX\^/)9U>_7?_H?)/ T<>.@1JECD_^-#.4!UD*&HX_FM/U?J!%,E#A+
M_1G-CWHA .&H7/W/[,)=MF""]TA1.64;!MM%@>XYU<"=N <F^*BVOYG!FPSD
MP)+L]3[;]CVB5W$DU=-@'MYRH &Y&V.Z&];:-&!0?BD6W/&MN&Y8C+;I:5D^
MZYKY25 AC0JN<=J8AU6OS+L@HP[WB8K'RNL8H!&1)/CU6!?SMS=)EH?%*,OU
MSU*I9A(6*U4Q)(D."Q1"*L0%2K\_2<+O0CO 6&\S]X#7U?V$IC'%?9>@9FZ(
MZSC @>C &BTQ\^C";\S2'],]N59]I$6B%RY@HNMQBKD$+I6@)?[#(@SX+M4!
M61&,A17N2I>O4CQ[]KVC&E+-=60'O1+$XV+GBXIH2P\)L9F8%[VD?T<7R5&?
M8R\@:#1ET$I8*:@)Q'TE:S&(.R+ IDLDQ(Z3V6NH=TY(1@-O;H-D-U>J0%/%
M#;&>,^^6L 83CK'.98:,-7)IM)]!#:&GIM7/QJ/ =#'WU'[CN8=GIN0PSN4!
MG.@P7!5QM>?)TW=9IEK/L?AVHXYVS/U5VIG$:?3J]Z.0?J!%M-?+B<9=2-2,
MN-B.:'<_S"=UCF'L&RV/TB&Z\<J$')L?-H//]WS2R4A0^"#2[[)^! 3(B&1^
MY>/^R;M5Z1K#.0U 8/ZKT=S<V]A0RDOFST#!2W>(*U<K9R*IQT*ORC/%>B/L
MCJVR%%3\E@Z(Y>D#VLIRY=V;-X'_\VH@#.E<N2N$5U^.N<@GBK[YK4U)ER'N
M;*+-=NZVUD:BK*;:YC60=S.?]DR)$3<\A_GEU/-7^&@Q2D511BESC]$H,!H3
M,:0#CW!M-N16S*8@1U'NM)21RJ<=J$G*^EAC;SK,&#%MJL(M'21N<U?6O;6Y
MQFM1LAWK%ZVWI]:.0<[9YK?'11Y&26 M*<[YQ>EYEB"AU]S80 7\L)BL<8HO
MY>%9KHF2DFQBYSB;TS!S#&:5IH!)IC3EQ/4\^@BU=_D*2/TD'F;0L$78 7<4
M$G@K[S\K79)H3:?#1PF:,7JREI<CJ% "A\S_#_)HP<FX7*VE"(!T(\(E2&_'
MMRSY!HN9K)COK)BYHYJV8MU HW'T!.+*ZM^B00/84^?*AX*WB.P 4$B:G2%S
MGO &X]BA2(YF'.>F]\J5.W/)//TY\U3(KBZF* XC;QZWBYE7WA9HOE6Z'&59
M;XW^CVO0E+HXG-_/=AV*D$:P__Z4EX[SQ<YHDXDA%.;7>S6O=W._^R>GDM6;
MC+)O'!1)UYJ[_LK!/^D_J\X:8:R#:!2V616J#$8#H).D4Q5=/+D0%O.FE^H6
M9PYDYMRV(9]=0,<@P6_7'-+K!/X<DQ2%@X&SD<Q]A2R2[!RS(2^P?QXS<>/U
M\TY.4([&XJN@24F$F7T58(YR>#Q1&6-/$5B!WU:":Q8(HT&[<4&++\-B1\)J
MM#;Y%CTF[I/7<B6NE"2.G"(DLQ)31TL.$^)P'!T>@?&(>ZYV8@05F74P*]%L
M=4@VS[T?JEAS<PW*6PZQZ*7*9M?)\B0%9CNJM947RA%33.CRU)H%L#]D>1M.
MFV5@Q[,\!2%T;3,?X^XSE8<^TGK/"HZE+P&"&F@E6L[ D/(^UZR6*$/'\F3J
M[?#!0.9/V+]!@MXE(30\6)J9"YRL/2_QV U7?S2AX9)WA<1)W/? \7G*K'A%
M.=#4Z+(J8VY3]WR<>E5Q-WQPUB1SC+&3_7>KSK4^8Y5M;>]LB92T+G\G#;9+
MYSL'+DK?[BD#EVL-TB$=3?1<&N0P681OWA]>.HR=QO;V#QI@G2=@V7"MSNR+
M/-HRC<#P^A[FZ_Y^/D[]DS"="$GB'S%>2I?, ;O%%U($X,3YU)YF"_5S'J>=
M>,C2:!#YI!#46E0V_<P62NP&L!CWI#VFL=0SCHS#P63%RRQ4MN1]*CHT!Y[O
M%I9SR! V'1G7\#[-E5=,6>*AY[ 7+"SSG$GBKR=)^2UAOV?-;1X/C$86=U'F
M7Q)0;NU,O8FV0P0]5. !ER0P5)K'7A7U#T>0]*(#($&%0J+57&OMRJI'J0;?
MK&DV==IX!OBD.UPOBEE=VX7,<FNZ8$CT]&XXH2-O?OGQ[UQM:S[>$@3-+_0A
M^E-SU_D3<S38/_G-O=5U_R.S*PTC/:\ -.%'KXB$L3+L<FC-E] # VTJ_@=W
MU2Q!/ATI59[^-ANOK*:.5N4!EF-"R3_Y(N0@*AN/<O%[Y3K1.^C+TUDQKOHM
M\U3R<;8]VA.G,H>3B/5NGDN8,?%7L'H&B;2+'V6XWH6P=B32&Y?M,'![X'_V
MA'S1J>W60O B_JZ5X ")95T+Y,3M##@\B33Z6H@98!Z75CU-9V$]72H9*IK4
M#XM9B[!J@L1B*F"!U!B8D7JVV2Q-L]JBUGL@N9XU%STYR0& -'2>N$XEUW8Q
MJ>T10IXIG1(]))5E+M$U@1X" <]@ )>::Q4'O=Y<HQF]L!NFKG@$!=2>H>@(
M.R9S6D88["T_:P%\A$UC].T;ONC?L_;3/(WC3I8\='+[)%'U]CG,O0\QW7$#
M_X^LO/K\HP%(/)V+K"QX^V HWZ5;B2,T)DI2A<9+T[U6RZ1UZ7"/M3Y%7>G-
M1ID^]AP95'R[ZQQ;OK\I'5>4<5FY<DM>'TW6L;DM(2U6@'!05S[KM:KC!Q4/
M @ZV?$^#N:3PC*-C C5SB&&>F+V^"+9I:XEMFL$V;326V*;'))RQ95%;K3T<
MKU.^.+[8[FYN:[>R&I;,EX/#X]7['-E3N4Y<CMDJ]&:&+I2,$@3NILI5LWP(
MO+)$@3@)IR4BGPZG:H)-=(.V@DPT!WY/9L<(UM98_!=CYJ'VGY..<9=,JJBH
M-N$+O#+H34.1AGUNH4M:AETD%:^5R3:5K2_75#E&9VQ^PVA&4G"PJL1JED(:
MM4I2L%GV=0=@'SY?"&N+C2/A\NT:*PV$9%P\@@)M1>$K'J' R-F:HA6K+*&S
M8)5R!6<., =?E@U4R03B?6N]<! GDU^O>B-_MHC_$\D 6?P]5_S)EJ$UC8L^
M!UM-/>E^]QQM%R?LF0,J%TU5W-73#W'9.'O,YJE P$]7P[M;['%DU&T[62/\
MVH!R6E.MTW"YFL$REW_.LQX=7\!1HB@-_8-^-LS#P/F]:X']&4[0<!J4ZMZE
MMEK@'T;(I8S\#RC99=[R\I'R$DZ3I_YLI9Q_-(QALG(VNM#&=F'9&]X6_\6I
M1[-RG_P9/2#?1&.FO.^"F*B(V1@K,[VU,PO\?Z-BXG+[4UF)]=LG83]._'^2
M4DO#P*M?+\T!?@@GF0[  B)51@:Z']93 G7XD.8[MKS]7.V6^C13R4S(SL/!
MX4LJE (+/^4Z%<\ESN>%*S4>KQ5>?XG,SNCW.#=";(AXZHM"'=8S[4;BE96L
MU?I5]>\ O"HG<QDG4SU%1& +2/FEXU@:EM=QI3'C%G/ZFZ?1?C'DDRL]J\08
M"EPN8PBO,X!$ 2LC'QT<, +1TAI"A0D\MQ;;"P(E7I,MC;A"RI=*39/;'QPE
M@1ECFNN8>VD"XE<@<F.(SMHPD]XV@;3.71.8'S>^*,AAC-9@5G#/'\D^CP=R
MVY]%:23UM]I:S\0V84E #Q6<\G*X@=1JX0@BK47<'9-''WB(UR"CR.Z]02=P
M29,^D3S@3L8+4O*]Z8ECE)6)SG4 N@Q,[Y"I[999VV(LOE$8!2:<A6C2,9T,
ME",=:SF587-BJ)\&JAA0<%EG#F@DI[*<U6#!A66JD,B_T3@A#V2<GW'"V;YH
MC<ZS7@)E]A]?",O4/X]"H5O2(2:JP,]X?_#"?E8,08TAU;G2XM4LB/LL#),$
M1 FQ2I@^=,;WF&Q,8,E:>TQJJ\'"ZE#2,03#P&809S<4LO)H& S\G*[/U!JF
M('!SJ\$/+3DQ//.P0!NG(&PRH6,C'^0M%WT+]A5C6G0B*7.;U\2$,9'6H(ZT
M8'%J?EL_:Z<1+GDS*86._8;,)O W&^:#X<PP>%N4D%BF"'Y;"9RBFM 6W)KJ
M4N[>S2Z",Q,L&@X&MVWA>]9DYV%B(VA4[JTA_.(6(850T30Y5^8L^M>3GYKK
M3;^MG8#CU/3U[/"]EG';0EWXRM:>RN)%G/7.M 7#FA4GW5T(8<@P1 5%D 0-
MI(-R>3&!G_,LC87D$AMCOTPGFMNBF'[/^ 84G9UC(261GED'#)&_G2)33FL6
ME)P]]6/AAM47,?,AVTY:^'<Q1'MPQ3:;59X]_@'7GC(P $:7)]6JSHNTO2MV
M^A(M[.:PM:<W34._ZV02"NY[(VS.\E>'+"?PW^2 UP?>VRA'"^7 /Z9%HO^<
MH%>1Q9AC3O\(A[A?$$:/&$V \4H@\Z?MC;(W-"THB<TV(XD3UB4D,#M68-I<
M(+,-=)'3V2@46!)=MWIJ#1*5Z[5IO$VZF'Y^89[<_,VG.\\3U6R;-%52;_;F
M1(USW(O61.U'J08 +(S&&K<@_+,MI.JNQOK1>)6KL>#+V-S#O7$RD ZB0":/
M8B1)HK.07R6NWSDW#*)+P+<8:@,1*#41M-PHPVDOY&:>OIB1#5(EHH])1\BZ
ML-+G2NH"NC'3H'@_S-N9PY9B[D::_<A@F.3V T3%/%DQ\U.J<MW_.L14-QH_
M2Z<1*.:+?J;E[4-N:07-01-#-9YFOPRVT]RITKZ>%&@^F1V7I7;-+I"*19E
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MCB^Q6K 59 V0A@W4G?Z.ZBI+]:P'U88N*I?N*>/N7P=(7 O AC/8UJ;Z0C;
MV]//[&)J!9+IL2(6#ZMW#Y>:PC]$ZDOC#.%)NK0Z85?[E$3?26KRMG#:Q44Q
M1G9C0/HJ<#J/LL%41.-NA@ KV81LP8GYM>[SDM#E9=%FN%T])R$DB7?T3)7
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MSM&?]DN25\F(%I%)-7C2'7=LF&3H*)R@@(,[HOE?F&BN\%?>C4>C+/51RYJ
ML/)<B$@L@J.DPC>Y8JGEJ..'&0^F2@8U/>LQ&)KSN2[&AF1!>MV=1\4J+<;!
M,8:UCJK6'?2I\YO;O^ZL-%=_W=C>WGHZX,C=919R-@NYL<Q"/DEZ%67=_N7X
M.)PFKE%>4\;-S3"O\/$U4.EG1L%R'0VZ7W8$ 6JN7*Z2EUT)L\$2@N)HPX@!
M)H@RO1LK.E[:F4SW9H%"4_X#MW6)(?77AVMCTGK6Z\ 3*F EO5,.[+)9FKN=
MHXQ4-B!5RD4]56>T<O*)V>1FP8ZS9+U *CZZA?^@4%C3W*:Y)W3EW-_!=$I
MP1+3/'&3<5I4 ^U$?GUL84EF(Z9.7-WJ!FQPGIDZL9PT8$<ZC6N?4=IEOJF!
MJ!(8GF?)"W'_UXAL[0&OOKF&:&E*O*?$MR+QD%9/1=TVD1CKH^G2)TL>K+.8
MA8 8M)F:DI.79^ 3D&%[AC]WNU&.LL3 .MT1;<&P)>EVF\\SD,QTXD 1(.A\
MC5&$ [KN_QFY'S!M+W1=G?.CU&?N@;5%O*'I+MNCH\C[!*E MP&>_IO#_<#
M:<V#0Z[@*@G&P EFJMP8!]<!#1N+%3\C3H<HE@,,EAXG^\QR4:%B-'QB4!C?
MAPG=G%Y?J87,0Z5/C-/KIQNA7@<V'MIVE+39MA5*[J+?2^1@J,PFXW1 IN)
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M_))2FK+QIS GTA#^[W;C9P2<+[A)NWJ.>3'R-_S_)5MYI)WN,09[A.D?37=
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MX=-:*X^XWL$L)[+0&^<<G]3A"!)218PCE-VL@(I!=.9ILYMO+@,DLP&2O66
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M/.#SM4.?\::@!KTXJ;:M8P]W5+;P%I43%Q8\>Q:ETK--AF+2/E&*2FX#6:C
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M0#%)541CRP9QAQYP'N<9I_$Q"@GH,& #3YZHD145W@J_<_LWX9^5&Q/6F;Y
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M1?OT?[<;/Y.MGEV,^@9*W(OS8N1O@$8^IY5E]+Z%VN\/\S@!;B6/UA@=C)T
M;*?$M](4:7J#C%9Z[FHR3#D>%7X1%X"-Z7H$: ,RHK6<S'XE,("SF)R+\4@K
M#,YHGR$$M#()34$Q9P^%5W\:QQ$- NK==T]A40[,JROM UQTW10.61W.2O6%
M<TCE5&;GB!HD]KLH(*E6CH3V;S2*>>&%*CJ=3J<*4$3SC@&IR>> Z9=(YM^Q
M#;#UAE:+, 3-DQH2W7G4Y- 1XT,L+GFIM&FW1^89!NF72&4(;8'1N^O^6_E>
MF%<$*=3WF3==]*.T?)X7XT5A03JYC:*B0DI<1OUP!#P@P_H@8/0W?C.^2&.5
M.AX6I;#35V&(Y;#+LS$W_G8[LC-9]PVXJ$05F4H63_1\.5% $9UIT*TDCC+4
M'VZ48A0"S3PD@R$D[;(4-'7/5^@HQMUQF*SJC@>>W(5Q(5<P:6+SE^F+GQVA
MJ>X= 9J1T)AB$@&]&<.T4M?2"0LY]_Q#]+_C^)SNM73TY/9DD4J"K64EP4PE
M 7D<RTJ"1S;Q2\#M=-])/GK5YFQ+8.T26#L5,5H":Y? VB6P=@FL70)KEV#3
MY5P?&EA[]U#))2YRB8M\^KC(:^<N9]V;YY^MNEY']KGIJF>]!-L[P<;.HD2<
M/^02M)JHB;^;G.7]<65>02EW\^;P#\3[=Z\T?U>R^MVH&?DM*/E?R*+NM!I!
M8^M:/<F7BWK%HC;V@NV=>UO2'QY:<>?-W@-!+ 17M'L/'K+?^T58^.T\"[O)
MA%D'\9JH*Y'++)7_ZO24[LRFF4=932-X3QK$[U9_C]3E/GCZD&6V7"F,C(AZ
MO2P?,3#D(_W0]_?)IZ'KKB1'8:(2CCW3&\T8_8C<H6P01YQ.Q6LBAF-$[8F9
MCV<^BVW#"^>NPCU@%!XI=?"#-:5?Y@>6^8%E?F"9'UCF!Y;Y@><?1U[.]<><
MZ[4/P$S_W'NZS9_?@Q\OU7*;QK,/&^+?")H[C:"QL_M\LQ1;06-C)]AM/.-$
MRTH3#-'!3NMZVW#-&._5:99K=%Z\K^K6>9W_'JO:-FAL;@9;LQOS6./9V R:
M6S-=M9Y!E>'U>@0^NWS-]5K'_;"E=KO;F\'VYHLOO-P.]AJ+MKZ[KQSZ;=)S
M5[>K>QEICQLU/UOFDBY?5#H<F_3_9VW.Y:+>?%%7D/;<#OX?>U_ZW#:2Y/L=
M?P6BMWN?_0)FDY2HHSW3$6K)[M:,97LMS_;.^[(!$D418Q#@XI#,_>M?7E4H
M')1$FSHH86.CQY)P%+*R\LY?[NUME%7OK_/Y,23I-CT.KM: :8S\VS5(VRV8
MK0/A:C.\W+N8X37P=G9W&EU>L&+=1>K092]&.SO>X6#XLI;!,PU^V&1V$9OQ
M5'IXUWE/YG?A=6>I^RF<S' FP=_\I?N;2F%S6QI;J6'Y1$W*(5J>TQB =2UA
M&J_GJ1B4."S[6_$Q1_5!6BW/U1ON6.V'53(\ML:V#:QAW8Y6'EV&VUS=*)S>
M<-UXM]MP2!C(T L:;8)["/\_R0L\GE&43*I,(6EM]56EDS!3G$YWY!CHE<"9
M._JQWQOUL:>>[WN"F_B8AJ6Q8WL[T;CY*6DQT.J&^6CN(EPH&<K5$$G=[+3-
MS$ZK<07Y43?Q!+:L7RGK5JS/8*@*Q@Z1LA '@28T= 4//%)?06W37D;^138+
M%ZPHYR5TQ6/;V=OT).]U/<G-GN1!UY/\V(WO^YI<UK#+]X>'WG P(@"CG?UR
M<-FNMS?:\W:'@\K@,A9 U;%F#Z$,'H?<-X/+KIM;UHTMZ\:6/7([F*H>3^.I
M(.4@#<X9Z ;K<.^J_A'>J3_H+EZP#F'/_!B4#%FZ8[!SP?!%<TSHX>@CPPAI
M<V#*%+DQ!#-ZDF-U+Q?%5JWJ9*$8T#S#XV3&3I>(0!(?\'.ZW;H<08GP=9,"
M>#W.HV5E)+?L"RVO8)Z^S^+4C6S[<8F*!.K#('=O(:.MPV1_*MI:E(\I2B:4
M;81U3\(H\J\P(%6.P 3?'#AF 5N=H*@5Z;@*/,R=^A.0K3D6<N-;R/6G8(RG
MG;YY$E\QI!P&=S31R:M,R;3SG"M>(D?(,.A&*(!L+"P2?/Q$XGY2-CZQ$:[L
MO41O1[FG((3=G=Y)S\5S,>R__KM:NB!HDG3.HH:.R^"U^RG,OKAO?0K+T:6#
MU^2RH"K,)FFXT&&,*5_#!V="HEP?2+/>VH&ZD_-Q T_1?WPW#/[Z@__?_<$^
M#FGV?]WDVW_KN97)0A33O@1MYN,SLSG0X]7$7V0__/HN_)\"U'B^I!#!L;\(
M,<'U265 I@GZIC)O:.L.W[I2_D\QM^!<%61&3(HYVA@8X;8,D!B,+ IF$T87
M F)F;!1;,CH+T8%"/L-_,'<"^P\.#W?9B*'@LBZ2YB'G9.W!GR;R6EB O)6#
MK2/O<&?H'1P<W)F1\1CC:J<QD F.+L6R[?B40UAZ"LF$EB,*RJLTS,$6=!?%
M. +1DZ!91TTI4W=GY] ;[/3=HY/SC!N&ZA=1K!,O_<?YC[N]/D<WX7)RG2ZH
M)W.1)A.P"3.\9.#M@/\S&O:=%W G>E<)R"(,B^##S'+PAP#\'\P<4*YA/@\)
M!](VR!'0<TX;;E:CHSXO*:)_YK<0P+4)X-Q$@%&_3['ZC1%@B(^C1QH".'=&
M #HI0(%]LL2II6AO8'\0/.I//R741C2#%B"Z9A@%W>\/*$5#5[U LPD.9%0$
ME,4!6NZ,O/[^"*3= C5GG-/)-D::?N1+B9R'<4B.1IUT$FO]1^^<@[#^Q06Z
M8CGZ$+E-82$?.FB9)U[X341C/,"2;AXUD\$.C+R]_1VD0<\]"EC)HI;S!/SW
ME0;]'1R0YK;8A6:2#_: - <CW/=+=-D6D3]A&U<:T2(XL_!1YRXZ:F%>2,@P
MC,'\S=FH@!7S%^._,O8!LV(!YHNQ3VGY[ ,Z"-I+)@)0XB+UY_ MYNH$4VL%
MK$Z'(<L8:&GT7"7I%R3.A+54ST6C"6Y$0RA7K/7A4P5KDY](>)HHTD6<.CH6
M@C9-IA1YI;Q >AYR'D(;X[,X?&J>9*PKW4VG<WBVI04G2**LU)T(;F,0!K Z
M^-@9&$ZN;_;*R7*P2#R+)36!@"[D/(=@V7FE8L$_E*X"QXF-9P(7@>D?J\A0
M@!U8\SI--8H1%T+14FDYQA6?@[A)?4P Y;,T*2Z0&8![QF&9I41HRGQI6!N^
M+5#C7"^.?B%N-GQS\ J[.9?T4AW@YK]2-]I81CLA-^@\@P.<'"(J*=,83AM(
M [H73R1_\=9Y-HUG7A>IWN\BU<U(];"+5#]T"^PUB6Q24JP9N 8C4]B^_2_%
M8$H@D5*4&Q49".*6L.PC+1T\M$XBY6>YB]46),W0Z=2=R6TA1F.)LR&N$?D3
M,!I UL]ALYVJ5"85K%4/AV>T^K$<0_=T"BN%)>/KM/ *.=CC7_IAA&ORM,0D
M=&;ZO("-P<A?>M(RC>7#L!1'1>$<I:C2K>:@819$'EE?-2SDYQBE)&HF8[J<
M]:P6RT4\]2]!>B)I;,'(&ERWT%.\%L4MN\4.+A8.P(1ZZN'1*:9N8>% 0ZJ8
MHE_J]<FZ<C69Q4F47%"LUU 1GER&7UE?TR\M]SN<+Q(L&(&5)/ ^H[X<O2H7
M8\Q ;"O(%F9Z0XCB>=F^7E+"8B$F2I88_8^QY+E2XNF#K7:A8V>@2S+@8_JR
MNXT /)9#J0^#?>1(>>,& )6I:A89B!0X[YE5+E+>%811H9'2*?R/E1\S,,6!
ML4SM =E\[$;@8L9@;L8*/(>KVG/I99E*+ZG I+9#]47(3HGE8&P,N.Y2Q52W
MQ1NO;Z,Q&/4H#YIVR!<:3R).&**=H,_I7)0/UFCKYI!K"Y]+P,@H).,J(?0&
M8F!TW,'3UV(*[?MP2IY6%)$D$3E6Q/J23$T*DH4B82S#4 N;4K30@0T8FN$+
M2AIR&B2LEE$I!\I.E*9Q67[%*R-I@-(N"F&O/+"F,.)#KZ0D"29W8"%P3K.0
M)!J0^6>05G!2\,'XE;!2.#01.@DQIH.T 0^N1[R4Q".<<E_6U(B\ :_,:4?&
M!9AQP!%/]LP!FP5)+4"/826'7';8M[ 2C(7=(\?KR=+CJ!GJ0I7I8*R+]#9%
MMX;@A^_N>\.# ?I<]AR.\IH=;SCJ>[M[!RWA,ZE^DBP+ _1CC$/R<G1N4"%(
M,K*T5#)'CK9V5S6#NI/E).*R/#A-I(10:&4TK"8.S/ 'T*4T%:0 [_$MG!(X
M2FAP>#+?P:Q'GWHZ.?C\D 93K*C.TN>+@B_&(,)'QD!DL$G!JHGSF0A>.)-8
MT9<JLF<P'T7IVP7\@LB(V2272@)X$DD:@T62A7AZ)Q-P"^ /T=*C>L/JHX)$
ML;G#+BK**-QM-C+LZ25<:C:A&2GCD.!Y2))'.%\"S#3C..)%:4##-#!M+0+5
M<\4GEY^=]IO!)1SK@T,B?TY0.6.D"LY7P6QN9A*X,OV"CJ+VX&G24(42#<:I
M_9WG]IABX&0!'CHR%+Z>=8@B@R4*OR@XZD +,@3]B'+UM'VQ?):+LXG(.+*U
M"6ZOC)6@!QD*A9PY/ :!BOX9QL><\QS^1X<9WII0P$?-YRV!Y5Y="CPI\5(+
MV) MSR?90<GA-29I&.5N^0]V0$0'2<269U:OG$)S^,P,,-BVK"!#@K2JKL,Q
MIFZF=PU.',)=B1326K[R*EI>H%CQ8A L7NJLEA4I\D!.Y<3:Z%%P8? OCQ:%
MZ/9OMT")KH<: G=]9>MY/7^QND_95%@U4F53?QY&RU]N6B]=F\%1Y\_#=Q[N
M[1^^-EFS&WI<2URIC:T 62]'-_-"C&F>A42K(!=83#@3C,W11F,>;P]<5KZF
MK>.EX[:.VV[@-K!%#,-E.<@PU7%<QW'?RG%Q00U.Q''@6H)ZA(OA39.,&6_:
MPE,F.K0HTJQ0'8MU+'8=BR5%SH/=2NE&J] 2SLV4^L+6VP66:V )K[_ Z!(H
MTXZY.N9:M8)4ADU4)PEC1 *[[L!;P.4P:"N&;3F\UJXFQ0G&="T_K(T9.U[L
M>/%:ZXVCUUC)P)).K#=R/'6XK)JF-^EXTSU-]^F$3B45I;4N<JG*D!7";-;Q
M9,>3U_&DCHRU,J7I66]/O&)^Q#-)2%W.PO*1:J,F6"5#B8IR$*_%T=,PHO\%
MZ8D9&KS.H]:2.%/&"E Q)61T)(Z7E=.JS#' $;$1]M467/&T4%@$PRG6[@!T
M!^"Z V"L3([A(T/2*I@Y.2NA^9/0\G,JM<,4WT1+:1N776[ 0?,:IOTZ]I3V
M@:F2@BUIUK)OH>64MRFN6)Y$?CC/7N/]'8=W''X-AU.FFD+ONNZ0%D%I=:K8
M?,4RF4IX_ G7#;%@->4GI!^LRI3>P_'<;4KZ#KJ2OF9)WTY7TO<HFS[7;-*H
M&U6L8:A<WFDIEV\IZ-?%]N[*^GTLIBF+\*LH-=*X,.A;G0N<VC5] 9194U\7
M*$BFZ"SC7 @KB:=S=SJ9Q[4MIFC?7&=>+'D^LW!3-A0$+,3:2M:?:IW'/Q:)
M%%)$229-)_#]SHJ>"=IWI+1:L?,[_7+C38&!W:61N2_PE](Y>$,'AS0-ONPY
MR!(W7$QU6K++7%M)_3+2#E/C.RS>HI)ZY+YA;R25*#>\PFE[!7 ;>#M<<\+<
MAC_AQX=S=EVN9DE$"A'+AOPT]S3@#O<S%.DKFG4B* \44^**-BR%I3^57$R]
MD-C;9N>L]?;<EO=OHN2S/A(KQ"*?!,<6A]C@A;MNM;K=<#R&W/V$-PUVO-'>
MZ#M/BE,_*8AP0+7)<%&TO!53?_.Y&?7Z?&R<;WG#W1T;YYICX][;L7&>P+'1
M@[..3<_LW8W.6H6B0PO0'WC/+Z<>N22"#R>V(]ZETMLI#6,C:)XTG%,!&_==
M4]U9(>V_W.  #*S\R4PS$;-KAL^1QXP5O.#QE@'=;A@9^<QKC/FH>*15/W<E
M[FUYV;=-21DT/NHFE%K[C6W#.H []=2R<ER96X[1&O^Z!G@MH];>:IQ; U#[
MKFG_;6N[:5#-K9^Z<J!5 Y_^.PBY'5_<.L+K*7]Q^UBP)W%8-C'LZ;OHN_%!
M4/?+B!W].OK=JP[]_ME:WQ;09?#Z]TJ:9@EAK]IBA]X-M5A<,W#IMN^^[:RH
M[_F6&Z=*?=O#]?" 71P!YNWO-F:6;&CYC3&0SY/,.]Y@=]_;N7;,5T?F[R;S
MP-L_//!&^PU+:+-DOKT4;#>/OENNO1#!]O)GBL$P9LWUXFTC7+#YK?^N_1["
M5C>FGCS<&K>)="\.FO-B-BJ GB31$!6L(<+O5:!\BUFU$9$C4/P:0^"9"9H]
M;_>@[PT.AIVT^1;Z#;S!:,\[''7D^T8]U]\[!.[;N2OR:?E3'?3U)(<-//2H
M@P\MKFC/P8S-29FTRZ]4=*ET'W8U6%Z.UV*PB?@VSFY]O,KASL#;'1SJ<0?&
M/>&A7L8IK&=);^58-P;\>#N[^#3S-F.E6^,3*"L@$Q8<:T'-2S081L'Y1O/Y
MB(@1129MQ/@ZNO^$T'(0"0)34 8#P\;/J7^:<_.G40O*5X+VC):P-3^U+':
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M4U6AFCCBHN=WP?+'OC@YYAPR4/D_8@(1)GAI6,*; H$]".U&#VJ"@Y^2T$C
M\*1W\O0022-<D%1V<>=5KB<"I/Y"%;!HG 6A<4FL:5?'_GRQC)(QP3?"2S^_
M.09RSL(+!=_ !QPL-WAM$"8(&.J<QE-NIF2G+*L@4UW69J  &Y%.U3/!DO0+
MD^,*'O]*TG;PS5_4TJ!Z1\K'<18\<XJ?F]!7\P@%M,RGX<1!Q.DT#SG/E(&M
MK0S(BL\YCWD2P%LD) ::4EWRG F68VC%ASB_.K4HX]%+T$#E.1K<MLM8Y'Z
MR12:CJ5M7#/NRZ$P&VEMC?B"Z!GP).RU9& 8W+Y,1=>/B)51/6[Y=6C1)9P5
MI.EJ2/$5G+;YH92/1+$BS+]/C$%A4BPL H'NA &/9R,D>S<K0NZ$PQX]@W,;
MV$(.6-# GZ$+*<3.E3^OT1F3M'$2OS+/83#\YD,=F0!7(#XX1XRM%!'&Z? .
MG A(_(^P^/JUK-[H5=Q[R+\N;P>QX)/JQ%>$$2P]B;49'U_@O7I%CN&()+T
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M_VPMC.TQ/5/V@NB9+.01?!HB/AE^;#UKFDP*,L6)X,C98N2B+4E;-:7)D_2
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M7T<G"LS@(;I>A+7%6,S(_(YA)^/!P8_JJ\A>\V1:AGYJQ\<='Z_D8VT1$_N
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M;6!,E0V,):$K-?2A.24&I6X=]+V,H6!9A:HZHEHZ<:_FVU9E5GYW/E],-T.
M>D7IUZ&:*]B[?K/R9%!=>0W)(E/-?*L,^;^Y2\B-C?8\\9%#M4/ZLM#5T')L
M>F&4YL[)VJ<[X2K4&G7%:N+W67G,;WY"2^'KJR6^?AI??USBZ]_$?LI51[6Y
M"2EK2P'>9^PXEFKC2/FJ!>Y#LA8IVY-01XY>XXBGDKSN>H:MY\CD.V)> _!G
M^--8@-JOCD;*R5/-;49R7Z2]^@E^8GEV0*1;3]#R"[CTO""Q,YFJ3542(=)Q
MS/+PHSWC[XXG;^WJ&UCSF1RP%M"$X28G =19-'A;$/6)CM2BF%8ZH2K;J)XM
M:R2![4$6*JNZ,.W0A_$=4L!@JOA3?+T\$@L\(7$[,=#)@4KL7WH/1RN].]-D
MT]#91B"&8"?VD^Y75]<QS<EF?#J.S,WWN%?M*-80(X%W4!#Q6>YZ#$$_@""?
MEN<'QCVD^E$D)I*71)F+1)=4W":)1WXX,H!"36]I"?0F_*'\/B7\9@1#R?L
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MMH>4!([ 7JF;6^*YFI\FT%SVPP-$M2(68QX@,R2BLZ)Y"4%GD!LL?A,5',A
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M.XD<5_>5Y&F82)"^(65/8?-.E\;F=:'$J9@ /8 2X*5E;S&SXA?/#-3[$]]
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M((ZB1Q@+?5M&1PB"G4P;41UER*C]N:TCM]3',/,DD4?2S90H[JFA \)9#-_
M<XF(H"&G18LQ%7751@X-T&&X4SG;4(Q4+5;7H2''\Z</X*$ICSZ-L)4ZX\:$
MNWR""<K712NB38N8)@>QDDV/W\[,.XLLGI%,!(E*AR"#7R->Q<SQ\!.?!4@!
M&+ !DH#XBFR.?^G0CKA?3_-2LJ:B4SYT0ZD6O25&[ <,\?AOJ/!T]R9TR;7,
MB)R8X\)*NX6@(-C73/4S(TI7_M^ .</N&-J,<8OXT8^CJD_,&[/88*"&"*6'
M3#'\7E-<I)=XMH%X294Q,!G(BOU0*.\0<1HKH;(Q9U'/#Z/4][F=#(G> FLL
M^![G6\<)'Q6#/=).,T^FK45=!+SJ(;"'V-V,&RQ@-Y!]M?EUUI%7X>QP4:80
M86-U _\GSKC/;)<%&B)3S%%.,8!J)K&=-4;/Z9@T)>9M:N3,[,!3E_6X.$8U
M!W_#?#>[5%UX(W?:=[N/E4<_0EE*=C$=T-W]E2Q>D>&EB(Q!_EIK96C$K0R?
MZ7";5YC'W:#(!TH2(IIN6M732LJ>I0H%^:,KLC_[5[)P_%D,S=M!Z^OW#T7K
MV)GKWGE:WCNG[YWU\MZYLN69=>],T@<<5[+I U8Z#X0*3"M EMYLTC;>M&[O
MC4[GS5G[U%I6EZ:"*"8+!+6_K$/[R\O6CV_W=Y9YT?EGYZ)]=6&V;F_;K=O6
M5VB[SG^\:'_K7/WC1_OJ_.WVO=R]>>UO7\2EN%N.:WNU81M'YO?6??NVT_IF
M?K^^Z%QVSEO0N?;.O+\V[_]HF[>=KW_<WVF-;/\R_[C^=M&^I;W\XZX-?[NY
MO3YOMR_*W;PK\RIW,^WF^E[MYN:1>7Y]=7][_8UV)V[+BQ^W;_:83:UV8Y]X
MMZ#'=,S\<LX_$?@N!0EO5/>V@JS[-A)JR][Q_V2J$Y^I4>;TA. P0*6UO5-1
MRCX+^=,IY\ \_ [U(4MTJ?GWV GH,UTF'T^X.T#E4I=//;2:Z*KCA*)9(.M;
M!HXA#"$8K"B@^@+]"T\17$,"T8<A[A$7C=\/3:#"5QP]@HM(L7T&2.","$(^
M[M"*(ZRBJV$\'6A/VNN-AZ)3D&!D'HX][-S8E[Q1?'7X=9GBPG&!+_SE_-%A
M SY'Z(H&!.;7@X'3$QCF^.^7#D2GH2N%^#LR/O%C*?!' <2%+<@$V= U-B9K
M[PF:Z+@QD!)^O*KAD8D $7U3Q&MKF9[/!Q\!0/J1/_N9N6Z\S#A&+E&8J64"
MH90(75-WQX#9H4^-#^R0OTO&U^T>G]-3C"D)<4AB!*:/7$I<%'QDURG1$44^
M>[+=L0CX9]'](U&7FJ Q8VI(&$NQ=/E OI[0&\^"L< :,;'J<SZ9?-<L,7*Y
M\8&H@18MA/<*8TBN+.@';F1CYH)BUMN#QJ]23Z 3P4#M"]KQ#C4%Y=^!6*T9
MQVKYYG*=_Y4JTPL<_C3'!N7C_^Z2&>B(5QCBA#B$7SQ0D^++P!ZR9PCL'M0J
MU?H'28 M2O/.(;_"=PGJ]]V([SH?T_K7P8/M.?]K)]I_W?.-T7^V)_0MS,J8
M!^?7=]>%B^UF^P;->4&US0SP'36B-[\K%9'&V;C%A09LJEPO>:*32L2F\E:J
M!!WM193L]H0W+3E0-^P-WH>35*0"WY1@9HSA8LQD]F6(: LI)\/N"7",_9-Y
MVE[G3N+$TNT7@*93AP8]#LV,R^V__1.M&71[B,CQF+93%7P.%E4SZ/7LD4^!
MG=@3]@QZ$?'3$'L@$Z\?$%IRIR**+9%%K2W 7#H>S7#H>\ X2]EQ.LG8S(XY
M(63Q$6;DFD(.!B7+?P)I88 I:_+,0J*?A$_K/HF^?:V8]1%V:8B=,B439WK@
MC_BX)S\BMP"[-:,;P<?)=[2!N /11S++W*\D>TE]R3U,ADTY>KB2U+T9#PVU
M?:0X^-F.0!]^_O/WX)O[C'O-0'*)S*0%M><O.8;?G<]3=H=X_HHHF:7H(?./
M4R.27($#4M(8-D:_XI%G *&USV7=@S<8-SH[/CE;%I.]U2&UA353H/8P L@,
MWYPN>V*N3LO:BYTQ\AX12V,'U/"'NN-ZS+7(T"D#Y_43II2P@GAY#&QJ)?L,
M'5V%&<1Q:*8PJTH@@1S?LC\P)6B]/B-7?*CH.V-.?+/<*HEL<@#:;NMUT0+)
M"DI,.&4$F,)60*P*'7R_](]1-RDMSH.?<7 W41]T[GIHO=.UKV(?8COHAPOW
MQ&MNB@6Q\7(WO.YNR,*OP$+G%?6[SS\@O@A^O6D#6M5ASSB4O/\#G=S@UFEC
MB0#?+J[=8W/V X+FY^\'BC+Z2PU#?UOF#D6"<+Q1Q-[O;_ F4@<=\5.\DZG<
MA(7>A)MC$\+@'#EO_-44U E8R"^'/?C>)K;5$EN%.';5=CEZ7=^M$*$C 4B=
MCKT9BV)O+QEC*L:--Q7:QHQ5""%A!PIVP*%2%0C4S:VOLFWX<Y_]&P,S^2/>
M!Q@OX7^A.#;T'S6K=?NPVCP8?)!19SV-]F*!YF*L2*S04A@BAF<D%\?<PN(<
MQ6%J^5$G3&1*9<XL,UT6Y^ZHB34W?EUN+*-)?']-93\$2^,H=O.3'U6]K\FY
M5_96%!V&1J+#+9G9SN7M'68<XZQ'IW67B,_#2,>N';@3&6:DTLG<@J(LJXHT
M0NX8HZY8TQ- J1[J>,]A_(L4<N3SG% W4MU8OVJTZ_5@05-OGH?'/ROQ^--X
M_$:)QR\ 7&F6TS\K&WG\0MG(\R.S%45P.J!-)0?'$.?);=P$^6;,3X\>/V65
M?WGI!,/7S[2EPGROV[_-2;N4?9^?/- HE] Q4$YJVIJX ^%Y4L:H1\>W<D_G
MBG_ Q6_V*6QK$SV1"'$A%B@^\(D6!<]9! ")M84N97!2BO9@_+2CJO"'P'_F
M9R.-A9](LB&81.YXOG?(#U+F$D &FI^)BTDT#@N:&4KMK9,7VEL71]!LS1--
MRW+?+5Y?DXO@W=XQ)G5S*M,F=-*PNUR&%,R-Y9QVS<+93FPIY1;:@^M>Y'>Y
MC&IG E@$YH([H'&8S?-%-;<FZ.7P2QFWN5"_S@5FM=G/OML9<+<C^('?$TQ/
M(DF-=P(R>#UXM<0N.8I60YA8_#;.1V;0N4MO(T  4'X '\ "?W%9F9BN\Q/P
MAI&O?<&@+UCZ94M9Z_QWIWC)7^/ ?"D$MC';N5F^;WDQ$=@$NC\^,F_;=^W;
M?[8O"H*V?F64_5YUMQ9KW#K2)=#];+9^7'3NS?/K[]\[]_?MMGG9N6I=G4,9
M5?M?-^W;^]0IOO<ZL'OS^I,91'0+;$E]WP0_'4\(6[/:0+?"CP_N6TL4KFT.
MV;!+]%@8J$><5T_BO #$!C IASVQ&#('_"U$Z$+1L8"IV)LQ]3+?RWJPB8_B
M!QLB_AWDC,$.QH"OMP&,39PJ9CBT$2&'QQ,-P6.LCWEMR"I,\.1V10]F)&%2
M60G9OK</^!)_)(.+\ 7^.F!P0@*L@>\ZONJJ',_7"67A09=P)'!["=4CD+U%
M<.,0##X]1Q(M1.O$?<E\=!X>^9!1- [!U^#C+$")N?;S!,L&(,B&=0U\8;J.
M'['>H^>[_@/QR(SXBX=VCXTQTZ5D<]Z^YG/P%00&100<%BA0VR N+1^7&C&4
MY /E?+XC2:GBZ<7Z)B06*A4!@JF?CLO=U9!%F!UZ8/ V0V6$PO%(WA:%[\%5
MNP>:)-ARSB]I.K8;^J"Q.(G^DQ-"U!(7U@EU?>)?@<70;I46=H>F*Z?XK8T5
M"E[?^/ZEQ=4"B(#XZ"2)5C@>4/ R$LKKA$Q09B7>164Q& 6.10R5*&./2,$4
M5A-HY@1'B22,@Y\%BC$R'/*T@+GDS58MGLP@@-CI$_8+U"Y>8#5Q^_Z/SOE;
M+5G<O7GQ@Y3.S;X_0B QW_A]K!GA%LSIR5(Z2&B3B87S*62>X^OW(Y]*P,)4
M-"Q=6=;#RC&F*LM\63F&?S"FGB?^H&?&Q5^(00SO:BY\#MKR4K]OG1<-J?;M
M0%DJ9=,3,X3C&$-T<*M\LODW("M*U7XBBM$1/(SF.? M,AE7$VT[GED7*(CA
MD/_=^?S\_'S4&0['@>\=<3D LIC[%0'84H^_>H29(CCLY:O,\4A4(?)W')F=
M 9S*"/6$?& X[@)P@#P%?J;WAW$_M?1,^  ? MLC#D?DK@-6MW@-X-<.P!5Z
M_("AOUNR32^>"J'(S<EGA_'#+>.9$7Y?%DB*IB018!B@E0ERKJL12O:\("6E
MMVOXEV>+*;KA3UZKJL?G1^8&4:&W'7XGN^&7LM;Y^?6/J_O6U;UYV18\-'!G
M[YRWXQZ?W73\8F>UZN6/FI>8$O((W@ Y';=='?[F$</7I](C0%>[9T?LBZWG
M*]!3\\NDZS]3VPPXRN#^ SY_]&@1EL/FAX(X4("V$"X ?2I$MV(65J [INCO
M5SR^[A_]P(OXN4%U6#?1Q/P6%>#*L)$:'8%+ .99>Q1R:<I_)7">RP"'#8!*
MSL2$TAF0L\>#A@9--[%X9E A1X?2;Z:8:(P: &!%-IJ4SP_6[>_OCM_->6 6
ML&(QA.,OH,)L*RI,*)U+#SYSI$*=]2$D)X^@RFW+=14AUMYEO2B_Q#:<L%#<
M@MW/D'V2Y["YO=>T_J8.^Z7%N<^RKQ1=]GFW%)<DE]Q#P-V!/IA)/_AD!@_=
M@UJE8=7JIU:MV?PP$^5^<OQ^ZP<ZG4I$Z@)E&C/1C+^'X]'G@^H'?G"-1Y\3
MH.VI@5??+[)),V:<^<6D#%PVF+D/Q%/.%C\E@#^\^UP].;-.&K5EIK'T:*KO
M\\Y\A6EFS>FX8IU53^?,:?Y[\JMVKO,BS_&ZL>,YZ9;,M%YK+>O:#Y^O>WF/
M^/P#WH;\-B>L_!H\0S+YM/EU&TF]:D'\W+V\N,IJRP<0'2FOUGX,CS_1/L,+
M'<H1*OIX#!@_^V.W;WI 2N9BQBS1S;0']>R4.\(,&0(0(U^DP@BVCS\20!$#
MF\Q[$+C^1$@S^=JX 0?2?<$%T]%"#;:*,2 UF(88$J/+**Q*[X.=AOWL77>*
MFX =MH#4X,EVC1L?(MMLFD:Q#"45?%[7X\!(<>X@Y8[,2HWTE=5([%2VF:N!
M+=0 Z0.4AXZ09_Q)60IJ<4;Q)L)!*@MA!#%LFW)">NX)8-M'YDWZ79YXG1],
MOPT;X'#K]P!,1H1 $38J,6:L9 +&#]GL)X6M4$!%_<6(*^CY(]44/C:1,45=
M;/P63@VS:-A@%X-TW!Z.^:;JVMS"$R,C<(<@,:82)?O58PSM\/2L^.>0Z20D
M3(,@>E0\E[WDHHFUF +D0+X.5W]B2,P,K& $U55QKFJI>6*%&R4)A?+0<YFN
M+2IEJ -?[^C0,FJ5JH+BVT'7]EAX>/W+91,D!!4ZF43LJ^:DJ)6J\C'FVQ,X
MF(2HLI!$6'Q&!%3&\R/"3#(6QA9UQ7:$580*AQ(+2C666BPPOOJNTC@\]V.2
M0H1Q&T FB>MIJK47"YK:U06,X>:I3CNKE-5IT]5IS;(Z;9-J. MR?;)?70N.
M+X[,]K_:WV^H5<'E[?5W;%;PK7-WW[GZ:M[=MZXN6K<7_$_7MVFH;@DLVI5Y
ME4T*://N5Y."XS9W@'_<GO_1NFMC8Y'V/WY 6Q'17Z3#?_GE+]S.G;N['^U;
MQ&JT+B\[WSJM^_:%^NYMN9'7G]?+3*H#! N!<3,.N,]*+:#;W#^-)II3NV>V
MJWBM'Z^8@Y[^,P/^^P"1?*H#:Q_:<^/B!%, 3+A%R[_V96]GQ//'-Q*M'B_5
M6C*F]RV0PYYM9V>T!]EX83#80;-Z?'ED<D-V]94;NBOSMOV5.R^WK:M[<5&_
M,\[;M_>=R[_ H8GA:Z!.N\USL\S"<0_ 3'@ K]["Y)5<@!GL]+OJ GP%L/_M
MS?4M/]'-K]?_;-]"]5R[/-!?F$UG2V8#(FY7K;N+UC]DUQGLX0*A5JS28OSC
MYBAPGI!T"IT#RR#P=Y@\>R+?)'P@_OK1'T),:NQ% 802@5:I1\7HKL/&2%\)
M])>."NK1(%3HL^<'(Q]X*\P'J,XFGF3%J0>E>T; ,/,#%0;#$47O$-TN'SS_
M$7'7(.+1#"829N_:SUR&* U+IJ>(L3G04D[ K '1:J,[#AVD=T_,LL4%S#_H
MV!C4Y(Z4-LHNPUP6$+NKOD4BP(:L[9]>[=!8)>FZ$HPQIT%;/3.;IFZ8C2N9
MLP_?&@_FG\CP-A%I :6QM*VF LHB<!U3N=E\#?_'#P0Y'%B!KL^W&OP@ZS.1
M-FT4Q/H^D=;GFQ-B"!KI)B@3T+K[5_+7LO97O-D<8XV2J 36WZUG"+17N]$C
M=E. !Y\KZ_ UM@XWW#7N.2/9?>N680$K-Q@B.>!C\R_\59XW'ID74QT:L&U[
MWX'L0V1EC3T>+U2(8JQ=U"5I[U!</XF,122$ML+<9(DP/HWHB?K.8( 4W+#Z
M*?,<?ZQ82?3:T7$S%1M>'4Y26K:W8]DT8R;X:U()U7A;#AG3V28=3ZMQA"YB
M:"JHH' 9VR:),^7FQ<= AC%E]-(9T'A@E)Y6GH<7,PL((XE^V_1@7VX+EQNS
MW)A+;LQ_C_U@/$PZ&QKC-K ^\?U(N+%!@K=B[A[L>%-<WMK&X5< :JUXSK='
MY$1CXNLCV)AB@@@82[X0'!O18E,4*,.=H8M8BE_\BF1S/0L\-D$2*Z"9HL_;
ML!LM>!2R@8@W@E\@)D_.E01=B/D>9<Y,,Q-PO?'$G4W10-"CQ'/M5!]20%MT
M)X=P :(/<MLAWB:O:7*JX. !+S#<FU &RH,0SP8H#)BM+K]0P>V(C\<SZ_7W
MYD'U8UT1A_GC"&]D>"'"QP@K1L-6_L:33X-(OK(T7*7A*JSATCV*Q3<>T:@8
MM9[O@2Y&,#3C$F/!1@&P,8A8!7Q!MK758OP9J%L9%;%[?%A$0(KL,!39P?8A
M9%P33[(DODF1E,IR?ZWV/X[EA)'?^VGZ* E+92(0:4:<A-SD,B^TR9RZ-G T
MM&)CGK3 RB/*N ?BU42_F20."*W9W_1WR1)J*#;!8T-RS10YGYDW'K+ YQ?.
MGA/TQD,P6M@:(L8F'S@?$LO!*&VFK4J,GZLVWRO0'C&:XWO-GCUR(GHAV-YJ
M[7#(]>Y1$B<>=,=TN/19Q(#T0B9RX'E($V4EM( >3<<@*BF$K$#T0GL@QH74
M#0C+SIHY# JL.$;R6/^#Q:>Y<)[(FD4$6H!RA%\=9%]4$ROS 1></U][04H=
MX=&:OXNJZ01 5^_W(#<6:I/EA[L_8> K S8*_%U0N)<Y,M8+8>=BH][8P?9:
M>9(9O-F[FB?YX\C\WKEJFW>MR_;]7^9%Y^[\V_7=C]LR4[(K\RH:ABE'*IP;
M5(_OI<H,LIEMI<,[1YI^0SZ\=7L!N>_+Z]MVY^N5^9\_;CMW%YUSQ/P9]W^T
M[LV;V_8_VU?W9N?J[J9-?RB[/Q/88V;BO"#Z5L@.(F?5$J,]C=$^+C':!3A(
MEO.#YO8X6(T3;%JC9G \;*XRKW5[;W0ZG5<_-%^74/MDO_C23XXTLNR[^Q;_
M)3_#2S#ORO/*Y1!<QZ@:!'0R%UL?(,!F''A.^&AD\H]0-37=NQT/"MXHSI((
M\7;XI\WJZ2NZ&:]E9Y?GNB_RUCPMMV8A7-37)H-;B81F!M])2M:Y.%*FO[,>
M5<KF71,^0G L$_H3-]+=*CW5664F/95M/@9L\/=W_W?0$Q=X8,G\!48><HX@
M&#3D<=>I.V7IR8RM0:64YD7:O- O#ZLK"3LGP9XF/L<C\=VJ!FTZW6B.OGBQ
M+.=);MOBJKV8;N82:.W=YX0:*N4# =\$_H 8$+[Y(?D=UYC>@68' 7MD7@CA
M]H['O1A6% '77U(?Z_/$%V_I&Y\2<4614:-82MB8)T7JUP<N+=6G%46&S9?4
ML^9<"4&_F$O7?PZ+(IOC8NG7,09?*:NXU*'[FC(\R9!ABKKM];WB?;UGS M(
MU\J ]'1 ^J0,2!=?N6>3D9PNW[ZHR$&3,^ B^:/SI?/V B6[$["8/LPW1%;;
M_H7$7^;5&#K7+:35G7N17O#"_"3A<E 7"! <T6U@I9$IWO+FYHGWX2HG2HH0
MP7C+!OQ.S2WY,I[<?"]-^DI)EMQE/:U-?COG)U=_<*[EV80:SHC=75)#^ N^
MJA_-&X(8MKU^L=?TE??KI0\QHU=:Q]SFI, C!&U[V?N?G%WUJ+JL"DY?'1^C
M:/3IXT=H^Q:RWM&#__2Q%?0>G2<6?F3]!SOXR*^0]L?J\7&ETCC^6*E4JL?5
MYLE)@[^O<GIV=OPQK%8:9\<G_\U^U0^K1X_1D.[PLLH$A\-O[Q2YA 8Y1^M<
M/3$0NV%[]IN965U0/]K\J_BJU3[6JA]K7(SK1E3F!K]GS*DV/:>E(NW-QL(,
MP.H:=5*IU*J5*FC4<:59YQK5D!H%9DIJ4FM(%#]4]?OD #70!1M![-%L09=8
M#!AU6?3,F&>*9H;F-]%U&+X%!8M?;.\G/ T\N[_\X*?YG;N,2&0*R&Y\FAU,
MB-?T^MF#*@;XYQ]4+R3'@L#O(3]J@)'[0GW-O,-ZGK43&]5T\X:YB\OWQL=6
MSBX0.;1WI3$TYBC8RXR@^?$4MM=)]O9:Q?AFO&;;^:;:07\N2?XL[V6.,&<9
MEFW?X]:P"[5J_8S;A$JE7C\^;7X<U"H#:!7$?M7Z_^V()J5H'K3;!NQ*G=K-
M_KQE.<[4AEKE\'+EE<BQ._(/!)6I  .I5C[68'-"MZ?-91/RVJ/7<)+XD59I
MU,[@2&M63\_XD5:MR#/M(NYTC\.!X^5N/!JY$_T8HZX2\TZSNXGGVOSL^^ZX
M/['3H$E1?Z3 JYT"!5ZUOKK/M<QALRU7K%K9@B\VRT7Z>#;G_-BN4S]3B6N%
M4^(:*?$_[<"Q=3]?T^HM:705-?K8Q#XR.Z[54\V@BJ75:^ELO7 Z6R>=_6X'
M/Y$$0)G=[S: :LP+N*$Z76)'6$IC?WC.I1.$T2'^UVPY?9WWQ.Q_['ZTS>_M
MB\X_?K0!;](?]Z*0M)H&@86ANL7>#_VN%UN_MVRU&Z^\ ZK-XU/< :?54]H!
MIRI @T/NN@R'(QQFTG.\NYJ*,7DYR_VE8W;XL\.(,-P"?\"ZP1BNQ=5CTNV=
MU^NI5G7;>E?C(SC-+VNXFX4SW%SBJ+=MR?4DM):Z%"VEH1?!D?F?+.#*^%^V
M!R&?4#D7W$VIU5%!FSNOH-7**UK>'0RX-(Z.7S7>LG:4I'I6J56K9R<B2E(]
M@^AI(QDFV9RXH"42"P!2AM/^QI(G!1)P_&E'D<O,;W87W" _ +Z+&W[&@$.O
M9&V_?%QF@U$ZC/#DUQK<+\6: CHI.SV#XX]U/"'/,L&811AAX^AD#VW+R;9L
M2_*0;R/O#5J5I<_YKYB*X>>]W?.[4[XHQ1'.2E-4D"DLN4T*.(,YINB%7"*%
M8SM[O]FE.5W>@L68NOFYSB6,F7IDL_%^([<-;MQ.ZV=P2:Z>-NL-N&W(\/P&
M0>Y:\OH'\'D]0W+*>UC.H-T_.MY/J@VQ3-N\<)Z<4.2[^ OZC_90P_E_MSW1
M3-6"NJ4C+=3TW5;7G!5MWZH+BSH[/Z>[T=UX^%]+VI.Y.VJ5R<Y[7'6C.Q3!
M0&]ELLV/M4;17;ZSG7?YJG5N)3\.CG]63JJGX/-QT[@MGZ]8)A)#02)6N2?^
MX6:,8=%FM1FK5[19G7RLGLTV;SL76(-0Y NZ]1LT@C7^K]-Z[?0CLZNU1J->
MHV#T2QA!K>5Z1B:&KK(R:0AQ:[S,UBISS2-U6H#D#+#-ND D@+\,F..55JZX
M]H#0+WLWK9./M;H @Q76BZLN*_B"VZ[:UH)VWH/PID1"( ) 10Z?[8^C\R/S
M3]OQN,<'_>/^PQYRH9S[1Y;Y[=MY(C='W5PKI:DJ[IXF2-/>36N^J=H]CVS9
M-2JX5:MORZJU9%,(G'/DF[&9VXZ)JY4FKNBV@%!M>S>MG?#&EA5\P>W6UN 9
M^DWR7.]1\Z<=0 DFF+(NDPU5N E+FRW^3PT/51JD(N]<;I"6Q7#LPK3F&*0=
M=+I.E[O"%S(AD,: G&XO% :-E%0H;-P-G;YC(X!,U-PFJLFW;IKFU<6]'H1C
M0]5Z+S.YE?1_1^8FRQH7X3XV#M9.H#VJM:/J_TN#?O.E<_,C+40);I6[+[7T
M[C^' 0[X$&49[OFCPP:F@G.9UP/^5^C=.0Z@&YJZ5$&W-+-:MP^KC0/[@VAY
M!KM<"X*W?_6((+/5B[!&WR86@*/5:^P7Y:OSLN?D39H7^7V%*)CA&EQ3&KQZ
M[4%"1VNY=#3."J=U=%H_<3"KZVC!.9PV_. 7J%>IUC6[MQ&MJ:]MV4!KJJ?F
MCZ.[H_,C66&%7Z[6FQ72C;X_PHZ2VE?DA\XJQ]+1N;.#KNVQ\/#ZE\LFV#^=
M_X5?)VNE5KVRM:IOVEK5-V*M2KU[=;U;0ZMJF[9FM6EKYGO0I1W6<W,^\-=
M.G3WCW[@15! />X[D:SX2=_22MUY#9NUR3M/E0Q,Y^KN_R6N/2NH;<=S'8^9
M__IR^\WL>-2+VKSP>V-(M)3JLJZIH=6Z._]C=<.BK]"]_<OW_.&$^S\1M,;@
M6_VN]\B&=KED+\O_R!?UO/5MPXMZ;KN]L4L>QS?'^]D%Y%FYL)O=BQ?MRZWM
MQ0MH2^^4Z_>Z&_-;Z\N&5_B;W65NN:3;VI(WM^T-+]A-P,#/+DWI"VW%)6@(
MUR#FF6[#L4R[@'.?CQ(;BG!'EP_&[F'\Z,*.;'ZM=YEY0'U.!;Q;URM $O7X
MBVS^F[X!?:($U3[7W@_4__0-JU2R9="^=KU8I>?%BFU,LGIN:STR^%!G[^+9
M2!IC.DN#+5DR\S<O)//T]77^_M\<1H=O=RHWR_L_4*D!S"I'B4PJ;H!]T7^I
M_*7BOX"PD6#P-53_W/<&#NB5Y _*^S]1P&QDEL-&XET W(;^&#"U_-CD>A#
MZ6A"XU3N<PFPB!.:?>5SO;5]DZO36[WL]#;=Z>VT[/2VLEYK0YW;D4WUBL[J
MR49CA-8LF['AV\4 =:XNVO\R[J_-\^NKN^MOG8O6??MB1DO[&8?;[EF=O6IF
MOU(#.&7KIEO*S>\-AY["[$[VT.$-IEO5YBN%<*A^+=%?M?>IOKG9#5]S7:[4
M4T_?3R>1,K"3"Z_T&YCIVD25*X][E3C$<C/;0NOW=22$G=O+9=WXLM;6;T!/
MZ59L0H_N+L T_F)V$$*3.\F.7Z<B64D' (\B8.I&=*->ZL86=*,^3S=B4WX#
MS:4@EAR3Q>,XY)*+Q8:"B8TL=J-<["TL=F-NBWO$CX8F1'>1QBBYT7$D+[;9
MF^7Z;V']FW/7WPX?S4O7?PZS+#P.Y 46/F=GPG+AEUKXXW>?K_R(;^[(-W,X
MZQM9R437@&2H:V]OG;E"7HW?S&ML%Q=^@C<+ .R>Q\$N#U>)A%7+0-CF F$9
M,3!YZYL= ]N!\!??DXF'X=OZK"<:('W">AG(9?/;;?OF^O;>N+XT(69VT^;_
MN;HW;]M?.W?W[=OVA7GSX\NWSKG9.C^__G%UW[GZ:EYV;K^KC5Z$2--+Y;O6
MF1#_WU-XQ1??#OK8F<T)N)GS12-;[/+S2-ULM_/B%*? 9E^"*G<]<CRLC/#0
M51JH@S14!ZE)"K/)5_./5I;<[UMZW9_,?+2?F&D#TIZX_$R[U_.'7)LF$!;J
M:7Z&H0F%:T,LK)&\5T+ *8.^)M3KKP_@'?_Q?T]KM<IOY_0B_*GZVP>]B=G4
MG=3"P07,Q:'HXS*3XQJI6(@K8R$^QD)Z>BR$WY @#F*9O?C&Q"3Q*P!EP)$>
M*$>:V;U'6=D2<:^,F1.\3SFD.",N<K]O,OUF)?QKR9LH1FYZZ,(=0)"7(7;'
MG?"_#5@ <3GNV7$9:!+*TD@IKB.SPT4^#@R?M-B:K<,C0I*9 ]L)7#Y#/FS;
M=;F*<"L.'^5_'O'1A.E'Z"L+?Q$+EK501KQ0\93#L4N+XL#_XU*R*:\*GX!?
MY9.R.4?*\AK#/\)U K!/? D-;!^#^"@/W\BG$CO)%!T%[>;NLM?GQBW$PB:-
MS"3Q32U*JKY@HE$\*HY=R/C6,DF(I%G\8H<.K8A0K45&<%-OEY9_@V8P<VA3
M+[Q_Y!LD>^] +SNAS2.NNT[7<4'%DCL"]F3UY+>0/UF20A^9U^,@]2VN8[#'
MV2_8D+ -E(#%"91^7.:(  :*##NP^=%TAT<F-^4P4ML<46S?CK5VX 1#/A 5
M_<?= 6\3:0"YJS5%O^97PA"YQNCT/_CA.2K8$'XP#X1]NCEO77^1!@E-  PB
M $LJ[!FP!&E)"'RW,#?P9]VJ@%7B0PCZ6+ZC1@G%B.: <3\#Q!!72[OV<ZAL
MC3T:\:G _=0(QBZC/_ YBTH$Q?NA55O#)U3%-?2CX@8 HZ/BD3BWS6SQ?$K(
MEY#;,.CL"<O+E8?6-D,N!HPO5,9(S(T&#/5SH?Y7L1K\(S:7/S>CKDV3Y/84
M#";)#VOM^(+X783 \#M7R*T?I#]M;A<#?+7=]<?\$8\,SU/^'V/FCAF ]>;C
M4D<,2%=^Q%+/Z(\9;H@@ &,3\*_Q@< 4-*T(X<Q,Z!3X+!;_;<"G$S"#SXDA
MK1[^4<P*CB$Q*W'^.&35703!!KYK(I0VGD$@SX4CL\6/3)LR:-HZ/+,I[1;2
MLCT#+R@H=-@_\,J\KS.[7*@P11FQ&XV#$2PA?XBP%/"I:6/!!@-R(3PP)J0$
M1MJ"+#-K5#+^3W 10*C"3'D^=^'@9*;7;_C4FW'B7>OZWW/'<.:+I05I<"^O
MQ_KC ,-A!E=1&"B::2?\&<[4/+E5LO1V@59:^IY)#X%O+8-,?9^L&JP?#N7(
MO /9:1]6TV&_^*7/XX^R8$5M+H<P N/N\*&P)\"W]4#;'FQ<%-JF0[#09+OZ
M3MCC+JYX9G):FJ].YY 0I>V&OC: )]L=VY%Z>&S_1P'_D#,"0SH.I1O/%PB+
MR;D8^4@=$# <>'T&/M-0ZX9@PUYQ7;XLZ5> \H'G.=)+&^:L"9YK7>8Z[$D8
M,&T_<IF"E+CD-&O5C7V7<?"R*KN-R]N,5WT,/YI?;UM7]^;]']>W5_?75V;K
MQT7GWKRY_\O\=G^QC:%L9X+Q)31DP1-5+61Y0KCF?%6Y+>2[HE:IGFYX4;<U
MO>_,Y<=FX/$3JS4&RC'7L3?]CNM>Y'>YX:J=T7UHSO,3MXU,I%V.Z'>S#'1G
M!+IK^Q3HUA&7.PJI7! ;G8JAUUX>1[J=[):>'316  H)D- RH?)=$L^E'^ %
M"H)+(II4KV! :8LSWE#B9RE$ZDQH::(@99GR0P-RR0N*+_.5S"9+^S93&(B+
M_<P@;D'KDPT/X%* )?[[N]J[F=_,MDUTMB[STA<>W533]B*-#O E2XWN(_&&
M;T7CYHQ>PC34&0M^R%RD22X1Y/%R$."QV2&NNF)YAMOZ6WJLF0,39G@E-2SG
MNL-SS;N!5X-328+9VOL9$=8DL.H,!IR$8)V!<&_9$_/&$++TAQ0ELWL0[8/X
M<X\_BGM"P=2>S,>@NJA7;6WF8Q>)=M:;LKZ8?#?,?)9&*C;@A4_!1B3<FW)^
M??)\[Q)Y"'S,P<&G;@&VUN..2)_UG*'MANB5$#/!W]\YOZ)/WGAXV/<1X@$?
M>&=Z_#+%_S0(PL/!V'4_B56YY(MR+M?D3[XDYW)%N-9S/6+XY+'GT#OM,1=3
MM=&T3DZ.?_^8'-QLEM]-R"RG)KQ?:3&6E7S]E21?LYK54ZMYO)3L=UG0C5<3
M=/WTQ&K4-BCH_+9ZOKNUI/4]]T.\F7[U_7YHWO&M]RIW@GPGZ#PMRF<P#[9G
M,4&2UX,[KC!S%*=9M2HGU85:DTL.'Y9=J7GB6UI6:]FX7+(Z/CVU3NN+MUC1
M)+.64<HGF>,3JYY#C69*9KN.X0+M7=)"?0T@5$:1L[VV3=LS32A"DN!LI3IK
M6">5YF9,T^[+>RWSEDO>5>NT=F:=U"NER#=@-W.*_*16L2K-+6CY*[EOFPSC
M;NFP7/S!K >6@UE7S]9E0UU2$RF/)3-7J^GC5#QFE\S76B<T2H^$-\?MJYY8
MU>I6SHLM:?CVCMA< FN<U*WCD\8*?O+K2V>MTS"7=)KU&C\+%ZM3(0\^,C</
MMN.%'P^@T@1@T8A6JOYF>FSEFT+13= 6 Q@HTJ\@T6\H3UUS 'SX]W>'TPY5
MO5&S:F?UW8AH;-D<S9!=2F1<9O7%#NA^FJ1<$N+>2:.Z6*-VU$\J/?8W-IAU
M#LC-1M+:OZ"1> QP*)5O[P=31#-(P+MWG[\R#VO*L&RM#Z48 ,]&/GVVIJ;6
MWZX7)Z3:\OJMA$S%YI]S[%IG)Z?\NG2V&[[<%K-3:XCPI,+%>+;*G6J'<U9K
MR.OXK&'5*VOD^%[^^BG-%Q)P'%(Q\,B>(,1[7;NU+$1S#PS7L/<))8F"O"$Y
MAM)3F8? J%:/K4J.>T(AK-7&C55NL<VXN3?KW%!5:T6]AV[>6JVH9Q#AJ%O-
MRAHFO<@^V"T+F1WT'JFBE3TQUQ]MQ)+M1#IRBVZ8%"P_%"]BL2X\$;FZ'9]8
ME>;BF'4AS-H6G;"5!5@%+_9TE0C;#KM@*TNKTFA8S=KI3CI@S'6)F:$/15X_
M&9:YEU?'E94(46=<@[Y+82[4G]KI"=]KI;%:7G*G)U6KV5P#PK>+5FH%,1TW
MK./&*AG<'40Z7A-#&S=BD- L/:_5E(Q 8)!D F2_DFD+J'J0>2K'[>C4JI^<
M66>5Q>?B<I9M)U=C+<NXB=6H\95H6LV3#<'V=GLUUC+ FU@-;I";QU;C>$,X
MI%=S(\ML[%L<3)&#,<21*KEQ]_K\WT88F?!N0H@Y#-F95:MLZ.KR,M@<C:OH
M,&2]0^?7X:/3YWKUR:3_?SC@DSA$6JG36K7VFR M*<9NW49$=]DEKR].;FX/
MS+$9XU &9E>U#U1:EU]9JG7KY/C-UFJN(+!:U3JN%S&DD==R5M>RG+L4:I#6
MI,>7.#0/UT%,OUV#(H0(VR2\8G/JSAI6LWE27EY7-D2Y!9W3 NV%I+?A3\T1
M].H>55E+65Z_"SF873JPD2_T"W+3RA["]_:O\LQ>-PY*(N6BS)<5.&U8C>,R
M#KVYK, R\J]99[43JY8#+OH&Y+^A/, R\A>1_]IF':Q7.NUC(VJ*+/2JQK11
MD-MKK:!QOYS#K^_V\!M[$#N8P3*ZA(<B>^C<8*^XM R69_:=WF\S1[G0HY\C
MC>4'MHC$=2U.R[4?_I(>U$8=I[P\MZN=YV]TH3?DJFW40RL7>@L+O2&?<*.N
MX 86NHP'[6T(IE"#*883ED\YKV?V5"X5]LT,9FUJ"?SW)].)^,=[:^EC)V)#
M:L1H#NT)M)T-6,^UP] 9.*(Q*)XO. S1'/Q3J:IO9C!%QMVI+L1]9S!@ 72-
M"['):V![H:N:9$*@C+]!:Z1>:/W=-E-8HF491=.N6'0]N+=_28%>Q/*\]NYC
M:>8!WS2LL^8J)% [5\F]%:FFA%GA%[/Z*D5^NXD,? &1'E>MT\8JO!4;/;\W
MYD[>^]P%2'4AG!/0*_.-R[+Z3ZE@OK#9V9G5J)952.OWFUA%_C7KM,:]CN-2
M_NMWM5A%_@VK>=;8>-U7$3W1,M[T%@?S2G'-+W;H]#Y>..XXXC=S/.7YC<9$
M=ASSP/%0I>AW(?QN:8]:JN3Q3AN\Q(%?RPVA1.D"#0?)MVT''I<_DMYR'PJ%
MO-#T\0^BY,-WG^M'>TC(]VK2K![EZ(U7--$U"B&Z^E%M%;:PU*'[$1MHJR;W
M16KM/9IK6FED2W=8!Q.<[K&.;= WUE#]_I$9=@\2 ;8W >X(#WH8HY)PXQ]@
M<S]^@0N9.4!PM\/O>:'L21\>3;=;SU@6)><,Z:E/_Y_#0_/286[_DWEC/[#?
M^(C_/88K-3]VCG\S_VF[8QBT>7@HOHK[A[ZK86QT\55K&?([AM\M[J&;5JH\
M2Y>%-LFUG)>'^O3EQ'\S[R<C/N=68'<AO'[%]R8)Y\H',=3U+WV4WT(!@7R5
M:&:)JALP^^=A%Q%\G_AB@]#UX1YG#!=$^BYK:74/=.;+]?'"/.+%7$IGM*?_
M;IM.GZ^1X_UWI5+G(_MH?Y[SJ-^[G\]]#Y?8!N_E3FHRJ/FE4O ;/W3 0/W^
ML?MYSDY//K@5PD/J%?,_QQY;\,UES<&&;!1:3ZZ:KBO\.C3=\#/?Q3WY<Q)S
MP*\NKCT*N8;(?_UFRJZDE<K[_*;M72YG=95F\"\:3EJU<?>[S[4*X!V6>>D+
MCZZRY.CR7D!66=.-8G-RB2#/J7 %A^-FA[@+C>#?TEQ75^I\(?64\X:?X.ZW
M3SG!3V-NWP/7\1B?T=U=^_Y.>5A;B^MDK,K<4V7Z45M\\D:7(R=H(?\2G8^#
M +R'5ABR*"R7:HN14>%S'#?>S\A4974GMT.B)N[!/[B#[#SQ^ZH739GPY9K3
MI[NQRP4\F?G8159GUINROI@_C"6><K;X*7DRJ;6U(OA\ 5I>'_Y?.UZ&.978
M3:O2.+%JIXL1HAN554X->+_2(BPK\>9+2KS.]UW%:N3(5N46PL8#U%F9Y\#N
M,]SC/D(: ]9C?++\GK,RO.:TX''G[>U2%"97&L(]T-EV&PMTCO+4H?OWAC@J
M7A\TLM;&6UV(-6!#?CF*J8WE)S/+(Y_XM/W 67T;%KV7R?:VH2:\.2?D6<UJ
MUA?'U-_"ELLEL),SOKU6ZJWTTF>: .>+NX4M[A:SUV8W\%';VR^ZI:6;V!PM
M ,NV(43.CN^:9<16KUO5LW4[81>A0$9A%5,W]U>()._^QLNI//PR=]*L62<G
MY;Y;0FH-JU$YX[?@51@1MWABE4"S8F&[-F0J9X9&M<"GJ2*?,TSKE>\=;L.P
M%FAA"C68EW!&;UP;G%"OC_%3[ M5GI:K5LB/^/),4*(MK]^6\ISK=IWD. #>
MPJFY@O1.*MSG6*4(K(RG[-7&TX2'SO^\AG:UXV.K>5I&,I>5VTFM9M4;K\F/
MO]S];UNNRIO;7%R0O7P7FJI5KU2L>HYND6]A<RTCMY.SNE5="3]=P/#+]7WK
MFRFQ+>666T%U%L9;H 4PUYA-,9WN^$Y;)*YCJU:I6=7CE_,4RT!+80;S.D9Q
MF:#*MT[K2^=;Y[[3WI"]+)#T"S68#3N?&XFH21?UFV-W'1=[+)9*4 PEV.9U
M/XUJ&MF3M2!-U24+#_;(6<J"X]P(<<X)'35/K4:.A.=;\)]6DR!0]M;/%@=2
M"A#A#OPG)P29 5M-"$W&S8!%XV!UAJYJ[<WN-ZD@4JCAI1^TAR/7GS#VA7EL
MX,R]NE3K5J6V4_LN)\%[$YY94(+WO#M%KJ/9I84T_2[_TF(RNS=Z81_V/J4T
M_UK):TZXIW9FG=;?= 1Z-<&=@MS69:E[>7R?F\^U?Z-[*!.MIMV&YAPE%>[!
ME;'FE637J%G5DY>C)WPYN-_&[]%O;A\NHT95JUJK6J<YB%C?PBY<1G+-ZK'5
MJ);0OS("M7VSN7'H7QFL+)RJE'>^ MSY^!X16V1.V.S8JIZ]Z;SMNA*LU:RS
MZLN5>6TSWD(713Z+P_4NBZ\<^CI>*_2U.YJ;O&_% )]\OO*I=5;;3?Q<>:G:
M'(@NEZZ4A\2JDFOPZVB]V"7VRP'I-HX.>7-[+V\DHWEJ57( G-_"ILL7PFB"
MAK]FO7W>G735OB\!J6L9829 S/D"\TWK]*QI59IO.L>UHO":UG&CSB\X.U?6
M5 8/BQX1V@18M?V/'YW[O\HU+L8:;[4B,0S'#)@51Q S7G7%J\TW>VB2 ,])
M?G-0#:=6_1A*I\HDVA)2.ZY9C=JQ=796L!1:YE:Z92$+GM9 ]Q:]4\Z642%2
M?O/(+1O'Q]QS*NG2EA :O_/6ZU:]L;A_VBZ<5ZU>;SP<N]CV ;I'[WFL<GY/
MH+7VW"V+;.X!JI9 .5KQ'3>MLWK-.CW=="_$+>V]^=);:_.M(+WF";_P'?,#
M;8V&QB^2&<"(Y":O  7=7-O;6\!J$DW*V,F&Q+7I:$FN_F.OUWI,;TBTR0YA
M9JX.84;.#F$;;P]V4K8'RV@/UGBK[<%F-PAK9#<(RW0AE]W++]:Q+]7#S$CT
M,#O'?O2AZ7@FV49J1+9H"^Z<!"[]P("^\A-F!R;CQK.?[+PVW95PA09S>]HN
M;4FG:O668A2K^;T;?/QLGB?CA/G&\)*#30=ABC="_0;[+7&#+=Y8$22TY/"*
MWTYN%_J7E7,MY[KK<WV13F+-VN*.4>KJ]<5V;?">[="T(^EJF+5*=:I9T%[U
M_#I>$;^-KJ>0V9S;.5^A^HE5KRZN]]]PDZ]]6)N3K:Y-W:J<'5OURE+MP-[0
MTLR/$)]N>&UF!89KUND9-W4GB_-:RXKIPZXOT-SU.=OJWCFU&O4SJYX#^[B.
M;#9>W EW"M,>\+/>=+R>/V1F9/\RV:\1\T*&W#CRQKWM>''.NI*3@M:5Y!S^
M:3&'/]^R5=>EP!\X$2A:#NO6L(Z;D/5:!<+QN@G"QB[)Z!60H(( Q1^. O;(
MK8OSQ*3)D69FQ +'[Q=DIYX5<Z?.WZC5U<XXX@K1EZ:#*P,*>>D'-[@N<X!7
M5>NTL2YSR*LO>+6R@RN^BM4IR(*_7-UBTN@ $&B&R2DJ]""O!E<7:/ F1UI@
M-,9*9C"F;)G>%FOOA/T1_#8]Q0627]L=6NT2O%,+L)87NJK\FV?\_TX60T:7
MD?\+U-OBO]>@O[D/;"^DJ8;FLQ,]FOZSQP),Q/.SQ0F@4,+N.=$$0LCTMRW[
M"CM?YU(.YC6+$NX>[0" ))C#MTR/(;ZDYX?+=TK:Z+6FLG;UR/5@(<K2JC1K
M5N-XW>*1U[_'U IZC\D[_GI!Q[^U<_>%-;08M1G7(SPX/S[; 3]'(VEU/HK8
M<U'"0-7&#FKCRG$@6I/KX$^Q*(3F:HLEF5<VU&C6K;/*NLP/K[_<ZU&V[X[Q
M*<)JOPCO=MK,L%\LZ#DO8& V[M%D+5E;SF;.:A5W5RX()FS*BF4*:<9M=C5I
M;3OUE-M\%95V+^_XUTOO%M2S04@X>C9.4!S'9C=3T>O9!+DDEWXP8$Z4RR+4
MJU7KN+Y*0?36K<+&0[$Y);4I 17+]JR7\7V)=-9,1.I.]WGG%_YM(K..*U8-
MVL1L*D"]$VF:^0)?\<*04^ -ZOE=W0IO8D'EO>#46I43>UELZ EW7\ZL2G/3
ME L%E?I\H6\7R'YBU9O EK*%Y&\QW%@J*X5D%E2"C[T(ZL!'ONOT)@4YL6M%
M1>SD'?\BO$8Q7? 5'4O2IX[74MIT@\J4YU)N-4Y6(7#>/43HJ\KI)5S86_8$
MD1@S0F060UL+SFR5^[+N9/=]V14#>[<,Z3/Z"%BC$Z@554$D()'2N=U^[F/5
M%2B]W4T=$/E7H'1_MY846G4;[),[O(-E4;4=!WW4"@KZ6&#I5JDI7*WHIV:=
MU;AYJZR"NG]=-WB5Z-ZKR6CC!9:[5O94VTF\RXJUUVN6P50K7./6[C[^^DN^
MBYB7%7,&A5CQ@O22>E.U4;5%R(C]N9UMWE2N5AN5=[/LC^2WZ2VN5IR3WR7:
MBQOQ%CW15>5_6N/&^GBS$8FUO=2RS*D<3#$'\PJY3_RE).,^.:H6N1)J%0*P
M9>M,JM8QU)GD".45_6*SXV1!M74AF@4]I;=W2&]<PU^;H2O;.KUV[=3&3=0Z
MU2B-TX9U?+JK-0ZK1J[R2VM6V?[*8BM*L4.MJ!1-.<=?7P^^5!!/:3>J'>J[
M";5:SSJL4NU0X_I0M>JU0AJ&C4=75JIW6$=$Q3) ZR6-7\35N66'3[8[QE@%
M7,%\6B[A\4 ,8A0X?E"L)%I]-[/9*UJ;6Z96Z'I VXF\D8YW VLSG529U3&P
M<F)5UJN_+.J-)Z_B+,J^KC#2G4GZ%TJ5"N)=81SJL&L#9'9D3[#ED[CE;3T0
ME5=G=S%]O*JM:P]'KC]A#-?EKO?(ABS$/G37 _FG.1BYNE7)T0VUZ%Y#46O,
MMV"/7G^Y7[.L%#S<8A^K<WNRK@C%SUM6FK_;_/XDN.<+?$7D?4Z!YV]-OC_R
M7M#1>T6@_0IEI7E[4>\%BF#CO8N7:(^4NWGQ?L+HBZH1>7VC11G'_3%-N46R
M*(FY*U?:VEI=RY<"LI]:]=.&U3@N(NG,?"&MQ=3ZTC)Z?;#_KN_M11FXG=G;
M+]5'8U;A=L,Z:RX^\W?0E<JI28U%N=!=T:15B1T+HDAE:<(KZ/[;:=NR!2N\
M)D [YX;9BWOM-OW;U:2?WXE[ PNPEN^\LOS/SJQ&M2Q/>&W<>SF8G1A,D=+"
MQ2M/J+T$>+O6X(?&L56IK,\X6]!C(K?CN B_M3^.8VZ1+$)>%><>N3U?X*4W
M4J%J'G9=@7<' ;:=B-JJ92!UKLC\_X[71^7NN@8MPF/MB 9MJD7*2RM005S$
M8C:^6<E#7+7QC56OG5GURDE1$7=;RDFLT_ZF5JU;)[7:6\Y$;($H9I?-9ZZ-
M5JTVK>;I;OJ1 UGQLR\*O 4,RFX;P$O__[/WKEUJ(\G:Z.?#K]#K=WI>>R]5
M->*./=OK5/O24[.[73ZV9^:<3[,$)(7&0J(E467FUY^(R$Q=0$!*I+A4J5>O
M;AN$E(K,N#\1$42TP[]1:>(.$Z W.+0 Y21*M20FK0BAM@U'*DVQIV5S:P<Y
MG8D5F0DT&I%O3)R C2._\AAZ)5;DU\@??^?^P/ME@)WU*8],B'[^\3?_O7S!
M'?JNTS6'5ADCZ6D=^@K0/Q=.DFX%,)9S)4D%QN>1^?,\F[M00G/* I2V(8I?
M3& ZD>U>HL25+_/-)TWRCK_)I9;(56.O[J?1%N.K-+&>BJ_>?3[(*662:,\)
MG@<D<&N-HG7N&[=39%0[HVXP,-L]RVPW*R@GNE""E^Q.IDCPMMGI]<Q>IP+;
MXVSIO4<IEBVT+UBCV .3K]TR!PKZ\$E "7<3O=)#WNJ:@V'7;';W)U9**YN?
M(WOD,M)Z;QOPC]!E"WGCN1W<.W"'9O+SA;QZ_=I<RQM7]MJPFHO(^.;,66A\
M8H_&%W]N>R;_P#2^@O,Q?6/P1UU%_@(>MXCB#[C6H\]@.\*%[67>>FK/'7?U
M>M_=Z=K0^0_CBP'S?\8:.'!S#C=<X<A-SX\81:GGQL(.".@5S1C63SH>;)1C
MNP:-;,+>(.$UD Z7\O;$]-BV*?_KZLKXZ#!W\MKX;-^S-W#3/Y8,CMMK8SAX
M8Y"G!\LPKJ[$#XFO^&]3%E!Z#58K9Q$]_&SD!Q,6Q)_]XH)]8EC777C'T'<=
M.,H)4=3?/TV^,="<!8HT^7B5?GWYXF^,;ZL%O/--8(^<\1OC$[ C)\XG'\G0
M3?_H9_DK(A!2-R;--E*- F9_OQHQ.$!PWP41/;W<7LYRD:0O\KAM;6OS'YY>
M+[Y'LIGG<113\H3^8QO.! Z X_VKV>S":_]LO[UL$?*7T=MWOD=''$>Y-;Y*
M\8"RXYT=SHR/KO\8_N7GT=OSD!9:7_VC'S1D6;G!O F;2'<A_X5+*1=23\#^
MKBLF)Y.>Q+^'"#87?Y<LR.40^$34&Q/$AOC3&^/1F40S7'SS)W6JOE#RQW:'
MH+CD*F"#R G1L8Q .7J(#21EYWXI_0DTX/H*"RP'J(U[_M\O6B^V4Z(J;9$2
MG48SCP!T9KD?.Z)C:53WF)L_R8<4)Z>VTY&S'=I."O8L,OXR"GY^:^"[*KRC
MD"%;#?LG?.1P9.T1CAP11?6? \ZGYDY97+7@UZ\-C,>B;4;O6*0XB93M%)6M
M\86YJ(PQJG^W8'@#[YZ6<0.NTX,3.<4;^N7+\#.JEJD7<YJ@JK JNJV?MIS+
M+VS,G 6"GP)_;HSA8W^>JHM;NX_UTTX]+Z^R?LJ7 OGTB>^]3P)O>US>#]6C
M+.(NP_UWJ;Q<0V[&1]B+K[;+PKOIK[X_"6^\R1>T7S$1>C<%J?O@C-FNM.>P
M95H*(#RM!%0\&S^5VIFBVW!0^9FN;6B90ZMC]JQ.D8VX9*H?5+6OC^H]:VAV
M^OMCDLK$T=X>Z#-OX!M29G^Y6+@.UBG;WL1@HIFH)A/@3&/6E71.D43]YG^5
M)/WH!_(,B8.C,@_%'/2Z9J^MNQ?$2: ()=$:NFC9,_N=@=GK[Q>!YT:XDA .
M782# ]@$HZYW0 '&"=H\\K9G5\:7/]OSQ9OWU.01J KR.D0"!VP*SWC2DJTZ
MXY!H>^N1#WFWC/C_I^A7OG-MH._489.;,/8H$V=R1Y*Z"[NK,/GI?.H$JC/Z
M*B!OMVV9@];98MBJ,^4JH*5E6L.FTOCB(YMRO_IP X]R*O>\C C-.)\$H?@@
M0,OVH7BY92WXA&/PP+PE0[\@(?:O1-H=7D ;VU17TI']XD1;*0):W8XY;):Q
MVXY#+5449/O%VZOS&ZJG"G;\Q*)4GM;X.TY_N?62N+&&F#&V_#IKR5)EKS0@
M+5$6>0.)>^OMT4I;?<9F?P"^CB8@U.7YC/I)VC:M3M]LE[*?+L]UU$\_R^P/
M!V:W/SRCMMCE5$.=W;K8Q1Q=B^I+UGY<3];>>@\LK).USWDQ524"J)WU8AF,
M9W;(0@3G+5PPSWE&X(^EL\"+GK3[6.4P"4'7N^GGP =5&JT^(W%OO,D'2=IT
M6")F<Y6P1,_LM37%SR[8YJN2PH/>\\@='(68+;.IX**<4T;A%F48O& =1#NP
M$ZB@XQ=!QM)':&BV%*)"9Q164PT4=4H&BBXP/J_M,+3+.)<50C558F@O11#M
MU<_H82=6O7:+_MG)F)S014'MU%4 "IR/:#EN%&T/*;?-=7ANYI,VRH&MU#P@
M]G@"6ZF.KCVSQ9QMH<-&[.PCKU"N8V?/=S$G$(C@0(\9FXCB!FI=2,$U< .6
M0:GSM_/]GXVA)^F**A:[L0%?\_:0.VP[\!L'5@W)*$]!RQQV^Z95RIX[/;4.
M"XF5.&_F8$CRXMSP8J*IFQ'83HA>9ZE139<DABK!^@LJO@/B[3H#_4[/'/0U
MB9S+"]"K$JK=[YC]9P*T4*7)H(6-C8XR4[PB>V?D!X'_"#+F28N7XU@YO\2T
M3,=*8Z]&*;IE@3P:7E)\2SETOF_.T+FO?]^@CR.;"%_80L "P%=Y'EQ<8?H_
MIF9X-STW-KX\DZ(JLK:Q6^8AZK;"6(>0#&<?['" V@MP+9C+6P"B^'"9'3)#
M;E4M0LI9 O%)_PW)^9MCCQR7#G3I\]YIFCV%>61/78I405G+; _/<G*/JCFR
M;VS3D<V1&(*3%+91T +%"^\\B@+&*8S,J85+!HSQ&4A8^M#CL+[>LXUS:*9E
MW^R4 K8\0TND) :'D#?QIAR0#[PD&7)4X$TQGZ9G=@9-TQI4TJW^XI(SAY+3
M,JUNSQQV#Y\+=G&9FH-/HMGL#>$@[N^]<V0CJ,;6/+/%G,"#1R4)/GQ +KL#
M;(D*$XUN^@/6 3T UY1PXVM\JK ..6W?,_[_6P_%U8TWP?]]2,B[0SRUS [L
M:[.YWSP\'T59J;U=G*);RY6'0\ML=<[2<Z\0B7_PD>P-S.[P[-KBO-LFNW!H
M%S;E'[%[Q_/0^N=C3*A+__,5;&4&-V>LKB)GI@U:J6EV>IHF))W>9K7*3$\K
M3;ZN:5E#<S H4TEW>EH-CTDJQ)5@..70N> GL,8^3*=LS*.<[,=X9GOWS CL
MB!G\S_#%<[70*@R&<J+?33\(BG\!@K_C]+XK;UOTFGW34M"19Q$>K<Y:.Y"X
M:_9:"YL;[@\YGZ,(/,ADTTS%MCE0"-Q79[VI17"WSG6)[3SZPX=-.^\#)HVX
MA??_I2R\'8^O;+[0EAOW*UG3OHDN![7</_CF5<V.+&TH(-JRT\<:@;V\H#J]
MYR"U]QPW_$Q]D'J_*]KO<_6:=&WXEA&RYSY!]ANHRLVYKPW5N:]G.N_UN&,D
M"XV;'=;C9G/&S?;J<;/5<,+&J-E>_JA9+0/XXG#&7T8T/9-&SJ QGID+^S$6
M)/&$V# >P)=/09VK$Q\ZWH3A39O7K:[CT9(E#?.6PK7(I^4<'C/>B$'@WQUO
MR28WH-#^]=X)QZX?+@-V-_VZG,.25O '6(,S!3?)BVY WB[Q!_>?@2ACAX4?
M?F +/COR@]75N/DOO-V_K!<& _6VP ,4+-FF3CSH,1IF/,;;#-+&$ M =9%:
M@I&LP9"+B.E[VMW].;.C.5R3WGJQOW9LUNC>;'!_D$6U'9WJ.-MY^\X/%CX%
M)V\];L0!58">%>XJ/5=NH)-L8'I?3KV%;:U;V*IN"]'D&Z<$<LJR"QCL+-E\
MM_/Y,@!*_>;,'13:+Q$/V&J^X=*<K$7ZQ'KSBOJ)KHV^QKG71KMI&CABF/[;
MI, -CG\U'NW0L)?1S ^<_^#CX>?4+@%A"&B+!A."^3XZT<RP84VPTB5MFS^E
M$=OOG8"-@5H4%;^#/XU88+2&_&'759["M%60?_Q.=?HZ6D]?N[K3MW:P8.=A
MCUTGQ#\OEB.7M"N=+_B4G[W1R@BI A\!*U+X3.@\3?PYO(2+]_&,&WA& ,^S
MC<>9#QZ+^!'\1]S971EP 9Y/6 ">I/@7'KR";--AR&"K\?+FZ__[BIX#/-/X
M=//U_<W_8\B:^M_MX#N+#,D8_%O)$R<^A2<[AEVMQ[!3K1#\-?"7"\(Y]]^$
MQB(N:;(Y=G"%9Q/.FMMPX,QZ5(Q@+U8HD$#0C7DD>L(>F.M3HU3Z^R+P)\LQ
MN%XX5!)$VW@9\N,V\A\<CU&:$,[<<@Z"$NR.&7S)Y1P08^1/'-XS9CSS'9"
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M6C6M\Y^E-U'7K)0!>QH8L'MX#'9##^6I'B/'M0)BV,8L/LD-/,G&"!?[W-6
MYGRQ5>DQ[&LXAKUST0-[(X/KT,TUN;_MZQSA?Y00':D6J5N2F)Q"U5+5ZTH=
M8UH-CE69VX@JPKC'OY>3>XD=<BH,)Z:$1)ETW)G%#RV]* 6K5:G@&&@0''VM
M^FL[.N57GS=8]\;@SNA"PU1S^$YW^O2B%*QVI:=OJ.'T#8YQ^M"DXAXZI7'!
M9EKXH4/4B'QCSEAD3)<1$!N==W#HN;WE< C$>!D$F%D>+4/'8V%HC%=CT+*4
M:+97A@-73M@(2ZRXW'V<,?KARIC:KFM,ENS:^+@,,#D^]P-FTDWCU9#&AD4L
M O\^P+OC_;8FT.DJ>T[P<RSIPGZBO+#+@_<VK)8Q!Q+.PFN#8.L>['F,69K!
M^G*LQ_LT6PK;D:(, 1H0[HJO-WNKB0][X_E1P_'&[G("7T^0UIQL <X9HI X
MA[8&;.R#'<!;2:YX?:YH!C>V99(>+PH0=P)?P&[8<SQ#L-TBY"[^GO_CAIOT
MJ82K@2QSK$J EP6JC(&F"+L,9_[2G:1H#\N/68&V+DL)W?;SDY!.>L$K5J=2
MZ91$@@X2<<=1CN_N_G'[_LH:UGHQ_ZCH17=8W6I/GJ4CL=L\QM'[FW02$O7
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M(TH-]!3"Y0A$HV,'CB8.+P$.NQ0)H!>M8E4+5[%TX%6L"HMD*"[Z\(IN$F:
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M?0KOCL(FI4FFU!PWE*O:O@H1\!$=>[.!3[&&M3UMJ.TI?_4YEKB[SG=,N?/
MJ<P;Q'D(#O#&=5&N0[Y0IF^,D,@QO5Y.&.P7^@"8:.;[SM-N^";9'',$]\&&
MP7A2A-(*?7>9WL&43GXE*^_C!7F^X<P7V 0GSGL1:XG?9]FK >SE\%C71@I&
ME_P^MX#2*<?;]/2BV7NZ^U;^QM!:J 2FNG'K<W&13XU1=0IA5#D9J\>GZHLC
MGS-HM:<7.=[K'Z?4J(Q!N(NUR11+ 046XAWC@G!2QO\GA%-KRT;T#.\DV[2
M,F8-JR/G,ZUM\J7D.$Y\%O4"J'L#W54,8%4X =I*=]-/OA?#=6XH0UU-:8/J
M(VM=PG7)OXO5.\3D35!<=>5#84[KZX55]_)@U6KY_1(<>H3J\AN//!)QTJB/
M?;9AGRQ@$![7:)5RC>E4QJ4*:T#"N!F*PTL=,4"9 KWP@.#FY[)$8N;<SWA_
M%HG0BUWI5'F[RU%XHJYRXH0+/P3?'.-=\?AC\ *3NL3%,H!+$FAD2,"YA 1F
M&M1#FC4!=KO^(T,7E#TP%U8!=XQ)(=JK)4%'V=14M&ZS0QR0,*4^J0(X#9>[
M"$$G^ 'W006S$_HR_0MR%CF40:S.#_CBPD8"\7R)O[D2<'!\*ZQN#,$)Q:G1
M"8!3WB$!-$J,)??4PR7!B[#H/WTT.,CIP6&/ F$)9 P=?#ELD1H U1MBZ>D?
M91#Q5)"RQY-]?DUK^GJ!U_VF3M/BF_]>!GC>Q2V[[J;OX*3=>!/\WX<_E@ZP
M&M/7SJ;0,VOC@AL7WPL9%TA$GA3 /["$G+6%49SA]$)M^WE0V_T61EE&/8*)
ML:9Z^42YU(11QY/]P;?,GZ-#2IK0Y'_..[DRMQGR;^"^H-HF6)I 54XXKL@E
M38Y%4#PNGAURY$04QPU-@?4/9Z"GKI"F)ADCH*==!YXW24\ZXC?R P=>'>XS
MMZ,ESPER/1XP#%M[T8PTMAAJ9TME:D\<E])V)#$$ZO>[YS]Z<2V&?'M\X\1N
M2-55H9+VTHU@ R?\3D1+ZCO)$N+SGD:V]YU2Q9/ GF()QR_9#_CM9[@$?#/X
M<3)S"=.)LI N7>.15R^2F0I9JWB](.-^2W/TX%M@3QB(B3L\^)]Y77(U08-]
M3ZK5.5?G;B%U3E0535B(HK4:+\Y4>F&7_<,GJ2MSI2HHJ@";'Z-KTOJAW1P:
MZ/#2-&QLE_+Y48]AZ1H!I3')/6<V;VJ$FG6.WB7F?:DC>E)3R5%3'/\/2AT=
M>5E<27J9C[;%22:HN*[AG:ARD1DMZ^7H%85!;!R *"F<R=C',9"4[ROC] <&
MV$^@)T_&@GIAB_W#88O*'*/:#J$ 3]>:,#-R3$43.F_?B>F=8XZ@*-*2'">2
M;.I1YV)2N6=N NO%WO4/[VFIS(JJK08*"(N3J5=9<#I9\M+[AFQ=SM/)O/NY
M'+D;MT 7<Z\2W+ ?@#C"6E0@0L!=>ED33W']%0^?4R@::\OI<71'K-\F]2C<
MRW;3F-BKL"'Z$014Q<27BHT)DV&\P)["^80G*)L.,@(M\6+3M2DJ'+-&,&+9
M\]!V&_'\><8;RB,@+>UC3^7,@]0< S.N?5]M-&A,FR\\[R$ =$#H4#8)6'LC
MI _%17SR]=%P 7=_[+LN$]@S7!FV*%S:;BI$8F0I*6PC>LH\:S85LY8:W%K"
M9@1 #S<-FMYK L5=(V6KG93]E+6[,J-GC!&#CR\%H%!$XE9B#1:KQ6S7M9@Y
MM9A6LR[&5#IMSZPHLZ\7&]K/ZW1<D?FBVENC@#U4NR;9T4MJO@G0/(#=/7__
M M8JV3LUF^DRW R]F-'^X7/.E=E*=<!: <8_3N_S,'$K%H$#/^=9K?F"&GRE
M3GLR,/0&?@Z>@0-G\)LL"KF;3G$^+YC:Z>;G>/67/]OSQ9OWO,V'AU8 &*;G
M8!9>,J/H!;3V#^\(K'RN^[H9I5<K-*G0BFFT9*A&H4@;>G[D[Z);R)/MM4ZL
MCM4'>B&P_<,["RMSYD WJQ^E!N3],AXSGX!(#,^FUF\\[-&00(K4P3?S&W)2
MBV(1M(I+->G>X+N*.=J9F4^U9CR,7?3B,0>'-\)5/MU#W>PRJ#6CT(P/N8I1
M!XS"295Z%$M8@?8DM!?[L:!C6FM.W:) +[1S4 [:64P"'&&[;ST^?(E*^>,L
M@),N6&IL)C0R,P3C;($\NY3<X",SZ$SCU1A#A2>+O,]XQ;\!>J,&G *-XO)&
MHV6="&9Q^.D^V>'6"TH<Z 8E_DZ9*_CDUGN 0^7C' 1]0,2\N]?*CH,/YP4'
M,\4$/#GL<"<WGC/Z<* 7?3@X''VXD_U4$8=[>%CSR7#>?K$?$8,/%]HNUS@A
M/!1__.@'WPW>NO@^P.0^*1C'P_$CDP;A'BH8!/J$32.]6+U!'E;O\".6:9!5
M57V+^J%KI ^= -M0P45D1]DRTX!#54+>C=MC$9^5$))Z$CB2=_BUC+.'HIEU
MLA)3?N*BC1;P$4)>9K ._@D!(!R-\6 'O%J5K_('MH@"_3-C]H0/-@/C#+:9
M-V-R;>J%-&(4J'"Q)5:43":+1_5X:"BZHGL6 69LU*/8QOL=5>W"Z^-,4M@4
M'MMPX"D/S@0Q+;Q;.-S$$3N[VKC](]B',R(=%A'?,UX*+.^-A4;+8#RS>1LH
M>1.D>*IME3W%%YFPR7*,*VP$;!0WV)O X:;,QC6<B\T]D+7*# [3G-<M@:5
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MN79CWMH9;C^WH_&,^H_@^<.2#)"9"S\4\(OMO27]9<3G]AI?V#R9$!3R;A]
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M;2GRC"IT2YFCCV!X?F%CYCR(>5W>)#N\BVR["1_<0),I-_@/F2R(;X$'7=R
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M.",@XQM<N&<6)IP-T3F27["I%=**0-S,C!.L]$OJ1H"-+6FP&O\R<,+O5].
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MI0MIZJ3T[B:FQ5[_M6>9O6;SF8N5\N3K=LQA<[/.Z5SD20JZM;-#D_7B[97
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M+XUF[TO@4;1_7X'2-. 5QDL<? -:57PN=.GK,ZR4.:O%Z!6G7_YLSQ=OWI,
MA0W \-W#N8\#K&1@*/(W'69_FE_:!Q?<2@(I,/^P9?8L38W!+T]Z5D!0, +[
M"M/C3RE,,X^]&8]1(L;ED1,'6T@:X7)$_5 BW[A$WJN4]>ZF"=$^)#3[RDD6
M^<7.T>; F*%"A\ZG77ES%%);PXXY4)BB?$P]1R-SKD8VYMT7]HI"Y<^;U8@B
MOR!!/@MZ[!I'T#2MWB4-J:I6I>VCWA859G5ZYJ!5IG[U)#IL:Z#R$XL,9[ZP
MN>7O8Z?DV/[?9O77*=^*^%AXI9_\Z'U,]EOO/8M8@&U/O?MO? =X*"A&+NQ
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M\[:X5L5>%RF=>A=\86#'8W@G9=.O<]5A[:%DKYITKYE,</(\P+F* ),!18+
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MHIQ]Y0W!ZG;L@G$H*H F.?'Y#"Q8KA[2Y71-<<(NUIU[[H.')>GO[O[UZ?U
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M-35)50QI*)\(I[T4KUB*+R9O>/?ZNUFD#7)J2"^Q'HTDS50D3=9ZZ=URZ5T
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M\$MX4CRGHBC:\9IW:=CAS,O:87C$5Z58C=K5[;HCD+]P0K6@0J0,9'4@=]*
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MAF2JV0D)%X".4D9/%=@82=K0DBPY.^R<!QO5^IIYZP_:4"*<L,*6GJ;9>M=
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M">=FW[K3J)=TTK+JP;[$GU5@1YP )G0^#^\^=G_B[\'2GD2_[^H#8.K.[64
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MV4&VCN2AE5)L2H%1EV0C6\EI(\Q*:2UE8&9(ZJBY]-[*$_CBTL@)5KXS7H?
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MSLH0IX">-I*,87;B:E[$[3>=;;YO9%9;VX9ZY^D5],[3+K*3Y+@%G20_>^X
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MK(%L#-3:O3MZ?<YCG9^@50+FF/.X:E6GZYI.@QYI9:AUMC>PHC?HDE9&2@6
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MGA30I^D,(6F7EA98D+JK3PO4LKMLGB?03]O0T%(O)4>M%-#[I,!34GD%28%
MYMF- "\5ZA4D!2J&0%O4.I,"C^NV6GWJNZ(,U-32(-%<*2$%O9I#)"GH\D V
M!UIJ\4]-&5\9E*RU7/$^49Y<'JB=:'Q.MQMV%Z2[&E1B_1P@V 7]]LAMWT$(
M7GR_[NKHKQK-L\@ B0Z"L(K:DI%:=MI&'?[B#,5,KZ_P'(NR4QVGE6J7U1PB
MO;2\]"FJ)7#]C+7+0H-@BN:YEP1]R]/:VZE@%23>&F;*E)VNT H(GGBFC-Q-
M+:L4""]>1ZV. "O0495KLP@C=Q"$5;@ZK=+7=U_TW&^FWTR_F4*;Z8N><RW?
M\OJQJC)>JTKX/7G1\^FMPY%P&E!?]-P7B?;G[<][:>>MMNBY(_7-PTKJ8,UZ
MZYMIZ%<A<V=&B3=CU<M1C;,3$+97XKE7CTX &T.]$:M2;&*[4_R[ZZV(2R<T
M"&S?F3\3QYW"=U;.=[88#;W?H)BL5M2')5>/]@HV]TR\R63M7Y.=/6PKQ8A/
M9W/X,&#[L8-@O6![NF+/XV>Q_<0>@QWM[F"V7@'@R<JG[A2@\_3H3![9^T%=
M\ YV/Z;\?9/5&M;UUJN)MZ#7E99J'R7=TQ#JJ!)"'>:MKQ8'9*S<^G@1]<I;
MIA9MX$!SQX5-8GG)C@X]LQ> _#=9NV#?#9S_HWS3L-+X[?CUSS^- 9.XYMM,
M8V_#>97N 5VC;@!/ 0T'V(!@YGL+M@VFH XX"R\Y&H$3;#?@ZFFPO_>*Y73A
MX4Y-,X!5"0.,:I34W@KD$4U"=!*2K^)(!E$Z\1Y<H)DIB76H6,+;O2EYHC[*
M5R"L^=Q["LZW+84J5X)DZWA87'M!*%B*2V1\?TUW0N2;OA4,FQ'7WG)<?@14
M'NSF6PR-+>A>(3!86-!#E%P3"[(LHINQJ.E\N$YBH>OATHU40<-KL9R-E>N2
MV[\V<:ZJ0%\./HGOJ/+2PR3DGX/U\JT"%QC\9UL1'8$Y=JV=D!H; NV89?]4
M0F>))Q<?+%ZBK-;4$Q/][S;62+#>:;BT?\18N4"^47S''BQ4AG&ZN=<AL#XQ
M6/V&H$)(I<4IL831&LJ2DJ_$J#R0FBZ">55=WTQ4(IP?OZOF[S-8*Q_L ]C3
M?[T8["/!E(?EJT@/VD"TL=ZHH+,^/U5KNB8951;FBDO 0_FVOW)JH*:Z*_+K
MUBK@+:JX1AF B4RF#I@$H-8&[ )5PPLT^<+L@TSYI7$D(?0#"7&@X0??O/<1
M-HZ0LVY(UK;G0ZO#2_D'\C:72EI(SAM587&H2;+ I(G& PJGQAA8_M$"@X!.
M!LZ/P:,SG5+X"O_O !$P4-'#. @=!94%)6K3:7.E+O12MHS.N^-/2><_55(4
M4Y)[.2K"E34HS,,#09J*N!0]V= TN >S"WZ$Q8%8Z[0VXZD.;5N0G\25[%+B
MN;:H\4YI48J3NG$OM5*%EUJ5ZXO%<9@.5MZ2P77S081;]ME.P.YXO"XEXG&5
M$,!CT;MD^XT']Y)(BCL)KR,C)SUQ<AN<VU#:7FA&W%5^+$0@'QJV89)9+$M_
MZ_6*^HR#W68S!J8^@-RU'S"0$UER!*A04<A'.O;7MO_,6XW;[O2*=9B<8F?)
MOUI#5L5$')?%?S29=R9G7YTYKNU.') 3/" 4K,?_AH7QI2R\] B7';S77BY]
M#Y:\)I]<,G?@Z2=G]4@^??SRE:@2+AM0O@#8G@MJ(_GBRZ^V;7&)23Y[WRGF
MWH6[G*W@QS'%X_#UX9'Q<_R] 7^-S?ME8E3_KYHY8B59T8/PPN]1'W#VA3KT
MC"_;=WS< .QV 7KA*E%*KH,COIT]/%RA0SN&A^M#$162[Q63C$TETXC'ZBH0
M6THOMG;$EII';+T'U@!^9?D[[H.';#'!V&* _/#N[E^?W@\4BS$I05MF&6S]
M0(P;IES( "\\>&1B!X];GQ%/"W+\K;R940Q#8PJ0&ZRH/<4@,\64&YX3RY\
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MG5HJH9!WH7 H([1KC58FS5J.G7^R7\ Q9TDI"4>UR.U%@)#9SXO8X!ZQPE!
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M!H(1K8;+3L&"XGU=H[2T8#6%Z2J?NKYZ9OH6)8__#:B3L_"OF04-X()*A1_
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M/<&+_J->EZYU8FCOI#OEB?P JZ%UIF+3C!8L\ZMB>/AW6ZK7_6?I#<F"90)
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M?<'G^PMIY"=U>;%K(<DV,8C&BVGG!;:(R?XSF7]63.6)%G6 />Q8IDD,#!8
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MIJC>@P@ZECHDD['W(()>10Z]Y-][$$&Q(L=9"N(]'(5LGJDSFCET@L.;BQ
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M,3(M,E]I;6UU<F]N+FAT;=U9;4_C.!#^7JG_P:JT*SB%E_*RTD(7J4![5.(
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M>Q=LB;BF]1K:BEF:&F_Q:T1#HBELJ:(R>N15X7SEE 5S"SY1I7;P.Q&4<XE
M3;:,1J@<C6EV0V$912R@"@/.-9=Q64@49>"R(,E4FA&AZS4M]Y+E,$4 !V!2
M)0^&A#(Q(%7B@-*EC"%8J=XC:H.NI,WE':<[< *#=,XO"^>)[K\/BAUUCL''
M<$LR11GG.R1=G'"SN]6.UVN*?LZ8HC$F96J \$I2=GI'!#FEH'-R%![?@_=
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M\QLPVM@P5^7B[EQ<L?\%4$L#!!0    ( %4R75,.H>[ & 0  %(/   :
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MU,RR]1HF85(.)UF"'V9RH:EN/29YSN@'/K\!HXT-<R,NKLC%3?I?4$L#!!0
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ML(5Y,'K-W!]X&M)/0/ 6^$6Y1"FR*\+__CLY0]OEVUT_YO6;_PM02P,$%
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MLA%X<>B0U%6A-]YE%@(O!&YT<MZJ+LO;OB( !LZPU5(G;[PR(.JSO=_(A0D
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MA[]!0NNH\5J'J"31MZ:L;9\E]*+Q#PNZ\CLE_6N=W6F 3B,<7&)<2N<>F&H
M1(*3SQP-K#TJ5F#99VT_\-T_"(!MT[S+2_'0?*UH9"OJM4[?Q]ARWH"E0!U>
M-("5MR1:T:1!C=4TZWMLXZ0>4Y]Z6_RKJABK>*1D\2_+(IPEMGN#.S:&="'F
M(4X'X8-3VJSGXP,U'%=E$"EI9FGS)&B^C/-.+[$096($C)EM<!?7)9<9Y.Q/
MPN2?B0U-C ;6"'C9.S;D(X\\(ZV\9;Q#;,!1?,+M!;!Y5X,\[MR%(G=5#<$@
M(=Z.[*Y*=DUA$Q#?S^X'],/J@L"UOCZ2+#5EX5W><^(B5#X):S_+/HWQ% GG
M?SQW(V)I8H"RRB37?E$>6,07CX+>_M)E1QN_V#"VH:S;!L(>(P'.$$]093:D
M&)5@OD(DU,M4/UZ,T@,NR?64M%KP#Z- CW5\G4=YCABP&+2O(]U>#&4J2BYA
M?9#M]QD(297]JX7JR[I31:+!7%663&O/O&MZ:+^[G]1$0,M[9_F73'1?,)Z5
MNL'"M<&F.P55JIIMN[M&OV$P;*/[_,'/4V]-/0OI '^X:;T8GR%)>EGJ=F[V
M]I!FKJJ'A:7#(1\?:Y"0U86-T)<5^\RW'7)^=^-%8.;-"0]SE5Y;<#"-73#<
MU*]JJQ9#C#.]R@O$!$+<VW"R!,";W9#6FA.W MPL78H=M_H_-HFUQ-MUDDVA
M?!7B^) NY5U9;M"I)-Q'2<TY^]WI$4DHZ;80;Q@'AX1(T8->H=5$T912<:HS
M*:)<A;N!@9)Z)4IG8H7KGRPC_#XAG*I'6[,6GKBWIG[WJ<@KMCEM?[FEVBTY
M"OSO*4CIW?1K,I(T=_EMM"''1E'8D'JU@^U>0<AQ9:3BBM7>8KX<(E^CQS92
M1-NEH[,C2X(B)X%T3;_BSF;,BP)LYRZ>_!Z:1 \A+@:[4;>847[$(!G]%D6U
M6I8/1_S-.C[],M%%UU/F*G/)8WL_;TDC2.3+"\R/'^R30SO+,11+719R- GI
MD=?,#A4@X:*FH'R1TB<I0JVKN7DW-(9BHT%1NRL05]?V7_U.6V0(L)V*[EB.
MIYG9Q^TMIN[]=#6^L-"6UJH5-4V%J<T?-T2UL9>CC0)S6UVPK*M%4E_?+UD[
M][M@;1WNMI&I=<8"2+&-TO%,N/),Q=.D[:5#LY1_^9M51Z5H9M147,Q#[$@_
M_G%7R=1F)<XF+.D\]3N]%TJNT$BR,7%G3AK$)V=YV2-08-8ZO1NO:V=_TIH]
MEJ? $-BV3J5LC %>QD[W2'G( FD) /?K"8K-O/(-*!TVY9B&>@*"X1\W6Q"#
M<=-@/7?AE@3 2H3?<M>C(,Z=ALZNK_W57]H"03_8EIK3/;8$48)SC8F-NC"V
M&L40T*14W-QR_U"/QW>9G]GIBXU!V<RQ0QN2C.CWOV2\^46H@.Y)<)306*ZG
M*=YZKL#$T'RN%G;<>.E.DAE(\S CCDN-ZV.&VC&IM+D8_]CIG.'<H6\(^T3@
M,86'3T.(UX^CV3.C]G0&O; 0JC1C6W7>P0\V2F 3TC>T#_\%6(YE:OOEOH$+
M49)_W:AAV7C;SP5;9BK)-]#Q;.F^VCL(*AZJ#"VXF#G8/B0 :-K]; (L.-Y=
M03$?B3/](S*&2W9_JT2Z9/Y'S",ZF';/.,]Y64WYO/R#F%\H[-N!;ZF$[I%8
MP^QR]VJKI=^,R+LWV2D W@V(+GH] =(B_KJ''UN'HGE]OK"HK+2UGJ#85>">
MJLR,.I"955:[E]UYV\K!I?JPI[J=O?$A2^Q'; 9M55V+WS967DROXG?JH^2Q
M9QN]*3W*V+<;C7?5ZP[\HV3RUO4QW.GUWEL08AU4.*]K+SH#VO!E@JNQX<]_
MXI?;H0&C/DZ\J7Y\_>V6Z>&@G?>>8Z5BVO*+-8H2H#'\;&%6D5VXV2<4:FXW
MC7$Q_>)2DI7:/:'2!N;-)5RLR.#Q2G@L6(!E((-_BL;"Q'-M\EO699#^L/ZR
M[)P>DI2GNJ+&A22#)F8$63[2R&T$&>B<_W2N+[</KE^!(,Y?Z)[YT8-1/@+#
M7!QHV;>;XU Z<*(]+-K/1#R,*[\"[#Y@;$_!?KOD>T;D5(P&*-DQM'V=\7:.
M'*]A_'68;H6H%-;^'1?04@@0;\XJ+#9RC?F+\=W[J^8;VP5% =_('#D:?\-,
MQ2H;AVPZ)G&QH"=AGT&2^G[N-=C(05E3X&7-M++ZYU_W0&*^, IY$Y5GP\<B
M*Y0__W _,I"I^I3FTBC$NW#E5Y\]-X7Y53W17YM27LD"FY(Q1.J8>MJ=QO&Q
M&QBEV64AS"/M00<:.1(F__%9O87E,+[P?25Y^KK=6Y;4KM3&^(_"^<-M;H/(
MW<7>DJFEU,N#FTJ\#'XE,^HIAB2YQ<<2WCGY82O=&>47Y_LHWCN*UFGCO>J(
M9PGM*;0D!"33D36FC;0MX\OMR@\C38Z%E,F\G#AU>T8S!E"J'"!1-7H8'N<.
MHBB2X&DUR#!*0UYF9AG9U-@_T3O#;45#-I:CJL@"'!R'/KB^F"*B#.%0#EC"
M\34KBM DY]HQR3:05VH/J*+*;8)S]FSL%@MVTK1\_(ZS#Q5X2_\3>I .YZ7Y
MD,^Z_=4N%^#.2YR=MA'2P#T"85"F0"]R*OJQ>S7]J:E3&; 22D#M1+[S+'&%
M:U 5C$J1/J#W9_"-@WP9UHSQG8%X3U%Z%?2^OH@6[U,5[L'R8.0&GV+9^R%L
MY_QO;:8-TU#SCGIMLU'&FP<DI1;HH9+Z&HT I\K]L*\-!TO/F>O\=@;9W[FQ
M*,*J$BI3X6:-NL+F7\\/3&J2*IE;:ITV3<PWF6 &9LXAM9VJ8^ 7YO+#E2]4
M/$QR.GAL@G^ST15G;Z>'\STS:7;8K_W=,)(/Z;?_!8'?LCHOJ2(:K,5I()R"
M 'CDH^R2G0:(+*)T1_;FWDZ@;*VP:Z4HXGFQ(D.77AIZK:P=J4[2$!\>FP7G
M^98]1S[GKN9P9WK;)CK!$)_OV@)71;<DLH>N%ZW?B]RT>@169=,^?2[;:N9Y
M!7:]VSKP'^OJ6-EP8!\YG@1/"^X=@5#@1*K!8^M;W(.&B=PT%YQN^W!#]/J;
MQD<^EBCF%)]'R2<^RD"GVN1S_<?K.@E6P$T>C/Y$%X@RWR@N8>>P2^\F_]SG
MI["K K5/P71A[=<N-;4N\K=QF!($4<*V<6-/7LS)MY8P/UMQ%'>E^SV3K=IV
MY80&63!9%Q<WMR$S.="F*KZ$F)6_V-/3/S6N4NY346&SOICX-0OIL.&8D@N7
MVA\UHS&U?5*!C(\/0,J#DW)I& 3/V_5,^<9Q*-:G-/G'RL-\U(N9(ZT,>\,M
M61C?>9+E=M:^OAS\4E9,JD&OOKNX'9KK(K C6WX#PPMFLA:.%$?0I)4(<BK2
MW7_??8:]]7'MYK"=FDU%E6%BK>!\4 T#ICW<YHG^@<+<7F3DE'XG]P!,-:T=
M-#I^$S3.%MI2EC<<QYNEHV,2$CWITG 1EATX,S:R=WQ^_$>UX?7Y5NSR%23^
MR6\\&OB,%'<V$>-"LZ*'LBWZH PF(P!J9U"/_B7,K";\=SRB N8@&SDJQX@2
MY6,0'P6V9+M'N>U)LR"J0247O5>K@Q8[!("EL'R5NR#JZVQ*Q/YOML TBXS3
M;&-[ER2(YA=>BRY0[+?.W@5),@]4R^_2)Z<I?X,7;/6X*Z_GYG>7(,D,"1J'
M0Z3;4OY$) ^SOMBR$LN35&\U &7I+W]B\_R?XY6.^K$CJ$=[_0+/1YQ*E@Y,
MVXX*,0]C/QFR)XP88Z#V2A&!VM.8UX:-C0R0>MSS?+FK-NM*7/L7J0C-IS.U
M)GHZ&I_G=/=:9CV89WK)CWPE^XY[1+GX&E.,%X5K<_*E>0LL?/BS%Z0N"C=[
MA_S8<'P+OC)3B9W3TQ=*!XY?]^ETG*L\%\^6/ZC.)7N'B'C]J&Q/P)B@UG:
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M=^?!;8%CW_DCO@W+6_O>*TF\5ZO;]_M3AEPR]?- +BH-;RA?KDW.'C8L<TM
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M3P,]N7I3E([4%IAK5]A D%SZVJ"/Z=#CO#G5HK+"<>6BTIY.&!:%L:<^F^@
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M2>M?Z2H!<'?"-^89?KKTJ^71)L9QRWT DD0 W':LC9I2!E4JK&D?GF5!&L(
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MBWIZFXBA+UTU^;M_SM<E=.Y7#2A2Z,Z -[:+ABB4[O\BWEW%$KU=.Q(C/X>
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M3W98-2]-+3G JA#T"SK52<^U+)6,F\9C)JK[J3A^]ZFUN\829&)\\Z.@DN%
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M?@#I]Q1^[N+%=Y328Y>*RC(C,ZWMIG^>@/S=\Y>$3.4:FG=K5P:<)HLB[=^
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M<AF=4'3(<;#@NW6^*X4\FN/@\4*Q'6MU-D[<_VS,EF3AVX(8X__1FA05G&P
MJ0<^H>19!60#.69-W=-0ZWAM0^&M8F90-Q'5IMK(2F; Q$*_$3[_.J*4%/RG
M0OEN\/V/F6J"MXC1@\5:V8[O>A-8I9S3?R%8\C2N=ICXSQB!R?K;@!G+UP$8
M"2X&V$A+VWU;UHFNG*ZA%X1^W-_3VG/28Y[/?[HP(A/AE]I$H*7?NV5 ^WF=
M^"08TS)# -$FQHS;C4>=J$#IL1SQM&AU5 CS>;]-"ZN1#(X7]\!XT\!_NR.@
MR-'0%&O 8EO%UQ)]>O7QO&7-$;GZ3M9S+XVK!HR*N!K\!?0>U<G&9(OLPKI=
MUU'R"_P4<2)B=A+26R3"O6LPDC\Q @4T 5+BRCUGN!##J>@O A BC7GX'^0.
M\38Q<N@1T9^Q=BG@\>?J9AX+_F1LA^0M;&PYC+>",4&(:>:*W[&I,L\14WR5
M'\C".IZ->UM!7$PI3^W4W3)L^/W:-HQJVVR_'IF]HDA8'3U8I">4M?9ESROA
M-*=36H?D6.!UU@/,WRTN3#35@C,J-%2-++!E696S3&GR74BMC;/ 4[ @L-E>
MI$IBMK8N)ZA<_%S+9%M2"<,.F'M<-KG;JC_2+EYUG:I$<G%.ZU%=C_+9V)>&
MX5^5YF7F)>+9QD'HZEED^JI32KM(S&7@600]@FU4!EUIT)C_AMA[PN"&PW%P
M:'3_2F1I14G#KH#Q9;P@BVM=GEGJ=%#8I@DG2J<Q8SOFA=KD@5MH+A@RJL/P
M3,'ML?RI#HRT2A@,U)#]K$:9@//B3P@/MPRO3"EO:78]G[^^.,[S:L60BQVR
M+P0%CI%S#T'GR@#1<&8+2I+95=1(5<)P 17+.R68G7\;)D/'Z.Y>0>><I^M;
MVD2*N-7DZK3WBL?F.PH>/?K'TN929D.NA!(VA_9ADCJS2SD$^=,>CZ7QWIU3
M-!CCLR+47?/RC;//#_,]?05K;*5ACQ7K$\C)DU4.-&CPC"7;#?W^\[XCFZHP
MDOW8(E>KU"IUQ230+LT\=%F\WE=>,;!:]CA%O\1Z.H.*;S^2.TA^:B,YS8FV
MW&UX'! EZQXG'H)Z8.OGV3": L27NB&-Q'0R <75[CG=X=!I?>N.O'QT\A9R
MFWNR>W8KS>WFHC'J=2-:> R]4"9.F!?&0X+Q\#;#,4UWTW82;XMA!1#>P5$8
M+4MH/U*V_&S3:-QJY-*SXE41!+7X$,2MGW/ >?6^HA +WZUU88AGU\*,EUW7
MMU6"=JH!3^;^#OJH+:VA3/<5@4,0S?U@/OG'"$J+.43U3413G0SBJE$N@,T'
MY,-5]Y'Z #VKT2"VJ\\"^ PC+RGT]YNUW+Y@U"ZT2B$FXP[PZJ@<AL;6Z<^G
M.N9Y-E!\1[:UZX[N8.NI )1)D0Z1M;B<''I@<9/(;,/X%O=7]S*7K48I?GQQ
M%21$Q8Q?[AXN[:"^<\RUKRB&AS^/^MZ+GDAU6P8G=SETW;],6]3-J;**TS)W
M\+?=R?8SY;,Q#W9CFLUIN076YP5ZVDDD%PG?_URJ3!XM-L_U5-:'7DF3U+X8
MIDC>#7&XM&J745<X$9J5NK >ANTVX#JH,@ #:#>@7K(-#)0OX$\!^W3#>(X6
MT@L6!Q/ $3+$5]*H/ -&^X9?I*^PI#\TVJUR_IHPF&ZV^_UC'CN;I&H3F&__
M?10%.R#4X].U#<^%[I.X5W.A\AEM B@#IF5>G.;&68M*I#5UIW1A(U$7F_*+
M;5'^<_+]I(CVW@R4[->Q-W=*M3AG%A_XX+G]BP,N*BD572O7R-PGYW>3%M#?
M 62\6=%F5Z1<$Z(*:;)NH.2*_%,Q]FM=!:55XK^KC>;Q9EZR(2]]7VW,EUA!
MP^/WC8B3F&/=+8:LV 73?V/T.)/!Y;LO6BR8(;0C<=@B7ZZ=M/!^':=5X(H_
MC^2Z-[5E>-R%'.![ID 9Z@7D3UE._9-B'6O3-+:^?2= F=84S[4O?HTMHB&6
M]!7^./YAW2-BFN)GZVJZNBA^^]3"1\O[Y8IGLH/52]?EJ)H39G:9MC#!/W>M
MA*X4\XH<._#J-RA^[:5TK[-%7]R\7C'BQ7)*KIJ 89""70E#]KQ5:NFU3;6G
M@SW5X&G$PD92VZD9I!Z,=% :"A.#9[(%:_/<F:(9FFG\W=(:]8"O\!;^^*YC
M+KDC'QVOF7B!,%R38HQ=I1!"IN?,3G3NQ4"W#)DV%A;\B5!TU[H%%9\1BA=%
MWY\!@LP!>#ER=(Z\8 =XK7:+%EU.H*EDQ%6,>;>U *\$Y/0P M/<6ZLD :-P
M7$_4N<P"OS;X027;@@ES9 X^"U@8L%[HQM& MHM #9T<#ON;K56%]+TS9@ R
M*'H)2) Q O'U00'2Q:RK4_>F.?FL@4K7:;D*M8V:!Y]C^W<Q?[&C#MYHS<I3
M=?[EZ/Z<XYIH$6/N[@0PK=X$X;NH?(Y!HC=9&"L@EA9PRY(+.J7\0_R(O6.W
M6L$.GSZSSKSREGQ*C(]3^?(\ F_#;I%YY:/YT7Y3_,V9Z-3RM*^;O":&7!#_
M=/D35IJ%?KKV4J<V1[J<X*Z.*TVRHB6YZ@/J&Y(?;09_,\ .I5;I_&"(II3D
MW5+7;[>R%W63SRU:9;6:9\*MRE;ZK#8L8=SH=E.UT*&_ >M;+;6LKS&:HZ%W
M(!<,FDL8!GSC,N-K_&E!$-LYG:B-L\Z,O=PZ^@J].7EPP[HEWE6O*F??WNEE
M<1@,D]4-=>I4HS3:L&J2J*U.[433I"-$%6*H PC7\>4)K6B#GTA31]<?I*;Q
M2W.!\B3!.7?G2H&5D@>-#=+0BQG8+)K:VIC/PH: !8W/=<>G@*Y?DU3&B,Q(
M:Q,#A%PQ'7E[W6ETYS#P2<#WB\&924U$]-4 (QMF1SFF$WP./OJSSB]D>F5)
M?B+D0QUJ!8?<M0(*]OV1]!ZB;'>601H-+X6D.P\OCFS5E<'WXK,YX$G!43O/
M"TDE^[?OMY*7EYU'=C:'*CM"?Z\9&&IW^[3HO5[<5GSP+2ZQ\^'YY(G'3 <$
MU?VNG 2/X]G4<FB^1W?Y;>RM:O_?[S?EV 9RE046?-FFX**%X.!TGUM9'0N/
MMSQ=O]N6IKR8A0YGOY64L,M><3<OO./2&-H2TEWM1":=E!1HYIQ;>M8O6-5=
M3S/*:N^)Z?F)* %NLIX?@JABP+.H$B,-?VDMIBY25Z_?TAG^F/()P),Y,LW[
M/N/\2Y:>$9[%;C^)+[2?F!SQ""GG4I^&PDJ+ )JY:<W"KS5&L+S.U\1(WV1.
MD^N0_\ZU!X>7YW#&60^@H93UN*RNZ#!JE25LK0XQV9!I&F;P-NO4VP?+JP4D
M<=2)(%ZD_V6VW;X4=OWZR;1*TTKDG&%\D7S&PE^->3UYHG8K^>DIVJ^58=V-
M,3RZR-$-[U%+S(Z]+NY]X7;$^B^[GW4U%\C4*\Z0_#;CC,'';W+%<Q2F.OKL
MX:-Q=^].0+1\S=,\_$9S1)7O9CFH7?YM$E"&:C@FN_.G2.9J^6O/)WW?%&NS
M%6@(JS#L>4\%>ZPJ-.N%'.M,B?U;?+A(V:B>5 CGM$! %6)R2I?T;XP<].><
M1EYGD<Q$BTR 6MQ68E@VJPA3MF*Q,,0S UW!NA*9FNMEQH_SE[*" W"F42<+
M55)Y'V%=D!B1F%EB3#GVOUP/+M9L0A*ZCG/!K^'CJK1ZO+Y2N[AA"D2"*SZK
M?6?DYRMXH\<_'\4GDA'AH\A,_G6$5]X5V?X>)5PD?UR,>LS 7GBB@0 R]@8K
M?.U/.6+NU'B;-*FS%4;C?XX*KP8<T0E[Q_/RB T%S*L=/_WSB"<6&UIE)\:@
MMQKR,I7W[N;^5LFIG^'['9Y0#GA2,1ESJN-L:]I& N?26-@Z?P]'E2F:%(9P
M=^H$\[#U6?)=0^_]#4 9-.T\1(#L9#&\M'RUING19#C4IZU4-F]Z)(#FET%>
M?./+2Y-_8X7E6;YV?>$3.U!K)%Y#S#%7$3OI$X]4O%<DW$YF;$RK^?W)C_M1
MDX6VR1C48*B=,,^-SO*2S_AZY9M\6N4+LBG#WC.>[(1-MMMA.94GI;R;8X^&
MCQ3-<JU/5<#WT)W.;*42MF^0,,IY\L>D3PH4*("'4=42(K>7_PU#_^T*!Y_6
M+)"0>?\-+M"/:P\I_V-G% T/J+-4KWWF8V#!XMI)(K!(SU!2S#J:Z9&WWWNH
MS@0^(Y=LH'C,<8IM48S2(#(]TJH8CGL3S825L \2[HY[O_<,&]R@-VIE^\V>
M&Y2.<F0X Q2=9,A?-4!(%_A3=Q(]^I@=8/J>'< RJ60N=X6PM2:W B09HAXZ
M"535],F_ _0Z/ZX.(,*JW5Q=G7$KXJ%$WE??C)3YJO Q(^!/"9T;J7OK0UT(
M_A.K)'Z"BA[5$XBF1:%Y&,2GK1^ HFF+R;46JS;=25HJ@TAZH1PTF"""P\ZY
M="<WU+JM3#ZIFA4=4^M>_*QL+/[9X S-Q?2$5<W#.EF'GBNE2<^Q<1V.Q9Q^
MJQ=%XCDYYZ-\Y8TWM=8E\;G>_W9[7:E?\?I<]T_:HS _'YOB6^GBYZ'94OXY
M#'L<M$B)HIA9S3 I_43 *+MG&C@#"OOWD#(+AZ!_0UO/;'QI4V(U)BZP M);
M91M*:?IRL!-^C0+6(6?P]" 0=^A*BRF57V(6L.5L=A!;TU]%'().->!X*//^
M"I<8Y7JA![7>HQ ]9@)UJ@/,!XR"06PEU@/*6R(L&6(:$!7.LNZ@E#<FN79+
MB[%R<ZC]SIIO%D@97=#"N*I;#Y^/]LWQ[-CG?_\>G;],FU]S\L4!$A9M3%C[
M:G.:':P)G2+>F+"5LC][1L5DJGTO"ZF(X'/8*I2W'FU10-"U1A+2,^()WM[1
MRNI9O+6F,:/  M#+3&@'UX>_X%Q$JDY3.1GOOAWMY^0KNE(AU]V"3FG0N,%%
M_[E3+-77N\3 @F#LBLB\7U,KQJPADVXZ1AN[E.]4-#C[%T;J''SQ3Y$2."F/
M._BDCJ@=_YMEP?(W#Y%O526DM)[CSWO))[Q0*/<X=Y^#M57?Z_2];)U9FG=U
M,SA,/2)0B/L61O"!\R,Y"8F\19(+>7%+R>O*E1R_J5SQU%6KZEI-'Q<B,FD\
MIEVI!N$\F;*S-ZG*]\,&R7-7U[B)]6/N'+.M^/T!ELPYGNM=TLN$[MZL2[XN
M)\062C%-U@O2?\J8]W]<TPNIAJ/N'=0M 95,_V7J[&#.>RB"DAO'W+S!T@S'
M48< XW\.07%1>AYM3=A35/= 2]/.O,S6]8/6K=S* *T)1M(O$90:F!72A3X6
MIO9"M&%."!T7I-5%(GLS@VXRK>/#"OEII+B@BX14E LL%=K*5JI@O)IUCZ[H
M^WZ!..Z=Y8! %,H&K+VB2Y/? <L[G@G=^2>Z:]'[D'FV5/UH(TJ5.4MZ 3'&
MLN\RAU(P[4Z/H3.HP,D?M<2QC5 )M/@?;)<@[! 4,.WN;O!*N]#W1';(=&]L
M\<NQ=L\ZE Z7;XJH2<W%,K]JG_#+DQTCY-5^7<F:UM6N@?Y<X0OF9;,NXQ:8
M"*]-!O#ACQ<-58'TWWI_+\W9\Z/Z4HY_O?BDMC_C;:9-N)69R30^.&NG&/!>
M&#H)I-# "=M'VA-U8RKFTC3[RE@]FAM.Z4D*W3B.NM[(W$C $\!",*2!%(P\
M&:GV+&R=.^S\0V;7C&Y#F?=X6LOC6-[N!POKAH^B>2R!\'+ L8=\")*L/P2=
M 4S)1--XY18CNK4T?/>W?Y%,+<MG*$4S0Q"9TBD>]H&AZU%9.CTS!X53M&I*
M@X.BL>Z6.P"OF>2KO<""?2-.KW8DB&F<,]31?VT#95'A'Z/ K-^2OA 4M]?=
M++P<]RLLVF.0PW]&J[PI;FL_I3D*X:ZJ<G+9L399JR'%NN@I+)<#9KL X(5H
MT9W7R;\V.@RNMA9T2<NQ^+^L6@L ,-N\]KD+;1GDR*(<*NDLF'MZD'A7Z<Q[
MCD-]_<];51*9QBT=,IM(2)9*U\C752]D.*3+T;E%^V(JK-&_1D(L*4[90>?:
M:.A!C7B@0:_\Y2C9""VYS#U(H'=RQ]")%U]8(I;FV7Y3Q0IC]GD3K&MW=;L<
M;+&V+?Z6CK;!!;#?VT%]63'4<LZ,;OE@_7LW2ZJAZ*KNP^*2ABRIYT ;/'#K
MO!S+-!UULQ+(,FXZZV;J24M49OLBX!7^58&_C0W>Q$>4OHZ &0)U/7NJY97?
MC$K<V+>B^$3-$^Z(@H4AIB>;:/":=Y^)F3!"+Z^92!Y"Z+\1XW+NAWZ7SJ"F
M-L_+WUP82L/P08195318"L0PA.JN1);6! 2\RTP% 9^:K<N<B_[BOK&J+998
M/^BC]OA,S+1(/KO62+)B\&K*N:NWC_M%;U@!K'TM@-X-/HMRHAVH4;-C= MZ
M8$(E@&4D1YS(W(C]U:*.#J^8 ]"NK('.2>@$;J<T7#*R<DS+TNEN?I1K2B^U
MR;YQ7\$ZQMD\XLR#VNOHTTM;S+ KY_U'/M1:!9<JW_;FIC*HBO>>Y_A=&F]2
MU#K75%+.!!N*_Q[\^+(TG:;\"?F:KI[]5HK;MM+Q'%;R+J*C7G'"6]S2S#C$
MY'=F?>8XRS AYJ)+?7/QTKHA,PFHL6QNND>4'3P@@P)[_JDQ.;U9!'^)3#>4
MDW0SY\J1/KFV\.B\V,8SY\B\)#9?)2J4M;U+=M7CX3_NAHSJQI6YKMAY])?I
MR<?:S\_ 33C7:K*L"NQ%0Z 7DB^GWOUT(^58=VG7.LI"[3N.=:'GU9GK4I"C
M(O!JF^9ZD2XO !-2UER!.(*YW.W>9_O;V;W(3!T-"%'2^TY M<D+;2N>8XYT
MW_*/EQ>UH-RR[ @4BIM1PZNUX4H8Z)OSS #/0U#J2:!$%]V-B!EEGWGK7R31
MLX*9)+U[#Z#2N17-) 7O2;UXU:O OO2[M18VE,"6L.)B7^'OG+?9A\>,OCM
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M7E$4<7KYVNG5_0?%JC][:84WGXY99YXFU6G>;V^F2]44^B*QJ>V0>J]SU?6
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M0!('!&KQER.D>NZ,@P+@K4/^ [H@"4P4P+,+UZ%\DL#+N:.G0Z=Z@13 .\5
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M=RF V6+@[?;GU+503YP8XP-S;4^0"SWMXL2]MRG\\9I)GKO=!@*F@=Z?7UO
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MZRTQC;VPB7]ATZ!_KL/"Y__W*1J]%W,40"<]<7+?C0((I0!NC#[^W_@."BB
M$0V3M$/ZP7_&_SLYE@*HUK]E&K%@E./TXZ86-B=_0W?I&5QN[Q+@C";R6Z@U
M/1H!LU"''9@<LY+O_-<-6\^D !K?6@J#J"68M;LXERQ05R,,KO&MWYO^1,5G
M<=1R+J-'.[A7<ZZP^DS,?PG64YMLX!'[%2JUH^S55JE>ZE:G(_UIS4IG)XOE
MB#E%@3=EH[6&7 I:KZ_E@^%TP4MR324@M%DGMMFGT':JB2OEW;*#O"K5HM;+
M6]7'^41NO 4A%[>!)@:?JY%T\4%1:;9MG3/5)*62Y>W!7A9O3^#72F+$?@-1
M0C;WZK"H$ZOU9DOG\)#5E9RZ=FI896<2>^1P[=Z2E.DK.4TE.'OYS"RWOIR/
MI9<E*J% >+@PQZG037;*S@![6*QP]5F?+1U53-GFHQ&1.4LN.QKH'[,!DP\X
MR';K= 7Z1VI@?GUOTUZN_!XJ/17T'2PE73@:+_[SJFL2DX351QK3EQ'RJ6QY
M__%FJ\[C$,V>3C1P56:^=UVG5%14'>%2(^>>I!>XY+.;Q><ZI-?$N:K%J*2#
MW9YGW:LWB-[>?DBQ&K?%B[DH.4E&8J;0+:&FV4QE<<3 [3CVNT5'2J#U[TCF
M)R+\Q/2AYG1!S&YRVK5K'A 3/YJMC?N>JMAL<F6XL$-Q%3"F1C]?MB48;VDY
MU*U=VEA\@Q^R4%'1X&8]2N;+FN1HE]R'H 335\M469033N96BY6&?9O<5!:J
MFG0)K\?N[CZD=^@%9?J?&0=/PJ# $H._FTBN-#*U*-YRWT2A#]W\29YD\Q2>
MX-O6\X7/L64G3$H?A#.D .+:D@2(:=,4P)@MX!@%CY9*VQ^$,TOVBX42%?T9
M5]<.(9K'1'G%M4E!AE$* "LS+!X$K^FO\%@<(WU%.1)DQF/8CQU/SG?)LK<+
M>!]:XG/\NOS4.D!<%MA!DBHOIH#]7+/_R@#L=^6SY9!\:M^3_;FI?"")21!3
MZG0)"W.;?07OS*@&)PN#C_^9I^ %I5/U54&Q7CLCNQ#-H Z$I[>'BL>_R#,^
MO5T>R6X5]ZDNA_PMDX/&K3W)+ZRDDW@R>9 "Z#=TB@W,E&BF "QCTOXZ@C]-
M7FJ[)V2ANG=34.VE<6UB#:MM@ I41$L).(%KS,<9@C^V='W%J/D$@UBN7%!%
M4<&W3Q!(#+\+?3A+'__:KJ(3L7'_5$;AKT&.FH1$M^0Y'(/4R2\[6]IZMF@Y
M\<-':^+%^NF^G> 'J$L5\5Y?B$*"ZH,*6LZ^UAM8>[>0(@V6S%6+QKSYQ#2J
M)*U%E8]!&D,-QQ&0GZ1 ,%&(OO_>,++/>6@+R)SU.'2KI[?QOP.M,6N#I2U,
M6D(6,1Z%[#?#XGA8E*C4"N$(/ZSB,?MGM,=+WW91\ZI[S%2:##I5@C>,<ZU-
MI@+@U.GPVQH>*^Y&0=9NH=FOPA,L1^O8HP=?-B_1Q_2_W$7UO=J=['84GBFV
M3D_?'K\792;4P.]\4,TR9P?R:Q<]UR2]Q"5FQ<LB[@V\%X.ZE.\H$QI8"DNV
M.9;=JMS)(3O* [D\Q9XJ;F>YF/$1\9F<'YV<OWLUHCNPAA<M4#-O7(P>,0@-
MHK4A6O0WOE7C^I&/>:[&VS8=^(PUZL#X5-?CEL1^ DZV3F*IN=K[A-/[_N?O
M[QT6."@ 14?"(3';4F8(S^K;A<5\QU9S :G3YM;RW\Q&A*_D,W("%?I\ER^7
M=<;>![9G=C(8OMJ ^Y>GW1O<*9$I<P_]VWTZ*@32(F*YK,:3ZU[OBBK0P[A-
M)BHZ"/?D*O)K?-_P%$"Y#ZXXY7'B9PTTV9_18NI_X/LO25S>BNBW*-/)#<D0
MF4EB+':;SF0IVC /JM#,_&X>EVX\1SCO ]9O#20S[G D%9<11WO..C,<OZWE
M"FI.UKL>R.[2ZLG]>=@4_Z*N*8ES!G^=P=TSG'4LI9?W+IV'KO5%9:<2)'56
MA=M@H!6V (V/#XW=(TFA1Q@@DMA'N_?L>YU<O+GWR75,YN+!,)\Q%6VJ![VO
MR< GYPZ0B3XU.\3: # 1?/O01>*3QU7P;:@>;EK,X$ ? 0=%_9U@MEKXL6FS
M+W]HE,F_M5?E<:<?"*0 / YOVEO9[.0#H=JEEAXL,4:XK=@ 1:A"&3&H;U&W
M12N0F]XD^9F6U]T4OJ"W06#G#I1SM(?G4S:)Z]H*\)@1HG[]#V)(#D,F>B,Z
M :NC&/?%4R2@4%DD$DYG*VNG[ZZ;$6HUNU'KJV.-O"2].M92&9*@ >RK'"[R
MF"U6/BHPD*D6/AIFW$P7<1#U>Y:=7:;8\RAA2WA8S]_MW"X4OX:9_=Y:NPK!
M&B6XDZ5^$#^&\5=G.0,'6K4^RNZ'@/AN-N2Q[2.>:=X)IOL5,2FO5(T7Q+KT
MT<=GG4D48_/O+MFO0F"AVZP<7KG%?VHU?54&Y5;VTMPR9ZOY2:ANFLTC?['O
MIN;&\(=(%I+,^9/P.7N)V;UZ>GJ2"]X97K8Z=#]I>1YBS.E:T)B\SWH:=#KU
M![]HZ79FUW2F7QP:I,K2.$G#;DEJ^%,7/FTOC8M'E!2</R&]("*JGV]R-N+J
MB K=]M>BMZVP>1-Z<X=0P=+=3E[Y6HT=K\H]V24KNVM+$X$ OK,9$9^#.^S1
MB ]H,82SJ?#L&4*5]@V-U'397"$7OY>;)KU^HJJ<NZ'IEDARWE2JMOHR/C^*
MRS&IUP%WC =R7WRQ0I/;;!AB!C4RK/^*C+#&^!7MFI5)5LSDU\.-$UX6R'DH
M"4PL()X1FHG',)XO;8,_%L!N603K9,) 5@$1IC/7X)$K)DD(6"0WN;S,RIY\
M$1QD!)8M"[KRND5;M\84MKB$;=N9RUY!)NW7[^X2Q3PE'D[]%;\YT'T?];TC
M8F'_S<O:(\^MVV5@U=0;XC++TB^.-%B!R7?#%Y ,Q4+:^-_OYT[%!?L5?\O
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M-_,)+'R#I=7GP%3T,AO+#SY-D(-KR&*%Q_AO'KH0H,%T?Y8<!XY3AXG4Y<.
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MX_8<'1$";$4VGO7+2"$+1%97PXN-OSX[ET "ER[634UY/Q#ZSN&M(?SDUI-
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M)NH1,O'!H)(QGTCYR'7RZT/58*'B1^$F[W+#VX<C]YS=A%LU?FAVJ(N%2"/
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MML "@K6FWNGI,Z0"<ES4W?EM!RUC1[]Z9/&PB,%/AW>*W^X/4T:?K%;$H<4
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M0.L-J_9P S:(0I3Q-X)P'=VHEA;8-BI^J;]V1A!8;*M+4(PI]UOGOK_+7OS
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MKPD2'BS-MRM<B*^PP4=<3_.P#!1<,"L_*+"MSHYM#5SOP%(/01*0!U;)AER
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M8&J\BKS.E2RB3N2-6_C+FC)N.C/"J6$C;@8"7F,D>!T/,JQK=L)=C(5)Z;B
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MZJRWBP<K*S7986%C;-A0\, 5S?!WV]-FWR9,'>,IV;C0E<H2%03@7G5CN_[
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M.JZSP&D/F4L)&NV^DZ-:*1 >OTQ>G/=8:9:I_PZTOD^?5[3KDZA3K8MB--Q
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MT_3DN6O'E7Y<NE$7'RW(5CC HB"PFDFV$6NL9129^-'0@#F^^ QUF[\O4</
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M5F][O9JYNBU).TR\A@K29ZK5B\C"#6"Z,DW=%V\!H<ON<0_K.NC<GFPT4B4
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MSXH,:'9VXR0A5!$Z+./0,'&W?>;3A"*_A]SQMOC$B&2RJ=+G_GNT!]"\)#E
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M_<IQ<EG%;[J>R$/\TAJMV#AQ.^Q0RC:@NM[0)8>H?^,=N/$ QKB)J76.I*H
M(0IMT%Y!]L\_6CE)V/Z6OK?8)3>Y"S_5Q2%ODOPK,QL^9?J:+7:_+(4-5&IY
M($E&3+BMMT)NR04)R8- <F39R[_A=UBCJP(B"BSCE!_X&%C(FA8N%RZU$$M]
MFJ$6JD*9,_C^7S9&8LNIRMNX^\T6T58&HP[V%KESML,[C@MH%TW\#&$T E=U
M<,:MC^E&LS/'^:V@PZEW^2[LO;+#QX=0G/!D7WC2U$81*N:YK39@G"%[;]$:
MHO8X7-'MI-P4V"-\ 4><@U@H+Z4(Z7TPMCI.LN)(@7*4S(&H5(^E$CZ\ZFAF
M8O=VDBI4#,Z%[^N[IE=@$O<&"P['U/9ORZS X]&\Z7V-RAB.>C"-+82##YM
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MK*]\G3\-RTGF$N$.Q9JV2U>*L*AX]UBEE!66CB?YEO9Q';D:CUL(L*WK^_B
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MAY?S3-:]H.BH6SYMXA-TW?R/05"(\!T.<U3:)[=5Y+D3P--C?C(HO6)NWN]
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MA"BL#B>HD("WH!KT*P#]:ZIA$3A!ZTX+?XQTP)U0RM^,BFB_D(]KF@US3KC
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MTJ)PCSK;XO,533BQ#[(EO4:U:74#H[2;IY]^EXD\'$R!]+DP4YE[:O05-C?
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M+FM3.3#BE.Z4<F232*B=WR#K6AY?07%^90T#66X,D7D$+R",,B[I+ORO6%%
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M^(R#>8'C,TM&]8>VDOI?*; PD=JEV@_Q)Q1;^/1D7/(6_N02)$VGW2K=M&\
M.;8YBF#$4NEI=NE^'*/9*XDI_/I8.APJHC_?!&#TJTEI&A+ /?_7:<ME9^?/
M%ZJZ!L!E8/-7GCU.2"E$40_LRI%:([M@KN/M@HZK:S$F;/IUS7(";>_6!</.
MKJK7EY8B4/M??[,;"X@]L.K\HODN^YQ(D< "HX8/YF]XXU%"FFZXWS:T:MYO
M3BREVS)3H8LO_O-$N1W/]?%R^5LEBV85&O@0F;_-5:I_%%&"F<]>^VI5AO"O
M4FLY#;D.ZJO.!4)FPGP?IK>].G0X+NP&G"2J \SO=O$*%(!AR-:WFJ[('['Y
M>E_)^OPW8?&Y_GVVW$,F[Q-A#051#S&,"/);P$1F=+GDU9Q+CT)W?9GL1VPQ
M_GIXX)%$TD4!6_3_AK +,B:Q[C3SV ZQ]07U+4*)KU3[XS72C;CG7^F]?>NC
MU>$@X.)B3+GC__C5?T)2Z%C0U?7>-\/J!7_D5^?NDN23B3F*;OA1TA;Z4_ZM
M0RS/DXB2P[RP3+A(N;:KL2\U_Q?9L:4E&"R"]I=@1[+3JVME,4B7=R[>) T4
MN YP?P\,=Y)3VD4GX!Z?ZAK]\H@7ZIK['U?>6A/L,QCU(!*\" G,6D+L;68O
M/0YS< 7A.[FU,4C%\!ESU62+R])A&Q]/V__Z(WA_0[#[9W&6W)5T-QMPZ+S"
M"6@QM(&]$YPL+BYQ\8,;$$D%)V%/@Z37=<H3E%7TY-R#JOQ /!-UGFGKUF,A
M43(#H<6>P3,6(A8C(3@0^===[OX7EJ[$?"@_JW.NSJ@'?@&42AN%)^XS,!&;
MPC]\)3A;'PNV^ AT=P0H3?34Y[W[J1CP'TXO1_#K@4W971%RHX\C3B>T^TZF
M.W_I@&YDE4TQ3-]R]8B-_2"L*V4@FN; ?:9:4]L^:8?VM>2]S8>*T2(3T0S<
M^0>^UC8?2H6$'RX9]_0.Y!CM5QV<8TW;CB*/E2"Z]>JMOE( W<<Z!R 8S<B'
MY"D@^3-(MQEK+BQ8Z^,E&MI<]HFB4(>QI+%PBF95=>6Y.20^0_.YM7\'#!.%
MO[;$?)&(O6;#W6%_@H67C'M0D%KH1P.S.)*/83]K_(C-,\KT#I!'+\"-=0NK
MT^CL\<Q+*D]WHRSAEP9YIF!,NP4EPS&=D.*54$,H8,34=5<:S]:\:+Z7$Z@6
M4(7ZPW:JDO:N7\XK_>Z5QR_3[,TZ%-Z<4+RMQ>U$PBB(KWZU_%7QC2)X6)8Z
MJT<,TSC&*'?:-G]02AZ8:NSV6^O?QRN=I8IF]WMO,"9$"TPLHY-,2MPA,U9A
M>QJAXY$_)0VIX1H=)X6D'O_3_5J3[S*/"*QX3K$C85K4X\7Z;[MN"/G?#76K
MMXC+P8VS<^;I:V9PQ[ L\;EOB$WXQ@:RXU(TLP3[.)QO$*V"FOF@,,727A-N
M+Z#!J2'+<3AE%74GZ)EU38V/#O_XER 6[,;?$4XJCW$I^8N&AP<*3%AO+_Q-
M.*Q'Z0#%YDVC('FF2M-XR#:7,^!E-,(T*/$^FQ.1ELJ=DBZ3@^^!^4\UC[&Z
M]+*;4P+2&7RWA>_=.N-X>+*K_?+ '\?7&ZXZK?)]7)88&6&\8M'IZQ4F5K%_
MR\_L!.P5S&9_^KNI=ZO'*%U..O)I:0C)Z%M.93WI-]B,&740"ORA5+]75PKJ
MMB6G87P/MOP5@]LT[9/(I]VJ]X3Y7SG,N$[),NMA.IO5':=BW3C ]WR.V.K-
M:ZES; C5;MML8:&X.IY+8C9J@R@11OM('0[4<1$-W&_5%!OJA^UP*"W=G]O\
ME/?JO>>,S7^_CMWY$1OO$9O?=H($GT.KYOQ*R*"7]3A'0_3HI,+4HEW_67^9
M;#4,Q.7MWY0EJ91%KT>?29OEW>#DL$+084X[)R9NS\*;I0M YS=53#%=5LZ<
MU[>+65\:/M+!\7D1F?4']V;>3A"XG!7LU\(>H!&)LOW[V0HQC1"!Q"[K_3*.
MH8ST?)]*Z_=?F?6+I18S^OKK.)>TAIP[F3Y=][<'!T*B<%&V@_OP7ZC73+M#
M'!,]OXRU'F-&*>.D6SRF2C>:]<).<74\76Q(,PU^_>H 7^]DS+&R=N++GLI4
M%6.=A+J.N+/M/$$0&19<592NHVTG/JG'W)T@4J0^O<'MHL^N,YY=<YJ=\7DO
MN,^%-C2J;:R!I3<V?B71P^BRC%1@HFI-2%P0)$0?+&62.+F6R3LP8Z_HGU]?
MN;BJ?RUG^'; >=.?-)IFB!:!#-*/&>@V49REWD/CHPA]AGE1\A*1IRF8>.&P
MV#K-L6Z(8%9XE8//_@A=C'E3J. X82&\ 5PS&Y7#HE-V".II'O/'G4CMUR-Q
M+A#VF(XAC5S<V=&4?)NLS)7?(8XS?_RW8?_4<PSEEI\++M6L<Y#>E!0H5_3
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M%,"X@?H#J!/V*5+OV)&D("(_NZH"JO3*:8I0&KY=&WF=YM6%B=-Y*4B\M$7
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M130P<C7JQYC:A^5$]V/F +Q]LUFJA]A- DR$,I<(\P<)FQW(J?_O" O6V$>
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M\FR//WPMEK>0\U*5+''I]VV6Q$E$,MZ?N9"&Z!/8X[_%Y+9Z7OW1N%>@0G9
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M.=/<KUL7G(>4Z3#9%K.M[/@UNS[L]'0O] +2X4 /"?T.$D+$W*4M=X%3VF\
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MX'D(UZK0?E^L6B3\;#];_3AYVV[\48N/>O*8_@?S62=ZW\+RQC)=E@'&F([
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M'Z;+_K]CK*R9N%-/.M5K&F3?EVT.LT)\]'<:QXB:1Q:^"U&6G%ST!N[OXQ@
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M'U1+$\:V8YERF=I+*QU@83)H8C&A]@0L1#+_N_GW;^T0R,PMTD^A]VJWU97
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MX*M.;O BUZO%T^,&U_$E G\ZA8AK;R(6)(:OC^]J62KU&@E.!&G%!<D-6T[
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MKLO/I]:5Y7X.A3?205RZ3[3]@4O(WMFH<,VE(>T5\5-TD'@P<80C!_S[Q7#
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M@/F ##18!);O']^A_0'SG'(SV&)CSN?[M<XQ]_8)Q<76]%L-G= SN)M**-:
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M//=&)U;Z<8;,.%H"W,NWKN.)$WF?JB)TGUK(\<P#0.V74E,4B7 ;O#(__#H
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M/'RXH*.C]5&@)48D?9<Q+KE(FN_> >)/L\W1.8XNF,*3'X<JL. )5*^/9!\
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M/CLI#70D'!_V_'L^PM@(.'IQ(")#RG]9HYHEI#T2I&.B>5*S3.L.GYOYB7K
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M"]%(C/WGZUAQ.Q>*KYNJLKP]Z)Q _A2*W2_P&1>2O?6U'<XN3@\'7.AJ$7-
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M"EYA9 Q_!ID#LA#E-QC[6'4V(%:)&8]9*V=-%-"NP?39@-^HQK][>I/,:#;
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MH2Z[$6 %_<-Y'],;4K?A63O-SO'[3NE-I.5E2CY-JG^WS__L$4-<O[&5M/J
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MK)GO"EMY$Y[*Q6<N\B"6H\V\<B!_.F?GY?L@VW4K*_ G*$'9O@-<,IAMNN$
MGYPR$' BW@9#/^<)'JX^D^"\'0PHV7&3)8%GTG-G<',6MQ]! ^+=S>ZCQ&G2
MSG&ISH$!'%NT5_"W\!/+Y"(;<*TJ+"F,]\YU-+E#>MM<U<SXC?@*SJ[ _D/$
M.FEV.D-?G8.M>M$<X/7XPUB!AWZB/PL3YC_1?7F?,8U#U1RLMC-<"0E%SEBA
MZ[5O+LF 'XQ(PLJO3<W.EJ+:H1);4JYZ-ZI9N!:Y^RB=*JI5#+D4)S!:/C$>
M/$J(YBF\'XBOFIS\4B=9=B[*YZG\&5:Y!OG6"9,;^_ Q9SG;MD2WV2=:/)CZ
MW$:N0W=]M&T2XB=P=\H+G*GV:WS$8]YS!D(_YPL>KKK&\83$;:2->"6:;MOI
M>V_\R%=G%X)?]=V@1%X92Q_HD9",_K:Y8F=GCZ'![XR!I[N.,-)#7+G1W8:Z
MR-H<WS%#U0>C5A/I8"24IX4'>9[N/W.KR94RE0CJT]./DCK8P%'ZN9F.L(T+
MQY[I9/-,CD@P73T\I4.JA[>@)^=\,Q1/SHYK)W,KPHN8!#['][-<SSKWT)5C
MTF Z;L/,]_^66)LK9\_*\<]!4P8U3TS?CJ  I_F="X*EDQ.5.T#^['^Y!0[]
MA'FF?I6&1,612*#I\6Q#_IHC[9,*ELX, XTIA/TN.!=#(UAX>L;Z?DPX[@6[
M$AC$0"GNN4C [T(39SB>)_:2ZO9%5 1Q?IVT6U#(E-'[]T0)R0G-T':8"_ $
M)71">GNWZ5*_$4<^!O_)1S+)D95#)W*358)E0FB'UF#=D78<86B,<8N9BP/G
MV0 C(5Z1PF-FR:!U$\;JR3=/-KJY["$*,E;0^<$9;&"C'_\W[=_KNEI6C<!Q
M1O?\NL-N(;K39HIJA][C0Q'#T0M)N.O8O7?&9_[2_^1!J0%XIJ@G-WB*XTSF
MX7ORD8M$)IQ8$+;9!6EO40RJKB+-;6UQ>N I$]E9K2#,R.SJTTN05<D-OWE[
M-[0<2X4Y#RXP\V ,Q66SG*EQV$X?^@4ZXQ-'[O(Y<J<(>D __]IC*B! Q \V
M('B-4SNP!4V&,9J<CQD#"R#HH>4$L1?2-B1FGXGC]L[?AP;H9=!\4")YLQ4/
M.A(WBS?&&-'@KB\UE^B[!F7,X=OQ_<[@R;><W)2A!Q#;81PBLH#B6=>/3\W'
M8VDBA4Q1#_#YOV?:B#WYRCT,9YM@#NLJC"),@[,LT-06!/,[='F; U4F&S"F
M+*<5_6\.[#MW9K=VBS\;\-\E[7( J-,&2[7#[!U!$<WJH=3B&T%$7P'NY:'"
MF5@811E&5VDY#XZP<EZ:2S-/2>CKSQP_R09@5O<Y+ GO.A*<R@;(Z-V!LVFO
M0D4XS*BA0:IQ,NEU8@/!Z8L%F(IFS&:I4/V_HW4Q@9O3DD;=G ABV4#,#C0;
MG='-O,)9U@$[8XY64L--A)6)\Q3^84X"H50[Q+\$XNE>MFP@XW :&2[,V883
M?BT<O1Z!$ZA25BU\54<7V\4N7K^;;*0"RFZP@?>#H55L(!#&63*G-G1P]-A+
M'!/ !BY@_IUW?%2+P0:&T;]0J.%93L8XGGJZI/#$$B=\4SAFDOMJ3@:H3US<
MY(3CE467DXY:3>&8-'[W*KKS_%<&B0VT_IO+X@^>N;$)[M3!_%E_>S&Z%]B
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M:?IE-'=:KVU0QE'P=8M<*\%<FK\IC#L9$3,IR#=Y?.A=(U]<!<\9-@"MTUE
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MR=='32CQ66$JD'&:LV#%088F -VS)/^K<KOVJ<1#]PHU_ZNW#>_B0/FX"AI
MK>XUKTRJ/9G3$'O7YI8$K$WI^21VU_I>[!7]6]8OCDE*;4'\0AGA)-\;?5OW
M!X!O>Q9-@-&%47OE.99L;PNOC%M?YI@)KBQY6IJ]/Z*W7RKP\[DZC2NTMB?0
MS4$]^][1F4$K=_WV#&5CQEJ&?]"Z)&T%3.1%465?D1B"N#5*EY"X#&4)] !<
M5L[^I?,6!HF7)I M-@\5P17O=6<N4<B2S;<972T:L^)=4[@ANS(7#L"ACV\7
MZ'VK%.GU@)G7C6!?NV^IP0"."X]:+^F]8._Y=<O@J/3>;T=)L*#B^=JL/$;%
M6R-/Y!I-%;L:5 ^Z1P5?SJZZ,F;T;&4L?KSI>U:SGR5MA0GXGTN*!E$08/>
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M_Y33CS\1'$^3,YMN=+-B+!FF[VX@L[:1K84XLD52 DX,[)ZT2P&C4-M#%4S
MRCZ+?N\LP;/Y,BD4PEZH>#M^1H?$!%PA+.K^80)RCJX! 4F)?PX/1YX3_H+3
M#Y@ R>6T1@L2.W;B.EJ;Q:?L',;7)\Y7'I<P 8^":6[B[ML39/  -^MU:+(%
M/(#2NQ<J,\$X#Q7_O+O(N,TVL@..8 +PLJR;?H?7P!43#+YL;59Q^6$XMTLK
MII^KUE@L"./Y2=<7 4UO,0%K13CB5?_DD54[4Q4F("D<"/DG>!CWG@D8:'RQ
M91?EEY89!!Z09UQB965$,G+(GYZ-).=3-@N02US+ \.1K !_8P7XE@Q#$+6V
M<QTHR0)WX@G/YRP1MMJ!<=S@-(N\K"# 44O(5$F#:<?W",MXML^D52-866>P
M3><COW#%],$JAMG>SL0/]/$GY\V4, G^GH6RC\.G=3;JG,=JMNH8^JQT>:#X
M.Y*$H_%&DW119$F27V+C#2):8)5Q9H06[O>-RF8][JM26YFY.MVGQ&F24M3A
M>:/6).ZFVU3D*[LG3R8XR>TNH[8M]>>SH ]^"J<[=M]>M,5)HM0#V1,U7;$.
M]"\LV2D]Q@1$I\  W.PT5]LWX> E+PKW .D/)=$4(0378(5&6?\0>L0$_++8
M!Y<@C9\'2800@/,';[6R8?63SR[;P$*3VF_7.& G4U".2Z556^ +1-'F;$[5
MCH<_*A>OZHK[JI!.RM9*[U@L&)5HY0=$T]&2]C@?0L32_&/H5'!K\Y-G.4-=
M-!EC>[,7UTL64DFB+P  VS4,ZN\\-8IR+,[7CVJGJ_P8GU('Q0M_B#)8>T]H
M- QRW2Z[^/#* ,E];;MKG<4^LUR&<' ;NQB%)2-_P.,X-VWX31@3T#6[HZM-
M"5%?\2=RW09_=B=W-2$B9\,7/RW"^YB ACFQ%-8>P?!P!9>!ZKT1/3(3D'?5
M[2HFVJ/S1DJ4DU^=RH%3,_;VB_X^79N=H# UWVB9&Q(R<O=2/'E(0DJ@--U[
ML_+77X3YR'P.H',S^K*E6%SQ64*>;&:CW9I@ MR;'#MT)=!Z@\T\-&^*01VY
M&,^0(4.C F]F,Q8[=:^-!>9%K06"N6'O.)V5[S:,6/SSOE=:\\S*", (4UF7
MMZ6<RW7_ D.:C 5F^=E]M%L.M8ESOY93Y*46D'NBLK+\E<K^>=U@OAC[:LF;
MY[B0CLAR:!<N2E-M+9.< J'P=^&!D?4UK5=T08;$@<@: GNC>5C1:CT3T-Z[
M_G2S(V7IO70$A9H,C7G^9\I@WT\^3N#U<25U4L4R9\;CZW5F)L*@J5TY[?[B
MCD=*HC,%ULYSJ[/%YCF6%\BCJX]EC$L<5#P'T151ZL0Y\[&7).G%+7&VV>?4
MSX3KEB'.<MP]/W:_V?:]* KIT[3,C2ET_JXX+F^1</:NIW%>L8&9M<[G+[F"
MNG=Q'T"BSK"G^UTNZ@UD_;QJ<?9:"BKF']GTS>;1*IBCN2;TI5;(8TFXM):B
MXF/PYGFELGMLG2W@%@TP-T.\*.ID8\CL+$A**8DHPE:S,._;,M6^D37Y4\H:
M':/9E/ZN69IF0I%.S8',)8C@P=S:T!)/%[&&2F?=_3MEH[N]T[]5&GH!)O;.
M#AV:5_?P0&F+)6L[?GX:*QTN"\X-LNKF42MF>V(-V89[B DACVEUYJM"+N;R
M0_B=']]PPLI%.7M_:U^]F64<&ZAS9&J\H10$5L!<,(SEQ5P9Q5B^*Y8+_#:X
MIR+SK"VOJ<=IQ(K_^Y@*,;W=YZHYBR2V!T@*SW[T,/^D,&(86IGQ=?:*%00(
MZ[M3]*W%:LK\%H#[RWX'$N.P [I-*Z;AD;.IR*TRQAODRCP3X(FD7Z<2:-YT
MS;':3H[65NV7K1JK(U\6V:=PO>CS^? ME,=@$7:8X(17[*B@V\T&LE(B!4G(
M9P*^C0H16:+>J$C:%()=(]VENI.\T0!8*9B':FM3,^'SZ^J$L$L<,5S1G'(N
MYL6UB_76(U5_SRD8FM:YZ:=J+UQ9N=?5=SC0BIXJ85R%WZ"<2Z&TF)!)=ZCK
M)(((C*37]+(\TXIJ@J7ZRH.YJ%P/JX<S6.:+U_J\B9O8GT$1TR2GIM'9@\"=
MFD[%8ZO(\XW\,F]I:B33@!;-7PAI<D&##U'LS(J)29E@M+9IP:IMO7YKN<CB
M2&"#O$F)W&'?1ZEN_Q@CD3ZXXQ=$'UC\)<NV(#@HSDS NKW._ML=R)0640U?
M8MGJOZJY4T9%M63LO59-RR)W*%P+9/-Y.:6_?:TP,.]^^;*F<E%SEL N_\'H
MI9>%W9-8;UU3ZVG_YRF%0H6&]>;QV)(_SU!E19F8EWN?59JPI>B)GSOH29E.
M$)\J^!VX"MG.JFE,P'G%9AE#,IKD@XK6%BKURA8?W.$RZVK7W'Q=J2AP[76(
MP&MW=_=OI9\"D5=OUHPX7AX=E.B^VO_+>T.[IAA)8*-YDZ=GL6LF0#QHBGV/
M8$O'X+QQ[-5Q%$)[]=+,.6K/H<5*T@J4"ZY5E'=8 02:34Q4/]T\TNVQ\;"%
MC#Q*'((3U6S'0.3UGTS TB[.EPF@@8>9@&T-EP51W.7".PG&M-L@'_4 J]RK
MJ.O-PK8U9=8VE[JXDVWWRAZ8+O>&.XVFNBL&12L9R3?:EBTU][S!KDRMN^Y$
M*ZP0]EM8#%&:8=5<.)""[=ND!LTC=T()-4@&:!EY\#F7(58'HHO7K!-81>,0
MRG"7AZS]BF1$C[)*5>]'Y!9)BXA<$D/.M3(!6[D[<=HO+C !+<C#W9A2C[VI
MO:QORX)EOYY5A8DTW=QI57;\HYJZGC>>+GN"4F[B(QOKON4KX7_U?)(<I0,1
MAJ9*CQIBUPN/@D'8KDG@-OFO#$W+E["!GC;9VY":9QD6SKW;OT&' @/8$P@K
MY%.6=M.!.<BKZ2 FH+?>0WQ"N-+.P<8QP#5OVL5ODC^=P1%P).-)X)B>;73P
MPZO#%13QJP.Q$\$/X$83<Y2;&&("Q#"<S?SMD?.+)^FWQBHMQ=.+E@4H^M[^
M9PR,N-)U!TC WZY[+ZFO_3$N,.S<6&EQ0 $\C!5U3T>3]%&LPE.P $M:)DS+
M)A3%)W/3+4>X$E*S\CNCOAGY%YB>;+S5FMH'_W0D0;M(T2%T@*9YYYXV'=UE
M##4K#>ERLQHJ3#1-,)P$BH%\]Q;(,*N8Y9*$-E5G,P%'T@(?$^Z$.,ALC49=
M,B:I[C^G9XV>_$M!DFZ<^2)*'0C@_G+.;OG@L?_H]D03',L]TJ?D-%[*!GSU
MUDWO')D:?U.>,S;W=3N13%VKX4K,M6CF%3*NTK=X4V:>:QT@7;2M/B.W6)9N
MWNO_P8-X0^,SV=K*GT]^"*9M(&M@_#WU [G*0Z. ^$=DK%A#OCKD%^%']-H(
M.+$2%1,WZ_B:A 92_4B"42_1W(;8E;;# 2/J>GC -_@=V$<G'\VH7_O!)CE>
M(Y($6!!GS,,1ERL+[T5P%>@U(S+GGFLY-1 #EQE47=<%O7500\%UYNP#T;Q>
MV1>S)TRIJ<1[C=8DOMKT!^\S"U7%0H<4+>;(>\OODHQU@F*.=*9+MX$=N(1+
M/_!*U G.VK.OD$3GI,^O3A^ZRGQF E[)EBYGRU KYG1L\5,LE;@*ER$V72,8
M-5(N[^\5Y)ZL(D27;#Q]XW1@PP3(0R2OZ]JK2[TPPJ)SLY\^Z%JHU>Z5/<RZ
MVFV5;_"R;/1&Y0]&V_D2X_0?>U9%(WN):A;Q!:ECN5\AY<W6$7L7?AE ,\-#
MW!B=@5=L6AY?MRC6ODLR#I3<C7;6N&V*BU'SD?JTZ\Q_(96C$T)JH74?_]%H
M3L2=HRJV3W7%:=N6>"+$R /1E4=9CBX3NR5W)NX/J_A(]RBK;N07>@F^Z/+Q
M=/<\4UDQH!(C?*7WNNC$6$#)NB+M.)(60[+?0P9H"LL/-)ZD0.<P'5=4P]!O
M&3KDZ,3U2I'I<#7'6C+JG<H MU[>BIK- R^;/<TW&6X=;5/.IAAGAYF.LQWB
M)M[O_EE?:47!W!ZT&FJ<H*QG:QPB*@]2JCYD34%/'*[OO72>'O)=>S.6XG>W
M8?E@=RT-^_5)U8E7R2'R(]D:;" ,J#]]P&R1_7,B21PW,#'^<4/CF0#[%])(
M >S"[.+G\< /7@964Z8NPXU%EL8V^SYR-IF-E?"$!B=/M9ZUW7$U4YG\W7J;
M$>=G_@@M:L(LY*V+6"/%'0\6A 6W(H1^P'(;)QI-BR:7#DTK^J<?V6/]W&+Y
ME'#=%Q32$ !L"@+ !+3>0SY&3R'Q#A.1S6<8@[K'*<%Q*J8(O[.0N:5 X!K=
M9=_NW2]A!>$N*Q.CW6]!K9+Y_1_3KROY^,Q>QQ;#G>=P[%2<4<,@S3W'(_O2
MX#6QITW#VK<+[+VFG/[=E/@]X(8\.][_.#U _\-30O<R5)EVBL[J#1YO1@A/
MO-/6(W/.$MK\V&%Q-A,+8]IZWV%0@Q'?JAM$L>&0X<S"_*;ZX8UA69>;$3V.
M5J<7Y_O"A(*4(Z^XJ1\*K3\;3^>W?N/Z08\MID?6S2^5Y:OUM9]=_O28%R6!
MEO.]UM]=W>]NJ(RWQKQKLPQH&?E BLG,L7F>4O_ 99@[5?U%E=3G!7%W<ITC
MY-L&R_XT:>'9V@Y1L3N<0![]4UE!4PI[Q:ZNB/'#RNW)Y1?Z)_^0*PE^]36U
M-57WX-W2:8()?#]:<^8VXUCJV6B?.T $<M%ND=,JOCKTAG&-8]RPG@.>7H>^
MQ;K1<%^IL#=;KC7C)?^&LSV/XP-/'LEI&=^9B*7=IZ?ILM-<J*@"^"W*8G3^
M&-P]1W_NDX^OSVYQG/W5'')S<<@W:JB>JT?'J'YX@/_5<SW:_Y*MSIY);K[/
MJA)FN$D]*QS%H"8/YFI?D=G9#!RAL17/P-P[!7_\3I"_0^D@H$CIIC75WG%:
M7 ]A19X%H]=R[1;JXC.]HX(,'BT4>PW#JZ,;Q\OAQ9_V/$WN;>75A8J=FUC]
MUZ#;^_/(99HH\VJ3]T$81 CFLN2I6"3][>+$2U:T-(4[#R<;K.JE^8?/>Z M
MW-LFO[]SEZU[D2&#AQR'I9B1&=@OL(;V^NI/Q'8UFL3$N&93_#CCLD";09TF
M6PP30/15&!9R<7UX[::A2-T!7\8!KS7+QX4C^H0W$^!ZE#/A@O@D:C&47)/8
MR%,,_0W#6;^=5!EXY^\Y2,V9*W_=EU50)NEIXYN.!:'/1NAI:1J]7IXY0T]'
MG* JMA'85!0$6P\1A9Y'6K>5:.+C5?:+XZK0,T8AWKJ?PKY->PWJU-8WXJH:
MLF?6>D7?WTCIX\%^, J.BR)N;(R53)M5G\>IHML+,+;?$2-(@#88E+@PCE"
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MKXP&2NY^?I9K8><  ;Y+\?=/T%CF:%/ZG MKK:$=P&^/:"M^I=VC)N7"I)F
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M]2S%;CKLX\+I\2C4H=AL:SH\V7[(P^O:)$N.K [!$=3'#P<<QOM''%EW"^[
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MKVP%8OM;49K]76ZK]"$<.5<T'&'V%W7>AU'DN,1W!O$$4;%O4C1!),)SY*0
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M3M4.(,5OW]93KH>G26(03?KQL4N^L WKDKQU-^(!5Z5%6].PEV#5YM9E4VE
M^D$0WO/NA[77GL#2:<*M$=)2U/5I.'5QY?*P+W[YIN?B33SZQ*;+TNDEBCQ>
M@JV-RV_0@AI:P59I0Y:-P EY: W83FPWDRYU.Q.S!E,GRLW\'HU!BDIW"*")
M]$KPM<D[6K0&1\97!J[=ED0H>:,A-XTXIRA]UB0. U$.DTQX(QYU#TU.UJ=%
MY]5=O6TX(K09*E2[AJ+UF3 F0AHP34+1TXY(DC4E.G?ZRDV#%Z-6-*@?,!$U
MZ_=!X*9'5N!5YPDNEUO;5"N(VL3S,EJMB&>1'(S2[!3#,*_',ZYNPMFS)>9H
M41L.8DDDPB32NA&*8[;S:@.BWV.4#$;9!YY6+$_*,&$ QY-4, X?WSK?)G&J
MO6&C?1["=0MMF$Y=ODL:>@CY$>\J3?&:/1$5]T]OKI*[ 'N#T0CQS>'Q1:X-
M6)VZVFS'2"ZH:"0[_)J'9>IY?H<3[HT)W"C"(XS\XVS[$>6*"RW2E.R/(0;K
MP5?>R*BW*M(>%^VR==]B.$")R:H4V3T3+1Y8R6[Y#,@U?SPORY0W1]4W /HQ
M%(_R>O M7HVV;Q6PW*Q&CV[!/4Y8 RB*^A[;S2*<MRP"X,M=#4-H$K,R<I6P
MV#8(5SFQID 3Q,?'ZBJA4<($:!CV_:BZ=T'AOB5.[0& H0G ZX 1NH'!ET2E
MDH+BKQ'FRF1"YZT&N=H"2[6$P>BC&_GNUWP3@,)1 SZML2ZO"9B)2LA*M]&R
MAG0OA\=%'4S-FVCZ^CO!4CER\[R4*VD@'$8FB+I]U%![J\Z<[?+TT+3!]./;
MF][3%Z6=&)YKQA:H<F6R;  RGZU),#G(^W'O66] EG)S=C.XNB4!CF+DI^8Z
M&(Z;D6Z 6LB;L#T-RCB90FZ.GI7;^-B_.>W_+M=#'G>.:W$:K2%C$[LQR?44
M6"QTF@9VA-E6.Y>F_LXS6J^S#+-7Y;B?/LO(%[5:Z![-1]H2M-8SVJHMP *Q
M C$63R2J6JNN)T>]HU[OQ=&+[/]?P1<3 W[-A:%6#>^PO#2W3=U"VN_U7N;^
M&I'!<.FLN4;$1PPK']S#P\,GCR\<*V V:XD6K0&6AA9$M)T;O)T 19%VC68#
M?<C&&NS*T8Z(K0P18.E9ARIU#%DI4W S#B_D7VGV%5IH96OHNA>K[=N"$SRY
M$FAU-'N6<T^(69JDXA1S=P4B6S[&6//ZE!ZW897(XJ9XYM_!/4$TNB3#"<+T
MQ)VY'G\R.$I_ADM_.S(T.:D:6;+3TVR4QJ%!WE>-T-M0O0M1/3K4;6C-'K7?
M)4(SR.IG&NKAD?!S=*@AJWEYC>:-?-.IT/,[USBD5P(W7*)M"3"Y%8:A&+[L
M/7!,3D,&!_QZK0&NS8+8F [,=A@AUL%N3>(E:K6$9X&*0G_Q^>N>7#ANN7FT
M;$]<9&-$1=G3V_)[ZY"N$:Q%E2:A8N5>O&CT;#H+P@5":7RGV/TG>';%R(!V
MBK0.>.4^( 8Z75!6&PE04V@5:E0KYQK#/2!U W"WQ(7C-ZPX[0:Y,2"[+C7Y
M"-E*CE#'!J.=7FS:TJ":6*7A7FM8H,K0"N.DU&36F,3#^Q"D&+7!O]%%J#$@
M4 6H[0BU7(1V8Z]2@K69+LO!M*,9E"2T(**5IBMM!>HJH02[ ?;#7@A:$+$!
M]D\HVJ'YG\+5'%#8#EZ3[)V4@6(X+(1@>9GQ[,'+O*!I,Z63LJJW!9I@K$*"
MK;"L/SYP)6A; ]>**WW/2Z:)2+@HR]^Z,]+5I&/3(F88J=V7LU9#F&44D5^$
M2#D'0H>UQ&D,^54U 5MI-4)?^XP&RH6K=G!7%6RFWD$AV!+GRH*]975\S:2/
M)N1*[:O0V-!#926,^O&_$0VO0DSB<]88%#:WQ*O,26?9#%R66U.@25YHV<0N
M\K\J YL8@=T7A5P<-K 0@-!EVD->>QG<LGKS;>1@J>"UNC??CV\C?X@(TQS.
M0QHOLL:AK RKP;:[H6S5(ES!:$O(JMD& ,J"%N<:U]-W@ML*Y&NR%\3:;P_5
MG& !Y*V]%:\ :*O]L:&LK%L77"7VMEELM(L_,$%NB7Q#0P%:HUF!EA7,'1!R
MH$6G3=6OJ@A\MAMP&RZB*YT=_+ )BAIBC71E_]NV3PBWZ9;*CP4W'E($]K2X
M'06;C(8%+B@K4Z1]WJ;]%=''D!/[.Y]KD E\+VA!@^8QX_Q4KW$%IWB?NWS;
M%EH0P9KX=2=7ZS0,7'(V09SZ^AD:\W^Q_8LIF9B,FP\KI04P&85T*LAC?_"K
MNJ*&> DO+0'NOO7&2=,DI]]<5W"N:V^%*)4R]);S$$^G">$O\/('>J-K-$=D
MNQ-SS;-V#6@5G1>(;?=NT"=^W^?O#G/L7&6$?^O3B%RSQ@0!DQ]6<X<>HM>!
M-JVF_2A"&W&?;N?]Q"I*XZKV'KMW.-C4H\1;NJ<HP:JQ.#^XGT.:35F^-L%X
MI56%:O7-N[0TAV2,PC%U9Q/LN0%%8ZYO[MR6;4?0&ANUJ8,=VI[M25%M5MEF
M)IYT>H@1)6YPDD1Q.-UR@I$UUP(M;)TY70PI=,6C!G3U!6+*EQPO'YR=6PYD
M\#<U&#LTTU7 =;*>3Q*V1.3W]WDVGGRB !9^$W+5:M;W/[,BPAYA=4^Y HOO
M1&?BQ2"XJJ@)N.&5XSDW3N8X8N4S#18NJ7*XVC6;^SJ.)3X1N$2J(:L5ET\(
MCR<Q\OMS9H2-4>Y%O*+8R_-MY(=I2<PU;)^O4J3A,>KSDXFQ:+E(9$R2*2=;
ME%U-EU]Q(+9"E.FXI=14J8='?X[6 &\3DG'!#Z5X=/QVI6+M_6[C%-G>H$I;
MM6KT\9WI*R-731#[82^2MWU'HF1-D^5=7XMF(^CR9(]>,\/L65!DV?J.Q,J:
MIE9BI6L5O%19@U=:<JUG-0?^'0E5"ZKL[J2G[5HW"T996@F\QCO8$,>&J3U.
MM]CBYF$X"E.>@/.=K$W+=L8)D%ME(U0HG^8NC+R3<,JM.]% 20ZS%[_+=F#_
MWJ4^LP5Q2MFI&Z/Z&WC*8=KBT^6;HL3\]J%8ZQZ?XBH<H_>A::,^_KZK F9+
MS%6V!9:/Q!YG6Y2BTNB;*XNK^(\PH;BX/KX4;HH04Q2]D'*)50U )3)#M,E"
M=<FT#9KP#^(%@K.O"8X7RQ^SMAY_SK;$:VG'BV$#S.-V<#437T2ZY2M$M=[C
M4ZD#9\R GX8-BZS+/&@4KF=;@=<^^7TT#$\Q15X<0DZ)KH>MS  ?QFX /_"I
M"E,SWZZ12!QTY=)X47[40Q>(X-Z%29R]]")JSWCMN%0;FAVU32KUY[/;Z!>.
M];5M^C2+*F^@W"4_/?X-+3ZXQ$T5*Q4VN)-V#9HT,_P<$P8.N\$UCKXLFQK<
M?69+'9ZCB!D55V& /2QYSXEQC>WLQ,N>.Z*L"6AS>SOTJ25OT_W!F<W;HTSY
MQ.1TQD@:$)ZW[CS/]04WYE8!UT2=F-?<_&.4L.$<I;8 >"H5L)5ZX%KBPTCE
M;U!Z",_%G8/O:I61$_=M!O([65[49.GT+X8FBDY<2A?\%L T3.K''H"FG0RK
M-BB,%>\'07C/.P=+517EEG95+XL@3)A]3GP<>7SPD.^YT63$NOZ^%A,[8K>E
M$)IZ_TZ6&WLRE:OXD*]8?>*+;?3*731E$-+5&RE:S>%A,ITRY.'HANE\>(0]
M!JGOB5%B?*X-*[3IMP+X#8T$G-FQ(FSU)9-RZHQH@\G'MK,MJ? :CLLWEZE^
M2Y<":S?MY2'T481YYQZZ<KTO;%F$? U( E:G%-U&:)0$[SE/!_24,YGM +R+
M:S=&T14-&>9XP;-TQ&RQXQ;-C-=.+;GJ,.04?=LCAO4(T,2?A21]LSJ^=N\_
ML+8HVQGASD\%7.7RP\;B=.@^G(3\^6U^Z^":#2.!_#ZI$K)2H>C[K#_N0 WR
MNM?"'@+]#*L&M(J90@6Y)%XX%3F9(N12;\(KHSD*PEDS=@T4P3;H-<KY<KQ*
M#0$F5XY7F3@AG"-*1(S#+FU"6MCZ\Q\9_],S8\@$ZW$K5ZCL()6_((SH''N0
M3T@E6 W9[7BO@]& ^LRPI&G4#E.0(X]BV>6C1X@UL@&IH7&(XX!I':-+9O#.
ML<],7Q )%92P-*2(M2A/I034"E5C-)QZUNK L2GUZ+3;?5:+:7H)Q?&"A[R!
MFEHV(*V?^(+].G&+]W2K14O!^X\?JJ6&IGM1X&9P58E^@KM]-:$J=V5Y%!T\
MDIH!=9H'KI#?CP&%^<I :3) EMZ\$G-C$@8^HE%_-J-,U?3!YS*TPJ^-.BM:
M*-STT<;.Y[:8LT*)6G<M0D3AY<OKX'XC<W [;A<95JL'U=/D)E6Z,)O&8V82
M/LJ=L@R01@:OV); '<!CGL65L+87M91!V6T)7NC;+B9J9*8@XVSMA*4ZJ9#I
M XJS;:T4D\M,M>$$Y?\\1Y"M2WL2=-.+0V263^FV"(P<=VI<ZDU;&R@*S3:S
M@KM&X"\<F\T:J.:]"N1&Z!H1U-C9?-;TMUUL*EB4=VN$QI)$/ M7*0]3G_B7
M9!YBCV=M >^_:D.$Z:)=ME")"SOY]9;'3RRD@::;>NJ!R<<#]M9AB5_G_:IX
M_V26[&-X&:2H+/6S\S2X^.S!F_ =1YR%UN3S<=4T*4"E@L-F*/M'2#&*^@_X
MVV\";./S,<,39<?;)1=R#9EZU6_DN05&B1R?5MMJ.)J!D:0 J(Y :ZIIT"A2
M(-0=D-9?N_^ N,GWR!JQ"I7Z,)^X/H[.KFZNXL7[V(=!A!23[D67+%A9Y" O
M9>T&08T)G8:N9? G?_#EG =\PB!)#4Q#3992M0^#A!H:E8Z>ESL&A?K8$O4)
M*-0GEJA/0:$^M41]!@KUF27J<U"HSRU17X!"?6&)^BTHU&\M45^"0GUI0'U*
M+[AM]\[UPCL0P"6 E,K8*7V'F++PFTM0$(0P]GHY)LTQ4^4]0N%A/P1!B :8
M92ZQ 4$P*)&#TMF4U=Q'^"%&B,"CI0K,DBO#^Q >)4M0.JZ<\Y>O)LB_"$,?
MQFR7(=)=X4O=32?997OAN \$ AC4F.#I[^RZQ ]"?YQ?9 %D(>NQ:1A61(6<
M\3Q98&AI0%(&;A>% WX4#8R ,B;UZE64/\=S&!N*#)&-$)V'"05&P!*1#0$?
M,9 M78;(A@ H*HD$D%+++<K>P)O"-]49;,"/'X"A+P"9!W\(;>B'E:73 )X_
M9@X,?@F247*&]RB MO97,%GL7E#T;@D@]8'GAY,3E[B^"T61DP!2@Y].$QJ2
M2^+!@%Z'HY:9K.A[/&5- !EX&235O/U K[$W<:G_[AC1J0MCX52 TIDT62:M
MA,04RNF8%)+VB@X<V$:Y;UR/!X%=A4I]G9*&,?+B!0RYKZ-1AGJ6+NSSH*4X
MI$!D7H=,'\Q)F*D_&/7)8#3B[K*$M<L?IOWDQG& WKMW(4,F@F8 ^2I61:T.
MX4TO]@$AK@)&%^"8W@1XR_JE?/,A* L*@D&($9[VK8?\35G9;6U(Y&D1*A]?
MR<(=F2#SU'_^\0*R:[ M6OT;'B&-ATR[.$_$@Q_],;-Q1'04#%)-\+11=M1E
M @!$EZN!T3V !WFI7W%%_Q32+Y>$K3>,?Q$,T9)"4IXYAYYX2X/K5.*:U.4R
MRW@_P_KH%RRL0.83YI<#1F3D3=#4%<KM_P-02P,$%     @ 53)=4\EX ?98
M#@  R*X  !0   !I;6,M,C R,3 V,S!?8V%L+GAM;.U=6W/;MA)^[Z_0<5_.
MF8PB6;;CV).T(\N7V'%L1Y+3))U.!B(AB3$)* "I2WY] 5XD421X-T%FSE-<
M%<0NOF^QV,7US9]+0V_,(:$:1F_W]E^V]QH0*5C5T.3MWN.@V1WTKJ_W_ORC
MT?CMS7^:S<851)  $ZJ-T:K1P\9LH&B-(0&(CC$Q&O\UC?\UFHVI:<Y.6ZW%
M8O%2866HHA%(L4442/D/C6:35>A5V2.05WC:N"1:XUXQ&YV31KM]>O3J]."X
M\3CL-3KMSK[SR6]O= T]C0"%#:8WHF_WMB0M1T1_B<FDU6FW#UI>P3VGY.F2
M_^ KOSBP2^^?G)RT[/^[+DJUL(*LVOW6YP^W V4*#=#4$#4!4K@ JIU2^\=;
MK #31C)6KX:P!/^OIE>LR7]J[G>:!_LOEU3=<W!K--X0K,,^'#=LS4_-U0R^
MW:.:,=.Y0O9O4P+';_<T0VER -NO#MJ\AM_9#]_(MQY&%.N:RI&_9H0;<&"R
MOPV(S+T&K_NQ?[UNA688%L&(4]?B_Z\5]77K.50\ SK'>C"%,*U^OD]MY0K6
MK0?H]%+'BY1ZK3]S "M"*VZ9JJ5#/"9P#I$% 5*Q.85$LSD:@A&O*%;+1-5P
MK0M5&2YG$%%(TVOI_Y(I5JA>3W!E  0FMG7/F*?$"$&=NS4FU.[MZ35.6F=1
MYKJ1/')Z [60"HG"3#"]\H(J"NOW&TDF >K:^ A4H#;GHC*82'1-Q</LDS<#
MJR+4]E?C]3\%Z(JEVS9SRQ3TJ0Z7)F0DJ9[RO/9L3MT1QL3I6/&)T/F(AXDG
M00<CJ#-\QH0VQY:N?[LBF-('@L>:Z8?0U<(>^GAQ>_PSP1(C;*Q:'-PF&_@Z
MARV[&EYB\U=3P>3;IHC#0*A(C]D,FO<=WW=)L,&084PH)OU+,Z<]BYH,&T++
M:D^\(JTU/5O6T"7^]@*B>!JS/WVF$(Q!W!(M:AF&75M38Y;@?3]FJL20;.*4
M6&+"O F+0/<:"ZA-IB;_<^U2,M#7P]2\'P\ ZS!E$;4M<LOP*LJ)#R 7_<X&
M_>9^GL[C"+YE*G#.[V<\9V I15<QM;EF:N5Q$J^([,Z3&"H_?3Y^B^X\]WR\
M<<: LHC:%BF]\V3DQ =;L$L5P,D58&DGUZN\'A206VMV? "Z%!T419$S.:)W
MD=I5#0UIU.2:S>&%DZ"4%@#%J%%7 F/A=?D\#(YB*1EET?Q@"@CD,S#J UCQ
M&)BZ8G8Z7F@J$/%QS<"/0<)%_"@$\:Q1-X6L/5-&\CD+&G4\XQ)+[D#12FPW
MKPX4)L76Y?)543&@'5HR61\ >8)<OY)9%,JO+8%B1%WNCG-RQWK[I8;X[ [/
M#N@=-!,XN]TOG FX5$*=F,FM*(%(?WE)$;P8+,]S[C1+$*6G!<M)W)*#Y2]?
M6;!VFB7,2/,FI&=PC D<@F7Y*>A&=)5<4  0O]-)X*M$Z6>5VQ=FD.)9D-Q6
M5[ZQ;5R+; +B[&J+H*(G,J[=%:NE.U+RV4<-6<Q^74/&J#1J$NE2H?0@G+9D
MB!;LO?E& P*G3!Y+]\J=EPH3+=][1P BZF7/-$L8H@GSI?=CVT*4*4 3>*Z-
MQY! OF9XC^R](@Y>I<Y@Y=&S1GSGYT0X;\E7&UL[RXU_/.,:I&_C1IZ5((NP
MAII=2J%9WEJ03V@.SP<HS]?Y/Q<_+&W.,D!48BO"I?NFU"1UB#!2=Q:X!-")
MW6!&CH9\E9Y)<OJ>HUA_L\>@+++BU) >6B3@+!;*HE=5KM&<B<"DQ"7);9%U
MX,0'4=%+)MM$E^NA0R3+SED3D!&&5W#9(_V\TEK '4:*##H"<O/M/F"YB+EZ
M8 &$R;P)=_\S9VMK:5FX0 ')2;F(W4#2(,*OB#G,,,\RQ";0)7A@1ZYT-YR,
MER!>HN$P&Q_E]OA@/Y>#?60,&>IIA1ET]1H0-*QB3<8%Z%8#(TTO=6=7B.3L
MS0B+.Q_<_;8RX_>U#A4)34)XC@_@-T 6.GIXM1,\U_CQ)7J)R84QT_$*PC.(
MX%@K/=V/UD6ZITM*8C)D"TK%#.7;3MWW(UV;A,P0AJYNBK^5'&K%@!W=;%&:
ME3_)DN"I1>+KXM.$\#U3XB6!HG#AF3:0"*V:R7!!S-.MMVJI3"Z5I8]OHU'X
MC*1ML5(-*D(#Z<-@/'&)@"PVD); 4:5(21J4A%%0L7PLMBFE&-0==%,^&<-)
MF&S9[CH"#S\],=E^/1H18UFYMF/P^4!S598QN=)RS =?4VKQ _<SK<Q)1I]0
MV;&NG[*=:44_/,^R383O/2?SDN./M= JH[\#3]$+G'UH @U!]0(0I*%)B:>6
M=^1*CS"B2 BB%)&!E[H+9GU-2)Y\P*O$WL+[2/GY?HEG<A-JDWU\LG<,S$R[
M?OO,Q/WX"F.5'YWH<QH(WZTX'K >IRGE-3NE5M+[2SJCV>U/Z1@H:,QA";=W
M1FV(!]9LIFN0\-E+3[@K,<$$1+)ZJK 3*CU-R6%ZED/,UVC,];VW3.??,6]"
M3P>4:F,-JETJT3=E5[">IE $,^(]0?FO7KG"<T@0-]4K DK<^1BE0LV9CD17
M,*5=:.C!MS'0RH0>8=ID#SVND0D)J\_9M,C"MZW.(['=:=6JIHE' +B[428E
M"X7/P#]81)D""N_'PLU4%3&- C2M8JB:V%:*8"KBX&!Q;M,YKE@5MQFF3:[C
MN0J$JET_GXYB]=K73I1Y;E*@@.QM!*D,(;"/4X2JT.$Y=_+^_=>'3T?__/U9
MF5G++^CH1/UY/)]\6:''<VMQ=4Q.CM]WOC\.5U0_GBL_V_J-V3('\.;G\<'3
M<E^Y-=M?+R\[@_>M^?*L]Z4]5P?DJ_[#O#P[?/WQ</)B?D[)S];-"W/Y\.(+
M^OA#-5\?TK-WBX[Z&CZ^NOJI'6L7[\X^OB<G/UX=TO;#S0?MQ>)H_OT[GG]M
MO59:JUEWM?ST[O#P.[R[.IP >'>IS<:?SE]WX&-;_3Q]US&F?59N>GYQ-S;!
M8?=0>74$H3&[^7QU#*WIJ+=__@7<+3IG1O]CYZ]!]QA=+6"_=W&ECN8W5\99
M[^OP[LMLV#H_NL%//S^,?O3)XNT_C=Z@[UU<G-O(SS A>,&GFK:=B\0NGDTY
MV1.K1?6.%'0(4N+4MS@XT^W\\'F"V8CMTE4<;>- WVUP,&7,?6_0S)W1N!]7
MKF]E4Z[.?2LC'<(+O#(ZW+4.MY!%>%M+HA4QC.P*5C-!2^Y[LS,CNG(L7[[^
M #2U(D:11J4Z^XA4T LO)\M\+PCAAG<.G7^OD=R#UHGUD9R-I,4M>"([R:RE
M.#GYE9J><";A5VQZ5!</+B.4L>2>Z,V+K(.,.^/.C\5XYE[N)39B!3(/G/^_
M'C]Q]XFEO[C+\M-FH5LW5G-Y=SA^7TAH?IJLGHQ7\78M?M.OK@%T"55^ W!?
M'8(EPT:!E!]/ZL.QA=0$6B:L2-X5B:GH\!+KI/ 4:S2;I<,ND^(\A17FU,3F
M$E&#K!$O*P6QB!0T:11^@V_8RG@H[)&?U\SJHZ&(BB6R.LB4?E!FCI[+CM>M
M%>T%^'7>+TAN!W?0O,2$P8"\&]1XE<&;/4.M(N)CZ;&]B!;/)*(:7NQE(,8,
M:(1WXC+O2]V1*O_P4"0?0K!$"]#EID[^A_C2=C.+-B< S-*_HD$]TQ@#.K)Q
M=ZNR+:,%=9-ZOS0=0]AWG]/\/:G,U&Z/QV6*@BUD.UQ6K:7NOH 6'J(&/Y(S
M,*=D8QV,AC2ZH'O/SP ;Z4>) IUUT5IAMVE@46N,&%%+WWHH( EV(1_5"L6P
M1@O"P6P#U3F<$:AH#@A,*0,34W->[2SYA8L$FL@:T+*0EPIAX4;5'-&I=UB_
M9!I#94N9Z,_%6CB$P>6ZS+?$L"H5?B**0-6YTCJ1/PO]K#;H"ML=7!#+9?_7
MS&D2/F-1LNT'Y$I*B')9?A"\X'L\F1\B<Y:),.E#!XHT[Y")OZU3!XA P,7Y
M=>YYGELX 7H*9/WE:Q4@[335A? D9ZQYJU$WZK>WF/;AA.NQ2@*EX,MZ@2IJ
MOI?\M(N917LTW7TR)?OI@-PZ^ND@>!X[>7/3@<4G5Q&RMH/4)'Y$\*&TJ>.,
MYB]JOX=OKDQVS=^0@#G42[9\O]#Z."41:AXE.==&=L)^I_:SU1TP+5)RYK0C
MNS:A30R$'E'%G<6LV>.J>==%,TU_):Y*\DZ\1%Q&+Y9&S)3EW"2P?<;"/E*W
M)97IP'[]SE+:#P"!"91@@BFUDKY&EYSKS,"++WK(R'PM7O]-W2BHZQ*:XI<J
M?XTRCMN=5XMW0"ML']*N^"3N/?A-!4Y2),(SO,&%]]MS'K)H(XLK;;^,6MIB
M1D!P79B)PDZ\\E3BNOP37!EKE\^&!8H1@CHKR-MBB]JLV&<TF_=PM1E5'CP1
MO2T19=E1 DWR# 'QU0^FF)@F)(:LQPCRJ"A_<$EN2?[.EXN8PL:D>"WL9&^M
MBJ?"-5)T2V4.9A.4>[>CV=/>4+U 9M+=V"4H(7M/?4HK*8F9(O9MI&CB QMC
MH&W+O$CUW(Q /^GYU/.Y&!$CA5^1EM":;S&:;!MS=6PC7#W)DRK/9Q@"-L37
MK3U?= ((' $*5?<,=G5,(JC:+^PI0G@0;Y4I.5\8.2]O4XO?U*H .EVG!]DO
MLRK+S&Q9V6:1[4.MYAE 3RSCNT;O0*)#96%?R8^BMR'?W, 2TCY1Y%NNQ9G\
MV3COR"W9//B<.R_UO4<G^U'NP&O<>1HEJS&5>E(\CMZ0QPG#GA//?>\CWP&"
M*;U'75W'"^X\HSD*WP@34T,]T$X"1='72G<5A5C\8@%^<LW6;C@%R#L]7?*S
MMDETJ0>5*?&-3G)DC28S]_71?%<X^/"2^C*L[TG8(ELSQ/;/Z_O@I;8NH$P%
M%@,B;2#B&5PQP 6OMMO=%.CENCHN3_9L8 IF-A@]R]L&9;N&H$NH"0\[1<1C
MAV#H>-/BE?($FK?Y7U!+ P04    " !5,EU3TQI@,[Y8  ")2 4 %    &EM
M8RTR,#(Q,#8S,%]D968N>&UL[7UI<]PXTN;W_15>[Y?=F-#XZ'MB>M\H76YU
MRZX:26[/S,8;'10+5<4VBZ@!24G5OWX!D*SB 9()$ <I=\3$V"T+F<DG<60F
M$IE__Z^G;?CB 9$XP-&/+]_\]?7+%RCR\3*(UC^^_'A[,KL]N[IZ^5__]\6+
M__'W_WER\N(=BA#Q$K1\<;]_<8:WNUL_>'%'O"A>8;)]\;^3[?]Y<?)BDR2[
MO[UZ]?CX^%>?_D[L!P3%."4^BMD/7IR<4((%R3."&,&_O;@DP8NYG[QX^\.+
MUZ__]LVW?_OJNQ<?[\Y>O'W]]DTVY'_\/0RBS_=>C%Y0N:/XQY<E3D_W)/PK
M)NM7;U^__NI5\8LOL]_\VQ/[0>7W'[_BO_WFAQ]^>,7_]?"K<2#Z14KVS:M_
MOK^^]3=HZYT$49QXD<\8Q,'?8O[#:^Q["4>R5ZX7K;_!_NND^+43]J.3-V]/
MOGKSUZ=X>1"1_LXR.; I$_CF5?:/+QE>+U[\G> 0W:#5"_Z)?TOV._3CRSC8
M[D(F.?_9AJ#5CR^#K7_"D'[][5>O&:O_17_P&_GM#$<Q#H,E4]$5G1E;=)O0
MOV]1E+Q\P6A_O+DZR!%LMRG!$=/Q*_9OK[I&O\KF@%X13[V0*>5V@Y"L?)6A
M7#@-LMUN/((V.%S2)7;QGS1(]G>4Q%M,O@)(US'XE7[MGGGQYC+$CY*P'89E
M^M0"6KK=>F2/5[?!.@I6@>]%R<SW<1HE=%]:4,Y^@&((@#!"5'(-4M^@!Q2E
MR(N6.-D@$O#I#A!2/$Z3@B^>=BB*06 =?E4/'-ERO_.>3NF1L0H@J[$Q1!,(
MOZ#]>R_RUGS?6=#%A*,(A>STHA_,-VR <  BNC:-:QS'.T3X\@=(5OEU?;LJ
M7=>0K8#]FJX/IX;$DBV$.5L(-\A'P8-W'X)F;^M07;)=1729)IC =I[R;^O;
MJQ-*(D3+"[I])3 Y!(/T+.\*W@MOKZ2GPSA-$"T(?@B8*4N-T5N/$KY!24HB
MB%RM0W7-'Z8)>NC061$&WGT0<F50(.@.L@T2MJE ]=E'1=]!?(T\V-F1_Z(F
M-?*=[,S;!8D70LVDXM>U[7_Y1A(C\@""H/K[>A;9+5HSE=Z@'29,[1 PZD-T
M[3ZYF7?%%L@6>FB*1FDUK9F/M*3;"'3]" ;ILOY"9@TO/$*M=.8/>S[[6HA,
MK4-U(7491-2S";SP)H@_'XV8^?WOB')ZX!N(A%4M14[7-URP\S3&OI\2:B*O
MO56""%UQAWE^3B&$&+D0,MH.[.W.B_;G*/&"$+:Y5P;H@J[I\9SN^=_V )DZ
M!FN"2>C_W$'MB:[1VLZ"PC4"2U4;H,\&K3I(8'E:!FH#J-\Y HL*)J71S"DY
M4& Y!8/TG"3LS 1+4?IE?7BT^5)@J7H(Z).TY&9)K(7Z&)V1R)JW!5=DVU C
MOG7A>*EIM#9:&WQM/AA8RAX"NATC^%Y1_G5M<)7]'K H@D%ZMJV*_P,61S1*
MFX-0<X7@&(D':@VMU;PBJ0U?/%9C_+WA),E-+]%074IM<Y8D#,9. OI0E'&3
MP-(K$-4X+_P-6J8APBO2:G5#Y@B$C*Y0TH$7*IOD4E)61VJ*[!RHIU%*5TOB
M/874H$3L&OUQ$_B;""_1"A'"_\FC_Y(0Y.-U%/R!EO*?H,Q$NQHR'5-V]R5/
M1.I;Q!2T"_H9[;>'];4K_!"_[H=(B0ZEJ>T$/'"F6S*[_5PN@S"ENU^8.2_Q
MP7F1^HQ>8OI,G!)/?CL?I]$2$;_P>B3%%I(P(&R26\M\5R,U_T=*YFY*^N=)
M4'..)%=F;;#V11FG]W&P##PU^9JC3>M^5_:4U!5?):,=U5W);8J9VT1*;I.4
MU-V4]$]7;\N"DY0+M>FHH9Y0NLS3"J)BK;-D'OG/D"!K8 91$.FQA@G;5ULD
M4=(,C*@)<Y$?#7[)Z91;MHW1!D#'9$E-:[+GS!3P%8W7/]_S8Z#D+LL)V1RN
MVYS=X@=NW=#%@G?<L:*;V*-'J*>5*$@,(*<?Y3CS_X.CBTW_PJ#C 0&^$V>_
MH7(&2=(V,-5+O'&T1GA-O!WU!KR0H/7!$Y8\^"$4#7S*UOL=$S^-$^H1$)7I
M)1BO?SXQIXHZ[6&0(;1BMN<JQ(\K@K=XQ_*I&4B/0;+ANS.[DSPX.2I.]5!N
M)HZ 8B$'491N[Q$]C2CH_N=\4>,T8=G4+.V<K6\4K#?4L? >J+1KA)ZHN1[$
M:$<"7\%;T<O9P"1>L\T,+1^\,,U5ELLF_ZT]I$PHMIOE:XWBO]9O^2:8VA1%
M?(?Z!?286;-U$A_"F+LLC)G4(X5RQKPZ&]WG<VFK]N[IY,]- AX3W;&8Z+ O
M52!O8E*65G5ALI<9WZ/D$:&H))>2/ZG.Q< N0G&GFU?$$EM0Y._I)/LL_T6M
M1/0?BNC)WWC46&"OB92"LHWANI<*=\&'1V^$41NM@OKL[IA.NI3NFW0VQCQC
M!RV+@U]!<!A%?;,8]$X#GD@E1T_?!B1,1H*+W3E<4W))?_ZP3+X:F)BVJ9)=
MI<-EK/Z^IBVB=(<N,2D%HW1MJY5K=+A(PF$:S^/:/;H$5BTC->JO<DDMJ47A
M6)W;B/B*6F8GZ::@Z0B2N8V&"Z]"=? 'G6,_95QF49: M9=+=.\<7IH9'O&A
M(K8\$"[>][*7P=]PT9<!Y<R"[B=+M/+2,'GY(F=3%OE (XB25W3(J_QW7C6'
MYZO,L*QXZP61LJC9Z..Q8D+8#25!_/0>G1P8R\DK(F!Z,G!@3K:(A3HDT:T,
M/1Q-)J3TPE!.-C;@(!&=IT$4L*5U37E7I$)/"8J6:%G(Q0:K/4_G:X R"[%?
MX1"R-_Z8% Q"[QZ%=#]9D?ADE8;A;S4ZL_N86])"H/CGLJ'\FQ/O"4=XNW_%
M-J:3UU^=O/WZ%2?)?N/XMQ,?D]^.OY)MQ[WL\PU2X8-RJ_22X.U9[A;$GX)D
M<U:$36U]6K\@QX\\3I$9J7XNG5&%P/GDDET9^6@6P)%0?((E0<6$^HX_OGQ-
M"?#5\S<_Q-3L^/%E0M*C0ZZ@T#,<)_,5SX^UI;HRRY+D8]=2!:E<'V]:]:&F
MC7<$Q_&"W\[:TD:9Y82T44$JU\9;S=K@'M%57KK!CC;*+-UJ0S 5JQJHH /8
MGX8HX1V5-[[FZ8I6-5'F.P5U5'#JW:.4=9(5?@JI?S-;;BD2;*$R9RQ_Z69M
MZ^H18TK;61^BN3*_TK/%48>]&;LXEH?I]?8[!H\?])Z/SY'^NFO9*%O/,:*?
MLZ%J/J<V7XAWC+?E5=,M1'E;&*G^H'#FBOQ&__['C4#*];U'/B,6DK2LPE;^
M4])>.XBYXK[5K[CL &4')'.VYED"3+2>L5!B7D7'C@;[!7'JOO9-\*HF :AJ
MMP_I)I[-MBQ # E15W]_].&!YA?F('[7#J(LA)E/"X>P^OM3@+#VA3F$W^N#
M,"?-^,0?4 ( L3[B8+S90[%-]05JC8\R%G\Z[AVGB"6<W'E/]O?@(VLW!VBG
M.KJA CAY0T+7E$>^]6?W^RG=U^>'O%&[<>P>6=PZ'AWSN*I%&*[]ZVWH<K._
MRD:WT0E1Z8TE#HMDL=HU!&W8_=\#RN:"[5NA7CDJ/N[8=-6/HMY022]C>C[.
M5WP]9TF(Y\%JA5C&)(KG$<^W"//$ ;?J!<LY)2=RN%+RV?*#_O4N$,O>%5N3
MM6.UZEH^]4LY <809U/:SC]E[]Q9I"E[YW[AD8B>V3S8OCB49^ZU_2%4'!R3
MD#E;^ 8@(* J^/NK:O[&\1^,Y'54ROJKV\:'S:DXJP(O7. X4Y7ETQPDRY $
M 9[^G\Q809#8]L>)F;NU]&647]NLQ%":NSME]:'H2F5_L)81#UZ85<:UI#PQ
M=T?6)6Q"UQ36@I_^ ^; DM?6F^6U]7)1*\7O[>BN3PRW2U!"A;UXFKLEKS0)
ML!4HJ78:F(2**CB9=K_+8MGUR"J<G8;.)70C LV0?^U$-2/2BB:[PEANX@><
M/P5U9 NV\G?LV*KKK1W1_EU0.?R[0R39+T(O>YY"K9I=UK[-6C2X10"77F_?
MU&Y$B]M [#4,!UL2=YCW0;%N3F1\W=H4<FIJ@M9OZNG9&5WMB)-UC)L ]MH8
MRF:@715-7#$U=73F1 ZR^JZ/;\8=Q9A$$DQ5;5V@FLN*%+G:QV9P[N(6]<9R
M3IVNCHG>'[@XHFG(T"CX%)4[XTM,+K:[$.\1RKO%V';-NF4919 #K%,8O-HC
M4EO_MQJ7^7T8K 6WTL([J_:Q3F^J8-AW?[LI/ZN\:$L2N@@XE=E/:@-LQ=!L
M_,F!NL:F*9V&!R";?ZC3Y=!V[!;B&02FNDQ(C7GHK5LTE22?4T,.JA*5<829
MAIQ:94@,7D3R[5<HL=533"S!6.)0<H=9"YKFPU(.E#=&O6G>$"&O251UYT!C
MST%/(NT8R.S\@/) I8N%)>+M\E0;L*J$,!;;H8%\*'93D^QM&XDUKI.U"NOH
M%8HR\/8HCE.TS,MC6KOLJC!UZH")YVGM>JN*D>$"+$5=4*NVWX'IZ)51P\A<
M3MD-*W$9';.N;>FCP=>MA0#121,J4]&^3!J[Q\ED3;0"K&*-=&;Z67HBP!\M
M;'!()8HS^>XHE;>8?/5RB M= NF,OVV)KZ*,/)477=%_L[9^(:(HA^+:B>?%
MYEU_8[5M@?85PPN8]JZ3OBE0JX[2AVGSP,=10J?]1<B'_?@R;QUE(#3$'@GA
MB*7"SU?Y3OP46"P?*>1N\%F!L/2OK+XK2Z'YB$V$IZ%+WHS%^\K^;N?0>E^J
M)FSH\&J4E&ZYC.J<PJ(3J\#+G*%=YO/;:V>:,:R6HBJY7KTPO$S%42N>EMUE
M(V+M.'X@VCTZ/%.)92-[:53X6R*5".^':@/&"J3@TS1/;<IAYOOI-N6-(;)Z
MH6 4VT:.P$D7@]GZJ7K+!K,[.RY%_L@8<F%9^?VQW/F##-7FUYH+>GQI16N&
M>P]R!6UDIWE;*0=> 1"3!2(!7@*F/XR.Z_?""BL#"! @R?W/RB,.5U%7<9'V
M5'C9U51NR<2Z/LP?(T2HB'<;%!!J17D^LX+C[,?BNROAZE*C.[5#2!$]<UGP
MW/HMG!>K?L*!J0L=#IW( A?B"*+F:GALA\Y:"<_)I[Q]?.:TY#7Y0(=7#P4G
M\7DM6H# 8R)'O<'T(N^XK:2.X^#GI8D2*-IK)8CX47LE00'SG;R=HBKJ)-S5
M%S2CD@9$D->+\@T;6*/Z;!V>IX2UKN5FY*]>F*+LQW?X/"#(I\-!/1RDZ+FI
MW:E%7Y+  =XZ*IEX*T3N<+GO*]2&:PZ<^ )J@P-BE*EN:(_'M;KB:Q6^D36'
M.JL2K7/_$B#2WWA!/D;[0)<9SUN?KS+&V9*[BA9T$<)C!4!"DS5]);#J?7ZA
M^OJ"KT;6]WV+8KX[4@L\_R=(,!- 9<*G" @D0$*X=(L&[@A?1;66]7N 1EJ'
M3BP@TXD"I%F,RM42DW')"X?D]Y#)FY_3</_V]9L?8%=-702F%%0&P '9D2Q7
M>F4U&R]#_/AR2)NG$E(Y.>LO##ME4+_3/@L]=A.6$>7U$'=)6_<>ZP4Y5&0;
MTRU!VURI19>55&"J,419 -[]:;YZA_&2-8&Z84N0^4WSU2TB#X%O+PU<4BK'
MU2 &K*EZZK*<,HP4/"\Z(U(O+=WMPH#:1M15*.3(F0..0A@=U^MWL/+@B$%B
MIT/>:EQ%*[;[S-,D^Y-_$O^^8!6@)35TW?6]4Q=P\A-$AY(,-;HN-:!_AQ\0
MB=@T?L>C _9V^G81GH_J.X$V5=>D,$<8UX\Q"R<XW " TKBM5*--WU#L^V/.
MVG3/RF+&C@U\.:E&\]():MA+@FZH7O,B)?[&B]%\U5JPMGS>"$2T-1\T2.K8
M\E=:9K64/0WJ,O<VX2I*$*$,L]8):#F2F2,KEG-+0L-$D5:%07\#]CWC.E<<
MVQ8:9@ 4=4/>@H!]_@9X9$9%EU3/P*CH!-V0[NG9Y".TY%*PRTG*G5^(V<S,
M;Q' :3%2I271R-EO@]; XZD\Z8(U7(7<))9^>W2F%A3I^E<;:YU=UN0I)@0_
MLOH3Y7-:(+*+!007;FQGYJ#5):$38P&W71XKGJ]&-T/4A)O\#%'4B:&HW>(@
MRS6B7F&I0MI(9HFZ@"-TPN2W$W7U0'II#/32%UZP',DTD1%I\EN(%/Z]V:XF
MO;-Q>673USP4=4/%T*\BG[!]Z!QE?UY%;EO_@N492R(<S F'PZS_!4AEJOW9
MU%E+0*5#<]JOXBY6*^13\2Z>?)YU>4,%SO,OYXY7JXIH4XN?*<$/.:)ME"=,
MMUN/[/'J-EA'U*3PV;U0-1&:'2X*SS/.@YA]4DK0O)OX'97XE-+Y+/$ ?0!Q
M]65689KAUL/]XFD7>A$C:NVY]C A7;UG'3Y9JDMRH*J@28\6%FB>UN-%2\QR
MNX*L5(1:VF49E9SNT,772F9 C%- W_%"$DCAYKF1C ;;5X0(5%#RMX7YGM<!
M&'SD%'1.]Q^\A/YDZ$3OIZ?L876Q<3SQN\1Q]E)52<WMJZ$3\A&=!%F5H#OO
M*6_;I.$0.) <NCHZ".FQMPX,'"\(H1SNWLS+*;-]#8CAA10)MC#Q?T'[]U2F
M-??*%HC$.(I0R"IHT76;==M4N::N?O\*DZV7E9C':2)F.7R5J'$9%-.1%\#Y
M$I,5<@Q>R\ 9U+4TI74&S-6TL'195<(=(CS9Y*5\]8#*,9WWVECDY 8;=+WT
M]!AT-3:N#;H.<<9AT$'5W&'0=4$^(H..Q00'GUP\L'C\0,7%T$9%H>)'!]EA
M0HW$S.H!O$@'ZX1A+,[V'?&6++24]YAB2=^LE40\>%9RPK,FX:&;-IRN'K>C
MC9_C71PBUCA6B_1$:-_60;H8B<O"<N8C*E%^=S+8.SE0&^Z"=)#28O"4.#AW
M)(22C,+,@:BTRR<08SPFXP9'"?U+B)8749)EJ"A$=)M4).9]QV"UO/8&O8/J
ME*0YCG:W5_<#?,AO[_IZV"L"VQ;-PML?S1F-!DU!5ZLUTTY4R[8LY#4F,T8D
MTRBV:CG5 ^T7H09&M'TO"'X(6%>M%2:\3- -2E(2#?<,#H0OJX0S( :XL!*$
MU<I7RS'3+OTHHISRVA/YPQ#T1K06V,D71&MJ<87'7'QZQISA[39(>*Z^0BG
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M)D.YW-%(YHA0MN?E&(GA+R9#9^15MVN4]8C.VM:Q:7I9/2TUN#Y]',9O>>B
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MO"$38#TTQSA,XY1$5_S)IA+7SIF)']RG#(PS'->S)(S65:DQGHZ*NM SEB+
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MIN\Y 1874" ZE:-)!2](EKKJ"XYCET,F"RM(%T0I7:C'MHBV3'Z0+!-9A)(
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M>%1YXSV^]Q)$ B]D54=NZ6^A^'WE8.^JH]@QVET$M76='2HE=GVT]LQ<=MN
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MB!_IU,_6A#5'3L1[JEH7 PEIBFJ_^!GK=>9[NR#QPN&MQ'CGM+.,FE*"O)"
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M6.YW "9?YW!''IDLS-T0&*DLQ5DN4A*G7I3<X=DR7J3W8>#/5RM$J&4./GB
MA*:D"0 L9HI0]3#7H(U1& 1Z5 %^>BNO@RMJ+J"4=:?F_BA[4(7(0^"C6&Y9
M]-)QV X".-<JVNC'Q4AYP6[6PY7AKFR[7B48Z85R\82('\1TV7[PXJ7WGT\>
M(51:^$KH(>"H<X<D\GTH:.ZCU\%Q .(.B^9K@EMW0FJ%U0V+<\5T27E)\(!R
ME@K3O(O.=#9\("Z0()YFE0Q7QF0V_%XD<OB_,;+A"WG&;X;C3VE,Q!\ @ $-
M8^M4@@8=O)F0*]"/!F =J-F=L^3C[>NOORNMV?-;-:\,0,G9^0R=;A5#% *-
M]@ YD#-D@8!)N3%1#>GD#3"HKJ*5U]^\GD='N2]NYXN/41C$"5K.>98 7"O]
MI":E%0 R^ET(*&^P"PVBY<JV,J496(Z!^C[V]ILR_P^SV_/9/R2</2 A1_:6
M^B;6#8L1HPO&7.YHZ:8TP0._!YI>0\R(4G2IQ*%-;$0C!WU\:\8P[F"M;9DX
M\Q6-:.2X1+[3NG<5U?DNJ?@W5%;R@.+AI[X*U:F<_TJ(Y;K[7J,E("^'$<5-
MQ)Y602M7V@_Z+.L^*:K'(M7.Z]??O?TN__,'#?KK83"=8VPHDH4OJS<G14XJ
M[?I\-GMHB]G^IC.71=$<F;U^_7UQ-\H2CDL7HS<LTX^@)9LV;]Z\^0INFL@0
MG<8&JH)6H39M#SJDY-"JK0EMC3((%1K2^ RB=7DS(4(4QYVF$E?1V]?J9YT<
ME^EH50NFA;KUQC\&B&96S=.)DPR"L-!JQRV6_#TB?V_%Q,FR2V.4)"%:\ONV
M>X\2S].(N.">SR5IRR_*"\%G=W6P*TASW-WWRH+>71K4 ""ZXW3&6)\D$THL
MT NSD:#2@F ?H67,I,R>/.4?E:C<@LM0FX@6I0 "Q(YTJ$B7<MK4,HUM%XA+
M?VA(X657@OW/&<_SE+&YVZ ;Y+/Z.<$J0,O37'3^>_GA7U@&$&=G&/VIG)L#
M403%A09K]E?V0N<@U?X.:],ID++K![2*NH3B!HD7*7DYV8%ZAN,DGI$@IB+-
M(W&&7[%Y@!.!A]&?RO(<B"(DHF1'LZ8T.A431A&T_H"3K/9.4\J7.LDSG]K#
M<5 (Q'L2ER6\P])+4IGT5%:C.G:@2)(I56I4W41.0C@R@&"0_=H'K-4?R<-:
MA]('TN4%&)4B.-:H75CA<2U1D%N)K&J%!#@O:,EM:9)6:VP/T=FAF( T:,ZJ
M:./M#D>L$E7Q*-]J(6TQ=X.^-ZB8MNJ<KY6":H'65+.?C(?=0KX5GG9J+W>7
MR^Z<SK4";16\S)4U+_.Q5QZ[H1FW);$5]0(KAJVFEWR!YU6;RH%HRZ7G^P5Q
MVN9,M*_46F'U(ZEYTZ.;]"4F*%A'6=,F?\^MRI!7[A-I3VB(]))P% 3NAQ[T
M_0:[4U=.2%OKI,K44=!AL'G8AJ&A^N)9_W*Z_1*T87OU [J*J+^#K"I-Q-]9
MHH-F#0JQU?_"K7PY^BE(-O/'")'X*KK;H("<>3O/9X=JG/U8+M('H.<@Y ">
MP8+P'@0A(Q7>BJ28.UPN!1E$YS@,/;A>.BBX;8TAI8LN'/3N=BP\53<]\K0#
M".;M8Z<P[SN^W$CMMOSN:A8MJY%RE+&%7#/TDG!M>$&Q[\>B_T'M</QEKE^[
M1D\7]>9%:D>4?SC@U/9>H2!1!/PX>KJ EQ#H+T@R'/!K;Z<ZO?.A;LQ-#4@7
MGV[B>>L-8H57N=,X7^6LLPWL*EJ0 ),%HO\/P1U*:2)J  ,#24:4U8K I3\/
M6!X7BF!%('L(N+D_U'&OTH<,Z+"U>H^XQ0_\ B<.(IQ-(R]:/N9+6T=)]?<%
M@ZNHN7<H55B'41P4/LINCO/)L*1G"5];']D3GR/+,QQQ5NRLN?4.Y?6MA9N&
M">D^GT)J9E0#&P/U8Z(T;IY'IV'&"*?_(/*N$S+D-3T84/V%M8!'+EBC<O0F
MJ4))R/0');\4^]&:J@Q4_<T[+HAS'.\>L5R=]WY"CNYE)*=BK1]%+SKZ[R_[
M.&O0B,-'+(;482!PS/WK^>ICA(H84K&JDW\C@A>8?ODEE0*\3B0)NC(4%34D
M"Y>1$#14"(W:<F0A&-:2F<XB4.Y&EE5U:3T_E0D6E]:,=ADY-*O-G75G06=&
M*MC+[<;S2*?&CC2?J]I*J!DH/P"50J_6"GT]/VV5]=01C]?5G6:6?(R7=RBB
M0E]BDNQSH08W"^JF.RW5*6+77S[ L!+UJV]ZKI@T9+T%!G2W9]'5L&CJ:ZL;
M'4AY -V:T:"3*2^8-E  ;_S-K!&8"0&G-<7++3FP )Z5VM5G'N$ZP]$#(DEP
M'Z*KB$J;\H^Q=;79+<0D8^Q0@/5G*PVM%CC&>H!RT[6YOKJ*_FF]%NYD^2NP
ML3: R+-1PZ_P3MM6/"79HTF2M-MT>46UR<+7&V,WK$DC.LRU]RQU5]::WCK&
MK<&2@5$D5V$C-75THZ#;MNMB"#V">@A,9B'T 0'I7JGY*IVB#K]E I.:C$;@
MX$ RS WH1HM6)F6@03 QD5C^(66?4"3Q<2DNMKL0[^D<X%4)^=/(3;!;A%Y4
MM1NAFAK,8DIZ'(XGI%"N4J9L%J_2K5UETA,RP]7ATQX U]6/0*;SP$2T)-EG
M0&?P&\0::O=)$'M^^JG%(G26OCU6W&W6I"G>1Y<[5U0?J@,4-Y#!I)0Y%$P3
M396&R01=GCJX?$&JKBUHG5VD!]A:9LW6:5Z7#$6TUU>T8+6:,5BG>KFI!"#
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M^>0E28BNO7M,V&_0@V*1[*^3)1CX'@(N*_M*&):%"OK@T+[-L C;,L3+=?$
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M*M5-6ZI?A$2/K6PVI_..4+PB?,PW=-M"=C6SL(B>HB+"@I7_,!_>,"-CVW'
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M!0/*1:J!HHZ=\6)FY(IKVQC)+&TO]].':Z[B]+GA"XWSQ!F J*<7SX8Y@S^
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M/6CNJY812$UMM,BF/ )&SLF/\^P^?4[&0TB#IML]K(0+(#QH!VI;:!<O>?\
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MB _E"[#OJ%YU996368VW%,5,'[242EF'">64FK=]B+9.^]F6$$&-<M#_UVU
MT_T"6K"P>T'DEI:32Y?;'/-K<*Y/J:SY]&X53;B6? 2L^5&Z/"(=^+N@^<ET
MZK38P$AN:(W%9[/:=PF[0GMO7!_GKUTFX&#TO*3+M-8&EW!Z%M$<Y@DT?$[7
M%E(ZOA?+)^-&Y0HV]Q^GW@\XAO391I-ROE8I\WR;WJ7O"E6RX3T<DDE8@::
M^,EP5VNOD\NNF*#YB>K^1J8O#"DX\'LA%PBE#Z)HF?>KN#!,#4QVQ/7.USKG
M!4- Y-RG11#S/6ES<?/KJ\. ,Q)<6CM97E%_GK&:^M6NEKUZ=)_R0(I69 -
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M2%@>^(#'4)MQG@]]MFG.G5]B,D3!UL.^NM8;VT,=+0$;JJ>Y-D&T8!N%34;
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MLR$+DN\;TY7>8[1<*?4Z9BZ?F]%UFS8] D1^9DTP=I[FH!/F(0J.CT;4W$A
MT&R'0MK0IX<'U(D8$N(I&P<NV\3+#!L!- ZW=55PX!!: '8&\JC:L/*R"QU6
M9GO+.3!7L\=Q<?!$\[B?HIS[A#2-#W)8)^SG^+!.Q(/LL(ZVI0%NWKA*N/1:
M4DPE^OKH3CI'D[Q;F@U\)K@N!PEP2ONZ3)^0<@'/$\_IO4CJH;UX*<H8=QT)
M'5))'115SMP@U4)B5CXF&0YB6K*._ -'*X*Y\)&(%%/_%N=O@ZA;T\/56@/B
MS'VL5)])"5;+KO\D4$UP0;U?VA^%VRS#2;A#*]K7>^C4'"VJQ0PL-I,R-8S0
M=5)NUY)5F>B2+ 1Y$0!+J$?/I774XDP6!V,TR$:_"@/0NPJ,#+NR$.\)_>C1
M;!KIM"X2HBVF\<SK!0YI)@/-BB__>Y\%"TS&GA>/...7;VB*LB<CJ\&??W<?
MSJPTVK! BY((A7Q!NS.<IY0 #955%*:T5= 'D<KV:DK1XG;/T+C7R1/Y6YI%
MTT%_DR4/]SDTV%- G#J\K,,+]+*%]VC?W?^M20-TZ,&Z*RSSI(*AD=B'X_:V
ML0Y+$P1R@ST3('-SW?58IFVS!2#1PW-79F/AN1IA/V)K02#[3X\."I0Y[Q@'
M,JI">X5PBO8*^2(W95/2\G1:,@Z,5-C7D>5(J6+=B_,S6M1ZA:=0V G,FY]\
M8Q-6 >&[*NSE/0)B Q-%#IF.I Q/DIOC\<+7Y OZ!4>KQP(O9D]D\5SAJG+F
M34:+091\E84S[X.';1QDYED:(PWJ^@1[_"E <B;3)UP6FT()&Y15H*(%G>LR
MKNFVR NR#E0%)9Y+GE# F=I7@MU0MJ:1SC0N\D1)&R/JR.A0335L>]2W]*4$
MO+A.5)__"> K&WU(EW'+L9F7^53"CX(]S<$+9_+/ZFM4CH(6VXQ^6;TJ"!X"
MGH>"5/7Y'$0%9A> 6T\R\$%!8P*^$F/2;@^V3=F4X/Y#O7J4ZP8(X3X?]C#0
MNO!!#UW9&9PNP3^<ZD].K3UX4-<^U?A3L+7Z]3@3^BH.ARY]PZ^E!R._2?#M
M*D?-K:T_G+Q+?\B&4?@: ,+[!)8!;0@HE@(],9KY+_ OZBK-ECAR[/^#!YWN
MB@"=@NV*4(]#/HB-ZD.9[*J@BS#]54%+%V.M"JI![1<%,'6?[__IL0I>%<"0
MG\;:H L$Q=*@)4J36H':GA8]T_"P5X ,ZQCYAYB#[>+P,V8O:M&P*]X/2E_6
M>G6,_KQ-O-5H/3#4C#<.4)U8OQ;+AP6/:K9(P,E[WCF &06O$1K(][]":,-
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MN '8,%$OQ_<(!"Q(*Q]178=E4Q2PMKZ2)Q7RKLR*;&8F-P,H1&9QG#[3TR>
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M@^PB8;;[;?91$5+)<?C-*GUZ63;F$97R'TS!3+D-4LZV#OLQ91'3+<U!BZ/
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M4<8(> N##BFE#ERH9FY2"'>V6$34C0WBBC2_M(XA>%!T=KN?D3,BVPG7'6I
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MVE/,GV%^G:"7X[5#P()$\>RK:6P#4])4=N_0M:<GE_[^T5/Q/$U6D7K_B%?
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MIK('92<5ZSQF18R7F_%3?)WEB\7]^4U:DIS>O'R1CW_X1LF7EV&<EB_+Q\8
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M!(EY1F*C"4-0 2L7Q"?G[QK$*$5J^A5MO4AN\PA6;8GHABAK"M<#_1#],/W
MH"(X[ZL"7PQ+]NMUE>? P/K/7$N'Y.FL*OOD_RFHU5 Z\@569YH\J!,E<_2?
MT<&L)PSW?O-Z(/'_=G2@Q(2_1E',",:ABH'%6RK:LT@)U@ZFY?T#22G7D-.R
MU =C?)1-1\BW@'SSY>("-(S014M1W*-T+=A4=+&@+!'#BD6<QEQ08>U92[S9
M[ZL\2V_2]3$*XLTF+^AU0;G [ECZ$7)#?\;3U\=H"=27HNU[YPNI ,?P0))>
M@6AE5* VYH.6 @A=_B Q\=@[J$GMQ.P#UL=D3',9G@C]1%A3DU_H!W(XC"FY
MS;.H6I?VY-=TS-EURT+^$5L7KZRH =4Q?^Q(@U!$O^E#(ZNM=@JNJ0K4X3<]
MTN&L8)^93"AU^;.\7)%\?UTQ]^NB42^..W6P:D"5CGVPX>MV>@OB+6A"5F"<
M%7$08G&HXI*0S^%#ED/[N)@4QUOTG]B:0=);- #;_N<2U36IQ53P15K097C&
MLB$*]-\P<43RB,1_7T01)5X!WK7+;$^5Q6;,+B<;CF=!$65(%F3]TS9[_#V=
M]WLH00,_O(,??GHNHG^3KW9BR69 3AT:0!29B82/"V!@\!L?^C<D%X^6_,!Z
M-6(G%V)D=(6==PD&A 0"I]I#M7C(JG)0N?*.64%8P<U1[T=9_-$12V):'8X
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M=3[W;9B7+V,;@5*LF+0B'F.GPRR518Z@IR^%/ X?XF10G>>]4B^7C$43Q67
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MUYA;=OA[E+G(-DQ,,NQ@$*)\U0=#D*I$1!!TNN&%ZYAZK)P\ARQ2)7 ZK<U
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ME'PTUK&00S,FN0Y#3T=@DQ?O-E62_/UK5GZFMV&^VH6\]-F7+"UW!LL-G11
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M3,*"6,3--1-;.P!]Z!.8*S< 814--F"GN 3MB.+;"\V%5WTL3B/AAC.I2#X
M6G$#BGAY+];)0F]8_(QEP<YN@E"T$TEM&Z.@TMCDJ.+$K-V1A"4SK+*_AE2_
M>4@(.VF-N^IK5M(7,:DB$MVDO(8,TR^7&]F!U(6FY?6'P/?W6'^JOJX.C?LP
MS2 ZFW\.PK3WW0?A#=-=;K@!-2>CHL("_BJ\\N%+; I7-E6'7FQL!.W@LX .
M#]KQ9\&G/"N0GC0M)GVV6: \N[#D7O0BB$NL4\)1H<EYMR"7/GDSB3F5?I]
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M+DCB!:'>YE[Z $IT=8_G;"?_M-/@J>5C(#$I_9\'77NB[6NPLR!WC;2YJGP
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M 4?CI_B7>89AJ68A@!D.AED(R;YW5'87F;SY<1/NWKY^\TXO*Z&-P'">9>N
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MQ/1];H:B@ER\X1\SWXN7[J=E2O"3('C."5J>D4U4[..^S<P<,:.ORCJVUG>
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M#X51K9)'W$8R7T>9;ES'\28+'U_>3V\U6&[X$+>((PA.8OTTB04J=.>6)O-
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M^Y!#KTK1R<P?9,O01 ;P\M=.@R1_J?5P:&]V$WB/XNE?T-^.TLG''T1ONO&
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ME6!&-$00?_O_4$L! A0#%     @ 53)=4ZCP?HLV: , 7O(@ !L
M     ( !     &8R,&8R,#(Q7VEM;75R;VYL:6UI=&5D+FAT;5!+ 0(4 Q0
M   ( %4R75.HUXY35 <  %4@   :              "  6]H P!F,C!F,C R
M,65X,3(M,5]I;6UU<F]N+FAT;5!+ 0(4 Q0    ( %4R75.[]WG+1P<  /<?
M   :              "  ?MO P!F,C!F,C R,65X,3(M,E]I;6UU<F]N+FAT
M;5!+ 0(4 Q0    ( %4R75/&A^J^&@0  &L/   :              "  7IW
M P!F,C!F,C R,65X,3,M,5]I;6UU<F]N+FAT;5!+ 0(4 Q0    ( %4R75,.
MH>[ & 0  %(/   :              "  <Q[ P!F,C!F,C R,65X,3,M,E]I
M;6UU<F]N+FAT;5!+ 0(4 Q0    ( %4R75/PI?M\/0(  /P'   :
M      "  1R  P!F,C!F,C R,65X,C,M,5]I;6UU<F]N+FAT;5!+ 0(4 Q0
M   ( %4R75.&!7CZ5B " !TD @ -              "  9&" P!I;6%G95\P
M,#$N:G!G4$L! A0#%     @ 53)=4W5$(5W"9   QF8   T
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M+3(P,C$P-C,P7V1E9BYX;6Q02P$"% ,4    " !5,EU3$B*')/;G  #A]@L
M%               @ $<8 < :6UC+3(P,C$P-C,P7VQA8BYX;6Q02P$"% ,4
M    " !5,EU3)#.R95)9  ",EP4 %               @ %$2 @ :6UC+3(P
D,C$P-C,P7W!R92YX;6Q02P4&      \ #P#C P  R*$(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
